Copy of ISGR Case Study
ABCDEFGJLMNQRSTUVW
1
ISRG
2
1/20/2020
Review this page to learn the history of key announcements by the company and see how the price and multiples responded after the announcement.
Note: stock price data per Google Finance; announcement data and financial statements per Capital IQ. Market cap data is estimated using most recent quarterly shares reported; any holes in the data are related to Google Finance price availability. www.huntervalue.com
3
(date of report)
4
Market Multiples as of date:TEV/LTM Total RevenueTEV/LTM EBITDATEV/LTM EBITP/LTM Normalized EPSTEV/LTM Unlevered FCFMarket Cap $MM30 day price change after announcementPrice as of Announce DateReturn from Announce Date to todayDateTypeHeadlineOther PartiesSituation
6
1/17/202015.67x44.92x50.86x79.90x73.77x$69,671$602.69-0.73%Jan-14-2020Company Conference PresentationIntuitive Surgical, Inc. Presents at 38th Annual J.P Morgan Healthcare Conference, Jan-14-2020 10:30 AM-Intuitive Surgical, Inc. Presents at 38th Annual J.P Morgan Healthcare Conference, Jan-14-2020 10:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Gary S. Guthart, CEO & Director.
7
1/17/202015.67x44.92x50.86x79.90x73.77x$69,721$603.12Jan-13-2020ConferenceJPMorgan Chase & Co., 38th Annual J.P Morgan Healthcare Conference, Jan 13, 2020 through Jan 16, 2020Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Repligen Corporation (NasdaqGS:RGEN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), United Therapeutics Corporation (NasdaqGS:UTHR), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), NVIDIA Corporation (NasdaqGS:NVDA), Omnicell, Inc. (NasdaqGS:OMCL), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), ICON Public Limited Company (NasdaqGS:ICLR), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Endologix, Inc. (NasdaqGS:ELGX), Novavax, Inc. (NasdaqGS:NVAX), ICU Medical, Inc. (NasdaqGS:ICUI), Patterson Companies, Inc. (NasdaqGS:PDCO), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Mylan N.V. (NasdaqGS:MYL), Quidel Corporation (NasdaqGS:QDEL), Mirati Therapeutics, Inc. (NasdaqGS:MRTX), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Cerner Corporation (NasdaqGS:CERN), CONMED Corporation (NasdaqGS:CNMD), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Bio-Techne Corporation (NasdaqGS:TECH), Accuray Incorporated (NasdaqGS:ARAY), Premier, Inc. (NasdaqGS:PINC), OraSure Technologies, Inc. (NasdaqGS:OSUR), Bruker Corporation (NasdaqGS:BRKR), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), ChemoCentryx, Inc. (NasdaqGS:CCXI), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Mersana Therapeutics, Inc. (NasdaqGS:MRSN), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), HealthEquity, Inc. (NasdaqGS:HQY), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Conformis, Inc. (NasdaqGS:CFMS), Intrexon Corporation (NasdaqGS:XON), Athenex, Inc. (NasdaqGS:ATNX), R1 RCM Inc. (NasdaqGS:RCM), Natera, Inc. (NasdaqGS:NTRA), Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Inogen, Inc. (NasdaqGS:INGN), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), AngioDynamics, Inc. (NasdaqGS:ANGO), LHC Group, Inc. (NasdaqGS:LHCG), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Alphabet Inc. (NasdaqGS:GOOG.L), HMS Holdings Corp. (NasdaqGS:HMSY), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Endo International plc (NasdaqGS:ENDP), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Amgen Inc. (NasdaqGS:AMGN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Alkermes plc (NasdaqGS:ALKS), Tivity Health, Inc. (NasdaqGS:TVTY), Almirall, S.A. (BME:ALM), Pharma Mar, S.A. (BME:PHM), DLA Piper LLP (US), Clayton, Dubilier & Rice, LLC, Domain Associates, L.L.C., Ancestry.com LLC, NxStage Medical, Inc., Sirona Dental Systems Inc., Intas Pharmaceuticals Limited, CommonSpirit Health, Kaiser Permanente Inc., University of California, Netsmart Technologies, Inc., ClearDATA Networks, Inc., Baylor Scott & White Health LLC, NorthShore University HealthSystem, Bon Secours Mercy Health, ProMedica Health System, Inc., National Institutes of Health, Silicon Valley Bank, Inc., The California Endowment, SEQENS SAS, Partners HealthCare System, Inc., Henry Ford Health System, Intermountain Healthcare, Inc., SSM Health Care Corporation, Mayo Clinic, City Of Hope, The Children's Hospital of Philadelphia, Pharmaceutical Research and Manufacturers of America, UC Health, LLC, Enterprise Community Partners, Cotiviti, Inc., Deerfield Management Company, L.P., Providence St. Joseph Health, Oregon Health & Science University, Northwestern Memorial Healthcare Corporation, Cottage Health System, Inc., Seattle Cancer Care Alliance, Duke University Medical Center, Hospital for Special Surgery, NYU Langone Hospitals, Jefferson Healthcare, U.S. Food and Drug Administration, Waystar, Inc, Centers for Medicare & Medicaid Services, OSF Healthcare System, Availity, LLC, GenScript Corporation, Christiana Care Health System, Inc., Pfizer Venture Investments, Cardiva Medical, Inc., Asklepios BioPharmaceutical, Inc., EUSA Pharma, Inc., Rafael Pharmaceuticals, Inc., Siemens Healthineers, Inc., Biomarck Pharmaceuticals, Ltd., SYNLAB International GmbH, Blau Farmacêutica S.A., Seattle Children's Home Inc., Broad Institute, TraceLink, Inc., RxSight, Inc., Welltok, Inc., Health Carousel, LLC, Sera Prognostics, Inc., Privia Health, LLC, SHINE Medical Technologies, Inc., Ginkgo Bioworks, Inc., Geisinger Health System, Social Finance, Inc., Foghorn Capital, LLC, Proaxis Therapy, LLC, Ascension Health Alliance, Adagene (Suzhou) Limited, Bioventus LLC, Grand Rounds, Inc., Oak Street Health, LLC, GE Healthcare Inc., GenapSys, Inc., Vohra Wound Physicians Mgnt Llc, Evidation Health, Inc., Oscar Insurance Corporation, ArcherDx, Inc., American Gene Technologies International Inc., Genomics England Limited, MedAvail Technologies Inc., Avidity Biosciences LLC, Maravai Life Sciences Inc., Benchling, Inc., LINK Document Services Group LLC, Recursion Pharmaceuticals, Inc., Compass Therapeutics LLC, ZyVersa Therapeutics, Inc., Wellington Management Company LLP, Rakuten Medical, Inc., Eargo, Inc., Outset Medical, Inc., Caris Life Sciences, Inc., China Pharmaceutical Innovation and Research Development Association, Ark Biosciences Inc., Checkmate Pharmaceuticals, Inc., Color Genomics, Inc., VillageMD, Berkeley Lights, Inc., Companion Medical, Inc., Evolve Biosystems, Inc., Butterfly Network, Inc., NantCell, Inc., PHC Holdings Corporation, ORIC Pharmaceuticals, Inc., QuVa Pharma, Inc., Immatics US Inc., Adicet Bio, Inc., E-Scape Bio, Inc., Ping An Health Cloud Company Limited, Akeso Biopharma, Inc., Savonix, Inc., Verily Life Sciences LLC, Tmunity Therapeutics, Inc., Freeline Therapeutics Limited, WuXi Nextcode Genomics, Inc., Roivant Sciences, Inc., 91streets Media Technologies Private Limited, Corvidia Therapeutics, Inc., Fox Business Network, CardioNXT, Inc., Relay Therapeutics, Inc., Insightec, Inc, Goldfinch Bio, Inc., Macrophage Pharma Limited, Landos Biopharma, Inc., Sigilon Therapeutics, Inc., Repare Therapeutics Inc., Medically Home Group, Inc., Antengene Corporation, Senti Biosciences, Inc., Nkarta, Inc., Precigen, Inc., Dizal Pharmaceutical, RemeGen LTD, Ada Digital Health Ltd, Fusion Pharmaceuticals Inc., Generation Bio Co., Legend Biotech Corporation, Spring Discovery, Inc, Seqster, Theragnostics Inc., Tempus, Kronos Bio, Inc., Advocate Aurora Health, Ocumension Therapeutics, Hypera Pharma, AllerGenis, Inc, Sana Biotechnology, Inc., WeDoctor Group (Zhejiang) Co., Ltd., BioAge Group, LLC, Trialspark, Inc., Lg Chem Life Sciences India Private Limited, Gracell Biotechnologies Co., Ltd., Aligos Therapeutics, IONTAS Limited, Medlife International Private Limited, Transcenta Holding Ltd., Nurix Therapeutics, Inc, Concerto HealthAI Solutions LLC, Carbon, Inc., Immutep Limited (ASX:IMM), CSL Limited (ASX:CSL), Immunicum AB (publ) (OM:IMMU), Immunovia AB (publ) (OM:IMMNOV), Diamyd Medical AB (publ) (OM:DMYD B), PledPharma AB (OM:PLED), Moberg Pharma AB (publ) (OM:MOB), Orexo AB (publ) (OM:ORX), Hansa Biopharma AB (publ) (OM:HNSA), Oncopeptides AB (publ) (OM:ONCO), Elekta AB (publ) (OM:EKTA B), BioInvent International AB (publ) (OM:BINV), Novartis AG (SWX:NOVN), Vifor Pharma AG (SWX:VIFN), Roche Holding AG (SWX:ROG), Alcon, Inc. (SWX:ALC), Lonza Group Ltd (SWX:LONN), Basilea Pharmaceutica AG (SWX:BSLN), Santhera Pharmaceuticals Holding AG (SWX:SANN), Molecular Partners AG (SWX:MOLN), Medacta Group SA (SWX:MOVE), Galapagos NV (ENXTAM:GLPG), Pharming Group N.V. (ENXTAM:PHARM), Koninklijke Philips N.V. (ENXTAM:PHIA), Signify N.V. (ENXTAM:LIGHT), IHH Healthcare Berhad (KLSE:IHH), Hanmi Pharm. Co., Ltd. (KOSE:A128940), Samsung Biologics Co.,Ltd. (KOSE:A207940), Celltrion, Inc. (KOSE:A068270), Daewoong Pharmaceutical Co., Ltd. (KOSE:A069620), Hikma Pharmaceuticals PLC (LSE:HIK), GlaxoSmithKline plc (LSE:GSK), Vectura Group plc (LSE:VEC), ScinoPharm Taiwan, Ltd. (TSEC:1789), Hutchison China MediTech Limited (AIM:HCM), Abcam plc (AIM:ABC), Mereo BioPharma Group plc (AIM:MPH), Horizon Discovery Group plc (AIM:HZD), Tiziana Life Sciences PLC (AIM:TILS), Intersect ENT, Inc. (NasdaqGM:XENT), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), Sutro Biopharma, Inc. (NasdaqGM:STRO), Quanterix Corporation (NasdaqGM:QTRX), Silk Road Medical, Inc (NasdaqGM:SILK), Axcella Health Inc. (NasdaqGM:AXLA), Sesen Bio, Inc. (NasdaqGM:SESN), Zai Lab Limited (NasdaqGM:ZLAB), Aeglea BioTherapeutics, Inc. (NasdaqGM:AGLE), UroGen Pharma Ltd. (NasdaqGM:URGN), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Adverum Biotechnologies, Inc. (NasdaqGM:ADVM), Clearside Biomedical, Inc. (NasdaqGM:CLSD), Karuna Therapeutics, Inc. (NasdaqGM:KRTX), Sage Therapeutics, Inc. (NasdaqGM:SAGE), RAPT Therapeutics, Inc. (NasdaqGM:RAPT), Magenta Therapeutics, Inc. (NasdaqGM:MGTA), Morphic Holding, Inc. (NasdaqGM:MORF), Kodiak Sciences Inc. (NasdaqGM:KOD), Valneva SE (ENXTPA:VLA), Innate Pharma S.A. (ENXTPA:IPH), Sanofi (ENXTPA:SAN), Quantum Genomics Société Anonyme (ENXTPA:ALQGC), Sensorion SA (ENXTPA:ALSEN), Inventiva S.A. (ENXTPA:IVA), Transgene SA (ENXTPA:TNG), Ipsen S.A. (ENXTPA:IPN), Novo Nordisk A/S (CPSE:NOVO B), WuXi AppTec Co., Ltd. (SHSE:603259), GN Store Nord A/S (CPSE:GN), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), Bavarian Nordic A/S (CPSE:BAVA), HealthCare Global Enterprises Limited (BSE:539787), Kamada Ltd. (TASE:KMDA), Ribomic Inc. (TSE:4591), Otsuka Holdings Co., Ltd. (TSE:4578), Healios K.K. (TSE:4593), SanBio Company Limited (TSE:4592), Daiichi Sankyo Company, Limited (TSE:4568), Sosei Group Corporation (TSE:4565), Santen Pharmaceutical Co., Ltd. (TSE:4536), Takeda Pharmaceutical Company Limited (TSE:4502), Achilles Corporation (TSE:5142), Olympus Corporation (TSE:7733), Innovent Biologics, Inc. (SEHK:1801), Viva Biotech Holdings (SEHK:1873), Hong Kong Exchanges and Clearing Limited (SEHK:388), 3SBio Inc. (SEHK:1530), Sino Biopharmaceutical Limited (SEHK:1177), Lupin Limited (BSE:500257), Dr. Reddy's Laboratories Limited (BSE:500124), Hangzhou Tigermed Consulting Co.,Ltd (SZSE:300347), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760), Raia Drogasil S.A. (BOVESPA:RADL3), Fleury S.A. (BOVESPA:FLRY3), IMV Inc. (TSX:IMV), Qualicorp Consultoria e Corretora de Seguros S.A. (BOVESPA:QUAL3), Biotoscana Investments S.A. (BOVESPA:GBIO33), Oxurion NV (ENXTBR:OXUR), UCB SA (ENXTBR:UCB), Mithra Pharmaceuticals S.A. (ENXTBR:MITRA), Biocartis Group NV (ENXTBR:BCART), argenx SE (ENXTBR:ARGX), Siemens Healthineers AG (XTRA:SHL), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Evotec SE (XTRA:EVT), Fresenius SE & Co. KGaA (XTRA:FRE), Bayer Aktiengesellschaft (XTRA:BAYN), MorphoSys AG (XTRA:MOR), 4SC AG (XTRA:VSC), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), AVRA Medical Robotics, Inc. (OTCPK:AVMR), STADA Arzneimittel Aktiengesellschaft (MUN:SAZ), Apollo Hospitals Enterprise Limited (NSEI:APOLLOHOSP), Hugel, Inc. (KOSDAQ:A145020), Genexine, Inc. (KOSDAQ:A095700), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), Hill-Rom Holdings, Inc. (NYSE:HRC), AmerisourceBergen Corporation (NYSE:ABC), AMN Healthcare Services, Inc. (NYSE:AMN), Waters Corporation (NYSE:WAT), Charles River Laboratories International, Inc. (NYSE:CRL), STERIS plc (NYSE:STE), Universal Health Services, Inc. (NYSE:UHS), QIAGEN N.V. (NYSE:QGEN), Encompass Health Corporation (NYSE:EHC), Laboratory Corporation of America Holdings (NYSE:LH), Humana Inc. (NYSE:HUM), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), Quest Diagnostics Incorporated (NYSE:DGX), Welltower Inc. (NYSE:WELL), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Abbott Laboratories (NYSE:ABT), The Cooper Companies, Inc. (NYSE:COO), Danaher Corporation (NYSE:DHR), PerkinElmer, Inc. (NYSE:PKI), Boston Scientific Corporation (NYSE:BSX), Perrigo Company plc (NYSE:PRGO), Owens & Minor, Inc. (NYSE:OMI), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), Tenet Healthcare Corporation (NYSE:THC), CVS Health Corporation (NYSE:CVS), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Cantel Medical Corp. (NYSE:CMD), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Agilent Technologies, Inc. (NYSE:A), salesforce.com, inc. (NYSE:CRM), Johnson & Johnson (NYSE:JNJ), Edwards Lifesciences Corporation (NYSE:EW), JPMorgan Chase & Co. (NYSE:JPM), JPMorgan Chase & Co. (NYSE:JPM), Glaukos Corporation (NYSE:GKOS), Molina Healthcare, Inc. (NYSE:MOH), Teladoc Health, Inc. (NYSE:TDOC), Emergent BioSolutions Inc. (NYSE:EBS), Avantor, Inc. (NYSE:AVTR), Myovant Sciences Ltd. (NYSE:MYOV), AbbVie Inc. (NYSE:ABBV), Zoetis Inc. (NYSE:ZTS), Invitae Corporation (NYSE:NVTA), Mallinckrodt plc (NYSE:MNK), Evolent Health, Inc. (NYSE:EVH), Avanos Medical, Inc. (NYSE:AVNS), Inspire Medical Systems, Inc. (NYSE:INSP), Catalent, Inc. (NYSE:CTLT), Veeva Systems Inc. (NYSE:VEEV), Penumbra, Inc. (NYSE:PEN), Nevro Corp. (NYSE:NVRO), Phreesia, Inc. (NYSE:PHR), Zymeworks Inc. (NYSE:ZYME), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Elanco Animal Health Incorporated (NYSE:ELAN), New Frontier Health Corporation (NYSE:NFH), Envista Holdings Corporation (NYSE:NVST), TransEnterix, Inc. (AMEX:TRXC), Radius Health, Inc. (NasdaqGM:RDUS), Acceleron Pharma Inc. (NasdaqGM:XLRN), Revance Therapeutics, Inc. (NasdaqGM:RVNC), NanoString Technologies, Inc. (NasdaqGM:NSTG), Cara Therapeutics, Inc. (NasdaqGM:CARA), GW Pharmaceuticals plc (NasdaqGM:GWPH), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Marinus Pharmaceuticals, Inc. (NasdaqGM:MRNS), Oxford Immunotec Global PLC (NasdaqGM:OXFD), AtriCure, Inc. (NasdaqGM:ATRC), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), TransMedics Group, Inc. (NasdaqGM:TMDX), Amarin Corporation plc (NasdaqGM:AMRN), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Misonix, Inc. (NasdaqGM:MSON), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), 111, Inc. (NasdaqGM:YI), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), AxoGen, Inc. (NasdaqCM:AXGN), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), Stemline Therapeutics, Inc. (NasdaqCM:STML), Applied DNA Sciences, Inc. (NasdaqCM:APDN), Agile Therapeutics, Inc. (NasdaqCM:AGRX), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), Heska Corporation (NasdaqCM:HSKA), Exact Sciences Corporation (NasdaqCM:EXAS), Salarius Pharmaceuticals, Inc. (NasdaqCM:SLRX), Cue Biopharma, Inc. (NasdaqCM:CUE), TFF Pharmaceuticals, Inc. (NasdaqCM:TFFP), AdaptHealth Corp. (NasdaqCM:AHCO), TG Therapeutics, Inc. (NasdaqCM:TGTX), CohBar, Inc. (NasdaqCM:CWBR), Option Care Health, Inc. (NasdaqCM:BIOS), Taiwan Liposome Company, Ltd. (GTSM:4152), OBI Pharma, Inc. (GTSM:4174), Oneness Biotech Co., Ltd. (GTSM:4743), PharmaEssentia Corporation (GTSM:6446), Scandion Oncology A/S (NGM:SCOL), RhoVac AB (NGM:RHOVAC), Kura Oncology, Inc. (NasdaqGS:KURA), NextCure, Inc. (NasdaqGS:NXTC), TCR2 Therapeutics Inc. (NasdaqGS:TCRR), Kaleido BioSciences, Inc. (NasdaqGS:KLDO), Rubius Therapeutics, Inc. (NasdaqGS:RUBY), Gritstone Oncology, Inc. (NasdaqGS:GRTS), Crinetics Pharmaceuticals, Inc. (NasdaqGS:CRNX), SmileDirectClub, Inc. (NasdaqGS:SDC), Denali Therapeutics Inc. (NasdaqGS:DNLI), Change Healthcare Inc. (NasdaqGS:CHNG), Vir Biotechnology, Inc. (NasdaqGS:VIR), Frequency Therapeutics, Inc. (NasdaqGS:FREQ), Oyster Point Pharma, Inc. (NasdaqGS:OYST), IDEAYA Biosciences, Inc. (NasdaqGS:IDYA), Orchard Therapeutics plc (NasdaqGS:ORTX), Aptinyx Inc. (NasdaqGS:APTX), Y-mAbs Therapeutics, Inc. (NasdaqGS:YMAB), BridgeBio Pharma, Inc. (NasdaqGS:BBIO), Afya Limited (NasdaqGS:AFYA), Covetrus, Inc. (NasdaqGS:CVET), SpringWorks Therapeutics, Inc. (NasdaqGS:SWTX), Allogene Therapeutics, Inc. (NasdaqGS:ALLO), Kiniksa Pharmaceuticals, Ltd. (NasdaqGS:KNSA), Cyclerion Therapeutics, Inc. (NasdaqGS:CYCN), Autolus Therapeutics plc (NasdaqGS:AUTL), Replimune Group, Inc. (NasdaqGS:REPL), Akero Therapeutics, Inc. (NasdaqGS:AKRO), Urovant Sciences Ltd. (NasdaqGS:UROV), BioNTech SE (NasdaqGS:BNTX), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), NovoCure Limited (NasdaqGS:NVCR), Clovis Oncology, Inc. (NasdaqGS:CLVS), Adaptive Biotechnologies Corporation (NasdaqGS:ADPT), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Progyny, Inc. (NasdaqGS:PGNY), BeiGene, Ltd. (NasdaqGS:BGNE), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Moderna, Inc. (NasdaqGS:MRNA), Health Catalyst, Inc. (NasdaqGS:HCAT), Surgery Partners, Inc. (NasdaqGS:SGRY), IVERIC bio, Inc. (NasdaqGS:ISEE), iRhythm Technologies, Inc. (NasdaqGS:IRTC), OPKO Health, Inc. (NasdaqGS:OPK), AnaptysBio, Inc. (NasdaqGS:ANAB), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST), Ascendis Pharma A/S (NasdaqGS:ASND), Precision BioSciences, Inc. (NasdaqGS:DTIL), InflaRx N.V. (NasdaqGS:IFRX), Inovalon Holdings, Inc. (NasdaqGS:INOV), G1 Therapeutics, Inc. (NasdaqGS:GTHX), Jounce Therapeutics, Inc. (NasdaqGS:JNCE), 10x Genomics, Inc. (NasdaqGS:TXG), MyoKardia, Inc. (NasdaqGS:MYOK), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), Stoke Therapeutics, Inc. (NasdaqGS:STOK), Editas Medicine, Inc. (NasdaqGS:EDIT), Turning Point Therapeutics, Inc. (NasdaqGS:TPTX), Tricida, Inc. (NasdaqGS:TCDA), Alector, Inc. (NasdaqGS:ALEC), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Twist Bioscience Corporation (NasdaqGS:TWST), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), ObsEva SA (NasdaqGS:OBSV), Livongo Health, Inc. (NasdaqGS:LVGO), Syneos Health, Inc. (NasdaqGS:SYNH), NantKwest, Inc. (NasdaqGS:NK), Guardant Health, Inc. (NasdaqGS:GH), Aprea Therapeutics, Inc. (NasdaqGS:APRE)JPMorgan Chase & Co., 38th Annual J.P Morgan Healthcare Conference, Jan 13, 2020 through Jan 16, 2020. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States.
8
1/17/202015.67x44.92x50.86x79.90x73.77x$67,717$585.792.13%Jan-09-2020Corporate Guidance - New/ConfirmedIntuitive Announces Unaudited Preliminary Unaudited Revenue Results Fourth Quarter and Full Year of 2019-Intuitive announced unaudited preliminary unaudited revenue results fourth quarter and full year of 2019. The company expects fourth quarter 2019 revenue of approximately $1.278 billion, an increase of 22% compared with $1.047 billion in the fourth quarter of 2018.

The company expects 2019 revenue of approximately $4.479 billion, an increase of 20% compared with $3.724 billion in 2018.
9
12/31/201915.43x44.23x50.07x78.71x72.63x$67,317$582.332.74%Dec-04-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at Piper Jaffray 31st Annual Healthcare Conference, Dec-04-2019 08:00 AM-Intuitive Surgical, Inc. Presents at Piper Jaffray 31st Annual Healthcare Conference, Dec-04-2019 08:00 AM. Venue: The Lotte New York Palace, 455 Madison Avenue, New York, New York, United States.
10
12/31/201915.43x44.23x50.07x78.71x72.63x$66,959$579.233.29%Dec-3-2019ConferencePiper Jaffray Companies, Piper Jaffray 31st Annual Healthcare Conference, Dec 03, 2019 through Dec 05, 2019Progyny, Inc. (NasdaqGS:PGNY), BeiGene, Ltd. (NasdaqGS:BGNE), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Health Catalyst, Inc. (NasdaqGS:HCAT), Moderna, Inc. (NasdaqGS:MRNA), Milestone Pharmaceuticals Inc. (NasdaqGS:MIST), Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST), Chiasma, Inc. (NasdaqGS:CHMA), Dermira, Inc. (NasdaqGS:DERM), Menlo Therapeutics Inc. (NasdaqGS:MNLO), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), uniQure N.V. (NasdaqGS:QURE), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Arvinas, Inc. (NasdaqGS:ARVN), scPharmaceuticals Inc. (NasdaqGS:SCPH), Stoke Therapeutics, Inc. (NasdaqGS:STOK), OptiNose, Inc. (NasdaqGS:OPTN), Turning Point Therapeutics, Inc. (NasdaqGS:TPTX), Axonics Modulation Technologies, Inc. (NasdaqGS:AXNX), Livongo Health, Inc. (NasdaqGS:LVGO), Unum Therapeutics Inc. (NasdaqGS:UMRX), SeaSpine Holdings Corporation (NasdaqGS:SPNE), Crinetics Pharmaceuticals, Inc. (NasdaqGS:CRNX), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Luminex Corporation (NasdaqGS:LMNX), Merit Medical Systems, Inc. (NasdaqGS:MMSI), PDL BioPharma, Inc. (NasdaqGS:PDLI), Incyte Corporation (NasdaqGS:INCY), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Apyx Medical Corporation (NasdaqGS:APYX), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), ChemoCentryx, Inc. (NasdaqGS:CCXI), Fluidigm Corporation (NasdaqGS:FLDM), OraSure Technologies, Inc. (NasdaqGS:OSUR), Insulet Corporation (NasdaqGS:PODD), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Collegium Pharmaceutical, Inc. (NasdaqGS:COLL), Alphatec Holdings, Inc. (NasdaqGS:ATEC), Athenex, Inc. (NasdaqGS:ATNX), Nabriva Therapeutics plc (NasdaqGS:NBRV), OPKO Health, Inc. (NasdaqGS:OPK), Trulieve Cannabis Corp. (CNSX:TRUL), CB2 Insights Inc. (CNSX:CBII), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), LivaNova PLC (NasdaqGS:LIVN), Cytokinetics, Incorporated (NasdaqGS:CYTK), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Exelixis, Inc. (NasdaqGS:EXEL), Inovio Pharmaceuticals, Inc. (NasdaqGS:INO), Gossamer Bio, Inc. (NasdaqGS:GOSS), HOOKIPA Pharma Inc. (NasdaqGS:HOOK), Replimune Group, Inc. (NasdaqGS:REPL), Bicycle Therapeutics plc (NasdaqGS:BCYC), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS), CytomX Therapeutics, Inc. (NasdaqGS:CTMX), Otonomy, Inc. (NasdaqGS:OTIC), Aravive, Inc. (NasdaqGS:ARAV), MeiraGTx Holdings plc (NasdaqGS:MGTX), Aptinyx Inc. (NasdaqGS:APTX), Oyster Point Pharma, Inc. (NasdaqGS:OYST), Harpoon Therapeutics, Inc. (NasdaqGS:HARP), Change Healthcare Inc. (NasdaqGS:CHNG), resTORbio, Inc. (NasdaqGS:TORC), Gritstone Oncology, Inc. (NasdaqGS:GRTS), IGM Biosciences, Inc. (NasdaqGS:IGMS), Ovid Therapeutics Inc. (NasdaqGS:OVID), NextCure, Inc. (NasdaqGS:NXTC), Kezar Life Sciences, Inc. (NasdaqGS:KZR), Akcea Therapeutics, Inc. (NasdaqGS:AKCA), Kura Oncology, Inc. (NasdaqGS:KURA), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Masimo Corporation (NasdaqGS:MASI), NuVasive, Inc. (NasdaqGS:NUVA), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), VIVUS, Inc. (NasdaqGS:VVUS), RTI Surgical Holdings, Inc. (NasdaqGS:RTIX), Quidel Corporation (NasdaqGS:QDEL), Cutera, Inc. (NasdaqGS:CUTR), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Vermillion, Inc. (NasdaqCM:VRML), Heska Corporation (NasdaqCM:HSKA), Molecular Templates, Inc. (NasdaqCM:MTEM), AxoGen, Inc. (NasdaqCM:AXGN), Stemline Therapeutics, Inc. (NasdaqCM:STML), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), Cytosorbents Corporation (NasdaqCM:CTSO), PolarityTE, Inc. (NasdaqCM:PTE), iCAD, Inc. (NasdaqCM:ICAD), Spring Bank Pharmaceuticals, Inc. (NasdaqCM:SBPH), OncoSec Medical Incorporated (NasdaqCM:ONCS), ContraFect Corporation (NasdaqCM:CFRX), Novus Therapeutics, Inc. (NasdaqCM:NVUS), Motus GI Holdings, Inc. (NasdaqCM:MOTS), BioXcel Therapeutics, Inc. (NasdaqCM:BTAI), Baudax Bio, Inc. (NasdaqCM:BXRX), NeuBase Therapeutics, Inc. (NasdaqCM:NBSE), vTv Therapeutics Inc. (NasdaqCM:VTVT), Edesa Biotech, Inc. (NasdaqCM:EDSA), Oncternal Therapeutics, Inc. (NasdaqCM:ONCT), Immunic, Inc. (NasdaqCM:IMUX), Sensei Biotherapeutics, Inc., CureVac AG, EarlySense Ltd., Diasome Pharmaceuticals, Inc., ArunA Biomedical, Inc., FORMA Therapeutics, Inc., Luc Therapeutics, Inc., Knopp Biosciences LLC, Sonendo, Inc., Sight Sciences, Inc., NexImmune, Inc., Alcyone Lifesciences, Inc., Iteos Therapeutics S.A., Audentes Therapeutics, Inc., Progenity, Inc., Compass Therapeutics LLC, ORIC Pharmaceuticals, Inc., Caris Life Sciences, Inc., StemoniX Inc., Teewinot Life Sciences Corp., Oncorus, Inc., Kleo Pharmaceuticals, Inc., Axial Biotherapeutics, Inc., Cerevance LLC, Landos Biopharma, Inc., CARISMA Therapeutics Inc., KSQ Therapeutics, Inc., Akoya Biosciences, Inc., Orchestra BioMed, Inc., Passage Bio, Inc., Cellibre, Inc., Nurix Therapeutics, Inc, Boundless Bio, Inc., Hutchison China MediTech Limited (AIM:HCM), Avadel Pharmaceuticals plc (NasdaqGM:AVDL), Curis, Inc. (NasdaqGM:CRIS), Pfenex Inc. (AMEX:PFNX), Matinas BioPharma Holdings, Inc. (AMEX:MTNB), Kiadis Pharma N.V. (ENXTAM:KDS), Itamar Medical Ltd. (TASE:ITMR), Cellectis S.A. (ENXTPA:ALCLS), argenx SE (ENXTBR:ARGX), Hamilton Thorne Ltd. (TSXV:HTL), Aptose Biosciences Inc. (TSX:APS), Titan Medical Inc. (TSX:TMD), IMV Inc. (TSX:IMV), Theratechnologies Inc. (TSX:TH), Liminal BioSciences Inc. (TSX:LMNL), Correvio Pharma Corp. (TSX:CORV), Greenbrook TMS Inc. (TSX:GTMS), Viemed Healthcare, Inc. (TSX:VMD), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Synlogic, Inc. (NasdaqGM:SYBX), Eloxx Pharmaceuticals, Inc. (NasdaqGM:ELOX), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Adverum Biotechnologies, Inc. (NasdaqGM:ADVM), Personalis, Inc. (NasdaqGM:PSNL), Protagonist Therapeutics, Inc. (NasdaqGM:PTGX), Karuna Therapeutics, Inc. (NasdaqGM:KRTX), Ardelyx, Inc. (NasdaqGM:ARDX), Castle Biosciences, Inc. (NasdaqGM:CSTL), SI-BONE, Inc. (NasdaqGM:SIBN), Sensus Healthcare, Inc. (NasdaqGM:SRTS), Proteostasis Therapeutics, Inc. (NasdaqGM:PTI), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS), Neoleukin Therapeutics, Inc. (NasdaqGM:NLTX), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), OrthoPediatrics Corp. (NasdaqGM:KIDS), Intersect ENT, Inc. (NasdaqGM:XENT), Apollo Endosurgery, Inc. (NasdaqGM:APEN), Sutro Biopharma, Inc. (NasdaqGM:STRO), Fate Therapeutics, Inc. (NasdaqGM:FATE), Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA), Ocular Therapeutix, Inc. (NasdaqGM:OCUL), ViewRay, Inc. (NasdaqGM:VRAY), Zogenix, Inc. (NasdaqGM:ZGNX), Oxford Immunotec Global PLC (NasdaqGM:OXFD), Lantheus Holdings, Inc. (NasdaqGM:LNTH), Exagen Inc. (NasdaqGM:XGN), MannKind Corporation (NasdaqGM:MNKD), CareDx, Inc (NasdaqGM:CDNA), Marker Therapeutics, Inc. (NasdaqGM:MRKR), Xencor, Inc. (NasdaqGM:XNCR), Neuronetics, Inc. (NasdaqGM:STIM), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), GlycoMimetics, Inc. (NasdaqGM:GLYC), GW Pharmaceuticals plc (NasdaqGM:GWPH), Tactile Systems Technology, Inc. (NasdaqGM:TCMD), Foamix Pharmaceuticals Ltd. (NasdaqGM:FOMX), AtriCure, Inc. (NasdaqGM:ATRC), Gamida Cell Ltd. (NasdaqGM:GMDA), Xenon Pharmaceuticals Inc. (NasdaqGM:XENE), Rockwell Medical, Inc. (NasdaqGM:RMTI), Misonix, Inc. (NasdaqGM:MSON), Immunomedics, Inc. (NasdaqGM:IMMU), Fulcrum Therapeutics, Inc. (NasdaqGM:FULC), Krystal Biotech, Inc. (NasdaqGM:KRYS), Alpine Immune Sciences, Inc. (NasdaqGM:ALPN), Fulgent Genetics, Inc. (NasdaqGM:FLGT), Aeglea BioTherapeutics, Inc. (NasdaqGM:AGLE), CRISPR Therapeutics AG (NasdaqGM:CRSP), Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), Integer Holdings Corporation (NYSE:ITGR), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Bausch Health Companies Inc. (NYSE:BHC), Agilent Technologies, Inc. (NYSE:A), Teleflex Incorporated (NYSE:TFX), Varian Medical Systems, Inc. (NYSE:VAR), Boston Scientific Corporation (NYSE:BSX), Piper Sandler Companies (NYSE:PIPR), Piper Sandler Companies (NYSE:PIPR), Glaukos Corporation (NYSE:GKOS), Teladoc Health, Inc. (NYSE:TDOC), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Inspire Medical Systems, Inc. (NYSE:INSP), Invitae Corporation (NYSE:NVTA), Evolent Health, Inc. (NYSE:EVH), Mallinckrodt plc (NYSE:MNK), GTX Corp (OTCPK:GTXO), MorphoSys AG (XTRA:MOR)Piper Jaffray Companies, Piper Jaffray 31st Annual Healthcare Conference, Dec 03, 2019 through Dec 05, 2019. Venue: The Lotte New York Palace, 455 Madison Avenue, New York, New York, United States.
11
12/31/201915.43x44.23x50.07x78.71x72.63x$67,742$586.002.10%Nov-26-2019Product-Related AnnouncementIntuitive Announces U.S. Food and Drug Administration Clearance of Two Innovative Technologies-Intuitive announced U.S. Food and Drug Administration clearance of two innovative technologies for two of the company’s da Vinci® surgical systems to help improve procedures that require sealing. The company's E-100 generator is its first internally developed robotic generator to power two key instruments on the da Vinci X® and Xi™ systems. Vessel Sealer Extend is the instrument in the da Vinci energy sealing portfolio today, and the new SynchroSeal instrument offers enhanced capabilities in general surgery. The E-100 is Intuitive’s first generator and is offered as an upgrade to power Vessel Sealer Extend and SynchroSeal. SynchroSeal will enable a surgeon to perform rapid one-step sealing and transection with a single pedal press. SynchroSeal uses advanced bipolar energy from its raised cut electrode to transect tissue then cool down quickly, and will allow surgeons to move on to the next step. With its wristed articulation, its rapid sealing cycle, and refined curved jaw, SynchroSeal offers enhanced versatility to the da Vinci Energy portfolio.
12
12/31/201915.43x44.23x50.07x78.71x72.63x$64,311$556.327.54%Oct-30-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at The Future is now: How Digital Workers & AI are Reshaping Life Sciences, Oct-30-2019 11:00 AM-Intuitive Surgical, Inc. Presents at The Future is now: How Digital Workers & AI are Reshaping Life Sciences, Oct-30-2019 11:00 AM. Speakers: Sivakumar Narayanan, Center of Excellence Lead.
13
12/31/201915.43x44.23x50.07x78.71x72.63x$64,311$556.327.54%Oct-30-2019ConferenceInforma plc, the Future is now: How Digital Workers & AI are Reshaping Life Sciences, Oct 30, 2019Informa plc (LSE:INF), Informa plc (LSE:INF), Automation Anywhere, Inc.Informa plc, The Future is now: How Digital Workers & AI are Reshaping Life Sciences, Oct 30, 2019.
14
12/31/201915.43x44.23x50.07x78.71x72.63x$64,293$556.177.57%Oct-29-2019Client AnnouncementIntuitive Surgical Limited Wins GBP 397 258.90 Contract-Intuitive Surgical Ltd. won a GBP397 258.90 contract award from University Hospitals of North Midlands NHS Trust for Provision of Instrumentation for Da Vinci Robot (Contract Award Notice No.: 2019/S 206-501751).
15
12/31/201915.43x44.23x50.07x78.71x72.63x$65,459$566.255.66%Oct-18-2019Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From July 1, 2019 to September 30, 2019, the company has repurchased 141,081 shares, representing 0.12% for $69.54 million. With this, the company has completed the repurchase of 9,196,189 shares, representing 7.95% for $2,495.79 million under the buyback announced on February 2, 2015.
16
12/31/201915.43x44.23x50.07x78.71x72.63x$61,199$529.4013.01%Oct-17-2019Earnings CallIntuitive Surgical, Inc., Q3 2019 Earnings Call, Oct 17, 2019-Intuitive Surgical, Inc., Q3 2019 Earnings Call, Oct 17, 2019
17
12/31/201915.43x44.23x50.07x78.71x72.63x$61,199$529.4013.01%Oct-17-2019Announcement of EarningsIntuitive Surgical, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019-Intuitive Surgical, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced total revenue was USD 1,128.2 million compared to USD 920.9 million a year ago. Operating income was USD 365.7 million compared to USD 313.3 million a year ago. Net income was USD 396.8 million compared to USD 292.5 million a year ago. Basic earnings per share was USD 3.44 compared to USD 2.57 a year ago. Diluted earnings per share was USD 3.33 compared to USD 2.45 a year ago. For the nine months, total revenue was USD 3,200.8 million compared to USD 2,677.7 million a year ago. Operating income was USD 976.9 million compared to USD 867.4 million a year ago. Net income was USD 1,021.6 million compared to USD 835.4 million a year ago. Basic earnings per share was USD 8.86 compared to USD 7.37 a year ago. Diluted earnings per share was USD 8.56 compared to USD 7.04 a year ago.
18
9/30/201914.75x42.36x47.53x75.09x75.98x$57,417$496.6920.46%Sep-9-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at Morgan Stanley 17th Annual Global Healthcare Conference, Sep-09-2019 03:40 PM-Intuitive Surgical, Inc. Presents at Morgan Stanley 17th Annual Global Healthcare Conference, Sep-09-2019 03:40 PM. Venue: Grand Hyatt New York, 109 E.42nd St., New York, New York, United States. Speakers: Jamie E. Samath, VP, Corporate Controller & Principal Accounting Officer.
19
9/30/201914.75x42.36x47.53x75.09x75.98x$57,417$496.6920.46%Sep-09-2019ConferenceMorgan Stanley, Morgan Stanley 17th Annual Global Healthcare Conference, Sep 09, 2019 through Sep 11, 2019Scholar Rock Holding Corporation (NasdaqGS:SRRK), Allogene Therapeutics, Inc. (NasdaqGS:ALLO), Autolus Therapeutics plc (NasdaqGS:AUTL), Akero Therapeutics, Inc. (NasdaqGS:AKRO), Change Healthcare Inc. (NasdaqGS:CHNG), Unity Biotechnology, Inc. (NasdaqGS:UBX), AVROBIO, Inc. (NasdaqGS:AVRO), Forty Seven, Inc. (NasdaqGS:FTSV), Evelo Biosciences, Inc. (NasdaqGS:EVLO), Orchard Therapeutics plc (NasdaqGS:ORTX), Kaleido BioSciences, Inc. (NasdaqGS:KLDO), Rubius Therapeutics, Inc. (NasdaqGS:RUBY), NextCure, Inc. (NasdaqGS:NXTC), Alector, Inc. (NasdaqGS:ALEC), Twist Bioscience Corporation (NasdaqGS:TWST), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Editas Medicine, Inc. (NasdaqGS:EDIT), ShockWave Medical, Inc. (NasdaqGS:SWAV), Denali Therapeutics Inc. (NasdaqGS:DNLI), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), Axonics Modulation Technologies, Inc. (NasdaqGS:AXNX), Livongo Health, Inc. (NasdaqGS:LVGO), Unum Therapeutics Inc. (NasdaqGS:UMRX), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), MyoKardia, Inc. (NasdaqGS:MYOK), Allena Pharmaceuticals, Inc. (NasdaqGS:ALNA), uniQure N.V. (NasdaqGS:QURE), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Xeris Pharmaceuticals, Inc. (NasdaqGS:XERS), Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS), BeiGene, Ltd. (NasdaqGS:BGNE), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Moderna, Inc. (NasdaqGS:MRNA), Blueprint Medicines Corporation (NasdaqGS:BPMC), REGENXBIO Inc. (NasdaqGS:RGNX), Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX), Natera, Inc. (NasdaqGS:NTRA), Nabriva Therapeutics plc (NasdaqGS:NBRV), Athenex, Inc. (NasdaqGS:ATNX), iRhythm Technologies, Inc. (NasdaqGS:IRTC), Ascendis Pharma A/S (NasdaqGS:ASND), NuCana plc (NasdaqGS:NCNA), Epizyme, Inc. (NasdaqGS:EPZM), Inovalon Holdings, Inc. (NasdaqGS:INOV), ICU Medical, Inc. (NasdaqGS:ICUI), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Anika Therapeutics, Inc. (NasdaqGS:ANIK), Incyte Corporation (NasdaqGS:INCY), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), CONMED Corporation (NasdaqGS:CNMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Inogen, Inc. (NasdaqGS:INGN), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), Cardiovascular Systems, Inc. (NasdaqGS:CSII), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Fluidigm Corporation (NasdaqGS:FLDM), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), Amgen Inc. (NasdaqGS:AMGN), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Cytokinetics, Incorporated (NasdaqGS:CYTK), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Biogen Inc. (NasdaqGS:BIIB), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Masimo Corporation (NasdaqGS:MASI), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), NxStage Medical, Inc., Alder BioPharmaceuticals, Inc., Luc Therapeutics, Inc., Audentes Therapeutics, Inc., Caris Life Sciences, Inc., Passage Bio, Inc., Greenwich Biosciences, Inc, Gilmartin Group LLC, Koninklijke Philips N.V. (ENXTAM:PHIA), Vifor Pharma AG (SWX:VIFN), Roche Holding AG (SWX:ROG), Alcon, Inc. (SWX:ALC), Lonza Group Ltd (SWX:LONN), Hansa Biopharma AB (publ) (OM:HNSA), Hutchison China MediTech Limited (AIM:HCM), AstraZeneca PLC (LSE:AZN), Takeda Pharmaceutical Company Limited (TSE:4502), Dr. Reddy's Laboratories Limited (BSE:500124), Sanofi (ENXTPA:SAN), ERYTECH Pharma S.A. (ENXTPA:ERYP), Coloplast A/S (CPSE:COLO B), Zealand Pharma A/S (CPSE:ZEAL), ALK-Abelló A/S (CPSE:ALK B), Odontoprev S.A. (BOVESPA:ODPV3), argenx SE (ENXTBR:ARGX), CryoLife, Inc. (NYSE:CRY), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Fresenius SE & Co. KGaA (XTRA:FRE), Sartorius Aktiengesellschaft (XTRA:SRT), Hill-Rom Holdings, Inc. (NYSE:HRC), AmerisourceBergen Corporation (NYSE:ABC), Bristol-Myers Squibb Company (NYSE:BMY), Laboratory Corporation of America Holdings (NYSE:LH), Medtronic plc (NYSE:MDT), Waters Corporation (NYSE:WAT), Charles River Laboratories International, Inc. (NYSE:CRL), CVS Health Corporation (NYSE:CVS), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), Emergent BioSolutions Inc. (NYSE:EBS), Morgan Stanley (NYSE:MS), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Teleflex Incorporated (NYSE:TFX), West Pharmaceutical Services, Inc. (NYSE:WST), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), QIAGEN N.V. (NYSE:QGEN), STERIS plc (NYSE:STE), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), Baxter International Inc. (NYSE:BAX), Quest Diagnostics Incorporated (NYSE:DGX), Perrigo Company plc (NYSE:PRGO), Penumbra, Inc. (NYSE:PEN), Avantor, Inc. (NYSE:AVTR), Quorum Health Corporation (NYSE:QHC), Arcus Biosciences, Inc. (NYSE:RCUS), Evolent Health, Inc. (NYSE:EVH), Mallinckrodt plc (NYSE:MNK), Avanos Medical, Inc. (NYSE:AVNS), AbbVie Inc. (NYSE:ABBV), Zoetis Inc. (NYSE:ZTS), Catalent, Inc. (NYSE:CTLT), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Nevro Corp. (NYSE:NVRO), Vocera Communications, Inc. (NYSE:VCRA), Elanco Animal Health Incorporated (NYSE:ELAN), Immunomedics, Inc. (NasdaqGM:IMMU), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), TransMedics Group, Inc. (NasdaqGM:TMDX), Phibro Animal Health Corporation (NasdaqGM:PAHC), NanoString Technologies, Inc. (NasdaqGM:NSTG), Radius Health, Inc. (NasdaqGM:RDUS), Revance Therapeutics, Inc. (NasdaqGM:RVNC), AtriCure, Inc. (NasdaqGM:ATRC), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), GlycoMimetics, Inc. (NasdaqGM:GLYC), GW Pharmaceuticals plc (NasdaqGM:GWPH), Tactile Systems Technology, Inc. (NasdaqGM:TCMD), Cerus Corporation (NasdaqGM:CERS), ViewRay, Inc. (NasdaqGM:VRAY), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), Veracyte, Inc. (NasdaqGM:VCYT), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), SI-BONE, Inc. (NasdaqGM:SIBN), Personalis, Inc. (NasdaqGM:PSNL), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Wave Life Sciences Ltd. (NasdaqGM:WVE), Axsome Therapeutics, Inc. (NasdaqGM:AXSM), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Rhythm Pharmaceuticals, Inc. (NasdaqGM:RYTM), Fulcrum Therapeutics, Inc. (NasdaqGM:FULC), Kodiak Sciences Inc. (NasdaqGM:KOD), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), Prevail Therapeutics Inc. (NasdaqGM:PRVL), Vericel Corporation (NasdaqCM:VCEL), IRadimed Corporation (NasdaqCM:IRMD), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), NeoGenomics, Inc. (NasdaqCM:NEO), Corcept Therapeutics Incorporated (NasdaqCM:CORT), Veru Inc. (NasdaqCM:VERU), Option Care Health, Inc. (NasdaqCM:BIOS), Viking Therapeutics, Inc. (NasdaqCM:VKTX), Establishment Labs Holdings Inc. (NasdaqCM:ESTA)Morgan Stanley, Morgan Stanley 17th Annual Global Healthcare Conference, Sep 09, 2019 through Sep 11, 2019. Venue: Grand Hyatt New York, 109 E.42nd St., New York, New York, United States.
20
9/30/201914.75x42.36x47.53x75.09x75.98x$57,363$496.2220.57%Sep-04-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at 14th Annual Wells Fargo Securities Healthcare Conference, Sep-04-2019 08:30 AM-Intuitive Surgical, Inc. Presents at 14th Annual Wells Fargo Securities Healthcare Conference, Sep-04-2019 08:30 AM. Venue: Westin Copley Place, 10 Huntington Ave., Boston, Massachusetts, United States. Speakers: Calvin Darling, Senior Director of IR, Marshall L. Mohr, Executive VP & CFO.
21
9/30/201914.75x42.36x47.53x75.09x75.98x$57,363$496.2220.57%Sep-04-2019ConferenceWells Fargo Securities, LLC, 14th Annual Wells Fargo Securities Healthcare Conference, Sep 04, 2019 through Sep 05, 2019Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Premier, Inc. (NasdaqGS:PINC), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Wright Medical Group N.V. (NasdaqGS:WMGI), Cerner Corporation (NasdaqGS:CERN), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Natus Medical Incorporated (NasdaqGS:NTUS), NuVasive, Inc. (NasdaqGS:NUVA), Omnicell, Inc. (NasdaqGS:OMCL), HMS Holdings Corp. (NasdaqGS:HMSY), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Kezar Life Sciences, Inc. (NasdaqGS:KZR), AVROBIO, Inc. (NasdaqGS:AVRO), SeaSpine Holdings Corporation (NasdaqGS:SPNE), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Autolus Therapeutics plc (NasdaqGS:AUTL), HOOKIPA Pharma Inc. (NasdaqGS:HOOK), Osmotica Pharmaceuticals plc (NasdaqGS:OSMT), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Conformis, Inc. (NasdaqGS:CFMS), HealthEquity, Inc. (NasdaqGS:HQY), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Computer Programs and Systems, Inc. (NasdaqGS:CPSI), Ascendis Pharma A/S (NasdaqGS:ASND), Precision BioSciences, Inc. (NasdaqGS:DTIL), Clovis Oncology, Inc. (NasdaqGS:CLVS), NovoCure Limited (NasdaqGS:NVCR), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), Xeris Pharmaceuticals, Inc. (NasdaqGS:XERS), Calithera Biosciences, Inc. (NasdaqGS:CALA), ShockWave Medical, Inc. (NasdaqGS:SWAV), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), Axonics Modulation Technologies, Inc. (NasdaqGS:AXNX), Jounce Therapeutics, Inc. (NasdaqGS:JNCE), Principia Biopharma Inc. (NasdaqGS:PRNB), Moderna, Inc. (NasdaqGS:MRNA), uniQure N.V. (NasdaqGS:QURE), MyoKardia, Inc. (NasdaqGS:MYOK), Teladoc Health, Inc. (NYSE:TDOC), Select Medical Holdings Corporation (NYSE:SEM), Emergent BioSolutions Inc. (NYSE:EBS), Globus Medical, Inc. (NYSE:GMED), Triple-S Management Corporation (NYSE:GTS), Glaukos Corporation (NYSE:GKOS), Inspire Medical Systems, Inc. (NYSE:INSP), Mallinckrodt plc (NYSE:MNK), Evolent Health, Inc. (NYSE:EVH), Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), Zymeworks Inc. (NYSE:ZYME), Penumbra, Inc. (NYSE:PEN), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Centene Corporation (NYSE:CNC), Hanger, Inc. (NYSE:HNGR), Medtronic plc (NYSE:MDT), Baxter International Inc. (NYSE:BAX), Universal Health Services, Inc. (NYSE:UHS), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Johnson & Johnson (NYSE:JNJ), Anthem, Inc. (NYSE:ANTM), Cigna Corporation (NYSE:CI), MAXIMUS, Inc. (NYSE:MMS), Abbott Laboratories (NYSE:ABT), HCA Healthcare, Inc. (NYSE:HCA), The Cooper Companies, Inc. (NYSE:COO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Service Corporation International (NYSE:SCI), Teleflex Incorporated (NYSE:TFX), Boston Scientific Corporation (NYSE:BSX), Vocera Communications, Inc. (NYSE:VCRA), Edwards Lifesciences Corporation (NYSE:EW), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Affimed N.V. (NasdaqGM:AFMD), Immunomedics, Inc. (NasdaqGM:IMMU), SIGA Technologies, Inc. (NasdaqGM:SIGA), IRIDEX Corporation (NasdaqGM:IRIX), Fate Therapeutics, Inc. (NasdaqGM:FATE), TRACON Pharmaceuticals, Inc. (NasdaqGM:TCON), Ocular Therapeutix, Inc. (NasdaqGM:OCUL), Veracyte, Inc. (NasdaqGM:VCYT), Evolus, Inc. (NasdaqGM:EOLS), Flexion Therapeutics, Inc. (NasdaqGM:FLXN), Karuna Therapeutics, Inc. (NasdaqGM:KRTX), Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA), MediWound Ltd. (NasdaqGM:MDWD), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), Neos Therapeutics, Inc. (NasdaqGM:NEOS), Applied Genetic Technologies Corporation (NasdaqGM:AGTC), Benefitfocus, Inc. (NasdaqGM:BNFT), Lantheus Holdings, Inc. (NasdaqGM:LNTH), Revance Therapeutics, Inc. (NasdaqGM:RVNC), Oxford Immunotec Global PLC (NasdaqGM:OXFD), Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM), Theravance Biopharma, Inc. (NasdaqGM:TBPH), CRISPR Therapeutics AG (NasdaqGM:CRSP), Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC), Mustang Bio, Inc. (NasdaqGM:MBIO), Morphic Holding, Inc. (NasdaqGM:MORF), C. R. Bard, Inc., Wells Fargo Securities, LLC, Wells Fargo Securities, LLC, OMNI life science, Inc., Alder BioPharmaceuticals, Inc., RxSight, Inc., Impulse Dynamics LLC, Optum, Inc., Rodin Therapeutics Inc., Akouos, Inc., Aveta Biomics, Inc, Relay Therapeutics, Inc., InterWest Partners LLC, Titan Medical Inc. (TSX:TMD), IMV Inc. (TSX:IMV), Ellex Medical Lasers Limited (ASX:ELX), Celyad SA (ENXTBR:CYAD), Novartis AG (SWX:NOVN), Alcon, Inc. (SWX:ALC), TransEnterix, Inc. (AMEX:TRXC), Cellectis S.A. (ENXTPA:ALCLS), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), Regulus Therapeutics Inc. (NasdaqCM:RGLS), MEI Pharma, Inc. (NasdaqCM:MEIP), Second Sight Medical Products, Inc. (NasdaqCM:EYES), Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT), Evofem Biosciences, Inc. (NasdaqCM:EVFM)Wells Fargo Securities, LLC, 14th Annual Wells Fargo Securities Healthcare Conference, Sep 04, 2019 through Sep 05, 2019. Venue: Westin Copley Place, 10 Huntington Ave., Boston, Massachusetts, United States.
22
9/30/201914.75x42.36x47.53x75.09x75.98x$0Aug-31-2019M&A Transaction ClosingIntuitive Surgical, Inc. (NasdaqGS:ISRG) completed the acquisition of robotic endoscope business from Schölly Fiberoptic GmbH for approximately $110 million.Schölly Fiberoptic GmbH, Robotic Endoscope Business of Schölly Fiberoptic GmbHIntuitive Surgical, Inc. (NasdaqGS:ISRG) entered into agreement to acquire robotic endoscope business from Schölly Fiberoptic GmbH on July 15, 2019. This acquisition will integrate Schölly’s robotic endoscope manufacturing line, and two Schölly sites into Intuitive operations: the robotic-related manufacturing line from Denzlingen, Germany; the manufacturing site in Biebertal, Germany; and the repair site in Worcester, Mass., USA. Intuitive will welcome and integrate into its team approximately 200 staff from these three sites over the next 18 months. The closing of the Schölly Acquisition is subject to certain substantive closing conditions.

Elisabeth Rotheaicher, Andreas Thun, Tim Joppich and Falk Loose of Hogan Lovells acted as a legal advisors to Intuitive Surgical, Inc.


Intuitive Surgical, Inc. (NasdaqGS:ISRG) completed the acquisition of robotic endoscope business from Schölly Fiberoptic GmbH for approximately $110 million on August 31, 2019.
23
9/30/201914.75x42.36x47.53x75.09x75.98x$61,223$529.6112.97%Jul-29-2019Executive/Board Change - OtherIntuitive Surgical, Inc. Appoints Amy L. Ladd to Board of Directors, Effective August 1, 2019-Intuitive Surgical, Inc. announced the appointment of Amy L. Ladd, M.D., from Stanford University Medical Center to its board of directors, effective August 1, 2019. Dr. Ladd has spent nearly three decades practicing orthopaedic surgery at Stanford University, specializing in hand surgery and research focused on deciphering the progression and treatment of common basilar thumb arthritis. She currently serves as the Elsbach-Richards Professor of Surgery, and by courtesy, Professor of Medicine (Immunology & Rheumatology) at the Stanford University Medical Center. She holds ten patents and trademarks for innovation that include treatment for wrist fractures, thumb arthritis and that promote musculoskeletal health awareness. Dr. Ladd also served as the chair of the American Academy of Orthopaedic Surgeons (AAOS) Board of Specialties Society and is a past member of the AAOS board of directors. She previously served as president of the Ruth Jackson Orthopaedic Society.
24
9/30/201914.75x42.36x47.53x75.09x75.98x$61,463$531.6912.53%Jul-25-2019Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $2.17216 billion.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $2.17216 billion.

Security Name: Common Stock
Securities Offered: 4,000,000
Transaction Features: ESOP Related Offering
25
9/30/201914.75x42.36x47.53x75.09x75.98x$62,034$536.6311.49%Jul-18-2019Earnings CallIntuitive Surgical, Inc., Q2 2019 Earnings Call, Jul 18, 2019-Intuitive Surgical, Inc., Q2 2019 Earnings Call, Jul 18, 2019
26
9/30/201914.75x42.36x47.53x75.09x75.98x$62,034$536.6311.49%Jul-18-2019Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From April 1, 2019 to June 30, 2019, the company has repurchased 418,918 shares, representing 0.36% for $200 million. With this, the company has completed the repurchase of 9,055,108 shares, representing 7.83% for $2,426.25 million under the buyback announced on February 2, 2015.
27
9/30/201914.75x42.36x47.53x75.09x75.98x$62,034$536.6311.49%Jul-18-2019Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2019-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2019. For the quarter, the company reported total revenue of $1,098.9 million against $909.3 million a year ago. Income from operations was $359.0 million against $277.4 million a year ago. Net income was $316.4 million against $254.6 million a year ago. Basic net income per share attributable to the company was $2.76 against $2.25 per share a year ago. Diluted net income per share attributable to the company was $2.67 against $2.15 per share a year ago.

For the six months, the company reported total revenue of $2,072.6 million against $1,756.8 million a year ago. Income from operations was $611.2 million against $554.1 million a year ago. Net income was $620.4 million against $541.9 million a year ago. Basic net income per share attributable to the company was $5.42 against $4.80 per share a year ago. Diluted net income per share attributable to the company was $5.23 against $4.59 per share a year ago.
28
9/30/201914.75x42.36x47.53x75.09x75.98x$61,008$527.7513.37%Jul-15-2019M&A Transaction AnnouncementIntuitive Surgical, Inc. (NasdaqGS:ISRG) entered into agreement to acquire robotic endoscope business from Schölly Fiberoptic GmbH.Schölly Fiberoptic GmbH, Robotic Endoscope Business of Schölly Fiberoptic GmbHIntuitive Surgical, Inc. (NasdaqGS:ISRG) entered into agreement to acquire robotic endoscope business from Schölly Fiberoptic GmbH on July 15, 2019. This acquisition will integrate Schölly’s robotic endoscope manufacturing line, and two Schölly sites into Intuitive operations: the robotic-related manufacturing line from Denzlingen, Germany; the manufacturing site in Biebertal, Germany; and the repair site in Worcester, Mass., USA. Intuitive will welcome and integrate into its team approximately 200 staff from these three sites over the next 18 months. The closing of the Schölly Acquisition is subject to certain substantive closing conditions.

Elisabeth Rotheaicher, Andreas Thun, Tim Joppich and Falk Loose of Hogan Lovells acted as a legal advisors to Intuitive Surgical, Inc.
29
9/30/201914.75x42.36x47.53x75.09x75.98x$61,962$536.0011.62%Jul-11-2019Executive/Board Change - OtherIntuitive Surgical, Inc. Announces Transition of Salvatore J. Brogna from Executive Vice President and Chief Operating Officer to Serve as Consultant and Advisor-On July 11, 2019, Intuitive Surgical, Inc. announced that Salvatore J. Brogna will transition from his role as Executive Vice President and Chief Operating Officer in 2019 and plans to serve as a consultant and advisor to the Company starting in 2020 on terms and conditions to be agreed between the Company and Mr. Brogna. Brogna joined Intuitive in October 1999 and held a number of key roles in the organization over the course of his career, including Executive Vice President of Product Operations, Senior Vice President of Product Development and Vice President of Engineering. Prior to joining Intuitive, Brogna led design and development of complex robotic systems for commercial and industrial use. Business unit general managers will report to Intuitive's CEO as part of Brogna's transition.
30
6/30/201915.02x42.84x47.61x75.94x79.60x$59,591$517.2815.66%Jun-18-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at Gartner Supply Chain Executive Conferences, Jun-18-2019 12:45 PM-Intuitive Surgical, Inc. Presents at Gartner Supply Chain Executive Conferences, Jun-18-2019 12:45 PM. Venue: Palau de Congressos de Catalunya, Avinguda Diagonal, 661-671, Barcelona, Spain. Speakers: Ana Maia, Business Development Manager.
31
6/30/201915.02x42.84x47.61x75.94x79.60x$0Jun-16-2019ConferenceGartner, Inc., Gartner Supply Chain Executive Conferences, Jun 17, 2019 through Jun 19, 2019Cisco Systems, Inc. (NasdaqGS:CSCO), Intel Corporation (NasdaqGS:INTC), Manhattan Associates, Inc. (NasdaqGS:MANH), Domo, Inc. (NasdaqGM:DOMO), Gartner, Inc. (NYSE:IT), Gartner, Inc. (NYSE:IT), HP Inc. (NYSE:HPQ), International Business Machines Corporation (NYSE:IBM), Johnson & Johnson (NYSE:JNJ), Colgate-Palmolive Company (NYSE:CL), The Procter & Gamble Company (NYSE:PG), Oracle Corporation (NYSE:ORCL), SAP SE (XTRA:SAP), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Henkel AG & Co. KGaA (XTRA:HEN3), Bayer Aktiengesellschaft (XTRA:BAYN), Lenzing Aktiengesellschaft (WBAG:LNZ), Loblaw Companies Limited (TSX:L), Kinaxis Inc. (TSX:KXS), A.P. Møller - Mærsk A/S (CPSE:MAERSK B), Danone S.A. (ENXTPA:BN), Airbus SE (ENXTPA:AIR), Schneider Electric S.E. (ENXTPA:SU), Sanofi (ENXTPA:SAN), L'Oréal S.A. (ENXTPA:OR), Diageo plc (LSE:DGE), Husqvarna AB (publ) (OM:HUSQ B), AB Electrolux (publ) (OM:ELUX B), JDA Software Group, Inc., Ernst & Young LLP, E2open, LLC, Robert Bosch GmbH, Data Systems International, Inc., CargoSmart Limited, IKEA AB, Barilla G. e R. Fratelli S.p.A., Magna Steyr Fahrzeugtechnik AG & Co. KG, MANN + HUMMEL Holding GmbH, Instituto de Empresa, Natural Factors Nutritional Products Ltd., BOARD International S.A., HealthSmart Holdings, Inc., Air France Industries and KLM Engineering & Maintenance, Transalis Ltd., Aera Technology, Inc., TRANSPOREON GmbH, Oliver Wight EAME LLP, Orchestr8 Ltd., Logistyx Technologies, LLC, Avetta, LLC, Blume Global Inc., IBM Europe, Circle K Stores Inc., Shippeo SAS, Project44, Inc., The Linde Group, Inc., GE Renewable Energy, The WOW Factor, Inc., SupplyStack, Bluecrux CVBA, Sixfold GmbH, BluJay Solutions Ltd, Amber Road, Inc., Infor (US), Inc., Bacardi LimitedGartner, Inc., Gartner Supply Chain Executive Conferences, Jun 17, 2019 through Jun 19, 2019. Venue: Palau de Congressos de Catalunya, Avinguda Diagonal, 661-671, Barcelona, Spain.
32
6/30/201915.02x42.84x47.61x75.94x79.60x$56,143$487.3522.76%May-14-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-14-2019 01:00 PM-Intuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-14-2019 01:00 PM. Venue: Encore Hotel, Wynn, Las Vegas, Nevada, United States. Speakers: Marshall L. Mohr, Executive VP & CFO.
33
6/30/201915.02x42.84x47.61x75.94x79.60x$56,143$487.3522.76%May-14-2019ConferenceBank of America Corporation, Bank of America Merrill Lynch 2019 Healthcare Conference, May 14, 2019 through May 16, 2019Eidos Therapeutics, Inc. (NasdaqGS:EIDX), Gossamer Bio, Inc. (NasdaqGS:GOSS), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Illumina, Inc. (NasdaqGS:ILMN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Wright Medical Group N.V. (NasdaqGS:WMGI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), LHC Group, Inc. (NasdaqGS:LHCG), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Intrexon Corporation (NasdaqGS:XON), Nabriva Therapeutics plc (NasdaqGS:NBRV), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), R1 RCM Inc. (NasdaqGS:RCM), AnaptysBio, Inc. (NasdaqGS:ANAB), Ascendis Pharma A/S (NasdaqGS:ASND), Surgery Partners, Inc. (NasdaqGS:SGRY), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Principia Biopharma Inc. (NasdaqGS:PRNB), Moderna, Inc. (NasdaqGS:MRNA), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Blueprint Medicines Corporation (NasdaqGS:BPMC), REGENXBIO Inc. (NasdaqGS:RGNX), CytomX Therapeutics, Inc. (NasdaqGS:CTMX), Clovis Oncology, Inc. (NasdaqGS:CLVS), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), MyoKardia, Inc. (NasdaqGS:MYOK), Spero Therapeutics, Inc. (NasdaqGS:SPRO), CONMED Corporation (NasdaqGS:CNMD), Hologic, Inc. (NasdaqGS:HOLX), Quidel Corporation (NasdaqGS:QDEL), Bio-Techne Corporation (NasdaqGS:TECH), Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Incyte Corporation (NasdaqGS:INCY), Brooks Automation, Inc. (NasdaqGS:BRKS), Henry Schein, Inc. (NasdaqGS:HSIC), Nuance Communications, Inc. (NasdaqGS:NUAN), Amedisys, Inc. (NasdaqGS:AMED), Mylan N.V. (NasdaqGS:MYL), Align Technology, Inc. (NasdaqGS:ALGN), Amgen Inc. (NasdaqGS:AMGN), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Neon Therapeutics, Inc. (NasdaqGS:NTGN), Alector, Inc. (NasdaqGS:ALEC), ShockWave Medical, Inc. (NasdaqGS:SWAV), Guardant Health, Inc. (NasdaqGS:GH), Axonics Modulation Technologies, Inc. (NasdaqGS:AXNX), NantKwest, Inc. (NasdaqGS:NK), Y-mAbs Therapeutics, Inc. (NasdaqGS:YMAB), MeiraGTx Holdings plc (NasdaqGS:MGTX), resTORbio, Inc. (NasdaqGS:TORC), Homology Medicines, Inc. (NasdaqGS:FIXX), Kura Oncology, Inc. (NasdaqGS:KURA), Array BioPharma Inc., The Medicines Company, Schrödinger, Inc., Avedro, Inc., SetPoint Medical Corporation, Audentes Therapeutics, Inc., Caris Life Sciences, Inc., Roche Holding AG (SWX:ROG), Alcon, Inc. (SWX:ALC), Vifor Pharma AG (SWX:VIFN), Hutchison China MediTech Limited (AIM:HCM), DBV Technologies S.A. (ENXTPA:DBV), Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Core Laboratories N.V. (NYSE:CLB), Bausch Health Companies Inc. (NYSE:BHC), Service Corporation International (NYSE:SCI), Teleflex Incorporated (NYSE:TFX), West Pharmaceutical Services, Inc. (NYSE:WST), Boston Scientific Corporation (NYSE:BSX), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), MEDNAX, Inc. (NYSE:MD), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Chemed Corporation (NYSE:CHE), Hanger, Inc. (NYSE:HNGR), Encompass Health Corporation (NYSE:EHC), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Danaher Corporation (NYSE:DHR), Bank of America Corporation (NYSE:BAC), Hill-Rom Holdings, Inc. (NYSE:HRC), Universal Health Services, Inc. (NYSE:UHS), Allergan plc (NYSE:AGN), Mettler-Toledo International Inc. (NYSE:MTD), Centene Corporation (NYSE:CNC), Humana Inc. (NYSE:HUM), Vapotherm, Inc. (NYSE:VAPO), Capital Senior Living Corporation (NYSE:CSU), Edwards Lifesciences Corporation (NYSE:EW), Vocera Communications, Inc. (NYSE:VCRA), Charles River Laboratories International, Inc. (NYSE:CRL), Glaukos Corporation (NYSE:GKOS), Penumbra, Inc. (NYSE:PEN), Physicians Realty Trust (NYSE:DOC), Invitae Corporation (NYSE:NVTA), Evolent Health, Inc. (NYSE:EVH), AbbVie Inc. (NYSE:ABBV), Catalent, Inc. (NYSE:CTLT), Inspire Medical Systems, Inc. (NYSE:INSP), Nevro Corp. (NYSE:NVRO), Quorum Health Corporation (NYSE:QHC), ArQule, Inc. (NasdaqGM:ARQL), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Immunomedics, Inc. (NasdaqGM:IMMU), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), Rhythm Pharmaceuticals, Inc. (NasdaqGM:RYTM), CRISPR Therapeutics AG (NasdaqGM:CRSP), Zai Lab Limited (NasdaqGM:ZLAB), Verrica Pharmaceuticals Inc. (NasdaqGM:VRCA), Kodiak Sciences Inc. (NasdaqGM:KOD), Zogenix, Inc. (NasdaqGM:ZGNX), Silk Road Medical, Inc (NasdaqGM:SILK), Intersect ENT, Inc. (NasdaqGM:XENT), SI-BONE, Inc. (NasdaqGM:SIBN), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Evolus, Inc. (NasdaqGM:EOLS), Xencor, Inc. (NasdaqGM:XNCR), Phibro Animal Health Corporation (NasdaqGM:PAHC), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Marker Therapeutics, Inc. (NasdaqGM:MRKR), GW Pharmaceuticals plc (NasdaqGM:GWPH), Foamix Pharmaceuticals Ltd. (NasdaqGM:FOMX), Cara Therapeutics, Inc. (NasdaqGM:CARA), NewLink Genetics Corporation (NasdaqGM:NLNK), Radius Health, Inc. (NasdaqGM:RDUS), Corcept Therapeutics Incorporated (NasdaqCM:CORT), Exact Sciences Corporation (NasdaqCM:EXAS), Heron Therapeutics, Inc. (NasdaqCM:HRTX), Heska Corporation (NasdaqCM:HSKA)Bank of America Corporation, Bank of America Merrill Lynch 2019 Healthcare Conference, May 14, 2019 through May 16, 2019. Venue: Encore Hotel, Wynn, Las Vegas, Nevada, United States.
34
6/30/201915.02x42.84x47.61x75.94x79.60x$57,260$497.0520.37%May-1-2019Business ExpansionIntuitive Surgical Widens Expansion Footprint with New Sunnyvale Deal-Intuitive Surgical has bought three low-slung buildings on Commercial Street on sites that are a short distance from the company's headquarters in Sunnyvale. Intuitive Surgical has bought some old research and office buildings in Sunnyvale, a deal that took place in area where the company has been busy lately attempting to expand its footprint. Intuitive Surgical paid $15.1 million for the buildings, which are located at 164 Commercial St. through 174 Commercial St. in Sunnyvale and are on the south side of Central Expressway, according to Santa Clara County property records that were filed on April 30, 2019. The property currently contains three buildings that together total 36,000 square feet.
35
6/30/201915.02x42.84x47.61x75.94x79.60x$59,648$517.7815.55%Apr-25-2019Annual General MeetingIntuitive Surgical, Inc., Annual General Meeting, Apr 25, 2019-Intuitive Surgical, Inc., Annual General Meeting, Apr 25, 2019, at 15:00 Pacific Daylight. Location: 1020 Kifer Road Sunnyvale California United States Agenda: To elect nine members to the board of directors of the company to serve until the 2020 annual meeting of stockholders; to consider and approve, on an advisory basis, the compensation of the company's Named Executive Officers as disclosed in the Proxy Statement; to ratify the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2019; to approve the amendment and restatement of the 2010 incentive award plan; to consider and vote upon a stockholder proposal regarding elimination of supermajority voting provisions, if properly presented at the annual meeting; and to transact any other business which is properly brought before the Annual Meeting or adjournments or postponements thereof.
36
6/30/201915.02x42.84x47.61x75.94x79.60x$0April-19-2019Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From January 1, 2019 to March 31, 2019, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
37
6/30/201915.02x42.84x47.61x75.94x79.60x$60,833$528.0613.30%Apr-18-2019Earnings CallIntuitive Surgical, Inc., Q1 2019 Earnings Call, Apr 18, 2019-Intuitive Surgical, Inc., Q1 2019 Earnings Call, Apr 18, 2019
38
6/30/201915.02x42.84x47.61x75.94x79.60x$60,833$528.0613.30%Apr-18-2019Announcement of Earnings, Impairments/Write OffIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019; Provides Impairment Charges for the First Quarter Ended March 31, 2019-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2019. For the quarter, the company reported total revenue of $973.7 million against $847.5 million a year ago. Income from operations was $252.2 million against $276.7 million a year ago. Net income was $304.0 million against $287.3 million a year ago. Basic net income per share attributable to the company was $2.67 against $2.55 per share a year ago. Diluted net income per share attributable to the company was $2.56 against $2.44 per share a year ago.

For the first quarter ended March 31, 2019, the company reported impairment charges of $1.5 million.
39
3/31/201916.85x45.99x50.43x81.59x87.21x$64,417$558.217.18%Mar-15-2019Product-Related AnnouncementIntuitive Receives Clearance for the da Vinci SP® Surgical System-Intuitive announced it has received clearance for the da Vinci SP® surgical system for use in certain transoral otolaryngology procedures in adults. The FDA cleared the single port approach for lateral oropharyngectomy procedures (commonly referred to as radical tonsillectomy) and tongue base resection. The da Vinci SP system provides surgeons with robotic-assisted technology designed for deep and narrow access to tissue in the body. The ability to enter the body through a single, small incision or through a natural orifice can provide a minimally invasive experience for complex procedures.
40
3/31/201916.85x45.99x50.43x81.59x87.21x$64,457$558.557.11%Mar-1-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at 8th Annual SVB Leerink Global Healthcare Conference, Mar-01-2019 10:00 AM-Intuitive Surgical, Inc. Presents at 8th Annual SVB Leerink Global Healthcare Conference, Mar-01-2019 10:00 AM. Venue: Lotte New York Palace Hotel, New York, New York, United States.
41
3/31/201916.85x45.99x50.43x81.59x87.21x$63,402$549.418.90%Feb-27-2019ConferenceLeerink Partners LLC, 8th Annual SVB Leerink Global Healthcare Conference, Feb 27, 2019 through Mar 01, 2019Bruker Corporation (NasdaqGS:BRKR), MacroGenics, Inc. (NasdaqGS:MGNX), Henry Schein, Inc. (NasdaqGS:HSIC), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), CONMED Corporation (NasdaqGS:CNMD), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Bio-Techne Corporation (NasdaqGS:TECH), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), Teligent, Inc. (NasdaqGS:TLGT), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), Dermira, Inc. (NasdaqGS:DERM), Translate Bio, Inc. (NasdaqGS:TBIO), uniQure N.V. (NasdaqGS:QURE), Adaptimmune Therapeutics plc (NasdaqGS:ADAP), BeiGene, Ltd. (NasdaqGS:BGNE), Blueprint Medicines Corporation (NasdaqGS:BPMC), Principia Biopharma Inc. (NasdaqGS:PRNB), ObsEva SA (NasdaqGS:OBSV), scPharmaceuticals Inc. (NasdaqGS:SCPH), Cellular Biomedicine Group, Inc. (NasdaqGS:CBMG), Crinetics Pharmaceuticals, Inc. (NasdaqGS:CRNX), Kura Oncology, Inc. (NasdaqGS:KURA), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), Guardant Health, Inc. (NasdaqGS:GH), Aptinyx Inc. (NasdaqGS:APTX), Rubius Therapeutics, Inc. (NasdaqGS:RUBY), Akcea Therapeutics, Inc. (NasdaqGS:AKCA), NantKwest, Inc. (NasdaqGS:NK), Synthorx, Inc. (NasdaqGS:THOR), Axovant Gene Therapies Ltd. (NasdaqGS:AXGT), Neon Therapeutics, Inc. (NasdaqGS:NTGN), Gritstone Oncology, Inc. (NasdaqGS:GRTS), IGM Biosciences, Inc. (NasdaqGS:IGMS), TCR2 Therapeutics Inc. (NasdaqGS:TCRR), Eidos Therapeutics, Inc. (NasdaqGS:EIDX), Oyster Point Pharma, Inc. (NasdaqGS:OYST), Provention Bio, Inc. (NasdaqGS:PRVB), Gossamer Bio, Inc. (NasdaqGS:GOSS), resTORbio, Inc. (NasdaqGS:TORC), BridgeBio Pharma, Inc. (NasdaqGS:BBIO), Harpoon Therapeutics, Inc. (NasdaqGS:HARP), Mersana Therapeutics, Inc. (NasdaqGS:MRSN), Computer Programs and Systems, Inc. (NasdaqGS:CPSI), ChemoCentryx, Inc. (NasdaqGS:CCXI), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Premier, Inc. (NasdaqGS:PINC), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Aduro BioTech, Inc. (NasdaqGS:ADRO), Inogen, Inc. (NasdaqGS:INGN), Cardiovascular Systems, Inc. (NasdaqGS:CSII), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Clovis Oncology, Inc. (NasdaqGS:CLVS), Xeris Pharmaceuticals, Inc. (NasdaqGS:XERS), Calithera Biosciences, Inc. (NasdaqGS:CALA), InflaRx N.V. (NasdaqGS:IFRX), Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST), Epizyme, Inc. (NasdaqGS:EPZM), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), Tocagen Inc. (NasdaqGS:TOCA), Intrexon Corporation (NasdaqGS:XON), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA), Ascendis Pharma A/S (NasdaqGS:ASND), Sientra, Inc. (NasdaqGS:SIEN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Alkermes plc (NasdaqGS:ALKS), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), HMS Holdings Corp. (NasdaqGS:HMSY), ImmunoGen, Inc. (NasdaqGS:IMGN), Insmed Incorporated (NasdaqGS:INSM), CymaBay Therapeutics, Inc. (NasdaqGS:CBAY), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), NuVasive, Inc. (NasdaqGS:NUVA), Repligen Corporation (NasdaqGS:RGEN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Replimune Group, Inc. (NasdaqGS:REPL), Vericel Corporation (NasdaqCM:VCEL), AxoGen, Inc. (NasdaqCM:AXGN), Cryoport, Inc. (NasdaqCM:CYRX), Sorrento Therapeutics, Inc. (NasdaqCM:SRNE), Dyadic International, Inc. (NasdaqCM:DYAI), Cytosorbents Corporation (NasdaqCM:CTSO), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), NeoGenomics, Inc. (NasdaqCM:NEO), HTG Molecular Diagnostics, Inc. (NasdaqCM:HTGM), Millendo Therapeutics, Inc. (NasdaqCM:MLND), Abeona Therapeutics Inc. (NasdaqCM:ABEO), CTI BioPharma Corp. (NasdaqCM:CTIC), Heron Therapeutics, Inc. (NasdaqCM:HRTX), DBV Technologies S.A. (ENXTPA:DBV), Genfit SA (ENXTPA:GNFT), Innate Pharma S.A. (ENXTPA:IPH), Novo Nordisk A/S (CPSE:NOVO B), H. Lundbeck A/S (CPSE:LUN), Zealand Pharma A/S (CPSE:ZEAL), RedHill Biopharma Ltd. (TASE:RDHL), GlaxoSmithKline plc (LSE:GSK), PureTech Health plc (LSE:PRTC), Newron Pharmaceuticals S.p.A. (SWX:NWRN), Cassiopea S.p.A. (SWX:SKIN), Novartis AG (SWX:NOVN), Galapagos NV (ENXTAM:GLPG), Celyad SA (ENXTBR:CYAD), Aptose Biosciences Inc. (TSX:APS), Correvio Pharma Corp. (TSX:CORV), Aurinia Pharmaceuticals Inc. (TSX:AUP), Neovasc Inc. (TSX:NVCN), HLS Therapeutics Inc. (TSX:HLS), Array BioPharma Inc., The Medicines Company, SVB Leerink LLC, Medidata Solutions, Inc., Inotek Pharmaceuticals Corporation, CureVac AG, Alder BioPharmaceuticals, Inc., Immune Design Corp., PsiOxus Therapeutics Limited, Apexigen Inc., Angion Biomedica Corp., Navitor Pharmaceuticals, Inc., Audentes Therapeutics, Inc., Clementia Pharmaceuticals Inc., Revolution Medicines, Inc., Torque Therapeutics Inc., ORIC Pharmaceuticals, Inc., Pliant Therapeutics, Inc., Imara, Inc., Relay Therapeutics, Inc., Dova Pharmaceuticals, Inc., Precigen, Inc., Everest Medicines Limited, Dermavant Sciences Ltd., Rainier Therapeutics, Inc, MannKind Corporation (NasdaqGM:MNKD), Marinus Pharmaceuticals, Inc. (NasdaqGM:MRNS), Acceleron Pharma Inc. (NasdaqGM:XLRN), Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), GW Pharmaceuticals plc (NasdaqGM:GWPH), Reata Pharmaceuticals, Inc. (NasdaqGM:RETA), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Xencor, Inc. (NasdaqGM:XNCR), Affimed N.V. (NasdaqGM:AFMD), Ra Pharmaceuticals, Inc. (NasdaqGM:RARX), Ardelyx, Inc. (NasdaqGM:ARDX), Veracyte, Inc. (NasdaqGM:VCYT), Quanterix Corporation (NasdaqGM:QTRX), Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS), Radius Health, Inc. (NasdaqGM:RDUS), Zogenix, Inc. (NasdaqGM:ZGNX), T2 Biosystems, Inc. (NasdaqGM:TTOO), Intersect ENT, Inc. (NasdaqGM:XENT), Fate Therapeutics, Inc. (NasdaqGM:FATE), Iterum Therapeutics plc (NasdaqGM:ITRM), LogicBio Therapeutics, Inc. (NasdaqGM:LOGC), Quotient Limited (NasdaqGM:QTNT), Fulcrum Therapeutics, Inc. (NasdaqGM:FULC), Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), Eton Pharmaceuticals, Inc. (NasdaqGM:ETON), Krystal Biotech, Inc. (NasdaqGM:KRYS), Wave Life Sciences Ltd. (NasdaqGM:WVE), Synlogic, Inc. (NasdaqGM:SYBX), Zai Lab Limited (NasdaqGM:ZLAB), Intellia Therapeutics, Inc. (NasdaqGM:NTLA), Eloxx Pharmaceuticals, Inc. (NasdaqGM:ELOX), Arcturus Therapeutics Holdings Inc. (NasdaqGM:ARCT), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Protagonist Therapeutics, Inc. (NasdaqGM:PTGX), Proteostasis Therapeutics, Inc. (NasdaqGM:PTI), Verastem, Inc. (NasdaqGM:VSTM), Retrophin, Inc. (NasdaqGM:RTRX), Adverum Biotechnologies, Inc. (NasdaqGM:ADVM), ArQule, Inc. (NasdaqGM:ARQL), STAAR Surgical Company (NasdaqGM:STAA), Amarin Corporation plc (NasdaqGM:AMRN), SIGA Technologies, Inc. (NasdaqGM:SIGA), Misonix, Inc. (NasdaqGM:MSON), Equillium, Inc. (NasdaqGM:EQ), Invitae Corporation (NYSE:NVTA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), Arcus Biosciences, Inc. (NYSE:RCUS), Diplomat Pharmacy, Inc. (NYSE:DPLO), Inspire Medical Systems, Inc. (NYSE:INSP), Vocera Communications, Inc. (NYSE:VCRA), Globus Medical, Inc. (NYSE:GMED), Medtronic plc (NYSE:MDT), Boston Scientific Corporation (NYSE:BSX), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Baxter International Inc. (NYSE:BAX), Johnson & Johnson (NYSE:JNJ), Agilent Technologies, Inc. (NYSE:A), Universal Health Services, Inc. (NYSE:UHS), Allergan plc (NYSE:AGN), CVS Health Corporation (NYSE:CVS), Stryker Corporation (NYSE:SYK), Becton, Dickinson and Company (NYSE:BDX), MorphoSys AG (XTRA:MOR), Achaogen, Inc. (OTCPK:AKAO.Q)Leerink Partners LLC, 8th Annual SVB Leerink Global Healthcare Conference, Feb 27, 2019 through Mar 01, 2019. Venue: Lotte New York Palace Hotel, New York, New York, United States.
42
3/31/201916.85x45.99x50.43x81.59x87.21x$63,259$548.179.14%Feb-19-2019Product-Related AnnouncementIntuitive Surgical, Inc. Announces U.S. Food and Drug Administration Cleared the Ion™ endoluminal System to Enable Minimally Invasive Biopsy in the Peripheral Lung-Intuitive Surgical, Inc. announced that the U.S. Food and Drug Administration (FDA) cleared the Ion™ endoluminal system to enable minimally invasive biopsy in the peripheral lung.
Lung cancer is the world’s leading cause of cancer deaths. Many suspicious lesions found in the lung may be small and difficult to access, which can make obtaining a diagnosis challenging.
The Ion system uses an ultra-thin articulating robotic catheter that can move 180 degrees in all directions. The outer diameter of the catheter is 3.5 mm, which physicians can navigate through small and tortuous airways to reach nodules in any airway segment within the lung. The Ion system’s flexible biopsy needle (called the Flexision Biopsy Needle) can also pass through very tight bends via Ion’s catheter to collect tissue in the peripheral lung. The catheter’s 2mm working channel can also accommodate other biopsy tools, such as biopsy forceps or cytology brushes, if necessary. Intuitive developed the system’s fiber optic shape sensor technology to provide the physician with the precise location and shape information of the catheter throughout the navigation and biopsy process. Intuitive designed the Ion system to easily integrate into existing lung nodule biopsy workflows, as well as existing imaging technology, including fluoroscopy, radial-endobronchial ultrasound, and cone-beam CT.
43
3/31/201916.85x45.99x50.43x81.59x87.21x$60,233$521.9514.63%Feb-06-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at West Pack 2019, Feb-06-2019 02:30 PM-Intuitive Surgical, Inc. Presents at West Pack 2019, Feb-06-2019 02:30 PM. Venue: Anaheim, United States. Speakers: Kyle Miller.
44
3/31/201916.85x45.99x50.43x81.59x87.21x$60,342$522.8914.42%Feb-05-2019ConferenceUBM plc, West Pack 2019, Feb 05, 2019 through Feb 07, 2019Insulet Corporation (NasdaqGS:PODD), Altair Engineering Inc. (NasdaqGS:ALTR), Autodesk, Inc. (NasdaqGS:ADSK), Cardiovascular Systems, Inc. (NasdaqGS:CSII), PolyOne Corporation (NYSE:POL), HP Inc. (NYSE:HPQ), Eastman Chemical Company (NYSE:EMN), International Business Machines Corporation (NYSE:IBM), Merck & Co., Inc. (NYSE:MRK), Owens Corning (NYSE:OC), Boston Scientific Corporation (NYSE:BSX), Celanese Corporation (NYSE:CE), Proto Labs, Inc. (NYSE:PRLB), Inspire Medical Systems, Inc. (NYSE:INSP), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Mitsubishi Chemical Holdings Corporation (TSE:4188), Nestlé S.A. (SWX:NESN), Koninklijke DSM N.V. (ENXTAM:DSM), SRI International, Inc., Sotera Health LLC, Tekni-Plex, Inc., Pharmaceutical Product Development, LLC, Branson Corporation, United Technologies Research Center, Battelle Memorial Institute, Inc., Dow Silicones Corporation, MicroVention, Inc., Medtronic MiniMed, Inc., E. I. du Pont de Nemours and Company, Sparton Corporation, UBM plc, Yaskawa America, Inc., University of Southern California, BASF Corporation, Latham & Watkins LLP, NSF International Inc., Solvay Specialty Polymers USA, L.L.C., L.E.K. Consulting LLC, British Standards Institution, Terumo Cardiovascular Systems Corporation, FANUC America Corporation, The University of California, San Francisco, Mayo Clinic, Edwards Lifesciences LLC, Ogilvy CommonHealth Worldwide LLC, Carl Zeiss Industrial Metrology LLC, Whitford Corporation, Banner Engineering Corp., Teel Plastics, Inc., California Manufacturing Technology Consulting, Inc., North American Science Associates, Inc., Arburg Inc, Toxikon Corp., Johnson & Johnson, Inc., Replenish, Inc., Eos Of North America, Inc., StarFish Product Engineering Inc., Ximedica, LLC, Metaphase Design Group, Inc, Hogan Lovells US LLP, Electro-Core, Inc., Kinsale Holdings, Inc., DiabetesMine.com, Back Bay Life Science Advisors, Cactus Semiconductor, Inc., Mueller Prost PC, Children's Hospital of Orange County, Applied Medical Inc., W.S. Badger Company, Inc., Dollar Shave Club, Inc., Novatec Inc, Innovize, Inc., Kc Pharmaceuticals Inc., OPS Solutions,LLC, CorInnova, Inc, GE Healthcare Inc., Kablooe Design, Prescient Surgical, Inc., Neural Analytics, Inc., Advanced Molding Technology, Inc., Procept Biorobotics Corp., Packsize LLC, Design Concepts Inc, Fathom, LLC, Product Creation Studio Ltd., Medtronic, Inc., Thrive Market, Inc., Fast Radius, Inc., Element22 LLC, Qure Medical, Carbon, Inc., Bigfoot Biomedical, Inc., Nalu Medical, Inc., Scope Technologies US Inc., Acknowledge - Regulatory Strategies, Elemental Machines, Inc., R. D. Abbott Co., Inc., inVia Robotics, LLC, Beta Bionics, Inc., natals, Inc., Universal Robots (USA), Inc., PostProcess Technologies Inc., Mcr Integrated Design Systems, Inc., Valeritas, Inc., Birlasoft Inc., 3DEO, Inc., Praxair, Inc., Vascular Sciences, Rramac Connected Systems, Bex Brands, LLC, 3Diligent Corporation, Ultimaker USA Inc., H&M Consulting Group, LLC, Dogtown Media, LLC, GE Additive, The Advanced Robotics for Manufacturing (ARM) Institute, Marquee Staffing, Waypoint Robotics, Inc., The Cedars-Sinai Accelerator, Oden Technologies Inc., MED Institute Inc, Farmgirl Flowers Inc., Essentium, Inc., ParaMatters Inc., OSKA, Inc., Packaging Digest, VYTAL Group, TransAutomation Technologies Inc., Tera Engineering Co., Springborne Life Sciences, Research Collective, LLC, Precys, Nectar Product Development, Kim Walker Consulting, Isometric Micro Molding, Inc., Inductive Intelligence LLC, Healthcare Evolution, Inc., Phasium, Formalloy, Betten Systems Solutions LLC, UpStart Product Development LLC, University of Southern California Liquid Propulsion Laboratory, Smartest Systems, Singer Instruments & Control, Ltd., HirLan, Inc., Fracture Labs, LLC, ElectroFab Sales, Eisner Safety Consultants, DesignAbly, Centaur Sports Medicine LLC, Centennial Software Solutions LLC, Additive Manufacturing Technologies Limited, Sterigenics U.S., LLC, Siemens Product Lifecycle Management Software Inc., California State University, Northridge, The Alfred E Mann Foundation For Scientific Research, Lapp USA, Inc., Clariant Produkte (Deutschland) GmbH, Choc Health Alliance, Nihon Kohden America, Inc., Nelson Laboratories, Inc., CeloNova Biosciences, Inc., Jet Propulsion Laboratory, The U.S. Small Business Administration, Accenture LLP, M3 Design Inc., Instrumental, Inc., Greenleaf Ventures, Inc., Lux Research Inc., Samtec, Inc., ZPower, Inc., Lawrence Berkeley National Laboratory, LLC, Sotera Wireless, Inc., Johnson Matthey Inc., DyAnsys Inc., AirXpanders, Inc., IBM Thomas J. Watson Research Center, Evolve Manufacturing Technologies, Inc., Applied Manufacturing Technologies, Inc., SetPoint Medical Corporation, Hantel Technologies, Inc., Devicix, LLC, EtherCAT Technology Group, HungaroTrial Ltd., RJG, Inc., Eag Laboratories, Cirtec Medical Corp., Delve LLC, FUTEK Advanced Sensor Technology, Inc., EH Publishing Inc.UBM plc, West Pack 2019, Feb 05, 2019 through Feb 07, 2019. Venue: Anaheim, United States.
45
3/31/201916.85x45.99x50.43x81.59x87.21x$60,428$523.6414.26%Jan-31-2019Buyback - Change in Plan TermsIntuitive Surgical, Inc. announces an Increase in Equity Buyback.-On January 31, 2019, the company announced an increase in its equity buyback plan. The company increased its remaining authorization to $2,000 million.
46
3/31/201916.85x45.99x50.43x81.59x87.21x$61,868$536.1211.60%Jan-24-2019Earnings CallIntuitive Surgical, Inc., Q4 2018 Earnings Call, Jan 24, 2019-Intuitive Surgical, Inc., Q4 2018 Earnings Call, Jan 24, 2019
47
3/31/201916.85x45.99x50.43x81.59x87.21x$61,868$536.1211.60%Jan-24-2019Announcement of EarningsIntuitive Surgical, Inc. Announces Earnings Results of Fourth Quarter and Year Ended December 31, 2018-Intuitive Surgical, Inc. announced earnings results of fourth quarter and year ended December 31, 2018. For the quarter, the company reported revenue of $1,046.5 million against $892.0 million a year ago. Income from operations was $332.0 million against $329.0 million a year ago. Net income was $291.3 million against loss $31.5 million a year ago. Earnings per basic share was $2.56 against loss of $0.28 and earnings per diluted share was $2.45 against loss $0.28 a year ago.


For the year, the company reported revenue of $3,724.2 million against $3,138.2 million a year ago. Income from operations was $1,199.4 million against $1,062.9 million a year ago. Net income was $1,125.0 million against $670.9 million a year ago. Earnings per basic share was $9.92 against $6.01 and earnings per diluted share was $9.49 against $5.77 a year ago.
48
3/31/201916.85x45.99x50.43x81.59x87.21x$61,868$536.1211.60%Jan-24-2019Earnings Release DateIntuitive Surgical, Inc. to Report Q4, 2018 Results on Jan 24, 2019-Intuitive Surgical, Inc. announced that they will report Q4, 2018 results at 7:05 PM, GMT Standard Time on Jan 24, 2019
49
3/31/201916.85x45.99x50.43x81.59x87.21x$61,868$536.1211.60%Jan-24-2019Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From October 1, 2018 to December 31, 2018, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
50
3/31/201916.85x45.99x50.43x81.59x87.21x$59,785$518.0715.48%Jan-10-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at JP Morgan 37th Annual Healthcare conference, Jan-10-2019 09:00 AM-Intuitive Surgical, Inc. Presents at JP Morgan 37th Annual Healthcare conference, Jan-10-2019 09:00 AM. Venue: Westin St. Francis Hotel, Union Square, 335 Powell St., San Francisco, California, United States. Speakers: Gary S. Guthart, CEO, President & Director.
51
3/31/201916.85x45.99x50.43x81.59x87.21x$59,674$517.1115.70%Jan-09-2019Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2018-Intuitive Surgical, Inc. provided revenue guidance for the fourth quarter and full year of 2018. The company expects revenue for the fourth quarter of 2018 of approximately $1.047 billion, an increase of approximately 17% compared with $0.892 billion for the fourth quarter of 2017.

The company expects 2018 revenue of approximately $3.724 billion, an increase of approximately 19% compared with $3.138 billion for 2017.
52
3/31/201916.85x45.99x50.43x81.59x87.21x$55,212$478.4425.05%Jan-07-2019ConferenceJPMorgan Chase & Co., JP Morgan 37th Annual Healthcare conference, Jan 07, 2019 through Jan 10, 2019Quidel Corporation (NasdaqGS:QDEL), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Mirati Therapeutics, Inc. (NasdaqGS:MRTX), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), CymaBay Therapeutics, Inc. (NasdaqGS:CBAY), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Repligen Corporation (NasdaqGS:RGEN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), Wright Medical Group N.V. (NasdaqGS:WMGI), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), United Therapeutics Corporation (NasdaqGS:UTHR), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Bio-Techne Corporation (NasdaqGS:TECH), Cerner Corporation (NasdaqGS:CERN), CONMED Corporation (NasdaqGS:CNMD), ICU Medical, Inc. (NasdaqGS:ICUI), Meridian Bioscience, Inc. (NasdaqGS:VIVO), Crinetics Pharmaceuticals, Inc. (NasdaqGS:CRNX), Syneos Health, Inc. (NasdaqGS:SYNH), Axovant Gene Therapies Ltd. (NasdaqGS:AXGT), Denali Therapeutics Inc. (NasdaqGS:DNLI), Gritstone Oncology, Inc. (NasdaqGS:GRTS), Solid Biosciences Inc. (NasdaqGS:SLDB), Kura Oncology, Inc. (NasdaqGS:KURA), IDEAYA Biosciences, Inc. (NasdaqGS:IDYA), Orchard Therapeutics plc (NasdaqGS:ORTX), Aptinyx Inc. (NasdaqGS:APTX), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Twist Bioscience Corporation (NasdaqGS:TWST), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Spero Therapeutics, Inc. (NasdaqGS:SPRO), Jounce Therapeutics, Inc. (NasdaqGS:JNCE), 10x Genomics, Inc. (NasdaqGS:TXG), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), MyoKardia, Inc. (NasdaqGS:MYOK), Stoke Therapeutics, Inc. (NasdaqGS:STOK), Editas Medicine, Inc. (NasdaqGS:EDIT), Tricida, Inc. (NasdaqGS:TCDA), Guardant Health, Inc. (NasdaqGS:GH), ObsEva SA (NasdaqGS:OBSV), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Livongo Health, Inc. (NasdaqGS:LVGO), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Masimo Corporation (NasdaqGS:MASI), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), NVIDIA Corporation (NasdaqGS:NVDA), Omnicell, Inc. (NasdaqGS:OMCL), Orthofix Medical Inc. (NasdaqGS:OFIX), Alkermes plc (NasdaqGS:ALKS), Tivity Health, Inc. (NasdaqGS:TVTY), Amgen Inc. (NasdaqGS:AMGN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Endo International plc (NasdaqGS:ENDP), R1 RCM Inc. (NasdaqGS:RCM), Natera, Inc. (NasdaqGS:NTRA), AnaptysBio, Inc. (NasdaqGS:ANAB), IVERIC bio, Inc. (NasdaqGS:ISEE), iRhythm Technologies, Inc. (NasdaqGS:IRTC), HealthEquity, Inc. (NasdaqGS:HQY), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Intrexon Corporation (NasdaqGS:XON), Conformis, Inc. (NasdaqGS:CFMS), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), BioNTech SE (NasdaqGS:BNTX), Otonomy, Inc. (NasdaqGS:OTIC), Clovis Oncology, Inc. (NasdaqGS:CLVS), Ascendis Pharma A/S (NasdaqGS:ASND), InflaRx N.V. (NasdaqGS:IFRX), Inovalon Holdings, Inc. (NasdaqGS:INOV), Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), Adaptive Biotechnologies Corporation (NasdaqGS:ADPT), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), NovoCure Limited (NasdaqGS:NVCR), Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Chiasma, Inc. (NasdaqGS:CHMA), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Blueprint Medicines Corporation (NasdaqGS:BPMC), Moderna, Inc. (NasdaqGS:MRNA), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Health Catalyst, Inc. (NasdaqGS:HCAT), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), REGENXBIO Inc. (NasdaqGS:RGNX), G1 Therapeutics, Inc. (NasdaqGS:GTHX), Atreca, Inc. (NasdaqGS:BCEL), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Nuance Communications, Inc. (NasdaqGS:NUAN), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Endologix, Inc. (NasdaqGS:ELGX), Novavax, Inc. (NasdaqGS:NVAX), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Mylan N.V. (NasdaqGS:MYL), Patterson Companies, Inc. (NasdaqGS:PDCO), PDL BioPharma, Inc. (NasdaqGS:PDLI), Incyte Corporation (NasdaqGS:INCY), Brooks Automation, Inc. (NasdaqGS:BRKS), Henry Schein, Inc. (NasdaqGS:HSIC), ICON Public Limited Company (NasdaqGS:ICLR), Bruker Corporation (NasdaqGS:BRKR), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Accuray Incorporated (NasdaqGS:ARAY), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), OraSure Technologies, Inc. (NasdaqGS:OSUR), Premier, Inc. (NasdaqGS:PINC), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Inogen, Inc. (NasdaqGS:INGN), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), AngioDynamics, Inc. (NasdaqGS:ANGO), LHC Group, Inc. (NasdaqGS:LHCG), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), Mersana Therapeutics, Inc. (NasdaqGS:MRSN), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Aduro BioTech, Inc. (NasdaqGS:ADRO), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), ChemoCentryx, Inc. (NasdaqGS:CCXI), Frequency Therapeutics, Inc. (NasdaqGS:FREQ), Vir Biotechnology, Inc. (NasdaqGS:VIR), Scholar Rock Holding Corporation (NasdaqGS:SRRK), Eidos Therapeutics, Inc. (NasdaqGS:EIDX), Oyster Point Pharma, Inc. (NasdaqGS:OYST), MeiraGTx Holdings plc (NasdaqGS:MGTX), BridgeBio Pharma, Inc. (NasdaqGS:BBIO), Rubius Therapeutics, Inc. (NasdaqGS:RUBY), Y-mAbs Therapeutics, Inc. (NasdaqGS:YMAB), Varex Imaging Corporation (NasdaqGS:VREX), Allogene Therapeutics, Inc. (NasdaqGS:ALLO), Kiniksa Pharmaceuticals, Ltd. (NasdaqGS:KNSA), Replimune Group, Inc. (NasdaqGS:REPL), Akero Therapeutics, Inc. (NasdaqGS:AKRO), Urovant Sciences Ltd. (NasdaqGS:UROV), Cabaletta Bio, Inc. (NasdaqGS:CABA), Almirall, S.A. (BME:ALM), New Enterprise Associates, Inc., Array BioPharma Inc., Acelity L.P. Inc., Intas Pharmaceuticals Limited, Ascension Health, Inc., CommonSpirit Health, Kaiser Permanente Inc., BioScrip, Inc., Celgene Corporation, Albany Molecular Research, Inc., GE Healthcare Limited, EndPoints Inc., Novacap, Inc., The Cleveland Clinic Foundation, SomaLogic, Inc., The General Hospital Corporation, AdventHealth, NorthShore University HealthSystem, University of Pittsburgh Medical Center, Bon Secours Mercy Health, Baylor Scott & White Health LLC, Medidata Solutions, Inc., InTouch Technologies, Inc., Genomic Health, Inc., National Institutes of Health, Henry Ford Health System, Intermountain Healthcare, Inc., SSM Health Care Corporation, Mayo Clinic, Northwell Health, Inc., Spectrum Health Systems, Inc., Hartford HealthCare Corporation, Medical College Of Wisconsin, Vizient, Inc., FOX News Network, LLC, Daiichi Sankyo, Inc., Biotechnology Innovation Organization, Lilly USA, LLC, Providence St. Joseph Health, Oregon Health & Science University, Sofinnova SA, Memorial Sloan Kettering Cancer Center, Northwestern Memorial Healthcare Corporation, Borsa Italiana S.p.A., Beacon Health Options, Hospital for Special Surgery, Jefferson Healthcare, U.S. Food and Drug Administration, Proteus Digital Health, Inc., immatics biotechnologies GmbH, Waystar, Inc, GenScript Corporation, Novant Health, Inc., Selexis SA, Aprea Therapeutics AB, Harvard School of Public Health, The Children's Hospital Corporation, BioCentury Publications, Inc., Alder BioPharmaceuticals, Inc., Mevion Medical Systems, Inc., EUSA Pharma, Inc., Rafael Pharmaceuticals, Inc., Cell Medica Limited, Advantagene, Inc., Hapvida Assistência Médica Ltda., PegBio Co., Ltd., TraceLink, Inc., Sharecare Inc., Minerva Surgical Inc., Mitra Biotech Pvt Ltd, Ob Hospitalist Group, Inc., Arrail Dental International Group Co. Ltd., Humacyte, Inc., Welltok, Inc., Quartet, Inc., Vohra Wound Physicians, LLC, Privia Health, LLC, Direct Vet Marketing, Inc., Fountain Biopharma Inc., One Medical Group, Inc., Ginkgo Bioworks, Inc., JLabs, LLC, Peloton Therapeutics, Inc., Geisinger Health System, Columbia Asia Group, Bioventus LLC, GoodRx, Inc., PT Soho Global Healthcare, HitGen Inc., Formation Biologics Inc., GenapSys, Inc., Cohealo Inc., MedAvail Technologies Inc., Spark Therapeutics, Inc., Audentes Therapeutics, Inc., Zymergen, Inc., Maravai Life Sciences Inc., Pear Therapeutics, Inc., Notre Dame Intermédica Saúde S.A., Companion Medical, Inc., Compass Therapeutics LLC, Revolution Medicines, Inc., Outset Medical, Inc., Caris Life Sciences, Inc., Carbon, Inc., China Pharmaceutical Innovation and Research Development Association, Ark Biosciences Inc., Color Genomics, Inc., NantCell, Inc., PHC Holdings Corporation, ORIC Pharmaceuticals, Inc., QuVa Pharma, Inc., Adicet Bio, Inc., Ping An Health Cloud Company Limited, Aerami Therapeutics, Codiak BioSciences, Inc., WuXi Nextcode Genomics, Inc., Roivant Sciences, Inc., CollectiveHealth, Inc., Tmunity Therapeutics, Inc., Freeline Therapeutics Limited, Corvidia Therapeutics, Inc., Pliant Therapeutics, Inc., Biosim Pharmaceuticals, LLC, AiVita Biomedical, Inc., Relay Therapeutics, Inc., Dova Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., BlueRock Therapeutics LP, Tempus Labs, Inc., Mindstrong, Inc., Aetion, Inc., Insight Rx, Inc., SpringWorks Therapeutics, LLC, Foghorn Therapeutics Inc., BenevolentAI Limited, Precigen, Inc., Generation Bio Co., Grace Therapeutics, LLC, Sinovant Sciences Ltd, Legend Biotech Corporation, Softhale NV, WuXi Biologics USA, LLC., We Doctor Holdings Limited, Systems Oncology, LLC, Hypera Pharma, MGI Tech Co., Ltd., Human Technopole Foundation, Concerto HealthAI Solutions LLC, Advocate Aurora Health, Wellforce, Inc., Reprieve Cardiovascular, Inc., EpiVario Inc., Ipsen S.A. (ENXTPA:IPN), NOXXON Pharma N.V. (ENXTPA:ALNOX), Onxeo SA (ENXTPA:ONXEO), Herantis Pharma Oyj (HLSE:HRTIS), Inventiva S.A. (ENXTPA:IVA), Valbiotis SA (ENXTPA:ALVAL), Sanofi (ENXTPA:SAN), Innate Pharma S.A. (ENXTPA:IPH), Transgene SA (ENXTPA:TNG), Valneva SE (ENXTPA:VLA), Adocia SA (ENXTPA:ADOC), GN Store Nord A/S (CPSE:GN), Zealand Pharma A/S (CPSE:ZEAL), Ambu A/S (CPSE:AMBU B), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), Kamada Ltd. (TASE:KMDA), Daiichi Sankyo Company, Limited (TSE:4568), Otsuka Holdings Co., Ltd. (TSE:4578), Sosei Group Corporation (TSE:4565), NanoCarrier Co., Ltd. (TSE:4571), Eisai Co., Ltd. (TSE:4523), Santen Pharmaceutical Co., Ltd. (TSE:4536), Konica Minolta, Inc. (TSE:4902), Takeda Pharmaceutical Company Limited (TSE:4502), Astellas Pharma Inc. (TSE:4503), SanBio Company Limited (TSE:4592), Healios K.K. (TSE:4593), Dr. Reddy's Laboratories Limited (BSE:500124), Lupin Limited (BSE:500257), Innovent Biologics, Inc. (SEHK:1801), 3SBio Inc. (SEHK:1530), Lee's Pharmaceutical Holdings Limited (SEHK:950), Luye Pharma Group Ltd. (SEHK:2186), Sino Biopharmaceutical Limited (SEHK:1177), Hong Kong Exchanges and Clearing Limited (SEHK:388), WuXi Biologics (Cayman) Inc. (SEHK:2269), Alphamab Oncology (SEHK:9966), TransEnterix, Inc. (AMEX:TRXC), Lineage Cell Therapeutics, Inc. (AMEX:LCTX), Hutchison China MediTech Limited (AIM:HCM), Abcam plc (AIM:ABC), Silence Therapeutics plc (AIM:SLN), Vectura Group plc (LSE:VEC), Smith & Nephew plc (LSE:SN.), GlaxoSmithKline plc (LSE:GSK), Aksa Akrilik Kimya Sanayii A.S. (IBSE:AKSA), Hikma Pharmaceuticals PLC (LSE:HIK), Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B), Galapagos NV (ENXTAM:GLPG), Koninklijke Philips N.V. (ENXTAM:PHIA), Pharming Group N.V. (ENXTAM:PHARM), Celltrion, Inc. (KOSE:A068270), Hanmi Science Co., Ltd. (KOSE:A008930), LG Chem, Ltd. (KOSE:A051910), Samsung Biologics Co.,Ltd. (KOSE:A207940), Kancera AB (publ) (OM:KAN), Moberg Pharma AB (publ) (OM:MOB), Elekta AB (publ) (OM:EKTA B), Vifor Pharma AG (SWX:VIFN), Lonza Group Ltd (SWX:LONN), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Tecan Group Ltd. (SWX:TECN), Basilea Pharmaceutica AG (SWX:BSLN), Molecular Partners AG (SWX:MOLN), Santhera Pharmaceuticals Holding AG (SWX:SANN), ASIT Biotech S.A. (ENXTBR:ASIT), UCB SA (ENXTBR:UCB), Biocartis Group NV (ENXTBR:BCART), argenx SE (ENXTBR:ARGX), Acrux Limited (ASX:ACR), Immutep Limited (ASX:IMM), CSL Limited (ASX:CSL), Spectral Medical Inc. (TSX:EDT), Aurinia Pharmaceuticals Inc. (TSX:AUP), Profound Medical Corp. (TSX:PRN), ImmunoPrecise Antibodies Ltd. (TSXV:IPA), Instituto Hermes Pardini S.A. (BOVESPA:PARD3), Fleury S.A. (BOVESPA:FLRY3), Raia Drogasil S.A. (BOVESPA:RADL3), Biotoscana Investments S.A. (BOVESPA:GBIO33), Ouro Fino Saúde Animal Participações S.A. (BOVESPA:OFSA3), Vocera Communications, Inc. (NYSE:VCRA), JPMorgan Chase & Co. (NYSE:JPM), JPMorgan Chase & Co. (NYSE:JPM), Edwards Lifesciences Corporation (NYSE:EW), Boston Scientific Corporation (NYSE:BSX), Perrigo Company plc (NYSE:PRGO), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), Quest Diagnostics Incorporated (NYSE:DGX), Alexandria Real Estate Equities, Inc. (NYSE:ARE), Molina Healthcare, Inc. (NYSE:MOH), Glaukos Corporation (NYSE:GKOS), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Diplomat Pharmacy, Inc. (NYSE:DPLO), Veeva Systems Inc. (NYSE:VEEV), Nevro Corp. (NYSE:NVRO), Phreesia, Inc. (NYSE:PHR), Penumbra, Inc. (NYSE:PEN), Teladoc Health, Inc. (NYSE:TDOC), Select Medical Holdings Corporation (NYSE:SEM), WellCare Health Plans, Inc. (NYSE:WCG), Emergent BioSolutions Inc. (NYSE:EBS), AbbVie Inc. (NYSE:ABBV), Inspire Medical Systems, Inc. (NYSE:INSP), Catalent, Inc. (NYSE:CTLT), Rite Aid Corporation (NYSE:RAD), CVS Health Corporation (NYSE:CVS), Haemonetics Corporation (NYSE:HAE), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), Charles River Laboratories International, Inc. (NYSE:CRL), Johnson & Johnson (NYSE:JNJ), QIAGEN N.V. (NYSE:QGEN), Hill-Rom Holdings, Inc. (NYSE:HRC), Medtronic plc (NYSE:MDT), STERIS plc (NYSE:STE), DaVita Inc. (NYSE:DVA), Universal Health Services, Inc. (NYSE:UHS), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Eli Lilly and Company (NYSE:LLY), Welltower Inc. (NYSE:WELL), Owens & Minor, Inc. (NYSE:OMI), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Cantel Medical Corp. (NYSE:CMD), The Cooper Companies, Inc. (NYSE:COO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Danaher Corporation (NYSE:DHR), PerkinElmer, Inc. (NYSE:PKI), Abbott Laboratories (NYSE:ABT), Agilent Technologies, Inc. (NYSE:A), Model N, Inc. (NYSE:MODN), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Humana Inc. (NYSE:HUM), Laboratory Corporation of America Holdings (NYSE:LH), AMN Healthcare Services, Inc. (NYSE:AMN), Encompass Health Corporation (NYSE:EHC), Mettler-Toledo International Inc. (NYSE:MTD), AmerisourceBergen Corporation (NYSE:ABC), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), Veracyte, Inc. (NasdaqGM:VCYT), Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA), Sutro Biopharma, Inc. (NasdaqGM:STRO), Quanterix Corporation (NasdaqGM:QTRX), Verastem, Inc. (NasdaqGM:VSTM), SI-BONE, Inc. (NasdaqGM:SIBN), Retrophin, Inc. (NasdaqGM:RTRX), Axcella Health Inc. (NasdaqGM:AXLA), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Adverum Biotechnologies, Inc. (NasdaqGM:ADVM), Sage Therapeutics, Inc. (NasdaqGM:SAGE), GW Pharmaceuticals plc (NasdaqGM:GWPH), Acceleron Pharma Inc. (NasdaqGM:XLRN), NanoString Technologies, Inc. (NasdaqGM:NSTG), Radius Health, Inc. (NasdaqGM:RDUS), MediciNova, Inc. (NasdaqGM:MNOV), ViewRay, Inc. (NasdaqGM:VRAY), Intersect ENT, Inc. (NasdaqGM:XENT), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), AtriCure, Inc. (NasdaqGM:ATRC), Chimerix, Inc. (NasdaqGM:CMRX), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), Oxford Immunotec Global PLC (NasdaqGM:OXFD), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Rockwell Medical, Inc. (NasdaqGM:RMTI), Amarin Corporation plc (NasdaqGM:AMRN), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Affimed N.V. (NasdaqGM:AFMD), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Immunomedics, Inc. (NasdaqGM:IMMU), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), UroGen Pharma Ltd. (NasdaqGM:URGN), Clearside Biomedical, Inc. (NasdaqGM:CLSD), Zai Lab Limited (NasdaqGM:ZLAB), RAPT Therapeutics, Inc. (NasdaqGM:RAPT), Rhythm Pharmaceuticals, Inc. (NasdaqGM:RYTM), 111, Inc. (NasdaqGM:YI), Morphic Holding, Inc. (NasdaqGM:MORF), Magenta Therapeutics, Inc. (NasdaqGM:MGTA), Avantor, Inc. (NYSE:AVTR), Myovant Sciences Ltd. (NYSE:MYOV), Elanco Animal Health Incorporated (NYSE:ELAN), Avanos Medical, Inc. (NYSE:AVNS), Zoetis Inc. (NYSE:ZTS), Invitae Corporation (NYSE:NVTA), Evolent Health, Inc. (NYSE:EVH), Mallinckrodt plc (NYSE:MNK), Cannabics Pharmaceuticals Inc. (OTCPK:CNBX), Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q), Generex Biotechnology Corporation (OTCPK:GNBT), INSYS Therapeutics, Inc. (OTCPK:INSY.Q), Apollo Hospitals Enterprise Limited (NSEI:APOLLOHOSP), Cadila Healthcare Limited (NSEI:CADILAHC), Glenmark Pharmaceuticals Limited (NSEI:GLENMARK), Aurobindo Pharma Limited (NSEI:AUROPHARMA), Cipla Limited (NSEI:CIPLA), Medigene AG (XTRA:MDG1), MorphoSys AG (XTRA:MOR), Biofrontera AG (XTRA:B8F), Heidelberg Pharma AG (XTRA:WL6), Siemens Healthineers AG (XTRA:SHL), Kolon TissueGene, Inc. (KOSDAQ:A950160), Helixmith Co., Ltd (KOSDAQ:A084990), Medy-Tox Inc. (KOSDAQ:A086900), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Evotec SE (XTRA:EVT), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Fresenius SE & Co. KGaA (XTRA:FRE), Heron Therapeutics, Inc. (NasdaqCM:HRTX), Heska Corporation (NasdaqCM:HSKA), La Jolla Pharmaceutical Company (NasdaqCM:LJPC), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), Exact Sciences Corporation (NasdaqCM:EXAS), Athersys, Inc. (NasdaqCM:ATHX), MRI Interventions, Inc. (NasdaqCM:MRIC), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), VistaGen Therapeutics, Inc. (NasdaqCM:VTGN), Onconova Therapeutics, Inc. (NasdaqCM:ONTX), Dynavax Technologies Corporation (NasdaqCM:DVAX), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), Diffusion Pharmaceuticals Inc. (NasdaqCM:DFFN), Brainstorm Cell Therapeutics Inc. (NasdaqCM:BCLI), Stemline Therapeutics, Inc. (NasdaqCM:STML), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), TG Therapeutics, Inc. (NasdaqCM:TGTX), CohBar, Inc. (NasdaqCM:CWBR), vTv Therapeutics Inc. (NasdaqCM:VTVT), BioXcel Therapeutics, Inc. (NasdaqCM:BTAI), Taiwan Liposome Company, Ltd. (GTSM:4152), OBI Pharma, Inc. (GTSM:4174), PharmaEngine, Inc. (GTSM:4162)JPMorgan Chase & Co., JP Morgan 37th Annual Healthcare conference, Jan 07, 2019 through Jan 10, 2019. Venue: Westin St. Francis Hotel, Union Square, 335 Powell St., San Francisco, California, United States.
53
12/31/201814.48x38.40x41.83x69.69x71.79x$58,173$508.0617.76%Dec-11-2018M&A Transaction ClosingIntuitive Surgical Medical Device Taiwan Ltd. completed the acquisition of Unison Surgicals Company from individual sellers.Unison Surgicals CompanyIntuitive Surgical Medical Device Taiwan Ltd. agreed to acquire Unison Surgicals Company from individual sellers on October 19, 2018. Alan Mendelson from Latham & Watkins LLP acted as the legal advisor for Intuitive Surgical, Inc.


Intuitive Surgical Medical Device Taiwan Ltd. completed the acquisition of Unison Surgicals Company from individual sellers on December 11, 2018.
54
12/31/201814.48x38.40x41.83x69.69x71.79x$60,785$530.8712.70%Nov-30-2018M&A Transaction AnnouncementIntuitive Surgical Medical Device Taiwan Ltd. agreed to acquire an unknown stake Unison Surgicals Company from individual sellers.Unison Surgicals CompanyIntuitive Surgical Medical Device Taiwan Ltd. agreed to acquire Unison Surgicals Company from individual sellers on October 19, 2018. Alan Mendelson from Latham & Watkins LLP acted as the legal advisor for Intuitive Surgical, Inc.
55
12/31/201814.48x38.40x41.83x69.69x71.79x$60,978$532.5612.34%Nov-09-2018Executive/Board Change - OtherIntuitive Surgical, Inc. Names Austin Kim as Vice President and General Manager in Korea-Intuitive Surgical, Inc. has named Austin Kim as Vice President and General Manager in Korea, where he will direct business strategy and operations for the company. Intuitive pioneered the field of robotic-assisted, minimally invasive surgery with the creation of its da Vinci Surgical System. Now on its fourth-generation system, the Silicon Valley-based company has seen more than five million robotic-assisted surgical procedures performed worldwide, and more than 43,000 physicians worldwide trained on da Vinci systems. Kim brings more than 25 years of experience in the life sciences industry, including healthcare, government, and academia, and has developed extensive knowledge and expertise working in diverse markets, including the Asia Pacific region, India, China, Brazil, and the Americas. Kim has led successful teams in the delivery of enterprise solutions. Most recently, he was the general manager in Korea for Agilent Technology, where he oversaw all aspects of the business from sales, marketing, service, finance, and regulatory affairs.
56
12/31/201814.48x38.40x41.83x69.69x71.79x$58,556$511.4116.99%Oct-22-2018Lawsuits & Legal IssueLabaton Sucharow LLP Announces Proposed Class Action Settlement with Intuitive Surgical, Inc-Labaton Sucharow LLP announced pursuant to an Order of the United States District Court for the Northern District of California, that Class Representatives Employees' Retirement System of the State of Hawaii and Greater Pennsylvania Carpenters' Pension Fund, on behalf of themselves and the certified Class, and Intuitive Surgical, Inc., Gary S. Guthart, Marshall L. Mohr, and Lonnie M. Smith (collectively, the ‘Defendants’), have reached a settlement in the amount of $42,500,000 in cash that, if approved by the Court, will resolve all claims in the Action. A hearing will be held before the Honorable Edward J. Davila of the United States District Court for the Northern District of California in Courtroom 4, 5th Floor, Robert F. Peckham Federal Building & United States Courthouse, 280 South 1st Street, San Jose, CA 95113 at 10:00 a.m. on December 20, 2018 to, among other things, determine whether (1) the Settlement should be approved by the Court as fair, reasonable, and adequate; (2) the Plan of Allocation for distribution of the Settlement Amount, and any interest thereon, less Court-awarded attorneys' fees, Notice and Administration Expenses, Taxes, and any other costs, fees, or expenses approved by the Court should be approved as fair, reasonable, and adequate; and (3) to approve the application of Class Counsel for an award of attorneys' fees of no more than 19% of the Settlement Fund (or up to $8,075,000) and payment of expenses of no more than $2,500,000 from the Settlement Fund, which will include the expenses of Class Representatives pursuant to the Private Securities Litigation Reform Act of 1995.
57
12/31/201814.48x38.40x41.83x69.69x71.79x$59,802$522.2914.55%Oct-18-2018Earnings CallIntuitive Surgical, Inc., Q3 2018 Earnings Call, Oct 18, 2018-Intuitive Surgical, Inc., Q3 2018 Earnings Call, Oct 18, 2018
58
12/31/201814.48x38.40x41.83x69.69x71.79x$59,802$522.2914.55%Oct-18-2018Corporate Guidance - New/Confirmed, Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Provides Earnings Guidance for the Year 2018-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company’s total revenue was $920.9 million compared with $807.8 million a year ago. Income from operations was $313.3 million compared with $280.6 million a year ago. Income before taxes was $335.2 million compared with $291.4 million a year ago. Net income was $291.8 million compared with $298.6 million a year ago. Diluted net income per share was $2.45 compared with $2.56 a year ago. Non-GAAP income from operations was $390.6 million compared with $349.1 million a year ago. Non-GAAP net income was $337.0 million compared with $324.9 million a year ago. Diluted non-GAAP net income per share was $2.83 compared with $2.78 a year ago. Net income attributable to company was $292.5 million compared with $298.6 million a year ago. Capital placement performance in the third quarter was strong with growth in total placements over third quarter of 2017 rising 37% from 169 to 231 this quarter. Total recurring revenue in the quarter was $660 million.


For the nine months, the company reported total revenue was $2,677.7 million compared with $2,246.2 million a year ago. Income from operations was $867.4 million compared with $733.9 million a year ago. Income before taxes was $920.7 million compared with $763.5 million a year ago. Net income was $833.7 million compared with $702.4 million a year ago. Diluted net income per share was $7.04 compared with $6.06 a year ago. Non-GAAP income from operations was $1,125.6 million compared with $929.8 million a year ago. Non-GAAP net income was $951.9 million compared with $751.8 million a year ago. Diluted non-GAAP net income per share was $8.03 compared with $6.49 a year ago. Net income attributable to company was $835.4 million compared with $702.4 million a year ago.

The company forecast 2018 pro forma gross profit margin to be within a range of between 70% and 71.5% of net revenue. The company now retiring the lower end of the range and expect pro forma gross profit margin to be between 70.5% and 71.5% of net revenue. The company previous forecasts 2018 pro forma income tax rates to be between 19.5% and 20.5% of pretax income. The company now shifting estimates slightly lowers to a range between 19% and 20% of pretax income.
59
12/31/201814.48x38.40x41.83x69.69x71.79x$59,802$522.2914.55%Oct-18-2018Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From July 1, 2018 to September 30, 2018, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
60
12/31/201814.48x38.40x41.83x69.69x71.79x$62,163$542.9110.20%Oct-16-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at Technology Services World Las Vegas 2018, Oct-16-2018 01:30 PM-Intuitive Surgical, Inc. Presents at Technology Services World Las Vegas 2018, Oct-16-2018 01:30 PM. Venue: ARIA Resort & Casino, Las Vegas, United States. Speakers: Suzanne Davison, Sr. Director, Customer Engagement.
61
12/31/201814.48x38.40x41.83x69.69x71.79x$59,459$519.2915.21%Oct-15-2018ConferenceTechnology Services Industry Association, Technology Services World Las Vegas 2018, Oct 15, 2018 through Oct 18, 2018Cisco Systems, Inc. (NasdaqGS:CSCO), Microsoft Corporation (NasdaqGS:MSFT), Microsoft Corporation (NasdaqGS:MSFT), Workday, Inc. (NasdaqGS:WDAY), Workday, Inc. (NasdaqGS:WDAY), Mimecast Limited (NasdaqGS:MIME), Zscaler, Inc. (NasdaqGS:ZS), NetScout Systems, Inc. (NasdaqGS:NTCT), PTC Inc. (NasdaqGS:PTC), Zebra Technologies Corporation (NasdaqGS:ZBRA), Citrix Systems, Inc. (NasdaqGS:CTXS), LogMeIn, Inc. (NasdaqGS:LOGM), Blackboard Inc., Ellucian Company L.P., Informatica LLC, The Ultimate Software Group, Inc., Changepoint Corporation, Changepoint Corporation, Deltek, Inc., FinancialForce.com, inc., FinancialForce.com, inc., Technology Services Industry Association, Technology Services Industry Association, Rtm Consulting LLC, ANCILE Solutions, Inc., Tricentis GmbH, Mavenlink, LLC, Mavenlink, LLC, DB Kay & Associates, Inc., Pretium Partners, Inc., Value and Pricing Partners, LLC, KeyedIn Solutions, Inc., KeyedIn Solutions, Inc., Gainsight, Inc., Gainsight, Inc., Gigamon Inc., nCino, Inc., iasset.com, Inc, YourPeople, Inc., Skilljar Inc., ImageNet Consulting, LLC, Kimble Applications Limited, Kimble Applications Limited, Rubrik, Inc., Miller Heiman Group, Inc., Answer 1 Communications, inc., Compugen USA, Inc, Emerson Automation Solutions, Totango, INC, Totango, INC, Konica Minolta Healthcare Americas, Inc., CSM Practice, Inc, TOP Step Consulting Inc., Grazitti Interactive, Grazitti Interactive, VMI Collective, nVision Consulting Group Inc, LIFTinnovate LLC, Klever Insight, PS Principles LLC, Tangoe, Inc., Ivanti Software, Inc., Riverbed Technology, Inc., Dimension Data North America, Inc., W.S. Emerson Company, Inc., Foss North America, Inc., ServiceSource, Inc., ServiceSource, Inc., JDA Software, Inc., Service 800, Inc., EnBW Energy Solutions GmbH, SumTotal Systems, LLC, Tableau Software, Inc., Sutherland Lumber Company, LP, Hitachi Vantara Corporation, Imprivata, Inc., TransLogic Corporation, Coveo Solutions Inc., Clarizen, Inc., Clarizen, Inc., CSS Corp., Aha!, Acquia Inc., Phase2 Technology, Inc., Waterstone Management Group, LLC, Oracle Corporation (NYSE:ORCL), Palo Alto Networks, Inc. (NYSE:PANW), ServiceNow, Inc. (NYSE:NOW), ServiceNow, Inc. (NYSE:NOW), Guidewire Software, Inc. (NYSE:GWRE), Juniper Networks, Inc. (NYSE:JNPR), NCR Corporation (NYSE:NCR), General Electric Company (NYSE:GE), Emerson Electric Co. (NYSE:EMR), Pitney Bowes Inc. (NYSE:PBI), Rockwell Automation, Inc. (NYSE:ROK), Motorola Solutions, Inc. (NYSE:MSI), HP Inc. (NYSE:HPQ), HP Inc. (NYSE:HPQ), FedEx Corporation (NYSE:FDX), VMware, Inc. (NYSE:VMW), Ciena Corporation (NYSE:CIEN), SAP SE (XTRA:SAP)Technology Services Industry Association, Technology Services World Las Vegas 2018, Oct 15, 2018 through Oct 18, 2018. Venue: ARIA Resort & Casino, Las Vegas, United States.
62
9/30/201818.09x47.41x51.48x85.27x82.21x$64,087$561.186.61%Sep-20-2018Client AnnouncementInTouch Health Signs Multi-Year Licensing Service Agreement with Intuitive Surgical, IncInTouch Technologies, Inc.InTouch Health announced it has signed a multi-year licensing service agreement with Intuitive Surgical, Inc. Under the agreement, the two companies will collaborate to deepen Intuitive's Internet of Medical Things (IoMT) network to connect into thousands of da Vinci surgical systems in medical institutions around the world on a single global network. InTouch Health's proprietary IoMT network will enable healthcare companies like Intuitive, to connect directly to their surgical systems worldwide to exchange real-time data for enhanced clinical insights, proactive service and maintenance monitoring, surgical collaboration between disparate locations, and the ability to extract data for data analytics and machine learning.
63
9/30/201818.09x47.41x51.48x85.27x82.21x$63,817$558.827.06%Sep-13-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at Morgan Stanley 16th Annual Global Healthcare Conference, Sep-13-2018 08:00 AM-Intuitive Surgical, Inc. Presents at Morgan Stanley 16th Annual Global Healthcare Conference, Sep-13-2018 08:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Calvin Darling, Senior Director of IR.
64
9/30/201818.09x47.41x51.48x85.27x82.21x$62,399$546.409.50%Sep-11-2018ConferenceMedtechWomen, MedtechVision 2018: the Impact of AI on Medicine, Sep 11, 2018Livongo Health, Inc. (NasdaqGS:LVGO), iRhythm Technologies, Inc. (NasdaqGS:IRTC), Abbott Laboratories (NYSE:ABT), Edwards Lifesciences Corporation (NYSE:EW), Kilpatrick Townsend & Stockton LLP, Venable LLP, Fish & Richardson P.C., Proteus Digital Health, Inc., Lazar Partners Ltd., BioQuest, Inc., HeartFlow, Inc., Experien Group, LLC, Ginger.io, Inc., Arterys Inc., Procept Biorobotics Corp., HealthReveal, Inc., Google LLC, GRAIL, Inc., KenSci Inc., MedtechWomen, MedTech ColorMedtechWomen, MedtechVision 2018: The Impact of AI on Medicine, Sep 11, 2018. Venue: Rosewood Hotel, 2825 Sand Hill Rd, Menlo Park, California, United States.
65
9/30/201818.09x47.41x51.48x85.27x82.21x$62,399$546.409.50%Sep-11-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at MedtechVision 2018: The Impact of AI on Medicine, Sep-11-2018-Intuitive Surgical, Inc. Presents at MedtechVision 2018: The Impact of AI on Medicine, Sep-11-2018 . Venue: Rosewood Hotel, 2825 Sand Hill Rd, Menlo Park, California, United States.
66
9/30/201818.09x47.41x51.48x85.27x82.21x$61,883$541.8810.41%Sep-10-2018ConferenceMorgan Stanley, Morgan Stanley 16th Annual Global Healthcare Conference, Sep 10, 2018 through Sep 14, 2018Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Masimo Corporation (NasdaqGS:MASI), LivaNova PLC (NasdaqGS:LIVN), Cytokinetics, Incorporated (NasdaqGS:CYTK), Endo International plc (NasdaqGS:ENDP), Amgen Inc. (NasdaqGS:AMGN), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Autolus Therapeutics plc (NasdaqGS:AUTL), AVROBIO, Inc. (NasdaqGS:AVRO), Forty Seven, Inc. (NasdaqGS:FTSV), Evelo Biosciences, Inc. (NasdaqGS:EVLO), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Inogen, Inc. (NasdaqGS:INGN), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), AngioDynamics, Inc. (NasdaqGS:ANGO), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Blueprint Medicines Corporation (NasdaqGS:BPMC), REGENXBIO Inc. (NasdaqGS:RGNX), Epizyme, Inc. (NasdaqGS:EPZM), Clovis Oncology, Inc. (NasdaqGS:CLVS), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), Assembly Biosciences, Inc. (NasdaqGS:ASMB), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Adaptimmune Therapeutics plc (NasdaqGS:ADAP), BeiGene, Ltd. (NasdaqGS:BGNE), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), iRhythm Technologies, Inc. (NasdaqGS:IRTC), Ascendis Pharma A/S (NasdaqGS:ASND), Neon Therapeutics, Inc. (NasdaqGS:NTGN), Rubius Therapeutics, Inc. (NasdaqGS:RUBY), Unity Biotechnology, Inc. (NasdaqGS:UBX), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), Unum Therapeutics Inc. (NasdaqGS:UMRX), Denali Therapeutics Inc. (NasdaqGS:DNLI), Editas Medicine, Inc. (NasdaqGS:EDIT), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), MyoKardia, Inc. (NasdaqGS:MYOK), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Fluidigm Corporation (NasdaqGS:FLDM), Bruker Corporation (NasdaqGS:BRKR), Luminex Corporation (NasdaqGS:LMNX), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), CONMED Corporation (NasdaqGS:CNMD), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Nuance Communications, Inc. (NasdaqGS:NUAN), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Anika Therapeutics, Inc. (NasdaqGS:ANIK), Incyte Corporation (NasdaqGS:INCY), DexCom, Inc. (NasdaqGS:DXCM), Bio-Techne Corporation (NasdaqGS:TECH), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), ICU Medical, Inc. (NasdaqGS:ICUI), Hologic, Inc. (NasdaqGS:HOLX), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Agiliti Health, Inc., Cambrex Corporation, Celgene Corporation, Alder BioPharmaceuticals, Inc., Loxo Oncology, Inc., Audentes Therapeutics, Inc., Clementia Pharmaceuticals Inc., Grace Therapeutics, LLC, Knight Therapeutics Inc. (TSX:GUD), Celyad SA (ENXTBR:CYAD), UCB SA (ENXTBR:UCB), Elekta AB (publ) (OM:EKTA B), Recipharm AB (publ) (OM:RECI B), Koninklijke Philips N.V. (ENXTAM:PHIA), Mediclinic International plc (LSE:MDC), Vifor Pharma AG (SWX:VIFN), Basilea Pharmaceutica AG (SWX:BSLN), Molecular Partners AG (SWX:MOLN), Hutchison China MediTech Limited (AIM:HCM), Zealand Pharma A/S (CPSE:ZEAL), ALK-Abelló A/S (CPSE:ALK B), Genmab A/S (CPSE:GMAB), Novo Nordisk A/S (CPSE:NOVO B), Sanofi (ENXTPA:SAN), DBV Technologies S.A. (ENXTPA:DBV), Cellectis S.A. (ENXTPA:ALCLS), ERYTECH Pharma S.A. (ENXTPA:ERYP), Genfit SA (ENXTPA:GNFT), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Fresenius SE & Co. KGaA (XTRA:FRE), Sartorius Aktiengesellschaft (XTRA:SRT), Siemens Healthineers AG (XTRA:SHL), Melinta Therapeutics, Inc. (OTCPK:MLNT.Q), Nuvectra Corporation (OTCPK:NVTR.Q), Arcus Biosciences, Inc. (NYSE:RCUS), Omeros Corporation (NasdaqGM:OMER), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), ViewRay, Inc. (NasdaqGM:VRAY), Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA), Radius Health, Inc. (NasdaqGM:RDUS), Acceleron Pharma Inc. (NasdaqGM:XLRN), MediciNova, Inc. (NasdaqGM:MNOV), NanoString Technologies, Inc. (NasdaqGM:NSTG), AtriCure, Inc. (NasdaqGM:ATRC), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), Chimerix, Inc. (NasdaqGM:CMRX), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), OrthoPediatrics Corp. (NasdaqGM:KIDS), Fate Therapeutics, Inc. (NasdaqGM:FATE), Veracyte, Inc. (NasdaqGM:VCYT), Rhythm Pharmaceuticals, Inc. (NasdaqGM:RYTM), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Phibro Animal Health Corporation (NasdaqGM:PAHC), Immunomedics, Inc. (NasdaqGM:IMMU), Boston Scientific Corporation (NYSE:BSX), AbbVie Inc. (NYSE:ABBV), Avanos Medical, Inc. (NYSE:AVNS), Quorum Health Corporation (NYSE:QHC), Catalent, Inc. (NYSE:CTLT), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Diplomat Pharmacy, Inc. (NYSE:DPLO), Globus Medical, Inc. (NYSE:GMED), WellCare Health Plans, Inc. (NYSE:WCG), Emergent BioSolutions Inc. (NYSE:EBS), Penumbra, Inc. (NYSE:PEN), Nevro Corp. (NYSE:NVRO), Hill-Rom Holdings, Inc. (NYSE:HRC), AmerisourceBergen Corporation (NYSE:ABC), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Humana Inc. (NYSE:HUM), Medtronic plc (NYSE:MDT), QIAGEN N.V. (NYSE:QGEN), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Charles River Laboratories International, Inc. (NYSE:CRL), CVS Health Corporation (NYSE:CVS), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), Ingersoll-Rand Plc (NYSE:IR), Invacare Corporation (NYSE:IVC), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), West Pharmaceutical Services, Inc. (NYSE:WST), International Business Machines Corporation (NYSE:IBM), Johnson & Johnson (NYSE:JNJ), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Edwards Lifesciences Corporation (NYSE:EW), Morgan Stanley (NYSE:MS), Vocera Communications, Inc. (NYSE:VCRA), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), Quest Diagnostics Incorporated (NYSE:DGX), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Danaher Corporation (NYSE:DHR), PerkinElmer, Inc. (NYSE:PKI), Exact Sciences Corporation (NasdaqCM:EXAS), PolarityTE, Inc. (NasdaqCM:PTE), AxoGen, Inc. (NasdaqCM:AXGN), Brainstorm Cell Therapeutics Inc. (NasdaqCM:BCLI)Morgan Stanley, Morgan Stanley 16th Annual Global Healthcare Conference, Sep 10, 2018 through Sep 14, 2018. Venue: Grand Hyatt, New York, New York, United States.
67
9/30/201818.09x47.41x51.48x85.27x82.21x$61,880$541.8610.41%Sep-06-2018Product-Related AnnouncementIntuitive Surgical, Inc. Submits New Robotic-Assisted Platform to FDA for Obtaining Lung Biopsies-Intuitive Surgical, Inc. announced it has submitted a premarket notification to the U.S. Food and Drug Administration (FDA) for the company’s new flexible robotic-assisted, catheter-based platform, designed to navigate through very small lung airways to reach peripheral nodules for biopsies. Lung cancer is the world’s leading cause of cancer deaths. The majority of suspicious lesions found in the lung are small and difficult to access, which can make obtaining a diagnosis challenging.
68
9/30/201818.09x47.41x51.48x85.27x82.21x$61,293$536.7211.47%Sep-05-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at 2018 Wells Fargo Securities Healthcare Conference, Sep-05-2018 through Sep-06-2018-Intuitive Surgical, Inc. Presents at 2018 Wells Fargo Securities Healthcare Conference, Sep-05-2018 through Sep-06-2018. Venue: The Westin Copley Place, 10 Huntington Ave, Boston, Massachusetts, United States. Presentation Date & Speakers: Sep-05-2018, Calvin Darling, Senior Director of IR, Marshall L. Mohr, Senior VP & CFO. Sep-06-2018, Salvatore J. Brogna, Executive VP & COO.
69
9/30/201818.09x47.41x51.48x85.27x82.21x$61,293$536.7211.47%Sep-05-2018ConferenceWells Fargo Securities, LLC, 2018 Wells Fargo Securities Healthcare Conference, Sep 05, 2018 through Sep 06, 2018Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), bluebird bio, Inc. (NasdaqGS:BLUE), NextGen Healthcare, Inc. (NasdaqGS:NXGN), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Omnicell, Inc. (NasdaqGS:OMCL), HMS Holdings Corp. (NasdaqGS:HMSY), BioTelemetry, Inc. (NasdaqGS:BEAT), resTORbio, Inc. (NasdaqGS:TORC), Kiniksa Pharmaceuticals, Ltd. (NasdaqGS:KNSA), Autolus Therapeutics plc (NasdaqGS:AUTL), Kezar Life Sciences, Inc. (NasdaqGS:KZR), Akcea Therapeutics, Inc. (NasdaqGS:AKCA), AVROBIO, Inc. (NasdaqGS:AVRO), Ascendis Pharma A/S (NasdaqGS:ASND), NovoCure Limited (NasdaqGS:NVCR), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), Xeris Pharmaceuticals, Inc. (NasdaqGS:XERS), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Calithera Biosciences, Inc. (NasdaqGS:CALA), Adaptimmune Therapeutics plc (NasdaqGS:ADAP), Jounce Therapeutics, Inc. (NasdaqGS:JNCE), MyoKardia, Inc. (NasdaqGS:MYOK), NantHealth, Inc. (NasdaqGS:NH), uniQure N.V. (NasdaqGS:QURE), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), Unum Therapeutics Inc. (NasdaqGS:UMRX), SeaSpine Holdings Corporation (NasdaqGS:SPNE), OPKO Health, Inc. (NasdaqGS:OPK), Surgery Partners, Inc. (NasdaqGS:SGRY), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), HealthEquity, Inc. (NasdaqGS:HQY), Conformis, Inc. (NasdaqGS:CFMS), Strongbridge Biopharma plc (NasdaqGS:SBBP), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Computer Programs and Systems, Inc. (NasdaqGS:CPSI), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), AngioDynamics, Inc. (NasdaqGS:ANGO), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Premier, Inc. (NasdaqGS:PINC), MEI Pharma, Inc. (NasdaqCM:MEIP), PolarityTE, Inc. (NasdaqCM:PTE), Regulus Therapeutics Inc. (NasdaqCM:RGLS), Avid Bioservices, Inc. (NasdaqCM:CDMO), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), Globus Medical, Inc. (NYSE:GMED), Teladoc Health, Inc. (NYSE:TDOC), Emergent BioSolutions Inc. (NYSE:EBS), Penumbra, Inc. (NYSE:PEN), Select Medical Holdings Corporation (NYSE:SEM), Diplomat Pharmacy, Inc. (NYSE:DPLO), Glaukos Corporation (NYSE:GKOS), Triple-S Management Corporation (NYSE:GTS), Owens & Minor, Inc. (NYSE:OMI), Service Corporation International (NYSE:SCI), Teleflex Incorporated (NYSE:TFX), Boston Scientific Corporation (NYSE:BSX), HCA Healthcare, Inc. (NYSE:HCA), The Cooper Companies, Inc. (NYSE:COO), Edwards Lifesciences Corporation (NYSE:EW), Baxter International Inc. (NYSE:BAX), Vocera Communications, Inc. (NYSE:VCRA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), American Renal Associates Holdings, Inc. (NYSE:ARA), Evolent Health, Inc. (NYSE:EVH), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Inspire Medical Systems, Inc. (NYSE:INSP), Zymeworks Inc. (NYSE:ZYME), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Allergan plc (NYSE:AGN), Charles River Laboratories International, Inc. (NYSE:CRL), Stryker Corporation (NYSE:SYK), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), Hanger, Inc. (NYSE:HNGR), Medtronic plc (NYSE:MDT), Mallinckrodt plc (NYSE:MNK), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Universal Health Services, Inc. (NYSE:UHS), Abbott Laboratories (NYSE:ABT), Quanterix Corporation (NasdaqGM:QTRX), Fate Therapeutics, Inc. (NasdaqGM:FATE), Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA), Flexion Therapeutics, Inc. (NasdaqGM:FLXN), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Aeglea BioTherapeutics, Inc. (NasdaqGM:AGLE), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Immunomedics, Inc. (NasdaqGM:IMMU), Affimed N.V. (NasdaqGM:AFMD), MediWound Ltd. (NasdaqGM:MDWD), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), TRACON Pharmaceuticals, Inc. (NasdaqGM:TCON), Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM), Concert Pharmaceuticals, Inc. (NasdaqGM:CNCE), Lantheus Holdings, Inc. (NasdaqGM:LNTH), Neos Therapeutics, Inc. (NasdaqGM:NEOS), Applied Genetic Technologies Corporation (NasdaqGM:AGTC), Benefitfocus, Inc. (NasdaqGM:BNFT), Avadel Pharmaceuticals plc (NasdaqGM:AVDL), Intellia Therapeutics, Inc. (NasdaqGM:NTLA), Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Cellectis S.A. (ENXTPA:ALCLS), Genfit SA (ENXTPA:GNFT), ALK-Abelló A/S (CPSE:ALK B), TransEnterix, Inc. (AMEX:TRXC), UDG Healthcare plc (LSE:UDG), Molecular Partners AG (SWX:MOLN), Novartis AG (SWX:NOVN), Celyad SA (ENXTBR:CYAD), Titan Medical Inc. (TSX:TMD), Array BioPharma Inc., Agiliti Health, Inc., Cambrex Corporation, Endocyte, Inc., Wells Fargo Securities, LLC, Mazor Robotics Ltd., Aprea Therapeutics AB, OncoMed Pharmaceuticals, Inc., OMNI life science, Inc., Alder BioPharmaceuticals, Inc., Corindus Vascular Robotics, Inc., VytronUS, Inc., Immune Design Corp., Tesaro, Inc., Nuvaira, Inc., Iteos Therapeutics S.A., Braeburn Inc., Neural Analytics, Inc., K2M Group Holdings, Inc., Outset Medical, Inc., Nouscom AG, Relay Therapeutics, Inc.Wells Fargo Securities, LLC, 2018 Wells Fargo Securities Healthcare Conference, Sep 05, 2018 through Sep 06, 2018. Venue: The Westin Copley Place, 10 Huntington Ave, Boston, Massachusetts, United States.
70
9/30/201818.09x47.41x51.48x85.27x82.21x$58,960$516.2915.88%Aug-1-2018Executive/Board Change - OtherIntuitive Surgical, Inc. Appoints Don Kania to the Board-The Board of Directors of Intuitive Surgical, Inc. appointed Don Kania, Ph.D. to the Board effective as of July 31, 2018. The Board also increased the authorized number of directors to ten (10) effective July 31, 2018. Kania, 63, has more than 25 years of experience in scientific research and development, global operations, and manufacturing. Most recently, Kania served as CEO and president of FEI Company until its 2016 acquisition by
Thermo Fisher Scientific Inc. Kania also held various positions at Veeco Instruments Inc., ultimately as chief operating officer.
71
9/30/201818.09x47.41x51.48x85.27x82.21x$59,016$516.7815.77%Jul-20-2018Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From April 1, 2018 to June 30, 2018, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
72
9/30/201818.09x47.41x51.48x85.27x82.21x$59,531$521.2914.77%Jul-19-2018Earnings CallIntuitive Surgical, Inc., Q2 2018 Earnings Call, Jul 19, 2018-Intuitive Surgical, Inc., Q2 2018 Earnings Call, Jul 19, 2018
73
9/30/201818.09x47.41x51.48x85.27x82.21x$59,531$521.2914.77%Jul-19-2018Corporate Guidance - New/Confirmed, Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018; Provides Gross Profit Margin and Income Tax Rate Guidance for the Year 2018-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2018. For the quarter, the company reported total revenue of $909.3 million against $758.8 million for the same period a year ago. Income from operations was $277.4 million against $259.9 million for the same period a year ago. Income before taxes was $295.6 million against $270.0 million for the same period a year ago. Net income was $254.6 million against $223.0 million for the same period a year ago. Net income attributable to the company was $255.3 million against $223.0 million for the same period a year ago. Net income per diluted share attributable to the company was $2.15 against $1.94 for the same period a year ago. Non-GAAP income from operations was $388.7 million against $314.9 million for the same period a year ago. Non-GAAP net income attributable to the company was $327.4 million against $229.9 million for the same period a year ago. Non-GAAP net income per share attributable to the company – diluted was $2.76 against $2.00 for the same period a year ago. Cash generated from operations was $220 million. The year-over-year revenue growth benefited by approximately 100 basis points from the weaker dollar.

For the six months, the company reported total revenue of $1,756.8 million against $1,438.4 million for the same period a year ago. Income from operations was $554.1 million against $453.3 million for the same period a year ago. Income before taxes was $585.5 million against $472.1 million for the same period a year ago. Net income was $541.9 million against $403.8 million for the same period a year ago. Net income attributable to the company was $542.9 million against $403.8 million a year ago. Net income per diluted share attributable to the company was $4.59 against $3.50 for the same period a year ago. Non-GAAP income from operations was $735.0 million against $580.7 million for the same period a year ago. Non-GAAP net income attributable to the company was $614.9 million against $426.9 million for the same period a year ago. Non-GAAP net income per share attributable to the company – diluted was $5.20 against $3.70 for the same period a year ago.

The4 company provided earnings guidance for the year 2018. For the year 2018, the company continues to expect pro forma gross profit margin to be within a range of between 70% and 71.5% of net revenue. The company forecasts 2018 pro forma income tax rate to be between 20% and 21% of pretax income. The company is now shifting estimates slightly lower to a range of between 19.5% and 20.5% of pretax income.
74
9/30/201818.09x47.41x51.48x85.27x82.21x$55,660$487.3922.75%Jul-05-2018Product-Related AnnouncementIntuitive Surgical Receives FDA Clearance for First 60mm Stapler-Intuitive Surgical, Inc. announced that the U.S. Food and Drug Administration granted clearance for the company’s fully wristed, 60mm stapler. SureForm 60™, a single-patient use 60mm stapler, offers 120 degrees of fully wristed articulation – an industry first. Surgeons control SureForm 60 through the da Vinci surgeon console, creating an immediate connection between clinical decision-making and instrument action. Combining da Vinci’s tremor filtration with SureForm 60’s tip stability and 120 degrees of articulation in all directions may help provide surgeons with precise stapler manipulation and placement. SureForm 60 uses SmartFire™ technology—integrated software that optimizes stapler and staple line performance. SmartFire measures tissue compression before and during staple firing, making automatic adjustments to the firing process as staples are formed and the transection is made. SmartFire makes more than 1,000 measurements per second, helping to ensure a more consistent staple line, while helping prevent tissue damage, across a range of tissue thicknesses.
75
6/30/201815.68x41.50x45.07x74.97x71.86x$55,766$490.4721.98%Jun-13-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at Goldman Sachs 39th Annual Global Healthcare Conference, Jun-13-2018 08:00 AM-Intuitive Surgical, Inc. Presents at Goldman Sachs 39th Annual Global Healthcare Conference, Jun-13-2018 08:00 AM. Venue: Terranea Resort, 100 Terranea Way, Rancho Palos Verdes, California, United States. Speakers: David J. Rosa, Executive VP & Chief Commercial Officer.
76
6/30/201815.68x41.50x45.07x74.97x71.86x$56,272$494.9220.89%Jun-12-2018ConferenceThe Goldman Sachs Group, Inc., Goldman Sachs 39th Annual Global Healthcare Conference, Jun 12, 2018 through Jun 14, 2018Hologic, Inc. (NasdaqGS:HOLX), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), LivaNova PLC (NasdaqGS:LIVN), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), NuVasive, Inc. (NasdaqGS:NUVA), Mylan N.V. (NasdaqGS:MYL), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Denali Therapeutics Inc. (NasdaqGS:DNLI), Unity Biotechnology, Inc. (NasdaqGS:UBX), Syneos Health, Inc. (NasdaqGS:SYNH), ICON Public Limited Company (NasdaqGS:ICLR), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Seres Therapeutics, Inc. (NasdaqGS:MCRB), TherapeuticsMD, Inc. (NasdaqGS:TXMD), BeiGene, Ltd. (NasdaqGS:BGNE), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Blueprint Medicines Corporation (NasdaqGS:BPMC), Clovis Oncology, Inc. (NasdaqGS:CLVS), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), FibroGen, Inc. (NasdaqGS:FGEN), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Illumina, Inc. (NasdaqGS:ILMN), Insmed Incorporated (NasdaqGS:INSM), Amgen Inc. (NasdaqGS:AMGN), Align Technology, Inc. (NasdaqGS:ALGN), Alkermes plc (NasdaqGS:ALKS), Exact Sciences Corporation (NasdaqCM:EXAS), GW Pharmaceuticals plc (NasdaqGM:GWPH), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Revance Therapeutics, Inc. (NasdaqGM:RVNC), Radius Health, Inc. (NasdaqGM:RDUS), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), CRISPR Therapeutics AG (NasdaqGM:CRSP), Zai Lab Limited (NasdaqGM:ZLAB), Surface Oncology, Inc. (NasdaqGM:SURF), Hill-Rom Holdings, Inc. (NYSE:HRC), AmerisourceBergen Corporation (NYSE:ABC), Humana Inc. (NYSE:HUM), Mallinckrodt plc (NYSE:MNK), Arcus Biosciences, Inc. (NYSE:RCUS), Inspire Medical Systems, Inc. (NYSE:INSP), Emergent BioSolutions Inc. (NYSE:EBS), Penumbra, Inc. (NYSE:PEN), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), AbbVie Inc. (NYSE:ABBV), Catalent, Inc. (NYSE:CTLT), The Goldman Sachs Group, Inc. (NYSE:GS), Edwards Lifesciences Corporation (NYSE:EW), Owens & Minor, Inc. (NYSE:OMI), Teleflex Incorporated (NYSE:TFX), West Pharmaceutical Services, Inc. (NYSE:WST), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Baxter International Inc. (NYSE:BAX), The Cooper Companies, Inc. (NYSE:COO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), QIAGEN N.V. (NYSE:QGEN), STERIS plc (NYSE:STE), Universal Health Services, Inc. (NYSE:UHS), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), Johnson & Johnson (NYSE:JNJ), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Cigna Corporation (NYSE:CI), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Sanofi (ENXTPA:SAN), Cellectis S.A. (ENXTPA:ALCLS), DBV Technologies S.A. (ENXTPA:DBV), Genmab A/S (CPSE:GMAB), Coloplast A/S (CPSE:COLO B), Dr. Reddy's Laboratories Limited (BSE:500124), GlaxoSmithKline plc (LSE:GSK), AstraZeneca PLC (LSE:AZN), Koninklijke Philips N.V. (ENXTAM:PHIA), Novartis AG (SWX:NOVN), Foundation Medicine, Inc., Acorn Management Partners, LLC, Spark Therapeutics, Inc.The Goldman Sachs Group, Inc., Goldman Sachs 39th Annual Global Healthcare Conference, Jun 12, 2018 through Jun 14, 2018. Venue: Terranea Resort, 100 Terranea Way, Rancho Palos Verdes, California, United States.
77
6/30/201815.68x41.50x45.07x74.97x71.86x$56,272$494.9220.89%Jun-12-2018Private PlacementBroncus Medical, Inc. announced that it has received $15 million in funding from Intuitive Surgical, Inc.Broncus Medical, Inc.Broncus Medical, Inc. announced that it has received $15 million in its series A round of equity funding from new investor, Intuitive Surgical, Inc. (NasdaqGS:ISRG) on June 12, 2018.
78
6/30/201815.68x41.50x45.07x74.97x71.86x$55,183$485.3423.27%Jun-07-2018Shelf Registration FilingDex Liquidating Co. has closed its Shelf Registration dated December 15, 2010 in the amount of $5.03565 million.Dex Liquidating Co.Dex Liquidating Co. has closed its Shelf Registration dated December 15, 2010 in the amount of $5.03565 million.

Security Name: Common Stock
Securities Offered: 1,249,541
79
6/30/201815.68x41.50x45.07x74.97x71.86x$52,264$459.6730.16%May-31-2018Product-Related AnnouncementIntuitive Surgical, Inc. Announces New U.S. Food and Drug Administration Clearance for the da Vinci SP Surgical System-Intuitive Surgical, Inc. announced a new U.S. Food and Drug Administration (FDA) clearance for the da Vinci SP surgical system for urologic surgical procedures that are appropriate for a single port approach. The da Vinci SP system provides surgeons with robotic-assisted technology designed for deep and narrow access to tissue in the body. The ability to enter the body through a single, small incision helps surgeons perform more complex procedures. Intuitive anticipates pursuing further regulatory clearances for da Vinci SP, including transoral, transanal, and extraperitoneal applications, broadening the applicability of the SP platform over time. The da Vinci SP system includes three, multi-jointed, wristed instruments and the first da Vinci fully wristed 3D HD camera. The instruments and the camera all emerge through a single cannula and are properly triangulated around the target anatomy to avoid external instrument collisions that can occur in narrow surgical workspaces. The system enables flexible port placement and excellent internal and external range of motion (e.g., 360-degrees of anatomical access) through the single SP arm. Surgeons control the fully articulating instruments and the camera on the da Vinci SP system, which uses the same surgeon console as the da Vinci X and Xi systems. Since the initial U.S. FDA clearance in April 2014 for the da Vinci SP surgical system, Intuitive invested in important platform refinements. Intuitive plans to launch the da Vinci SP surgical system in the United States in a measured fashion, with customer shipments beginning in the third quarter of 2018.
80
6/30/201815.68x41.50x45.07x74.97x71.86x$52,263$459.6630.16%May-30-2018Business Expansion, Executive/Board Change - OtherIntuitive Surgical, Inc. Begins Direct Operations in India; Names Mandeep Singh Kumar as its General Manager in India-Intuitive Surgical, Inc. announced that it has begun direct operations in India, following seven years of doing business in the country through a distributor, Vattikuti Technologies Pvt. Ltd. Intuitive’s sixth international office will be headquartered in Bengaluru, where employees in sales, marketing, field service engineering, and business operations will be based to support customers throughout the country. More than 65 da Vinci surgical systems are currently in use in India, with surgeons performing robotic-assisted procedures in urology, gynecology, thoracic, and general surgery.


In support of the company’s commitment to India, Intuitive also named Mandeep Singh Kumar as its general manager. Mandeep will direct and implement Intuitive’s in-country strategy and commercial operations. He has more than 20 years of global business experience in health care, pharmaceuticals, medical devices, and advertising. Most recently, Mandeep served as the chief commercial officer for GE Healthcare, India and South Asia.
81
6/30/201815.68x41.50x45.07x74.97x71.86x$51,942$456.8330.97%May-15-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2018 Healthcare Conference, May-15-2018 04:20 PM-Intuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2018 Healthcare Conference, May-15-2018 04:20 PM. Venue: Encore at Wynn Hotel, Las Vegas, Nevada, United States. Speakers: Calvin Darling, Senior Director of IR.
82
6/30/201815.68x41.50x45.07x74.97x71.86x$51,942$456.8330.97%May-15-2018ConferenceBank of America Corporation, Bank of America Merrill Lynch 2018 Healthcare Conference, May 15, 2018 through May 17, 2018Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Pacira BioSciences, Inc. (NasdaqGS:PCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Illumina, Inc. (NasdaqGS:ILMN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Alkermes plc (NasdaqGS:ALKS), Amgen Inc. (NasdaqGS:AMGN), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Intrexon Corporation (NasdaqGS:XON), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Nabriva Therapeutics plc (NasdaqGS:NBRV), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), AnaptysBio, Inc. (NasdaqGS:ANAB), Surgery Partners, Inc. (NasdaqGS:SGRY), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Premier, Inc. (NasdaqGS:PINC), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), LHC Group, Inc. (NasdaqGS:LHCG), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Aduro BioTech, Inc. (NasdaqGS:ADRO), Cardiovascular Systems, Inc. (NasdaqGS:CSII), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Hologic, Inc. (NasdaqGS:HOLX), CONMED Corporation (NasdaqGS:CNMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Magellan Health, Inc. (NasdaqGS:MGLN), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Healthcare Services Group, Inc. (NasdaqGS:HCSG), ICON Public Limited Company (NasdaqGS:ICLR), Diversified Healthcare Trust (NasdaqGS:DHC), Ascendis Pharma A/S (NasdaqGS:ASND), Savara Inc. (NasdaqGS:SVRA), Clovis Oncology, Inc. (NasdaqGS:CLVS), CytomX Therapeutics, Inc. (NasdaqGS:CTMX), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), Puma Biotechnology, Inc. (NasdaqGS:PBYI), REGENXBIO Inc. (NasdaqGS:RGNX), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), MyoKardia, Inc. (NasdaqGS:MYOK), Seres Therapeutics, Inc. (NasdaqGS:MCRB), NantHealth, Inc. (NasdaqGS:NH), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Spero Therapeutics, Inc. (NasdaqGS:SPRO), Editas Medicine, Inc. (NasdaqGS:EDIT), Homology Medicines, Inc. (NasdaqGS:FIXX), Varex Imaging Corporation (NasdaqGS:VREX), resTORbio, Inc. (NasdaqGS:TORC), Abaxis, Inc., Array BioPharma Inc., Celgene Corporation, Legacy LifePoint Health, Inc., Genomic Health, Inc., Alder BioPharmaceuticals, Inc., Synthetic Genomics, Inc., Civitas Solutions, Inc., Tesaro, Inc., Audentes Therapeutics, Inc., Berkeley Lights, Inc., Koninklijke Philips N.V. (ENXTAM:PHIA), VolitionRx Limited (AMEX:VNRX), Hutchison China MediTech Limited (AIM:HCM), DBV Technologies S.A. (ENXTPA:DBV), Evotec SE (XTRA:EVT), MiMedx Group, Inc. (OTCPK:MDXG), Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q), Bank of America Corporation (NYSE:BAC), Hill-Rom Holdings, Inc. (NYSE:HRC), Centene Corporation (NYSE:CNC), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Mettler-Toledo International Inc. (NYSE:MTD), QIAGEN N.V. (NYSE:QGEN), Universal Health Services, Inc. (NYSE:UHS), Allergan plc (NYSE:AGN), Charles River Laboratories International, Inc. (NYSE:CRL), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Intersect ENT, Inc. (NasdaqGM:XENT), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS), CRISPR Therapeutics AG (NasdaqGM:CRSP), Zai Lab Limited (NasdaqGM:ZLAB), Evolus, Inc. (NasdaqGM:EOLS), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Rhythm Pharmaceuticals, Inc. (NasdaqGM:RYTM), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), Zogenix, Inc. (NasdaqGM:ZGNX), NanoString Technologies, Inc. (NasdaqGM:NSTG), Radius Health, Inc. (NasdaqGM:RDUS), NewLink Genetics Corporation (NasdaqGM:NLNK), GW Pharmaceuticals plc (NasdaqGM:GWPH), Tactile Systems Technology, Inc. (NasdaqGM:TCMD), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Phibro Animal Health Corporation (NasdaqGM:PAHC), RadNet, Inc. (NasdaqGM:RDNT), Physicians Realty Trust (NYSE:DOC), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Danaher Corporation (NYSE:DHR), Capital Senior Living Corporation (NYSE:CSU), U.S. Physical Therapy, Inc. (NYSE:USPH), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), MEDNAX, Inc. (NYSE:MD), Chemed Corporation (NYSE:CHE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Tenet Healthcare Corporation (NYSE:THC), Eli Lilly and Company (NYSE:LLY), Merck & Co., Inc. (NYSE:MRK), Owens & Minor, Inc. (NYSE:OMI), Service Corporation International (NYSE:SCI), Teleflex Incorporated (NYSE:TFX), West Pharmaceutical Services, Inc. (NYSE:WST), Boston Scientific Corporation (NYSE:BSX), Glaukos Corporation (NYSE:GKOS), Cigna Corporation (NYSE:CI), Genesis Healthcare, Inc. (NYSE:GEN), WellCare Health Plans, Inc. (NYSE:WCG), Nevro Corp. (NYSE:NVRO), Teladoc Health, Inc. (NYSE:TDOC), Brookdale Senior Living Inc. (NYSE:BKD), Quorum Health Corporation (NYSE:QHC), AbbVie Inc. (NYSE:ABBV), Invitae Corporation (NYSE:NVTA), Evolent Health, Inc. (NYSE:EVH), Penumbra, Inc. (NYSE:PEN), Catalent, Inc. (NYSE:CTLT), American Renal Associates Holdings, Inc. (NYSE:ARA), IQVIA Holdings Inc. (NYSE:IQV), Aileron Therapeutics, Inc. (NasdaqCM:ALRN), Exact Sciences Corporation (NasdaqCM:EXAS), Heron Therapeutics, Inc. (NasdaqCM:HRTX)Bank of America Corporation, Bank of America Merrill Lynch 2018 Healthcare Conference, May 15, 2018 through May 17, 2018. Venue: Encore at Wynn Hotel, Las Vegas, Nevada, United States.
83
6/30/201815.68x41.50x45.07x74.97x71.86x$52,610$462.7129.30%Apr-19-2018Annual General MeetingIntuitive Surgical, Inc., Annual General Meeting, Apr 19, 2018-Intuitive Surgical, Inc., Annual General Meeting, Apr 19, 2018, at 15:00 Pacific Standard Time. Location: 1020 Kifer Road Sunnyvale California United States Agenda: To elect nine members to the board of directors of the company to serve until the 2019 annual meeting of stockholders; to consider and approve, on an advisory basis, the compensation of the company's named executive officers as disclosed in the proxy statement; to ratify the appointment of Pricewaterhousecoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2018; and to transact any other business which is properly brought before the annual meeting or adjournments or postponements thereof.
84
6/30/201815.68x41.50x45.07x74.97x71.86x$53,556$471.0327.02%Apr-18-2018Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From January 1, 2018 to March 31, 2018, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
85
6/30/201815.68x41.50x45.07x74.97x71.86x$49,511$435.4537.40%Apr-17-2018Earnings CallIntuitive Surgical, Inc., Q1 2018 Earnings Call, Apr 17, 2018-Intuitive Surgical, Inc., Q1 2018 Earnings Call, Apr 17, 2018
86
6/30/201815.68x41.50x45.07x74.97x71.86x$49,511$435.4537.40%Apr-17-2018Announcement of Earnings, Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2018; Provides Earnings Results Guidance for the Year 2018-Intuitive Surgical, Inc. reported earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported total revenue of $847.5 million against $679.6 million a year ago. Income from operations was $276.7 million against $193.4 million a year ago. Net income was $287.3 million against $180.8 million a year ago. Income before taxes was $289.9 million against $202.1 million a year ago. Net income attributable to company was $287.6 million compared to $180.8 million a year ago. Diluted net income per share was $2.44 against $1.57 per share a year ago. Non-GAAP income from operations was $346.3 million against $265.8 million a year ago. Non-GAAP net income attributable to company was $287.5 million compared to $197.0 million a year ago. Non-GAAP diluted net income per share attributable to company was $2.44 compared to $1.71 a year ago.

The company provided earnings results guidance for the year 2018. The company forecast full year 2018 procedure growth within a range of 11% to 15%. The company refined the range and estimate full year 2018 procedure growth of 12% to 15%. The company forecast 2018 pro forma income tax rate to be between 20% and 22% of pretax income.
87
3/31/201814.29x38.06x41.41x68.48x60.25x$49,939$440.7735.74%Mar-14-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at Barclays Global Healthcare Conference 2018, Mar-14-2018 10:45 AM-Intuitive Surgical, Inc. Presents at Barclays Global Healthcare Conference 2018, Mar-14-2018 10:45 AM. Venue: The Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Calvin Darling, Senior Director of IR, Jamie E. Samath, Principal Accounting Officer, Vice President and Corporate Controller.
88
3/31/201814.29x38.06x41.41x68.48x60.25x$49,877$440.2235.91%Mar-13-2018ConferenceBarclays Capital PLC, Barclays Global Healthcare Conference 2018, Mar 13, 2018 through Mar 15, 2018Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), LivaNova PLC (NasdaqGS:LIVN), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Alkermes plc (NasdaqGS:ALKS), Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR), Mylan N.V. (NasdaqGS:MYL), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), Mirati Therapeutics, Inc. (NasdaqGS:MRTX), Quidel Corporation (NasdaqGS:QDEL), Wright Medical Group N.V. (NasdaqGS:WMGI), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Seattle Genetics, Inc. (NasdaqGS:SGEN), Masimo Corporation (NasdaqGS:MASI), MeiraGTx Holdings plc (NasdaqGS:MGTX), Forty Seven, Inc. (NasdaqGS:FTSV), Syneos Health, Inc. (NasdaqGS:SYNH), Editas Medicine, Inc. (NasdaqGS:EDIT), Advaxis, Inc. (NasdaqGS:ADXS), Cardiovascular Systems, Inc. (NasdaqGS:CSII), Clovis Oncology, Inc. (NasdaqGS:CLVS), CytomX Therapeutics, Inc. (NasdaqGS:CTMX), Precision BioSciences, Inc. (NasdaqGS:DTIL), Moderna, Inc. (NasdaqGS:MRNA), BeiGene, Ltd. (NasdaqGS:BGNE), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), uniQure N.V. (NasdaqGS:QURE), REGENXBIO Inc. (NasdaqGS:RGNX), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Prothena Corporation plc (NasdaqGS:PRTA), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Henry Schein, Inc. (NasdaqGS:HSIC), ICON Public Limited Company (NasdaqGS:ICLR), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Magellan Health, Inc. (NasdaqGS:MGLN), Incyte Corporation (NasdaqGS:INCY), Cerner Corporation (NasdaqGS:CERN), Insulet Corporation (NasdaqGS:PODD), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), AngioDynamics, Inc. (NasdaqGS:ANGO), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Premier, Inc. (NasdaqGS:PINC), Barclays Capital PLC, Genoptix, Inc., Celgene Corporation, Impax Laboratories, Inc., Ortho-Clinical Diagnostics, Inc., Mazor Robotics Ltd., Civitas Solutions, Inc., Celtaxsys, Inc., Tesaro, Inc., Spark Therapeutics, Inc., AveXis, Inc., K2M Group Holdings, Inc., Oxford Nanopore Technologies, Inc., Cotiviti Holdings, Inc., Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Koninklijke Philips N.V. (ENXTAM:PHIA), Pfenex Inc. (AMEX:PFNX), AstraZeneca PLC (LSE:AZN), UDG Healthcare plc (LSE:UDG), Exalenz Bioscience Ltd (TASE:EXEN), DiaSorin S.p.A. (BIT:DIA), EssilorLuxottica Société anonyme (ENXTPA:EL), DBV Technologies S.A. (ENXTPA:DBV), H. Lundbeck A/S (CPSE:LUN), Coloplast A/S (CPSE:COLO B), Novo Nordisk A/S (CPSE:NOVO B), QIAGEN N.V. (NYSE:QGEN), DaVita Inc. (NYSE:DVA), Universal Health Services, Inc. (NYSE:UHS), Allergan plc (NYSE:AGN), Integer Holdings Corporation (NYSE:ITGR), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Tenet Healthcare Corporation (NYSE:THC), Charles River Laboratories International, Inc. (NYSE:CRL), Johnson & Johnson (NYSE:JNJ), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), MAXIMUS, Inc. (NYSE:MMS), Abbott Laboratories (NYSE:ABT), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), HCA Healthcare, Inc. (NYSE:HCA), Eli Lilly and Company (NYSE:LLY), Merck & Co., Inc. (NYSE:MRK), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), AmerisourceBergen Corporation (NYSE:ABC), Bayer Aktiengesellschaft (XTRA:BAYN), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Fresenius SE & Co. KGaA (XTRA:FRE), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Laboratory Corporation of America Holdings (NYSE:LH), Medtronic plc (NYSE:MDT), Hill-Rom Holdings, Inc. (NYSE:HRC), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), Avanos Medical, Inc. (NYSE:AVNS), Mallinckrodt plc (NYSE:MNK), AbbVie Inc. (NYSE:ABBV), Zymeworks Inc. (NYSE:ZYME), WellCare Health Plans, Inc. (NYSE:WCG), Genesis Healthcare, Inc. (NYSE:GEN), Brookdale Senior Living Inc. (NYSE:BKD), Globus Medical, Inc. (NYSE:GMED), Diplomat Pharmacy, Inc. (NYSE:DPLO), Bausch Health Companies Inc. (NYSE:BHC), Teleflex Incorporated (NYSE:TFX), Varian Medical Systems, Inc. (NYSE:VAR), Boston Scientific Corporation (NYSE:BSX), Perrigo Company plc (NYSE:PRGO), Myovant Sciences Ltd. (NYSE:MYOV), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND), CRISPR Therapeutics AG (NasdaqGM:CRSP), Intellia Therapeutics, Inc. (NasdaqGM:NTLA), Foamix Pharmaceuticals Ltd. (NasdaqGM:FOMX), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), Revance Therapeutics, Inc. (NasdaqGM:RVNC), Marinus Pharmaceuticals, Inc. (NasdaqGM:MRNS), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Oxford Immunotec Global PLC (NasdaqGM:OXFD), Acceleron Pharma Inc. (NasdaqGM:XLRN), Leap Therapeutics, Inc. (NasdaqGM:LPTX), Protagonist Therapeutics, Inc. (NasdaqGM:PTGX), Retrophin, Inc. (NasdaqGM:RTRX), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), Exact Sciences Corporation (NasdaqCM:EXAS), Abeona Therapeutics Inc. (NasdaqCM:ABEO), aTyr Pharma, Inc. (NasdaqCM:LIFE), Intec Pharma Ltd. (NasdaqCM:NTEC), ReWalk Robotics Ltd. (NasdaqCM:RWLK)Barclays Capital PLC, Barclays Global Healthcare Conference 2018, Mar 13, 2018 through Mar 15, 2018. Venue: The Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States.
89
3/31/201814.29x38.06x41.41x68.48x60.25x$48,322$426.5040.28%Mar-06-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at Raymond James 39th Annual Institutional Investors Conference, Mar-06-2018 09:15 AM-Intuitive Surgical, Inc. Presents at Raymond James 39th Annual Institutional Investors Conference, Mar-06-2018 09:15 AM. Venue: J.W. Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, Florida, United States.
90
3/31/201814.29x38.06x41.41x68.48x60.25x$48,068$424.2541.02%Mar-5-2018Executive/Board Change - OtherIntuitive Surgical Name Phil Bradshaw as First General Manager in the United Kingdom and Ireland-Intuitive Surgical has named Phil Bradshaw as its first General Manager in the United Kingdom and Ireland (UK&I). Mr. Bradshaw will direct business strategy and operations for the company in these countries. Mr. Bradshaw brings nearly three decades of experience in the medical device field working for market-leading companies, and more than eight years of general management experience in the UK and European markets. Before joining Intuitive Surgical, Mr. Bradshaw worked at Medtronic as Strategic Alliance Director for EMEA within the Integrated Health Solutions Division.
91
3/31/201814.29x38.06x41.41x68.48x60.25x$0Mar-04-2018ConferenceRaymond James & Associates, Inc., Raymond James 39th Annual Institutional Investors Conference, Mar 04, 2018 through Mar 07, 2018Teligent, Inc. (NasdaqGS:TLGT), Wintrust Financial Corporation (NasdaqGS:WTFC), Cogent Communications Holdings, Inc. (NasdaqGS:CCOI), Ruth's Hospitality Group, Inc. (NasdaqGS:RUTH), Masimo Corporation (NasdaqGS:MASI), Natus Medical Incorporated (NasdaqGS:NTUS), SS&C Technologies Holdings, Inc. (NasdaqGS:SSNC), Stericycle, Inc. (NasdaqGS:SRCL), Qorvo, Inc. (NasdaqGS:QRVO), SBA Communications Corporation (NasdaqGS:SBAC), E*TRADE Financial Corporation (NasdaqGS:ETFC), Herman Miller, Inc. (NasdaqGS:MLHR), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Internap Corporation (NasdaqGS:INAP), Citrix Systems, Inc. (NasdaqGS:CTXS), Cognex Corporation (NasdaqGS:CGNX), CommScope Holding Company, Inc. (NasdaqGS:COMM), NCS Multistage Holdings, Inc. (NasdaqGS:NCSM), Alarm.com Holdings, Inc. (NasdaqGS:ALRM), Gogo Inc. (NasdaqGS:GOGO), CyrusOne Inc. (NasdaqGS:CONE), Atlassian Corporation Plc (NasdaqGS:TEAM), Paylocity Holding Corporation (NasdaqGS:PCTY), ORBCOMM Inc. (NasdaqGS:ORBC), PRA Group, Inc. (NasdaqGS:PRAA), Beacon Roofing Supply, Inc. (NasdaqGS:BECN), Preferred Bank (NasdaqGS:PFBC), Iridium Communications Inc. (NasdaqGS:IRDM), Premier, Inc. (NasdaqGS:PINC), Nasdaq, Inc. (NasdaqGS:NDAQ), Allegiant Travel Company (NasdaqGS:ALGT), IPG Photonics Corporation (NasdaqGS:IPGP), OraSure Technologies, Inc. (NasdaqGS:OSUR), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), Adaptimmune Therapeutics plc (NasdaqGS:ADAP), Uniti Group Inc. (NasdaqGS:UNIT), BlackRock TCP Capital Corp. (NasdaqGS:TCPC), Carrols Restaurant Group, Inc. (NasdaqGS:TAST), Ares Capital Corporation (NasdaqGS:ARCC), Home Bancshares, Inc. (Conway, AR) (NasdaqGS:HOMB), LKQ Corporation (NasdaqGS:LKQ), HealthEquity, Inc. (NasdaqGS:HQY), SunPower Corporation (NasdaqGS:SPWR), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Trimble Inc. (NasdaqGS:TRMB), Quidel Corporation (NasdaqGS:QDEL), ACI Worldwide, Inc. (NasdaqGS:ACIW), Willis Towers Watson Public Limited Company (NasdaqGS:WLTW), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Avnet, Inc. (NasdaqGS:AVT), PotlatchDeltic Corporation (NasdaqGS:PCH), SEI Investments Company (NasdaqGS:SEIC), Seacoast Banking Corporation of Florida (NasdaqGS:SBCF), Mylan N.V. (NasdaqGS:MYL), Dawson Geophysical Company (NasdaqGS:DWSN), Fastenal Company (NasdaqGS:FAST), Red Robin Gourmet Burgers, Inc. (NasdaqGS:RRGB), TripAdvisor, Inc. (NasdaqGS:TRIP), Texas Capital Bancshares, Inc. (NasdaqGS:TCBI), FLIR Systems, Inc. (NasdaqGS:FLIR), Tractor Supply Company (NasdaqGS:TSCO), ATN International, Inc. (NasdaqGS:ATNI), The Cheesecake Factory Incorporated (NasdaqGS:CAKE), Merit Medical Systems, Inc. (NasdaqGS:MMSI), ICU Medical, Inc. (NasdaqGS:ICUI), Hancock Whitney Corporation (NasdaqGS:HWC), Patterson-UTI Energy, Inc. (NasdaqGS:PTEN), ScanSource, Inc. (NasdaqGS:SCSC), TD Ameritrade Holding Corporation (NasdaqGS:AMTD), Viasat, Inc. (NasdaqGS:VSAT), Atlantic Union Bankshares Corporation (NasdaqGS:AUB), CDW Corporation (NasdaqGS:CDW), United Bankshares, Inc. (NasdaqGS:UBSI), Bank OZK (NasdaqGS:OZK), Pacific Premier Bancorp, Inc. (NasdaqGS:PPBI), Cboe Global Markets, Inc. (BATS:CBOE), Viveve Medical, Inc. (NasdaqCM:VIVE), Antares Pharma, Inc. (NasdaqCM:ATRS), TG Therapeutics, Inc. (NasdaqCM:TGTX), The Habit Restaurants, Inc. (NasdaqGM:HABT), Adverum Biotechnologies, Inc. (NasdaqGM:ADVM), TPI Composites, Inc. (NasdaqGM:TPIC), ADMA Biologics, Inc. (NasdaqGM:ADMA), Flexion Therapeutics, Inc. (NasdaqGM:FLXN), First Foundation Inc. (NasdaqGM:FFWM), Everbridge, Inc. (NasdaqGM:EVBG), Malibu Boats, Inc. (NasdaqGM:MBUU), Rapid7, Inc. (NasdaqGM:RPD), Newtek Business Services Corp. (NasdaqGM:NEWT), Applied Optoelectronics, Inc. (NasdaqGM:AAOI), ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP), The Allstate Corporation (NYSE:ALL), S&P Global Inc. (NYSE:SPGI), Raymond James Financial, Inc. (NYSE:RJF), Roper Technologies, Inc. (NYSE:ROP), Alliance Data Systems Corporation (NYSE:ADS), American Tower Corporation (REIT) (NYSE:AMT), AutoZone, Inc. (NYSE:AZO), Ethan Allen Interiors Inc. (NYSE:ETH), FleetCor Technologies, Inc. (NYSE:FLT), Concho Resources Inc. (NYSE:CXO), Crown Castle International Corp. (REIT) (NYSE:CCI), Dine Brands Global, Inc. (NYSE:DIN), Kansas City Southern (NYSE:KSU), Laboratory Corporation of America Holdings (NYSE:LH), Leggett & Platt, Incorporated (NYSE:LEG), WEX Inc. (NYSE:WEX), Charles River Laboratories International, Inc. (NYSE:CRL), Superior Energy Services, Inc. (NYSE:SPN), Helix Energy Solutions Group, Inc. (NYSE:HLX), CACI International Inc (NYSE:CACI), Oil States International, Inc. (NYSE:OIS), Fortive Corporation (NYSE:FTV), AAC Holdings, Inc. (OTCPK:AACH), Vocera Communications, Inc. (NYSE:VCRA), Tempur Sealy International, Inc. (NYSE:TPX), American Equity Investment Life Holding Company (NYSE:AEL), Whiting Petroleum Corporation (NYSE:WLL), Spirit Airlines, Inc. (NYSE:SAVE), Broadridge Financial Solutions, Inc. (NYSE:BR), QEP Resources, Inc. (NYSE:QEP), Lannett Company, Inc. (NYSE:LCI), Moody's Corporation (NYSE:MCO), Enterprise Products Partners L.P. (NYSE:EPD), WESCO International, Inc. (NYSE:WCC), Cadence Bancorporation (NYSE:CADE), Main Street Capital Corporation (NYSE:MAIN), Cable One, Inc. (NYSE:CABO), CatchMark Timber Trust, Inc. (NYSE:CTT), Palo Alto Networks, Inc. (NYSE:PANW), Delek US Holdings, Inc. (NYSE:DK), Prestige Consumer Healthcare Inc. (NYSE:PBH), Digital Realty Trust, Inc. (NYSE:DLR), MSCI Inc. (NYSE:MSCI), Alteryx, Inc. (NYSE:AYX), WellCare Health Plans, Inc. (NYSE:WCG), Catalent, Inc. (NYSE:CTLT), Envestnet, Inc. (NYSE:ENV), Switch, Inc. (NYSE:SWCH), Chegg, Inc. (NYSE:CHGG), Wayfair Inc. (NYSE:W), Q2 Holdings, Inc. (NYSE:QTWO), New Relic, Inc. (NYSE:NEWR), MRC Global Inc. (NYSE:MRC), Steelcase Inc. (NYSE:SCS), Waste Connections, Inc. (NYSE:WCN), Republic Services, Inc. (NYSE:RSG), Quest Diagnostics Incorporated (NYSE:DGX), Toll Brothers, Inc. (NYSE:TOL), Rayonier Inc. (NYSE:RYN), New York Community Bancorp, Inc. (NYSE:NYCB), Teleflex Incorporated (NYSE:TFX), Service Corporation International (NYSE:SCI), Stanley Black & Decker, Inc. (NYSE:SWK), Union Pacific Corporation (NYSE:UNP), Valero Energy Corporation (NYSE:VLO), Walmart Inc. (NYSE:WMT), Covanta Holding Corporation (NYSE:CVA), Ryman Hospitality Properties, Inc. (NYSE:RHP), ProAssurance Corporation (NYSE:PRA), Baxter International Inc. (NYSE:BAX), HCA Healthcare, Inc. (NYSE:HCA), Cubic Corporation (NYSE:CUB), First Republic Bank (NYSE:FRC), W.W. Grainger, Inc. (NYSE:GWW), HNI Corporation (NYSE:HNI), The Home Depot, Inc. (NYSE:HD), La-Z-Boy Incorporated (NYSE:LZB), Pioneer Natural Resources Company (NYSE:PXD), Polaris Inc. (NYSE:PII), Booz Allen Hamilton Holding Corporation (NYSE:BAH), Brunswick Corporation (NYSE:BC), Cardinal Health, Inc. (NYSE:CAH), Masco Corporation (NYSE:MAS), Waste Management, Inc. (NYSE:WM), Unit Corporation (NYSE:UNT), United Parcel Service, Inc. (NYSE:UPS), Agnico Eagle Mines Limited (NYSE:AEM), Aflac Incorporated (NYSE:AFL), Argo Group International Holdings, Ltd. (NYSE:ARGO), Arrow Electronics, Inc. (NYSE:ARW), Becton, Dickinson and Company (NYSE:BDX), D.R. Horton, Inc. (NYSE:DHI), Weyerhaeuser Company (NYSE:WY), TETRA Technologies, Inc. (NYSE:TTI), salesforce.com, inc. (NYSE:CRM), Instructure, Inc. (NYSE:INST), Parsley Energy, Inc. (NYSE:PE), Pebblebrook Hotel Trust (NYSE:PEB), California Resources Corporation (NYSE:CRC), Zayo Group Holdings, Inc. (NYSE:ZAYO), Foundation Building Materials, Inc. (NYSE:FBM), Mallinckrodt plc (NYSE:MNK), Murphy USA Inc. (NYSE:MUSA), Physicians Realty Trust (NYSE:DOC), NOW Inc. (NYSE:DNOW), EnLink Midstream, LLC (NYSE:ENLC), Avanos Medical, Inc. (NYSE:AVNS), Fortress Transportation and Infrastructure Investors LLC (NYSE:FTAI), AquaVenture Holdings Limited (NYSE:WAAS), Jernigan Capital, Inc. (NYSE:JCAP), Safehold Inc. (NYSE:SAFE), Abaxis, Inc., Spectrum Brands Legacy, Inc., ARRIS International Limited, Oclaro, Inc., SunTrust Banks, Inc., Andeavor, Carrizo Oil & Gas, Inc., Genesee & Wyoming Inc., Envision Healthcare Corporation, Raymond James & Associates, Inc., EnLink Midstream Partners, LP, J.B. Hunt Transport, Inc., Vital Therapies, Inc., Control4 Corporation, Civitas Solutions, Inc., SRC Energy Inc., Cotiviti Holdings, Inc., Senseonics Holdings, Inc. (AMEX:SENS), Lineage Cell Therapeutics, Inc. (AMEX:LCTX), MiX Telematics Limited (JSE:MIX), Norbord Inc. (TSX:OSB), Algonquin Power & Utilities Corp. (TSX:AQN), Gildan Activewear Inc. (TSX:GIL)Raymond James & Associates, Inc., Raymond James 39th Annual Institutional Investors Conference, Mar 04, 2018 through Mar 07, 2018. Venue: J.W. Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, Florida, United States.
92
3/31/201814.29x38.06x41.41x68.48x60.25x$47,242$416.9643.49%Feb-2-2018Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From October 1, 2017 to December 31, 2017, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
93
3/31/201814.29x38.06x41.41x68.48x60.25x$50,963$449.8133.01%Jan-25-2018Earnings CallIntuitive Surgical, Inc., Q4 2017 Earnings Call, Jan 25, 2018-Intuitive Surgical, Inc., Q4 2017 Earnings Call, Jan 25, 2018
94
3/31/201814.29x38.06x41.41x68.48x60.25x$50,963$449.8133.01%Jan-25-2018Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Provides Earnings Guidance for the Year 2018-Intuitive Surgical, Inc. provided earnings guidance for the year 2018. For the year, the company expects pro forma gross profit margin to be within a range of between 70% and 71.5% net revenue. The company is projecting a modestly lower gross profit margin in 2018, reflecting higher costs associated with new products. The company expects pro forma income tax rate to be between 20% and 22% of pretax income. The company announced that will continue to make substantive investments in several strategic areas that are poised to benefit the company over the long run. As a result, the company expects to grow 2018 pro forma operating expenses between 16% and 18% above 2017 levels and expects other income, which is comprised mostly of interest income, to total between $45 million and $55 million in 2018.
95
3/31/201814.29x38.06x41.41x68.48x60.25x$50,963$449.8133.01%Jan-25-2018Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended Dec. 31, 2017-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended Dec. 31, 2017. For the quarter, the company’s total revenue was $892.4 million compared with $756.9 million a year ago. Income from operations was $327.0 million compared with $264.4 million a year ago. Income before taxes was $339.3 million compared with $276.1 million a year ago. Net loss was $38.8 million compared with net income of $204.0 million a year ago. Diluted net loss per share was $0.35 compared with income of $1.71 a year ago. Non-GAAP income from operations was $384.1 million compared with $319.7 million a year ago. Non-GAAP net income was $297.7 million compared with $242.3 million a year ago. Diluted non-GAAP net income per share was $2.54 compared with $2.03 a year ago. Higher fourth quarter revenue was driven by increased procedures and systems placements. Fourth quarter 2017 GAAP net loss reflected $318 million, or $2.83 per diluted share, of income tax expense as a result of the Tax Cuts and Jobs Act (2017 Tax Act") enacted on December 22, 2017. This amount primarily relates to a one-time deemed repatriation tax on undistributed foreign earnings and revaluation of deferred taxes due to a reduction of the U.S. corporate income tax rate.


For the full year, the company reported total revenue was $3,128.9 million compared with $2,704.4 million a year ago. Income from operations was $1,054.6 million compared with $945.2 million a year ago. Income before taxes was $1,096.5 million compared with $980.8 million a year ago. Net income was $660.0 million compared with $735.9 million a year ago. Diluted net income per share was $5.67 compared with $6.24 a year ago. Non-GAAP income from operations was $1,307.6 million compared with $1,153.5 million a year ago. Non-GAAP net income was $1,045.9 million compared with $878.7 million a year ago. Diluted non-GAAP net income per share was $8.99 compared with $7.45 a year ago.
96
3/31/201814.29x38.06x41.41x68.48x60.25x$47,741$421.3741.99%Jan-11-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-11-2018 09:00 AM-Intuitive Surgical, Inc. Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-11-2018 09:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Gary S. Guthart, CEO, President & Director.
97
3/31/201814.29x38.06x41.41x68.48x60.25x$48,012$423.7641.19%Jan-10-2018Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2017-Intuitive Surgical, Inc. provided unaudited revenue guidance for the fourth quarter and full year of 2017. The company expects revenue for the fourth quarter of 2017 of approximately $892 million, an increase of approximately 18% compared with $757 million for the fourth quarter of 2016.

The company expects 2017 revenue of approximately $3.1 billion, an increase of approximately 16% compared with $2.7 billion for 2016.
98
3/31/201814.29x38.06x41.41x68.48x60.25x$44,398$391.8652.68%Jan-8-2018ConferenceJPMorgan Chase & Co., 36th Annual J.P. Morgan Healthcare Conference, Jan 08, 2018 through Jan 11, 2018Microsoft Corporation (NasdaqGS:MSFT), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Aduro BioTech, Inc. (NasdaqGS:ADRO), ChemoCentryx, Inc. (NasdaqGS:CCXI), Mersana Therapeutics, Inc. (NasdaqGS:MRSN), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), LHC Group, Inc. (NasdaqGS:LHCG), AngioDynamics, Inc. (NasdaqGS:ANGO), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), ICON Public Limited Company (NasdaqGS:ICLR), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Endologix, Inc. (NasdaqGS:ELGX), Patterson Companies, Inc. (NasdaqGS:PDCO), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), ICU Medical, Inc. (NasdaqGS:ICUI), Mylan N.V. (NasdaqGS:MYL), Premier, Inc. (NasdaqGS:PINC), Accuray Incorporated (NasdaqGS:ARAY), OraSure Technologies, Inc. (NasdaqGS:OSUR), Bruker Corporation (NasdaqGS:BRKR), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Cerner Corporation (NasdaqGS:CERN), CONMED Corporation (NasdaqGS:CNMD), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Quidel Corporation (NasdaqGS:QDEL), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Bio-Techne Corporation (NasdaqGS:TECH), Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR), CymaBay Therapeutics, Inc. (NasdaqGS:CBAY), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Repligen Corporation (NasdaqGS:RGEN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), United Therapeutics Corporation (NasdaqGS:UTHR), Wright Medical Group N.V. (NasdaqGS:WMGI), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Teligent, Inc. (NasdaqGS:TLGT), DexCom, Inc. (NasdaqGS:DXCM), Hologic, Inc. (NasdaqGS:HOLX), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Masimo Corporation (NasdaqGS:MASI), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Omnicell, Inc. (NasdaqGS:OMCL), Orthofix Medical Inc. (NasdaqGS:OFIX), Alkermes plc (NasdaqGS:ALKS), Tivity Health, Inc. (NasdaqGS:TVTY), Amgen Inc. (NasdaqGS:AMGN), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Endo International plc (NasdaqGS:ENDP), Biogen Inc. (NasdaqGS:BIIB), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Vir Biotechnology, Inc. (NasdaqGS:VIR), Eidos Therapeutics, Inc. (NasdaqGS:EIDX), Orchard Therapeutics plc (NasdaqGS:ORTX), Aptinyx Inc. (NasdaqGS:APTX), Rubius Therapeutics, Inc. (NasdaqGS:RUBY), Varex Imaging Corporation (NasdaqGS:VREX), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Twist Bioscience Corporation (NasdaqGS:TWST), ObsEva SA (NasdaqGS:OBSV), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Editas Medicine, Inc. (NasdaqGS:EDIT), Tricida, Inc. (NasdaqGS:TCDA), Guardant Health, Inc. (NasdaqGS:GH), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), Prothena Corporation plc (NasdaqGS:PRTA), 10x Genomics, Inc. (NasdaqGS:TXG), MyoKardia, Inc. (NasdaqGS:MYOK), Seres Therapeutics, Inc. (NasdaqGS:MCRB), Jounce Therapeutics, Inc. (NasdaqGS:JNCE), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Crinetics Pharmaceuticals, Inc. (NasdaqGS:CRNX), Syneos Health, Inc. (NasdaqGS:SYNH), Livongo Health, Inc. (NasdaqGS:LVGO), TCR2 Therapeutics Inc. (NasdaqGS:TCRR), Kaleido BioSciences, Inc. (NasdaqGS:KLDO), Axovant Gene Therapies Ltd. (NasdaqGS:AXGT), Denali Therapeutics Inc. (NasdaqGS:DNLI), Kezar Life Sciences, Inc. (NasdaqGS:KZR), Forty Seven, Inc. (NasdaqGS:FTSV), IDEAYA Biosciences, Inc. (NasdaqGS:IDYA), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), InflaRx N.V. (NasdaqGS:IFRX), Inovalon Holdings, Inc. (NasdaqGS:INOV), Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST), Clovis Oncology, Inc. (NasdaqGS:CLVS), BioNTech SE (NasdaqGS:BNTX), Otonomy, Inc. (NasdaqGS:OTIC), NovoCure Limited (NasdaqGS:NVCR), Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS), Assembly Biosciences, Inc. (NasdaqGS:ASMB), Adaptive Biotechnologies Corporation (NasdaqGS:ADPT), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Progyny, Inc. (NasdaqGS:PGNY), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), Moderna, Inc. (NasdaqGS:MRNA), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), G1 Therapeutics, Inc. (NasdaqGS:GTHX), iRhythm Technologies, Inc. (NasdaqGS:IRTC), Ascendis Pharma A/S (NasdaqGS:ASND), IVERIC bio, Inc. (NasdaqGS:ISEE), Conformis, Inc. (NasdaqGS:CFMS), Intrexon Corporation (NasdaqGS:XON), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), R1 RCM Inc. (NasdaqGS:RCM), Natera, Inc. (NasdaqGS:NTRA), China Biologic Products Holdings, Inc. (NasdaqGS:CBPO), AnaptysBio, Inc. (NasdaqGS:ANAB), HealthEquity, Inc. (NasdaqGS:HQY), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Inogen, Inc. (NasdaqGS:INGN), Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH), Race Oncology Limited (ASX:RAC), Mesoblast Limited (ASX:MSB), Immutep Limited (ASX:IMM), Benitec Biopharma Limited (ASX:BLT), CSL Limited (ASX:CSL), Biocartis Group NV (ENXTBR:BCART), UCB SA (ENXTBR:UCB), Qualicorp Consultoria e Corretora de Seguros S.A. (BOVESPA:QUAL3), Instituto Hermes Pardini S.A. (BOVESPA:PARD3), Fleury S.A. (BOVESPA:FLRY3), Ouro Fino Saúde Animal Participações S.A. (BOVESPA:OFSA3), Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079), Raia Drogasil S.A. (BOVESPA:RADL3), Medivir AB (publ) (OM:MVIR B), Swedish Orphan Biovitrum AB (publ) (OM:SOBI), Hanmi Pharm. Co., Ltd. (KOSE:A128940), Samsung Biologics Co.,Ltd. (KOSE:A207940), Celltrion, Inc. (KOSE:A068270), LG Chem, Ltd. (KOSE:A051910), Isofol Medical AB (publ) (OM:ISOFOL), Moberg Pharma AB (publ) (OM:MOB), Molecular Partners AG (SWX:MOLN), Kiadis Pharma N.V. (ENXTAM:KDS), Koninklijke Philips N.V. (ENXTAM:PHIA), Curetis N.V. (ENXTAM:CURE), Daiichi Sankyo Company, Limited (TSE:4568), Otsuka Holdings Co., Ltd. (TSE:4578), SanBio Company Limited (TSE:4592), Healios K.K. (TSE:4593), IHH Healthcare Berhad (KLSE:IHH), Abcam plc (AIM:ABC), TransEnterix, Inc. (AMEX:TRXC), Hikma Pharmaceuticals PLC (LSE:HIK), NMC Health Plc (LSE:NMC), Indivior PLC (LSE:INDV), Basilea Pharmaceutica AG (SWX:BSLN), Tecan Group Ltd. (SWX:TECN), Vifor Pharma AG (SWX:VIFN), Roche Holding AG (SWX:ROG), Lonza Group Ltd (SWX:LONN), Novartis AG (SWX:NOVN), UDG Healthcare plc (LSE:UDG), Mediclinic International plc (LSE:MDC), Vectura Group plc (LSE:VEC), GlaxoSmithKline plc (LSE:GSK), Innate Pharma S.A. (ENXTPA:IPH), Sanofi (ENXTPA:SAN), Transgene SA (ENXTPA:TNG), Cellectis S.A. (ENXTPA:ALCLS), DBV Technologies S.A. (ENXTPA:DBV), Onxeo SA (ENXTPA:ONXEO), Ipsen S.A. (ENXTPA:IPN), ERYTECH Pharma S.A. (ENXTPA:ERYP), Valbiotis SA (ENXTPA:ALVAL), GN Store Nord A/S (CPSE:GN), Ambu A/S (CPSE:AMBU B), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294), DiaSorin S.p.A. (BIT:DIA), Konica Minolta, Inc. (TSE:4902), Takeda Pharmaceutical Company Limited (TSE:4502), Astellas Pharma Inc. (TSE:4503), NanoCarrier Co., Ltd. (TSE:4571), Sosei Group Corporation (TSE:4565), Santen Pharmaceutical Co., Ltd. (TSE:4536), Lupin Limited (BSE:500257), Sino Biopharmaceutical Limited (SEHK:1177), Dr. Reddy's Laboratories Limited (BSE:500124), 3SBio Inc. (SEHK:1530), Lee's Pharmaceutical Holdings Limited (SEHK:950), Innovent Biologics, Inc. (SEHK:1801), Hua Medicine (Shanghai) Ltd. (SEHK:2552), VR Adviser, LLC, Abaxis, Inc., Array BioPharma Inc., The Medicines Company, Agiliti Health, Inc., Temasek Holdings (Private) Limited, athenahealth, Inc., BTG Limited, Intas Pharmaceuticals Limited, Ascension Health, Inc., CommonSpirit Health, Dignity Health, Analogic Corporation, Celgene Corporation, Express Scripts Holding Company, Legacy LifePoint Health, Inc., Apricus Biosciences, Inc., Impax Laboratories, Inc., Shire plc, Keryx Biopharmaceuticals, Inc., The MicroBio Group Limited, Aetna Inc., Ortho-Clinical Diagnostics, Inc., Advocate Health Care, Inc., PHC Corporation, AdventHealth, Blue Cross and Blue Shield of Florida, Inc., Baylor Scott & White Health LLC, Cable News Network, Inc., Medidata Solutions, Inc., Cogentix Medical, Inc., InTouch Technologies, Inc., Genomic Health, Inc., Prospect Medical Holdings, Inc., Ablynx NV, Johns Hopkins University, Partners HealthCare System, Inc., Bill & Melinda Gates Foundation, Henry Ford Health System, Intermountain Healthcare, Inc., Northwell Health, Inc., Steward Health Care System, LLC, Parkview Health System, Inc., WakeMed Health & Hospitals, Inc., Aurora Health Care, Inc., FOX News Network, LLC, Phoenix Children's Hospital, Inc., Pharmaceutical Research and Manufacturers of America, Northwestern Memorial Healthcare Corporation, Cincinnati Children's Hospital Medical Center, Boehringer Ingelheim GmbH, American Specialty Health Incorporated, LTS Lohmann Therapie-Systeme AG, ABILITY Network Inc., Straith Hospital For Special Surgery Inc, Indiana University School of Medicine, Capitol Street Corporation, Centers for Medicare & Medicaid Services, Fresenius Medical Care Groupe France SAS, Stanford University School of Medicine, U.S. Food and Drug Administration, GenScript Corporation, Selexis SA, TxCell S.A., MedDay SA, CureVac AG, Alder BioPharmaceuticals, Inc., Prolong Pharmaceuticals, LLC, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Orchid Orthopedic Solutions LLC, EUSA Pharma, Inc., Envigo International Holdings, Inc., PatientsLikeMe, Inc., 23andMe, Inc., Amplyx Pharmaceuticals, Inc., Grupo Farmaceutico Biotoscana S.A., Inspire Medical, Inc., Vascular Therapies, Inc., Femasys Inc., RCCH HealthCare Partners, Augmenix, Inc., DNAnexus, Inc., TraceLink, Inc., Ascentage Pharma Group Corporation, Ltd., Mitra Biotech Pvt Ltd, Foundation Medicine, Inc., HeartFlow, Inc., Sharecare Inc., Arrail Dental International Group Co. Ltd., Prognos Health Inc., Welltok, Inc., Nuvaira, Inc., Springstone, Inc., Genalyte, Inc., Direct Vet Marketing, Inc., Ascletis, Inc., One Medical Group, Inc., Fountain Biopharma Inc., SK Biopharmaceuticals Co., Ltd., Columbia Pacific Healthcare Sdn Bhd, Geisinger Health System, OvaScience, Inc., Ignyta, Inc., Hookipa Biotech AG, NantWorks, LLC, Abide Therapeutics Inc., H3 Biomedicine Inc., Cartiva, Inc., HealthLoop, Inc., GoodRx, Inc., NuMedii, Inc., Practo Technologies Private Limited, NeuClone Pty. Limited, Audentes Therapeutics, Inc., Oscar Insurance Corporation, MedAvail Technologies Inc., Spark Therapeutics, Inc., Juno Therapeutics, Inc., Centrexion Therapeutics Corporation, Agilis Biotherapeutics, LLC, Clementia Pharmaceuticals Inc., Guang Dong No.1 Pharmacy Chains Co. Ltd., K2M Group Holdings, Inc., Maravai Life Sciences Inc., Pear Therapeutics, Inc., Notre Dame Intermédica Saúde S.A., University Wisconsin Health, Centogene AG, Big3Bio, WuXi Nextcode Genomics, Inc., Outset Medical, Inc., Caris Life Sciences, Inc., Carbon, Inc., China Pharmaceutical Innovation and Research Development Association, Ping An Health Cloud Company Limited, Codiak BioSciences, Inc., Verily Life Sciences LLC, NeuroRx, Inc., Mercy Health, Smart Labs, LLC, iCarbonx, IBM Watson Health, Inc., Luye Medical Group Co., Ltd, Cotiviti Holdings, Inc., Virtual Frameworks, Inc., Bioventus LLC, CStone Pharmaceuticals (Suzhou) Co., Ltd., Bioverativ Inc., Dova Pharmaceuticals, Inc., Kiniksa Pharmaceuticals Corp., BenevolentAI Limited, PepVax, Inc, General Catalyst LLC, MOBE LLC, Froedtert & the Medical College of Wisconsin, Three Lakes Partners, Ginkgo, SpringWorks Therapeutics, LLC, Prestige Bio Pharmaceuticals Co. Ltd., Pneuma Respiratory, Inc., BGI Group Limited, Grace Therapeutics, LLC, Glenmark Pharmaceuticals Limited (NSEI:GLENMARK), Aurobindo Pharma Limited (NSEI:AUROPHARMA), Wockhardt Limited (NSEI:WOCKPHARMA), Cipla Limited (NSEI:CIPLA), Melinta Therapeutics, Inc. (OTCPK:MLNT.Q), Medizone International, Inc. (OTCPK:MZEI.Q), Achaogen, Inc. (OTCPK:AKAO.Q), GeoVax Labs, Inc. (OTCPK:GOVX), MiMedx Group, Inc. (OTCPK:MDXG), INSYS Therapeutics, Inc. (OTCPK:INSY.Q), Propanc Biopharma, Inc. (OTCPK:PPCB), Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q), MorphoSys AG (XTRA:MOR), Medigene AG (XTRA:MDG1), Bayer Aktiengesellschaft (XTRA:BAYN), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Evotec SE (XTRA:EVT), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Seegene, Inc. (KOSDAQ:A096530), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Diplomat Pharmacy, Inc. (NYSE:DPLO), Veeva Systems Inc. (NYSE:VEEV), Nevro Corp. (NYSE:NVRO), Penumbra, Inc. (NYSE:PEN), Select Medical Holdings Corporation (NYSE:SEM), Teladoc Health, Inc. (NYSE:TDOC), WellCare Health Plans, Inc. (NYSE:WCG), Emergent BioSolutions Inc. (NYSE:EBS), Catalent, Inc. (NYSE:CTLT), AbbVie Inc. (NYSE:ABBV), Castlight Health, Inc. (NYSE:CSLT), Avanos Medical, Inc. (NYSE:AVNS), Evolent Health, Inc. (NYSE:EVH), Zoetis Inc. (NYSE:ZTS), Invitae Corporation (NYSE:NVTA), Myovant Sciences Ltd. (NYSE:MYOV), Mallinckrodt plc (NYSE:MNK), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Amarin Corporation plc (NasdaqGM:AMRN), Immunomedics, Inc. (NasdaqGM:IMMU), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), Chimerix, Inc. (NasdaqGM:CMRX), AtriCure, Inc. (NasdaqGM:ATRC), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Magenta Therapeutics, Inc. (NasdaqGM:MGTA), Quotient Limited (NasdaqGM:QTNT), Zai Lab Limited (NasdaqGM:ZLAB), Verrica Pharmaceuticals Inc. (NasdaqGM:VRCA), Coherus BioSciences, Inc. (NasdaqGM:CHRS), UroGen Pharma Ltd. (NasdaqGM:URGN), Quanterix Corporation (NasdaqGM:QTRX), Ardelyx, Inc. (NasdaqGM:ARDX), Retrophin, Inc. (NasdaqGM:RTRX), Clearside Biomedical, Inc. (NasdaqGM:CLSD), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Axcella Health Inc. (NasdaqGM:AXLA), NanoString Technologies, Inc. (NasdaqGM:NSTG), Radius Health, Inc. (NasdaqGM:RDUS), Lantheus Holdings, Inc. (NasdaqGM:LNTH), Acceleron Pharma Inc. (NasdaqGM:XLRN), Oxford Immunotec Global PLC (NasdaqGM:OXFD), NewLink Genetics Corporation (NasdaqGM:NLNK), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Merus N.V. (NasdaqGM:MRUS), Intersect ENT, Inc. (NasdaqGM:XENT), Glaukos Corporation (NYSE:GKOS), Vocera Communications, Inc. (NYSE:VCRA), Molina Healthcare, Inc. (NYSE:MOH), Genesis Healthcare, Inc. (NYSE:GEN), Invacare Corporation (NYSE:IVC), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), 3M Company (NYSE:MMM), Owens & Minor, Inc. (NYSE:OMI), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), Perrigo Company plc (NYSE:PRGO), Bausch Health Companies Inc. (NYSE:BHC), Edwards Lifesciences Corporation (NYSE:EW), Boston Scientific Corporation (NYSE:BSX), ResMed Inc. (NYSE:RMD), Quest Diagnostics Incorporated (NYSE:DGX), Alexandria Real Estate Equities, Inc. (NYSE:ARE), JPMorgan Chase & Co. (NYSE:JPM), JPMorgan Chase & Co. (NYSE:JPM), Laboratory Corporation of America Holdings (NYSE:LH), Mettler-Toledo International Inc. (NYSE:MTD), AmerisourceBergen Corporation (NYSE:ABC), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Hill-Rom Holdings, Inc. (NYSE:HRC), Rite Aid Corporation (NYSE:RAD), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), International Business Machines Corporation (NYSE:IBM), Tenet Healthcare Corporation (NYSE:THC), Charles River Laboratories International, Inc. (NYSE:CRL), Becton, Dickinson and Company (NYSE:BDX), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), DaVita Inc. (NYSE:DVA), STERIS plc (NYSE:STE), Universal Health Services, Inc. (NYSE:UHS), Medtronic plc (NYSE:MDT), QIAGEN N.V. (NYSE:QGEN), Welltower Inc. (NYSE:WELL), Danaher Corporation (NYSE:DHR), PerkinElmer, Inc. (NYSE:PKI), The Cooper Companies, Inc. (NYSE:COO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Agilent Technologies, Inc. (NYSE:A), Abbott Laboratories (NYSE:ABT), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Cantel Medical Corp. (NYSE:CMD), Johnson & Johnson (NYSE:JNJ), Model N, Inc. (NYSE:MODN), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), General Electric Company (NYSE:GE), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), Heron Therapeutics, Inc. (NasdaqCM:HRTX), Exact Sciences Corporation (NasdaqCM:EXAS), La Jolla Pharmaceutical Company (NasdaqCM:LJPC), Plus Therapeutics, Inc. (NasdaqCM:PSTV), Tyme Technologies, Inc. (NasdaqCM:TYME), Millendo Therapeutics, Inc. (NasdaqCM:MLND), TG Therapeutics, Inc. (NasdaqCM:TGTX), DelMar Pharmaceuticals, Inc. (NasdaqCM:DMPI), aTyr Pharma, Inc. (NasdaqCM:LIFE), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), Stemline Therapeutics, Inc. (NasdaqCM:STML), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), Dynavax Technologies Corporation (NasdaqCM:DVAX), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), VistaGen Therapeutics, Inc. (NasdaqCM:VTGN), Microbio Co., Ltd. (GTSM:4128), OBI Pharma, Inc. (GTSM:4174), Oneness Biotech Co., Ltd. (GTSM:4743), Taiwan Liposome Company, Ltd. (GTSM:4152), JHL Biotech, Inc. (GTSM:6540), ASLAN Pharmaceuticals Limited (GTSM:6497)JPMorgan Chase & Co., 36th Annual J.P. Morgan Healthcare Conference, Jan 08, 2018 through Jan 11, 2018. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States.
99
12/31/201712.94x34.71x37.84x63.92x51.24x$43,098$383.7855.89%Dec-07-2017Company Conference PresentationIntuitive Surgical, Inc. Presents at Citi Global Healthcare Conference, Dec-07-2017 10:15 AM-Intuitive Surgical, Inc. Presents at Citi Global Healthcare Conference, Dec-07-2017 10:15 AM. Venue: Lotte New York Palace, New York, New York, United States. Speakers: Calvin Darling, Senior Director, IR, Marshall L. Mohr, Senior VP & CFO.
100
12/31/201712.94x34.71x37.84x63.92x51.24x$42,566$379.0457.84%Dec-6-2017Company Conference PresentationIntuitive Surgical, Inc. Presents at Embedded Systems Conference & Expo 2017, Dec-06-2017 03:00 PM-Intuitive Surgical, Inc. Presents at Embedded Systems Conference & Expo 2017, Dec-06-2017 03:00 PM. Venue: San Jose Convention Center, San Jose, California, United States. Speakers: Jonathan Sorger.
101
12/31/201712.94x34.71x37.84x63.92x51.24x$42,566$379.0457.84%Dec-06-2017ConferenceCitigroup Inc., Citi Global Healthcare Conference, Dec 06, 2017 through Dec 07, 2017Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), MacroGenics, Inc. (NasdaqGS:MGNX), Illumina, Inc. (NasdaqGS:ILMN), Inovio Pharmaceuticals, Inc. (NasdaqGS:INO), Bavarian Nordic A/S (CPSE:BAVA), Zealand Pharma A/S (CPSE:ZEAL), Genmab A/S (CPSE:GMAB), Novo Nordisk A/S (CPSE:NOVO B), Innate Pharma S.A. (ENXTPA:IPH), DBV Technologies S.A. (ENXTPA:DBV), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Legacy LifePoint Health, Inc., Tesaro, Inc., Cotiviti Holdings, Inc., Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Humana Inc. (NYSE:HUM), Bristol-Myers Squibb Company (NYSE:BMY), Community Health Systems, Inc. (NYSE:CYH), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), Universal Health Services, Inc. (NYSE:UHS), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Johnson & Johnson (NYSE:JNJ), MEDNAX, Inc. (NYSE:MD), HCA Healthcare, Inc. (NYSE:HCA), PerkinElmer, Inc. (NYSE:PKI), Merck & Co., Inc. (NYSE:MRK), Varian Medical Systems, Inc. (NYSE:VAR), Boston Scientific Corporation (NYSE:BSX), Citigroup Inc. (NYSE:C), CRISPR Therapeutics AG (NasdaqGM:CRSP), OBI Pharma, Inc. (GTSM:4174), PharmaEssentia Corporation (GTSM:6446)Citigroup Inc., Citi Global Healthcare Conference, Dec 06, 2017 through Dec 07, 2017. Venue: Lotte New York Palace, New York, New York, United States.
102
12/31/201712.94x34.71x37.84x63.92x51.24x$41,495$369.5061.92%Dec-5-2017ConferenceUBM plc, Embedded Systems Conference & Expo 2017, Dec 05, 2017 through Dec 07, 2017Amazon.com, Inc. (NasdaqGS:AMZN), Intel Corporation (NasdaqGS:INTC), Cadence Design Systems, Inc. (NasdaqGS:CDNS), Illumina, Inc. (NasdaqGS:ILMN), NVIDIA Corporation (NasdaqGS:NVDA), Rambus Inc. (NasdaqGS:RMBS), Xilinx, Inc. (NasdaqGS:XLNX), Maxim Integrated Products, Inc. (NasdaqGS:MXIM), Texas Instruments Incorporated (NasdaqGS:TXN), Advanced Micro Devices, Inc. (NasdaqGS:AMD), UBM Development AG (WBAG:UBS), IAR Systems Group AB (publ) (OM:IAR B), Schweitzer Engineering Laboratories, Inc., Rohde & Schwarz USA, Inc., Transguard Insurance Company of America, Inc., eASIC Corporation, PTR Group, LP, Topcon Positioning Systems, Inc., Spinal Kinetics, Inc., Ada Core Technologies, Inc., Universidade Federal De Itajuba, Monotype Imaging Holdings Inc., NXP Semiconductors Singapore Pte. Ltd., The Linley Group, Inc., NXP B.V., Intrinsic ID B.V., Valencell, Inc., Paper Battery Company, Inc., Brooks Kushman P.C., Intelligent Product Solutions Inc, Procept Biorobotics Corp., Velodyne Lidar, Inc., ATEK Access Technologies, LLC, iFixit, Toyota InfoTechnology Center, U.S.A., Inc, Runtime, Telomere Diagnostics, Inc., Google LLC, SiFive, Inc., AspenCore LLC, Senrio Inc., Verb Surgical Inc., rLoop, Incorporated, Galen Robotics, Inc, Embarcados, Osso VR Inc., Blue Ridge Advanced Design and Automation, PLLC, Beningo Embedded Group, Northern.tech AS, Cratus Technology Inc, PowerRox, LLC, Pifocal LLC, Brain2bot Inc., Spatika Technologies Inc., Medtech Executive Search, Inc., FS Studio, Mentor Graphics Corporation, UBM plc, UBM plc, GE Healthcare Limited, Engility Corporation, Green Hills Software, Inc.UBM plc, Embedded Systems Conference & Expo 2017, Dec 05, 2017 through Dec 07, 2017. Venue: San Jose Convention Center, San Jose, California, United States.
103
12/31/201712.94x34.71x37.84x63.92x51.24x$41,975$373.7860.06%Oct-27-2017Executive/Board Change - OtherIntuitive Surgical, Inc. Appoints Salvatore J. Brogna as Executive Vice President and Chief Operating Officer, Effective November 1, 2017-On October 25, 2017, the Board of Directors of Intuitive Surgical, Inc. approved the appointment of Salvatore J. Brogna as Executive Vice President and Chief Operating Officer, effective November 1, 2017.
104
12/31/201712.94x34.71x37.84x63.92x51.24x$41,504$369.5861.88%October-20-2017Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From July 1, 2017 to September 30, 2017, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
105
12/31/201712.94x34.71x37.84x63.92x51.24x$41,504$369.5861.88%Oct-20-2017Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $1.715808 billion.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $1.715808 billion.

Security Name: Common Stock
Securities Offered: 4,800,000
Transaction Features: ESOP Related Offering
106
12/31/201712.94x34.71x37.84x63.92x51.24x$40,143$357.4667.37%October-19-2017Earnings CallIntuitive Surgical, Inc., Q3 2017 Earnings Call, Oct 19, 2017-Intuitive Surgical, Inc., Q3 2017 Earnings Call, Oct 19, 2017
107
12/31/201712.94x34.71x37.84x63.92x51.24x$40,143$357.4667.37%Oct-19-2017Announcement of Earnings, Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended of September 30, 2017; Provides Earnings Guidance for the Fourth Quarter and Full Year of 2017-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2017. For the quarter, the company’s total revenue was $806.1 million compared with $682.9 million a year ago. Income from operations was $278.6 million compared with $256.4 million a year ago. Income before taxes was $289.4 million compared with $266.8 million a year ago. Net income was $297.5 million compared with $211.0 million a year ago. Diluted net income per share was $2.55 compared with $1.77 a year ago. Non-GAAP income from operations was $347.1 million compared with $307.6 million a year ago. Non-GAAP net income was $323.8 million compared with $245.7 million a year ago. Diluted non-GAAP net income per share was $2.77 compared with $2.06 a year ago. Total recurring revenue in the quarter was $548 million, representing 68% of total revenue. Pro forma operating profit was $347 million in the quarter, up 13% over third quarter of 2016. Pro forma net income was $324 million, aided by onetime favorability in tax items. Pro forma net income was $324 million or $2.77 per share compared with $246 million or $2.06 per share for the third quarter of 2016 and $228 million or $1.98 per share for the second quarter of 2017. GAAP net income included $10 million of net charges associated with legal settlements compared with no charges recorded in the third quarter of 2016 and $5 million of net benefits recorded last quarter.

For the nine months, the company reported total revenue was $2,236.5 million compared with $1,947.5 million a year ago. Income from operations was $727.6 million compared with $680.8 million a year ago. Income before taxes was $757.2 million compared with $704.7 million a year ago. Net income was $698.8 million compared with $531.9 million a year ago. Diluted net income per share was $6.03 compared with $4.52 a year ago. Non-GAAP income from operations was $923.5 million compared with $833.8 million a year ago. Non-GAAP net income was $748.2 million compared with $636.4 million a year ago. Diluted non-GAAP net income per share was $6.46 compared with $5.41 a year ago.

The company provided earnings guidance for the fourth quarter and full year of 2017. For the full year, the company expects anticipates pro forma gross profit margin to be between 71% and 71.5% of net revenue.

For the quarter, the company expects pro forma income tax rate to be between 26.5% and 28.5% of pretax income compared to the previous guidance of 28% to 29.5%.
108
12/31/201712.94x34.71x37.84x63.92x51.24x$40,593$361.4765.52%October-6-2017Stock Splits & Significant Stock DividendIntuitive Surgical, Inc., 3 : 1, Stock Split or Significant Stock Dividend, Oct-06-2017-Intuitive Surgical, Inc., 3 : 1, Stock Split or Significant Stock Dividend, Oct-06-2017
109
9/30/201712.95x34.36x37.47x63.34x53.52x$38,510$343.8474.00%Sep-22-2017Special/Extraordinary Shareholders MeetingIntuitive Surgical, Inc., Special/Extraordinary Shareholders Meeting, Sep 22, 2017-Intuitive Surgical, Inc., Special/Extraordinary Shareholders Meeting, Sep 22, 2017, at 15:00 Pacific Standard Time. Location: 1020 Kifer Road Sunnyvale California California United States Agenda: To consider the implementation of the stock; and to consider the amendments to the Certificate of Incorporation.
110
9/30/201712.95x34.36x37.47x63.34x53.52x$39,013$348.3371.76%September-12-2017Company Conference PresentationIntuitive Surgical, Inc. Presents at Morgan Stanley 15th Annual Global Healthcare Conference, Sep-12-2017 11:10 AM-Intuitive Surgical, Inc. Presents at Morgan Stanley 15th Annual Global Healthcare Conference, Sep-12-2017 11:10 AM. Venue: Grand Hyatt New York, 109 E. 42nd Street, New York, New York, United States. Speakers: Calvin Darling, Sr. Director, Investor Relations, Patrick Clingan, VP, Finance & Sales Operations.
111
9/30/201712.95x34.36x37.47x63.34x53.52x$39,031$348.4971.68%Sep-11-2017ConferenceMorgan Stanley, Morgan Stanley 15th Annual Global Healthcare Conference, Sep 11, 2017 through Sep 14, 2017Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI), Pharma Mar, S.A. (BME:PHM), Amgen Inc. (NasdaqGS:AMGN), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Innoviva, Inc. (NasdaqGS:INVA), Align Technology, Inc. (NasdaqGS:ALGN), Alkermes plc (NasdaqGS:ALKS), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Biogen Inc. (NasdaqGS:BIIB), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Cytokinetics, Incorporated (NasdaqGS:CYTK), Endo International plc (NasdaqGS:ENDP), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), Teligent, Inc. (NasdaqGS:TLGT), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Masimo Corporation (NasdaqGS:MASI), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), ICU Medical, Inc. (NasdaqGS:ICUI), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), CONMED Corporation (NasdaqGS:CNMD), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Henry Schein, Inc. (NasdaqGS:HSIC), Anika Therapeutics, Inc. (NasdaqGS:ANIK), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), Bruker Corporation (NasdaqGS:BRKR), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Luminex Corporation (NasdaqGS:LMNX), Fluidigm Corporation (NasdaqGS:FLDM), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), AngioDynamics, Inc. (NasdaqGS:ANGO), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Ascendis Pharma A/S (NasdaqGS:ASND), Inovalon Holdings, Inc. (NasdaqGS:INOV), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), Nabriva Therapeutics plc (NasdaqGS:NBRV), iRhythm Technologies, Inc. (NasdaqGS:IRTC), Conformis, Inc. (NasdaqGS:CFMS), Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX), Natera, Inc. (NasdaqGS:NTRA), China Biologic Products Holdings, Inc. (NasdaqGS:CBPO), SeaSpine Holdings Corporation (NasdaqGS:SPNE), Gritstone Oncology, Inc. (NasdaqGS:GRTS), Axovant Gene Therapies Ltd. (NasdaqGS:AXGT), Principia Biopharma Inc. (NasdaqGS:PRNB), Moderna, Inc. (NasdaqGS:MRNA), Blueprint Medicines Corporation (NasdaqGS:BPMC), REGENXBIO Inc. (NasdaqGS:RGNX), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), TherapeuticsMD, Inc. (NasdaqGS:TXMD), BeiGene, Ltd. (NasdaqGS:BGNE), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Epizyme, Inc. (NasdaqGS:EPZM), Editas Medicine, Inc. (NasdaqGS:EDIT), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), Guardant Health, Inc. (NasdaqGS:GH), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), ASLAN Pharmaceuticals Limited (GTSM:6497), La Jolla Pharmaceutical Company (NasdaqCM:LJPC), Corcept Therapeutics Incorporated (NasdaqCM:CORT), Veru Inc. (NasdaqCM:VERU), Cerus Corporation (NasdaqGM:CERS), ViewRay, Inc. (NasdaqGM:VRAY), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Quotient Limited (NasdaqGM:QTNT), Magenta Therapeutics, Inc. (NasdaqGM:MGTA), Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA), NanoString Technologies, Inc. (NasdaqGM:NSTG), Zynerba Pharmaceuticals, Inc. (NasdaqGM:ZYNE), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), Ocular Therapeutix, Inc. (NasdaqGM:OCUL), Veracyte, Inc. (NasdaqGM:VCYT), Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK), AtriCure, Inc. (NasdaqGM:ATRC), GW Pharmaceuticals plc (NasdaqGM:GWPH), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), Radius Health, Inc. (NasdaqGM:RDUS), Acceleron Pharma Inc. (NasdaqGM:XLRN), Immunomedics, Inc. (NasdaqGM:IMMU), Phibro Animal Health Corporation (NasdaqGM:PAHC), Pfenex Inc. (AMEX:PFNX), Senseonics Holdings, Inc. (AMEX:SENS), AbbVie Inc. (NYSE:ABBV), Invitae Corporation (NYSE:NVTA), Mallinckrodt plc (NYSE:MNK), Avanos Medical, Inc. (NYSE:AVNS), Global Cord Blood Corporation (NYSE:CO), Catalent, Inc. (NYSE:CTLT), Morgan Stanley (NYSE:MS), Quest Diagnostics Incorporated (NYSE:DGX), Edwards Lifesciences Corporation (NYSE:EW), Vocera Communications, Inc. (NYSE:VCRA), Invacare Corporation (NYSE:IVC), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Teleflex Incorporated (NYSE:TFX), West Pharmaceutical Services, Inc. (NYSE:WST), Johnson & Johnson (NYSE:JNJ), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), PerkinElmer, Inc. (NYSE:PKI), Boston Scientific Corporation (NYSE:BSX), Perrigo Company plc (NYSE:PRGO), Globus Medical, Inc. (NYSE:GMED), Veeva Systems Inc. (NYSE:VEEV), Diplomat Pharmacy, Inc. (NYSE:DPLO), Penumbra, Inc. (NYSE:PEN), Nevro Corp. (NYSE:NVRO), Teladoc Health, Inc. (NYSE:TDOC), Quorum Health Corporation (NYSE:QHC), Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), Nuvectra Corporation (OTCPK:NVTR.Q), MiMedx Group, Inc. (OTCPK:MDXG), Glenmark Pharmaceuticals Limited (NSEI:GLENMARK), Biotest Aktiengesellschaft (XTRA:BIO3), Sartorius Aktiengesellschaft (XTRA:SRT), Fresenius SE & Co. KGaA (XTRA:FRE), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Evotec SE (XTRA:EVT), LegoChem Biosciences, Inc. (KOSDAQ:A141080), MEDIPOST Co., Ltd. (KOSDAQ:A078160), Helixmith Co., Ltd (KOSDAQ:A084990), Seegene, Inc. (KOSDAQ:A096530), AmerisourceBergen Corporation (NYSE:ABC), Humana Inc. (NYSE:HUM), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Hill-Rom Holdings, Inc. (NYSE:HRC), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), STERIS plc (NYSE:STE), International Business Machines Corporation (NYSE:IBM), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Laboratory Corporation of America Holdings (NYSE:LH), QIAGEN N.V. (NYSE:QGEN), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Charles River Laboratories International, Inc. (NYSE:CRL), CVS Health Corporation (NYSE:CVS), Abaxis, Inc., Aceto Corporation, Celgene Corporation, Shire plc, Impax Laboratories, Inc., Keryx Biopharmaceuticals, Inc., Schrödinger, Inc., Aetna Inc., Pharmaceutical Research and Manufacturers of America, Alder BioPharmaceuticals, Inc., Cempra, Inc., GENEWIZ, Inc., Ascentage Pharma Group Corporation, Ltd., Humacyte, Inc., Signature Healthcare Services, LLC, Generon (Shanghai) Corporation Ltd., Abide Therapeutics Inc., TWi Pharmaceuticals, Inc., Loxo Oncology, Inc., Spark Therapeutics, Inc., Clementia Pharmaceuticals Inc., Juno Therapeutics, Inc., AveXis, Inc., K2M Group Holdings, Inc., Bigfoot Biomedical, Inc., PHC Holdings Corporation, Berkeley Lights, Inc., Cotiviti Holdings, Inc., Kiniksa Pharmaceuticals Corp., Idorsia Ltd (SWX:IDIA), Molecular Partners AG (SWX:MOLN), Basilea Pharmaceutica AG (SWX:BSLN), Vifor Pharma AG (SWX:VIFN), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), ScinoPharm Taiwan, Ltd. (TSEC:1789), Hikma Pharmaceuticals PLC (LSE:HIK), GlaxoSmithKline plc (LSE:GSK), AstraZeneca PLC (LSE:AZN), Indivior PLC (LSE:INDV), Hutchison China MediTech Limited (AIM:HCM), Swedish Orphan Biovitrum AB (publ) (OM:SOBI), Elekta AB (publ) (OM:EKTA B), Hansa Biopharma AB (publ) (OM:HNSA), Galapagos NV (ENXTAM:GLPG), Koninklijke Philips N.V. (ENXTAM:PHIA), Takeda Pharmaceutical Company Limited (TSE:4502), Astellas Pharma Inc. (TSE:4503), Chugai Pharmaceutical Co., Ltd. (TSE:4519), Olympus Corporation (TSE:7733), Tsumura & Co. (TSE:4540), Nippon Shinyaku Co., Ltd. (TSE:4516), Santen Pharmaceutical Co., Ltd. (TSE:4536), Nichi-Iko Pharmaceutical Co., Ltd. (TSE:4541), Daiichi Sankyo Company, Limited (TSE:4568), Otsuka Holdings Co., Ltd. (TSE:4578), Ipsen S.A. (ENXTPA:IPN), Sanofi (ENXTPA:SAN), DBV Technologies S.A. (ENXTPA:DBV), Genfit SA (ENXTPA:GNFT), Cellectis S.A. (ENXTPA:ALCLS), ERYTECH Pharma S.A. (ENXTPA:ERYP), Zealand Pharma A/S (CPSE:ZEAL), ALK-Abelló A/S (CPSE:ALK B), Bavarian Nordic A/S (CPSE:BAVA), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), Coloplast A/S (CPSE:COLO B), Demant A/S (CPSE:DEMANT), Novo Nordisk A/S (CPSE:NOVO B), China Resources Medical Holdings Company Limited (SEHK:1515), WuXi Biologics (Cayman) Inc. (SEHK:2269), 3SBio Inc. (SEHK:1530), MicroPort Scientific Corporation (SEHK:853), CSPC Pharmaceutical Group Limited (SEHK:1093), Lee's Pharmaceutical Holdings Limited (SEHK:950), Dr. Reddy's Laboratories Limited (BSE:500124), Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC), UCB SA (ENXTBR:UCB), Liminal BioSciences Inc. (TSX:LMNL), Knight Therapeutics Inc. (TSX:GUD)Morgan Stanley, Morgan Stanley 15th Annual Global Healthcare Conference, Sep 11, 2017 through Sep 14, 2017. Venue: Grand Hyatt New York, 109 E. 42nd Street, New York, New York, United States.
112
9/30/201712.95x34.36x37.47x63.34x53.52x$36,919$329.6381.50%Aug-16-2017Company Conference PresentationIntuitive Surgical, Inc. Presents at Wedbush PacGrow Healthcare Conference, Aug-16-2017 10:55 AM-Intuitive Surgical, Inc. Presents at Wedbush PacGrow Healthcare Conference, Aug-16-2017 10:55 AM. Venue: Le Parker Meridien Hotel, 119 West 56th St., New York, New York, United States.
113
9/30/201712.95x34.36x37.47x63.34x53.52x$36,788$328.4682.15%Aug-15-2017ConferenceWedbush Securities Inc., Wedbush PacGrow Healthcare Conference, Aug 15, 2017 through Aug 16, 2017Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), United Therapeutics Corporation (NasdaqGS:UTHR), Pacira BioSciences, Inc. (NasdaqGS:PCRX), bluebird bio, Inc. (NasdaqGS:BLUE), Mersana Therapeutics, Inc. (NasdaqGS:MRSN), DexCom, Inc. (NasdaqGS:DXCM), Apyx Medical Corporation (NasdaqGS:APYX), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), Epizyme, Inc. (NasdaqGS:EPZM), CytomX Therapeutics, Inc. (NasdaqGS:CTMX), NovoCure Limited (NasdaqGS:NVCR), Arbutus Biopharma Corporation (NasdaqGS:ABUS), Ascendis Pharma A/S (NasdaqGS:ASND), NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM), AnaptysBio, Inc. (NasdaqGS:ANAB), Nabriva Therapeutics plc (NasdaqGS:NBRV), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), ObsEva SA (NasdaqGS:OBSV), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), MyoKardia, Inc. (NasdaqGS:MYOK), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), G1 Therapeutics, Inc. (NasdaqGS:GTHX), Blueprint Medicines Corporation (NasdaqGS:BPMC), Unum Therapeutics Inc. (NasdaqGS:UMRX), TCR2 Therapeutics Inc. (NasdaqGS:TCRR), AVROBIO, Inc. (NasdaqGS:AVRO), AxoGen, Inc. (NasdaqCM:AXGN), Molecular Templates, Inc. (NasdaqCM:MTEM), Stemline Therapeutics, Inc. (NasdaqCM:STML), Regulus Therapeutics Inc. (NasdaqCM:RGLS), Valeritas Holdings, Inc. (NasdaqCM:VLRX), Albireo Pharma, Inc. (NasdaqCM:ALBO), Miragen Therapeutics, Inc. (NasdaqCM:MGEN), Fennec Pharmaceuticals Inc. (NasdaqCM:FENC), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), Millendo Therapeutics, Inc. (NasdaqCM:MLND), Applied Genetic Technologies Corporation (NasdaqGM:AGTC), Sierra Oncology, Inc. (NasdaqGM:SRRA), Ardelyx, Inc. (NasdaqGM:ARDX), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Eiger BioPharmaceuticals, Inc. (NasdaqGM:EIGR), Merus N.V. (NasdaqGM:MRUS), Sutro Biopharma, Inc. (NasdaqGM:STRO), Fate Therapeutics, Inc. (NasdaqGM:FATE), Omeros Corporation (NasdaqGM:OMER), XOMA Corporation (NasdaqGM:XOMA), Xencor, Inc. (NasdaqGM:XNCR), Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK), Catabasis Pharmaceuticals, Inc. (NasdaqGM:CATB), Axcella Health Inc. (NasdaqGM:AXLA), KalVista Pharmaceuticals, Inc. (NasdaqGM:KALV), Clearside Biomedical, Inc. (NasdaqGM:CLSD), Synlogic, Inc. (NasdaqGM:SYBX), Intellia Therapeutics, Inc. (NasdaqGM:NTLA), Corvus Pharmaceuticals, Inc. (NasdaqGM:CRVS), Nuvectra Corporation (OTCPK:NVTR.Q), Achaogen, Inc. (OTCPK:AKAO.Q), Wedbush Securities Inc., Cogentix Medical, Inc., Dex Liquidating Co., Flowonix Medical, Inc., SteadyMed Ltd., Iteos Therapeutics S.A., Micro Interventional Devices, Inc., Audentes Therapeutics, Inc., Juno Therapeutics, Inc., Clementia Pharmaceuticals Inc., Newron Pharmaceuticals S.p.A. (SWX:NWRN), Verona Pharma plc (AIM:VRP), Nordic Nanovector ASA (OB:NANO), Hansa Biopharma AB (publ) (OM:HNSA), argenx SE (ENXTBR:ARGX), Avita Medical Limited (ASX:AVH), Opthea Limited (ASX:OPT)Wedbush Securities Inc., Wedbush PacGrow Healthcare Conference, Aug 15, 2017 through Aug 16, 2017. Venue: Le Parker Meridien Hotel, 119 West 56th St., New York, New York, United States.
114
9/30/201712.95x34.36x37.47x63.34x53.52x$35,177$314.0890.49%Aug-11-2017Change in Company Bylaws/RulesIntuitive Surgical, Inc. Proposes Amendments to the Certificate of Incorporation-Intuitive Surgical, Inc. at its special meeting of stockholders to be held on September 22, 2017, will approve the amendments to the certificate of incorporation for the implementation three-for-one split of the company's common stock.
115
9/30/201712.95x34.36x37.47x63.34x53.52x$34,626$309.1693.52%Jul-21-2017Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From April 1, 2017 to June 30, 2017, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
116
9/30/201712.95x34.36x37.47x63.34x53.52x$36,278$323.9184.71%Jul-20-2017Earnings CallIntuitive Surgical, Inc., Q2 2017 Earnings Call, Jul 20, 2017-Intuitive Surgical, Inc., Q2 2017 Earnings Call, Jul 20, 2017
117
9/30/201712.95x34.36x37.47x63.34x53.52x$36,278$323.9184.71%Jul-20-2017Corporate Guidance - New/Confirmed, Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017; Revises Financial Guidance for the Year 2017-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, the company reported total revenue of $756.2 million against $670.1 million a year ago. Income from operations was $257.5 million against $245.4 million a year ago. Net income was $221.5 million against $184.5 million a year ago. Income before taxes was $267.6 million against $253.4 million a year ago. Diluted net income per share was $5.77 against $4.71 per share a year ago. Non-GAAP income from operations was $312.5 million against $297.1 million a year ago. Non-GAAP net income was $228.4 million or $5.95 per share diluted against $220.4 million or $5.62 per share diluted a year ago. Higher second quarter revenue was driven by growth in recurring instrument, accessory, and service revenue, and higher systems revenue.

For the six months, the company reported total revenue of $1,430.4 million against $1,264.6 million a year ago. Income from operations was $449 million against $424.4 million a year ago. Net income was $401.3 million against $320.9 million a year ago. Income before taxes was $467.8 million against $437.9 million a year ago. Diluted net income per share was $10.42 against $8.25 per share a year ago. Non-GAAP income from operations was $576.4 million against $526.2 million a year ago. Non-GAAP net income was $424.4 million or $11.02 per share diluted against $390.7 million or $10.04 per share diluted a year ago.

The company now modestly raising the top end of the range and expect pro forma gross profit margin to be between 70% and 71.5% of net revenue. On its last call, the forecast 2017 growth pro forma gross profit margin to be within a range of between 70% and 71% of net revenue. The company now expect 2017 pro forma income tax rate to be between 28% and 29.5% of pretax income, higher than previous guidance of 26.5% to 28.5% based upon a higher anticipated mix of U.S. pretax profits.
118
6/30/201711.85x30.63x33.37x57.23x41.65x$33,606$301.9498.15%Jun-14-2017Company Conference PresentationIntuitive Surgical, Inc. Presents at The William Blair 2017 Growth Stock Conference, Jun-14-2017 02:40 PM-Intuitive Surgical, Inc. Presents at The William Blair 2017 Growth Stock Conference, Jun-14-2017 02:40 PM. Venue: The Four Seasons Hotel, 120 East Delaware Place, Chicago, Illinois, United States.
119
6/30/201711.85x30.63x33.37x57.23x41.65x$33,695$302.7497.63%Jun-13-2017Company Conference PresentationIntuitive Surgical, Inc. Presents at Goldman Sachs 38th Annual Global Healthcare Conference, Jun-13-2017 02:00 PM-Intuitive Surgical, Inc. Presents at Goldman Sachs 38th Annual Global Healthcare Conference, Jun-13-2017 02:00 PM. Venue: Terranea Rancho Palos Verdes, Rancho Palos Verdes, California, United States. Speakers: Jamie E. Samath, Principal Accounting Officer, Vice President and Corporate Controller, Patrick Clingan, Vice President of Finance and Sales Operations.
120
6/30/201711.85x30.63x33.37x57.23x41.65x$33,695$302.7497.63%Jun-13-2017ConferenceThe Goldman Sachs Group, Inc., Goldman Sachs 38th Annual Global Healthcare Conference, Jun 13, 2017 through Jun 15, 2017Microsoft Corporation (NasdaqGS:MSFT), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Alkermes plc (NasdaqGS:ALKS), Amgen Inc. (NasdaqGS:AMGN), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), TherapeuticsMD, Inc. (NasdaqGS:TXMD), BeiGene, Ltd. (NasdaqGS:BGNE), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), Seres Therapeutics, Inc. (NasdaqGS:MCRB), R1 RCM Inc. (NasdaqGS:RCM), Blueprint Medicines Corporation (NasdaqGS:BPMC), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Intrexon Corporation (NasdaqGS:XON), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Bruker Corporation (NasdaqGS:BRKR), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Hologic, Inc. (NasdaqGS:HOLX), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Abiomed, Inc. (NasdaqGS:ABMD), Mylan N.V. (NasdaqGS:MYL), Patterson Companies, Inc. (NasdaqGS:PDCO), Henry Schein, Inc. (NasdaqGS:HSIC), Incyte Corporation (NasdaqGS:INCY), FibroGen, Inc. (NasdaqGS:FGEN), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Endo International plc (NasdaqGS:ENDP), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), Illumina, Inc. (NasdaqGS:ILMN), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Exact Sciences Corporation (NasdaqCM:EXAS), Aurobindo Pharma Limited (NSEI:AUROPHARMA), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), GW Pharmaceuticals plc (NasdaqGM:GWPH), Radius Health, Inc. (NasdaqGM:RDUS), AmerisourceBergen Corporation (NYSE:ABC), Hill-Rom Holdings, Inc. (NYSE:HRC), ResMed Inc. (NYSE:RMD), Edwards Lifesciences Corporation (NYSE:EW), The Goldman Sachs Group, Inc. (NYSE:GS), Owens & Minor, Inc. (NYSE:OMI), Teleflex Incorporated (NYSE:TFX), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Baxter International Inc. (NYSE:BAX), Danaher Corporation (NYSE:DHR), QIAGEN N.V. (NYSE:QGEN), Allergan plc (NYSE:AGN), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), STERIS plc (NYSE:STE), Universal Health Services, Inc. (NYSE:UHS), Becton, Dickinson and Company (NYSE:BDX), Johnson & Johnson (NYSE:JNJ), Agilent Technologies, Inc. (NYSE:A), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Bayer Aktiengesellschaft (XTRA:BAYN), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Fresenius SE & Co. KGaA (XTRA:FRE), Bristol-Myers Squibb Company (NYSE:BMY), Community Health Systems, Inc. (NYSE:CYH), Humana Inc. (NYSE:HUM), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), AbbVie Inc. (NYSE:ABBV), Globus Medical, Inc. (NYSE:GMED), Veeva Systems Inc. (NYSE:VEEV), Invitae Corporation (NYSE:NVTA), Evolent Health, Inc. (NYSE:EVH), Mallinckrodt plc (NYSE:MNK), Array BioPharma Inc., Express Scripts Holding Company, Shire plc, Impax Laboratories, Inc., Marwood Group LLC, Foundation Medicine, Inc., Tesaro, Inc., Kite Pharma, Inc., AveXis, Inc., Zebra Medical Vision Ltd., GRAIL, Inc., Cotiviti Holdings, Inc., Greenwich Biosciences, Inc, Spark Therapeutics, Inc., Juno Therapeutics, Inc., Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH), Galapagos NV (ENXTAM:GLPG), Koninklijke Philips N.V. (ENXTAM:PHIA), Swedish Orphan Biovitrum AB (publ) (OM:SOBI), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), GlaxoSmithKline plc (LSE:GSK), AstraZeneca PLC (LSE:AZN), Hikma Pharmaceuticals PLC (LSE:HIK), EssilorLuxottica Société anonyme (ENXTPA:EL), DBV Technologies S.A. (ENXTPA:DBV), GN Store Nord A/S (CPSE:GN), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), Coloplast A/S (CPSE:COLO B), Demant A/S (CPSE:DEMANT), Novo Nordisk A/S (CPSE:NOVO B), Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC), Takeda Pharmaceutical Company Limited (TSE:4502), Terumo Corporation (TSE:4543), Santen Pharmaceutical Co., Ltd. (TSE:4536), 3SBio Inc. (SEHK:1530), Dr. Reddy's Laboratories Limited (BSE:500124)The Goldman Sachs Group, Inc., Goldman Sachs 38th Annual Global Healthcare Conference, Jun 13, 2017 through Jun 15, 2017. Venue: Terranea Rancho Palos Verdes, Rancho Palos Verdes, California, United States.
121
6/30/201711.85x30.63x33.37x57.23x41.65x$33,695$302.7497.63%Jun-13-2017ConferenceWilliam Blair & Company, L.L.C., the William Blair 2017 Growth Stock Conference, Jun 13, 2017 through Jun 15, 2017Tivity Health, Inc. (NasdaqGS:TVTY), Pool Corporation (NasdaqGS:POOL), SPS Commerce, Inc. (NasdaqGS:SPSC), SS&C Technologies Holdings, Inc. (NasdaqGS:SSNC), Stericycle, Inc. (NasdaqGS:SRCL), Laureate Education, Inc. (NasdaqGS:LAUR), Ulta Beauty, Inc. (NasdaqGS:ULTA), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), ICF International, Inc. (NasdaqGS:ICFI), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Myriad Genetics, Inc. (NasdaqGS:MYGN), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Wright Medical Group N.V. (NasdaqGS:WMGI), CECO Environmental Corp. (NasdaqGS:CECE), Trimble Inc. (NasdaqGS:TRMB), Viavi Solutions Inc. (NasdaqGS:VIAV), Cogent Communications Holdings, Inc. (NasdaqGS:CCOI), RealPage, Inc. (NasdaqGS:RP), j2 Global, Inc. (NasdaqGS:JCOM), The Middleby Corporation (NasdaqGS:MIDD), Exponent, Inc. (NasdaqGS:EXPO), Fastenal Company (NasdaqGS:FAST), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), The Cheesecake Factory Incorporated (NasdaqGS:CAKE), Exelixis, Inc. (NasdaqGS:EXEL), Aspen Technology, Inc. (NasdaqGS:AZPN), Citrix Systems, Inc. (NasdaqGS:CTXS), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), Alarm.com Holdings, Inc. (NasdaqGS:ALRM), SecureWorks Corp. (NasdaqGS:SCWX), Atlassian Corporation Plc (NasdaqGS:TEAM), Paylocity Holding Corporation (NasdaqGS:PCTY), Medpace Holdings, Inc. (NasdaqGS:MEDP), Gogo Inc. (NasdaqGS:GOGO), Fox Factory Holding Corp. (NasdaqGS:FOXF), Nutanix, Inc. (NasdaqGS:NTNX), Dave & Buster's Entertainment, Inc. (NasdaqGS:PLAY), CyberArk Software Ltd. (NasdaqGS:CYBR), Acacia Communications, Inc. (NasdaqGS:ACIA), BeiGene, Ltd. (NasdaqGS:BGNE), BlackLine, Inc. (NasdaqGS:BL), Duluth Holdings Inc. (NasdaqGS:DLTH), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), LKQ Corporation (NasdaqGS:LKQ), Zumiez Inc. (NasdaqGS:ZUMZ), Collegium Pharmaceutical, Inc. (NasdaqGS:COLL), Inogen, Inc. (NasdaqGS:INGN), Sientra, Inc. (NasdaqGS:SIEN), Lululemon Athletica Inc. (NasdaqGS:LULU), Kornit Digital Ltd. (NasdaqGS:KRNT), Workday, Inc. (NasdaqGS:WDAY), QAD Inc. (NasdaqGS:QADA), Mercury Systems, Inc. (NasdaqGS:MRCY), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Encore Capital Group, Inc. (NasdaqGS:ECPG), Zebra Technologies Corporation (NasdaqGS:ZBRA), ICON Public Limited Company (NasdaqGS:ICLR), Insulet Corporation (NasdaqGS:PODD), Bruker Corporation (NasdaqGS:BRKR), Verisk Analytics, Inc. (NasdaqGS:VRSK), Iridium Communications Inc. (NasdaqGS:IRDM), Premier, Inc. (NasdaqGS:PINC), Vonage Holdings Corp. (NasdaqGS:VG), Huron Consulting Group Inc. (NasdaqGS:HURN), Fortinet, Inc. (NasdaqGS:FTNT), Boingo Wireless, Inc. (NasdaqGS:WIFI), Potbelly Corporation (NasdaqGS:PBPB), Cardtronics plc (NasdaqGS:CATM), PRA Group, Inc. (NasdaqGS:PRAA), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Beacon Roofing Supply, Inc. (NasdaqGS:BECN), MiX Telematics Limited (JSE:MIX), Financial Engines, Inc., BroadSoft, Inc., Callidus Software Inc., Electronics for Imaging, Inc., The Ultimate Software Group, Inc., NxStage Medical, Inc., Sonic Corp., Express Scripts Holding Company, Navigant Consulting, Inc., Envision Healthcare Corporation, WageWorks, Inc., William Blair & Company, L.L.C., Cavium, Inc., Imperva, Inc., Luxoft Holding, Inc., Carbonite, Inc., AmTrust Financial Services, Inc., Entellus Medical, Inc., Quantenna Communications, Inc., Zoe's Kitchen, Inc., Invuity, Inc., Milacron Holdings Corp., Foundation Medicine, Inc., Aratana Therapeutics, Inc., Gigamon Inc., K2M Group Holdings, Inc., Cotiviti Holdings, Inc., Amplify Snack Brands, Inc., American Express Company (NYSE:AXP), WEX Inc. (NYSE:WEX), SiteOne Landscape Supply, Inc. (NYSE:SITE), MSC Industrial Direct Co., Inc. (NYSE:MSM), FTI Consulting, Inc. (NYSE:FCN), ASGN Incorporated (NYSE:ASGN), AMN Healthcare Services, Inc. (NYSE:AMN), Ciena Corporation (NYSE:CIEN), LiveRamp Holdings, Inc. (NYSE:RAMP), Alliance Data Systems Corporation (NYSE:ADS), Carvana Co. (NYSE:CVNA), Zoetis Inc. (NYSE:ZTS), AAC Holdings, Inc. (OTCPK:AACH), CPI Card Group Inc. (OTCPK:PMTS), Fortive Corporation (NYSE:FTV), salesforce.com, inc. (NYSE:CRM), TriNet Group, Inc. (NYSE:TNET), VMware, Inc. (NYSE:VMW), MEDNAX, Inc. (NYSE:MD), Welbilt, Inc. (NYSE:WBT), Gartner, Inc. (NYSE:IT), Booz Allen Hamilton Holding Corporation (NYSE:BAH), Donaldson Company, Inc. (NYSE:DCI), General Electric Company (NYSE:GE), The Scotts Miracle-Gro Company (NYSE:SMG), Fair Isaac Corporation (NYSE:FICO), Tyler Technologies, Inc. (NYSE:TYL), Watsco, Inc. (NYSE:WSO), AGCO Corporation (NYSE:AGCO), The Cooper Companies, Inc. (NYSE:COO), Curtiss-Wright Corporation (NYSE:CW), Ecolab Inc. (NYSE:ECL), W.W. Grainger, Inc. (NYSE:GWW), Robert Half International Inc. (NYSE:RHI), RingCentral, Inc. (NYSE:RNG), Lennox International Inc. (NYSE:LII), Moody's Corporation (NYSE:MCO), WESCO International, Inc. (NYSE:WCC), 8x8, Inc. (NYSE:EGHT), ResMed Inc. (NYSE:RMD), Ritchie Bros. Auctioneers Incorporated (NYSE:RBA), Mastercard Incorporated (NYSE:MA), Guidewire Software, Inc. (NYSE:GWRE), Glaukos Corporation (NYSE:GKOS), MSCI Inc. (NYSE:MSCI), Alteryx, Inc. (NYSE:AYX), Discover Financial Services (NYSE:DFS), MaxLinear, Inc. (NYSE:MXL), Shutterstock, Inc. (NYSE:SSTK), GTT Communications, Inc. (NYSE:GTT), Ooma, Inc. (NYSE:OOMA), Teladoc Health, Inc. (NYSE:TDOC), Nevro Corp. (NYSE:NVRO), Wayfair Inc. (NYSE:W), Arista Networks, Inc. (NYSE:ANET), Veeva Systems Inc. (NYSE:VEEV), PROS Holdings, Inc. (NYSE:PRO), Zendesk, Inc. (NYSE:ZEN), Dolby Laboratories, Inc. (NYSE:DLB), e.l.f. Beauty, Inc. (NYSE:ELF), Twilio Inc. (NYSE:TWLO), Catalent, Inc. (NYSE:CTLT), IQVIA Holdings Inc. (NYSE:IQV), Envestnet, Inc. (NYSE:ENV), TransUnion (NYSE:TRU), Evolent Health, Inc. (NYSE:EVH), Foundation Building Materials, Inc. (NYSE:FBM), EVERTEC, Inc. (NYSE:EVTC), Shake Shack Inc. (NYSE:SHAK), RE/MAX Holdings, Inc. (NYSE:RMAX), Globant S.A. (NYSE:GLOB), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Freshpet, Inc. (NasdaqGM:FRPT), Veracyte, Inc. (NasdaqGM:VCYT), Talend S.A. (NasdaqGM:TLND), Rapid7, Inc. (NasdaqGM:RPD), Revance Therapeutics, Inc. (NasdaqGM:RVNC), Everbridge, Inc. (NasdaqGM:EVBG), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), Tactile Systems Technology, Inc. (NasdaqGM:TCMD), Proofpoint, Inc. (NasdaqGM:PFPT), Upland Software, Inc. (NasdaqGM:UPLD), Mitek Systems, Inc. (NasdaqCM:MITK), RADCOM Ltd. (NasdaqCM:RDCM), Exact Sciences Corporation (NasdaqCM:EXAS), Hudson Technologies Inc. (NasdaqCM:HDSN), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), Airgain, Inc. (NasdaqCM:AIRG)William Blair & Company, L.L.C., The William Blair 2017 Growth Stock Conference, Jun 13, 2017 through Jun 15, 2017. Venue: The Four Seasons Hotel, 120 East Delaware Place, Chicago, Illinois, United States.
122
6/30/201711.85x30.63x33.37x57.23x41.65x$33,925$304.8196.28%May-30-2017Product-Related AnnouncementIntuitive Surgical, Inc. Receives FDA Clearance for its New da Vinci X Surgical System in the United States-Intuitive Surgical, Inc. announced that its new da Vinci X Surgical System received FDA clearance in the United States. The da Vinci X System will provide surgeons and hospitals with access to some of the most advanced robotic-assisted surgery technology at a lower cost. FDA clearance of the da Vinci X System follows CE Mark, which was announced in April. The launch of the da Vinci X System underscores Intuitive’s commitment to meeting customers’ needs with a strong value-oriented portfolio and an array of financing options. The da Vinci X System offers surgeons and hospitals access to Intuitive’s portfolio of advanced, innovative robotic-assisted surgical technologies – and its full ecosystem of programs, support, services, and solutions – at a lower price. The System uses the same vision cart and surgeon console that are found on the company's product, the da Vinci Xi® System, enabling company's customers the option of adding advanced capabilities, and providing a pathway for upgrading should they choose to do so as their practice and needs grow. The da Vinci X System enables optimized, focused-quadrant surgery including procedures like prostatectomy, partial nephrectomy, benign hysterectomy and sacrocolpopexy, among others. The System features flexible port placement and 3D digital optics, while incorporating the same advanced instruments and accessories as Intuitive’s system. The new system drives operational efficiencies through set-up technology that uses voice and laser guidance, drape design that simplifies surgery prep, and a lightweight, fully integrated endoscope.
123
6/30/201711.85x30.63x33.37x57.23x41.65x$31,571$283.66110.92%May-17-2017Company Conference PresentationIntuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2017 Healthcare Conference, May-17-2017 11:20 AM-Intuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2017 Healthcare Conference, May-17-2017 11:20 AM. Venue: Encore at the Wynn Hotel, Las Vegas, Nevada, United States. Speakers: Calvin Darling, Senior Director, Investor Relations, Marshall L. Mohr, Chief Financial Officer and Senior Vice President.
124
6/30/201711.85x30.63x33.37x57.23x41.65x$31,886$286.49108.83%May-16-2017ConferenceBank of America Corporation, Bank of America Merrill Lynch 2017 Healthcare Conference, May 16, 2017 through May 18, 2017Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), Seres Therapeutics, Inc. (NasdaqGS:MCRB), Editas Medicine, Inc. (NasdaqGS:EDIT), NantKwest, Inc. (NasdaqGS:NK), Prothena Corporation plc (NasdaqGS:PRTA), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Puma Biotechnology, Inc. (NasdaqGS:PBYI), REGENXBIO Inc. (NasdaqGS:RGNX), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Illumina, Inc. (NasdaqGS:ILMN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), LivaNova PLC (NasdaqGS:LIVN), Pacira BioSciences, Inc. (NasdaqGS:PCRX), bluebird bio, Inc. (NasdaqGS:BLUE), Inovio Pharmaceuticals, Inc. (NasdaqGS:INO), Gilead Sciences, Inc. (NasdaqGS:GILD), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Repligen Corporation (NasdaqGS:RGEN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Hologic, Inc. (NasdaqGS:HOLX), Quidel Corporation (NasdaqGS:QDEL), Teligent, Inc. (NasdaqGS:TLGT), Amgen Inc. (NasdaqGS:AMGN), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Innoviva, Inc. (NasdaqGS:INVA), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), MacroGenics, Inc. (NasdaqGS:MGNX), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), Luminex Corporation (NasdaqGS:LMNX), Bio-Techne Corporation (NasdaqGS:TECH), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Surgery Partners, Inc. (NasdaqGS:SGRY), Ascendis Pharma A/S (NasdaqGS:ASND), Otonomy, Inc. (NasdaqGS:OTIC), HealthEquity, Inc. (NasdaqGS:HQY), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Conformis, Inc. (NasdaqGS:CFMS), Intrexon Corporation (NasdaqGS:XON), Cardiovascular Systems, Inc. (NasdaqGS:CSII), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Aduro BioTech, Inc. (NasdaqGS:ADRO), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), LHC Group, Inc. (NasdaqGS:LHCG), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Cellectis S.A. (ENXTPA:ALCLS), DBV Technologies S.A. (ENXTPA:DBV), Novo Nordisk A/S (CPSE:NOVO B), Hutchison China MediTech Limited (AIM:HCM), Novartis AG (SWX:NOVN), Roche Holding AG (SWX:ROG), The Medicines Company, Celgene Corporation, Almost Family, Inc., Kindred Healthcare, LLC, Express Scripts Holding Company, Envision Healthcare Corporation, Legacy LifePoint Health, Inc., Impax Laboratories, Inc., Genomic Health, Inc., Sucampo Pharmaceuticals, Inc., TiGenix NV, Orexigen Therapeutics, Inc., Alder BioPharmaceuticals, Inc., Civitas Solutions, Inc., Edge Therapeutics, Inc., Tesaro, Inc., Audentes Therapeutics, Inc., Juno Therapeutics, Inc., Bioverativ Inc., Capital Senior Living Corporation (NYSE:CSU), Bausch Health Companies Inc. (NYSE:BHC), National Health Investors, Inc. (NYSE:NHI), West Pharmaceutical Services, Inc. (NYSE:WST), Boston Scientific Corporation (NYSE:BSX), Teleflex Incorporated (NYSE:TFX), Chemed Corporation (NYSE:CHE), HCA Healthcare, Inc. (NYSE:HCA), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Danaher Corporation (NYSE:DHR), Owens & Minor, Inc. (NYSE:OMI), Service Corporation International (NYSE:SCI), Cigna Corporation (NYSE:CI), MEDNAX, Inc. (NYSE:MD), Baxter International Inc. (NYSE:BAX), WellCare Health Plans, Inc. (NYSE:WCG), Glaukos Corporation (NYSE:GKOS), Lannett Company, Inc. (NYSE:LCI), Catalent, Inc. (NYSE:CTLT), Penumbra, Inc. (NYSE:PEN), Nevro Corp. (NYSE:NVRO), Diplomat Pharmacy, Inc. (NYSE:DPLO), American Renal Associates Holdings, Inc. (NYSE:ARA), Avanos Medical, Inc. (NYSE:AVNS), Zoetis Inc. (NYSE:ZTS), Invitae Corporation (NYSE:NVTA), Quorum Health Corporation (NYSE:QHC), Bank of America Corporation (NYSE:BAC), Hill-Rom Holdings, Inc. (NYSE:HRC), AMN Healthcare Services, Inc. (NYSE:AMN), Fresenius SE & Co. KGaA (XTRA:FRE), Zyla Life Sciences (OTCPK:ZCOR), Laboratory Corporation of America Holdings (NYSE:LH), Humana Inc. (NYSE:HUM), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), International Business Machines Corporation (NYSE:IBM), Stryker Corporation (NYSE:SYK), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), Universal Health Services, Inc. (NYSE:UHS), Allergan plc (NYSE:AGN), Charles River Laboratories International, Inc. (NYSE:CRL), Mettler-Toledo International Inc. (NYSE:MTD), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Avadel Pharmaceuticals plc (NasdaqGM:AVDL), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), CRISPR Therapeutics AG (NasdaqGM:CRSP), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Intersect ENT, Inc. (NasdaqGM:XENT), NewLink Genetics Corporation (NasdaqGM:NLNK), Radius Health, Inc. (NasdaqGM:RDUS), GW Pharmaceuticals plc (NasdaqGM:GWPH), Tactile Systems Technology, Inc. (NasdaqGM:TCMD), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), Phibro Animal Health Corporation (NasdaqGM:PAHC), Heron Therapeutics, Inc. (NasdaqCM:HRTX), Exact Sciences Corporation (NasdaqCM:EXAS), Corcept Therapeutics Incorporated (NasdaqCM:CORT)Bank of America Corporation, Bank of America Merrill Lynch 2017 Healthcare Conference, May 16, 2017 through May 18, 2017. Venue: Encore at the Wynn Hotel, Las Vegas, Nevada, United States.
125
6/30/201711.85x30.63x33.37x57.23x41.65x$30,943$278.01115.20%Apr-26-2017Product-Related AnnouncementIntuitive Surgical Receives CE Mark for Latest da Vinci Robotic-Assisted Surgical System-Intuitive Surgical, Inc. received CE Mark approval in Europe. The da Vinci X System will provide surgeons and hospitals with access to some of the most advanced robotic-assisted surgery technology at a lower cost. The launch of the da Vinci X System underscores Intuitive’s commitment to meeting customers’ needs with a strong value-oriented portfolio of cost-appropriate technologies and an array of financing options. The da Vinci X System offers surgeons and hospitals access to Intuitive’s portfolio of advanced, innovative robotic-assisted surgical technologies, and its full ecosystem of programs, support, services, and solutions, at a lower price. The System uses the same vision cart and surgeon consoles that are found on company's product, the da Vinci Xi System, enabling company's customers the option of adding advanced capabilities, and providing a pathway for upgrading should they choose to do so as their practice and needs grow. The da Vinci X System enables optimized, focused-quadrant surgery and features flexible port placement and 3D digital optics, while incorporating company's latest advanced instruments and accessories as Intuitive’s system. The new system drives operational efficiencies through set-up technology that uses voice and laser guidance, drape design that simplifies surgery prep, and a lightweight, fully integrated endoscope.
126
6/30/201711.85x30.63x33.37x57.23x41.65x$30,691$275.75116.97%Apr-25-2017Executive/Board Change - OtherIntuitive Surgical, Inc. Appoints Jami Dover Nachtsheim to the Board of Directors-Intuitive Surgical, Inc. announced that at the AGM, it has approved appointment of Jami Dover Nachtsheim to the board of directors to serve a one-year term expiring at the 2018 annual meeting of Stockholders.
127
6/30/201711.85x30.63x33.37x57.23x41.65x$30,216$271.48120.38%Apr-20-2017Annual General MeetingIntuitive Surgical, Inc., Annual General Meeting, Apr 20, 2017-Intuitive Surgical, Inc., Annual General Meeting, Apr 20, 2017, at 15:00 Pacific Standard Time. Location: 1020 Kifer Road Sunnyvale California United States Agenda: To elect nine members to the board of directors of the company to serve until the 2018 annual meeting of stockholders; to consider and approve, on an advisory basis, the compensation of the company's named executive officers as disclosed in the proxy statement; to vote, on an advisory basis, on the frequency of the advisory vote on the compensation of the company's named executive officers as disclosed in the proxy statement; to ratify the appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2017; to approve the amendment and restatement of the 2000 employee stock purchase plan; to approve the amendment and restatement of the 2010 incentive award plan; and to transact any other business which is properly brought before the annual meeting or adjournments or postponements thereof.
128
6/30/201711.85x30.63x33.37x57.23x41.65x$29,965$269.23122.22%Apr-19-2017Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From January 1, 2017 to March 31, 2017, the company has repurchased 7,327,908 shares, representing 6.3% for $2,000 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
129
6/30/201711.85x30.63x33.37x57.23x41.65x$28,171$253.11136.38%Apr-18-2017Earnings CallIntuitive Surgical, Inc., Q1 2017 Earnings Call, Apr 18, 2017-Intuitive Surgical, Inc., Q1 2017 Earnings Call, Apr 18, 2017
130
6/30/201711.85x30.63x33.37x57.23x41.65x$28,171$253.11136.38%Apr-18-2017Announcement of Earnings, Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Provides Earnings Guidance for the Year 2017-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported total revenue of $674.2 million against $594.5 million a year ago. Income from operations was $191.5 million against $179.0 million a year ago. Net income was $179.8 million against $136.4 million a year ago. Income before taxes was $200.2 million against $184.5 million a year ago. Diluted net income per share was $4.67 against $3.54 per share a year ago. Non-GAAP income from operations was $263.9 million against $229.1 million a year ago. Non-GAAP net income was $196.0 million or $5.09 per share diluted against $242.3 million or $4.42 per share diluted a year ago. Pro forma net income, which excludes income associated with the revenue deferral, was $196 million or $5.09 per share compared with $170 million or $4.42 per share for the first quarter of 2016 and $242 million or $6.09 per share for the fourth quarter of 2016.

The company forecast 2017 pro forma gross profit margin to be within a range of between 69% and 71% of net revenue. The company now expect its full year 2017 gross profit margin to be in the upper half of that range expects its 2017 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and international profits.
131
3/31/20179.46x24.46x26.74x48.54x29.91x$27,477$248.89140.38%Mar-15-2017Company Conference PresentationIntuitive Surgical, Inc. Presents at Barclays Global Healthcare Conference 2017, Mar-15-2017 09:00 AM-Intuitive Surgical, Inc. Presents at Barclays Global Healthcare Conference 2017, Mar-15-2017 09:00 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami Beach, Florida, United States. Speakers: Calvin Darling, Sr. Director, Investor Relations, Jamie E. Samath, Principal Accounting Officer, Vice President and Corporate Controller.
132
3/31/20179.46x24.46x26.74x48.54x29.91x$27,235$246.69142.53%Mar-14-2017ConferenceBarclays Capital PLC, Barclays Global Healthcare Conference 2017, Mar 14, 2017 through Mar 16, 2017BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Alkermes plc (NasdaqGS:ALKS), Tivity Health, Inc. (NasdaqGS:TVTY), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), LivaNova PLC (NasdaqGS:LIVN), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Seattle Genetics, Inc. (NasdaqGS:SGEN), United Therapeutics Corporation (NasdaqGS:UTHR), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), NuVasive, Inc. (NasdaqGS:NUVA), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), Quidel Corporation (NasdaqGS:QDEL), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Cerner Corporation (NasdaqGS:CERN), Mylan N.V. (NasdaqGS:MYL), Magellan Health, Inc. (NasdaqGS:MGLN), Incyte Corporation (NasdaqGS:INCY), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Henry Schein, Inc. (NasdaqGS:HSIC), Luminex Corporation (NasdaqGS:LMNX), Axovant Gene Therapies Ltd. (NasdaqGS:AXGT), Aravive, Inc. (NasdaqGS:ARAV), CytomX Therapeutics, Inc. (NasdaqGS:CTMX), Precision BioSciences, Inc. (NasdaqGS:DTIL), Trevena, Inc. (NasdaqGS:TRVN), Sabra Health Care REIT, Inc. (NasdaqGS:SBRA), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Moderna, Inc. (NasdaqGS:MRNA), NantKwest, Inc. (NasdaqGS:NK), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Prothena Corporation plc (NasdaqGS:PRTA), Bruker Corporation (NasdaqGS:BRKR), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), AngioDynamics, Inc. (NasdaqGS:ANGO), Advaxis, Inc. (NasdaqGS:ADXS), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Surgery Partners, Inc. (NasdaqGS:SGRY), OPKO Health, Inc. (NasdaqGS:OPK), Arbutus Biopharma Corporation (NasdaqGS:ABUS), SELLAS Life Sciences Group, Inc. (NasdaqCM:SLS), Cocrystal Pharma, Inc. (NasdaqCM:COCP), CRISPR Therapeutics AG (NasdaqGM:CRSP), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), Foamix Pharmaceuticals Ltd. (NasdaqGM:FOMX), Reata Pharmaceuticals, Inc. (NasdaqGM:RETA), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Revance Therapeutics, Inc. (NasdaqGM:RVNC), Acceleron Pharma Inc. (NasdaqGM:XLRN), Concert Pharmaceuticals, Inc. (NasdaqGM:CNCE), Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM), Coherus BioSciences, Inc. (NasdaqGM:CHRS), ProQR Therapeutics N.V. (NasdaqGM:PRQR), Leap Therapeutics, Inc. (NasdaqGM:LPTX), Protagonist Therapeutics, Inc. (NasdaqGM:PTGX), Retrophin, Inc. (NasdaqGM:RTRX), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Avanos Medical, Inc. (NYSE:AVNS), AbbVie Inc. (NYSE:ABBV), American Renal Associates Holdings, Inc. (NYSE:ARA), Diplomat Pharmacy, Inc. (NYSE:DPLO), Mallinckrodt plc (NYSE:MNK), Myovant Sciences Ltd. (NYSE:MYOV), WellCare Health Plans, Inc. (NYSE:WCG), Genesis Healthcare, Inc. (NYSE:GEN), Fresenius SE & Co. KGaA (XTRA:FRE), Bausch Health Companies Inc. (NYSE:BHC), Quest Diagnostics Incorporated (NYSE:DGX), Varian Medical Systems, Inc. (NYSE:VAR), Boston Scientific Corporation (NYSE:BSX), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Welltower Inc. (NYSE:WELL), Merck & Co., Inc. (NYSE:MRK), HCA Healthcare, Inc. (NYSE:HCA), PerkinElmer, Inc. (NYSE:PKI), MEDNAX, Inc. (NYSE:MD), MAXIMUS, Inc. (NYSE:MMS), Abbott Laboratories (NYSE:ABT), Baxter International Inc. (NYSE:BAX), Johnson & Johnson (NYSE:JNJ), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Medtronic plc (NYSE:MDT), Universal Health Services, Inc. (NYSE:UHS), Allergan plc (NYSE:AGN), Integer Holdings Corporation (NYSE:ITGR), Charles River Laboratories International, Inc. (NYSE:CRL), CVS Health Corporation (NYSE:CVS), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Tenet Healthcare Corporation (NYSE:THC), QIAGEN N.V. (NYSE:QGEN), Humana Inc. (NYSE:HUM), Laboratory Corporation of America Holdings (NYSE:LH), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), Hill-Rom Holdings, Inc. (NYSE:HRC), AmerisourceBergen Corporation (NYSE:ABC), Barclays Capital PLC, Air Methods Corporation, Cascadian Therapeutics, Inc., PAREXEL International Corporation, NxStage Medical, Inc., C. R. Bard, Inc., Celgene Corporation, Kindred Healthcare, LLC, Express Scripts Holding Company, Envision Healthcare Corporation, Albany Molecular Research, Inc., Impax Laboratories, Inc., Aetna Inc., Ortho-Clinical Diagnostics, Inc., The Advisory Board Company, Mazor Robotics Ltd., America's Health Insurance Plans, PharMerica Corporation, Civitas Solutions, Inc., Celtaxsys, Inc., Berkeley Research Group, LLC, Tesaro, Inc., Aratana Therapeutics, Inc., Juno Therapeutics, Inc., K2M Group Holdings, Inc., Vesey Street Capital Partners, L.L.C., Cotiviti Holdings, Inc., Spark Therapeutics, Inc., VWR Corporation, Ion Beam Applications SA (ENXTBR:IBAB), Koninklijke Philips N.V. (ENXTAM:PHIA), GlaxoSmithKline plc (LSE:GSK), AstraZeneca PLC (LSE:AZN), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), DiaSorin S.p.A. (BIT:DIA), Ipsen S.A. (ENXTPA:IPN), Novo Nordisk A/S (CPSE:NOVO B), EssilorLuxottica Société anonyme (ENXTPA:EL), DBV Technologies S.A. (ENXTPA:DBV), Genfit SA (ENXTPA:GNFT)Barclays Capital PLC, Barclays Global Healthcare Conference 2017, Mar 14, 2017 through Mar 16, 2017. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami Beach, Florida, United States.
133
3/31/20179.46x24.46x26.74x48.54x29.91x$26,794$242.70146.51%Mar-08-2017Company Conference PresentationIntuitive Surgical, Inc. Presents at The Raymond James 38th Annual Institutional Investors Conference 2017, Mar-08-2017 01:55 PM-Intuitive Surgical, Inc. Presents at The Raymond James 38th Annual Institutional Investors Conference 2017, Mar-08-2017 01:55 PM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Pkwy, Orlando, Florida, United States.
134
3/31/20179.46x24.46x26.74x48.54x29.91x$26,794$242.70146.51%Mar-08-2017Seeking Acquisition/InvestmentIntuitive Surgical Mull Acquisitions-Calvin Darling, Senior Director of Finance of Intuitive Surgical, Inc. (NasdaqGS:ISRG) said, "Yes, Larry, one of the strengths of our business is the ability to generate cash. We are at a point now where we are generating roughly, give or take about $1 billion of free cash flow each year. So it does tend to accumulate our priorities for capital allocation, direct organic investment in areas we think that can add value, some of the things I described are clearly top priority, we have been and we will continue to make technology acquisitions that we can tuck in to with an eye on improving outcomes or expanding markets, we have been doing that, to-date there haven't been large ticket items, but there could be in the future."
135
3/31/20179.46x24.46x26.74x48.54x29.91x$0Mar-05-2017ConferenceRaymond James & Associates, Inc., the Raymond James 38th Annual Institutional Investors Conference 2017, Mar 05, 2017 through Mar 08, 2017Willis Towers Watson Public Limited Company (NasdaqGS:WLTW), ACI Worldwide, Inc. (NasdaqGS:ACIW), Wintrust Financial Corporation (NasdaqGS:WTFC), Cogent Communications Holdings, Inc. (NasdaqGS:CCOI), Ruth's Hospitality Group, Inc. (NasdaqGS:RUTH), E*TRADE Financial Corporation (NasdaqGS:ETFC), SS&C Technologies Holdings, Inc. (NasdaqGS:SSNC), Stericycle, Inc. (NasdaqGS:SRCL), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Rent-A-Center, Inc. (NasdaqGS:RCII), Qorvo, Inc. (NasdaqGS:QRVO), SBA Communications Corporation (NasdaqGS:SBAC), Lumentum Holdings Inc. (NasdaqGS:LITE), Allegiant Travel Company (NasdaqGS:ALGT), United Community Banks, Inc. (NasdaqGS:UCBI), Iridium Communications Inc. (NasdaqGS:IRDM), Premier, Inc. (NasdaqGS:PINC), ICON Public Limited Company (NasdaqGS:ICLR), Synchronoss Technologies, Inc. (NasdaqGS:SNCR), Nasdaq, Inc. (NasdaqGS:NDAQ), IPG Photonics Corporation (NasdaqGS:IPGP), OraSure Technologies, Inc. (NasdaqGS:OSUR), Insulet Corporation (NasdaqGS:PODD), ORBCOMM Inc. (NasdaqGS:ORBC), Verisk Analytics, Inc. (NasdaqGS:VRSK), LKQ Corporation (NasdaqGS:LKQ), PRA Group, Inc. (NasdaqGS:PRAA), Beacon Roofing Supply, Inc. (NasdaqGS:BECN), Northern Trust Corporation (NasdaqGS:NTRS), ATN International, Inc. (NasdaqGS:ATNI), WesBanco, Inc. (NasdaqGS:WSBC), ICU Medical, Inc. (NasdaqGS:ICUI), Hancock Whitney Corporation (NasdaqGS:HWC), United Bankshares, Inc. (NasdaqGS:UBSI), PotlatchDeltic Corporation (NasdaqGS:PCH), SEI Investments Company (NasdaqGS:SEIC), Seacoast Banking Corporation of Florida (NasdaqGS:SBCF), Patterson-UTI Energy, Inc. (NasdaqGS:PTEN), ScanSource, Inc. (NasdaqGS:SCSC), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), TD Ameritrade Holding Corporation (NasdaqGS:AMTD), Atlantic Union Bankshares Corporation (NasdaqGS:AUB), Bank OZK (NasdaqGS:OZK), CDW Corporation (NasdaqGS:CDW), FLIR Systems, Inc. (NasdaqGS:FLIR), Pacific Premier Bancorp, Inc. (NasdaqGS:PPBI), Shenandoah Telecommunications Company (NasdaqGS:SHEN), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Trimble Inc. (NasdaqGS:TRMB), Red Robin Gourmet Burgers, Inc. (NasdaqGS:RRGB), TripAdvisor, Inc. (NasdaqGS:TRIP), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Fastenal Company (NasdaqGS:FAST), Avnet, Inc. (NasdaqGS:AVT), J.B. Hunt Transport Services, Inc. (NasdaqGS:JBHT), Huntington Bancshares Incorporated (NasdaqGS:HBAN), Masimo Corporation (NasdaqGS:MASI), Natus Medical Incorporated (NasdaqGS:NTUS), NVIDIA Corporation (NasdaqGS:NVDA), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Check Point Software Technologies Ltd. (NasdaqGS:CHKP), Citrix Systems, Inc. (NasdaqGS:CTXS), Cognex Corporation (NasdaqGS:CGNX), CommScope Holding Company, Inc. (NasdaqGS:COMM), BlackRock TCP Capital Corp. (NasdaqGS:TCPC), MobileIron, Inc. (NasdaqGS:MOBL), BlackLine, Inc. (NasdaqGS:BL), Carrols Restaurant Group, Inc. (NasdaqGS:TAST), HealthEquity, Inc. (NasdaqGS:HQY), SunPower Corporation (NasdaqGS:SPWR), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Ares Capital Corporation (NasdaqGS:ARCC), Home Bancshares, Inc. (Conway, AR) (NasdaqGS:HOMB), CME Group Inc. (NasdaqGS:CME), MACOM Technology Solutions Holdings, Inc. (NasdaqGS:MTSI), Chuy's Holdings, Inc. (NasdaqGS:CHUY), Uniti Group Inc. (NasdaqGS:UNIT), Cboe Global Markets, Inc. (BATS:CBOE), Norbord Inc. (TSX:OSB), Algonquin Power & Utilities Corp. (TSX:AQN), BroadSoft, Inc., Spectrum Brands Legacy, Inc., Shutterfly, Inc., athenahealth, Inc., Buffalo Wild Wings, Inc., Microsemi Corporation, Agrium Inc., Carrizo Oil & Gas, Inc., Envision Healthcare Corporation, Impax Laboratories, Inc., Keryx Biopharmaceuticals, Inc., Raymond James & Associates, Inc., Cavium, Inc., Worldpay, Inc., Pandora Media, LLC, Control4 Corporation, Mobileye N.V., Cempra, Inc., Civitas Solutions, Inc., SRC Energy Inc., Tesaro, Inc., Brazos Valley Longhorn, L.L.C., MSCI Inc. (NYSE:MSCI), QEP Resources, Inc. (NYSE:QEP), WellCare Health Plans, Inc. (NYSE:WCG), Compass Diversified Holdings LLC (NYSE:CODI), Palo Alto Networks, Inc. (NYSE:PANW), Delek US Holdings, Inc. (NYSE:DK), Prestige Consumer Healthcare Inc. (NYSE:PBH), Digital Realty Trust, Inc. (NYSE:DLR), Chegg, Inc. (NYSE:CHGG), Axos Financial, Inc. (NYSE:AX), Diplomat Pharmacy, Inc. (NYSE:DPLO), Castlight Health, Inc. (NYSE:CSLT), Catalent, Inc. (NYSE:CTLT), Envestnet, Inc. (NYSE:ENV), TPG Specialty Lending, Inc. (NYSE:TSLX), Instructure, Inc. (NYSE:INST), WPX Energy, Inc. (NYSE:WPX), NOW Inc. (NYSE:DNOW), Avanos Medical, Inc. (NYSE:AVNS), Fortress Transportation and Infrastructure Investors LLC (NYSE:FTAI), Parsley Energy, Inc. (NYSE:PE), Zayo Group Holdings, Inc. (NYSE:ZAYO), Murphy USA Inc. (NYSE:MUSA), MRC Global Inc. (NYSE:MRC), California Resources Corporation (NYSE:CRC), AquaVenture Holdings Limited (NYSE:WAAS), The Allstate Corporation (NYSE:ALL), S&P Global Inc. (NYSE:SPGI), Raymond James Financial, Inc. (NYSE:RJF), Alliance Data Systems Corporation (NYSE:ADS), American Tower Corporation (REIT) (NYSE:AMT), AmerisourceBergen Corporation (NYSE:ABC), AutoZone, Inc. (NYSE:AZO), Moody's Corporation (NYSE:MCO), InterXion Holding N.V. (NYSE:INXN), Main Street Capital Corporation (NYSE:MAIN), Lannett Company, Inc. (NYSE:LCI), Tempur Sealy International, Inc. (NYSE:TPX), American Equity Investment Life Holding Company (NYSE:AEL), Whiting Petroleum Corporation (NYSE:WLL), Broadridge Financial Solutions, Inc. (NYSE:BR), Vocera Communications, Inc. (NYSE:VCRA), Spirit Airlines, Inc. (NYSE:SAVE), Enterprise Products Partners L.P. (NYSE:EPD), Steelcase Inc. (NYSE:SCS), Waste Connections, Inc. (NYSE:WCN), Republic Services, Inc. (NYSE:RSG), ProAssurance Corporation (NYSE:PRA), SM Energy Company (NYSE:SM), Rayonier Inc. (NYSE:RYN), New York Community Bancorp, Inc. (NYSE:NYCB), Covanta Holding Corporation (NYSE:CVA), Union Pacific Corporation (NYSE:UNP), United States Cellular Corporation (NYSE:USM), Walmart Inc. (NYSE:WMT), PulteGroup, Inc. (NYSE:PHM), Pioneer Natural Resources Company (NYSE:PXD), Pier 1 Imports, Inc. (NYSE:PIR), Polaris Inc. (NYSE:PII), Service Corporation International (NYSE:SCI), Stanley Black & Decker, Inc. (NYSE:SWK), Teleflex Incorporated (NYSE:TFX), Toll Brothers, Inc. (NYSE:TOL), Crown Castle International Corp. (REIT) (NYSE:CCI), Superior Energy Services, Inc. (NYSE:SPN), Helix Energy Solutions Group, Inc. (NYSE:HLX), Oil States International, Inc. (NYSE:OIS), STERIS plc (NYSE:STE), TETRA Technologies, Inc. (NYSE:TTI), Allergan plc (NYSE:AGN), Callaway Golf Company (NYSE:ELY), Ethan Allen Interiors Inc. (NYSE:ETH), FleetCor Technologies, Inc. (NYSE:FLT), Encompass Health Corporation (NYSE:EHC), Kansas City Southern (NYSE:KSU), Laboratory Corporation of America Holdings (NYSE:LH), Leggett & Platt, Incorporated (NYSE:LEG), D.R. Horton, Inc. (NYSE:DHI), Weyerhaeuser Company (NYSE:WY), Charles River Laboratories International, Inc. (NYSE:CRL), The Home Depot, Inc. (NYSE:HD), First Republic Bank (NYSE:FRC), W.W. Grainger, Inc. (NYSE:GWW), HNI Corporation (NYSE:HNI), Agnico Eagle Mines Limited (NYSE:AEM), Aflac Incorporated (NYSE:AFL), Argo Group International Holdings, Ltd. (NYSE:ARGO), Arrow Electronics, Inc. (NYSE:ARW), Baxter International Inc. (NYSE:BAX), HCA Healthcare, Inc. (NYSE:HCA), Delta Air Lines, Inc. (NYSE:DAL), MSC Industrial Direct Co., Inc. (NYSE:MSM), salesforce.com, inc. (NYSE:CRM), Brunswick Corporation (NYSE:BC), Masco Corporation (NYSE:MAS), RPC, Inc. (NYSE:RES), Telephone and Data Systems, Inc. (NYSE:TDS), The Toro Company (NYSE:TTC), Unit Corporation (NYSE:UNT), MEDNAX, Inc. (NYSE:MD), MAXIMUS, Inc. (NYSE:MMS), United Parcel Service, Inc. (NYSE:UPS), Key Energy Services, Inc. (OTCPK:KEG.X), Basic Energy Services, Inc. (OTCPK:BASX), AAC Holdings, Inc. (OTCPK:AACH), Applied Optoelectronics, Inc. (NasdaqGM:AAOI), Upland Software, Inc. (NasdaqGM:UPLD), FedNat Holding Company (NasdaqGM:FNHC), Newtek Business Services Corp. (NasdaqGM:NEWT), The Habit Restaurants, Inc. (NasdaqGM:HABT), First Foundation Inc. (NasdaqGM:FFWM), Green Plains Partners LP (NasdaqGM:GPP), Flexion Therapeutics, Inc. (NasdaqGM:FLXN), TPI Composites, Inc. (NasdaqGM:TPIC), Rapid7, Inc. (NasdaqGM:RPD), Everbridge, Inc. (NasdaqGM:EVBG), Benefitfocus, Inc. (NasdaqGM:BNFT), Senseonics Holdings, Inc. (AMEX:SENS), Oasis Petroleum Inc. (NasdaqCM:OAS)Raymond James & Associates, Inc., The Raymond James 38th Annual Institutional Investors Conference 2017, Mar 05, 2017 through Mar 08, 2017. Venue: JW Marriott Grande Lakes, 4040 Central Florida Pkwy, Orlando, Florida, United States.
136
3/31/20179.46x24.46x26.74x48.54x29.91x$25,858$234.22155.44%Feb-8-2017Executive/Board Change - OtherGeorge J. Stalk Decides to Retire from the Board of Intuitive Surgical, Inc-On February 2, 2017, George J. Stalk, Jr. informed the Board of Directors of Intuitive Surgical, Inc. that he has decided to retire from the Board and accordingly will not stand for re-election to the Board at the company's 2017 annual meeting of stockholders. Mr. Stalk plans to continue to serve on the Board and as a member of the Audit Committee of the Board until the Company's 2017 annual meeting of stockholders.
137
3/31/20179.46x24.46x26.74x48.54x29.91x$24,511$222.02169.48%Jan-24-2017Earnings CallIntuitive Surgical, Inc., Q4 2016 Earnings Call, Jan 24, 2017-Intuitive Surgical, Inc., Q4 2016 Earnings Call, Jan 24, 2017
138
3/31/20179.46x24.46x26.74x48.54x29.91x$24,511$222.02169.48%Jan-24-2017Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported total revenue of USD 756.9 million against USD 676.5 million a year ago. Income from operations was USD 264.4 million against USD 245.9 million a year ago. Income before taxes was USD 276.1 million against USD 251.8 million a year ago. Net income was USD 204.0 million or USD 5.13 per diluted share against USD 190.0 million or USD 4.99 per diluted share a year ago. Non-GAAP income from operations was USD 319.7 million against USD 292.6 million a year ago. Non-GAAP income per diluted share was USD 6.09 against USD 5.89 a year ago. Non-GAAP net income was USD 242.3 million against USD 224.3 million a year ago. Higher fourth quarter revenue was driven by growth in recurring instrument, accessory, and service revenue, and higher systems revenue.

For the year, the company reported total revenue of USD 2,704.4 million against USD 2,384.4 million a year ago. Income from operations was USD 945.2 million against USD 740.0 million a year ago. Income before taxes was USD 980.8 against USD 758.5 million a year ago. Net income was USD 735.9 million or USD 18.73 per diluted share against USD 588.8 million or USD 15.54 per diluted share a year ago. Non-GAAP income from operations was USD 1,153.5 million against USD 945.7 million a year ago. Non-GAAP income per diluted share was USD 22.36 against USD 19.28 a year ago. Non-GAAP net income was USD 878.7 million against USD 730.9 million a year ago.
139
3/31/20179.46x24.46x26.74x48.54x29.91x$24,511$222.02169.48%Jan-24-2017Earnings Release DateIntuitive Surgical, Inc. to Report Q4, 2016 Results on Jan 24, 2017-Intuitive Surgical, Inc. announced that they will report Q4, 2016 results at 8:35 PM, GMT Standard Time on Jan 24, 2017
140
3/31/20179.46x24.46x26.74x48.54x29.91x$24,511$222.02169.48%Jan-24-2017Seeking Acquisition/InvestmentIntuitive Surgical Seeks Acquisitions-Intuitive Surgical, Inc. is seeking acquisitions. Gary Guthart, the Chief Executive Officer and President of the company recently stated, "We look for acquisitions as a third priority or things that can add to our company, and if we have excess capital, then opportunities to return it to shareholders."
141
3/31/20179.46x24.46x26.74x48.54x29.91x$24,511$222.02169.48%Jan-24-2017Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From October 1, 2016 to December 31, 2016, the company has repurchased 164,082 shares, representing 0.14% for $34.47 million. With this, the company has completed the repurchase of 1,308,282 shares, representing 1.17% for $226.25 million under the buyback announced on February 2, 2015.
142
3/31/20179.46x24.46x26.74x48.54x29.91x$24,468$221.63169.95%Jan-12-2017Company Conference PresentationIntuitive Surgical, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-12-2017 09:00 AM-Intuitive Surgical, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-12-2017 09:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Gary S. Guthart, Chief Executive Officer, President and Director.
143
3/31/20179.46x24.46x26.74x48.54x29.91x$24,956$226.05164.67%Jan-11-2017Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2016-Intuitive Surgical, Inc. provided revenue guidance for the fourth quarter and full year of 2016. The company expected revenue for the fourth quarter of 2016 of approximately $757 million, an increase of approximately 12% compared with $677 million for the fourth quarter of 2015.

The company expects 2016 revenue of approximately $2.7 billion, an increase of approximately 13% compared with $2.4 billion for 2015.
144
3/31/20179.46x24.46x26.74x48.54x29.91x$23,600$213.77179.88%Jan-9-2017ConferenceJPMorgan Chase & Co., 35th Annual JP Morgan Healthcare Conference, Jan 09, 2017 through Jan 12, 2017Almirall, S.A. (BME:ALM), Oryzon Genomics S.A. (BME:ORY), Alkermes plc (NasdaqGS:ALKS), Tivity Health, Inc. (NasdaqGS:TVTY), Amgen Inc. (NasdaqGS:AMGN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Endo International plc (NasdaqGS:ENDP), Biogen Inc. (NasdaqGS:BIIB), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Omnicell, Inc. (NasdaqGS:OMCL), Orthofix Medical Inc. (NasdaqGS:OFIX), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Masimo Corporation (NasdaqGS:MASI), The Providence Service Corporation (NasdaqGS:PRSC), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Repligen Corporation (NasdaqGS:RGEN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Premier, Inc. (NasdaqGS:PINC), Accuray Incorporated (NasdaqGS:ARAY), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), Bruker Corporation (NasdaqGS:BRKR), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Endologix, Inc. (NasdaqGS:ELGX), Novavax, Inc. (NasdaqGS:NVAX), ICON Public Limited Company (NasdaqGS:ICLR), Mylan N.V. (NasdaqGS:MYL), ICU Medical, Inc. (NasdaqGS:ICUI), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Patterson Companies, Inc. (NasdaqGS:PDCO), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), United Therapeutics Corporation (NasdaqGS:UTHR), Wright Medical Group N.V. (NasdaqGS:WMGI), Teligent, Inc. (NasdaqGS:TLGT), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Quidel Corporation (NasdaqGS:QDEL), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Akorn, Inc. (NasdaqGS:AKRX), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Bio-Techne Corporation (NasdaqGS:TECH), CONMED Corporation (NasdaqGS:CNMD), Cerner Corporation (NasdaqGS:CERN), Meridian Bioscience, Inc. (NasdaqGS:VIVO), Mersana Therapeutics, Inc. (NasdaqGS:MRSN), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Aduro BioTech, Inc. (NasdaqGS:ADRO), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), ChemoCentryx, Inc. (NasdaqGS:CCXI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), AngioDynamics, Inc. (NasdaqGS:ANGO), LHC Group, Inc. (NasdaqGS:LHCG), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), Inogen, Inc. (NasdaqGS:INGN), Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), HealthEquity, Inc. (NasdaqGS:HQY), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), Intrexon Corporation (NasdaqGS:XON), Conformis, Inc. (NasdaqGS:CFMS), iRhythm Technologies, Inc. (NasdaqGS:IRTC), OPKO Health, Inc. (NasdaqGS:OPK), Surgery Partners, Inc. (NasdaqGS:SGRY), Ascendis Pharma A/S (NasdaqGS:ASND), China Biologic Products Holdings, Inc. (NasdaqGS:CBPO), R1 RCM Inc. (NasdaqGS:RCM), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Twist Bioscience Corporation (NasdaqGS:TWST), 10x Genomics, Inc. (NasdaqGS:TXG), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Syneos Health, Inc. (NasdaqGS:SYNH), Editas Medicine, Inc. (NasdaqGS:EDIT), OptiNose, Inc. (NasdaqGS:OPTN), Tricida, Inc. (NasdaqGS:TCDA), Guardant Health, Inc. (NasdaqGS:GH), Axovant Gene Therapies Ltd. (NasdaqGS:AXGT), Y-mAbs Therapeutics, Inc. (NasdaqGS:YMAB), Varex Imaging Corporation (NasdaqGS:VREX), Solid Biosciences Inc. (NasdaqGS:SLDB), Neon Therapeutics, Inc. (NasdaqGS:NTGN), uniQure N.V. (NasdaqGS:QURE), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), Prothena Corporation plc (NasdaqGS:PRTA), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), NantHealth, Inc. (NasdaqGS:NH), Allena Pharmaceuticals, Inc. (NasdaqGS:ALNA), G1 Therapeutics, Inc. (NasdaqGS:GTHX), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Moderna, Inc. (NasdaqGS:MRNA), Principia Biopharma Inc. (NasdaqGS:PRNB), Monroe Capital Corporation (NasdaqGS:MRCC), Inovalon Holdings, Inc. (NasdaqGS:INOV), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), NuCana plc (NasdaqGS:NCNA), BioNTech SE (NasdaqGS:BNTX), Epizyme, Inc. (NasdaqGS:EPZM), CytomX Therapeutics, Inc. (NasdaqGS:CTMX), Otonomy, Inc. (NasdaqGS:OTIC), Clovis Oncology, Inc. (NasdaqGS:CLVS), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), NovoCure Limited (NasdaqGS:NVCR), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), Abeona Therapeutics Inc. (NasdaqCM:ABEO), Dynavax Technologies Corporation (NasdaqCM:DVAX), Agile Therapeutics, Inc. (NasdaqCM:AGRX), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), Exact Sciences Corporation (NasdaqCM:EXAS), Heron Therapeutics, Inc. (NasdaqCM:HRTX), Pieris Pharmaceuticals, Inc. (NasdaqCM:PIRS), aTyr Pharma, Inc. (NasdaqCM:LIFE), Evoke Pharma, Inc. (NasdaqCM:EVOK), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), Stemline Therapeutics, Inc. (NasdaqCM:STML), Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT), SELLAS Life Sciences Group, Inc. (NasdaqCM:SLS), Millendo Therapeutics, Inc. (NasdaqCM:MLND), TG Therapeutics, Inc. (NasdaqCM:TGTX), Cipla Limited (NSEI:CIPLA), Glenmark Pharmaceuticals Limited (NSEI:GLENMARK), Aurobindo Pharma Limited (NSEI:AUROPHARMA), JHL Biotech, Inc. (GTSM:6540), Microbio Co., Ltd. (GTSM:4128), EDAP TMS S.A. (NasdaqGM:EDAP), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), NanoString Technologies, Inc. (NasdaqGM:NSTG), Radius Health, Inc. (NasdaqGM:RDUS), Oxford Immunotec Global PLC (NasdaqGM:OXFD), Acceleron Pharma Inc. (NasdaqGM:XLRN), MannKind Corporation (NasdaqGM:MNKD), Cara Therapeutics, Inc. (NasdaqGM:CARA), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), AtriCure, Inc. (NasdaqGM:ATRC), Chimerix, Inc. (NasdaqGM:CMRX), Corvus Pharmaceuticals, Inc. (NasdaqGM:CRVS), Zai Lab Limited (NasdaqGM:ZLAB), Quotient Limited (NasdaqGM:QTNT), ProQR Therapeutics N.V. (NasdaqGM:PRQR), Intersect ENT, Inc. (NasdaqGM:XENT), Quanterix Corporation (NasdaqGM:QTRX), Ardelyx, Inc. (NasdaqGM:ARDX), Sensus Healthcare, Inc. (NasdaqGM:SRTS), Clearside Biomedical, Inc. (NasdaqGM:CLSD), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Retrophin, Inc. (NasdaqGM:RTRX), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Axcella Health Inc. (NasdaqGM:AXLA), Melinta Therapeutics, Inc. (OTCPK:MLNT.Q), REVA Medical, Inc. (OTCPK:RVAL.L), MiMedx Group, Inc. (OTCPK:MDXG), INSYS Therapeutics, Inc. (OTCPK:INSY.Q), Novelion Therapeutics Inc. (OTCPK:NVLN.F), Fresenius SE & Co. KGaA (XTRA:FRE), Bayer Aktiengesellschaft (XTRA:BAYN), MorphoSys AG (XTRA:MOR), 4SC AG (XTRA:VSC), Epigenomics AG (XTRA:ECX), Medigene AG (XTRA:MDG1), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Evotec SE (XTRA:EVT), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Genexine, Inc. (KOSDAQ:A095700), Seegene, Inc. (KOSDAQ:A096530), Kolon TissueGene, Inc. (KOSDAQ:A950160), Edwards Lifesciences Corporation (NYSE:EW), Ventas, Inc. (NYSE:VTR), JPMorgan Chase & Co. (NYSE:JPM), Vocera Communications, Inc. (NYSE:VCRA), Alexandria Real Estate Equities, Inc. (NYSE:ARE), Bausch Health Companies Inc. (NYSE:BHC), Boston Scientific Corporation (NYSE:BSX), Quest Diagnostics Incorporated (NYSE:DGX), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), ResMed Inc. (NYSE:RMD), Perrigo Company plc (NYSE:PRGO), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), McKesson Corporation (NYSE:MCK), 3M Company (NYSE:MMM), Owens & Minor, Inc. (NYSE:OMI), CVS Health Corporation (NYSE:CVS), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Universal Health Services, Inc. (NYSE:UHS), Charles River Laboratories International, Inc. (NYSE:CRL), QIAGEN N.V. (NYSE:QGEN), DaVita Inc. (NYSE:DVA), Tenet Healthcare Corporation (NYSE:THC), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Welltower Inc. (NYSE:WELL), Healthpeak Properties, Inc. (NYSE:PEAK), Invacare Corporation (NYSE:IVC), Eli Lilly and Company (NYSE:LLY), The Cooper Companies, Inc. (NYSE:COO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Danaher Corporation (NYSE:DHR), PerkinElmer, Inc. (NYSE:PKI), HCA Healthcare, Inc. (NYSE:HCA), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Cantel Medical Corp. (NYSE:CMD), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Abbott Laboratories (NYSE:ABT), Johnson & Johnson (NYSE:JNJ), Model N, Inc. (NYSE:MODN), Agilent Technologies, Inc. (NYSE:A), Becton, Dickinson and Company (NYSE:BDX), MEDNAX, Inc. (NYSE:MD), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), Hill-Rom Holdings, Inc. (NYSE:HRC), Safeguard Scientifics, Inc. (NYSE:SFE), AmerisourceBergen Corporation (NYSE:ABC), AMN Healthcare Services, Inc. (NYSE:AMN), Encompass Health Corporation (NYSE:EHC), Laboratory Corporation of America Holdings (NYSE:LH), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), AbbVie Inc. (NYSE:ABBV), Zoetis Inc. (NYSE:ZTS), Evolent Health, Inc. (NYSE:EVH), Mallinckrodt plc (NYSE:MNK), Catalent, Inc. (NYSE:CTLT), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Invitae Corporation (NYSE:NVTA), Avanos Medical, Inc. (NYSE:AVNS), Quorum Health Corporation (NYSE:QHC), Avantor, Inc. (NYSE:AVTR), Glaukos Corporation (NYSE:GKOS), Molina Healthcare, Inc. (NYSE:MOH), Genesis Healthcare, Inc. (NYSE:GEN), Emergent BioSolutions Inc. (NYSE:EBS), WellCare Health Plans, Inc. (NYSE:WCG), Globus Medical, Inc. (NYSE:GMED), Diplomat Pharmacy, Inc. (NYSE:DPLO), Veeva Systems Inc. (NYSE:VEEV), Teladoc Health, Inc. (NYSE:TDOC), Nevro Corp. (NYSE:NVRO), Penumbra, Inc. (NYSE:PEN), Sanofi (ENXTPA:SAN), Innate Pharma S.A. (ENXTPA:IPH), EssilorLuxottica Société anonyme (ENXTPA:EL), Ipsen S.A. (ENXTPA:IPN), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), Ambu A/S (CPSE:AMBU B), Zealand Pharma A/S (CPSE:ZEAL), Bavarian Nordic A/S (CPSE:BAVA), Meinian Onehealth Healthcare Holdings Co., Ltd. (SZSE:002044), Berry Genomics Co.,Ltd (SZSE:000710), Cellectis S.A. (ENXTPA:ALCLS), Medicrea International SA (ENXTPA:ALMED), ORPEA Société Anonyme (ENXTPA:ORP), Pharnext SA (ENXTPA:ALPHA), ERYTECH Pharma S.A. (ENXTPA:ERYP), Poxel SA (ENXTPA:POXEL), Adocia SA (ENXTPA:ADOC), Biocorp Production (ENXTPA:ALCOR), China Resources Pharmaceutical Group Limited (SEHK:3320), Innovent Biologics, Inc. (SEHK:1801), Luye Pharma Group Ltd. (SEHK:2186), Lee's Pharmaceutical Holdings Limited (SEHK:950), Sino Biopharmaceutical Limited (SEHK:1177), RedHill Biopharma Ltd. (TASE:RDHL), Dr. Reddy's Laboratories Limited (BSE:500124), Lupin Limited (BSE:500257), HealthCare Global Enterprises Limited (BSE:539787), Oscar Investments Limited (BSE:501179), Torrent Pharmaceuticals Limited (BSE:500420), Basilea Pharmaceutica AG (SWX:BSLN), Tecan Group Ltd. (SWX:TECN), Molecular Partners AG (SWX:MOLN), Roche Holding AG (SWX:ROG), Lonza Group Ltd (SWX:LONN), Novartis AG (SWX:NOVN), ScinoPharm Taiwan, Ltd. (TSEC:1789), GlaxoSmithKline plc (LSE:GSK), Vectura Group plc (LSE:VEC), Hikma Pharmaceuticals PLC (LSE:HIK), NMC Health Plc (LSE:NMC), Indivior PLC (LSE:INDV), Abcam plc (AIM:ABC), Circassia Pharmaceuticals plc (AIM:CIR), DeepMatter Group Plc (AIM:DMTR), Kiadis Pharma N.V. (ENXTAM:KDS), Curetis N.V. (ENXTAM:CURE), Koninklijke Philips N.V. (ENXTAM:PHIA), IHH Healthcare Berhad (KLSE:IHH), Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B), Otsuka Holdings Co., Ltd. (TSE:4578), Healios K.K. (TSE:4593), SanBio Company Limited (TSE:4592), Daiichi Sankyo Company, Limited (TSE:4568), Santen Pharmaceutical Co., Ltd. (TSE:4536), NanoCarrier Co., Ltd. (TSE:4571), Takeda Pharmaceutical Company Limited (TSE:4502), Orexo AB (publ) (OM:ORX), Swedish Orphan Biovitrum AB (publ) (OM:SOBI), Elekta AB (publ) (OM:EKTA B), Camurus AB (publ) (OM:CAMX), Samsung Biologics Co.,Ltd. (KOSE:A207940), Celltrion, Inc. (KOSE:A068270), Green Cross Corporation (KOSE:A006280), argenx SE (ENXTBR:ARGX), Oxurion NV (ENXTBR:OXUR), UCB SA (ENXTBR:UCB), Raia Drogasil S.A. (BOVESPA:RADL3), Odontoprev S.A. (BOVESPA:ODPV3), Hypera S.A. (BOVESPA:HYPE3), Fleury S.A. (BOVESPA:FLRY3), Tasly Pharmaceutical Group Co., Ltd (SHSE:600535), Mesoblast Limited (ASX:MSB), CSL Limited (ASX:CSL), Abaxis, Inc., AccentCare, Inc., ARIAD Pharmaceuticals, Inc., Array BioPharma Inc., Intarcia Therapeutics, Inc., PAREXEL International Corporation, Catalent Pharma Solutions, Inc., Select Medical Corporation, The Spectranetics Corporation, The Medicines Company, Agiliti Health, Inc., Ancestry.com LLC, athenahealth, Inc., Patheon N.V., BTG Limited, Ascension Health, Inc., Blue Cross Blue Shield of Michigan Mutual Insurance Company, Dignity Health, Kaiser Permanente Inc., Aceto Corporation, Analogic Corporation, C. R. Bard, Inc., Celgene Corporation, Kindred Healthcare, LLC, Express Scripts Holding Company, Almost Family, Inc., Shire plc, Envision Healthcare Corporation, Albany Molecular Research, Inc., Legacy LifePoint Health, Inc., Apricus Biosciences, Inc., Impax Laboratories, Inc., Keryx Biopharmaceuticals, Inc., Solutionreach, Inc., The Cleveland Clinic Foundation, Ortho-Clinical Diagnostics, Inc., Advocate Health Care, Inc., The Advisory Board Company, Presence Legacy Association, Medidata Solutions, Inc., Novadaq Technologies Inc., Genomic Health, Inc., Endocyte, Inc., Ablynx NV, Mercy Health, Henry Ford Health System, CHRISTUS Hopkins Health Alliance, RWJBarnabas Health, Inc., Intermountain Healthcare, Inc., Memorial Hermann Healthcare System, Inc., Indiana University Health, Inc., Northwell Health, Inc., University Of Maryland Medical System Corporation, Hospital Sisters Health System, Marshfield Medical Center-Ladysmith, The Children's Hospital of Philadelphia, Integrated DNA Technologies, Inc., Northwestern Memorial Healthcare Corporation, LTS Lohmann Therapie-Systeme AG, ABILITY Network Inc., GetWellNetwork, Inc., TLC, ZirMed, Inc., Orexigen Therapeutics, Inc., CareCentrix, Inc., Integrium, LLC, Neuroderm Ltd., Aprea Therapeutics AB, CureVac AG, BioElectron Technology Corporation, Astellas US, LLC, Alder BioPharmaceuticals, Inc., Orchid Orthopedic Solutions LLC, NeoTract, Inc., Cempra, Inc., EXOS, Inc., GreatCall, Inc., Ouro Fino Agronegócio Ltda., ZELTIQ Aesthetics, Inc., AmeriHealth Caritas, Grupo Farmaceutico Biotoscana S.A., Vascular Therapies, Inc., Advanced Accelerator Applications S.A., Bill and Melinda Gates Investments, Augmenix, Inc., DNAnexus, Inc., TraceLink, Inc., Sharecare Inc., Foundation Medicine, Inc., Arrail Dental International Group Co. Ltd., Welltok, Inc., SCAI Holdings, LLC, Sera Prognostics, Inc., Aspire Bariatrics, Inc., Direct Vet Marketing, Inc., Kite Pharma, Inc., One Medical Group, Inc., Ginkgo Bioworks, Inc., PrinJohnson BioPharm, Inc., Geisinger Health System, Cleave Therapeutics, Inc., OvaScience, Inc., Ignyta, Inc., New York Presbyterian Regional Hospital Network, Stratus Video, LLC, Remedy Partners, Inc., U.S. Anesthesia Partners, Braeburn Inc., Audentes Therapeutics, Inc., Spark Therapeutics, Inc., Bioverativ USA Inc., Envisia Therapeutics Inc., LINET Group SE, Juno Therapeutics, Inc., NantBioscience, Inc., Xenex Disinfection Services LLC, Centogene AG, AveXis, Inc., University Wisconsin Health, VWR Corporation, Nightstar Therapeutics Limited, K2M Group Holdings, Inc., Synaptive Medical Inc., Nexvet Biopharma Public Limited Company, WuXi Nextcode Genomics, Inc., Autolus Limited, Outset Medical, Inc., Caris Life Sciences, Inc., Gamma Medica, Inc., Albumedix A/S, IBM Watson Health, Inc., Landmark Health, LLC, Cotiviti Holdings, Inc., Owlstone Medical Ltd, PHC Holdings Corporation, Ping An Health Cloud Company Limited, Codiak BioSciences, Inc., Dova Pharmaceuticals, Inc., Kiniksa Pharmaceuticals Corp., Turner Imaging Systems, Inc.JPMorgan Chase & Co., 35th Annual JP Morgan Healthcare Conference, Jan 09, 2017 through Jan 12, 2017. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States.
145
12/31/20168.54x21.89x23.97x41.06x27.87x$24,751$212.64181.36%Dec-19-2016Index Constituent DropIntuitive Surgical, Inc.(NasdaqGS:ISRG) dropped from S&P 500 ValueS&P 500 Value (^SVX)Intuitive Surgical, Inc.(NasdaqGS:ISRG) dropped from S&P 500 Value
146
12/31/20168.54x21.89x23.97x41.06x27.87x$24,676$211.99182.23%Dec-13-2016Change in Company Bylaws/RulesIntuitive Surgical, Inc. Announces Amendments to Bylaws-On December 12, 2016, the Board of Directors of Intuitive Surgical, Inc. adopted an amendment and restatement of Company's amended and restated bylaws to implement additional proxy access. Article III, Section 5(e) has been added to permit a stockholder, or group of up to 20 stockholders, owning 3% or more of Company's common stock continuously for at least three years to nominate and include in Company's proxy materials for an annual meeting of stockholders, director candidates constituting up to 25% of the Board, provided that the stockholder (or group) and each nominee satisfy the requirements specified in the Bylaws.
147
12/31/20168.54x21.89x23.97x41.06x27.87x$24,590$211.25183.21%Dec-12-2016Buyback - Change in Plan TermsIntuitive Surgical, Inc. announces an Increase in Equity Buyback.-On December 12, 2016, the company announced an increase in its equity buyback plan. The company increased its authorization by $2,000 million, thereby taking the total authorization to $3,000 million.
148
12/31/20168.54x21.89x23.97x41.06x27.87x$24,035$206.49189.74%Dec-8-2016Company Conference PresentationIntuitive Surgical, Inc. Presents at Citi Global Healthcare Conference, Dec-08-2016 09:30 AM-Intuitive Surgical, Inc. Presents at Citi Global Healthcare Conference, Dec-08-2016 09:30 AM. Venue: The Lotte New York Palace, New York, New York, United States. Speakers: Calvin Darling, Senior Director, IR, Marshall L. Mohr, Chief Financial Officer and Senior Vice President.
149
12/31/20168.54x21.89x23.97x41.06x27.87x$24,018$206.34189.95%Dec-07-2016ConferenceCitigroup Inc., Citi Global Healthcare Conference, Dec 07, 2016 through Dec 08, 2016Amgen Inc. (NasdaqGS:AMGN), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Cytokinetics, Incorporated (NasdaqGS:CYTK), Illumina, Inc. (NasdaqGS:ILMN), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Novavax, Inc. (NasdaqGS:NVAX), Accuray Incorporated (NasdaqGS:ARAY), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), Ovid Therapeutics Inc. (NasdaqGS:OVID), Varex Imaging Corporation (NasdaqGS:VREX), C. R. Bard, Inc., Legacy LifePoint Health, Inc., Tesaro, Inc., Envision Healthcare Holdings, Inc., Zealand Pharma A/S (CPSE:ZEAL), Novo Nordisk A/S (CPSE:NOVO B), DBV Technologies S.A. (ENXTPA:DBV), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Koninklijke Philips N.V. (ENXTAM:PHIA), Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI), VolitionRx Limited (AMEX:VNRX), Bristol-Myers Squibb Company (NYSE:BMY), Community Health Systems, Inc. (NYSE:CYH), Pfizer Inc. (NYSE:PFE), Citigroup Inc. (NYSE:C), HCA Healthcare, Inc. (NYSE:HCA), PerkinElmer, Inc. (NYSE:PKI), Merck & Co., Inc. (NYSE:MRK), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Varian Medical Systems, Inc. (NYSE:VAR), Boston Scientific Corporation (NYSE:BSX), Bayer Aktiengesellschaft (XTRA:BAYN), Fresenius SE & Co. KGaA (XTRA:FRE), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Hill-Rom Holdings, Inc. (NYSE:HRC), AmerisourceBergen Corporation (NYSE:ABC), MEDNAX, Inc. (NYSE:MD), Mettler-Toledo International Inc. (NYSE:MTD), Universal Health Services, Inc. (NYSE:UHS), Allergan plc (NYSE:AGN)Citigroup Inc., Citi Global Healthcare Conference, Dec 07, 2016 through Dec 08, 2016. Venue: The Lotte New York Palace, New York, New York, United States.
150
12/31/20168.54x21.89x23.97x41.06x27.87x$24,977$214.58178.82%Nov-30-2016Company Conference PresentationIntuitive Surgical, Inc. Presents at 28th Annual Piper Jaffray Healthcare Conference, Nov-30-2016 09:30 AM-Intuitive Surgical, Inc. Presents at 28th Annual Piper Jaffray Healthcare Conference, Nov-30-2016 09:30 AM. Venue: The Lotte New York Palace, 50th St. and Madison Avenue, New York, New York, United States.
151
12/31/20168.54x21.89x23.97x41.06x27.87x$25,232$216.77176.00%Nov-29-2016ConferencePiper Jaffray Companies, 28th Annual Piper Jaffray Healthcare Conference, Nov 29, 2016 through Nov 30, 2016Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Tivity Health, Inc. (NasdaqGS:TVTY), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), LivaNova PLC (NasdaqGS:LIVN), Cytokinetics, Incorporated (NasdaqGS:CYTK), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Inovio Pharmaceuticals, Inc. (NasdaqGS:INO), Gilead Sciences, Inc. (NasdaqGS:GILD), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Masimo Corporation (NasdaqGS:MASI), CymaBay Therapeutics, Inc. (NasdaqGS:CBAY), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Omnicell, Inc. (NasdaqGS:OMCL), Orthofix Medical Inc. (NasdaqGS:OFIX), Surmodics, Inc. (NasdaqGS:SRDX), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Fluidigm Corporation (NasdaqGS:FLDM), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Geron Corporation (NasdaqGS:GERN), Akorn, Inc. (NasdaqGS:AKRX), Apyx Medical Corporation (NasdaqGS:APYX), Anika Therapeutics, Inc. (NasdaqGS:ANIK), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), Endologix, Inc. (NasdaqGS:ELGX), Novavax, Inc. (NasdaqGS:NVAX), Hologic, Inc. (NasdaqGS:HOLX), Wright Medical Group N.V. (NasdaqGS:WMGI), Quidel Corporation (NasdaqGS:QDEL), DexCom, Inc. (NasdaqGS:DXCM), Merit Medical Systems, Inc. (NasdaqGS:MMSI), PDL BioPharma, Inc. (NasdaqGS:PDLI), AngioDynamics, Inc. (NasdaqGS:ANGO), Inogen, Inc. (NasdaqGS:INGN), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Collegium Pharmaceutical, Inc. (NasdaqGS:COLL), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Mersana Therapeutics, Inc. (NasdaqGS:MRSN), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Axovant Gene Therapies Ltd. (NasdaqGS:AXGT), NantKwest, Inc. (NasdaqGS:NK), Unum Therapeutics Inc. (NasdaqGS:UMRX), SeaSpine Holdings Corporation (NasdaqGS:SPNE), Conformis, Inc. (NasdaqGS:CFMS), HealthEquity, Inc. (NasdaqGS:HQY), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX), Natera, Inc. (NasdaqGS:NTRA), Aravive, Inc. (NasdaqGS:ARAV), Otonomy, Inc. (NasdaqGS:OTIC), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), REGENXBIO Inc. (NasdaqGS:RGNX), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), Array BioPharma Inc., The Spectranetics Corporation, VCA Inc., NxStage Medical, Inc., C. R. Bard, Inc., Impax Laboratories, Inc., The Advisory Board Company, Novadaq Technologies Inc., Medidata Solutions, Inc., GTx, Inc., Z-Medica, LLC, Inotek Pharmaceuticals Corporation, Singulex, Inc., Innocoll Holdings plc, OncoMed Pharmaceuticals, Inc., Alder BioPharmaceuticals, Inc., Synthetic Genomics, Inc., CoLucid Pharmaceuticals, Inc., Ology Bioservices, Inc., Entellus Medical, Inc., ZELTIQ Aesthetics, Inc., miraDry, Inc., Invuity, Inc., Pathway Genomics Corporation, Augmenix, Inc., Proclara Biosciences, Inc., Sera Prognostics, Inc., Alcobra Ltd., Sonendo, Inc., Ignyta, Inc., Graybug Vision, Inc., Scholar Rock, Inc., Audentes Therapeutics, Inc., SYMIC Biomedical, Inc., BackBeat Medical, Inc., Rebiotix, Inc., K2M Group Holdings, Inc., Flex Pharma, Inc., Gemphire Therapeutics Inc., Spero Therapeutics, LLC, Abaxis, Inc., argenx SE (ENXTBR:ARGX), MDxHealth SA (ENXTBR:MDXH), Newron Pharmaceuticals S.p.A. (SWX:NWRN), Cellectis S.A. (ENXTPA:ALCLS), ABIVAX Société Anonyme (ENXTPA:ABVX), EOS imaging SA (ENXTPA:EOSI), Sophiris Bio, Inc. (DB:BFF1), Novo Nordisk A/S (CPSE:NOVO B), Kadmon Holdings, Inc. (NYSE:KDMN), Evolent Health, Inc. (NYSE:EVH), Mallinckrodt plc (NYSE:MNK), Teladoc Health, Inc. (NYSE:TDOC), Nevro Corp. (NYSE:NVRO), Piper Sandler Companies (NYSE:PIPR), Baxter International Inc. (NYSE:BAX), Cantel Medical Corp. (NYSE:CMD), PerkinElmer, Inc. (NYSE:PKI), Teleflex Incorporated (NYSE:TFX), Boston Scientific Corporation (NYSE:BSX), Allergan plc (NYSE:AGN), Becton, Dickinson and Company (NYSE:BDX), Vocera Communications, Inc. (NYSE:VCRA), Glaukos Corporation (NYSE:GKOS), CryoLife, Inc. (NYSE:CRY), MiMedx Group, Inc. (OTCPK:MDXG), INSYS Therapeutics, Inc. (OTCPK:INSY.Q), Nuvectra Corporation (OTCPK:NVTR.Q), AtriCure, Inc. (NasdaqGM:ATRC), Xencor, Inc. (NasdaqGM:XNCR), Altimmune, Inc. (NasdaqGM:ALT), Vascular Biogenics Ltd. (NasdaqGM:VBLT), Chimerix, Inc. (NasdaqGM:CMRX), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), NewLink Genetics Corporation (NasdaqGM:NLNK), MediciNova, Inc. (NasdaqGM:MNOV), Revance Therapeutics, Inc. (NasdaqGM:RVNC), GW Pharmaceuticals plc (NasdaqGM:GWPH), Benefitfocus, Inc. (NasdaqGM:BNFT), Compugen Ltd. (NasdaqGM:CGEN), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), IRIDEX Corporation (NasdaqGM:IRIX), Fulgent Genetics, Inc. (NasdaqGM:FLGT), Novan, Inc. (NasdaqGM:NOVN), Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC), CRISPR Therapeutics AG (NasdaqGM:CRSP), Ocular Therapeutix, Inc. (NasdaqGM:OCUL), Veracyte, Inc. (NasdaqGM:VCYT), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA), AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX), TRACON Pharmaceuticals, Inc. (NasdaqGM:TCON), Zynerba Pharmaceuticals, Inc. (NasdaqGM:ZYNE), Cara Therapeutics, Inc. (NasdaqGM:CARA), CareDx, Inc (NasdaqGM:CDNA), Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA), Oxford Immunotec Global PLC (NasdaqGM:OXFD), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Adverum Biotechnologies, Inc. (NasdaqGM:ADVM), Axcella Health Inc. (NasdaqGM:AXLA), Intersect ENT, Inc. (NasdaqGM:XENT), Eiger BioPharmaceuticals, Inc. (NasdaqGM:EIGR), Selecta Biosciences, Inc. (NasdaqGM:SELB), Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS), Stealth BioTherapeutics Corp (NasdaqGM:MITO), Castle Biosciences, Inc. (NasdaqGM:CSTL), TransEnterix, Inc. (AMEX:TRXC), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), Antares Pharma, Inc. (NasdaqCM:ATRS), Aevi Genomic Medicine, Inc. (NasdaqCM:GNMX), Vericel Corporation (NasdaqCM:VCEL), Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX), Abeona Therapeutics Inc. (NasdaqCM:ABEO), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), Organovo Holdings, Inc. (NasdaqCM:ONVO), ContraFect Corporation (NasdaqCM:CFRX), Recro Pharma, Inc. (NasdaqCM:REPH), Genocea Biosciences, Inc. (NasdaqCM:GNCA), Capricor Therapeutics, Inc. (NasdaqCM:CAPR), aTyr Pharma, Inc. (NasdaqCM:LIFE), Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX), TrovaGene, Inc. (NasdaqCM:TROV), AxoGen, Inc. (NasdaqCM:AXGN), ReWalk Robotics Ltd. (NasdaqCM:RWLK), Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT), vTv Therapeutics Inc. (NasdaqCM:VTVT), Aptevo Therapeutics Inc. (NasdaqCM:APVO)Piper Jaffray Companies, 28th Annual Piper Jaffray Healthcare Conference, Nov 29, 2016 through Nov 30, 2016. Venue: The Lotte New York Palace, 50th St. and Madison Avenue, New York, New York, United States.
152
12/31/20168.54x21.89x23.97x41.06x27.87x$26,445$227.19163.34%Oct-19-2016Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From July 1, 2016 to September 30, 2016, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 1,144,200 shares, representing 1.03% for $191.77 million under the buyback announced on February 2, 2015.
153
12/31/20168.54x21.89x23.97x41.06x27.87x$28,004$240.58148.69%Oct-18-2016Earnings CallIntuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016-Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016
154
12/31/20168.54x21.89x23.97x41.06x27.87x$28,004$240.58148.69%Oct-18-2016Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2016 For the quarter, the company’s revenue was $682.9 million compared with $589.7 million a year ago. Income from operations was $256.4 million compared with $189.9 million a year ago. Income before taxes was $266.8 million compared with $193.6 million a year ago. Net income was $211.0 million compared with $167.3 million a year ago. Diluted net income per share was $5.31 compared with $4.40 a year ago. Non-GAAP revenue was $682.9 million compared with $589.7 million a year ago. Non-GAAP income from operations was $307.6 million compared with $240.3 million a year ago. Non-GAAP net income was $245.7 million compared with $199.2 million a year ago. Diluted non-GAAP net income per share was $6.19 compared with $5.24 a year ago.


For the nine months, the company reported revenue was $1,947.5 million compared with $1,707.9 million a year ago. Income from operations was $680.8 million compared with $494.1 million a year ago. Income before taxes was $704.7 million compared with $506.7 million a year ago. Net income was $531.9 million compared with $398.8 million a year ago. Diluted net income per share was $13.57 compared with $10.55 a year ago. Non-GAAP revenue was $1,947.5 million compared with $1,707.9 million a year ago. Non-GAAP income from operations was $833.8 million compared with $653.1 million a year ago. Non-GAAP net income was $636.4 million compared with $506.6 million a year ago. Diluted non-GAAP net income per share was $16.23 compared with $13.40 a year ago.
155
12/31/20168.54x21.89x23.97x41.06x27.87x$28,004$240.58148.69%Oct-18-2016Seeking Acquisition/InvestmentIntuitive Surgical Mulls Acquisitions-Intuitive Surgical, Inc. (NasdaqGS:ISRG) is seeking acquisitions. Marshall Mohr, Chief Financial Officer of Intuitive Surgical, said, "We're in a period where there is now -- we're facing future competition and we want to have the ability to expand and to deal with competition. And we're also going to see additional opportunities as companies get into this game for acquisition of technologies that may expand our marketplace and enhance our products."
156
12/31/20168.54x21.89x23.97x41.06x27.87x$27,526$236.48153.00%Oct-17-2016Corporate Guidance - New/ConfirmedIntuitive Surgical Provides Earnings Guidance for the Third Quarter of 2016-Intuitive Surgical provided earnings guidance for the third quarter of 2016. For the quarter, the company is expected to report profit of $5.16 per share on revenue of $651 million.
157
9/30/201610.20x26.90x29.69x50.21x36.40x$27,864$240.00149.29%Sep-29-2016Strategic AllianceIntuitive Surgical, Inc. and Shanghai Fosun Pharmaceutical (Group) Co., Ltd Establish Joint Venture to Research, Develop, Manufacture and Sell Lung Cancer Diagnostic and Therapeutic Tools in ChinaShanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196)Intuitive Surgical, Inc. and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced a joint venture to research, develop, manufacture and sell innovative, robotic-assisted catheter-based medical devices. The joint venture between Intuitive Surgical and Fosun Pharma will initially produce products targeting early diagnosis and cost-effective treatment of lung cancer. The technology will be used in robotic-assisted medical devices based on catheters, and incorporates proprietary intellectual property developed or owned by Intuitive Surgical. The joint venture will be registered in Shanghai, where it will perform research and development activities and manufacture catheter-based products for global distribution. Distribution in China will be conducted by the joint venture. Distribution outside of China will be conducted by Intuitive Surgical. The companies will contribute up to $100 million as required by the joint venture, an arrangement representing a significant expansion of Intuitive Surgical’s relationship with Fosun Pharma.
158
9/30/201610.20x26.90x29.69x50.21x36.40x$26,049$224.37166.65%Sep-14-2016Company Conference PresentationIntuitive Surgical, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-14-2016 01:35 PM-Intuitive Surgical, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-14-2016 01:35 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Calvin Darling, Sr. Director, Investor Relations.
159
9/30/201610.20x26.90x29.69x50.21x36.40x$26,448$227.80162.64%Sep-12-2016ConferenceMorgan Stanley, the 2016 Morgan Stanley Global Healthcare Conference, Sep 12, 2016 through Sep 14, 2016Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), LivaNova PLC (NasdaqGS:LIVN), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Amgen Inc. (NasdaqGS:AMGN), Innoviva, Inc. (NasdaqGS:INVA), Alkermes plc (NasdaqGS:ALKS), Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX), Conformis, Inc. (NasdaqGS:CFMS), IVERIC bio, Inc. (NasdaqGS:ISEE), Ascendis Pharma A/S (NasdaqGS:ASND), Surgery Partners, Inc. (NasdaqGS:SGRY), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), HealthEquity, Inc. (NasdaqGS:HQY), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), AngioDynamics, Inc. (NasdaqGS:ANGO), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), Prothena Corporation plc (NasdaqGS:PRTA), Blueprint Medicines Corporation (NasdaqGS:BPMC), REGENXBIO Inc. (NasdaqGS:RGNX), Adaptimmune Therapeutics plc (NasdaqGS:ADAP), BeiGene, Ltd. (NasdaqGS:BGNE), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Epizyme, Inc. (NasdaqGS:EPZM), Aravive, Inc. (NasdaqGS:ARAV), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Editas Medicine, Inc. (NasdaqGS:EDIT), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Axovant Gene Therapies Ltd. (NasdaqGS:AXGT), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), Masimo Corporation (NasdaqGS:MASI), Hologic, Inc. (NasdaqGS:HOLX), Teligent, Inc. (NasdaqGS:TLGT), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Mylan N.V. (NasdaqGS:MYL), CONMED Corporation (NasdaqGS:CNMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Akorn, Inc. (NasdaqGS:AKRX), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), Premier, Inc. (NasdaqGS:PINC), Accuray Incorporated (NasdaqGS:ARAY), Bruker Corporation (NasdaqGS:BRKR), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Anika Therapeutics, Inc. (NasdaqGS:ANIK), Incyte Corporation (NasdaqGS:INCY), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Endologix, Inc. (NasdaqGS:ELGX), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Henry Schein, Inc. (NasdaqGS:HSIC), Abaxis, Inc., ARIAD Pharmaceuticals, Inc., Array BioPharma Inc., Patheon N.V., Aceto Corporation, Celgene Corporation, C. R. Bard, Inc., Express Scripts Holding Company, Shire plc, Albany Molecular Research, Inc., Impax Laboratories, Inc., Keryx Biopharmaceuticals, Inc., Aetna Inc., Ablynx NV, Novadaq Technologies Inc., Innocoll Holdings plc, Alder BioPharmaceuticals, Inc., Cempra, Inc., Perrigo Finance Unlimited Company, Foundation Medicine, Inc., Kite Pharma, Inc., Envision Healthcare Holdings, Inc., Loxo Oncology, Inc., K2M Group Holdings, Inc., Adeptus Health Inc., Juno Therapeutics, Inc., IBM Watson Health, Inc., Cotiviti Holdings, Inc., ALK-Abelló A/S (CPSE:ALK B), Genmab A/S (CPSE:GMAB), Coloplast A/S (CPSE:COLO B), Novo Nordisk A/S (CPSE:NOVO B), Sanofi (ENXTPA:SAN), DBV Technologies S.A. (ENXTPA:DBV), Sartorius Stedim Biotech S.A. (ENXTPA:DIM), Koninklijke Philips N.V. (ENXTAM:PHIA), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Molecular Partners AG (SWX:MOLN), ScinoPharm Taiwan, Ltd. (TSEC:1789), AstraZeneca PLC (LSE:AZN), Cerus Corporation (NasdaqGM:CERS), Phibro Animal Health Corporation (NasdaqGM:PAHC), Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND), T2 Biosystems, Inc. (NasdaqGM:TTOO), Zynerba Pharmaceuticals, Inc. (NasdaqGM:ZYNE), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), AtriCure, Inc. (NasdaqGM:ATRC), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), Chimerix, Inc. (NasdaqGM:CMRX), Acceleron Pharma Inc. (NasdaqGM:XLRN), NanoString Technologies, Inc. (NasdaqGM:NSTG), GW Pharmaceuticals plc (NasdaqGM:GWPH), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Ocular Therapeutix, Inc. (NasdaqGM:OCUL), Veracyte, Inc. (NasdaqGM:VCYT), Stealth BioTherapeutics Corp (NasdaqGM:MITO), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Intellia Therapeutics, Inc. (NasdaqGM:NTLA), MiMedx Group, Inc. (OTCPK:MDXG), INSYS Therapeutics, Inc. (OTCPK:INSY.Q), Fresenius SE & Co. KGaA (XTRA:FRE), Sartorius Aktiengesellschaft (XTRA:SRT), MorphoSys AG (XTRA:MOR), CryoLife, Inc. (NYSE:CRY), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Medtronic plc (NYSE:MDT), AmerisourceBergen Corporation (NYSE:ABC), Hill-Rom Holdings, Inc. (NYSE:HRC), Avanos Medical, Inc. (NYSE:AVNS), Mallinckrodt plc (NYSE:MNK), Zoetis Inc. (NYSE:ZTS), AbbVie Inc. (NYSE:ABBV), Castlight Health, Inc. (NYSE:CSLT), Catalent, Inc. (NYSE:CTLT), Diplomat Pharmacy, Inc. (NYSE:DPLO), Nevro Corp. (NYSE:NVRO), Penumbra, Inc. (NYSE:PEN), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), QIAGEN N.V. (NYSE:QGEN), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Integer Holdings Corporation (NYSE:ITGR), Charles River Laboratories International, Inc. (NYSE:CRL), CVS Health Corporation (NYSE:CVS), Laboratory Corporation of America Holdings (NYSE:LH), Johnson & Johnson (NYSE:JNJ), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Chemed Corporation (NYSE:CHE), HCA Healthcare, Inc. (NYSE:HCA), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), PerkinElmer, Inc. (NYSE:PKI), Invacare Corporation (NYSE:IVC), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Morgan Stanley (NYSE:MS), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), Quest Diagnostics Incorporated (NYSE:DGX), Perrigo Company plc (NYSE:PRGO), Baxter International Inc. (NYSE:BAX), Teleflex Incorporated (NYSE:TFX), West Pharmaceutical Services, Inc. (NYSE:WST), Boston Scientific Corporation (NYSE:BSX), Forward Pharma A/S (NasdaqCM:FWP)Morgan Stanley, The 2016 Morgan Stanley Global Healthcare Conference, Sep 12, 2016 through Sep 14, 2016. Venue: The Grand Hyatt Hotel, New York, New York, United States.
160
9/30/201610.20x26.90x29.69x50.21x36.40x$26,428$227.63162.83%Aug-17-2016ConferenceBarclays Capital PLC, Barclays International Medtech Summit, Aug 17, 2016NuVasive, Inc. (NasdaqGS:NUVA), Wright Medical Group N.V. (NasdaqGS:WMGI), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Quidel Corporation (NasdaqGS:QDEL), Barclays Capital PLC, Sightline Partners LLC, Cepheid, Genomic Health, Inc., The University of California Berkeley Foundation, UC Davis Cancer Center, ZELTIQ Aesthetics, Inc., GE Ventures, LLC, Stanford University Medical Center Auxiliary, Edwards Lifesciences Corporation (NYSE:EW), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Fresenius Medical Care AG & Co. KGaA (XTRA:FME)Barclays Capital PLC, Barclays International Medtech Summit, Aug 17, 2016. Venue: Le Meridien - SF, 333 Battery Street, San Francisco, CA 94111, United States.
161
9/30/201610.20x26.90x29.69x50.21x36.40x$26,428$227.63162.83%Aug-17-2016ConferenceBarclays Capital PLC, Barclays Capital plc California MedTools Summit, Aug 17, 2016NuVasive, Inc. (NasdaqGS:NUVA), Wright Medical Group N.V. (NasdaqGS:WMGI), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Quidel Corporation (NasdaqGS:QDEL), Barclays Capital PLC, Sightline Partners LLC, Cepheid, Genomic Health, Inc., University of California Berkeley, UC Davis Cancer Center, ZELTIQ Aesthetics, Inc., GE Ventures, LLC, Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Edwards Lifesciences Corporation (NYSE:EW)Barclays Capital PLC, Barclays Capital PLC California MedTools Summit, Aug 17, 2016. Venue: Le Meridien, 333 Battery Street, San Francisco, CA 94111, California, United States.
162
9/30/201610.20x26.90x29.69x50.21x36.40x$26,428$227.63162.83%Aug-17-2016Company Conference PresentationIntuitive Surgical, Inc. Presents at Barclays International Medtech Summit, Aug-17-2016-Intuitive Surgical, Inc. Presents at Barclays International Medtech Summit, Aug-17-2016 . Venue: Le Meridien - SF, 333 Battery Street, San Francisco, CA 94111, United States.
163
9/30/201610.20x26.90x29.69x50.21x36.40x$26,428$227.63162.83%Aug-17-2016Company Conference PresentationIntuitive Surgical, Inc. Presents at Barclays Capital PLC California MedTools Summit, Aug-17-2016-Intuitive Surgical, Inc. Presents at Barclays Capital PLC California MedTools Summit, Aug-17-2016 . Venue: Le Meridien, 333 Battery Street, San Francisco, CA 94111, California, United States.
164
9/30/201610.20x26.90x29.69x50.21x36.40x$26,853$231.29158.68%Aug-1-2016Client AnnouncementDextera Surgical and Intuitive Surgical Initiate Joint Development Program on New Robotic Stapler Products for da Vinci Surgical SystemDex Liquidating Co.Dextera Surgical Inc. announced that the company has entered into a joint development program with Intuitive Surgical, Inc. on a surgical stapler and cartridge for use with Intuitive’s da Vinci®Surgical System. The initiation of this development agreement follows the successful completion of a six-month feasibility evaluation of Dextera’s MicroCutter technology as part of an ongoing license agreement between the two companies. Under the terms of the joint development program, as specified in an amendment to the license agreement in December 2015, Intuitive Surgical will be responsible for the development work on the stapler and Dextera Surgical will be responsible for the development work on the stapler cartridge.
165
9/30/201610.20x26.90x29.69x50.21x36.40x$26,435$227.69162.77%Jul-27-2016M&A Transaction ClosingAuris Surgical Robotics, Inc. completed the acquisition of Hansen Medical, Inc. (NasdaqGM:HNSN) from a group of sellers.Oracle Investment Management, Inc., The Vanguard Group, Inc., Hansen Medical, Inc., BlackRock Advisors, LLC, Schuler Family Foundation, Endowment Arm, Auris Health, Inc.Auris Surgical Robotics, Inc. entered into a definitive agreement to acquire Hansen Medical, Inc. (NasdaqGM:HNSN) from a group of sellers for $79.9 million in cash on April 19, 2016. Under the terms, each share of Hansen common stock issued and outstanding will receive a payment in cash of an amount equal to $4 each in cash, each outstanding award of restricted stock units with respect to shares of Hansen common stock will be entitled to receive, in consideration of the cancellation of such RSU Award, a payment in cash of an amount equal to $4 each in cash. The sellers include BlackRock Advisors, LLC, Oracle Institutional Partners LP, Oracle Partners Lp, Oracle Institutional Partners LP, Oracle Ten Fund Master, LP managed by Oracle Investment Management, Inc., Schuler Family Foundation, Endowment Arm, Larry Feinberg, Jack Schuler, Lawrence T. Kennedy and others. In a related transaction, certain significant stockholders of Hansen Medical have agreed to invest approximately $49 million into Auris contemporaneously with the closing of the transaction. Post closing, Hansen Medical, Inc. will operate as a subsidiary of Auris Surgical Robotics, Inc. Hansen Medical may be required to pay Auris Surgical Robotics a termination fee of $3.33 million, including if Hansen Medical were to terminate the merger agreement in order to accept an unsolicited superior acquisition proposal.

The transaction is subject to customary closing conditions, Hart-Scott-Rodino Antitrust Improvements Act of 1976 approval, Hansen Medical shareholder approval. The transaction is unanimously approved by the Board of Directors of Hansen Medical. The Special Committee unanimously recommended that to Hansen Medical’s Board approve the merger agreement. The Board of Directors of Auris Surgical Robotics approved the transaction. The merger is not subject to a financing condition. On April 19, 2016, Oracle Institutional Partners LP, Oracle Partners Lp, Oracle Institutional Partners LP, Oracle Ten Fund Master, LP managed by Oracle Investment Management, Inc. entered into voting agreements to vote in favor of the transaction. Holders of approximately 65.4% of Hansen Medical's outstanding shares, including all Executive Officers and Directors of Hansen Medical and the significant stockholders have entered into voting agreements with Auris and Hansen Medical and have agreed to vote in favor of the transaction. On July 23, 2016, shareholders of Hansen Medical approved the transaction. The transaction is expected to close in mid of 2016.

PJT Partners acted as financial advisor and Michael J. O’Donnell and Mika Reiner Meyer of Morrison & Foerster LLP acted as legal advisor for Auris. Perella Weinberg Partners LP acted as financial advisor, will receive a fees of $1 million, and Morris, Nichols, Arsht & Tunnell LLP acted as legal advisor for Special Committee of the Board of Directors of Hansen Medical. Sharon R. Flanagan of Sidley Austin LLP acted as legal advisor for Hansen Medical. Robert M. Katz and Carlos Manuel Soto Garcia of Shearman & Sterling LLP acted as legal advisor for Perella Weinberg Partners LP. Jeffrey Hochman and Ginger Ellison of Willkie Farr & Gallagher acted as legal advisos to funds owned by Oracle Management and other majority stockholders of Hansen Medical, Inc


Auris Surgical Robotics, Inc. completed the acquisition of Hansen Medical, Inc. (NasdaqGM:HNSN) from a group of sellers on July 27, 2016. Each member of the Board of Directors of Hansen including Marjorie L. Bowen, Kevin Hykes and Nadim Yared, Michael L. Eagle, Christopher P. Lowe, Dr. Stephen L. Newman, William R. Rohn and Cary G. Vance, resigned as Directors of Hansen. In accordance with the terms of the merger agreement, David Styka, became the sole Director of Hansen Medical.
166
9/30/201610.20x26.90x29.69x50.21x36.40x$27,208$234.35155.30%Jul-20-2016Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From April 1, 2016 to June 30, 2016, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 1,144,200 shares, representing 1.03% for $191.77 million under the buyback announced on February 2, 2015.
167
9/30/201610.20x26.90x29.69x50.21x36.40x$26,003$223.97167.13%Jul-19-2016Earnings CallIntuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016-Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016
168
9/30/201610.20x26.90x29.69x50.21x36.40x$26,003$223.97167.13%Jul-19-2016Corporate Guidance - New/Confirmed, Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Result for the Second Quarter and Six Months Ended June 30, 2016; Provides Earnings Guidance for the Year 2016-Intuitive Surgical, Inc. reported unaudited consolidated earnings result for the second quarter and six months ended June 30, 2016. For the quarter, the company reported revenue was $670 million, an increase of approximately 14% compared with $586 million in the second quarter of 2015. Higher second quarter revenue was driven by growth in recurring instrument, accessory, and service revenue, and higher systems revenue. Income from operations increased to $245 million, compared with $174 million in the second quarter of 2015. Non-GAAP income from operations increased to $297 million, compared with $228 million in the second quarter of 2015. GAAP net income was $185 million, or $4.71 per diluted share, compared with $135 million, or $3.56 per diluted share, for the second quarter of 2015. Non-GAAP net income was $220 million, or $5.62 per diluted share, compared with $173 million, or $4.57 per diluted share, for the second quarter of 2015. Income before taxes was $253.4 million against $178.4 million a year ago. The company ended the quarter with cash and investments of $4.2 billion, up from $3.8 billion as of March 31, 2016. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises.

For the six months, the company reported total revenue was $1,264.6 million against $1,118.2 million a year ago. Income from operations was $424.4 million against $304.2 million a year ago. Income before taxes was $437.9 million against $313.1 million a year ago. Net income was $320.9 million or $8.25 per share against $231.5 million or $8.25 per share a year ago. Non-GAAP income from operations was $526.2 million against $412.8 million a year ago. Non-GAAP net income was $390.7 million or $10.01 per share against $307.4 million or $8.15 per share a year ago.

The company now expects full year 2016 pro forma gross profit to be within a range of between 70% and 71% of net revenue compared to previous guidance of 69% and 70% of net revenue. The company continue to expect the company's 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and international profits.
169
6/30/20169.60x26.39x29.32x49.38x34.36x$24,837$215.04178.22%Jun-15-2016Company Conference PresentationIntuitive Surgical, Inc. Presents at The William Blair & Company 36th Annual Growth Stock Conference, Jun-15-2016 08:00 AM-Intuitive Surgical, Inc. Presents at The William Blair & Company 36th Annual Growth Stock Conference, Jun-15-2016 08:00 AM. Venue: The Four Seasons Hotel, 120 East Delaware Place, Chicago, Illinois, United States.
170
6/30/20169.60x26.39x29.32x49.38x34.36x$24,833$215.00178.27%Jun-14-2016ConferenceWilliam Blair & Company, L.L.C., the William Blair & Company 36th Annual Growth Stock Conference, Jun 14, 2016 through Jun 16, 2016Aspen Technology, Inc. (NasdaqGS:AZPN), Citrix Systems, Inc. (NasdaqGS:CTXS), NuVasive, Inc. (NasdaqGS:NUVA), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Illumina, Inc. (NasdaqGS:ILMN), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), Atlassian Corporation Plc (NasdaqGS:TEAM), Paylocity Holding Corporation (NasdaqGS:PCTY), Syneos Health, Inc. (NasdaqGS:SYNH), SecureWorks Corp. (NasdaqGS:SCWX), Abiomed, Inc. (NasdaqGS:ABMD), Akorn, Inc. (NasdaqGS:AKRX), SEI Investments Company (NasdaqGS:SEIC), Fastenal Company (NasdaqGS:FAST), Trimble Inc. (NasdaqGS:TRMB), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), j2 Global, Inc. (NasdaqGS:JCOM), Pool Corporation (NasdaqGS:POOL), Willis Towers Watson Public Limited Company (NasdaqGS:WLTW), SPS Commerce, Inc. (NasdaqGS:SPSC), SS&C Technologies Holdings, Inc. (NasdaqGS:SSNC), Stericycle, Inc. (NasdaqGS:SRCL), Ulta Beauty, Inc. (NasdaqGS:ULTA), F5 Networks, Inc. (NasdaqGS:FFIV), HealthStream, Inc. (NasdaqGS:HSTM), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Cogent Communications Holdings, Inc. (NasdaqGS:CCOI), C.H. Robinson Worldwide, Inc. (NasdaqGS:CHRW), QAD Inc. (NasdaqGS:QADA), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Mercury Systems, Inc. (NasdaqGS:MRCY), Zebra Technologies Corporation (NasdaqGS:ZBRA), Patterson Companies, Inc. (NasdaqGS:PDCO), Henry Schein, Inc. (NasdaqGS:HSIC), WisdomTree Investments, Inc. (NasdaqGS:WETF), Encore Capital Group, Inc. (NasdaqGS:ECPG), Iridium Communications Inc. (NasdaqGS:IRDM), Vonage Holdings Corp. (NasdaqGS:VG), ExlService Holdings, Inc. (NasdaqGS:EXLS), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), RigNet, Inc. (NasdaqGS:RNET), Verisk Analytics, Inc. (NasdaqGS:VRSK), Boingo Wireless, Inc. (NasdaqGS:WIFI), Potbelly Corporation (NasdaqGS:PBPB), Cardtronics plc (NasdaqGS:CATM), PRA Group, Inc. (NasdaqGS:PRAA), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Beacon Roofing Supply, Inc. (NasdaqGS:BECN), Huron Consulting Group Inc. (NasdaqGS:HURN), Fortinet, Inc. (NasdaqGS:FTNT), Zumiez Inc. (NasdaqGS:ZUMZ), Sportsman's Warehouse Holdings, Inc. (NasdaqGS:SPWH), Collegium Pharmaceutical, Inc. (NasdaqGS:COLL), Inogen, Inc. (NasdaqGS:INGN), Kornit Digital Ltd. (NasdaqGS:KRNT), Inovalon Holdings, Inc. (NasdaqGS:INOV), Gogo Inc. (NasdaqGS:GOGO), Duluth Holdings Inc. (NasdaqGS:DLTH), Dave & Buster's Entertainment, Inc. (NasdaqGS:PLAY), CyberArk Software Ltd. (NasdaqGS:CYBR), Fox Factory Holding Corp. (NasdaqGS:FOXF), Financial Engines, Inc., Bojangles', Inc., BroadSoft, Inc., Cepheid, Harman International Industries, Incorporated, ShoreTel, Inc., The Ultimate Software Group, Inc., NxStage Medical, Inc., Sonic Corp., Express Scripts Holding Company, Chicago Bridge & Iron Company N.V., Inventure Foods, Inc., William Blair & Company, L.L.C., WageWorks, Inc., Infoblox Inc., Worldpay, Inc., The Advisory Board Company, Novadaq Technologies Inc., Imperva, Inc., Pandora Media, LLC, Luxoft Holding, Inc., Tokai Pharmaceuticals, Inc., Mattress Firm Holding Corp., Medivation, Inc., Mobileye N.V., Carbonite, Inc., AmTrust Financial Services, Inc., Entellus Medical, Inc., ZELTIQ Aesthetics, Inc., OPOWER, Inc., Invuity, Inc., Milacron Holdings Corp., Nimble Storage, Inc., ExamWorks Group, Inc., Press Ganey Holdings, Inc., Gigamon Inc., Fleetmatics Group PLC, K2M Group Holdings, Inc., Amplify Snack Brands, Inc., VWR Corporation, EndoChoice Holdings, Inc., MiX Telematics Limited (JSE:MIX), Upland Software, Inc. (NasdaqGM:UPLD), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), National General Holdings Corp. (NasdaqGM:NGHC), Intersect ENT, Inc. (NasdaqGM:XENT), Veracyte, Inc. (NasdaqGM:VCYT), DAVIDsTEA Inc. (NasdaqGM:DTEA), AppFolio, Inc. (NasdaqGM:APPF), Rapid7, Inc. (NasdaqGM:RPD), Revance Therapeutics, Inc. (NasdaqGM:RVNC), Proofpoint, Inc. (NasdaqGM:PFPT), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), FTI Consulting, Inc. (NYSE:FCN), Laboratory Corporation of America Holdings (NYSE:LH), Alliance Data Systems Corporation (NYSE:ADS), AMN Healthcare Services, Inc. (NYSE:AMN), CPI Card Group Inc. (OTCPK:PMTS), Guidewire Software, Inc. (NYSE:GWRE), Glaukos Corporation (NYSE:GKOS), RingCentral, Inc. (NYSE:RNG), WNS (Holdings) Limited (NYSE:WNS), Dolby Laboratories, Inc. (NYSE:DLB), Mastercard Incorporated (NYSE:MA), Marcus & Millichap, Inc. (NYSE:MMI), MSCI Inc. (NYSE:MSCI), GTT Communications, Inc. (NYSE:GTT), Ooma, Inc. (NYSE:OOMA), TreeHouse Foods, Inc. (NYSE:THS), Teladoc Health, Inc. (NYSE:TDOC), MRC Global Inc. (NYSE:MRC), Zoetis Inc. (NYSE:ZTS), U.S. Silica Holdings, Inc. (NYSE:SLCA), Envestnet, Inc. (NYSE:ENV), TransUnion (NYSE:TRU), Diplomat Pharmacy, Inc. (NYSE:DPLO), Palo Alto Networks, Inc. (NYSE:PANW), MaxLinear, Inc. (NYSE:MXL), Shutterstock, Inc. (NYSE:SSTK), Arista Networks, Inc. (NYSE:ANET), Veeva Systems Inc. (NYSE:VEEV), PROS Holdings, Inc. (NYSE:PRO), Genpact Limited (NYSE:G), Globant S.A. (NYSE:GLOB), Evolent Health, Inc. (NYSE:EVH), EVERTEC, Inc. (NYSE:EVTC), Shake Shack Inc. (NYSE:SHAK), MSC Industrial Direct Co., Inc. (NYSE:MSM), WEX Inc. (NYSE:WEX), Charles River Laboratories International, Inc. (NYSE:CRL), American Express Company (NYSE:AXP), ASGN Incorporated (NYSE:ASGN), MEDNAX, Inc. (NYSE:MD), The Cooper Companies, Inc. (NYSE:COO), Ecolab Inc. (NYSE:ECL), W.W. Grainger, Inc. (NYSE:GWW), salesforce.com, inc. (NYSE:CRM), Welbilt, Inc. (NYSE:WBT), Gartner, Inc. (NYSE:IT), Cardinal Health, Inc. (NYSE:CAH), Donaldson Company, Inc. (NYSE:DCI), General Electric Company (NYSE:GE), Moody's Corporation (NYSE:MCO), Proto Labs, Inc. (NYSE:PRLB), AECOM (NYSE:ACM), WESCO International, Inc. (NYSE:WCC), Lennox International Inc. (NYSE:LII), ResMed Inc. (NYSE:RMD), 8x8, Inc. (NYSE:EGHT), Teleflex Incorporated (NYSE:TFX), Tyler Technologies, Inc. (NYSE:TYL), Watsco, Inc. (NYSE:WSO), Dynavax Technologies Corporation (NasdaqCM:DVAX), Exact Sciences Corporation (NasdaqCM:EXAS), Hudson Technologies Inc. (NasdaqCM:HDSN), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), Mitek Systems, Inc. (NasdaqCM:MITK), RADCOM Ltd. (NasdaqCM:RDCM), Agile Therapeutics, Inc. (NasdaqCM:AGRX), AAC Holdings, Inc. (OTCPK:AACH)William Blair & Company, L.L.C., The William Blair & Company 36th Annual Growth Stock Conference, Jun 14, 2016 through Jun 16, 2016. Venue: The Four Seasons Hotel, 120 East Delaware Place, Chicago, Illinois, United States.
171
6/30/20169.60x26.39x29.32x49.38x34.36x$24,798$214.70178.66%Jun-13-2016Private PlacementInTouch Technologies, Inc. announced that it has received $15 million in funding from Intuitive Surgical, Inc.InTouch Technologies, Inc.On June 13, 2016, InTouch Technologies, Inc. closed the transaction. The transaction included participation from new investor Intuitive Surgical, Inc. (NasdaqGS:ISRG).
172
6/30/20169.60x26.39x29.32x49.38x34.36x$24,481$211.96182.27%Jun-7-2016Company Conference PresentationIntuitive Surgical, Inc. Presents at Goldman Sachs 37th Annual Global Healthcare Conference, Jun-07-2016 08:40 AM-Intuitive Surgical, Inc. Presents at Goldman Sachs 37th Annual Global Healthcare Conference, Jun-07-2016 08:40 AM. Venue: The Terranea Resort, Rancho Palos Verdes, California, United States.
173
6/30/20169.60x26.39x29.32x49.38x34.36x$24,481$211.96182.27%Jun-07-2016ConferenceThe Goldman Sachs Group, Inc., Goldman Sachs 37th Annual Global Healthcare Conference, Jun 07, 2016 through Jun 09, 2016Editas Medicine, Inc. (NasdaqGS:EDIT), Seres Therapeutics, Inc. (NasdaqGS:MCRB), TherapeuticsMD, Inc. (NasdaqGS:TXMD), BeiGene, Ltd. (NasdaqGS:BGNE), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Intrexon Corporation (NasdaqGS:XON), IVERIC bio, Inc. (NasdaqGS:ISEE), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), Mylan N.V. (NasdaqGS:MYL), Patterson Companies, Inc. (NasdaqGS:PDCO), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Hologic, Inc. (NasdaqGS:HOLX), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), NuVasive, Inc. (NasdaqGS:NUVA), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), FibroGen, Inc. (NasdaqGS:FGEN), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Illumina, Inc. (NasdaqGS:ILMN), Amgen Inc. (NasdaqGS:AMGN), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Align Technology, Inc. (NasdaqGS:ALGN), Alkermes plc (NasdaqGS:ALKS), LivaNova PLC (NasdaqGS:LIVN), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Blueprint Medicines Corporation (NasdaqGS:BPMC), Exact Sciences Corporation (NasdaqCM:EXAS), Glaukos Corporation (NYSE:GKOS), Castlight Health, Inc. (NYSE:CSLT), Nevro Corp. (NYSE:NVRO), Bristol-Myers Squibb Company (NYSE:BMY), Quest Diagnostics Incorporated (NYSE:DGX), Edwards Lifesciences Corporation (NYSE:EW), The Goldman Sachs Group, Inc. (NYSE:GS), AmerisourceBergen Corporation (NYSE:ABC), Community Health Systems, Inc. (NYSE:CYH), Hill-Rom Holdings, Inc. (NYSE:HRC), Eli Lilly and Company (NYSE:LLY), International Business Machines Corporation (NYSE:IBM), HCA Healthcare, Inc. (NYSE:HCA), The Cooper Companies, Inc. (NYSE:COO), Danaher Corporation (NYSE:DHR), Owens & Minor, Inc. (NYSE:OMI), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Boston Scientific Corporation (NYSE:BSX), Universal Health Services, Inc. (NYSE:UHS), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), Waters Corporation (NYSE:WAT), CVS Health Corporation (NYSE:CVS), Stryker Corporation (NYSE:SYK), Becton, Dickinson and Company (NYSE:BDX), Johnson & Johnson (NYSE:JNJ), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Baxter International Inc. (NYSE:BAX), AbbVie Inc. (NYSE:ABBV), Zoetis Inc. (NYSE:ZTS), MorphoSys AG (XTRA:MOR), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Evolent Health, Inc. (NYSE:EVH), T2 Biosystems, Inc. (NasdaqGM:TTOO), GW Pharmaceuticals plc (NasdaqGM:GWPH), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Radius Health, Inc. (NasdaqGM:RDUS), Sage Therapeutics, Inc. (NasdaqGM:SAGE), GlaxoSmithKline plc (LSE:GSK), Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Sanofi (ENXTPA:SAN), Innate Pharma S.A. (ENXTPA:IPH), Genmab A/S (CPSE:GMAB), Coloplast A/S (CPSE:COLO B), Novo Nordisk A/S (CPSE:NOVO B), Cepheid, Team Health Holdings, Inc., PAREXEL International Corporation, The Medicines Company, Celgene Corporation, Express Scripts Holding Company, Shire plc, Impax Laboratories, Inc., Aetna Inc., Medivation, Inc., Heartware International Inc., ZELTIQ Aesthetics, Inc., Foundation Medicine, Inc., Juno Therapeutics, Inc., AveXis, Inc., Adeptus Health Inc., VWR Corporation, Kite Pharma, Inc., Dimension Therapeutics, Inc., Spark Therapeutics, Inc.The Goldman Sachs Group, Inc., Goldman Sachs 37th Annual Global Healthcare Conference, Jun 07, 2016 through Jun 09, 2016. Venue: The Terranea Resort, Rancho Palos Verdes, California, United States.
174
6/30/20169.60x26.39x29.32x49.38x34.36x$24,518$212.28181.84%Jun-3-2016Private PlacementInTouch Technologies, Inc. announced that it expects to receive $15 million in funding from Intuitive Surgical, Inc.InTouch Technologies, Inc.InTouch Technologies, Inc. announced that it will receive $14,999,996 in funding on June 3, 2016. The company will issue common stock in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
175
6/30/20169.60x26.39x29.32x49.38x34.36x$24,122$208.85186.47%May-10-2016Company Conference PresentationIntuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2016 Healthcare Conference, May-10-2016 04:20 PM-Intuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2016 Healthcare Conference, May-10-2016 04:20 PM. Venue: The Encore at Wynn, 3131 S Las Vegas Blvd, Las Vegas, NV 89109, United States. Speakers: Calvin Darling, Sr. Director, Investor Relations, Patrick Clingan, Sr. Director, Finance & Sales Operations.
176
6/30/20169.60x26.39x29.32x49.38x34.36x$24,122$208.85186.47%May-10-2016ConferenceBank of America Corporation, Bank of America Merrill Lynch 2016 Healthcare Conference, May 10, 2016 through May 12, 2016Surgery Partners, Inc. (NasdaqGS:SGRY), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), DexCom, Inc. (NasdaqGS:DXCM), Quidel Corporation (NasdaqGS:QDEL), Incyte Corporation (NasdaqGS:INCY), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Endologix, Inc. (NasdaqGS:ELGX), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Aduro BioTech, Inc. (NasdaqGS:ADRO), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Premier, Inc. (NasdaqGS:PINC), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Diversified Healthcare Trust (NasdaqGS:DHC), MacroGenics, Inc. (NasdaqGS:MGNX), Luminex Corporation (NasdaqGS:LMNX), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), Illumina, Inc. (NasdaqGS:ILMN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Endo International plc (NasdaqGS:ENDP), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Hologic, Inc. (NasdaqGS:HOLX), Teligent, Inc. (NasdaqGS:TLGT), Mylan N.V. (NasdaqGS:MYL), Amgen Inc. (NasdaqGS:AMGN), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Innoviva, Inc. (NasdaqGS:INVA), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Seres Therapeutics, Inc. (NasdaqGS:MCRB), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Puma Biotechnology, Inc. (NasdaqGS:PBYI), REGENXBIO Inc. (NasdaqGS:RGNX), Prothena Corporation plc (NasdaqGS:PRTA), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), Adaptimmune Therapeutics plc (NasdaqGS:ADAP), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Ascendis Pharma A/S (NasdaqGS:ASND), Epizyme, Inc. (NasdaqGS:EPZM), CytomX Therapeutics, Inc. (NasdaqGS:CTMX), Otonomy, Inc. (NasdaqGS:OTIC), Invitae Corporation (NYSE:NVTA), Community Health Systems, Inc. (NYSE:CYH), Chemed Corporation (NYSE:CHE), HCA Healthcare, Inc. (NYSE:HCA), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), PerkinElmer, Inc. (NYSE:PKI), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Universal Health Services, Inc. (NYSE:UHS), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Tenet Healthcare Corporation (NYSE:THC), Capital Senior Living Corporation (NYSE:CSU), Lannett Company, Inc. (NYSE:LCI), U.S. Physical Therapy, Inc. (NYSE:USPH), National Health Investors, Inc. (NYSE:NHI), West Pharmaceutical Services, Inc. (NYSE:WST), Boston Scientific Corporation (NYSE:BSX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Cigna Corporation (NYSE:CI), MEDNAX, Inc. (NYSE:MD), Baxter International Inc. (NYSE:BAX), QIAGEN N.V. (NYSE:QGEN), Service Corporation International (NYSE:SCI), Emergent BioSolutions Inc. (NYSE:EBS), Glaukos Corporation (NYSE:GKOS), Genesis Healthcare, Inc. (NYSE:GEN), WellCare Health Plans, Inc. (NYSE:WCG), Nevro Corp. (NYSE:NVRO), Penumbra, Inc. (NYSE:PEN), Brookdale Senior Living Inc. (NYSE:BKD), Zyla Life Sciences (OTCPK:ZCOR), AAC Holdings, Inc. (OTCPK:AACH), AMN Healthcare Services, Inc. (NYSE:AMN), Centene Corporation (NYSE:CNC), AmerisourceBergen Corporation (NYSE:ABC), Bank of America Corporation (NYSE:BAC), Hill-Rom Holdings, Inc. (NYSE:HRC), Mallinckrodt plc (NYSE:MNK), AbbVie Inc. (NYSE:ABBV), Catalent, Inc. (NYSE:CTLT), Pfenex Inc. (AMEX:PFNX), Hutchison China MediTech Limited (AIM:HCM), Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Intersect ENT, Inc. (NasdaqGM:XENT), Health Insurance Innovations, Inc. (NasdaqGM:HIIQ), Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI), AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX), Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), GW Pharmaceuticals plc (NasdaqGM:GWPH), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Radius Health, Inc. (NasdaqGM:RDUS), NewLink Genetics Corporation (NasdaqGM:NLNK), MannKind Corporation (NasdaqGM:MNKD), NanoString Technologies, Inc. (NasdaqGM:NSTG), Phibro Animal Health Corporation (NasdaqGM:PAHC), DBV Technologies S.A. (ENXTPA:DBV), Novo Nordisk A/S (CPSE:NOVO B), Array BioPharma Inc., Cepheid, Team Health Holdings, Inc., Select Medical Corporation, The Medicines Company, Celgene Corporation, VCA Inc., Almost Family, Inc., Kindred Healthcare, LLC, Express Scripts Holding Company, FEI Company, Legacy LifePoint Health, Inc., Impax Laboratories, Inc., Aetna Inc., Genomic Health, Inc., Sucampo Pharmaceuticals, Inc., Vital Therapies, Inc., Orexigen Therapeutics, Inc., Medivation, Inc., Heartware International Inc., Alder BioPharmaceuticals, Inc., Cynapsus Therapeutics Inc., Tokai Pharmaceuticals, Inc., PharMerica Corporation, Civitas Solutions, Inc., Relypsa, Inc., Foundation Medicine, Inc., Aratana Therapeutics, Inc., NantWorks, LLC, Envision Healthcare Holdings, Inc., Adeptus Health Inc., VWR Corporation, EndoChoice Holdings, Inc., Juno Therapeutics, Inc., Centerra Gold Inc. (TSX:CG), aTyr Pharma, Inc. (NasdaqCM:LIFE), Regulus Therapeutics Inc. (NasdaqCM:RGLS), Heron Therapeutics, Inc. (NasdaqCM:HRTX), Exact Sciences Corporation (NasdaqCM:EXAS)Bank of America Corporation, Bank of America Merrill Lynch 2016 Healthcare Conference, May 10, 2016 through May 12, 2016. Venue: The Encore at Wynn, 3131 S Las Vegas Blvd, Las Vegas, NV 89109, United States.
177
6/30/20169.60x26.39x29.32x49.38x34.36x$24,714$213.97179.61%Apr-21-2016Annual General MeetingIntuitive Surgical, Inc., Annual General Meeting, Apr 21, 2016-Intuitive Surgical, Inc., Annual General Meeting, Apr 21, 2016, at 15:00 Pacific Standard Time. Agenda: To elect nine members to the board of directors of the company to serve until the 2017 annual meeting of stockholders; to consider the compensation of named executive officers; to ratify the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2016; to approve the amendment and restatement of the 2010 incentive award plan; and to transact any other business which is properly brought before the annual meeting or adjournments or postponements thereof.
178
6/30/20169.60x26.39x29.32x49.38x34.36x$24,815$214.85178.47%Apr-20-2016M&A Transaction AnnouncementAuris Surgical Robotics, Inc. entered into a definitive agreement to acquire Hansen Medical, Inc. (NasdaqGM:HNSN) from a group of sellers for $80.1 million.Oracle Investment Management, Inc., The Vanguard Group, Inc., Hansen Medical, Inc., BlackRock Advisors, LLC, Schuler Family Foundation, Endowment Arm, Auris Health, Inc.Auris Surgical Robotics, Inc. entered into a definitive agreement to acquire Hansen Medical, Inc. (NasdaqGM:HNSN) from a group of sellers for $79.9 million in cash on April 19, 2016. Under the terms, each share of Hansen common stock issued and outstanding will receive a payment in cash of an amount equal to $4 each in cash, each outstanding award of restricted stock units with respect to shares of Hansen common stock will be entitled to receive, in consideration of the cancellation of such RSU Award, a payment in cash of an amount equal to $4 each in cash. The sellers include BlackRock Advisors, LLC, Oracle Institutional Partners LP, Oracle Partners Lp, Oracle Institutional Partners LP, Oracle Ten Fund Master, LP managed by Oracle Investment Management, Inc., Schuler Family Foundation, Endowment Arm, Larry Feinberg, Jack Schuler, Lawrence T. Kennedy and others. In a related transaction, certain significant stockholders of Hansen Medical have agreed to invest approximately $49 million into Auris contemporaneously with the closing of the transaction. Post closing, Hansen Medical, Inc. will operate as a subsidiary of Auris Surgical Robotics, Inc. Hansen Medical may be required to pay Auris Surgical Robotics a termination fee of $3.33 million, including if Hansen Medical were to terminate the merger agreement in order to accept an unsolicited superior acquisition proposal.

The transaction is subject to customary closing conditions, Hart-Scott-Rodino Antitrust Improvements Act of 1976 approval, Hansen Medical shareholder approval. The transaction is unanimously approved by the Board of Directors of Hansen Medical. The Special Committee unanimously recommended that to Hansen Medical’s Board approve the merger agreement. The Board of Directors of Auris Surgical Robotics approved the transaction. The merger is not subject to a financing condition. On April 19, 2016, Oracle Institutional Partners LP, Oracle Partners Lp, Oracle Institutional Partners LP, Oracle Ten Fund Master, LP managed by Oracle Investment Management, Inc. entered into voting agreements to vote in favor of the transaction. Holders of approximately 65.4% of Hansen Medical's outstanding shares, including all Executive Officers and Directors of Hansen Medical and the significant stockholders have entered into voting agreements with Auris and Hansen Medical and have agreed to vote in favor of the transaction. On July 23, 2016, shareholders of Hansen Medical approved the transaction. The transaction is expected to close in mid of 2016.

PJT Partners acted as financial advisor and Michael J. O’Donnell and Mika Reiner Meyer of Morrison & Foerster LLP acted as legal advisor for Auris. Perella Weinberg Partners LP acted as financial advisor, will receive a fees of $1 million, and Morris, Nichols, Arsht & Tunnell LLP acted as legal advisor for Special Committee of the Board of Directors of Hansen Medical. Sharon R. Flanagan of Sidley Austin LLP acted as legal advisor for Hansen Medical. Robert M. Katz and Carlos Manuel Soto Garcia of Shearman & Sterling LLP acted as legal advisor for Perella Weinberg Partners LP. Jeffrey Hochman and Ginger Ellison of Willkie Farr & Gallagher acted as legal advisos to funds owned by Oracle Management and other majority stockholders of Hansen Medical, Inc
179
6/30/20169.60x26.39x29.32x49.38x34.36x$24,012$207.90187.78%Apr-19-2016Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2016-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2016. For the quarter, the company reported total revenue of $594.5 million compared to $532.1 million a year ago. Income from operations was $179.0 million compared to $130.4 million a year ago. Income before taxes was $184.5 million compared to $134.7 million a year ago. Net income was $136.4 million or $3.54 per diluted share compared to $97.0 million or $2.57 per diluted share a year ago. Non-GAAP income from operations was $229.1 million compared to $185.0 million a year ago. Non-GAAP net income was $170.3 million or $4.42 per diluted share compared to $134.6 million or $3.57 per diluted share a year ago.
180
6/30/20169.60x26.39x29.32x49.38x34.36x$24,012$207.90187.78%Apr-19-2016Earnings CallIntuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016-Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016
181
6/30/20169.60x26.39x29.32x49.38x34.36x$24,012$207.90187.78%Apr-19-2016Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From January 1, 2016 to March 31, 2016, the company has repurchased 46,671 shares, representing 0.04% for $8.04 million. With this, the company has completed the repurchase of 1,144,200 shares, representing 1.03% for $191.77 million under the buyback announced on February 2, 2015.
182
3/31/20168.91x25.14x28.00x47.23x36.50x$22,379$195.79205.58%Mar-16-2016Product-Related AnnouncementIntuitive Surgical Announces U.S. Clearance for da Vinci Xi Single-Site Instruments and Accessories-Intuitive Surgical, Inc. announced that the United States Food and Drug Administration has provided 510(k) clearance for the company’s da Vinci® Xi® Single-Site instruments and accessories. Intuitive Surgical’s Single-Site technology enables surgeons to operate through a single incision in the patient’s umbilicus during cholecystectomy, benign hysterectomy and salpingo-oophorectomy procedures. The da Vinci Xi Surgical System improves upon this platform with new technology, access, and functionality, including: Improved Vision: The da Vinci Xi 8 mm endoscope provides the surgeon a brighter, higher resolution view of the surgical field with integrated Firefly® fluorescence imaging to highlight specific tissues such as vessels and bile ducts. Easier Setup: A single-fin attachment system makes docking easier and faster with added Single-Site features like guided setup to improve OR team usability. Great Patient Access: The boom-mounted architecture of the da Vinci Xi Surgical System improves access around the patient with redesigned arms to provide greater range of motion. The Single-Site product is immediately available for order, with rollout occurring in first quarter of 2016.
183
3/31/20168.91x25.14x28.00x47.23x36.50x$22,379$195.79205.58%Mar-16-2016Company Conference PresentationIntuitive Surgical, Inc. Presents at Barclays Global Healthcare Conference, Mar-16-2016 08:00 AM-Intuitive Surgical, Inc. Presents at Barclays Global Healthcare Conference, Mar-16-2016 08:00 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami Beach, Florida, United States. Speakers: Calvin Darling, Sr. Director IR, Patrick Clingan, Sr. Director Finance & Sales Operations.
184
3/31/20168.91x25.14x28.00x47.23x36.50x$22,380$195.80205.56%Mar-15-2016ConferenceBarclays Capital PLC, Barclays Global Healthcare Conference, Mar 15, 2016 through Mar 17, 2016BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), LivaNova PLC (NasdaqGS:LIVN), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Endo International plc (NasdaqGS:ENDP), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), United Therapeutics Corporation (NasdaqGS:UTHR), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Wright Medical Group N.V. (NasdaqGS:WMGI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Premier, Inc. (NasdaqGS:PINC), Advaxis, Inc. (NasdaqGS:ADXS), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), AngioDynamics, Inc. (NasdaqGS:ANGO), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Bruker Corporation (NasdaqGS:BRKR), ICON Public Limited Company (NasdaqGS:ICLR), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Patterson Companies, Inc. (NasdaqGS:PDCO), Henry Schein, Inc. (NasdaqGS:HSIC), Magellan Health, Inc. (NasdaqGS:MGLN), Incyte Corporation (NasdaqGS:INCY), Cerner Corporation (NasdaqGS:CERN), Mylan N.V. (NasdaqGS:MYL), Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), Mirati Therapeutics, Inc. (NasdaqGS:MRTX), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Exelixis, Inc. (NasdaqGS:EXEL), Gilead Sciences, Inc. (NasdaqGS:GILD), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Alkermes plc (NasdaqGS:ALKS), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Surgery Partners, Inc. (NasdaqGS:SGRY), IVERIC bio, Inc. (NasdaqGS:ISEE), Trevena, Inc. (NasdaqGS:TRVN), Prothena Corporation plc (NasdaqGS:PRTA), Chiasma, Inc. (NasdaqGS:CHMA), Conformis, Inc. (NasdaqGS:CFMS), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), OPKO Health, Inc. (NasdaqGS:OPK), Arbutus Biopharma Corporation (NasdaqGS:ABUS), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Seres Therapeutics, Inc. (NasdaqGS:MCRB), AmerisourceBergen Corporation (NYSE:ABC), Genesis Healthcare, Inc. (NYSE:GEN), Perrigo Company plc (NYSE:PRGO), Edwards Lifesciences Corporation (NYSE:EW), ResMed Inc. (NYSE:RMD), Quest Diagnostics Incorporated (NYSE:DGX), CVS Health Corporation (NYSE:CVS), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Tenet Healthcare Corporation (NYSE:THC), MAXIMUS, Inc. (NYSE:MMS), Abbott Laboratories (NYSE:ABT), Johnson & Johnson (NYSE:JNJ), Anthem, Inc. (NYSE:ANTM), Cigna Corporation (NYSE:CI), Welltower Inc. (NYSE:WELL), Eli Lilly and Company (NYSE:LLY), Merck & Co., Inc. (NYSE:MRK), Baxter International Inc. (NYSE:BAX), Boston Scientific Corporation (NYSE:BSX), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), HCA Healthcare, Inc. (NYSE:HCA), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Encompass Health Corporation (NYSE:EHC), Owens & Minor, Inc. (NYSE:OMI), Universal Health Services, Inc. (NYSE:UHS), QIAGEN N.V. (NYSE:QGEN), Laboratory Corporation of America Holdings (NYSE:LH), Medtronic plc (NYSE:MDT), Community Health Systems, Inc. (NYSE:CYH), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Lombard Medical, Inc. (OTCPK:EVAR.F), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Fresenius SE & Co. KGaA (XTRA:FRE), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), IQVIA Holdings Inc. (NYSE:IQV), AbbVie Inc. (NYSE:ABBV), Fitbit, Inc. (NYSE:FIT), WellCare Health Plans, Inc. (NYSE:WCG), Brookdale Senior Living Inc. (NYSE:BKD), Zoetis Inc. (NYSE:ZTS), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), Chimerix, Inc. (NasdaqGM:CMRX), ProQR Therapeutics N.V. (NasdaqGM:PRQR), Revance Therapeutics, Inc. (NasdaqGM:RVNC), Concert Pharmaceuticals, Inc. (NasdaqGM:CNCE), Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM), Acceleron Pharma Inc. (NasdaqGM:XLRN), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Retrophin, Inc. (NasdaqGM:RTRX), Pfenex Inc. (AMEX:PFNX), Barclays Capital PLC, ARIAD Pharmaceuticals, Inc., Cepheid, Team Health Holdings, Inc., PAREXEL International Corporation, Universal American Corp., Actelion Ltd, NxStage Medical, Inc., C. R. Bard, Inc., Celgene Corporation, St. Jude Medical, Inc., Kindred Healthcare, LLC, Express Scripts Holding Company, Shire plc, Envision Healthcare Corporation, Impax Laboratories, Inc., Aetna Inc., The Advisory Board Company, Alere Inc., Novadaq Technologies Inc., Imprivata, Inc., Mazor Robotics Ltd., Medivation, Inc., Heartware International Inc., Cerulean Pharma Inc., Civitas Solutions, Inc., SCAI Holdings, LLC, Aratana Therapeutics, Inc., Alcobra Ltd., Kite Pharma, Inc., Press Ganey Holdings, Inc., Envision Healthcare Holdings, Inc., Juno Therapeutics, Inc., K2M Group Holdings, Inc., Baxalta Incorporated, Adeptus Health Inc., VWR Corporation, Foamix Pharmaceuticals Inc., Roche Holding AG (SWX:ROG), AstraZeneca PLC (LSE:AZN), GlaxoSmithKline plc (LSE:GSK), H. Lundbeck A/S (CPSE:LUN), Coloplast A/S (CPSE:COLO B), Novo Nordisk A/S (CPSE:NOVO B), DBV Technologies S.A. (ENXTPA:DBV), Genfit SA (ENXTPA:GNFT), Cocrystal Pharma, Inc. (NasdaqCM:COCP), ReWalk Robotics Ltd. (NasdaqCM:RWLK)Barclays Capital PLC, Barclays Global Healthcare Conference, Mar 15, 2016 through Mar 17, 2016. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami Beach, Florida, United States.
185
3/31/20168.91x25.14x28.00x47.23x36.50x$22,596$197.69202.64%Mar-14-2016Product-Related AnnouncementIntuitive Surgical, Inc. Announces U.S. Clearance for da Vinci Xi Endowrist Stapler 30 Instruments and Reloads-Intuitive Surgical, Inc. announced that the United States Food and Drug Administration has provided 510(k) clearance for the company’s da Vinci® Xi™EndoWrist Stapler 30 (30mm) instruments and reloads. Availability of the Stapler 30 for the da Vinci Xi Surgical System expands the company’s EndoWrist Stapler portfolio through the offering of new curved and straight tip instruments and four reloads. With General Surgery, Thoracic, Gynecologic and Urologic surgery indications, the Stapler 30 Curved-Tip instrument provides enhanced placement and visualization around tenuous vasculature. The Stapler 30 instruments and reloads — ranging from gray (0.75mm closed) to green (2.0mm closed) — provide a robust offering of 30mm stapling options for the da Vinci Xi Surgical System. The da Vinci Xi Surgical System design enables control of stapling from the surgeon console, creating a more direct relationship between clinical decision-making and instrument action. Other features include: Surgeon Control and Autonomy: Places control of the stapler directly in the hands of the surgeon. Positioning, grip, clamp and fire are fully controlled by the surgeon through the da Vinci surgeon console. Fully Wristed Articulation: The EndoWrist Stapler has the side-to-side articulation currently available, with a range of 108° total side-to-side. The EndoWrist Stapler articulates through a range of 54° total up-and-down, providing a fully-wristed cone of articulation. SmartClamp Feedback: Reduces the guesswork associated with conventional, handheld stapling by detecting whether the jaws can adequately close on the target tissue for the given staple height.
186
3/31/20168.91x25.14x28.00x47.23x36.50x$21,597$188.95216.64%Mar-08-2016Company Conference PresentationIntuitive Surgical, Inc. Presents at Raymond James 37th Annual Institutional Investors Conference, Mar-08-2016 11:35 AM-Intuitive Surgical, Inc. Presents at Raymond James 37th Annual Institutional Investors Conference, Mar-08-2016 11:35 AM. Venue: JW Marriott Grande Lakes Hotel, Orlando, Florida, United States.
187
3/31/20168.91x25.14x28.00x47.23x36.50x$0Mar-06-2016ConferenceRaymond James & Associates, Inc., Raymond James 37th Annual Institutional Investors Conference, Mar 06, 2016 through Mar 09, 2016Wintrust Financial Corporation (NasdaqGS:WTFC), Cogent Communications Holdings, Inc. (NasdaqGS:CCOI), NortonLifeLock Inc. (NasdaqGS:NLOK), ACI Worldwide, Inc. (NasdaqGS:ACIW), SBA Communications Corporation (NasdaqGS:SBAC), SS&C Technologies Holdings, Inc. (NasdaqGS:SSNC), Stericycle, Inc. (NasdaqGS:SRCL), E*TRADE Financial Corporation (NasdaqGS:ETFC), Check Point Software Technologies Ltd. (NasdaqGS:CHKP), Citrix Systems, Inc. (NasdaqGS:CTXS), Herman Miller, Inc. (NasdaqGS:MLHR), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Masimo Corporation (NasdaqGS:MASI), Natus Medical Incorporated (NasdaqGS:NTUS), NVIDIA Corporation (NasdaqGS:NVDA), Rent-A-Center, Inc. (NasdaqGS:RCII), Qorvo, Inc. (NasdaqGS:QRVO), Fiesta Restaurant Group, Inc. (NasdaqGS:FRGI), Chuy's Holdings, Inc. (NasdaqGS:CHUY), Carrols Restaurant Group, Inc. (NasdaqGS:TAST), MobileIron, Inc. (NasdaqGS:MOBL), Criteo S.A. (NasdaqGS:CRTO), Dave & Buster's Entertainment, Inc. (NasdaqGS:PLAY), Syneos Health, Inc. (NasdaqGS:SYNH), Akamai Technologies, Inc. (NasdaqGS:AKAM), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), ORBCOMM Inc. (NasdaqGS:ORBC), Verisk Analytics, Inc. (NasdaqGS:VRSK), Allegiant Travel Company (NasdaqGS:ALGT), Premier, Inc. (NasdaqGS:PINC), Synchronoss Technologies, Inc. (NasdaqGS:SNCR), Nasdaq, Inc. (NasdaqGS:NDAQ), Pinnacle Financial Partners, Inc. (NasdaqGS:PNFP), Patterson-UTI Energy, Inc. (NasdaqGS:PTEN), ScanSource, Inc. (NasdaqGS:SCSC), TD Ameritrade Holding Corporation (NasdaqGS:AMTD), Atlantic Union Bankshares Corporation (NasdaqGS:AUB), Bank OZK (NasdaqGS:OZK), Encore Capital Group, Inc. (NasdaqGS:ECPG), OraSure Technologies, Inc. (NasdaqGS:OSUR), iRobot Corporation (NasdaqGS:IRBT), Insulet Corporation (NasdaqGS:PODD), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Home Bancshares, Inc. (Conway, AR) (NasdaqGS:HOMB), HealthEquity, Inc. (NasdaqGS:HQY), LKQ Corporation (NasdaqGS:LKQ), CME Group Inc. (NasdaqGS:CME), Skyworks Solutions, Inc. (NasdaqGS:SWKS), PRA Group, Inc. (NasdaqGS:PRAA), Beacon Roofing Supply, Inc. (NasdaqGS:BECN), CDW Corporation (NasdaqGS:CDW), ADTRAN, Inc. (NasdaqGS:ADTN), Forward Air Corporation (NasdaqGS:FWRD), BOK Financial Corporation (NasdaqGS:BOKF), Hancock Whitney Corporation (NasdaqGS:HWC), ATN International, Inc. (NasdaqGS:ATNI), The Cheesecake Factory Incorporated (NasdaqGS:CAKE), ICU Medical, Inc. (NasdaqGS:ICUI), PotlatchDeltic Corporation (NasdaqGS:PCH), SEI Investments Company (NasdaqGS:SEIC), J.B. Hunt Transport Services, Inc. (NasdaqGS:JBHT), Heartland Express, Inc. (NasdaqGS:HTLD), Tech Data Corporation (NasdaqGS:TECD), United Bankshares, Inc. (NasdaqGS:UBSI), Micron Technology, Inc. (NasdaqGS:MU), Mylan N.V. (NasdaqGS:MYL), Avnet, Inc. (NasdaqGS:AVT), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Dawson Geophysical Company (NasdaqGS:DWSN), Fastenal Company (NasdaqGS:FAST), US Ecology, Inc. (NasdaqGS:ECOL), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Willis Towers Watson Public Limited Company (NasdaqGS:WLTW), Paylocity Holding Corporation (NasdaqGS:PCTY), Cboe Global Markets, Inc. (BATS:CBOE), TG Therapeutics, Inc. (NasdaqCM:TGTX), Oasis Petroleum Inc. (NasdaqCM:OAS), Moody's Corporation (NYSE:MCO), Enterprise Products Partners L.P. (NYSE:EPD), WESCO International, Inc. (NYSE:WCC), Waste Connections, Inc. (NYSE:WCN), Republic Services, Inc. (NYSE:RSG), New York Community Bancorp, Inc. (NYSE:NYCB), The Home Depot, Inc. (NYSE:HD), Broadridge Financial Solutions, Inc. (NYSE:BR), Spirit Airlines, Inc. (NYSE:SAVE), Lincoln National Corporation (NYSE:LNC), Main Street Capital Corporation (NYSE:MAIN), QEP Resources, Inc. (NYSE:QEP), NeoPhotonics Corporation (NYSE:NPTN), RingCentral, Inc. (NYSE:RNG), Tempur Sealy International, Inc. (NYSE:TPX), American Equity Investment Life Holding Company (NYSE:AEL), Whiting Petroleum Corporation (NYSE:WLL), MSCI Inc. (NYSE:MSCI), Palo Alto Networks, Inc. (NYSE:PANW), Delek US Holdings, Inc. (NYSE:DK), Prestige Consumer Healthcare Inc. (NYSE:PBH), Digital Realty Trust, Inc. (NYSE:DLR), WellCare Health Plans, Inc. (NYSE:WCG), StoneMor Inc. (NYSE:STON), D.R. Horton, Inc. (NYSE:DHI), Booz Allen Hamilton Holding Corporation (NYSE:BAH), Apache Corporation (NYSE:APA), Brunswick Corporation (NYSE:BC), Cardinal Health, Inc. (NYSE:CAH), GATX Corporation (NYSE:GATX), Masco Corporation (NYSE:MAS), Telephone and Data Systems, Inc. (NYSE:TDS), The Toro Company (NYSE:TTC), Unit Corporation (NYSE:UNT), MEDNAX, Inc. (NYSE:MD), United Parcel Service, Inc. (NYSE:UPS), Delta Air Lines, Inc. (NYSE:DAL), Devon Energy Corporation (NYSE:DVN), CenturyLink, Inc. (NYSE:CTL), HCA Healthcare, Inc. (NYSE:HCA), Cubic Corporation (NYSE:CUB), salesforce.com, inc. (NYSE:CRM), Agnico Eagle Mines Limited (NYSE:AEM), Aflac Incorporated (NYSE:AFL), Argo Group International Holdings, Ltd. (NYSE:ARGO), Arrow Electronics, Inc. (NYSE:ARW), Teleflex Incorporated (NYSE:TFX), Toll Brothers, Inc. (NYSE:TOL), Service Corporation International (NYSE:SCI), Stanley Black & Decker, Inc. (NYSE:SWK), Synovus Financial Corp. (NYSE:SNV), W.W. Grainger, Inc. (NYSE:GWW), Harley-Davidson, Inc. (NYSE:HOG), HNI Corporation (NYSE:HNI), Pioneer Natural Resources Company (NYSE:PXD), Pier 1 Imports, Inc. (NYSE:PIR), Polaris Inc. (NYSE:PII), Union Pacific Corporation (NYSE:UNP), United States Cellular Corporation (NYSE:USM), Walmart Inc. (NYSE:WMT), Whirlpool Corporation (NYSE:WHR), Perrigo Company plc (NYSE:PRGO), Covanta Holding Corporation (NYSE:CVA), Linde plc (NYSE:LIN), The Scotts Miracle-Gro Company (NYSE:SMG), SM Energy Company (NYSE:SM), Rayonier Inc. (NYSE:RYN), Parsley Energy, Inc. (NYSE:PE), Murphy USA Inc. (NYSE:MUSA), NOW Inc. (NYSE:DNOW), Avanos Medical, Inc. (NYSE:AVNS), Fortress Transportation and Infrastructure Investors LLC (NYSE:FTAI), Zayo Group Holdings, Inc. (NYSE:ZAYO), Lannett Company, Inc. (NYSE:LCI), Q2 Holdings, Inc. (NYSE:QTWO), MRC Global Inc. (NYSE:MRC), Enviva Partners, LP (NYSE:EVA), HubSpot, Inc. (NYSE:HUBS), Chegg, Inc. (NYSE:CHGG), Cinemark Holdings, Inc. (NYSE:CNK), Diplomat Pharmacy, Inc. (NYSE:DPLO), Catalent, Inc. (NYSE:CTLT), Shopify Inc. (NYSE:SHOP), Envestnet, Inc. (NYSE:ENV), STORE Capital Corporation (NYSE:STOR), Laredo Petroleum, Inc. (NYSE:LPI), IQVIA Holdings Inc. (NYSE:IQV), Callaway Golf Company (NYSE:ELY), AutoZone, Inc. (NYSE:AZO), The Allstate Corporation (NYSE:ALL), S&P Global Inc. (NYSE:SPGI), Alliance Data Systems Corporation (NYSE:ADS), American Tower Corporation (REIT) (NYSE:AMT), AmerisourceBergen Corporation (NYSE:ABC), Kansas City Southern (NYSE:KSU), Laboratory Corporation of America Holdings (NYSE:LH), Leggett & Platt, Incorporated (NYSE:LEG), FleetCor Technologies, Inc. (NYSE:FLT), Clean Harbors, Inc. (NYSE:CLH), Concho Resources Inc. (NYSE:CXO), Ryder System, Inc. (NYSE:R), Dine Brands Global, Inc. (NYSE:DIN), STERIS plc (NYSE:STE), Charles River Laboratories International, Inc. (NYSE:CRL), Superior Energy Services, Inc. (NYSE:SPN), Helix Energy Solutions Group, Inc. (NYSE:HLX), Oil States International, Inc. (NYSE:OIS), Haemonetics Corporation (NYSE:HAE), Jabil Inc. (NYSE:JBL), AAC Holdings, Inc. (OTCPK:AACH), Kona Grill, Inc. (OTCPK:KONA.Q), Basic Energy Services, Inc. (OTCPK:BASX), CPI Card Group Inc. (OTCPK:PMTS), Health Insurance Innovations, Inc. (NasdaqGM:HIIQ), The Habit Restaurants, Inc. (NasdaqGM:HABT), Rapid7, Inc. (NasdaqGM:RPD), Benefitfocus, Inc. (NasdaqGM:BNFT), Applied Optoelectronics, Inc. (NasdaqGM:AAOI), Upland Software, Inc. (NasdaqGM:UPLD), Newtek Business Services Corp. (NasdaqGM:NEWT), MiX Telematics Limited (JSE:MIX), Applied Micro Circuits Corporation, BroadSoft, Inc., Cepheid, DigitalGlobe, Inc., Spectrum Brands Legacy, Inc., Regal Entertainment Group, WCI Communities, Inc., ARRIS International Limited, Energen Corporation, athenahealth, Inc., Celgene Corporation, Northrop Grumman Innovation Systems, Inc., Microsemi Corporation, Genesee & Wyoming Inc., Agrium Inc., Envision Healthcare Corporation, Impax Laboratories, Inc., Raymond James & Associates, Inc., Cavium, Inc., Worldpay, Inc., The Advisory Board Company, DH Corporation, TIAA FSB Holdings, Inc., Pandora Media, LLC, Control4 Corporation, Inteliquent, Inc., Enel X North America, Inc., Demandware, LLC, Heartware International Inc., Mobileye N.V., Civitas Solutions, Inc., Dipexium Pharmaceuticals, Inc., Range Resources - Louisiana, Inc., Gigamon Inc., Fleetmatics Group PLCRaymond James & Associates, Inc., Raymond James 37th Annual Institutional Investors Conference, Mar 06, 2016 through Mar 09, 2016. Venue: JW Marriott Grande Lakes Hotel, Orlando, Florida, United States. To provide an annual forum for portfolio managers and generalists to learn about sound investment opportunities from wide range of companies across the nine industries.
188
3/31/20168.91x25.14x28.00x47.23x36.50x$21,453$187.69218.76%Feb-29-2016Product-Related AnnouncementIntuitive Surgical, Inc. Publishes Results from a New Study Titled, Multicenter Analysis Comparing Robotic, Open, Laparoscopic and Vaginal Hysterectomies Performed by High Volume Surgeons for Benign Indication-Intuitive Surgical, Inc. announced the published results from a new study titled, “Multicenter analysis comparing robotic, open, laparoscopic and vaginal hysterectomies performed by high volume surgeons for benign indication.” When evaluating comparable surgeon experience, the study found that women undergoing benign hysterectomies by robotic-assisted surgeons using da Vinci® Surgical Systems had better outcomes and experienced fewer complications compared to conventional abdominal, vaginal and laparoscopic hysterectomies outcomes. The study, which was published in the International Journal of Gynecology and Obstetrics, and led by Peter Lim, M.D. at Renown Regional Medical Center in Reno, Nevada, analyzed over 32,000 benign hysterectomy cases and compared the outcomes of high-volume surgeons across the four surgical approaches. The study compared 30-day outcomes from robotic-assisted hysterectomies performed by high-volume surgeons (greater than or equal to 60 procedures) with data from high-volume surgeons obtained from the Premier Perspective database for abdominal, vaginal, and laparoscopic hysterectomies. The data evaluated included: 2,300 robotic-assisted, 9,745 abdominal, 8,121 vaginal and 11,952 laparoscopic hysterectomies. The study found subjects undergoing robotic assisted procedures with Intuitive Surgical’s da Vinci robotic surgical systems experienced significantly fewer intraoperative complications than patients who underwent abdominal or vaginal procedures and fewer than those who had a laparoscopic procedure. These better outcomes were observed despite the increased complexity of patients in the robotic-assisted group.
189
3/31/20168.91x25.14x28.00x47.23x36.50x$21,621$189.16216.29%Feb-26-2016Executive/Board Change - OtherJerome J. McNamara to Resign as Senior Advisor, Commercial Operations of Intuitive Surgical, Inc. Effective May 31, 2016-On February 23, 2016, Jerome J. McNamara, Senior Advisor, Commercial Operations, of Intuitive Surgical, Inc. has informed the company of his decision to resign from the company, effective May 31, 2016.
190
3/31/20168.91x25.14x28.00x47.23x36.50x$20,694$181.05230.46%Feb-01-2016Executive/Board Change - OtherIntuitive Surgical, Inc. Announces Director Changes-Intuitive Surgical, Inc. announced that the retirement of Eric H. Halvorson who has served on the Board of Directors since 2003, has informed the company of his decision to retire from the Board and will not seek re-election as a director at the 2016 Annual Meeting of Stockholders. His retirement from the Board will be effective on the date of the Annual Meeting. On January 28, 2016, Mr. Keith R. Leonard, Jr. was appointed to the Board, effective January 28, 2016. Concurrent with his appointment as a director, Mr. Leonard was also appointed to serve as a member of the Compensation Committee of the Board. Mr. Leonard has served on the Board of Directors of Anacor Pharmaceuticals, Inc. since May 2014. From August 2005 until the October 2015 acquisition by Allergan plc, Mr. Leonard served as President, Chief Executive Officer and a Member of the Board of Directors of Kythera Biopharmaceuticals, Inc. From 1991 to 2004, Mr. Leonard held various positions at Amgen Inc., most recently as Senior Vice President and General Manager of Amgen Europe, where he was responsible for commercial operations in 28 European countries.
191
3/31/20168.91x25.14x28.00x47.23x36.50x$21,168$185.20223.05%Jan-21-2016Earnings CallIntuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016-Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016
192
3/31/20168.91x25.14x28.00x47.23x36.50x$21,168$185.20223.05%Jan-21-2016Product-Related AnnouncementIntuitive Surgical and Trumpf Medical Announce U.S. Clearance for Integrated Table Motion-Intuitive Surgical, Inc. and Trumpf Medical announced that the Food and Drug Administration has cleared Intuitive Surgical’s 510 (k) to offer Integrated Table Motion for the da Vinci Xi Surgical System in the United States. Integrated Table Motion seamlessly combines the da Vinci Xi, Intuitive Surgical’s latest robotic-assisted surgical system, and Trumpf Medical’s advanced operating table, the TruSystem 7000dV, to allow surgeons and anesthesiologists the ability to make a comprehensive range of table adjustments easily and efficiently during a surgical procedure. In a first-of-its-kind product offering, Integrated Table Motion delivers surgical teams the real-time ability to reposition the operating table with the surgical robotic arms docked. This surgical advancement addresses the need for operating room efficiency by maximizing access, exposure and reach during a robotic-assisted surgical procedure. Integrated Table Motion also gives operating room (OR) teams, while conducting robot-assisted surgery, the ability to leverage the TruSystem 7000dv operating table’s capabilities to: Optimally position the table so that gravity exposes anatomy during multi-quadrant da Vinci System procedures; Maximize reach and access to target anatomy – enabling surgeons to interact with tissue at an ideal working angle; and Reposition the table during the procedure to enhance anesthesiologists’ care of the patient. The da Vinci Surgical System and TruSystem 7000dV table are synchronized in movement — the table’s positioning is relayed to the da Vinci Surgical System and is met with an intuitive adjustment of its instrument arms, boom and endoscope to maintain consistent orientation to the patient’s anatomy. Intuitive Surgical and Trumpf Medical spent five years working together to make the integration of the two systems possible. Over the next several months, Integrated Table Motion will be available for sale in the United States and introduced to hospitals around the country.
193
3/31/20168.91x25.14x28.00x47.23x36.50x$21,168$185.20223.05%Jan-21-2016Corporate Guidance - New/Confirmed, Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015; Provides Earnings Guidance for the Full Year 2016-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2015. For the quarter, the company reported total revenue of USD 676.5 million against USD 604.7 million a year ago. Income from operations was USD 245.9 million against USD 186.1 million a year ago. Income before taxes was USD 251.8 million against USD 184.8 million a year ago. Net income was USD 190.0 million or USD 4.99 per diluted share against USD 146.8 million or USD 3.94 per diluted share a year ago. Non-GAAP revenue was USD 676.5 million against USD 600.8 million a year ago. Non-GAAP income from operations was USD 292.6 million against USD 237.0 million a year ago. Non-GAAP income per diluted share was USD 5.89 against USD 4.92 a year ago. Non-GAAP net income was USD 224.3 million against USD 183.5 million a year ago.

For the year, the company reported total revenue of USD 2,384.4 million against USD 2,131.7 million a year ago. Income from operations was USD 740 million against USD 544.8 million a year ago. Income before taxes was USD 758.5 against USD 549.0 million a year ago. Net income was USD 588.8 million or USD 15.54 per diluted share against USD 418.8 million or USD 11.11 per diluted share a year ago. Non-GAAP revenue was USD 2,384.4 million against USD 2,131.7 million a year ago. Non-GAAP income from operations was USD 945.7 million against USD 818.7 million a year ago. Non-GAAP income per diluted share was USD 19.28 against USD 16.10 a year ago. Non-GAAP net income was USD 730.9 million against USD 606.9 million a year ago.

For 2016, the company expects pro forma gross profit margin to be within a range of between 68% and 69.5% of net revenue. With regard to income tax, expects pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and OUS profits.
194
3/31/20168.91x25.14x28.00x47.23x36.50x$21,168$185.20223.05%Jan-21-2016Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From October 1, 2015 to December 31, 2015, the company has repurchased 499,977 shares, representing 0.45% for $84.18 million. With this, the company has completed the repurchase of 1,097,529 shares, representing 0.99% for $183.74 million under the buyback announced on February 2, 2015.
195
3/31/20168.91x25.14x28.00x47.23x36.50x$21,175$185.26222.95%Jan-14-2016Company Conference PresentationIntuitive Surgical, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-14-2016 09:00 AM-Intuitive Surgical, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-14-2016 09:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Gary S. Guthart, Chief Executive Officer, President and Director.
196
3/31/20168.91x25.14x28.00x47.23x36.50x$20,769$181.71229.26%Jan-13-2016Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year 2015-Intuitive Surgical, Inc. provided preliminary earnings guidance for the fourth quarter and full year 2015. For the quarter, the company expects revenue of approximately $677 million, an increase of approximately 12% compared with $605 million for the fourth quarter of 2014. GAAP and non-GAAP revenue are the same for the fourth quarter of 2015.

For the full year, the company expects revenue of approximately $2.4 billion, an increase of approximately 12% compared with $2.1 billion for 2014.
197
3/31/20168.91x25.14x28.00x47.23x36.50x$20,558$179.86232.64%Jan-11-2016ConferenceJPMorgan Chase & Co., JPMorgan 34th Annual Healthcare Conference, Jan 11, 2016 through Jan 14, 2016Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Amgen Inc. (NasdaqGS:AMGN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Alkermes plc (NasdaqGS:ALKS), Tivity Health, Inc. (NasdaqGS:TVTY), Endologix, Inc. (NasdaqGS:ELGX), Novavax, Inc. (NasdaqGS:NVAX), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), ICON Public Limited Company (NasdaqGS:ICLR), ICU Medical, Inc. (NasdaqGS:ICUI), Patterson Companies, Inc. (NasdaqGS:PDCO), Magellan Health, Inc. (NasdaqGS:MGLN), Incyte Corporation (NasdaqGS:INCY), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Henry Schein, Inc. (NasdaqGS:HSIC), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), CONMED Corporation (NasdaqGS:CNMD), Cerner Corporation (NasdaqGS:CERN), Mylan N.V. (NasdaqGS:MYL), Insulet Corporation (NasdaqGS:PODD), Bruker Corporation (NasdaqGS:BRKR), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Premier, Inc. (NasdaqGS:PINC), Accuray Incorporated (NasdaqGS:ARAY), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), ChemoCentryx, Inc. (NasdaqGS:CCXI), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Aduro BioTech, Inc. (NasdaqGS:ADRO), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Orthofix Medical Inc. (NasdaqGS:OFIX), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Masimo Corporation (NasdaqGS:MASI), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), Wright Medical Group N.V. (NasdaqGS:WMGI), United Therapeutics Corporation (NasdaqGS:UTHR), Hologic, Inc. (NasdaqGS:HOLX), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Teligent, Inc. (NasdaqGS:TLGT), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Quidel Corporation (NasdaqGS:QDEL), DexCom, Inc. (NasdaqGS:DXCM), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Bio-Techne Corporation (NasdaqGS:TECH), Biogen Inc. (NasdaqGS:BIIB), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Endo International plc (NasdaqGS:ENDP), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), NuCana plc (NasdaqGS:NCNA), BioNTech SE (NasdaqGS:BNTX), Otonomy, Inc. (NasdaqGS:OTIC), Clovis Oncology, Inc. (NasdaqGS:CLVS), IVERIC bio, Inc. (NasdaqGS:ISEE), Surgery Partners, Inc. (NasdaqGS:SGRY), Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST), Inovalon Holdings, Inc. (NasdaqGS:INOV), iRhythm Technologies, Inc. (NasdaqGS:IRTC), OPKO Health, Inc. (NasdaqGS:OPK), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), China Biologic Products Holdings, Inc. (NasdaqGS:CBPO), Conformis, Inc. (NasdaqGS:CFMS), Intrexon Corporation (NasdaqGS:XON), HealthEquity, Inc. (NasdaqGS:HQY), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), Advaxis, Inc. (NasdaqGS:ADXS), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), AngioDynamics, Inc. (NasdaqGS:ANGO), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), LHC Group, Inc. (NasdaqGS:LHCG), Inogen, Inc. (NasdaqGS:INGN), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), OptiNose, Inc. (NasdaqGS:OPTN), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), 10x Genomics, Inc. (NasdaqGS:TXG), Seres Therapeutics, Inc. (NasdaqGS:MCRB), NovoCure Limited (NasdaqGS:NVCR), Adaptive Biotechnologies Corporation (NasdaqGS:ADPT), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Progyny, Inc. (NasdaqGS:PGNY), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Health Catalyst, Inc. (NasdaqGS:HCAT), Moderna, Inc. (NasdaqGS:MRNA), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Allena Pharmaceuticals, Inc. (NasdaqGS:ALNA), NantKwest, Inc. (NasdaqGS:NK), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Syneos Health, Inc. (NasdaqGS:SYNH), Gritstone Oncology, Inc. (NasdaqGS:GRTS), Solid Biosciences Inc. (NasdaqGS:SLDB), Almirall, S.A. (BME:ALM), Acacia Pharma Group plc (ENXTBR:ACPH), Celyad SA (ENXTBR:CYAD), Fleury S.A. (BOVESPA:FLRY3), Hypera S.A. (BOVESPA:HYPE3), Odontoprev S.A. (BOVESPA:ODPV3), Ouro Fino Saúde Animal Participações S.A. (BOVESPA:OFSA3), Raia Drogasil S.A. (BOVESPA:RADL3), Tasly Pharmaceutical Group Co., Ltd (SHSE:600535), Mesoblast Limited (ASX:MSB), Immutep Limited (ASX:IMM), CSL Limited (ASX:CSL), UCB SA (ENXTBR:UCB), Abaxis, Inc., AccentCare, Inc., Array BioPharma Inc., Intarcia Therapeutics, Inc., Cepheid, WebMD Health Corp., Team Health Holdings, Inc., PAREXEL International Corporation, Sequenom Inc., The Spectranetics Corporation, The Medicines Company, Universal American Corp., TFCF Corporation, Actelion Ltd, Ancestry.com LLC, athenahealth, Inc., Connecture, Inc., BTG Limited, Ascension Health, Inc., Blue Cross and Blue Shield Association, Dignity Health, C. R. Bard, Inc., Celgene Corporation, St. Jude Medical, Inc., Almost Family, Inc., Kindred Healthcare, LLC, Express Scripts Holding Company, Affymetrix Inc., FEI Company, Young Innovations, Inc., Shire plc, Envision Healthcare Corporation, Albany Molecular Research, Inc., Legacy LifePoint Health, Inc., Syneos Health US, Inc., Impax Laboratories, Inc., Keryx Biopharmaceuticals, Inc., National Surgical Hospitals, Inc., Aetna Inc., The Cleveland Clinic Foundation, Advocate Health Care, Inc., AdventHealth, Baylor Scott & White Health LLC, EnGeneIC Ltd, The Advisory Board Company, Alere Inc., Cable News Network, Inc., Novadaq Technologies Inc., Imprivata, Inc., Santen Incorporated, Medidata Solutions, Inc., Apogenix GmbH, Genomic Health, Inc., National Cancer Institute, AcuFocus, Inc., Ablynx NV, Partners HealthCare System, Inc., Bill & Melinda Gates Foundation, Henry Ford Health System, RWJBarnabas Health, Inc., Intermountain Healthcare, Inc., Memorial Hermann Healthcare System, Inc., Mayo Clinic, Northwell Health, Inc., Genticel SA, Norton Healthcare, Inc., Trinity Health Corporation, American Medical Association Inc., Aurora Health Care, Inc., FOX News Network, LLC, Iowa Health System, Inc., BSN medical Inc., American Family Care, Inc., Integrated DNA Technologies, Inc., Oregon Health & Science University, Northwestern Memorial Healthcare Corporation, Everyday Health, Inc., Echosens SAS, 21st Century Oncology, LLC, Symphogen A/S, Helsinn Healthcare S.A., Centers for Medicare & Medicaid Services, Orexigen Therapeutics, Inc., Astellas Pharma US, Inc., ZirMed, Inc., CareCentrix, Inc., GenScript Corporation, Neuroderm Ltd., Singulex, Inc., TxCell S.A., Vanderbilt University School of Medicine, Medivation, Inc., Heartware International Inc., CureVac AG, OncoMed Pharmaceuticals, Inc., Emcure Pharmaceuticals Limited, BioElectron Technology Corporation, Alder BioPharmaceuticals, Inc., Synthetic Genomics, Inc., Aegerion Pharmaceuticals, Inc., Cempra, Inc., GreatCall, Inc., 23andMe, Inc., ReShape Medical Inc., ZELTIQ Aesthetics, Inc., Weill Cornell Medical College, New York, Grupo Farmaceutico Biotoscana S.A., Elixir Medical Corporation, Valence Health, Inc., Guangzhou Pharmaceutical Holdings Limited, DNAnexus, Inc., PercuVision LLC, Edge Therapeutics, Inc., Sharecare Inc., Minerva Surgical Inc., Cognosante, LLC, Myriad Women's Health, Inc., St. Luke's Health System Ltd., Welltok, Inc., Epic Health Services, Inc., Sagent Pharmaceuticals, Inc., SCAI Holdings, LLC, Foundation Medicine, Inc., Arrail Dental International Group Co. Ltd., Syapse, Inc., Direct Vet Marketing, Inc., Imaging Advantage LLC, Kite Pharma, Inc., Phlexglobal Ltd., Sera Prognostics, Inc., Aratana Therapeutics, Inc., One Medical Group, Inc., Ginkgo Bioworks, Inc., Geisinger Health System, OvaScience, Inc., Ignyta, Inc., NantWorks, LLC, Alcresta Therapeutics, Inc., Tolero Pharmaceuticals, Inc., PIQUR Therapeutics AG, Envision Healthcare Holdings, Inc., Remedy Partners, Inc., U.S. Anesthesia Partners, Grand Rounds, Inc., ARMO BioSciences, Inc., Scholar Rock, Inc., Braeburn Inc., Evidation Health, Inc., Spark Therapeutics, Inc., Bioverativ USA Inc., Envisia Therapeutics Inc., Juno Therapeutics, Inc., Doctor on Demand, Inc., Capitol Street, Cardiorentis AG, Cloud Pharmaceuticals, Inc., Human Longevity, Inc., University Wisconsin Health, Aledade, Inc., VWR Corporation, Helix, EndoChoice Holdings, Inc., Independence Health Group, Inc., Outset Medical, Inc., Caris Life Sciences, Inc., HealthReveal, Inc., ZENII LLC, Cardeation Capital Management, Ipsen S.A. (ENXTPA:IPN), Cellectis S.A. (ENXTPA:ALCLS), Sanofi (ENXTPA:SAN), EssilorLuxottica Société anonyme (ENXTPA:EL), Innate Pharma S.A. (ENXTPA:IPH), OSE Immunotherapeutics SA (ENXTPA:OSE), ORPEA Société Anonyme (ENXTPA:ORP), Sartorius Stedim Biotech S.A. (ENXTPA:DIM), China Medical System Holdings Limited (SEHK:867), 3SBio Inc. (SEHK:1530), Lee's Pharmaceutical Holdings Limited (SEHK:950), Sino Biopharmaceutical Limited (SEHK:1177), China Resources Pharmaceutical Group Limited (SEHK:3320), Innovent Biologics, Inc. (SEHK:1801), UMP Healthcare Holdings Limited (SEHK:722), CSPC Pharmaceutical Group Limited (SEHK:1093), Takeda Pharmaceutical Company Limited (TSE:4502), NanoCarrier Co., Ltd. (TSE:4571), Otsuka Holdings Co., Ltd. (TSE:4578), Daiichi Sankyo Company, Limited (TSE:4568), Healios K.K. (TSE:4593), Dr. Reddy's Laboratories Limited (BSE:500124), Lupin Limited (BSE:500257), PT Siloam International Hospitals Tbk (IDX:SILO), BioLineRx Ltd. (TASE:BLRX), Novozymes A/S (CPSE:NZYM B), Ambu A/S (CPSE:AMBU B), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), Zealand Pharma A/S (CPSE:ZEAL), Advanced Proteome Therapeutics Corporation (TSXV:APC), Meinian Onehealth Healthcare Holdings Co., Ltd. (SZSE:002044), Berry Genomics Co.,Ltd (SZSE:000710), Circassia Pharmaceuticals plc (AIM:CIR), AstraZeneca PLC (LSE:AZN), GlaxoSmithKline plc (LSE:GSK), Vectura Group plc (LSE:VEC), Hikma Pharmaceuticals PLC (LSE:HIK), NMC Health Plc (LSE:NMC), Indivior PLC (LSE:INDV), Spire Healthcare Group plc (LSE:SPI), ScinoPharm Taiwan, Ltd. (TSEC:1789), Roche Holding AG (SWX:ROG), Basilea Pharmaceutica AG (SWX:BSLN), Novartis AG (SWX:NOVN), Santhera Pharmaceuticals Holding AG (SWX:SANN), Tecan Group Ltd. (SWX:TECN), Molecular Partners AG (SWX:MOLN), Nordic Nanovector ASA (OB:NANO), Raffles Medical Group Ltd (SGX:BSL), Life Healthcare Group Holdings Limited (JSE:LHC), Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B), Samsung Biologics Co.,Ltd. (KOSE:A207940), Hanmi Pharm. Co., Ltd. (KOSE:A128940), Green Cross Corporation (KOSE:A006280), Celltrion, Inc. (KOSE:A068270), Swedish Orphan Biovitrum AB (publ) (OM:SOBI), Elekta AB (publ) (OM:EKTA B), Kancera AB (publ) (OM:KAN), Orexo AB (publ) (OM:ORX), Karolinska Development AB (publ) (OM:KDEV), TransEnterix, Inc. (AMEX:TRXC), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), Chimerix, Inc. (NasdaqGM:CMRX), Affimed N.V. (NasdaqGM:AFMD), Obalon Therapeutics, Inc. (NasdaqGM:OBLN), Veracyte, Inc. (NasdaqGM:VCYT), Intersect ENT, Inc. (NasdaqGM:XENT), Quanterix Corporation (NasdaqGM:QTRX), T2 Biosystems, Inc. (NasdaqGM:TTOO), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Radius Health, Inc. (NasdaqGM:RDUS), Sierra Oncology, Inc. (NasdaqGM:SRRA), Oxford Immunotec Global PLC (NasdaqGM:OXFD), NanoString Technologies, Inc. (NasdaqGM:NSTG), MannKind Corporation (NasdaqGM:MNKD), Synlogic, Inc. (NasdaqGM:SYBX), Zai Lab Limited (NasdaqGM:ZLAB), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Quotient Limited (NasdaqGM:QTNT), Vocera Communications, Inc. (NYSE:VCRA), JPMorgan Chase & Co. (NYSE:JPM), JPMorgan Chase & Co. (NYSE:JPM), Ventas, Inc. (NYSE:VTR), Glaukos Corporation (NYSE:GKOS), Welltower Inc. (NYSE:WELL), Healthpeak Properties, Inc. (NYSE:PEAK), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), 3M Company (NYSE:MMM), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), The Cooper Companies, Inc. (NYSE:COO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Danaher Corporation (NYSE:DHR), PerkinElmer, Inc. (NYSE:PKI), Chemed Corporation (NYSE:CHE), HCA Healthcare, Inc. (NYSE:HCA), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Cantel Medical Corp. (NYSE:CMD), Johnson & Johnson (NYSE:JNJ), Model N, Inc. (NYSE:MODN), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), MEDNAX, Inc. (NYSE:MD), Abbott Laboratories (NYSE:ABT), Owens & Minor, Inc. (NYSE:OMI), Boston Scientific Corporation (NYSE:BSX), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), Perrigo Company plc (NYSE:PRGO), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), Alexandria Real Estate Equities, Inc. (NYSE:ARE), Quest Diagnostics Incorporated (NYSE:DGX), Edwards Lifesciences Corporation (NYSE:EW), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), Laboratory Corporation of America Holdings (NYSE:LH), QIAGEN N.V. (NYSE:QGEN), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Integer Holdings Corporation (NYSE:ITGR), CVS Health Corporation (NYSE:CVS), Charles River Laboratories International, Inc. (NYSE:CRL), Universal Health Services, Inc. (NYSE:UHS), Tenet Healthcare Corporation (NYSE:THC), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Encompass Health Corporation (NYSE:EHC), Community Health Systems, Inc. (NYSE:CYH), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), AmerisourceBergen Corporation (NYSE:ABC), AMN Healthcare Services, Inc. (NYSE:AMN), Hill-Rom Holdings, Inc. (NYSE:HRC), Safeguard Scientifics, Inc. (NYSE:SFE), Seegene, Inc. (KOSDAQ:A096530), REVA Medical, Inc. (OTCPK:RVAL.L), PharmaCyte Biotech, Inc. (OTCPK:PMCB), Melinta Therapeutics, Inc. (OTCPK:MLNT.Q), Anthera Pharmaceuticals, Inc. (OTCPK:ANTH), INSYS Therapeutics, Inc. (OTCPK:INSY.Q), MiMedx Group, Inc. (OTCPK:MDXG), MorphoSys AG (XTRA:MOR), Bayer Aktiengesellschaft (XTRA:BAYN), Medigene AG (XTRA:MDG1), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Fresenius SE & Co. KGaA (XTRA:FRE), Avanos Medical, Inc. (NYSE:AVNS), Mallinckrodt plc (NYSE:MNK), Zoetis Inc. (NYSE:ZTS), Evolent Health, Inc. (NYSE:EVH), Invitae Corporation (NYSE:NVTA), AbbVie Inc. (NYSE:ABBV), IQVIA Holdings Inc. (NYSE:IQV), Catalent, Inc. (NYSE:CTLT), WellCare Health Plans, Inc. (NYSE:WCG), Globus Medical, Inc. (NYSE:GMED), Emergent BioSolutions Inc. (NYSE:EBS), Molina Healthcare, Inc. (NYSE:MOH), Nevro Corp. (NYSE:NVRO), Penumbra, Inc. (NYSE:PEN), Teladoc Health, Inc. (NYSE:TDOC), Select Medical Holdings Corporation (NYSE:SEM), Inspire Medical Systems, Inc. (NYSE:INSP), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Diplomat Pharmacy, Inc. (NYSE:DPLO), Veeva Systems Inc. (NYSE:VEEV), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), Exact Sciences Corporation (NasdaqCM:EXAS), Antares Pharma, Inc. (NasdaqCM:ATRS), Abeona Therapeutics Inc. (NasdaqCM:ABEO), Dynavax Technologies Corporation (NasdaqCM:DVAX), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), aTyr Pharma, Inc. (NasdaqCM:LIFE), Stemline Therapeutics, Inc. (NasdaqCM:STML), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), SELLAS Life Sciences Group, Inc. (NasdaqCM:SLS), TG Therapeutics, Inc. (NasdaqCM:TGTX), Aurobindo Pharma Limited (NSEI:AUROPHARMA), Glenmark Pharmaceuticals Limited (NSEI:GLENMARK), Cipla Limited (NSEI:CIPLA), JHL Biotech, Inc. (GTSM:6540), Taiwan Liposome Company, Ltd. (GTSM:4152)JPMorgan Chase & Co., JPMorgan 34th Annual Healthcare Conference, Jan 11, 2016 through Jan 14, 2016. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States.
198
3/31/20168.91x25.14x28.00x47.23x36.50x$20,456$178.97234.30%Jan-07-2016Client AnnouncementCardica and Intuitive Surgical Amend License AgreementDex Liquidating Co.Cardica, Inc. announced that the company has amended its license agreement, initially signed in August 2010, with Intuitive Surgical, Inc. to include an agreement providing for the evaluation and potential development of a surgical stapling cartridge for use with Intuitive Surgical's da Vinci Surgical Systems. Under the terms of the amendment, Intuitive Surgical has paid Cardica $2 million to extend its rights to improvements in Cardica's stapling technology and certain patents until August 2018 and to provide for a feasibility evaluation period of up to six months. The feasibility evaluation allows Intuitive Surgical to test and evaluate Cardica's MicroCutter XCHANGE technology. Upon completion of the evaluation, Intuitive Surgical will have the option to initiate a joint development program, for an 8 millimeters in diameter surgical stapling cartridge for use with the da Vinci Surgical System. Cardica may receive further funding for development of the cartridge and tooling as well as a unit-based royalty on commercial sales.
199
12/31/20158.13x23.79x26.69x45.98x38.87x$20,170$179.77232.81%Dec-21-2015Index Constituent AddIntuitive Surgical, Inc.(NasdaqGS:ISRG) added to S&P 500 Value IndexS&P 500 Value (^SVX)Intuitive Surgical, Inc.(NasdaqGS:ISRG) added to S&P 500 Value Index
200
12/31/20158.13x23.79x26.69x45.98x38.87x$18,644$166.17260.05%Nov-17-2015Company Conference PresentationIntuitive Surgical, Inc. Presents at Stifel Healthcare Conference 2015, Nov-17-2015 03:45 PM-Intuitive Surgical, Inc. Presents at Stifel Healthcare Conference 2015, Nov-17-2015 03:45 PM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: Calvin Darling, Sr. Director, Investor Relations, Patrick Clingan, Sr. Director, Finance.
201
12/31/20158.13x23.79x26.69x45.98x38.87x$18,644$166.17260.05%Nov-17-2015ConferenceStifel, Nicolaus & Company, Incorporated, Stifel Healthcare Conference 2015, Nov 17, 2015 through Nov 18, 2015Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Innoviva, Inc. (NasdaqGS:INVA), Align Technology, Inc. (NasdaqGS:ALGN), Tivity Health, Inc. (NasdaqGS:TVTY), MacroGenics, Inc. (NasdaqGS:MGNX), Novanta Inc. (NasdaqGS:NOVT), ChemoCentryx, Inc. (NasdaqGS:CCXI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Geron Corporation (NasdaqGS:GERN), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Progenics Pharmaceuticals, Inc. (NasdaqGS:PGNX), Endologix, Inc. (NasdaqGS:ELGX), Novavax, Inc. (NasdaqGS:NVAX), Exelixis, Inc. (NasdaqGS:EXEL), Inovio Pharmaceuticals, Inc. (NasdaqGS:INO), Magellan Health, Inc. (NasdaqGS:MGLN), Henry Schein, Inc. (NasdaqGS:HSIC), Inogen, Inc. (NasdaqGS:INGN), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Tetraphase Pharmaceuticals, Inc. (NasdaqGS:TTPH), Strongbridge Biopharma plc (NasdaqGS:SBBP), Intrexon Corporation (NasdaqGS:XON), eHealth, Inc. (NasdaqGS:EHTH), Endo International plc (NasdaqGS:ENDP), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Insmed Incorporated (NasdaqGS:INSM), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), CymaBay Therapeutics, Inc. (NasdaqGS:CBAY), Repligen Corporation (NasdaqGS:RGEN), Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA), Ascendis Pharma A/S (NasdaqGS:ASND), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Chiasma, Inc. (NasdaqGS:CHMA), G1 Therapeutics, Inc. (NasdaqGS:GTHX), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), IVERIC bio, Inc. (NasdaqGS:ISEE), DURECT Corporation (NasdaqCM:DRRX), Rexahn Pharmaceuticals, Inc. (NasdaqCM:REXN), Zosano Pharma Corporation (NasdaqCM:ZSAN), TrovaGene, Inc. (NasdaqCM:TROV), Cytosorbents Corporation (NasdaqCM:CTSO), MEI Pharma, Inc. (NasdaqCM:MEIP), Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX), Genocea Biosciences, Inc. (NasdaqCM:GNCA), Conatus Pharmaceuticals Inc. (NasdaqCM:CNAT), Viking Therapeutics, Inc. (NasdaqCM:VKTX), vTv Therapeutics Inc. (NasdaqCM:VTVT), Lombard Medical, Inc. (OTCPK:EVAR.F), Zyla Life Sciences (OTCPK:ZCOR), Castlight Health, Inc. (NYSE:CSLT), Inspire Medical Systems, Inc. (NYSE:INSP), Teladoc Health, Inc. (NYSE:TDOC), WellCare Health Plans, Inc. (NYSE:WCG), Triple-S Management Corporation (NYSE:GTS), MEDNAX, Inc. (NYSE:MD), Baxter International Inc. (NYSE:BAX), Cantel Medical Corp. (NYSE:CMD), PerkinElmer, Inc. (NYSE:PKI), Boston Scientific Corporation (NYSE:BSX), AMN Healthcare Services, Inc. (NYSE:AMN), Waters Corporation (NYSE:WAT), Becton, Dickinson and Company (NYSE:BDX), Humana Inc. (NYSE:HUM), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Misonix, Inc. (NasdaqGM:MSON), BioSpecifics Technologies Corp. (NasdaqGM:BSTC), Xenon Pharmaceuticals Inc. (NasdaqGM:XENE), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), AtriCure, Inc. (NasdaqGM:ATRC), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Rockwell Medical, Inc. (NasdaqGM:RMTI), Chimerix, Inc. (NasdaqGM:CMRX), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), Neos Therapeutics, Inc. (NasdaqGM:NEOS), Applied Genetic Technologies Corporation (NasdaqGM:AGTC), Marinus Pharmaceuticals, Inc. (NasdaqGM:MRNS), GlycoMimetics, Inc. (NasdaqGM:GLYC), NewLink Genetics Corporation (NasdaqGM:NLNK), Zogenix, Inc. (NasdaqGM:ZGNX), Cara Therapeutics, Inc. (NasdaqGM:CARA), Concert Pharmaceuticals, Inc. (NasdaqGM:CNCE), ViewRay, Inc. (NasdaqGM:VRAY), Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI), Ocular Therapeutix, Inc. (NasdaqGM:OCUL), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), T2 Biosystems, Inc. (NasdaqGM:TTOO), TRACON Pharmaceuticals, Inc. (NasdaqGM:TCON), Trupanion, Inc. (NasdaqGM:TRUP), Flexion Therapeutics, Inc. (NasdaqGM:FLXN), Navidea Biopharmaceuticals, Inc. (AMEX:NAVB), TransEnterix, Inc. (AMEX:TRXC), Nicox S.A. (ENXTPA:COX), Mainstay Medical International plc (ENXTPA:MSTY), Array BioPharma Inc., Cynosure, Inc., The Spectranetics Corporation, Vascular Solutions, Inc., Vical Incorporated, VCA Inc., C. R. Bard, Inc., Apricus Biosciences, Inc., Keryx Biopharmaceuticals, Inc., Stifel, Nicolaus & Company, Incorporated, Aviragen Therapeutics, Inc., EnGeneIC Ltd, OncoGenex Pharmaceuticals, Inc., Novadaq Technologies Inc., Biotie Therapies Corp., Vitae Pharmaceuticals, Inc., Syneron Medical Ltd., Threshold Pharmaceuticals, Inc., Everyday Health, Inc., BONESUPPORT AB, Medtech SA, Tokai Pharmaceuticals, Inc., Cynapsus Therapeutics Inc., CoLucid Pharmaceuticals, Inc., Ocera Therapeutics, Inc., Proteon Therapeutics, Inc., Cempra, Inc., Corindus Vascular Robotics, Inc., Symmetry Surgical Inc., Relypsa, Inc., Nivalis Therapeutics, Inc., Kolltan Pharmaceuticals, Inc., Invuity, Inc., DNIB Unwind, Inc., Pernix Therapeutics Holdings, Inc., Aratana Therapeutics, Inc., Alcobra Ltd., Kite Pharma, Inc., Alliqua BioMedical, Inc., Spark Therapeutics, Inc., Flex Pharma, Inc., EndoChoice Holdings, Inc., Loxo Oncology, Inc., Alzheon, Inc., Abaxis, Inc., Neovasc Inc. (TSX:NVCN), argenx SE (ENXTBR:ARGX)Stifel, Nicolaus & Company, Incorporated, Stifel Healthcare Conference 2015, Nov 17, 2015 through Nov 18, 2015. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States.
202
12/31/20158.13x23.79x26.69x45.98x38.87x$18,654$166.26259.85%Nov-13-2015Strategic Alliance3D Systems Collaborates with Intuitive Surgical and Fundamentals of Robotic Gynecologic Surgery to Develop Unique Training Modules for the Minimally Invasive Robotic Hysterectomy Procedure3D Systems Corporation (NYSE:DDD)3D Systems announced two healthcare collaborations, one with Intuitive Surgical and one with Fundamentals of Robotic Gynecologic Surgery group, to develop unique training modules for the minimally invasive (MIS) robotic hysterectomy procedure. Robotic surgery has developed rapidly since its approval by the U.S. Food and Drug Administration in 1999, as documented by the Society of Gynecologic Surgeons' Committee on Gynecologic Practice. To perform robot-assisted procedures, doctors operate through small surface incisions with equipment outfitted with tiny cameras to transmit real-time data to a large OR monitor. This type of surgery has grown popular due to lower levels of post-operative discomfort and faster recovery times, not to mention its cosmetic appeal over open surgeries. Today, robot-assisted surgery is performed at over 2,025 sites in the U.S., with the number of procedures growing at a rate of 25% annually. As the second most common surgical procedure in the United States, nearly 433,000 hysterectomies are performed each year. While the majority of these operations are still performed abdominally, MIS procedures are on the rise, with 9.5% of all hysterectomies performed robotically in 2010, up from 0.5% in 2007. 3D Systems has been working to address the growing demand for training in this technologically advanced field of MIS robotic procedures by partnering with leading industry and scientific groups. The company's collaboration with Intuitive Surgical has enabled the offering of a training module for Hysterectomy on the da Vinci Xi surgical system. Using the newest robotic technology, the simulation enables hands-on training of a complete surgical procedure, with the ultimate goal of increasing patient safety. This collaboration is part of a mutual commitment to provide leading procedural simulation training to surgical institutions. 3D Systems' collaboration with the FRGS group has led to the development of the Hysterectomy Procedural Tasks training module. The task-based module, which runs on 3D Systems'RobotiX Mentor, provides hands-on training of the key steps of the robotic hysterectomy surgical procedure as a part of the full education and training curriculum specified by the FRGS group. The new robotic training modules join 3D Systems' comprehensive line of Simbionix training products for Women's Health professionals, which will be available for hands-on demonstrations at the upcoming AAGL Global Congress, November 15-19, in Las Vegas, NV. The company also offers training for laparoscopic gynecologic surgery on the LAP Mentor, including a hysterectomy team training option, transabdominal and transvaginal ultrasound practice on the U/S Mentor, pelvic exam competency training on the PELVIC Mentor, and 3D printed models for planning and training.
203
12/31/20158.13x23.79x26.69x45.98x38.87x$18,678$166.47259.40%Oct-21-2015Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From July 1, 2015 to September 30, 2015, the company has repurchased 209,157 shares, representing 0.19% for $35.51 million. With this, the company has completed the repurchase of 597,552 shares, representing 0.54% for $99.55 million under the buyback announced on February 2, 2015.
204
12/31/20158.13x23.79x26.69x45.98x38.87x$17,691$157.67279.46%Oct-20-2015Earnings CallIntuitive Surgical, Inc., Q3 2015 Earnings Call, Oct 20, 2015-Intuitive Surgical, Inc., Q3 2015 Earnings Call, Oct 20, 2015
205
12/31/20158.13x23.79x26.69x45.98x38.87x$17,691$157.67279.46%Oct-20-2015Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company’s revenue was $589.7 million compared with $550.1 million in the third quarter of 2014. Income from operations was $189.9 million compared with $159.1 million a year ago. Income before taxes was $193.6 million compared with $161.1 million a year ago. Net income was $167.3 million compared with $123.7 million a year ago. Diluted net income per share was $4.40 compared with $3.35 a year ago. Non-gaap revenue was $589.7 million compared with $534.1 million a year ago. Non-gaap income from operations was $240.3 million compared with $196.9 million a year ago. Non-gaap net income was $199.2 million compared with $144.7 million a year ago. Diluted non-gaap net income per share was $5.24 compared with $4.57 a year ago.


For the nine months, the company reported revenue was $1,707.9 million compared with $1,527.0 million a year ago. Income from operations was $494.1 million compared with $358.7 million a year ago. Income before taxes was $506.7 million compared with $364.2 million a year ago. Net income was $398.8 million compared with $272.0 million a year ago. Diluted net income per share was $10.55 compared with $7.18 a year ago. Non-gaap revenue was $1,707.9 million compared with $1,530.9 million a year ago. Non-gaap income from operations was $653.1 million compared with $581.7 million a year ago. Non-gaap net income was $506.6 million compared with $423.4 million a year ago. Diluted non-gaap net income per share was $13.40 compared with $11.17 a year ago.
206
12/31/20158.13x23.79x26.69x45.98x38.87x$17,012$151.62294.60%Oct-14-2015Client AnnouncementIntuitive Surgical and Trumpf Medical Team Up to Address Hospitals' Need for Operating Room IntegrationTrumpf Medical Systems, Inc.Intuitive Surgical and Trumpf Medical are now offering Integrated Table Motion for the da Vinci Xi Surgical System in Europe. This product includes the latest Intuitive Surgical robotic-assisted surgical system and Trumpf Medical's advanced operating table, the TruSystem 7000dV. The surgical system and table have been seamlessly integrated to allow surgeons and anesthesiologists - for the first time - to make a comprehensive range of table adjustments easily and efficiently during da Vinci Surgery. The ability to reposition the operating table - in real time - with the surgical robotic arms docked addresses the need for operating room efficiency and maximizes access, exposure and reach during a robotic-assisted surgical procedure. This integrated functionality gives operating room (OR) staff the ability to: Optimally position the table so that gravity exposes anatomy during multi-quadrant da Vinci System procedures, such as colorectal surgery; Maximize reach and access to target anatomy - enabling surgeons to interact with tissue at an ideal working angle; Achieve precise positioning by leveraging the table's wide range of motion-trend, tilt, slide, height and flex; Use the intelligent remote control and platform to make table movements and synchronize the OR team through real-time audio and visual feedback; Reposition the table during the procedure to enhance anesthesiologists' care of the patient.
207
9/30/20156.85x20.60x23.11x40.05x31.66x$19,078$170.49250.92%Sep-18-2015Company Conference PresentationIntuitive Surgical, Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-18-2015 09:20 AM-Intuitive Surgical, Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-18-2015 09:20 AM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: Calvin Darling, Sr. Director, Investor Relations, Marshall L. Mohr, Chief Financial Officer and Senior Vice President.
208
9/30/20156.85x20.60x23.11x40.05x31.66x$19,191$171.50248.86%Sep-16-2015ConferenceMorgan Stanley, Morgan Stanley Global Healthcare Conference - New York, Sep 16, 2015 through Sep 18, 2015Global Blood Therapeutics, Inc. (NasdaqGS:GBT), Syneos Health, Inc. (NasdaqGS:SYNH), Mylan N.V. (NasdaqGS:MYL), ICU Medical, Inc. (NasdaqGS:ICUI), CONMED Corporation (NasdaqGS:CNMD), Hologic, Inc. (NasdaqGS:HOLX), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Amgen Inc. (NasdaqGS:AMGN), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Teligent, Inc. (NasdaqGS:TLGT), Masimo Corporation (NasdaqGS:MASI), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Innoviva, Inc. (NasdaqGS:INVA), Align Technology, Inc. (NasdaqGS:ALGN), Alkermes plc (NasdaqGS:ALKS), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Adaptimmune Therapeutics plc (NasdaqGS:ADAP), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), IVERIC bio, Inc. (NasdaqGS:ISEE), Zafgen, Inc. (NasdaqGS:ZFGN), China Biologic Products Holdings, Inc. (NasdaqGS:CBPO), Inovalon Holdings, Inc. (NasdaqGS:INOV), Epizyme, Inc. (NasdaqGS:EPZM), Clovis Oncology, Inc. (NasdaqGS:CLVS), Aravive, Inc. (NasdaqGS:ARAV), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Sinovac Biotech Ltd. (NasdaqGS:SVA), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), AngioDynamics, Inc. (NasdaqGS:ANGO), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Cardiovascular Systems, Inc. (NasdaqGS:CSII), HealthEquity, Inc. (NasdaqGS:HQY), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), Accuray Incorporated (NasdaqGS:ARAY), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Endologix, Inc. (NasdaqGS:ELGX), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Forward Pharma A/S (NasdaqCM:FWP), Community Health Systems, Inc. (NYSE:CYH), Laboratory Corporation of America Holdings (NYSE:LH), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Charles River Laboratories International, Inc. (NYSE:CRL), CVS Health Corporation (NYSE:CVS), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), AMN Healthcare Services, Inc. (NYSE:AMN), AmerisourceBergen Corporation (NYSE:ABC), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Baxter International Inc. (NYSE:BAX), Johnson & Johnson (NYSE:JNJ), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Tenet Healthcare Corporation (NYSE:THC), HCA Healthcare, Inc. (NYSE:HCA), Boston Scientific Corporation (NYSE:BSX), Perrigo Company plc (NYSE:PRGO), Teleflex Incorporated (NYSE:TFX), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), PerkinElmer, Inc. (NYSE:PKI), W.W. Grainger, Inc. (NYSE:GWW), Invacare Corporation (NYSE:IVC), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Fresenius SE & Co. KGaA (XTRA:FRE), Sartorius Aktiengesellschaft (XTRA:SRT), Evotec SE (XTRA:EVT), Hill-Rom Holdings, Inc. (NYSE:HRC), Owens & Minor, Inc. (NYSE:OMI), Morgan Stanley (NYSE:MS), Quest Diagnostics Incorporated (NYSE:DGX), ResMed Inc. (NYSE:RMD), Nevro Corp. (NYSE:NVRO), Avanos Medical, Inc. (NYSE:AVNS), Castlight Health, Inc. (NYSE:CSLT), Diplomat Pharmacy, Inc. (NYSE:DPLO), Catalent, Inc. (NYSE:CTLT), IQVIA Holdings Inc. (NYSE:IQV), AbbVie Inc. (NYSE:ABBV), Zoetis Inc. (NYSE:ZTS), Invitae Corporation (NYSE:NVTA), Cerus Corporation (NasdaqGM:CERS), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Ocular Therapeutix, Inc. (NasdaqGM:OCUL), Veracyte, Inc. (NasdaqGM:VCYT), Acceleron Pharma Inc. (NasdaqGM:XLRN), GW Pharmaceuticals plc (NasdaqGM:GWPH), NanoString Technologies, Inc. (NasdaqGM:NSTG), Chimerix, Inc. (NasdaqGM:CMRX), Phibro Animal Health Corporation (NasdaqGM:PAHC), AtriCure, Inc. (NasdaqGM:ATRC), Pfenex Inc. (AMEX:PFNX), T2 Biosystems, Inc. (NasdaqGM:TTOO), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), Basilea Pharmaceutica AG (SWX:BSLN), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), ScinoPharm Taiwan, Ltd. (TSEC:1789), Koninklijke Philips N.V. (ENXTAM:PHIA), Galapagos NV (ENXTAM:GLPG), DBV Technologies S.A. (ENXTPA:DBV), Genfit SA (ENXTPA:GNFT), Sartorius Stedim Biotech S.A. (ENXTPA:DIM), Cellectis S.A. (ENXTPA:ALCLS), Genmab A/S (CPSE:GMAB), Novo Nordisk A/S (CPSE:NOVO B), ALK-Abelló A/S (CPSE:ALK B), Array BioPharma Inc., Dyax Corp., Sequenom Inc., Connecture, Inc., NxStage Medical, Inc., Xenoport, Inc., C. R. Bard, Inc., St. Jude Medical, Inc., Celgene Corporation, Shire plc, Albany Molecular Research, Inc., Impax Laboratories, Inc., Keryx Biopharmaceuticals, Inc., Aetna Inc., Synergy Pharmaceuticals Inc., Alere Inc., Novadaq Technologies Inc., Anacor Pharmaceuticals, Inc., Elekta Inc., Medivation, Inc., Alder BioPharmaceuticals, Inc., Cempra, Inc., Relypsa, Inc., Pernix Therapeutics Holdings, Inc., Foundation Medicine, Inc., ZS Pharma, Inc., Juno Therapeutics, Inc., K2M Group Holdings, Inc., Baxalta Incorporated, Adeptus Health Inc., VWR Corporation, UCB SA (ENXTBR:UCB)Morgan Stanley, Morgan Stanley Global Healthcare Conference - New York, Sep 16, 2015 through Sep 18, 2015. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States.
209
9/30/20156.85x20.60x23.11x40.05x31.66x$19,763$176.61238.76%Aug-11-2015Company Conference PresentationIntuitive Surgical, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 08:35 AM-Intuitive Surgical, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 08:35 AM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States.
210
9/30/20156.85x20.60x23.11x40.05x31.66x$19,763$176.61238.76%Aug-11-2015ConferenceWedbush Securities Inc., Wedbush PacGrow Healthcare Conference 2015, Aug 11, 2015 through Aug 12, 2015Unum Therapeutics Inc. (NasdaqGS:UMRX), Kura Oncology, Inc. (NasdaqGS:KURA), Tetraphase Pharmaceuticals, Inc. (NasdaqGS:TTPH), Mersana Therapeutics, Inc. (NasdaqGS:MRSN), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), MacroGenics, Inc. (NasdaqGS:MGNX), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Novavax, Inc. (NasdaqGS:NVAX), United Therapeutics Corporation (NasdaqGS:UTHR), DexCom, Inc. (NasdaqGS:DXCM), Mirati Therapeutics, Inc. (NasdaqGS:MRTX), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), bluebird bio, Inc. (NasdaqGS:BLUE), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Twist Bioscience Corporation (NasdaqGS:TWST), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Trevena, Inc. (NasdaqGS:TRVN), Epizyme, Inc. (NasdaqGS:EPZM), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Arbutus Biopharma Corporation (NasdaqGS:ABUS), Blueprint Medicines Corporation (NasdaqGS:BPMC), G1 Therapeutics, Inc. (NasdaqGS:GTHX), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Prothena Corporation plc (NasdaqGS:PRTA), Adaptimmune Therapeutics plc (NasdaqGS:ADAP), argenx SE (ENXTBR:ARGX), Spectral Medical Inc. (TSX:EDT), Wedbush Securities Inc., Cepheid, Dyax Corp., VisionCare Ophthalmic Technologies, Inc., Health Net, Inc., Fibrocell Science, Inc., Vitae Pharmaceuticals, Inc., Dex Liquidating Co., Endocyte, Inc., Anacor Pharmaceuticals, Inc., ReVision Optics, Inc., Rapid Micro Biosystems, Inc., Flowonix Medical, Inc., Carbylan Therapeutics, Inc., Biodel Inc., Cempra, Inc., Cerulean Pharma Inc., Sagimet Biosciences, Entellus Medical, Inc., Relypsa, Inc., Sorrento Tech, Inc., EndoStim, Inc., Vascular Dynamics, Inc., CeQur SA, Foundation Medicine, Inc., Decipher Biosciences, Inc, OvaScience, Inc., Scholar Rock, Inc., Lazarus Effect, Inc., VolitionRx Limited (AMEX:VNRX), Cerus Corporation (NasdaqGM:CERS), Catabasis Pharmaceuticals, Inc. (NasdaqGM:CATB), Fate Therapeutics, Inc. (NasdaqGM:FATE), Intersect ENT, Inc. (NasdaqGM:XENT), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Ardelyx, Inc. (NasdaqGM:ARDX), Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM), Cidara Therapeutics, Inc. (NasdaqGM:CDTX), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Intellia Therapeutics, Inc. (NasdaqGM:NTLA), Omeros Corporation (NasdaqGM:OMER), Xencor, Inc. (NasdaqGM:XNCR), Applied Genetic Technologies Corporation (NasdaqGM:AGTC), XOMA Corporation (NasdaqGM:XOMA), Centene Corporation (NYSE:CNC), Achaogen, Inc. (OTCPK:AKAO.Q), EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q), Exact Sciences Corporation (NasdaqCM:EXAS), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), Tenax Therapeutics, Inc. (NasdaqCM:TENX), MEI Pharma, Inc. (NasdaqCM:MEIP), Bionano Genomics, Inc. (NasdaqCM:BNGO), Stemline Therapeutics, Inc. (NasdaqCM:STML), Regulus Therapeutics Inc. (NasdaqCM:RGLS), Miragen Therapeutics, Inc. (NasdaqCM:MGEN), AxoGen, Inc. (NasdaqCM:AXGN)Wedbush Securities Inc., Wedbush PacGrow Healthcare Conference 2015, Aug 11, 2015 through Aug 12, 2015. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States.
211
9/30/20156.85x20.60x23.11x40.05x31.66x$20,296$181.38229.85%Jul-27-2015Executive/Board Change - OtherIntuitive Surgical, Inc. Appoints Michael A. Friedman to Board of Directors and Governance and Nominating Committee of the Board-On July 23, 2015, Michael A. Friedman, M.D. was appointed to the Board of Directors of Intuitive Surgical, Inc., effective immediately. Concurrent with his appointment as a director, Dr. Friedman was also appointed to the Governance and Nominating Committee of the Board. Dr. Friedman is an Emeritus Cancer Center Director of City of Hope. Dr. Friedman was the President and Chief Executive Officer of City of Hope from May 2003 to December 2013 and holder of the Irell & Manella Cancer Center Director's Chair. Before leading City of Hope, from September 2001 until April 2003, Dr. Friedman held the position of Senior Vice President of Research and Development, Medical and Public Policy, for Pharmacia Corporation and, from July 1999 until September 2001, was a Senior Vice President of Searle.
212
9/30/20156.85x20.60x23.11x40.05x31.66x$20,510$183.29226.42%Jul-22-2015Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From April 1, 2015 to June 30, 2015, the company has repurchased 299,223 shares, representing 0.27% for $49.31 million. With this, the company has completed the repurchase of 388,395 shares, representing 0.35% for $64.04 million under the buyback announced on February 2, 2015.
213
9/30/20156.85x20.60x23.11x40.05x31.66x$18,839$168.36255.36%Jul-21-2015Earnings CallIntuitive Surgical, Inc., Q2 2015 Earnings Call, Jul 21, 2015-Intuitive Surgical, Inc., Q2 2015 Earnings Call, Jul 21, 2015
214
9/30/20156.85x20.60x23.11x40.05x31.66x$18,839$168.36255.36%Jul-21-2015Corporate Guidance - New/Confirmed, Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015; Provides Pro Outlook for the Second Half of 2015-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $586.1 million, income from operations of $173.8 million, income before taxes of $178.4 million, net income of $134.5 million or $3.56 per diluted share, non-GAAP revenue of $586.1 million, non-GAAP income from operations of $227.8 million, non-GAAP net income of $172.8 million or $4.57 per diluted share compared to the total revenue of $512.2 million, income from operations of $143 million, income before taxes of $142.6 million, net income of $104 million or $2.77 per diluted share, non-GAAP revenue of $506.5 million, non-GAAP income from operations of $195.8 million, non-GAAP net income of $140.2 million or $3.73 per diluted share for the same quarter a year ago.

For the six months period, the company reported total revenue of $1,118.2 million, income from operations of $304.2 million, income before taxes of $313.1 million, net income of $231.5 million or $6.14 per diluted share, non-GAAP revenue of $1,118.2 million, non-GAAP income from operations of $412.8 million, non-GAAP net income of $307.4 million or $8.15 per diluted share compared to the total revenue of $976.9 million, income from operations of $199.6 million, income before taxes of $203.1 million, net income of $148.3 million or $3.87 per diluted share, non-GAAP revenue of $996.8 million, non-GAAP income from operations of $384.8 million, non-GAAP net income of $278.7 million or $7.28 per diluted share for the same period a year ago.


The company expects its second half 2015 pro forma gross profit margin to be within a range of 67% to 68% of revenue. With regard to income tax, for the remainder of the year, the company continues to expect 2015 pro forma income tax rate to be between 28% and 30% of pretax income, depending primarily on the mix of U.S. and international profits. This forecast does not assume the reinstatement of the R&D tax credit in 2015.
215
9/30/20156.85x20.60x23.11x40.05x31.66x$18,349$163.98264.86%Jul-14-2015Product-Related AnnouncementIntuitive Surgical Brings Stapler Instrumentation to da Vinci Robotic-Assisted Surgical Systems in the U.S., Europe & Asia-Intuitive Surgical, Inc. announced new clearances in Europe and Asia and provided an update on the status of its EndoWrist Staplers in the United States. The da Vinci Si and Xi Surgical System staplers are the only devices of their type that provide fully wristed articulation and SmartClamp technology that detects when instrument jaws are adequately closed on target tissue. The design enables control of stapling from the surgeon console, creating a more direct relationship between clinical decision-making and instrument action. Intuitive Surgical has received clearance for stapler use on the da VinciSi and Xi Surgical Systems by various regulatory bodies in the United States, Europe and Asia.
216
6/30/20157.55x22.96x25.74x44.28x36.70x$18,656$168.07255.98%Jun-10-2015Company Conference PresentationIntuitive Surgical, Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 11:20 AM-Intuitive Surgical, Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 11:20 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Patrick Clingan, Director of Finance.
217
6/30/20157.55x22.96x25.74x44.28x36.70x$18,397$165.74260.98%Jun-09-2015ConferenceThe Goldman Sachs Group, Inc., Goldman Sachs 36th Annual Global Healthcare Conference, Jun 09, 2015 through Jun 11, 2015Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), IVERIC bio, Inc. (NasdaqGS:ISEE), Accuray Incorporated (NasdaqGS:ARAY), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Syneos Health, Inc. (NasdaqGS:SYNH), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Blueprint Medicines Corporation (NasdaqGS:BPMC), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), FibroGen, Inc. (NasdaqGS:FGEN), Gilead Sciences, Inc. (NasdaqGS:GILD), Illumina, Inc. (NasdaqGS:ILMN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Alkermes plc (NasdaqGS:ALKS), Amgen Inc. (NasdaqGS:AMGN), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Masimo Corporation (NasdaqGS:MASI), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), NuVasive, Inc. (NasdaqGS:NUVA), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Hologic, Inc. (NasdaqGS:HOLX), Quidel Corporation (NasdaqGS:QDEL), Mylan N.V. (NasdaqGS:MYL), Magellan Health, Inc. (NasdaqGS:MGLN), Henry Schein, Inc. (NasdaqGS:HSIC), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Exact Sciences Corporation (NasdaqCM:EXAS), Bayer Aktiengesellschaft (XTRA:BAYN), MorphoSys AG (XTRA:MOR), Hill-Rom Holdings, Inc. (NYSE:HRC), Brookdale Senior Living Inc. (NYSE:BKD), Globus Medical, Inc. (NYSE:GMED), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Johnson & Johnson (NYSE:JNJ), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Baxter International Inc. (NYSE:BAX), Universal Health Services, Inc. (NYSE:UHS), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), The Goldman Sachs Group, Inc. (NYSE:GS), Edwards Lifesciences Corporation (NYSE:EW), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Quest Diagnostics Incorporated (NYSE:DGX), Boston Scientific Corporation (NYSE:BSX), HCA Healthcare, Inc. (NYSE:HCA), PerkinElmer, Inc. (NYSE:PKI), QIAGEN N.V. (NYSE:QGEN), Laboratory Corporation of America Holdings (NYSE:LH), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Haemonetics Corporation (NYSE:HAE), Thermo Fisher Scientific Inc. (NYSE:TMO), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Medtronic plc (NYSE:MDT), Community Health Systems, Inc. (NYSE:CYH), AmerisourceBergen Corporation (NYSE:ABC), AbbVie Inc. (NYSE:ABBV), Mallinckrodt plc (NYSE:MNK), Castlight Health, Inc. (NYSE:CSLT), Catalent, Inc. (NYSE:CTLT), MannKind Corporation (NasdaqGM:MNKD), Radius Health, Inc. (NasdaqGM:RDUS), T2 Biosystems, Inc. (NasdaqGM:TTOO), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Holland Colours NV (ENXTAM:HOLCO), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), GlaxoSmithKline plc (LSE:GSK), Genmab A/S (CPSE:GMAB), ALK-Abelló A/S (CPSE:ALK B), DBV Technologies S.A. (ENXTPA:DBV), Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC), ARIAD Pharmaceuticals, Inc., Cepheid, Team Health Holdings, Inc., PAREXEL International Corporation, Universal American Corp., Celgene Corporation, Thoratec LLC, Health Net, Inc., FEI Company, Envision Healthcare Corporation, Legacy LifePoint Health, Inc., Impax Laboratories, Inc., Aetna Inc., Alere Inc., Anacor Pharmaceuticals, Inc., Heartware International Inc., ZELTIQ Aesthetics, Inc., Juno Therapeutics, Inc., Baxalta Incorporated, Adeptus Health Inc., VWR CorporationThe Goldman Sachs Group, Inc., Goldman Sachs 36th Annual Global Healthcare Conference, Jun 09, 2015 through Jun 11, 2015. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
218
6/30/20157.55x22.96x25.74x44.28x36.70x$18,151$163.52265.88%Jun-08-2015Executive/Board Change - OtherIntuitive Surgical, Inc. Announces Executive Appointments-On June 5, 2015, Intuitive Surgical, Inc. appointed David J. Rosa as executive vice president and chief commercial officer, effective June 8, 2015. In addition, the company also appointed Salvatore J. Brogna as executive vice president, product operations, effective June 8, 2015. Mr. Rosa, joined company in March 1996 and has held leadership positions in marketing, clinical development, and product development. Mr. Brogna, age 60, joined company as Director, Mechanical Engineering, in October 1999 and was promoted to Vice President, Engineering in July 2005.
219
6/30/20157.55x22.96x25.74x44.28x36.70x$18,587$167.45257.29%May-14-2015Company Conference PresentationIntuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:00 AM-Intuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:00 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Calvin Darling, IR, Marshall L. Mohr, Chief Financial Officer and Senior Vice President.
220
6/30/20157.55x22.96x25.74x44.28x36.70x$18,309$164.95262.71%May-12-2015ConferenceBank of America Corporation, Bank of America Merrill Lynch 2015 Health Care Conference, May 12, 2015 through May 14, 2015Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Aduro BioTech, Inc. (NasdaqGS:ADRO), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Premier, Inc. (NasdaqGS:PINC), Accuray Incorporated (NasdaqGS:ARAY), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Endologix, Inc. (NasdaqGS:ELGX), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Incyte Corporation (NasdaqGS:INCY), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), MacroGenics, Inc. (NasdaqGS:MGNX), Bruker Corporation (NasdaqGS:BRKR), DexCom, Inc. (NasdaqGS:DXCM), Quidel Corporation (NasdaqGS:QDEL), Hologic, Inc. (NasdaqGS:HOLX), Geron Corporation (NasdaqGS:GERN), CONMED Corporation (NasdaqGS:CNMD), Mylan N.V. (NasdaqGS:MYL), Healthcare Services Group, Inc. (NasdaqGS:HCSG), IVERIC bio, Inc. (NasdaqGS:ISEE), Intrexon Corporation (NasdaqGS:XON), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), AngioDynamics, Inc. (NasdaqGS:ANGO), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Calithera Biosciences, Inc. (NasdaqGS:CALA), Ascendis Pharma A/S (NasdaqGS:ASND), Adaptive Biotechnologies Corporation (NasdaqGS:ADPT), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Aravive, Inc. (NasdaqGS:ARAV), Otonomy, Inc. (NasdaqGS:OTIC), Prothena Corporation plc (NasdaqGS:PRTA), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Jounce Therapeutics, Inc. (NasdaqGS:JNCE), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Stericycle, Inc. (NasdaqGS:SRCL), Teligent, Inc. (NasdaqGS:TLGT), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Innoviva, Inc. (NasdaqGS:INVA), Syneos Health, Inc. (NasdaqGS:SYNH), Abaxis, Inc., Array BioPharma Inc., Cepheid, Dyax Corp., IPC Healthcare, Inc., Team Health Holdings, Inc., The Spectranetics Corporation, The Medicines Company, Universal American Corp., Vascular Solutions, Inc., VCA Inc., Celgene Corporation, C. R. Bard, Inc., Omnicare Inc., St. Jude Medical, Inc., Thoratec LLC, Kindred Healthcare, LLC, Health Net, Inc., Almost Family, Inc., Affymetrix Inc., FEI Company, Albany Molecular Research, Inc., Impax Laboratories, Inc., Keryx Biopharmaceuticals, Inc., Aetna Inc., The Advisory Board Company, Novadaq Technologies Inc., Genomic Health, Inc., Orexigen Therapeutics, Inc., Anacor Pharmaceuticals, Inc., Heartware International Inc., Tokai Pharmaceuticals, Inc., FUJIFILM Cellular Dynamics, Inc., Kythera Biopharmaceuticals, Inc., Aegerion Pharmaceuticals, Inc., iKang Healthcare Group, Inc., Horizon Pharmaceutical LLC, Tobira Therapeutics, Inc., PharMerica Corporation, Civitas Solutions, Inc., Entellus Medical, Inc., Immune Design Corp., Sorrento Tech, Inc., Receptos, Inc., Relypsa, Inc., Foundation Medicine, Inc., ZS Pharma, Inc., SCAI Holdings, LLC, Aratana Therapeutics, Inc., Kite Pharma, Inc., Envision Healthcare Holdings, Inc., Juno Therapeutics, Inc., Arog Pharmaceuticals, Inc., Nexvet Biopharma Public Limited Company, Cellectis S.A. (ENXTPA:ALCLS), DBV Technologies S.A. (ENXTPA:DBV), Roche Holding AG (SWX:ROG), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Rockwell Medical, Inc. (NasdaqGM:RMTI), Phibro Animal Health Corporation (NasdaqGM:PAHC), Acceleron Pharma Inc. (NasdaqGM:XLRN), NewLink Genetics Corporation (NasdaqGM:NLNK), MannKind Corporation (NasdaqGM:MNKD), Radius Health, Inc. (NasdaqGM:RDUS), T2 Biosystems, Inc. (NasdaqGM:TTOO), AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX), Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA), GW Pharmaceuticals plc (NasdaqGM:GWPH), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Bank of America Corporation (NYSE:BAC), Hill-Rom Holdings, Inc. (NYSE:HRC), Community Health Systems, Inc. (NYSE:CYH), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), AmerisourceBergen Corporation (NYSE:ABC), AMN Healthcare Services, Inc. (NYSE:AMN), Mettler-Toledo International Inc. (NYSE:MTD), Humana Inc. (NYSE:HUM), Laboratory Corporation of America Holdings (NYSE:LH), CVS Health Corporation (NYSE:CVS), Waters Corporation (NYSE:WAT), Universal Health Services, Inc. (NYSE:UHS), Capital Senior Living Corporation (NYSE:CSU), Teva Pharmaceutical Industries Limited (NYSE:TEVA), West Pharmaceutical Services, Inc. (NYSE:WST), Boston Scientific Corporation (NYSE:BSX), National Health Investors, Inc. (NYSE:NHI), U.S. Physical Therapy, Inc. (NYSE:USPH), Service Corporation International (NYSE:SCI), Owens & Minor, Inc. (NYSE:OMI), Cantel Medical Corp. (NYSE:CMD), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), PerkinElmer, Inc. (NYSE:PKI), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Chemed Corporation (NYSE:CHE), HCA Healthcare, Inc. (NYSE:HCA), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), MEDNAX, Inc. (NYSE:MD), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), Catalent, Inc. (NYSE:CTLT), MorphoSys AG (XTRA:MOR), Achaogen, Inc. (OTCPK:AKAO.Q), EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q), Zoetis Inc. (NYSE:ZTS), Mallinckrodt plc (NYSE:MNK), IQVIA Holdings Inc. (NYSE:IQV), AbbVie Inc. (NYSE:ABBV), Brookdale Senior Living Inc. (NYSE:BKD), Emergent BioSolutions Inc. (NYSE:EBS), Genesis Healthcare, Inc. (NYSE:GEN), Forward Pharma A/S (NasdaqCM:FWP), Heron Therapeutics, Inc. (NasdaqCM:HRTX), Antares Pharma, Inc. (NasdaqCM:ATRS), MEI Pharma, Inc. (NasdaqCM:MEIP), Exact Sciences Corporation (NasdaqCM:EXAS)Bank of America Corporation, Bank of America Merrill Lynch 2015 Health Care Conference, May 12, 2015 through May 14, 2015. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States.
221
6/30/20157.55x22.96x25.74x44.28x36.70x$18,425$165.99260.44%May-01-2015Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $843.17 million.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $843.17 million.
222
6/30/20157.55x22.96x25.74x44.28x36.70x$18,972$170.92250.04%Apr-23-2015Annual General MeetingIntuitive Surgical, Inc., Annual General Meeting, Apr 23, 2015-Intuitive Surgical, Inc., Annual General Meeting, Apr 23, 2015., at 15:00 Pacific Daylight. Location: 1020 Kifer Road. Agenda: To elect eight members to the board of directors to serve until the 2016 annual meeting of stockholders; to consider an advisory vote on the approval of the compensation of named executive officers; to ratify the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2015; to approve the amendment and restatement of the 2010 incentive award plan; and to transact any other business which is properly brought before the annual meeting or adjournments or postponements thereof.
223
6/30/20157.55x22.96x25.74x44.28x36.70x$19,126$172.31247.22%Apr-22-2015Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From January 29, 2015 to March 31, 2015, the company has repurchased 89,172 shares, representing 0.08% for $14.73 million. With this, the company has completed the repurchase of 89,172 shares, representing 0.08% for $14.73 million under the buyback announced on February 2, 2015.
224
6/30/20157.55x22.96x25.74x44.28x36.70x$20,229$182.24228.30%Apr-21-2015Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015-Intuitive Surgical, Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $532.1 million against $464.7 million a year ago. Income from operations was $130.4 million against $56.6 million a year ago. Net income was $97.0 million or $2.57 per diluted share against $44.3 million or $1.13 per diluted share a year ago. Non-GAAP revenue was $532.1 million against $490.3 million a year ago. Non-GAAP income from operations was $185.0 million against $189.0 million a year ago. Non-GAAP net income was 134.6 million or $3.57 per diluted share against $138.5 million or $3.54 per diluted share a year ago.
225
6/30/20157.55x22.96x25.74x44.28x36.70x$20,229$182.24228.30%Apr-21-2015Earnings CallIntuitive Surgical, Inc., Q1 2015 Earnings Call, Apr 21, 2015-Intuitive Surgical, Inc., Q1 2015 Earnings Call, Apr 21, 2015
226
3/31/20158.21x24.76x27.70x47.61x30.77x$18,734$169.69252.58%Mar-03-2015Company Conference PresentationIntuitive Surgical, Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-03-2015 09:50 AM-Intuitive Surgical, Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-03-2015 09:50 AM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, Florida, United States.
227
3/31/20158.21x24.76x27.70x47.61x30.77x$0Mar-01-2015ConferenceRaymond James & Associates, Inc., Raymond James & Associates 36th Annual Institutional Investors Conference, Mar 01, 2015 through Mar 05, 2015Intuit Inc. (NasdaqGS:INTU), ArcBest Corporation (NasdaqGS:ARCB), Dollar Tree, Inc. (NasdaqGS:DLTR), E*TRADE Financial Corporation (NasdaqGS:ETFC), Principal Financial Group, Inc. (NasdaqGS:PFG), Avnet, Inc. (NasdaqGS:AVT), DexCom, Inc. (NasdaqGS:DXCM), Red Robin Gourmet Burgers, Inc. (NasdaqGS:RRGB), Texas Capital Bancshares, Inc. (NasdaqGS:TCBI), ACI Worldwide, Inc. (NasdaqGS:ACIW), SBA Communications Corporation (NasdaqGS:SBAC), Stericycle, Inc. (NasdaqGS:SRCL), MarketAxess Holdings Inc. (NasdaqGS:MKTX), Wintrust Financial Corporation (NasdaqGS:WTFC), Cogent Communications Holdings, Inc. (NasdaqGS:CCOI), Paylocity Holding Corporation (NasdaqGS:PCTY), Carrols Restaurant Group, Inc. (NasdaqGS:TAST), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Home Bancshares, Inc. (Conway, AR) (NasdaqGS:HOMB), HealthEquity, Inc. (NasdaqGS:HQY), LKQ Corporation (NasdaqGS:LKQ), PRA Group, Inc. (NasdaqGS:PRAA), Beacon Roofing Supply, Inc. (NasdaqGS:BECN), CME Group Inc. (NasdaqGS:CME), Saia, Inc. (NasdaqGS:SAIA), ORBCOMM Inc. (NasdaqGS:ORBC), Skyworks Solutions, Inc. (NasdaqGS:SWKS), Premier, Inc. (NasdaqGS:PINC), Synchronoss Technologies, Inc. (NasdaqGS:SNCR), Nasdaq, Inc. (NasdaqGS:NDAQ), Bottomline Technologies (de), Inc. (NasdaqGS:EPAY), Encore Capital Group, Inc. (NasdaqGS:ECPG), Pinnacle Financial Partners, Inc. (NasdaqGS:PNFP), OraSure Technologies, Inc. (NasdaqGS:OSUR), iRobot Corporation (NasdaqGS:IRBT), Insulet Corporation (NasdaqGS:PODD), ATN International, Inc. (NasdaqGS:ATNI), ScanSource, Inc. (NasdaqGS:SCSC), KVH Industries, Inc. (NasdaqGS:KVHI), TD Ameritrade Holding Corporation (NasdaqGS:AMTD), Viasat, Inc. (NasdaqGS:VSAT), Atlantic Union Bankshares Corporation (NasdaqGS:AUB), Bank OZK (NasdaqGS:OZK), Newell Brands Inc. (NasdaqGS:NWL), Dawson Geophysical Company (NasdaqGS:DWSN), PotlatchDeltic Corporation (NasdaqGS:PCH), J.B. Hunt Transport Services, Inc. (NasdaqGS:JBHT), Cerner Corporation (NasdaqGS:CERN), Werner Enterprises, Inc. (NasdaqGS:WERN), Tech Data Corporation (NasdaqGS:TECD), ICU Medical, Inc. (NasdaqGS:ICUI), United Bankshares, Inc. (NasdaqGS:UBSI), Insight Enterprises, Inc. (NasdaqGS:NSIT), Patterson-UTI Energy, Inc. (NasdaqGS:PTEN), Herman Miller, Inc. (NasdaqGS:MLHR), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Equinix, Inc. (REIT) (NasdaqGS:EQIX), Check Point Software Technologies Ltd. (NasdaqGS:CHKP), Marriott International, Inc. (NasdaqGS:MAR), Masimo Corporation (NasdaqGS:MASI), Natus Medical Incorporated (NasdaqGS:NTUS), Rent-A-Center, Inc. (NasdaqGS:RCII), HD Supply Holdings, Inc. (NasdaqGS:HDS), Fiesta Restaurant Group, Inc. (NasdaqGS:FRGI), Chuy's Holdings, Inc. (NasdaqGS:CHUY), Dave & Buster's Entertainment, Inc. (NasdaqGS:PLAY), Cboe Global Markets, Inc. (BATS:CBOE), Cameron International Corporation, Abaxis, Inc., Airgas, Inc., Cepheid, DigitalGlobe, Inc., Regal Entertainment Group, Constant Contact, Inc., ARRIS International Limited, Connecture, Inc., VCA Inc., C. R. Bard, Inc., XPO CNW, Inc., Thoratec LLC, HCC Insurance Holdings Inc., Starwood Hotels & Resorts Worldwide, LLC, Genesee & Wyoming Inc., Agrium Inc., Envision Healthcare Corporation, Cardinal Financial Corporation, Interactive Intelligence Group, Inc., WTW Delaware Holdings LLC, Aetna Inc., Amber Road, Inc., Raymond James & Associates, Inc., Worldpay, Inc., The Advisory Board Company, TIAA FSB Holdings, Inc., Tangoe, Inc., EnLink Midstream Partners, LP, Progressive Waste Solutions Ltd., Pandora Media, LLC, Enel X North America, Inc., Control4 Corporation, Virgin America Inc., Demandware, LLC, Heartware International Inc., HomeAway, Inc., Energy XXI Ltd, Blackhawk Network Holdings, Inc., Del Frisco's Restaurant Group, Inc., Civitas Solutions, Inc., Gigamon Inc., CST Brands, Inc., Celestica Inc. (TSX:CLS), MiX Telematics Limited (JSE:MIX), TransEnterix, Inc. (AMEX:TRXC), Goodrich Petroleum Corporation (AMEX:GDP), FedNat Holding Company (NasdaqGM:FNHC), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), CareDx, Inc (NasdaqGM:CDNA), Health Insurance Innovations, Inc. (NasdaqGM:HIIQ), Benefitfocus, Inc. (NasdaqGM:BNFT), Applied Optoelectronics, Inc. (NasdaqGM:AAOI), Malibu Boats, Inc. (NasdaqGM:MBUU), Upland Software, Inc. (NasdaqGM:UPLD), Lincoln National Corporation (NYSE:LNC), Main Street Capital Corporation (NYSE:MAIN), Broadridge Financial Solutions, Inc. (NYSE:BR), RingCentral, Inc. (NYSE:RNG), Continental Resources, Inc. (NYSE:CLR), Tempur Sealy International, Inc. (NYSE:TPX), American Equity Investment Life Holding Company (NYSE:AEL), Lumber Liquidators Holdings, Inc. (NYSE:LL), Axos Financial, Inc. (NYSE:AX), Digital Realty Trust, Inc. (NYSE:DLR), StoneMor Inc. (NYSE:STON), EnLink Midstream, LLC (NYSE:ENLC), California Resources Corporation (NYSE:CRC), Castlight Health, Inc. (NYSE:CSLT), Pebblebrook Hotel Trust (NYSE:PEB), Intelsat S.A. (NYSE:I), Marathon Petroleum Corporation (NYSE:MPC), Manning & Napier, Inc. (NYSE:MN), Kinder Morgan, Inc. (NYSE:KMI), Q2 Holdings, Inc. (NYSE:QTWO), MRC Global Inc. (NYSE:MRC), Compass Diversified Holdings LLC (NYSE:CODI), Delek US Holdings, Inc. (NYSE:DK), HubSpot, Inc. (NYSE:HUBS), Chegg, Inc. (NYSE:CHGG), Cinemark Holdings, Inc. (NYSE:CNK), Superior Energy Services, Inc. (NYSE:SPN), Helix Energy Solutions Group, Inc. (NYSE:HLX), Range Resources Corporation (NYSE:RRC), CACI International Inc (NYSE:CACI), Oil States International, Inc. (NYSE:OIS), Haemonetics Corporation (NYSE:HAE), Jabil Inc. (NYSE:JBL), Weyerhaeuser Company (NYSE:WY), MSC Industrial Direct Co., Inc. (NYSE:MSM), Ryder System, Inc. (NYSE:R), STERIS plc (NYSE:STE), MEDNAX, Inc. (NYSE:MD), MAXIMUS, Inc. (NYSE:MMS), Agnico Eagle Mines Limited (NYSE:AEM), Aflac Incorporated (NYSE:AFL), Arrow Electronics, Inc. (NYSE:ARW), Booz Allen Hamilton Holding Corporation (NYSE:BAH), Brunswick Corporation (NYSE:BC), GATX Corporation (NYSE:GATX), Masco Corporation (NYSE:MAS), Telephone and Data Systems, Inc. (NYSE:TDS), Waste Management, Inc. (NYSE:WM), Unit Corporation (NYSE:UNT), Callaway Golf Company (NYSE:ELY), S&P Global Inc. (NYSE:SPGI), Raymond James Financial, Inc. (NYSE:RJF), Clean Harbors, Inc. (NYSE:CLH), Concho Resources Inc. (NYSE:CXO), Crown Castle International Corp. (REIT) (NYSE:CCI), Alliance Data Systems Corporation (NYSE:ADS), AmerisourceBergen Corporation (NYSE:ABC), The Allstate Corporation (NYSE:ALL), Dine Brands Global, Inc. (NYSE:DIN), Kansas City Southern (NYSE:KSU), Leggett & Platt, Incorporated (NYSE:LEG), Ethan Allen Interiors Inc. (NYSE:ETH), Encompass Health Corporation (NYSE:EHC), Grubhub Inc. (NYSE:GRUB), ProAssurance Corporation (NYSE:PRA), Moody's Corporation (NYSE:MCO), Linde plc (NYSE:LIN), Covanta Holding Corporation (NYSE:CVA), Enterprise Products Partners L.P. (NYSE:EPD), Citigroup Inc. (NYSE:C), Steelcase Inc. (NYSE:SCS), Waste Connections, Inc. (NYSE:WCN), Republic Services, Inc. (NYSE:RSG), Rayonier Inc. (NYSE:RYN), Knight-Swift Transportation Holdings Inc. (NYSE:KNX), New York Community Bancorp, Inc. (NYSE:NYCB), Toll Brothers, Inc. (NYSE:TOL), Whirlpool Corporation (NYSE:WHR), Service Corporation International (NYSE:SCI), Stanley Black & Decker, Inc. (NYSE:SWK), Charles River Laboratories International, Inc. (NYSE:CRL), Teleflex Incorporated (NYSE:TFX), Union Pacific Corporation (NYSE:UNP), Unisys Corporation (NYSE:UIS), United States Cellular Corporation (NYSE:USM), The Home Depot, Inc. (NYSE:HD), Pier 1 Imports, Inc. (NYSE:PIR), Brown & Brown, Inc. (NYSE:BRO), Polaris Inc. (NYSE:PII), Brinker International, Inc. (NYSE:EAT), HCA Healthcare, Inc. (NYSE:HCA), Coeur Mining, Inc. (NYSE:CDE), Delta Air Lines, Inc. (NYSE:DAL), Devon Energy Corporation (NYSE:DVN), Dycom Industries, Inc. (NYSE:DY), W.W. Grainger, Inc. (NYSE:GWW), HNI Corporation (NYSE:HNI), Parsley Energy, Inc. (NYSE:PE), AAC Holdings, Inc. (OTCPK:AACH), Harvest Oil & Gas Corp. (OTCPK:HRST), Key Energy Services, Inc. (OTCPK:KEG.X), Basic Energy Services, Inc. (OTCPK:BASX), Oasis Petroleum Inc. (NasdaqCM:OAS)Raymond James & Associates, Inc., Raymond James & Associates 36th Annual Institutional Investors Conference, Mar 01, 2015 through Mar 05, 2015. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, Florida, United States.
228
3/31/20158.21x24.76x27.70x47.61x30.77x$18,852$170.76250.37%Feb-06-2015Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on March 5, 2009.-From October 1, 2014 to December 31, 2014, the company has repurchased 188,168 shares, representing 0.52% for $94.38 million. With this, the company has completed the repurchase of 8,873,031 shares, representing 22.76% for $3,027.8 million under the buyback announced on March 5, 2009.
229
3/31/20158.21x24.76x27.70x47.61x30.77x$18,662$169.04253.93%Feb-02-2015Buyback Transaction AnnouncementsIntuitive Surgical, Inc. (NasdaqGS:ISRG) announces an Equity Buyback for $1,000 million worth of its shares.-Intuitive Surgical, Inc. (NasdaqGS:IRSG) announces a share repurchase program. Under the program, the company will repurchase up to $1,000 million worth of its outstanding common stock. The timing and total amount of stock repurchases will depend upon market conditions and may be made from time to time in open market purchases, privately negotiated transactions, accelerated share repurchase programs, issuer self-tender offers or otherwise, as determined by the company’s management. The company expects to fund the repurchase program through cash and investments. The repurchases will be made in compliance with, and at such times as permitted by, federal securities law and may be suspended or discontinued at any time. The repurchase program does not obligate the company to acquire any particular amount of common stock. The program does not have an expiration date.
230
3/31/20158.21x24.76x27.70x47.61x30.77x$18,584$168.33255.43%Jan-29-2015Buyback Transaction AnnouncementsIntuitive Surgical, Inc. authorizes a Buyback Plan.-The Board of Directors of Intuitive Surgical, Inc. has authorized a buyback plan on January 29, 2015.
231
3/31/20158.21x24.76x27.70x47.61x30.77x$19,334$175.13241.63%Jan-22-2015Earnings CallIntuitive Surgical, Inc., Q4 2014 Earnings Call, Jan 22, 2015-Intuitive Surgical, Inc., Q4 2014 Earnings Call, Jan 22, 2015
232
3/31/20158.21x24.76x27.70x47.61x30.77x$19,334$175.13241.63%Jan-22-2015Announcement of Earnings, Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year of 2015-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of USD 604.7 million against USD 576.2 million a year ago. Income from operations was USD 186.1 million against USD 208.6 million a year ago. Income before taxes was USD 184.8 million against USD 214.5 million a year ago. Net income was USD 146.8 million or USD 3.94 per diluted share against USD 166.2 million or USD 4.28 per diluted share a year ago. Non-GAAP revenue was USD 600.8 million against USD 576.2 million a year ago. Non-GAAP income from operations was USD 237 million against USD 254.9 million a year ago. Non-GAAP income per diluted share was USD 4.92 against USD 4.98 a year ago. Non-GAAP net income was USD 183.5 million against USD 193.4 million a year ago. The company generated an operating profit of USD 237 million in the quarter before noncash stock compensation expense, down 8% from the fourth quarter of last year.

For the year, the company reported total revenue of USD 2,131.7 million against USD 2,265.1 million a year ago. Income from operations was USD 544.8 million against USD 852.5 million a year ago. Income before taxes was USD 549.0 against USD 870.9 million a year ago. Net income was USD 418.8 million or USD 11.11 per diluted share against USD 671 million or USD 16.73 per diluted share a year ago. Non-GAAP income from operations was USD 818.7 million against USD 1,042.7 million a year ago. Non-GAAP income per diluted share was USD 16.10 against USD 19.83 a year ago. Non-GAAP net income was USD 606.9 million against USD 795 million a year ago. The company generated USD 819 million in operating profit before noncash stock option expense, down 21% from last year.

The company expects pro forma effective rate for 2015 will reflect a more normal range of 28% to 30%. The tax rate will fluctuate with changes in mix of U.S. and OUS income, and will not reflect a federal research and development credit, unless such credit is reinstated. The company expects 2015 pro forma gross profit margin to be fairly consistent with fourth quarter of 2014. The company expects to grow pro forma 2015 operating expenses between 7% and 10% above 2014 levels.
233
3/31/20158.21x24.76x27.70x47.61x30.77x$19,334$175.13241.63%Jan-22-2015Corporate Guidance - New/Confirmed, Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year of 2015-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of USD 604.7 million against USD 576.2 million a year ago. Income from operations was USD 186.1 million against USD 208.6 million a year ago. Income before taxes was USD 184.8 million against USD 214.5 million a year ago. Net income was USD 146.8 million or USD 3.94 per diluted share against USD 166.2 million or USD 4.28 per diluted share a year ago. Non-GAAP revenue was USD 600.8 million against USD 576.2 million a year ago. Non-GAAP income from operations was USD 237 million against USD 254.9 million a year ago. Non-GAAP income per diluted share was USD 4.92 against USD 4.98 a year ago. Non-GAAP net income was USD 183.5 million against USD 193.4 million a year ago. The company generated an operating profit of USD 237 million in the quarter before noncash stock compensation expense, down 8% from the fourth quarter of last year.

For the year, the company reported total revenue of USD 2,131.7 million against USD 2,265.1 million a year ago. Income from operations was USD 544.8 million against USD 852.5 million a year ago. Income before taxes was USD 549.0 against USD 870.9 million a year ago. Net income was USD 418.8 million or USD 11.11 per diluted share against USD 671 million or USD 16.73 per diluted share a year ago. Non-GAAP income from operations was USD 818.7 million against USD 1,042.7 million a year ago. Non-GAAP income per diluted share was USD 16.10 against USD 19.83 a year ago. Non-GAAP net income was USD 606.9 million against USD 795 million a year ago. The company generated USD 819 million in operating profit before noncash stock option expense, down 21% from last year.

The company expects pro forma effective rate for 2015 will reflect a more normal range of 28% to 30%. The tax rate will fluctuate with changes in mix of U.S. and OUS income, and will not reflect a federal research and development credit, unless such credit is reinstated. The company expects 2015 pro forma gross profit margin to be fairly consistent with fourth quarter of 2014. The company expects to grow pro forma 2015 operating expenses between 7% and 10% above 2014 levels.
234
3/31/20158.21x24.76x27.70x47.61x30.77x$19,197$173.89244.06%Jan-13-2015Company Conference PresentationIntuitive Surgical, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 03:30 PM-Intuitive Surgical, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 03:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Gary S. Guthart, Chief Executive Officer, President and Director.
235
3/31/20158.21x24.76x27.70x47.61x30.77x$19,197$173.89244.06%Jan-13-2015Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2014-Intuitive Surgical, Inc. provided revenue guidance for the fourth quarter and full year ended December 31, 2014. The company expects GAAP revenue for the fourth quarter of 2014 of approximately $605 million, up approximately 5% from $576 million for the fourth quarter of 2013. The company expects non-GAAP revenue for the fourth quarter of 2014 of approximately $601 million, which excludes approximately $4 million of revenue associated with da Vinci Xi trade-out offers. Preliminary fourth quarter 2014 GAAP service revenue is expected to increase approximately 6% to approximately $110 million from $103 million during the fourth quarter of 2013.

The company expects GAAP revenue for the year ended December 31, 2014 to total approximately $2.1 billion, down approximately 6% from $2.3 billion for the year ended December 31, 2013. Preliminary full year 2014 service revenue is expected to increase approximately 8% to approximately $429 million from $397 million during 2013. For the year, the company expects non-GAAP revenue of $2,131.7 million.
236
3/31/20158.21x24.76x27.70x47.61x30.77x$19,339$175.17241.55%Jan-12-2015ConferenceJPMorgan Chase & Co., 33rd Annual J.P. Morgan Healthcare Conference, Jan 12, 2015 through Jan 16, 2015Almirall, S.A. (BME:ALM), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Principia Biopharma Inc. (NasdaqGS:PRNB), Allena Pharmaceuticals, Inc. (NasdaqGS:ALNA), Moderna, Inc. (NasdaqGS:MRNA), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Blueprint Medicines Corporation (NasdaqGS:BPMC), 10x Genomics, Inc. (NasdaqGS:TXG), MyoKardia, Inc. (NasdaqGS:MYOK), NantHealth, Inc. (NasdaqGS:NH), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), Jounce Therapeutics, Inc. (NasdaqGS:JNCE), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), OPKO Health, Inc. (NasdaqGS:OPK), IVERIC bio, Inc. (NasdaqGS:ISEE), Adaptive Biotechnologies Corporation (NasdaqGS:ADPT), Otonomy, Inc. (NasdaqGS:OTIC), Clovis Oncology, Inc. (NasdaqGS:CLVS), BeiGene, Ltd. (NasdaqGS:BGNE), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Health Catalyst, Inc. (NasdaqGS:HCAT), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), HealthEquity, Inc. (NasdaqGS:HQY), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Inogen, Inc. (NasdaqGS:INGN), Conformis, Inc. (NasdaqGS:CFMS), Intrexon Corporation (NasdaqGS:XON), R1 RCM Inc. (NasdaqGS:RCM), Bruker Corporation (NasdaqGS:BRKR), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Accuray Incorporated (NasdaqGS:ARAY), Fluidigm Corporation (NasdaqGS:FLDM), Premier, Inc. (NasdaqGS:PINC), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), ICON Public Limited Company (NasdaqGS:ICLR), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Endologix, Inc. (NasdaqGS:ELGX), Novavax, Inc. (NasdaqGS:NVAX), Patterson Companies, Inc. (NasdaqGS:PDCO), Magellan Health, Inc. (NasdaqGS:MGLN), Henry Schein, Inc. (NasdaqGS:HSIC), Incyte Corporation (NasdaqGS:INCY), ICU Medical, Inc. (NasdaqGS:ICUI), Mylan N.V. (NasdaqGS:MYL), LHC Group, Inc. (NasdaqGS:LHCG), AngioDynamics, Inc. (NasdaqGS:ANGO), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), ChemoCentryx, Inc. (NasdaqGS:CCXI), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), United Therapeutics Corporation (NasdaqGS:UTHR), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), VIVUS, Inc. (NasdaqGS:VVUS), Wright Medical Group N.V. (NasdaqGS:WMGI), Teligent, Inc. (NasdaqGS:TLGT), DexCom, Inc. (NasdaqGS:DXCM), Hologic, Inc. (NasdaqGS:HOLX), RTI Surgical Holdings, Inc. (NasdaqGS:RTIX), Quidel Corporation (NasdaqGS:QDEL), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Bio-Techne Corporation (NasdaqGS:TECH), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Akorn, Inc. (NasdaqGS:AKRX), CONMED Corporation (NasdaqGS:CNMD), Cerner Corporation (NasdaqGS:CERN), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Masimo Corporation (NasdaqGS:MASI), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), Biogen Inc. (NasdaqGS:BIIB), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), LivaNova PLC (NasdaqGS:LIVN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Endo International plc (NasdaqGS:ENDP), bluebird bio, Inc. (NasdaqGS:BLUE), Inovio Pharmaceuticals, Inc. (NasdaqGS:INO), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Amgen Inc. (NasdaqGS:AMGN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Align Technology, Inc. (NasdaqGS:ALGN), Alkermes plc (NasdaqGS:ALKS), Tivity Health, Inc. (NasdaqGS:TVTY), Air Methods Corporation, Abaxis, Inc., ARIAD Pharmaceuticals, Inc., Array BioPharma Inc., Synageva BioPharma Corp., Intarcia Therapeutics, Inc., Cepheid, Univo Pharmaceuticals Ltd, Skilled Healthcare Group, Inc., WebMD Health Corp., IPC Healthcare, Inc., Team Health Holdings, Inc., Merge Healthcare Incorporated, PAREXEL International Corporation, Pharmacyclics LLC, Sequenom Inc., The Spectranetics Corporation, Sotera Health LLC, The Medicines Company, Actelion Ltd, athenahealth, Inc., Connecture, Inc., NxStage Medical, Inc., IMS Health Holdings, Inc., Patheon N.V., Catamaran Corporation, BTG Limited, Sirona Dental Systems Inc., CommonSpirit Health, Dignity Health, Kaiser Permanente Inc., Pall Corporation, Analogic Corporation, C. R. Bard, Inc., Celgene Corporation, Immucor, Inc., Omnicare Inc., St. Jude Medical, Inc., Almost Family, Inc., Thoratec LLC, VWR International, LLC, Kindred Healthcare, LLC, Health Net, Inc., Affymetrix Inc., Physio-Control, Inc., FEI Company, Shire plc, Envision Healthcare Corporation, Albany Molecular Research, Inc., Legacy LifePoint Health, Inc., Impax Laboratories, Inc., Keryx Biopharmaceuticals, Inc., Gland Pharma Limited, Stallergenes SA, MedAssets, Inc., Aetna Inc., The Cleveland Clinic Foundation, Polymer Technology Systems, Inc., Advocate Health Care, Inc., AdventHealth, Blue Cross and Blue Shield of Florida, Inc., Baylor Scott & White Health LLC, The Advisory Board Company, Alere Inc., Banner Health, Legacy Health, Imprivata, Inc., Santen Incorporated, Novadaq Technologies Inc., Genomic Health, Inc., The Trout Group LLC, National Institutes of Health, AcuFocus, Inc., Ablynx NV, CBR Systems, Inc., MWI Veterinary Supply, Inc., Partners HealthCare System, Inc., Mercy Health, RWJBarnabas Health, Inc., Intermountain Healthcare, Inc., University Of Maryland Medical System Corporation, Trinity Health Corporation, Atos Medical AB, Northwestern Memorial Healthcare Corporation, Everyday Health, Inc., Zuellig Pharma Corporation, Harvard Apparatus, Inc., Unilife Corporation, Seattle Children's Hospital, The Queen's Health Systems Inc., GetWellNetwork, Inc., OriGene Technologies, Inc., Helsinn Healthcare S.A., ZirMed, Inc., WuXi PharmaTech (Cayman) Inc., Orexigen Therapeutics, Inc., CareCentrix, Inc., Hospira Inc., Outset Media Corp., Flatiron Construction Corp., Medpace Research, Inc., Medivation, Inc., OptiNose AS, Heartware International Inc., IASIS Healthcare Corporation, OncoMed Pharmaceuticals, Inc., BioElectron Technology Corporation, FUJIFILM Cellular Dynamics, Inc., Biosensors International Group, Ltd., Kythera Biopharmaceuticals, Inc., Netsmartz, LLC, iKang Healthcare Group, Inc., Cohera Medical, Inc., Mindray Medical International Limited, Benvenue Medical, Inc., Cytograft Tissue Engineering, Inc., Aegerion Pharmaceuticals, Inc., PaxVax Corporation, Ouro Fino Agronegócio Ltda., Medi Assist India Pvt. Ltd., 23andMe, Inc., WCCT Global, LLC, ReShape Medical Inc., Practice Fusion, Inc., TriVascular Technologies, Inc., Auspex Pharmaceuticals, Inc., Immune Design Corp., ZELTIQ Aesthetics, Inc., AirStrip Technologies, Inc., Bio-Cancer Treatment International Ltd., Elixir Medical Corporation, Valence Health, Inc., Novira Therapeutics, Inc., Bill and Melinda Gates Investments, R-Pharm JSC, Suneva Medical, Inc., Sharecare Inc., Alltech Medical Systems, LLC, Naurex, Inc., Accolade, Inc., Minerva Surgical Inc., Spectrum Health Lakeland, Genesis Care Pty Ltd, Foundation Medicine, Inc., HeartFlow, Inc., Well Force International Inc., ZS Pharma, Inc., Welltok, Inc., Sagent Pharmaceuticals, Inc., SCAI Holdings, LLC, Agronomy Connection Limited, MedExpress Pharmacy, Ltd., Applied Proteomics, Inc., Sera Prognostics, Inc., Kite Pharma, Inc., Doximity, Inc., Truven Holding Corp., Kyruus, Inc., Lumeris, Inc., Express Scripts, Inc., Geisinger Health System, OvaScience, Inc., Alcobra Ltd., Omada Health, Inc., naviHealth, Inc., Samsungbioepis Co,.Ltd, Sprout Pharmaceuticals, Inc., Ascension Health Alliance, Envision Healthcare Holdings, Inc., Venrock Associates, xG Health Solutions, Inc., Cambian Group plc, Scioderm, LLC, YourPeople, Inc., CARsgen Therapeutics, Ltd, Independence Health Group, Inc., Genetron Health (Beijing) Co., Ltd., MedAvail Technologies Inc., Novocure Inc., Juno Therapeutics, Inc., Doctor on Demand, Inc., NantOmics, LLC, Capitol Street, DPx Holdings B.V., VWR Corporation, Portea Medical Private Limited, GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Circassia Pharmaceuticals plc (AIM:CIR), Hikma Pharmaceuticals PLC (LSE:HIK), AstraZeneca PLC (LSE:AZN), Smith & Nephew plc (LSE:SN.), GlaxoSmithKline plc (LSE:GSK), Vectura Group plc (LSE:VEC), Lonza Group Ltd (SWX:LONN), Tecan Group Ltd. (SWX:TECN), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Cosmo Pharmaceuticals N.V. (SWX:COPN), Molecular Partners AG (SWX:MOLN), ScinoPharm Taiwan, Ltd. (TSEC:1789), Bumrungrad Hospital Public Company Limited (SET:BH), Actinium Pharmaceuticals, Inc. (AMEX:ATNM), Protalix BioTherapeutics, Inc. (AMEX:PLX), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), Novozymes A/S (CPSE:NZYM B), GN Store Nord A/S (CPSE:GN), Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294), Cegedim SA (ENXTPA:CGM), Sanofi (ENXTPA:SAN), EssilorLuxottica Société anonyme (ENXTPA:EL), ORPEA Société Anonyme (ENXTPA:ORP), Ipsen S.A. (ENXTPA:IPN), GenSight Biologics S.A. (ENXTPA:SIGHT), Lee's Pharmaceutical Holdings Limited (SEHK:950), Sino Biopharmaceutical Limited (SEHK:1177), MicroPort Scientific Corporation (SEHK:853), Regent Pacific Group Limited (SEHK:575), One Media Group Limited (SEHK:426), China Resources Medical Holdings Company Limited (SEHK:1515), PT Siloam International Hospitals Tbk (IDX:SILO), RedHill Biopharma Ltd. (TASE:RDHL), Lupin Limited (BSE:500257), HealthCare Global Enterprises Limited (BSE:539787), Dr. Reddy's Laboratories Limited (BSE:500124), Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B), IHH Healthcare Berhad (KLSE:IHH), Otsuka Holdings Co., Ltd. (TSE:4578), NanoCarrier Co., Ltd. (TSE:4571), Takeda Pharmaceutical Company Limited (TSE:4502), Astellas Pharma Inc. (TSE:4503), Miraca Holdings Inc. (TSE:4544), Celltrion, Inc. (KOSE:A068270), Green Cross Corporation (KOSE:A006280), Hanmi Pharm. Co., Ltd. (KOSE:A128940), Raffles Medical Group Ltd (SGX:BSL), Medivir AB (publ) (OM:MVIR B), Elekta AB (publ) (OM:EKTA B), Active Biotech AB (publ) (OM:ACTI), Oxurion NV (ENXTBR:OXUR), UCB SA (ENXTBR:UCB), Biocartis Group NV (ENXTBR:BCART), Mesoblast Limited (ASX:MSB), Acrux Limited (ASX:ACR), Immutep Limited (ASX:IMM), CSL Limited (ASX:CSL), Aeterna Zentaris Inc. (TSX:AEZS), Intellipharmaceutics International Inc. (TSX:IPCI), Hypera S.A. (BOVESPA:HYPE3), Fleury S.A. (BOVESPA:FLRY3), Odontoprev S.A. (BOVESPA:ODPV3), Raia Drogasil S.A. (BOVESPA:RADL3), Athersys, Inc. (NasdaqCM:ATHX), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), Exact Sciences Corporation (NasdaqCM:EXAS), Soligenix, Inc. (NasdaqCM:SNGX), ThermoGenesis Holdings, Inc. (NasdaqCM:THMO), TG Therapeutics, Inc. (NasdaqCM:TGTX), United BioPharma, Inc. (GTSM:6471), JHL Biotech, Inc. (GTSM:6540), Taiwan Liposome Company, Ltd. (GTSM:4152), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), Antares Pharma, Inc. (NasdaqCM:ATRS), Agile Therapeutics, Inc. (NasdaqCM:AGRX), Nephros, Inc. (NasdaqCM:NEPH), Bionano Genomics, Inc. (NasdaqCM:BNGO), Dynavax Technologies Corporation (NasdaqCM:DVAX), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), Heat Biologics, Inc. (NasdaqCM:HTBX), Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT), Capricor Therapeutics, Inc. (NasdaqCM:CAPR), Anavex Life Sciences Corp. (NasdaqCM:AVXL), Relmada Therapeutics, Inc. (NasdaqCM:RLMD), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), Stemline Therapeutics, Inc. (NasdaqCM:STML), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), Tactile Systems Technology, Inc. (NasdaqGM:TCMD), Chimerix, Inc. (NasdaqGM:CMRX), Amarin Corporation plc (NasdaqGM:AMRN), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), NanoString Technologies, Inc. (NasdaqGM:NSTG), Sierra Oncology, Inc. (NasdaqGM:SRRA), NewLink Genetics Corporation (NasdaqGM:NLNK), MannKind Corporation (NasdaqGM:MNKD), Oxford Immunotec Global PLC (NasdaqGM:OXFD), T2 Biosystems, Inc. (NasdaqGM:TTOO), Veracyte, Inc. (NasdaqGM:VCYT), Intersect ENT, Inc. (NasdaqGM:XENT), SI-BONE, Inc. (NasdaqGM:SIBN), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Arcturus Therapeutics Holdings Inc. (NasdaqGM:ARCT), Trevi Therapeutics, Inc. (NasdaqGM:TRVI), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Millennium Healthcare, Inc. (OTCPK:MHCC), REVA Medical, Inc. (OTCPK:RVAL.L), GeoVax Labs, Inc. (OTCPK:GOVX), Protea Biosciences Group, Inc (OTCPK:PRGB.Q), Lixte Biotechnology Holdings, Inc. (OTCPK:LIXT), MiMedx Group, Inc. (OTCPK:MDXG), INSYS Therapeutics, Inc. (OTCPK:INSY.Q), Arch Therapeutics, Inc. (OTCPK:ARTH), AtheroNova Inc. (OTCPK:AHRO.Q), Glenmark Pharmaceuticals Limited (NSEI:GLENMARK), Aurobindo Pharma Limited (NSEI:AUROPHARMA), Seegene, Inc. (KOSDAQ:A096530), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), MorphoSys AG (XTRA:MOR), Bayer Aktiengesellschaft (XTRA:BAYN), Medigene AG (XTRA:MDG1), Invitae Corporation (NYSE:NVTA), AbbVie Inc. (NYSE:ABBV), IQVIA Holdings Inc. (NYSE:IQV), Zoetis Inc. (NYSE:ZTS), Mallinckrodt plc (NYSE:MNK), Kadmon Holdings, Inc. (NYSE:KDMN), Inspire Medical Systems, Inc. (NYSE:INSP), Catalent, Inc. (NYSE:CTLT), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Global Cord Blood Corporation (NYSE:CO), Veeva Systems Inc. (NYSE:VEEV), Diplomat Pharmacy, Inc. (NYSE:DPLO), Genesis Healthcare, Inc. (NYSE:GEN), Select Medical Holdings Corporation (NYSE:SEM), Nevro Corp. (NYSE:NVRO), Teladoc Health, Inc. (NYSE:TDOC), Emergent BioSolutions Inc. (NYSE:EBS), Quest Diagnostics Incorporated (NYSE:DGX), JPMorgan Chase & Co. (NYSE:JPM), JPMorgan Chase & Co. (NYSE:JPM), Owens & Minor, Inc. (NYSE:OMI), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Boston Scientific Corporation (NYSE:BSX), Perrigo Company plc (NYSE:PRGO), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), Glaukos Corporation (NYSE:GKOS), Molina Healthcare, Inc. (NYSE:MOH), Lannett Company, Inc. (NYSE:LCI), Vocera Communications, Inc. (NYSE:VCRA), Laboratory Corporation of America Holdings (NYSE:LH), QIAGEN N.V. (NYSE:QGEN), Mettler-Toledo International Inc. (NYSE:MTD), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Community Health Systems, Inc. (NYSE:CYH), Hill-Rom Holdings, Inc. (NYSE:HRC), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), AMN Healthcare Services, Inc. (NYSE:AMN), AmerisourceBergen Corporation (NYSE:ABC), Rite Aid Corporation (NYSE:RAD), CVS Health Corporation (NYSE:CVS), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Integer Holdings Corporation (NYSE:ITGR), Universal Health Services, Inc. (NYSE:UHS), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), Medtronic plc (NYSE:MDT), Charles River Laboratories International, Inc. (NYSE:CRL), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Johnson & Johnson (NYSE:JNJ), Model N, Inc. (NYSE:MODN), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Chemed Corporation (NYSE:CHE), HCA Healthcare, Inc. (NYSE:HCA), The Cooper Companies, Inc. (NYSE:COO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Danaher Corporation (NYSE:DHR), PerkinElmer, Inc. (NYSE:PKI), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Cantel Medical Corp. (NYSE:CMD), MEDNAX, Inc. (NYSE:MD), Abbott Laboratories (NYSE:ABT)JPMorgan Chase & Co., 33rd Annual J.P. Morgan Healthcare Conference, Jan 12, 2015 through Jan 16, 2015. Venue: Westin St. Francis Hotel, San Francisco, California, United States.
237
12/31/20148.63x25.22x28.03x48.67x28.67x$19,359$176.31239.34%Dec-31-2014Buyback Transaction ClosingsIntuitive Surgical, Inc.’s Equity Buyback announced on March 3, 2009 has closed with 8,873,031 shares, representing 22.76% for $3,027.8 million.-The company closed its plan on December 31, 2014.
238
12/31/20148.63x25.22x28.03x48.67x28.67x$19,539$177.95236.21%Dec-22-2014Index Constituent DropIntuitive Surgical, Inc.(NasdaqGS:ISRG) dropped from S&P 500 Value IndexS&P 500 Value (^SVX)Intuitive Surgical, Inc.(NasdaqGS:ISRG) dropped from S&P 500 Value Index
239
12/31/20148.63x25.22x28.03x48.67x28.67x$18,892$172.06247.72%Nov-18-2014Company Conference PresentationIntuitive Surgical, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 09:45 AM-Intuitive Surgical, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 09:45 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.
240
12/31/20148.63x25.22x28.03x48.67x28.67x$18,892$172.06247.72%Nov-18-2014ConferenceStifel, Nicolaus & Company, Incorporated, Stifel Healthcare Conference 2014, Nov 18, 2014 through Nov 19, 2014Puma Biotechnology, Inc. (NasdaqGS:PBYI), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Alphatec Holdings, Inc. (NasdaqGS:ATEC), Tetraphase Pharmaceuticals, Inc. (NasdaqGS:TTPH), Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA), IVERIC bio, Inc. (NasdaqGS:ISEE), Arbutus Biopharma Corporation (NasdaqGS:ABUS), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Innoviva, Inc. (NasdaqGS:INVA), Align Technology, Inc. (NasdaqGS:ALGN), Henry Schein, Inc. (NasdaqGS:HSIC), Endologix, Inc. (NasdaqGS:ELGX), Geron Corporation (NasdaqGS:GERN), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), MacroGenics, Inc. (NasdaqGS:MGNX), Progenics Pharmaceuticals, Inc. (NasdaqGS:PGNX), ChemoCentryx, Inc. (NasdaqGS:CCXI), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), AngioDynamics, Inc. (NasdaqGS:ANGO), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Inogen, Inc. (NasdaqGS:INGN), eHealth, Inc. (NasdaqGS:EHTH), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Exelixis, Inc. (NasdaqGS:EXEL), Inovio Pharmaceuticals, Inc. (NasdaqGS:INO), CymaBay Therapeutics, Inc. (NasdaqGS:CBAY), Repligen Corporation (NasdaqGS:RGEN), HealthStream, Inc. (NasdaqGS:HSTM), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), DURECT Corporation (NasdaqCM:DRRX), MEI Pharma, Inc. (NasdaqCM:MEIP), Caladrius Biosciences, Inc. (NasdaqCM:CLBS), Genocea Biosciences, Inc. (NasdaqCM:GNCA), Conatus Pharmaceuticals Inc. (NasdaqCM:CNAT), Forward Pharma A/S (NasdaqCM:FWP), OncoSec Medical Incorporated (NasdaqCM:ONCS), Rexahn Pharmaceuticals, Inc. (NasdaqCM:REXN), TrovaGene, Inc. (NasdaqCM:TROV), Sorrento Therapeutics, Inc. (NasdaqCM:SRNE), Triple-S Management Corporation (NYSE:GTS), WellCare Health Plans, Inc. (NYSE:WCG), MEDNAX, Inc. (NYSE:MD), Stryker Corporation (NYSE:SYK), Becton, Dickinson and Company (NYSE:BDX), Baxter International Inc. (NYSE:BAX), Cantel Medical Corp. (NYSE:CMD), Boston Scientific Corporation (NYSE:BSX), Safeguard Scientifics, Inc. (NYSE:SFE), Capital Senior Living Corporation (NYSE:CSU), Waters Corporation (NYSE:WAT), Humanigen, Inc. (OTCPK:HGEN), Aradigm Corporation (OTCPK:ARDM.Q), Castlight Health, Inc. (NYSE:CSLT), Zyla Life Sciences (OTCPK:ZCOR), Lombard Medical, Inc. (OTCPK:EVAR.F), MiMedx Group, Inc. (OTCPK:MDXG), ARIAD Pharmaceuticals, Inc., Array BioPharma Inc., Cascadian Therapeutics, Inc., Argos Therapeutics, Inc., The Spectranetics Corporation, Vascular Solutions, Inc., Vical Incorporated, VCA Inc., C. R. Bard, Inc., IMS Health Holdings, Inc., Vectura Group Services Limited, Apricus Biosciences, Inc., Keryx Biopharmaceuticals, Inc., Symmetry Medical, Inc., Stifel, Nicolaus & Company, Incorporated, Isto Biologics, OncoGenex Pharmaceuticals, Inc., Vitae Pharmaceuticals, Inc., Syneron Medical Ltd., Sucampo Pharmaceuticals, Inc., Novadaq Technologies Inc., Celator Pharmaceuticals, Inc., Threshold Pharmaceuticals, Inc., Synta Pharmaceuticals Corp., GTx, Inc., Everyday Health, Inc., Tokai Pharmaceuticals, Inc., Alexza Pharmaceuticals Inc., Ocera Therapeutics, Inc., Proteon Therapeutics, Inc., Cempra, Inc., Corindus Vascular Robotics, Inc., Galena Biopharma, Inc., DNIB Unwind, Inc., Relypsa, Inc., ZELTIQ Aesthetics, Inc., TriVascular Technologies, Inc., Neovasc Inc. (TSX:NVCN), Oncolytics Biotech Inc. (TSX:ONC), Aptose Biosciences Inc. (TSX:APS), Sophiris Bio, Inc. (DB:BFF1), Curis, Inc. (NasdaqGM:CRIS), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Ocular Therapeutix, Inc. (NasdaqGM:OCUL), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Trupanion, Inc. (NasdaqGM:TRUP), NewLink Genetics Corporation (NasdaqGM:NLNK), Zogenix, Inc. (NasdaqGM:ZGNX), Cara Therapeutics, Inc. (NasdaqGM:CARA), Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI), Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA), Concert Pharmaceuticals, Inc. (NasdaqGM:CNCE), Trevi Therapeutics, Inc. (NasdaqGM:TRVI), Flexion Therapeutics, Inc. (NasdaqGM:FLXN), AtriCure, Inc. (NasdaqGM:ATRC), Chimerix, Inc. (NasdaqGM:CMRX), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), BioSpecifics Technologies Corp. (NasdaqGM:BSTC), GlycoMimetics, Inc. (NasdaqGM:GLYC), Applied Genetic Technologies Corporation (NasdaqGM:AGTC), Marinus Pharmaceuticals, Inc. (NasdaqGM:MRNS), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), TransEnterix, Inc. (AMEX:TRXC), Roche Holding AG (SWX:ROG), Ergomed plc (AIM:ERGO), Abaxis, Inc., Invuity, Inc., Alcobra Ltd., Kite Pharma, Inc., Sonendo, Inc., Loxo Oncology, Inc.Stifel, Nicolaus & Company, Incorporated, Stifel Healthcare Conference 2014, Nov 18, 2014 through Nov 19, 2014. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.
241
12/31/20148.63x25.22x28.03x48.67x28.67x$17,770$161.84269.68%Oct-23-2014Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on March 5, 2009.-From July 1, 2014 to September 30, 2014, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,684,863 shares, representing 22.24% for $2,933.42 million under the buyback announced on March 5, 2009.
242
12/31/20148.63x25.22x28.03x48.67x28.67x$18,146$165.26262.03%Oct-21-2014Earnings CallIntuitive Surgical, Inc., Q3 2014 Earnings Call, Oct 21, 2014-Intuitive Surgical, Inc., Q3 2014 Earnings Call, Oct 21, 2014
243
12/31/20148.63x25.22x28.03x48.67x28.67x$18,146$165.26262.03%Oct-21-2014Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company’s revenue was $550 million, an increase of approximately 10% compared with $499 million in the third quarter of 2013. Non-GAAP revenue was $534 million, an increase of approximately 7% compared with $499 million in the third quarter of 2013. Income from operations decreased to $159 million, compared with $174 million in the third quarter of 2013. Non-GAAP income from operations decreased to $197 million, compared with $230 million in the third quarter of 2013. Net income was $124 million, or $3.35 per diluted share, compared with $157 million, or $3.99 per diluted share, for the third quarter of 2013. Non-GAAP net income was $145 million, or $3.92 per diluted share, compared with $194 million, or $4.94 per diluted share, for the third quarter of 2013. Income before taxes was $161.1 million against $178.1 million a year ago.

For the nine months, the company reported total revenue of $1,527.0 million against $1,688.9 million a year ago. Income from operations was $358.7 million against $643.9 million a year ago. Income before taxes was $364.2 million against $656.4 million a year ago. Net income was $272.0 million or $7.18 per diluted share against $504.8 million or $12.46 per diluted share a year ago. Non-GAAP revenue was $1,530.9 million against $1,688.9 million a year ago. Non-GAAP income from operations was $581.7 million against $787.8 million a year ago. Non-GAAP net income was $423.4 million or $11.17 per diluted share against $601.6 million or $14.85 per diluted share a year ago.
244
9/30/20147.61x21.35x23.57x42.29x22.66x$16,870$154.91286.22%Sep-29-2014Product-Related AnnouncementIntuitive Surgical, Inc. Receives FDA Clearance for First Single-Site Wristed Needle Driver for Da Vinci Si Surgical System-Intuitive Surgical, Inc. announced that it has received U.S. Food and Drug Administration (FDA) clearance for the Single-Site Wristed Needle Driver for use in single-incision surgery. This new addition to the Single-Site suite of instruments has been cleared for use with the da Vinci Si Surgical System for minimally invasive removal of the uterus (hysterectomy), the ovaries and fallopian tubes for benign conditions, as well as removal of the gallbladder. Single-Site Instrumentation facilitates virtually scarless surgeries through a single-incision, while providing surgeons the benefits of robotic and computer assistance. These include surgical precision, control, stability, 3D-HD visualization and an ergonomic seated position. Together, the da Vinci System and Single-Site instruments are designed to minimize instrument crowding while maximizing available working space as compared with hand-held, laparoscopic single-incision instrumentation.
245
9/30/20147.61x21.35x23.57x42.29x22.66x$17,262$158.51277.45%Sep-18-2014Product-Related AnnouncementIntuitive Surgical, Inc. Receives FDA Clearance for da Vinci(R) System Use in Benign Base of Tongue Resection Procedures-Intuitive Surgical announced that it has received FDA clearance for use of the da Vinci S(R) and da Vinci Si(R) Surgical Systems in benign, base of tongue resection procedures. These procedures are performed transorally, or through the mouth opening, by otolaryngologic surgeons. Otolaryngologists specialize in diseases of the ear, nose and throat (ENT). These procedures involve removal or resection of non-cancerous or benign tissue at the base of the tongue, near the opening of the throat.
246
9/30/20147.61x21.35x23.57x42.29x22.66x$17,190$157.85279.02%Sep-10-2014Company Conference PresentationIntuitive Surgical, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 08:35 AM-Intuitive Surgical, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 08:35 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Marshall L. Mohr, Chief Financial Officer and Senior Vice President.
247
9/30/20147.61x21.35x23.57x42.29x22.66x$16,944$155.59284.53%Sep-08-2014ConferenceMorgan Stanley, 2014 Morgan Stanley Global Healthcare Conference, Sep 08, 2014 through Sep 11, 2014Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI), Organovo Holdings, Inc. (NasdaqCM:ONVO), Antares Pharma, Inc. (NasdaqCM:ATRS), Celldex Therapeutics, Inc. (NasdaqCM:CLDX), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), United Therapeutics Corporation (NasdaqGS:UTHR), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Hologic, Inc. (NasdaqGS:HOLX), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), NextGen Healthcare, Inc. (NasdaqGS:NXGN), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Wright Medical Group N.V. (NasdaqGS:WMGI), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Henry Schein, Inc. (NasdaqGS:HSIC), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Sinovac Biotech Ltd. (NasdaqGS:SVA), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Insulet Corporation (NasdaqGS:PODD), Accuray Incorporated (NasdaqGS:ARAY), Fluidigm Corporation (NasdaqGS:FLDM), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Clovis Oncology, Inc. (NasdaqGS:CLVS), Aravive, Inc. (NasdaqGS:ARAV), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Blueprint Medicines Corporation (NasdaqGS:BPMC), IVERIC bio, Inc. (NasdaqGS:ISEE), China Biologic Products Holdings, Inc. (NasdaqGS:CBPO), Amgen Inc. (NasdaqGS:AMGN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Align Technology, Inc. (NasdaqGS:ALGN), Alkermes plc (NasdaqGS:ALKS), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), LivaNova PLC (NasdaqGS:LIVN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Endo International plc (NasdaqGS:ENDP), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), AmerisourceBergen Corporation (NYSE:ABC), Hill-Rom Holdings, Inc. (NYSE:HRC), Sartorius Aktiengesellschaft (XTRA:SRT), MorphoSys AG (XTRA:MOR), INSYS Therapeutics, Inc. (OTCPK:INSY.Q), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), QIAGEN N.V. (NYSE:QGEN), Medtronic plc (NYSE:MDT), Humana Inc. (NYSE:HUM), Charles River Laboratories International, Inc. (NYSE:CRL), CVS Health Corporation (NYSE:CVS), Haemonetics Corporation (NYSE:HAE), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Tenet Healthcare Corporation (NYSE:THC), Baxter International Inc. (NYSE:BAX), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), West Pharmaceutical Services, Inc. (NYSE:WST), Boston Scientific Corporation (NYSE:BSX), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), HCA Healthcare, Inc. (NYSE:HCA), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Morgan Stanley (NYSE:MS), Quest Diagnostics Incorporated (NYSE:DGX), Lannett Company, Inc. (NYSE:LCI), Mallinckrodt plc (NYSE:MNK), IQVIA Holdings Inc. (NYSE:IQV), AbbVie Inc. (NYSE:ABBV), Zoetis Inc. (NYSE:ZTS), Castlight Health, Inc. (NYSE:CSLT), Catalent, Inc. (NYSE:CTLT), Veeva Systems Inc. (NYSE:VEEV), Brookdale Senior Living Inc. (NYSE:BKD), Array BioPharma Inc., Synageva BioPharma Corp., Cubist Pharmaceuticals LLC, Sequenom Inc., The Spectranetics Corporation, Xenoport, Inc., Catamaran Corporation, BTG Limited, Celgene Corporation, St. Jude Medical, Inc., Sigma-Aldrich Corporation, Thoratec LLC, Kindred Healthcare, LLC, Avanir Pharmaceuticals, Inc., Covance Inc., Albany Molecular Research, Inc., Aetna Inc., Auxilium Pharmaceuticals, LLC, Volcano Corporation, Anacor Pharmaceuticals, Inc., Hospira Inc., Medivation, Inc., OncoMed Pharmaceuticals, Inc., Alexza Pharmaceuticals Inc., Aegerion Pharmaceuticals, Inc., AMN Healthcare, Inc., Horizon Pharmaceutical LLC, Relypsa, Inc., CareFusion Corporation, Foundation Medicine, Inc., Tesaro, Inc., Aratana Therapeutics, Inc., Envision Healthcare Holdings, Inc., ScinoPharm Taiwan, Ltd. (TSEC:1789), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Basilea Pharmaceutica AG (SWX:BSLN), NanoString Technologies, Inc. (NasdaqGM:NSTG), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), Zogenix, Inc. (NasdaqGM:ZGNX), T2 Biosystems, Inc. (NasdaqGM:TTOO), AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX), Ocular Therapeutix, Inc. (NasdaqGM:OCUL), Veracyte, Inc. (NasdaqGM:VCYT), Chimerix, Inc. (NasdaqGM:CMRX), Acceleron Pharma Inc. (NasdaqGM:XLRN), MannKind Corporation (NasdaqGM:MNKD), GW Pharmaceuticals plc (NasdaqGM:GWPH), Phibro Animal Health Corporation (NasdaqGM:PAHC), Cerus Corporation (NasdaqGM:CERS), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Ipsen S.A. (ENXTPA:IPN), Sanofi (ENXTPA:SAN), Sartorius Stedim Biotech S.A. (ENXTPA:DIM), ALK-Abelló A/S (CPSE:ALK B), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), Novo Nordisk A/S (CPSE:NOVO B), Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)Morgan Stanley, 2014 Morgan Stanley Global Healthcare Conference, Sep 08, 2014 through Sep 11, 2014. Venue: The Grand Hyatt Hotel, New York, New York, United States.
248
9/30/20147.61x21.35x23.57x42.29x22.66x$17,130$157.30280.35%Aug-21-2014Product-Related AnnouncementIntuitive Surgical, Inc. Receives Firefly FDA Clearance for da Vinci(R) Xi(TM) Surgical System-Intuitive Surgical, Inc. announced the FDA clearance of Firefly Fluorescence Imaging for the da Vinci(R) Xi(TM) Surgical System, which provides surgeons with enhanced visualization during minimally invasive surgical procedures. Firefly Imaging has been available since 2011 as an optional feature for the da Vinci(R) Si(TM) System, and this clearance means that Firefly Imaging will now ship with all da Vinci Xi Systems. The first and second clearances allow the company to market advanced technologies for vessel sealing and stapling for use with the da Vinci Xi System. All three technologies were previously cleared for use with the da Vinci Si System. The Firefly Imaging System enables real-time visual assessment of vessels, blood flow and related tissue perfusion. It also enables assessment of the major ducts that connect to the gallbladder for transport of bile, a digestive fluid. This assessment is helpful during surgical removal of the gallbladder. The Firefly System enables surgeons to switch between standard, visible light and near-infrared imaging during minimally invasive procedures. When a surgeon uses the Firefly System in conjunction with an injectable fluorescent dye, tissue with blood flow is highlighted in a green color and tissue without blood flow appears gray in the surgeon's view. The Firefly System is intended to be used for biliary duct visualization in conjunction with standard, visible light in bile-duct imaging and where indicated, X-ray examination of the bile ducts during surgery.
249
9/30/20147.61x21.35x23.57x42.29x22.66x$16,391$150.51297.51%Aug-12-2014Company Conference PresentationIntuitive Surgical, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 10:20 AM-Intuitive Surgical, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 10:20 AM. Venue: Le Parker Meridien, New York, New York, United States.
250
9/30/20147.61x21.35x23.57x42.29x22.66x$16,391$150.51297.51%Aug-12-2014ConferenceWedbush Securities Inc., Wedbush 2014 Life Sciences Management Access Conference, Aug 12, 2014 through Aug 13, 2014Blueprint Medicines Corporation (NasdaqGS:BPMC), Progyny, Inc. (NasdaqGS:PGNY), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Prothena Corporation plc (NasdaqGS:PRTA), Guardant Health, Inc. (NasdaqGS:GH), Tetraphase Pharmaceuticals, Inc. (NasdaqGS:TTPH), NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM), Epizyme, Inc. (NasdaqGS:EPZM), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), MacroGenics, Inc. (NasdaqGS:MGNX), Novavax, Inc. (NasdaqGS:NVAX), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Pacira BioSciences, Inc. (NasdaqGS:PCRX), bluebird bio, Inc. (NasdaqGS:BLUE), EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q), Ardelyx, Inc. (NasdaqGM:ARDX), Tonix Pharmaceuticals Holding Corp. (NasdaqGM:TNXP), Cidara Therapeutics, Inc. (NasdaqGM:CDTX), La Jolla Pharmaceutical Company (NasdaqCM:LJPC), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), MEI Pharma, Inc. (NasdaqCM:MEIP), Tenax Therapeutics, Inc. (NasdaqCM:TENX), Stemline Therapeutics, Inc. (NasdaqCM:STML), AxoGen, Inc. (NasdaqCM:AXGN), Regulus Therapeutics Inc. (NasdaqCM:RGLS), Zosano Pharma Corporation (NasdaqCM:ZSAN), argenx SE (ENXTBR:ARGX), Oncolytics Biotech Inc. (TSX:ONC), XOMA Corporation (NasdaqGM:XOMA), STAAR Surgical Company (NasdaqGM:STAA), IRIDEX Corporation (NasdaqGM:IRIX), Omeros Corporation (NasdaqGM:OMER), Cerus Corporation (NasdaqGM:CERS), Sesen Bio, Inc. (NasdaqGM:SESN), Catabasis Pharmaceuticals, Inc. (NasdaqGM:CATB), Fate Therapeutics, Inc. (NasdaqGM:FATE), Applied Genetic Technologies Corporation (NasdaqGM:AGTC), Xencor, Inc. (NasdaqGM:XNCR), Wedbush Securities Inc., Synageva BioPharma Corp., Cascadian Therapeutics, Inc., Cepheid, Sequenom Inc., Avanir Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc., Fibrocell Science, Inc., Dex Liquidating Co., Endocyte, Inc., Anacor Pharmaceuticals, Inc., GTx, Inc., Vital Therapies, Inc., BioMarin Nederland B.V., OHR Pharmaceutical, Inc., Celladon Corporation, Biodel Inc., Promedior, Inc., DNIB Unwind, Inc., Cerulean Pharma Inc., Hyperion Therapeutics, Inc., Relypsa, Inc., Advanced Cell Diagnostics, Inc., Tarsa Therapeutics, Inc., Receptos, Inc., Foundation Medicine, Inc., Durata Therapeutics, Inc., Cleave Therapeutics, Inc., OvaScience, Inc., Blaze Bioscience, Inc.Wedbush Securities Inc., Wedbush 2014 Life Sciences Management Access Conference, Aug 12, 2014 through Aug 13, 2014. Venue: Le Parker Meridien, New York, New York, United States.
251
9/30/20147.61x21.35x23.57x42.29x22.66x$16,951$155.66284.36%Jul-30-2014Executive/Board Change - OtherIntuitive Surgical, Inc. Appoints David Rosa as the Executive Vice President and Chief Scientific Officer-Intuitive Surgical, Inc. appointed David Rosa as the Executive Vice President and Chief Scientific Officer, effective immediately. Mr. Rosa, age 46, joined Intuitive in March 1996 and has held leadership positions in engineering, clinical development, marketing and product development. In 2013, Mr. Rosa assumed the position of Senior Vice President, Scientific Affairs. Prior to joining Intuitive, Mr. Rosa contributed to the development of trans-esophageal transducers for Acuson Corporation.
252
9/30/20147.61x21.35x23.57x42.29x22.66x$16,758$153.88288.80%Jul-23-2014Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on March 5, 2009.-From April 1, 2014 to June 30, 2014, the company has repurchased 2,515,619 shares, representing 6.55% for $905.1 million. With this, the company has completed the repurchase of 8,684,863 shares, representing 22.24% for $2,933.42 million under the buyback announced on March 5, 2009.
253
9/30/20147.61x21.35x23.57x42.29x22.66x$14,235$130.72357.69%Jul-22-2014Corporate Guidance - New/Confirmed, Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Year 2014-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of USD 512.2 million against USD 578.5 million a year ago. Income from operations was USD 143 million against USD 218.5 million a year ago. Income before taxes was USD 142.6 million against USD 222.8 million a year ago. Net income was USD 104 million or USD 2.77 per diluted share against USD 159.1 million or USD 3.90 per diluted share a year ago. Non-GAAP revenue was USD 506.5 million against USD 578.5 million a year ago. Non-GAAP income from operations was USD 195.8 million against USD 262.9 million a year ago. Non-GAAP net income was USD 140.2 million or USD 3.73 per diluted share against USD 189 million or USD 4.63 per diluted share a year ago. The decrease in revenue relative to the second quarter of 2013 reflected lower stocking orders associated with fewer system sales. The increase relative to the first quarter reflects increased procedures and number of stocking orders associated with higher systems placed, partially offset by customer buying patterns and fewer sales of energy-generator units and Single-Site starter kits.

For the six months, the company reported total revenue of USD 976.9 million against USD 1,189.9 million a year ago. Income from operations was USD 199.6 million against USD 469.7 million a year ago. Income before taxes was USD 203.1 against USD 478.3 million a year ago. Net income was USD 148.3 million or USD 3.87 per diluted share against USD 348 million or USD 8.47 per diluted share a year ago. Non-GAAP revenue was USD 966.8 million against USD 1,189.9 million a year ago. Non-GAAP income from operations was USD 384.8 million against USD 557.9 million a year ago. Non-GAAP net income was USD 278.7 million or USD 7.28 per diluted share against USD 407.5 million or USD 9.91 per diluted share a year ago.

For the year 2014, the company expects gross profit margin to be to move differentially lower, based upon the impact of new products, product mix and market conditions. Actual gross profit margin will vary quarter-to-quarter, depending largely upon product mix and systems production volume. The company expects to grow operating expenses roughly 10% to 13% above the 2013 levels. The company expects income tax rate to be between 25% and 28% pretax income, depending primarily on the mix of U.S. and international profits.
254
9/30/20147.61x21.35x23.57x42.29x22.66x$14,235$130.72357.69%Jul-22-2014Earnings CallIntuitive Surgical, Inc., Q2 2014 Earnings Call, Jul 22, 2014-Intuitive Surgical, Inc., Q2 2014 Earnings Call, Jul 22, 2014
255
9/30/20147.61x21.35x23.57x42.29x22.66x$14,642$134.45344.99%Jul-02-2014Client AnnouncementIntuitive Surgical and Adachi Co. Ltd. Announce an Agreement to Transition Japanese Sales, Marketing, Service, Support and Training for da Vinci(R) Systems-Intuitive Surgical and Adachi Co. Ltd. announced an agreement to transition Japanese sales, marketing, service, support and training for da Vinci(R) Systems, instruments and accessories to Intuitive Surgical, a transition that began June 26, 2014. With this agreement, Intuitive Surgical will further expand its presence in the Asia Pacific region. Intuitive Surgical and Adachi will work together to ensure da Vinci customers in Japan experience a smooth transition. In addition, Intuitive Surgical will offer employment to a number of Adachi employees who have experience with the da Vinci business. These employees will be added to Intuitive Surgical's existing regulatory team, call center and other departments to further strengthen the highly capable organization. The terms of the arrangement were not disclosed and are not expected to have a material impact on Intuitive Surgical's results of operations.
256
6/30/20146.73x17.88x19.56x34.87x20.75x$14,583$135.03343.08%Jun-25-2014Product-Related AnnouncementIntuitive Surgical, Inc. Receives CE Mark for its da Vinci Xi Surgical System-Intuitive Surgical, Inc. announced it has received a CE Mark for its da Vinci Xi Surgical System. Achieving this milestone allows the company to market the Xi System in Europe and other countries that require the CE Mark. In April, the da Vinci Xi System received clearance from the U.S. Food and Drug Administration (FDA) and is now commercialized in the United States. The da Vinci Xi System is intended to be a technological leap forward in replacing large-incision open surgeries with a minimally invasive approach. Intuitive Surgical designed the new da Vinci Xi System to optimize ease-of-use. With the U.S. and European introductions underway, Intuitive Surgical is seeking additional regulatory clearances to market the da Vinci Xi System around the world. These include clearances for advanced technologies such as vessel sealing, stapling and fluorescence imaging, which are designed to enhance the capabilities of the da Vinci Xi System. This month, Intuitive Surgical received the first of these clearances from the FDA to market the EndoWrist(r) One(tm) Vessel Sealer instrument for the da Vinci Xi System in the United States. Vinci Xi System expands upon the core da Vinci System features, which include wristed instruments, 3D-HD visualization, intuitive motion and an ergonomic design. As with all da Vinci Surgical Systems, the da Vinci Xi System's immersive 3D-HD vision system provides surgeons with a highly magnified view, virtually extending their eyes and hands into the patient. Compared with prior da Vinci Systems, the da Vinci Xi System's key features include: A new overhead instrument arm architecture designed to facilitate anatomical access from virtually any position; A new endoscope digital architecture that creates a simpler, more compact design with improved visual definition and clarity; An ability to attach the endoscope to any arm, providing flexibility for visualizing the surgical site; Smaller, thinner arms with newly designed joints that offer a greater range of motion than ever before; and Longer instrument shafts designed to give surgeons greater operative reach. The da Vinci Xi System is an expandable technology platform that is designed to accommodate and seamlessly integrate a range of current technologies in areas such as fluorescence imaging, advanced instruments and anatomical access, as well as future innovations.
257
6/30/20146.73x17.88x19.56x34.87x20.75x$13,766$127.46369.39%Jun-11-2014Company Conference PresentationIntuitive Surgical, Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 10:40 AM-Intuitive Surgical, Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 10:40 AM. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States. Speakers: Baird Radford, VP of FP&A.
258
6/30/20146.73x17.88x19.56x34.87x20.75x$13,766$127.46369.39%Jun-11-2014Company Conference PresentationIntuitive Surgical, Inc. Presents at William Blair & Company's 34th Annual Growth Stock Conference, Jun-11-2014 12:40 PM-Intuitive Surgical, Inc. Presents at William Blair & Company's 34th Annual Growth Stock Conference, Jun-11-2014 12:40 PM. Venue: Four Seasons Hotel, 120 East Delaware Place, Chicago, Illinois, United States.
259
6/30/20146.73x17.88x19.56x34.87x20.75x$13,594$125.87375.32%Jun-10-2014ConferenceThe Goldman Sachs Group, Inc., Goldman Sachs 35th Annual Global Healthcare Conference, Jun 10, 2014 through Jun 12, 2014Zealand Pharma A/S (CPSE:ZEAL), ALK-Abelló A/S (CPSE:ALK B), Novo Nordisk A/S (CPSE:NOVO B), Sanofi (ENXTPA:SAN), Amarin Corporation plc (NasdaqGM:AMRN), Acceleron Pharma Inc. (NasdaqGM:XLRN), MannKind Corporation (NasdaqGM:MNKD), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Turkiye Garanti Bankasi A.S. (IBSE:GARAN), ARIAD Pharmaceuticals, Inc., Synageva BioPharma Corp., Cepheid, Cubist Pharmaceuticals LLC, IPC Healthcare, Inc., Team Health Holdings, Inc., PAREXEL International Corporation, The Medicines Company, Universal American Corp., Catamaran Corporation, Celgene Corporation, Pall Corporation, St. Jude Medical, Inc., Thoratec LLC, Health Net, Inc., NPS Pharmaceuticals, Inc., Covance Inc., FEI Company, Shire plc, Impax Laboratories, Inc., Aetna Inc., Keryx Biopharmaceuticals, Inc., Alere Inc., Volcano Corporation, Genomic Health, Inc., Heartware International Inc., Kythera Biopharmaceuticals, Inc., ZELTIQ Aesthetics, Inc., CareFusion Corporation, Foundation Medicine, Inc., Icon Limited, ExamWorks Group, Inc., Envision Healthcare Holdings, Inc., Community Health Systems, Inc. (NYSE:CYH), AmerisourceBergen Corporation (NYSE:ABC), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), QIAGEN N.V. (NYSE:QGEN), Humana Inc. (NYSE:HUM), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), Boston Scientific Corporation (NYSE:BSX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Baxter International Inc. (NYSE:BAX), HCA Healthcare, Inc. (NYSE:HCA), Danaher Corporation (NYSE:DHR), PerkinElmer, Inc. (NYSE:PKI), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Becton, Dickinson and Company (NYSE:BDX), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cigna Corporation (NYSE:CI), Universal Health Services, Inc. (NYSE:UHS), Allergan plc (NYSE:AGN), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Brookdale Senior Living Inc. (NYSE:BKD), WellCare Health Plans, Inc. (NYSE:WCG), Globus Medical, Inc. (NYSE:GMED), Castlight Health, Inc. (NYSE:CSLT), Hill-Rom Holdings, Inc. (NYSE:HRC), Allianz SE (XTRA:ALV), Bayer Aktiengesellschaft (XTRA:BAYN), MorphoSys AG (XTRA:MOR), Mallinckrodt plc (NYSE:MNK), IQVIA Holdings Inc. (NYSE:IQV), AbbVie Inc. (NYSE:ABBV), Zoetis Inc. (NYSE:ZTS), Edwards Lifesciences Corporation (NYSE:EW), The Goldman Sachs Group, Inc. (NYSE:GS), Owens & Minor, Inc. (NYSE:OMI), Quest Diagnostics Incorporated (NYSE:DGX), ResMed Inc. (NYSE:RMD), Molina Healthcare, Inc. (NYSE:MOH), Alkermes plc (NasdaqGS:ALKS), Amgen Inc. (NasdaqGS:AMGN), Exelixis, Inc. (NasdaqGS:EXEL), Gilead Sciences, Inc. (NasdaqGS:GILD), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), NuVasive, Inc. (NasdaqGS:NUVA), Illumina, Inc. (NasdaqGS:ILMN), Hologic, Inc. (NasdaqGS:HOLX), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Mylan N.V. (NasdaqGS:MYL), Patterson Companies, Inc. (NasdaqGS:PDCO), ICU Medical, Inc. (NasdaqGS:ICUI), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Accuray Incorporated (NasdaqGS:ARAY), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Henry Schein, Inc. (NasdaqGS:HSIC), Magellan Health, Inc. (NasdaqGS:MGLN), Incyte Corporation (NasdaqGS:INCY), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Exact Sciences Corporation (NasdaqCM:EXAS)The Goldman Sachs Group, Inc., Goldman Sachs 35th Annual Global Healthcare Conference, Jun 10, 2014 through Jun 12, 2014. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States.
260
6/30/20146.73x17.88x19.56x34.87x20.75x$13,594$125.87375.32%Jun-10-2014ConferenceWilliam Blair & Company, L.L.C., William Blair & Company's 34th Annual Growth Stock Conference, Jun 10, 2014 through Jun 12, 2014RBC Bearings Incorporated (NasdaqGS:ROLL), Performant Financial Corporation (NasdaqGS:PFMT), Echo Global Logistics, Inc. (NasdaqGS:ECHO), Cardiovascular Systems, Inc. (NasdaqGS:CSII), MoneyGram International, Inc. (NasdaqGS:MGI), Gogo Inc. (NasdaqGS:GOGO), Sabre Corporation (NasdaqGS:SABR), Paylocity Holding Corporation (NasdaqGS:PCTY), Citrix Systems, Inc. (NasdaqGS:CTXS), Commvault Systems, Inc. (NasdaqGS:CVLT), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), LivaNova PLC (NasdaqGS:LIVN), AudioCodes Ltd. (NasdaqGS:AUDC), Aspen Technology, Inc. (NasdaqGS:AZPN), Akamai Technologies, Inc. (NasdaqGS:AKAM), Align Technology, Inc. (NasdaqGS:ALGN), Gilead Sciences, Inc. (NasdaqGS:GILD), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), NuVasive, Inc. (NasdaqGS:NUVA), Silicon Laboratories Inc. (NasdaqGS:SLAB), SPS Commerce, Inc. (NasdaqGS:SPSC), Starbucks Corporation (NasdaqGS:SBUX), Stericycle, Inc. (NasdaqGS:SRCL), HealthStream, Inc. (NasdaqGS:HSTM), Cogent Communications Holdings, Inc. (NasdaqGS:CCOI), DexCom, Inc. (NasdaqGS:DXCM), Trimble Inc. (NasdaqGS:TRMB), RealPage, Inc. (NasdaqGS:RP), CECO Environmental Corp. (NasdaqGS:CECE), Abiomed, Inc. (NasdaqGS:ABMD), Virtusa Corporation (NasdaqGS:VRTU), Cornerstone OnDemand, Inc. (NasdaqGS:CSOD), Encore Capital Group, Inc. (NasdaqGS:ECPG), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Mercury Systems, Inc. (NasdaqGS:MRCY), Bottomline Technologies (de), Inc. (NasdaqGS:EPAY), Henry Schein, Inc. (NasdaqGS:HSIC), WisdomTree Investments, Inc. (NasdaqGS:WETF), FLIR Systems, Inc. (NasdaqGS:FLIR), Tractor Supply Company (NasdaqGS:TSCO), Urban Outfitters, Inc. (NasdaqGS:URBN), Exponent, Inc. (NasdaqGS:EXPO), Insulet Corporation (NasdaqGS:PODD), Garmin Ltd. (NasdaqGS:GRMN), Huron Consulting Group Inc. (NasdaqGS:HURN), Verisk Analytics, Inc. (NasdaqGS:VRSK), RigNet, Inc. (NasdaqGS:RNET), Boingo Wireless, Inc. (NasdaqGS:WIFI), Potbelly Corporation (NasdaqGS:PBPB), Cardtronics plc (NasdaqGS:CATM), PRA Group, Inc. (NasdaqGS:PRAA), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), LKQ Corporation (NasdaqGS:LKQ), CEVA, Inc. (NasdaqGS:CEVA), Zumiez Inc. (NasdaqGS:ZUMZ), ServiceSource International, Inc. (NasdaqGS:SREV), InnerWorkings, Inc. (NasdaqGS:INWK), Inogen, Inc. (NasdaqGS:INGN), Exact Sciences Corporation (NasdaqCM:EXAS), Mitek Systems, Inc. (NasdaqCM:MITK), Sapiens International Corporation N.V. (NasdaqCM:SPNS), Dynavax Technologies Corporation (NasdaqCM:DVAX), MSCI Inc. (NYSE:MSCI), Abercrombie & Fitch Co. (NYSE:ANF), Globus Medical, Inc. (NYSE:GMED), Discover Financial Services (NYSE:DFS), CBRE Group, Inc. (NYSE:CBRE), Marcus & Millichap, Inc. (NYSE:MMI), RingCentral, Inc. (NYSE:RNG), Grubhub Inc. (NYSE:GRUB), Vocera Communications, Inc. (NYSE:VCRA), Proto Labs, Inc. (NYSE:PRLB), The Western Union Company (NYSE:WU), Edwards Lifesciences Corporation (NYSE:EW), ResMed Inc. (NYSE:RMD), WESCO International, Inc. (NYSE:WCC), Tyler Technologies, Inc. (NYSE:TYL), Keurig Dr Pepper Inc. (NYSE:KDP), Teleflex Incorporated (NYSE:TFX), AGCO Corporation (NYSE:AGCO), The Scotts Miracle-Gro Company (NYSE:SMG), Jacobs Engineering Group Inc. (NYSE:J), W.W. Grainger, Inc. (NYSE:GWW), Robert Half International Inc. (NYSE:RHI), The Cooper Companies, Inc. (NYSE:COO), Flowserve Corporation (NYSE:FLS), Ecolab Inc. (NYSE:ECL), Argo Group International Holdings, Ltd. (NYSE:ARGO), Abbott Laboratories (NYSE:ABT), MEDNAX, Inc. (NYSE:MD), Cardinal Health, Inc. (NYSE:CAH), Donaldson Company, Inc. (NYSE:DCI), Dover Corporation (NYSE:DOV), Haemonetics Corporation (NYSE:HAE), WEX Inc. (NYSE:WEX), ASGN Incorporated (NYSE:ASGN), Charles River Laboratories International, Inc. (NYSE:CRL), Adtalem Global Education Inc. (NYSE:ATGE), S&P Global Inc. (NYSE:SPGI), Alliance Data Systems Corporation (NYSE:ADS), ChannelAdvisor Corporation (NYSE:ECOM), Chipotle Mexican Grill, Inc. (NYSE:CMG), Ciena Corporation (NYSE:CIEN), Zoetis Inc. (NYSE:ZTS), Roadrunner Transportation Systems, Inc. (NYSE:RRTS), Envestnet, Inc. (NYSE:ENV), EVERTEC, Inc. (NYSE:EVTC), RE/MAX Holdings, Inc. (NYSE:RMAX), Vince Holding Corp. (NYSE:VNCE), U.S. Silica Holdings, Inc. (NYSE:SLCA), Palo Alto Networks, Inc. (NYSE:PANW), PROS Holdings, Inc. (NYSE:PRO), MaxLinear, Inc. (NYSE:MXL), Shutterstock, Inc. (NYSE:SSTK), GTT Communications, Inc. (NYSE:GTT), Financial Engines, Inc., Airgas, Inc., ARIAD Pharmaceuticals, Inc., BroadSoft, Inc., Cabela's Incorporated, Cepheid, Concur Technologies, Inc., Datawatch Corporation, Peregrine Semiconductor Corporation, JAGGAER, Inc., The Ultimate Software Group, Inc., Blue Nile, Inc., Blount International Inc., Rackspace Hosting, Inc., NxStage Medical, Inc., Capella Education Company, Sirona Dental Systems Inc., Neustar, Inc., Life Time, Inc., NetSuite Inc., Pall Corporation, Sonic Corp., Celgene Corporation, Komatsu Mining Corp., MICROS Systems, Inc., The Navigators Group, Inc., Thoratec LLC, Covance Inc., FEI Company, WageWorks, Inc., Infoblox Inc., WTW Delaware Holdings LLC, ADS Alliance Data Systems, Inc., William Blair & Company, L.L.C., Annie's, Inc., Borderfree, Inc., The Advisory Board Company, Cavium, Inc., Novadaq Technologies Inc., Riverbed Technology, Inc., MWI Veterinary Supply, Inc., HPE Aruba, Sandvine Corporation, Fairway Group Holdings Corp., Demandware, LLC, Ruckus Wireless, Inc., LDR Holding Corporation, Heartware International Inc., Boulder Brands, Inc., Tumi Holdings, Inc., Carbonite, Inc., AmTrust Financial Services, Inc., Aerohive Networks, Inc., ZELTIQ Aesthetics, Inc., Zoe's Kitchen, Inc., Qlik Technologies, Inc., Nimble Storage, Inc., Zulily, LLC, Textura Corporation, RetailMeNot, Inc., ExamWorks Group, Inc., Aratana Therapeutics, Inc., Wesco Aircraft Holdings, Inc., Fleetmatics Group PLC, Envision Healthcare Holdings, Inc., Nord Anglia Education, Inc., The ADT Security Corporation, Gigamon Inc., Papa Murphy's Holdings, Inc., K2M Group Holdings, Inc., MiX Telematics Limited (JSE:MIX), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Proofpoint, Inc. (NasdaqGM:PFPT), Veracyte, Inc. (NasdaqGM:VCYT)William Blair & Company, L.L.C., William Blair & Company's 34th Annual Growth Stock Conference, Jun 10, 2014 through Jun 12, 2014. Venue: Four Seasons Hotel, 120 East Delaware Place, Chicago, Illinois, United States.
261
6/30/20146.73x17.88x19.56x34.87x20.75x$13,157$121.82391.13%May-13-2014Company Conference PresentationIntuitive Surgical, Inc. Presents at Bank of America Merrill Lynch Health Care Conference, May-13-2014 01:00 PM-Intuitive Surgical, Inc. Presents at Bank of America Merrill Lynch Health Care Conference, May-13-2014 01:00 PM. Venue: Encore at Wynn Las Vegas, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States. Speakers: Calvin Darling, IR, Marshall L. Mohr, Chief Financial Officer and Senior Vice President.
262
6/30/20146.73x17.88x19.56x34.87x20.75x$13,157$121.82391.13%May-13-2014ConferenceBank of America Corporation, Bank of America Merrill Lynch Health Care Conference, May 13, 2014 through May 15, 2014Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), Biogen Inc. (NasdaqGS:BIIB), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), NuVasive, Inc. (NasdaqGS:NUVA), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Stericycle, Inc. (NasdaqGS:SRCL), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Masimo Corporation (NasdaqGS:MASI), Innoviva, Inc. (NasdaqGS:INVA), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Endo International plc (NasdaqGS:ENDP), Celldex Therapeutics, Inc. (NasdaqCM:CLDX), Regulus Therapeutics Inc. (NasdaqCM:RGLS), MEI Pharma, Inc. (NasdaqCM:MEIP), Antares Pharma, Inc. (NasdaqCM:ATRS), Corcept Therapeutics Incorporated (NasdaqCM:CORT), Cassava Sciences, Inc. (NasdaqCM:SAVA), Fortress Biotech, Inc. (NasdaqCM:FBIO), Prothena Corporation plc (NasdaqGS:PRTA), Quidel Corporation (NasdaqGS:QDEL), DexCom, Inc. (NasdaqGS:DXCM), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), VIVUS, Inc. (NasdaqGS:VVUS), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Akorn, Inc. (NasdaqGS:AKRX), Geron Corporation (NasdaqGS:GERN), Mylan N.V. (NasdaqGS:MYL), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Diversified Healthcare Trust (NasdaqGS:DHC), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Endologix, Inc. (NasdaqGS:ELGX), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Incyte Corporation (NasdaqGS:INCY), PDL BioPharma, Inc. (NasdaqGS:PDLI), Magellan Health, Inc. (NasdaqGS:MGLN), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Premier, Inc. (NasdaqGS:PINC), Fluidigm Corporation (NasdaqGS:FLDM), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Bruker Corporation (NasdaqGS:BRKR), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), AngioDynamics, Inc. (NasdaqGS:ANGO), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Cardiovascular Systems, Inc. (NasdaqGS:CSII), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Principia Biopharma Inc. (NasdaqGS:PRNB), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Heron Therapeutics, Inc. (NasdaqCM:HRTX), Exact Sciences Corporation (NasdaqCM:EXAS), MagForce AG (XTRA:MF6), MorphoSys AG (XTRA:MOR), TetraLogic Pharmaceuticals Corporation (OTCPK:TLOG), STERIS plc (NYSE:STE), Waters Corporation (NYSE:WAT), Integer Holdings Corporation (NYSE:ITGR), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Chemed Corporation (NYSE:CHE), HCA Healthcare, Inc. (NYSE:HCA), PerkinElmer, Inc. (NYSE:PKI), Eli Lilly and Company (NYSE:LLY), Merck & Co., Inc. (NYSE:MRK), Bio-Rad Laboratories, Inc. (NYSE:BIO), Baxter International Inc. (NYSE:BAX), MEDNAX, Inc. (NYSE:MD), Agnico Eagle Mines Limited (NYSE:AEM), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Service Corporation International (NYSE:SCI), Owens & Minor, Inc. (NYSE:OMI), U.S. Physical Therapy, Inc. (NYSE:USPH), Perrigo Company plc (NYSE:PRGO), West Pharmaceutical Services, Inc. (NYSE:WST), Boston Scientific Corporation (NYSE:BSX), Tenet Healthcare Corporation (NYSE:THC), Capital Senior Living Corporation (NYSE:CSU), Lannett Company, Inc. (NYSE:LCI), Globus Medical, Inc. (NYSE:GMED), WellCare Health Plans, Inc. (NYSE:WCG), Medical Properties Trust, Inc. (NYSE:MPW), Emergent BioSolutions Inc. (NYSE:EBS), Brookdale Senior Living Inc. (NYSE:BKD), Select Medical Holdings Corporation (NYSE:SEM), Mallinckrodt plc (NYSE:MNK), AbbVie Inc. (NYSE:ABBV), Community Health Systems, Inc. (NYSE:CYH), AmerisourceBergen Corporation (NYSE:ABC), AMN Healthcare Services, Inc. (NYSE:AMN), Abaxis, Inc., Array BioPharma Inc., Cepheid, IPC Healthcare, Inc., Team Health Holdings, Inc., PAREXEL International Corporation, Pharmacyclics LLC, Quintiles Transnational Corp., Idenix Pharmaceuticals, Inc., The Medicines Company, Universal American Corp., Vascular Solutions, Inc., Repros Therapeutics Inc., Actelion Ltd, VCA Inc., Catamaran Corporation, Sirona Dental Systems Inc., Gentiva Health Services, Inc., Allergan, Inc., C. R. Bard, Inc., BioReference Laboratories, Inc., Celgene Corporation, Omnicare Inc., St. Jude Medical, Inc., Almost Family, Inc., Sigma-Aldrich Corporation, Thoratec LLC, Kindred Healthcare, LLC, Express Scripts Holding Company, Avanir Pharmaceuticals, Inc., Health Net, Inc., NPS Pharmaceuticals, Inc., Affymetrix Inc., Covance Inc., FEI Company, Impax Laboratories, Inc., MedAssets, Inc., Aetna Inc., Salix Pharmaceuticals Ltd., One Call Care Management, Inc., Zeltia SA, The Advisory Board Company, Auxilium Pharmaceuticals, LLC, Novadaq Technologies Inc., MWI Veterinary Supply, Inc., Volcano Corporation, Orexigen Therapeutics, Inc., Hospira Inc., FUJIFILM Cellular Dynamics, Inc., Capella Healthcare, Inc., Envision Healthcare Corporation, Heartware International Inc., Kythera Biopharmaceuticals, Inc., Aegerion Pharmaceuticals, Inc., Horizon Pharmaceutical LLC, Cempra, Inc., Skilled Healthcare, LLC, Covidien plc, PharMerica Corporation, Hyperion Therapeutics, Inc., Relypsa, Inc., Receptos, Inc., Foundation Medicine, Inc., Sagent Pharmaceuticals, Inc., SCAI Holdings, LLC, CareFusion Corporation, Tornier N.V., Durata Therapeutics, Inc., Seragon Pharmaceuticals Inc., Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), InspireMD, Inc. (AMEX:NSPR), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Chimerix, Inc. (NasdaqGM:CMRX), NanoString Technologies, Inc. (NasdaqGM:NSTG), MannKind Corporation (NasdaqGM:MNKD), GW Pharmaceuticals plc (NasdaqGM:GWPH), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), RadNet, Inc. (NasdaqGM:RDNT), STAAR Surgical Company (NasdaqGM:STAA), XOMA Corporation (NasdaqGM:XOMA), Health Insurance Innovations, Inc. (NasdaqGM:HIIQ), Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Hanger, Inc. (NYSE:HNGR), Humana Inc. (NYSE:HUM), Laboratory Corporation of America Holdings (NYSE:LH), Mettler-Toledo International Inc. (NYSE:MTD), Universal Health Services, Inc. (NYSE:UHS), Bank of America Corporation (NYSE:BAC), Hill-Rom Holdings, Inc. (NYSE:HRC), DiaSorin S.p.A. (BIT:DIA), H. Lundbeck A/S (CPSE:LUN)Bank of America Corporation, Bank of America Merrill Lynch Health Care Conference, May 13, 2014 through May 15, 2014. Venue: Encore at Wynn Las Vegas, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States.
263
6/30/20146.73x17.88x19.56x34.87x20.75x$13,022$120.57396.22%Apr-30-2014Strategic AllianceTeleflex Incorporated Partners with Intuitive Surgical to Create Access Solutions for New da Vinci(R) Xi(TM) Surgical SystemTeleflex Incorporated (NYSE:TFX)Teleflex Incorporated has partnered with Intuitive Surgical to manufacture Weck(R) disposable trocar seals and obturators for the new da Vinci Xi Surgical System. This partnership provides surgeons performing robotic procedures with an access solution that offers the same level of confidence, clarity, and control as Teleflex's Weck Vista(R) Bladeless Laparoscopic Access Ports, used in standard laparoscopic cases. Weck(R) brand seals and trocars developed for the da Vinci Xi System use the same technology as Weck Vista(R) Access Ports, specifically the patented atraumatic dilating obturator tip. In standard laparoscopic cases, the Weck Vista(R) Access portfolio can meet all access needs by providing the broadest offering of primary entry access ports: high clarity in optical ports with uniquely designed ridged cannulas, wide variety of balloon and cone open access ports, standard ridged and smooth cannula access ports. The da Vinci Xi System is the fourth generation of the da Vinci technology and is designed as a minimally invasive approach to large-incision abdominal surgeries. Intuitive Surgical says the robot has been optimized for multi-quadrant surgeries. The da Vinci Xi System was first made commercially available on April 1, 2014.
264
6/30/20146.73x17.88x19.56x34.87x20.75x$13,189$122.12389.92%Apr-25-2014Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on March 5, 2009.-From January 1, 2014 to March 31, 2014, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 6,169,244 shares, representing 15.69% for $2,028.32 million under the buyback announced on March 5, 2009.
265
6/30/20146.73x17.88x19.56x34.87x20.75x$13,367$123.77383.39%Apr-24-2014Annual General MeetingIntuitive Surgical, Inc., Annual General Meeting, Apr 24, 2014-Intuitive Surgical, Inc., Annual General Meeting, Apr 24, 2014., at 15:00 Pacific Daylight. Location: 1020 kifer road. Agenda: To consider and elect six members to the board of directors to serve until the 2015 annual meeting of stockholders; to consider an advisory vote on the approval of the compensation of named executive officers; to ratify the appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2014; and to transact any other business which is properly brought before the annual meeting or adjournments or postponements thereof.
266
6/30/20146.73x17.88x19.56x34.87x20.75x$15,204$140.78324.98%Apr-22-2014Earnings CallIntuitive Surgical, Inc., Q1 2014 Earnings Call, Apr 22, 2014-Intuitive Surgical, Inc., Q1 2014 Earnings Call, Apr 22, 2014
267
6/30/20146.73x17.88x19.56x34.87x20.75x$15,204$140.78324.98%Apr-22-2014Corporate Guidance - New/Confirmed, Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Reaffirms Financial Guidance for 2014-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported total revenue of $464.7 million compared to $611.4 million for the same period a year ago. Income from operations was of $56.6 million compared to $251.2 million for the same period a year ago. Income before taxes was of $60.5 million compared to $255.5 million for the same period a year ago. Net income was of $44.3 million or $1.13 per diluted share compared to $188.9 million or $4.56 per diluted share for the same period a year ago. Revenue reflects a reduction of first quarter of 2014 system revenue by approximately $24 million as well as instrument and accessory revenue by $2 million associated with a customer trade-out program for the newly launched da Vinci(R) Xi(TM) Surgical System. Excluding the $26 million deferral relating to the trade-out program, revenue would have been $491 million, a decrease of approximately 20% compared with first quarter of 2013. Excluding the legal accrual of $67 million and the deferral of $26 million, the company generated $135 million in non-GAAP net income or $3.46 per share compared with $205 million or $4.99 [ph] share for the fourth quarter of 2013.

Excluding the impact of this quarter's $67 million charge for estimated legal settlements, the company continue to expect to grow operating expenses roughly 12% to 15% above 2013 levels. The company expects 2014 noncash stock compensation expense to be towards the lower end of the $180 million to $190 million range communicated on last quarter's call, compared to $169 million in 2013. The company continue to expect other income, which is comprised mostly of interest income, to total between $15 million and $20 million in 2014, also towards the lower end of the range. With regard to income tax, the company continue to expect 2014 income tax rate to be between 25% and 28% of pretax income, depending primarily on the mix of U.S. and international profits. This forecast does not assumed the reinstatement of the R&D tax credit in 2014.
268
6/30/20146.73x17.88x19.56x34.87x20.75x$15,204$140.78324.98%Apr-22-2014Earnings Release DateIntuitive Surgical, Inc. to Report Q1, 2014 Results on Apr 22, 2014-Intuitive Surgical, Inc. announced that they will report Q1, 2014 results at 7:05 PM, GMT Standard Time on Apr 22, 2014
269
6/30/20146.73x17.88x19.56x34.87x20.75x$15,204$140.78324.98%Apr-22-2014Product-Related AnnouncementIntuitive Surgical, Inc. Announces FDA Clearance of da Vinci Sp Surgical System-Intuitive Surgical, Inc. announced it has received FDA 510(k) clearance for the da Vinci Sp Surgical System, which is designed to expand the Company's single-incision product offering. This initial clearance is specific to urologic surgical procedures that are appropriate for a single port approach. da Vinci Sp technology is a dedicated single-port innovation designed to deliver an articulating 3D HD camera and three fully articulating instruments through a single 25 mm cannula. The fully wristed EndoWrist(R) Sp Instruments have two more degrees of freedom than the da Vinci Single-Site(R) Instruments, which are not wristed and are used in single port surgeries. The surgeon controls the instruments and endoscope while seated at the da Vinci Surgical System console. The Company does not intend to commercialize the da Vinci Sp technology until the current technology is engineered to be fully compatible with the newly released da Vinci Xi(TM) Surgical System, currently projected for the second half of 2015. This will require product refinements, supply chain optimization and additional regulatory clearances.
270
6/30/20146.73x17.88x19.56x34.87x20.75x$16,439$152.21293.07%Apr-09-2014Company Conference PresentationDa Vinci Presents at 10th Annual CIS Private Equity and Venture Capital, Apr-09-2014 11:00 AM-Da Vinci Presents at 10th Annual CIS Private Equity and Venture Capital, Apr-09-2014 11:00 AM. Venue: Marriott Moscow Royal Aurora, Moscow, Russia. Speakers: Oleg Jelezko, Managing Partner.
271
6/30/20146.73x17.88x19.56x34.87x20.75x$17,634$163.28266.42%Apr-08-2014ConferenceC5, 10th Annual CIS Private Equity and Venture Capital, Apr 09, 2014 through Apr 10, 2014Sirit, Inc., The European Bank for Reconstruction and Development, Mint Capital, C5 Communications Limited, Baker Botts L.L.P., Baker Botts L.L.P., Joint-Stock Company Sberbank CIB, State Development Corporation "VEB.RF", Alpha Associates AG, Investment Arm, DEG-Deutsche Investitions- und Entwicklungsgesellschaft mbH, UFG Asset Management, JSC Future, Almaz Capital Partners, VIYM, I2BF Global Ventures Ltd., Pride Capital Partners, Llc, Genezis Technology Capital, Runa Capital Management, Zubr Capital, Pantheon Ventures Ltd., RT Invest Joint-Stock Company, O2 Consulting, O2 Consulting, DS Law. Attorneys, Fund of Mezzanine Finance, MegasalesC5, 10th Annual CIS Private Equity and Venture Capital, Apr 09, 2014 through Apr 10, 2014. Venue: Marriott Moscow Royal Aurora, Moscow, Russia.
272
6/30/20146.73x17.88x19.56x34.87x20.75x$17,634$163.28266.42%Apr-08-2014Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Provides Preliminary Unaudited Earnings Guidance for the First Quarter of 2014-Intuitive Surgical, Inc. provided preliminary unaudited earnings guidance for the first quarter of 2014. For the quarter, the company anticipates revenue to be approximately $465 million, down 24% compared with $611 million for the first quarter of 2013. Revenue reflects a $26 million deferral associated with a customer trade-out program for the newly launched da Vinci Xi Surgical System. Excluding the impact of the trade-out program, revenue would have been $491 million, a decrease of 20% compared with the prior year. The company also announced a pre-tax charge of $67 million to reflect estimated costs of settling a number of product liability legal claims against the company. The claims are related to alleged complications from surgeries performed with certain versions of Monopolar Curved Scissors instruments that were the subject of a recall in 2013 and with a first-generation MCS tip cover that was the subject of a market withdrawal in 2012. The deferrals reduced first quarter 2014 system revenue by approximately $24 million as well as instrument and accessory revenue by $2 million. The Company expects to recognize all $26 million of the revenue deferrals within 2014.
273
6/30/20146.73x17.88x19.56x34.87x20.75x$17,769$164.53263.64%Apr-01-2014Product-Related AnnouncementIntuitive Surgical Announces New da Vinci Xi Surgical System-Intuitive Surgical, Inc. announced the FDA clearance and U.S. introduction of the da Vinci Xi Surgical System, a technological leap forward in replacing large-incision abdominal surgeries (open surgery) with a minimally invasive approach. The da Vinci Xi System has broader capabilities than prior generations of the da Vinci System. It can be used across a wide spectrum of minimally invasive surgical procedures and has been optimized for complex, multi-quadrant surgeries. For more than a decade, da Vinci Surgical Systems have provided patients with a minimally invasive alternative to open surgery that reduces many of the costs and complications associated with open procedures. Intuitive Surgical designed the new da Vinci Xi System with the goal of further advancing the technology used in minimally invasive surgery for complex diseases and conditions in gynecology, urology, thoracic, cardiac, and general surgery. With the U.S. introduction now underway, Intuitive Surgical will be seeking regulatory clearances to market the da Vinci Xi System around the world. Efficient Anatomical Access, Crystal Clear 3D-HD Visualization: By enabling efficient access throughout the abdomen and chest, the da Vinci Xi System expands upon core da Vinci System features, including wristed instruments, 3D-HD visualization, intuitive motion, and an ergonomic design. As with all da Vinci Surgical Systems, the da Vinci Xi System's immersive 3D-HD vision system provides surgeons a highly magnified view, virtually extending their eyes and hands into the patient. Compared to prior da Vinci Systems, the da Vinci Xi System's key features include: A new overhead instrument arm architecture designed to facilitate anatomical access from virtually any position. A new endoscope digital architecture that creates a simpler, more compact design with improved visual definition and clarity. An ability to attach the endoscope to any arm, providing flexibility for visualizing the surgical site. Smaller, thinner arms with newly designed joints that offer a greater range of motion than ever before. Longer instrument shafts designed to give surgeons greater operative reach. In addition, the da Vinci Xi System is built to be compatible with Intuitive Surgical's Firefly(TM) Fluorescence Imaging System. While it is not currently available, the company plan to seek regulatory clearance for use of Firefly Imaging with the da Vinci Xi System. This technology is currently available as an option with the da Vinci Si(TM) model, and it is used to provide the surgeon with additional visual information in a variety of surgical procedures by enabling real-time visualization and assessment of vessels, bile ducts and tissue perfusion. A System Designed For the Future: The da Vinci Xi System is an expandable technology platform that is designed to accommodate and seamlessly integrate a range of current technologies in areas such as imaging, advanced instruments and anatomical access, as well as future innovations. To provide hospitals with choices to match their needs, Intuitive Surgical will continue to offer the current da Vinci Si System, which addresses a broad span of procedure complexity, and the da Vinci Si-e(TM) System, a lower-cost system suited for less complex surgeries.
274
3/31/20146.79x16.73x18.05x32.27x22.52x$17,161$148.97301.62%Mar-05-2014Company Conference PresentationIntuitive Surgical, Inc. Presents at Raymond James 35th Annual Institutional Investors Conference, Mar-05-2014 08:40 AM-Intuitive Surgical, Inc. Presents at Raymond James 35th Annual Institutional Investors Conference, Mar-05-2014 08:40 AM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, Florida, United States.
275
3/31/20146.79x16.73x18.05x32.27x22.52x$17,262$149.84299.29%Mar-04-2014Auditor ChangeIntuitive Surgical, Inc. Appoints PricewaterhouseCoopers as New Independent Registered Public Accounting FirmPricewaterhouseCoopers LLPOn February 26, 2014, Intuitive Surgical, Inc. appointed PricewaterhouseCoopers (PwC) as the Company's new independent registered public accounting firm to audit the Company's financial statements for the fiscal year ending December 31, 2014, based on the recommendation and authorization of the Audit Committee of its Board of Directors following a competitive selection process.
276
3/31/20146.79x16.73x18.05x32.27x22.52x$0Mar-02-2014ConferenceRaymond James & Associates, Inc., Raymond James 35th Annual Institutional Investors Conference, Mar 02, 2014 through Mar 05, 2014Cboe Global Markets, Inc. (BATS:CBOE), Akamai Technologies, Inc. (NasdaqGS:AKAM), Intuit Inc. (NasdaqGS:INTU), Gildan Activewear Inc. (TSX:GIL), CGI Inc. (TSX:GIB.A), MiX Telematics Limited (JSE:MIX), Spirit Airlines, Inc. (NYSE:SAVE), Intercontinental Exchange, Inc. (NYSE:ICE), Continental Resources, Inc. (NYSE:CLR), Moody's Corporation (NYSE:MCO), Calix, Inc. (NYSE:CALX), Under Armour, Inc. (NYSE:UAA), WellCare Health Plans, Inc. (NYSE:WCG), MSCI Inc. (NYSE:MSCI), Tempur Sealy International, Inc. (NYSE:TPX), American Equity Investment Life Holding Company (NYSE:AEL), Whiting Petroleum Corporation (NYSE:WLL), NeoPhotonics Corporation (NYSE:NPTN), AXIS Capital Holdings Limited (NYSE:AXS), Chegg, Inc. (NYSE:CHGG), Delek US Holdings, Inc. (NYSE:DK), CatchMark Timber Trust, Inc. (NYSE:CTT), Axos Financial, Inc. (NYSE:AX), Digital Realty Trust, Inc. (NYSE:DLR), Health Insurance Innovations, Inc. (NasdaqGM:HIIQ), Logitech International S.A. (SWX:LOGN), Goodrich Petroleum Corporation (AMEX:GDP), Abaxis, Inc., Cepheid, DigitalGlobe, Inc., Lexmark International, Inc., PAREXEL International Corporation, Regal Entertainment Group, SanDisk LLC, JAGGAER, Inc., Qorvo US, Inc., WCI Communities, Inc., VCA Inc., ARRIS International Limited, Protective Life Corporation, C. R. Bard, Inc., Arctic Cat Inc., CA, Inc., XPO CNW, Inc., MICROS Systems, Inc., Parkway Properties Inc., Plum Creek Timber Co. Inc., Thoratec LLC, HCC Insurance Holdings Inc., NTELOS Holdings Corp., Starwood Hotels & Resorts Worldwide, LLC, Covance Inc., Genesee & Wyoming Inc., Cardinal Financial Corporation, TW Telecom Inc., Interactive Intelligence Group, Inc., MedAssets, Inc., WTW Delaware Holdings LLC, Aetna Inc., Angie's List, Inc., Raymond James & Associates, Inc., Ocean Rig UDW Inc., Kinder Morgan Management, LLC, Cavium, Inc., Heartland Payment Systems, Inc., Oritani Financial Corp., The Advisory Board Company, Alere Inc., Worldpay, Inc., TIAA FSB Holdings, Inc., Tangoe, Inc., Progressive Waste Solutions Ltd., Linn Energy, Inc., Pandora Media, LLC, Enel X North America, Inc., Control4 Corporation, Hospira Inc., BPZ Resources, Inc., Demandware, LLC, TerraVia Holdings, Inc., Heartware International Inc., Dresser-Rand Group Inc., Energy XXI Ltd, HD Supply, Inc., Susser Holdings Corporation, Alliance Holdings GP, L.P., Ignite Restaurant Group, Inc., Covidien plc, Del Frisco's Restaurant Group, Inc., KiOR, Inc., CareFusion Corporation, American Residential Properties, Inc., Gigamon Inc., Union Pacific Corporation (NYSE:UNP), Unisys Corporation (NYSE:UIS), Walmart Inc. (NYSE:WMT), Whirlpool Corporation (NYSE:WHR), Marathon Oil Corporation (NYSE:MRO), Covanta Holding Corporation (NYSE:CVA), The Home Depot, Inc. (NYSE:HD), Delta Air Lines, Inc. (NYSE:DAL), Dycom Industries, Inc. (NYSE:DY), W.W. Grainger, Inc. (NYSE:GWW), Harley-Davidson, Inc. (NYSE:HOG), Arrow Electronics, Inc. (NYSE:ARW), CenturyLink, Inc. (NYSE:CTL), Brinker International, Inc. (NYSE:EAT), HCA Healthcare, Inc. (NYSE:HCA), Coeur Mining, Inc. (NYSE:CDE), salesforce.com, inc. (NYSE:CRM), Model N, Inc. (NYSE:MODN), Cincinnati Bell Inc. (NYSE:CBB), Brunswick Corporation (NYSE:BC), Central Pacific Financial Corp. (NYSE:CPF), GATX Corporation (NYSE:GATX), The Toro Company (NYSE:TTC), Waste Management, Inc. (NYSE:WM), MEDNAX, Inc. (NYSE:MD), MAXIMUS, Inc. (NYSE:MMS), United Parcel Service, Inc. (NYSE:UPS), Agnico Eagle Mines Limited (NYSE:AEM), Aflac Incorporated (NYSE:AFL), STERIS plc (NYSE:STE), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), MSC Industrial Direct Co., Inc. (NYSE:MSM), Charles River Laboratories International, Inc. (NYSE:CRL), Superior Energy Services, Inc. (NYSE:SPN), Helix Energy Solutions Group, Inc. (NYSE:HLX), Range Resources Corporation (NYSE:RRC), CACI International Inc (NYSE:CACI), Oil States International, Inc. (NYSE:OIS), Haemonetics Corporation (NYSE:HAE), Jabil Inc. (NYSE:JBL), Ryder System, Inc. (NYSE:R), Plantronics, Inc. (NYSE:PLT), Dine Brands Global, Inc. (NYSE:DIN), Kansas City Southern (NYSE:KSU), Leggett & Platt, Incorporated (NYSE:LEG), Ethan Allen Interiors Inc. (NYSE:ETH), FleetCor Technologies, Inc. (NYSE:FLT), Encompass Health Corporation (NYSE:EHC), Concho Resources Inc. (NYSE:CXO), Crown Castle International Corp. (REIT) (NYSE:CCI), Denbury Resources Inc. (NYSE:DNR), Clean Harbors, Inc. (NYSE:CLH), Alliance Data Systems Corporation (NYSE:ADS), AmerisourceBergen Corporation (NYSE:ABC), ChannelAdvisor Corporation (NYSE:ECOM), AutoZone, Inc. (NYSE:AZO), MRC Global Inc. (NYSE:MRC), Cinemark Holdings, Inc. (NYSE:CNK), Bonanza Creek Energy, Inc. (NYSE:BCEI), Marathon Petroleum Corporation (NYSE:MPC), Pebblebrook Hotel Trust (NYSE:PEB), Rayonier Inc. (NYSE:RYN), New York Community Bancorp, Inc. (NYSE:NYCB), Toll Brothers, Inc. (NYSE:TOL), ProAssurance Corporation (NYSE:PRA), SM Energy Company (NYSE:SM), Teleflex Incorporated (NYSE:TFX), WESCO International, Inc. (NYSE:WCC), Enterprise Products Partners L.P. (NYSE:EPD), The Williams Companies, Inc. (NYSE:WMB), Citigroup Inc. (NYSE:C), Steelcase Inc. (NYSE:SCS), Waste Connections, Inc. (NYSE:WCN), Capital Senior Living Corporation (NYSE:CSU), Polaris Inc. (NYSE:PII), Service Corporation International (NYSE:SCI), Southwestern Energy Company (NYSE:SWN), Pioneer Natural Resources Company (NYSE:PXD), Pier 1 Imports, Inc. (NYSE:PIR), S&P Global Inc. (NYSE:SPGI), Raymond James Financial, Inc. (NYSE:RJF), Intelsat S.A. (NYSE:I), Malibu Boats, Inc. (NasdaqGM:MBUU), Applied Optoelectronics, Inc. (NasdaqGM:AAOI), Key Energy Services, Inc. (OTCPK:KEG.X), Harvest Oil & Gas Corp. (OTCPK:HRST), Ultra Petroleum Corp. (OTCPK:UPLC), Basic Energy Services, Inc. (OTCPK:BASX), Oasis Petroleum Inc. (NasdaqCM:OAS), HD Supply Holdings, Inc. (NasdaqGS:HDS), Carrols Restaurant Group, Inc. (NasdaqGS:TAST), Fiesta Restaurant Group, Inc. (NasdaqGS:FRGI), MACOM Technology Solutions Holdings, Inc. (NasdaqGS:MTSI), Chuy's Holdings, Inc. (NasdaqGS:CHUY), Allegiant Travel Company (NasdaqGS:ALGT), Iridium Communications Inc. (NasdaqGS:IRDM), Insulet Corporation (NasdaqGS:PODD), OraSure Technologies, Inc. (NasdaqGS:OSUR), Pinnacle Financial Partners, Inc. (NasdaqGS:PNFP), Alliance Resource Partners, L.P. (NasdaqGS:ARLP), Encore Capital Group, Inc. (NasdaqGS:ECPG), PRA Group, Inc. (NasdaqGS:PRAA), Skyworks Solutions, Inc. (NasdaqGS:SWKS), Verisk Analytics, Inc. (NasdaqGS:VRSK), ORBCOMM Inc. (NasdaqGS:ORBC), Nasdaq, Inc. (NasdaqGS:NDAQ), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Ares Capital Corporation (NasdaqGS:ARCC), Home Bancshares, Inc. (Conway, AR) (NasdaqGS:HOMB), Brightcove Inc. (NasdaqGS:BCOV), CME Group Inc. (NasdaqGS:CME), Saia, Inc. (NasdaqGS:SAIA), LKQ Corporation (NasdaqGS:LKQ), Tech Data Corporation (NasdaqGS:TECD), PotlatchDeltic Corporation (NasdaqGS:PCH), ATN International, Inc. (NasdaqGS:ATNI), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Avnet, Inc. (NasdaqGS:AVT), Dawson Geophysical Company (NasdaqGS:DWSN), J.B. Hunt Transport Services, Inc. (NasdaqGS:JBHT), Fastenal Company (NasdaqGS:FAST), Meridian Bioscience, Inc. (NasdaqGS:VIVO), Micron Technology, Inc. (NasdaqGS:MU), ScanSource, Inc. (NasdaqGS:SCSC), Shenandoah Telecommunications Company (NasdaqGS:SHEN), Bottomline Technologies (de), Inc. (NasdaqGS:EPAY), United Bankshares, Inc. (NasdaqGS:UBSI), Tractor Supply Company (NasdaqGS:TSCO), KVH Industries, Inc. (NasdaqGS:KVHI), TD Ameritrade Holding Corporation (NasdaqGS:AMTD), Atlantic Union Bankshares Corporation (NasdaqGS:AUB), Insight Enterprises, Inc. (NasdaqGS:NSIT), Patterson-UTI Energy, Inc. (NasdaqGS:PTEN), Virtus Investment Partners, Inc. (NasdaqGS:VRTS), ArcBest Corporation (NasdaqGS:ARCB), Commvault Systems, Inc. (NasdaqGS:CVLT), Check Point Software Technologies Ltd. (NasdaqGS:CHKP), Citrix Systems, Inc. (NasdaqGS:CTXS), E*TRADE Financial Corporation (NasdaqGS:ETFC), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Marriott International, Inc. (NasdaqGS:MAR), Masimo Corporation (NasdaqGS:MASI), Natus Medical Incorporated (NasdaqGS:NTUS), NVIDIA Corporation (NasdaqGS:NVDA), SS&C Technologies Holdings, Inc. (NasdaqGS:SSNC), Stericycle, Inc. (NasdaqGS:SRCL), SBA Communications Corporation (NasdaqGS:SBAC), Viavi Solutions Inc. (NasdaqGS:VIAV), Wintrust Financial Corporation (NasdaqGS:WTFC), Cogent Communications Holdings, Inc. (NasdaqGS:CCOI), MarketAxess Holdings Inc. (NasdaqGS:MKTX), ACI Worldwide, Inc. (NasdaqGS:ACIW), DexCom, Inc. (NasdaqGS:DXCM), Principal Financial Group, Inc. (NasdaqGS:PFG), Texas Capital Bancshares, Inc. (NasdaqGS:TCBI), Red Robin Gourmet Burgers, Inc. (NasdaqGS:RRGB)Raymond James & Associates, Inc., Raymond James 35th Annual Institutional Investors Conference, Mar 02, 2014 through Mar 05, 2014. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, Florida, United States.
277
3/31/20146.79x16.73x18.05x32.27x22.52x$16,857$146.33308.86%Jan-23-2014Earnings CallIntuitive Surgical, Inc., Q4 2013 Earnings Call, Jan 23, 2014-Intuitive Surgical, Inc., Q4 2013 Earnings Call, Jan 23, 2014
278
3/31/20146.79x16.73x18.05x32.27x22.52x$16,857$146.33308.86%Jan-23-2014Corporate Guidance - New/Confirmed, Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Tax Rate Guidance for 2014-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported total revenue of USD 576.2 million against USD 609.3 million a year ago. Income from operations was USD 208.6 million against USD 248.1 million a year ago. Income before taxes was USD 214.5 million against USD 251.8 million a year ago. Net income was USD 166.2 million or USD 4.28 per diluted share against USD 174.9 million or USD 4.25 per diluted share a year ago. Operating results for the fourth quarter of 2013 included USD 42 million of non-cash share-based compensation expense, compared with USD 38 million for the fourth quarter of 2012. The company generated USD 193 million in non-GAAP net income or USD 4.98 per share compared with USD 205 million or USD 4.99 per share for the fourth quarter of 2012.

For the year, the company reported total revenue of USD 2,265.1 million against USD 2,178.8 million a year ago. Income from operations was USD 852.5 million against USD 878.1 million a year ago. Income before taxes was USD 870.9 against USD 893.9 million a year ago. Net income was USD 671 million or USD 16.73 per diluted share against USD 656.6 million or USD 15.98 per diluted share a year ago. Net income for the years ended December 31, 2013 and 2012, included one-time tax benefits of USD 34 million and USD 47 million, respectively, associated with various items, including the expiration of the statutes of limitations in multiple jurisdictions. Excluding these one-time benefits, net income and earnings per share for the years ended December 31, 2013 and 2012, would have been USD 637 million or USD 15.88 per share and USD 610 million, or USD 14.84 per share, respectively. Finally, the company generated USD 880 million in cash flows from operations for the year. The company generated USD 795 million in non-GAAP net income or USD 19.83 per share compared with USD 777 million or USD 18.91 per share last year.

For 2014, the company expects income tax rate to be between 25% and 28% of pretax income, depending primarily on the mix of U.S. and international profits.
279
3/31/20146.79x16.73x18.05x32.27x22.52x$16,857$146.33308.86%Jan-23-2014Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on March 5, 2009.-From October 1, 2013 to December 31, 2013, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 6,169,244 shares, representing 15.69% for $2,028.32 million under the buyback announced on March 5, 2009.
280
3/31/20146.79x16.73x18.05x32.27x22.52x$16,862$146.37308.75%Jan-22-2014M&A Transaction ClosingIntuitive Surgical International Ltd. acquired medical shape sensing business from Luna Technologies, Inc. for $30 million.Luna Technologies, Inc., Luna Technologies, Inc., Medical Shape Sensing BusinessIntuitive Surgical International Ltd. entered into an asset purchase agreement to acquire medical shape sensing business from Luna Technologies, Inc. for $30 million in cash on January 17, 2014. Under the terms, Intuitive Surgical International paid $6 million in cash at closing and a second $6 million in cash to be paid no later than 90 days after closing, plus up to $8 million upon the accomplishment by Intuitive Surgical International of certain technical specifications and up to $10 million in potential future royalties. The second $6 million to be paid within 90 days has been placed in escrow. If these technical specifications are not achieved but the fiber optical shape sensing and localization technology is nevertheless included in an ISI medical system that receives Food and Drug Administration approval as the system’s only localization solution, then Intuitive Surgical International shall pay $6 million upon such approval. The royalties will be paid at a rate of $10,000 per commercially-sold medical robotic system. Also, as a part of the transaction, for a period of 15 years after closing, Luna has agreed to exit and not develop or commercialize its fiber optical shape sensing and localization technology in the field of medicine. Also as a part of the transaction, Intuitive Surgical International have hired certain employees of Luna. KPMG Corporate Finance LLC acted as financial advisor for Luna Innovations.


Intuitive Surgical International Ltd. completed the acquisition of medical shape sensing business from Luna Technologies, Inc. on January 21, 2014.
281
3/31/20146.79x16.73x18.05x32.27x22.52x$16,123$139.96327.47%Jan-14-2014Company Conference PresentationIntuitive Surgical, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-14-2014 11:30 AM-Intuitive Surgical, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-14-2014 11:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Gary S. Guthart, Chief Executive Officer, President and Director.
282
3/31/20146.79x16.73x18.05x32.27x22.52x$16,123$139.96327.47%Jan-14-2014Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Announces Preliminary Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2013-Intuitive Surgical, Inc. announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2013. The company expects revenue for the fourth quarter of 2013 of approximately $576 million, down approximately 5% from $609 million for the fourth quarter of 2012. Preliminary fourth quarter 2013 instruments and accessories revenue is expected to increase approximately 6% to approximately $268 million from $254 million during the fourth quarter of 2012. Preliminary fourth quarter 2013 da Vinci Surgical Systems revenue is expected to decrease approximately 23% to approximately $205 million from $265 million during the fourth quarter of 2012. Preliminary fourth quarter 2013 service revenue is expected to increase approximately 14% to approximately $103 million from $91 million during the fourth quarter of 2012.

The company expects revenue for the year ended December 31, 2013 to total approximately $2,265 million, up approximately 4% compared to full year 2012 revenue of $2,179 million. Full year 2013 instruments and accessories revenue is expected to increase approximately 14% to approximately $1,033 million. Full year 2013 systems revenue is expected to decrease approximately 11% to approximately $835 million. Intuitive sold 138 da Vinci Surgical Systems during the fourth quarter of 2013, compared with 175 systems during the fourth quarter of 2012. Preliminary full year 2013 service revenue is expected to increase approximately 16% to approximately $397 million from $343 million during 2012.
283
3/31/20146.79x16.73x18.05x32.27x22.52x$15,094$131.02356.64%Jan-13-2014ConferenceJPMorgan Chase & Co., the JPMorgan 32nd Annual Healthcare Conference, Jan 13, 2014 through Jan 16, 2014Almirall, S.A. (BME:ALM), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Innoviva, Inc. (NasdaqGS:INVA), Wright Medical Group N.V. (NasdaqGS:WMGI), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Masimo Corporation (NasdaqGS:MASI), NuVasive, Inc. (NasdaqGS:NUVA), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), VIVUS, Inc. (NasdaqGS:VVUS), United Therapeutics Corporation (NasdaqGS:UTHR), Stericycle, Inc. (NasdaqGS:SRCL), Quidel Corporation (NasdaqGS:QDEL), DexCom, Inc. (NasdaqGS:DXCM), Telenav, Inc. (NasdaqGS:TNAV), Geron Corporation (NasdaqGS:GERN), NextGen Healthcare, Inc. (NasdaqGS:NXGN), ICU Medical, Inc. (NasdaqGS:ICUI), Patterson Companies, Inc. (NasdaqGS:PDCO), Henry Schein, Inc. (NasdaqGS:HSIC), Incyte Corporation (NasdaqGS:INCY), Magellan Health, Inc. (NasdaqGS:MGLN), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Akorn, Inc. (NasdaqGS:AKRX), Cerner Corporation (NasdaqGS:CERN), Mylan N.V. (NasdaqGS:MYL), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), Biogen Inc. (NasdaqGS:BIIB), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Amgen Inc. (NasdaqGS:AMGN), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), LivaNova PLC (NasdaqGS:LIVN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Endo International plc (NasdaqGS:ENDP), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Align Technology, Inc. (NasdaqGS:ALGN), Tivity Health, Inc. (NasdaqGS:TVTY), NantHealth, Inc. (NasdaqGS:NH), Allena Pharmaceuticals, Inc. (NasdaqGS:ALNA), BeiGene, Ltd. (NasdaqGS:BGNE), Clovis Oncology, Inc. (NasdaqGS:CLVS), Adaptive Biotechnologies Corporation (NasdaqGS:ADPT), Moderna, Inc. (NasdaqGS:MRNA), Conformis, Inc. (NasdaqGS:CFMS), Intrexon Corporation (NasdaqGS:XON), Zafgen, Inc. (NasdaqGS:ZFGN), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), IVERIC bio, Inc. (NasdaqGS:ISEE), Surgery Partners, Inc. (NasdaqGS:SGRY), OPKO Health, Inc. (NasdaqGS:OPK), Epizyme, Inc. (NasdaqGS:EPZM), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), Inovalon Holdings, Inc. (NasdaqGS:INOV), AngioDynamics, Inc. (NasdaqGS:ANGO), LHC Group, Inc. (NasdaqGS:LHCG), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Insulet Corporation (NasdaqGS:PODD), Bruker Corporation (NasdaqGS:BRKR), ICON Public Limited Company (NasdaqGS:ICLR), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Progenics Pharmaceuticals, Inc. (NasdaqGS:PGNX), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Endologix, Inc. (NasdaqGS:ELGX), Accuray Incorporated (NasdaqGS:ARAY), Fluidigm Corporation (NasdaqGS:FLDM), WW International, Inc. (NasdaqGS:WW), Premier, Inc. (NasdaqGS:PINC), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), ChemoCentryx, Inc. (NasdaqGS:CCXI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), JHL Biotech, Inc. (GTSM:6540), Exact Sciences Corporation (NasdaqCM:EXAS), Antares Pharma, Inc. (NasdaqCM:ATRS), Onconova Therapeutics, Inc. (NasdaqCM:ONTX), Dynavax Technologies Corporation (NasdaqCM:DVAX), Stemline Therapeutics, Inc. (NasdaqCM:STML), Bionano Genomics, Inc. (NasdaqCM:BNGO), Valeritas Holdings, Inc. (NasdaqCM:VLRX), Regulus Therapeutics Inc. (NasdaqCM:RGLS), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), TG Therapeutics, Inc. (NasdaqCM:TGTX), Glenmark Pharmaceuticals Limited (NSEI:GLENMARK), Biocon Limited (NSEI:BIOCON), Cipla Limited (NSEI:CIPLA), ERBA Diagnostics, Inc. (OTCPK:ERBA), Generex Biotechnology Corporation (OTCPK:GNBT), Melinta Therapeutics, Inc. (OTCPK:MLNT.Q), REVA Medical, Inc. (OTCPK:RVAL.L), MiMedx Group, Inc. (OTCPK:MDXG), INSYS Therapeutics, Inc. (OTCPK:INSY.Q), BluePrint Technologies, Inc. (OTCPK:BKSD), Seegene, Inc. (KOSDAQ:A096530), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Gerresheimer AG (XTRA:GXI), MorphoSys AG (XTRA:MOR), Bayer Aktiengesellschaft (XTRA:BAYN), AbbVie Inc. (NYSE:ABBV), Mallinckrodt plc (NYSE:MNK), Rite Aid Corporation (NYSE:RAD), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Integer Holdings Corporation (NYSE:ITGR), CVS Health Corporation (NYSE:CVS), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Universal Health Services, Inc. (NYSE:UHS), QIAGEN N.V. (NYSE:QGEN), Laboratory Corporation of America Holdings (NYSE:LH), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), AmerisourceBergen Corporation (NYSE:ABC), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Abbott Laboratories (NYSE:ABT), Chemed Corporation (NYSE:CHE), HCA Healthcare, Inc. (NYSE:HCA), The Cooper Companies, Inc. (NYSE:COO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Danaher Corporation (NYSE:DHR), PerkinElmer, Inc. (NYSE:PKI), Boston Scientific Corporation (NYSE:BSX), Perrigo Company plc (NYSE:PRGO), Owens & Minor, Inc. (NYSE:OMI), Varian Medical Systems, Inc. (NYSE:VAR), Tenet Healthcare Corporation (NYSE:THC), Charles River Laboratories International, Inc. (NYSE:CRL), Becton, Dickinson and Company (NYSE:BDX), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Invitae Corporation (NYSE:NVTA), Safeguard Scientifics, Inc. (NYSE:SFE), Air Methods Corporation, ARIAD Pharmaceuticals, Inc., Array BioPharma Inc., ArthroCare Corporation, Synageva BioPharma Corp., Intarcia Therapeutics, Inc., Cepheid, IPC Healthcare, Inc., Idenix Pharmaceuticals, Inc., PAREXEL International Corporation, Pharmacyclics LLC, Sequenom Inc., The Spectranetics Corporation, Sotera Health LLC, The Medicines Company, Universal American Corp., Dendreon Corporation, InterMune, Inc., Baker & McKenzie LLP, Actelion Ltd, IASIS Healthcare LLC, athenahealth, Inc., Connecture, Inc., NxStage Medical, Inc., Catamaran Corporation, BTG Limited, Sirona Dental Systems Inc., Ascension Health, Inc., Catholic Health East, Inc., CommonSpirit Health, Dignity Health, Biomet, Inc., Pall Corporation, Gentiva Health Services, Inc., Allergan, Inc., Analogic Corporation, C. R. Bard, Inc., Celgene Corporation, Forest Laboratories, LLC, St. Jude Medical, Inc., Almost Family, Inc., Sigma-Aldrich Corporation, Thoratec LLC, Kindred Healthcare, LLC, Omnicare Inc., Express Scripts Holding Company, Avanir Pharmaceuticals, Inc., Health Net, Inc., NPS Pharmaceuticals, Inc., Affymetrix Inc., Questcor Pharmaceuticals, Inc., Chindex International Inc., Covance Inc., FEI Company, Shire plc, Albany Molecular Research, Inc., Impax Laboratories, Inc., Legacy LifePoint Health, Inc., Keryx Biopharmaceuticals, Inc., Stallergenes SA, MedAssets, Inc., GE Healthcare Limited, QUALCOMM Ventures, Aetna Inc., Salix Pharmaceuticals Ltd., The Cleveland Clinic Foundation, SomaLogic, Inc., Advocate Health Care, Inc., Blue Cross and Blue Shield of Florida, Inc., The Advisory Board Company, Alere Inc., Auxilium Pharmaceuticals, LLC, Novadaq Technologies Inc., Volcano Corporation, Ganymed Pharmaceuticals AG, Genomic Health, Inc., Partners HealthCare System, Inc., Mercy Health, Intermountain Healthcare, Inc., Memorial Hermann Healthcare System, Inc., Summa Health System, Aurora Health Care, Inc., Virtua, Inc., InTouch Technologies, Inc., Ablynx NV, Yale-New Haven Health Services Corporation, Algeta ASA, Wellmont Health System, Inc., MWI Veterinary Supply, Inc., Northwestern Memorial Healthcare Corporation, Sebia SA, NYU Langone Hospitals, PathGroup, Inc., University of Pennsylvania Health System, Inc., Symphogen A/S, Hansen Medical, Inc., GetWellNetwork, Inc., OriGene Technologies, Inc., OSCAR, ZirMed, Inc., WuXi PharmaTech (Cayman) Inc., Proteus Digital Health, Inc., Orexigen Therapeutics, Inc., ProteinSimple, Inc., Novant Health, Inc., Hospira Inc., SonaCare Medical, LLC, Clarus Therapeutics, Inc., BioMarin Nederland B.V., AngioScore, Inc., Symetis SA, Rush University Medical Center, Medivation, Inc., Heartware International Inc., BioElectron Technology Corporation, FUJIFILM Cellular Dynamics, Inc., Biosensors International Group, Ltd., PneumRx, Inc., Vibra Healthcare, LLC, Kythera Biopharmaceuticals, Inc., Brooklyn ImmunoTherapeutics LLC, Paradigm Spine, LLC, PointClickCare Corp., OxySure Therapeutics, Inc., Aegerion Pharmaceuticals, Inc., RainDance Technologies, Inc., Viamet Pharmaceuticals, Inc., Cohera Medical, Inc., SurgiQuest, Inc., Mindray Medical International Limited, HTL-STREFA S.A., Covidien plc, PharMerica Corporation, Hyperion Therapeutics, Inc., Practice Fusion, Inc., ZELTIQ Aesthetics, Inc., Urgent Care MSO, LLC, Change Healthcare Engagement Solutions, Inc., EndoChoice, Inc., SYNLAB International GmbH, CareFusion Corporation, MDX Medical, Inc., AirStrip Technologies, Inc., Bio-Cancer Treatment International Ltd., Tornier N.V., Elixir Medical Corporation, American Civil Liberties Union, Inc., Advanced Accelerator Applications S.A., Independent Living Systems, LLC, Zuellig Pharma Holdings Pte. Ltd., Visterra, Inc., Simply Healthcare Plans, Inc., Sharecare Inc., Boston Heart Diagnostics Corporation, Naurex, Inc., Foundation Medicine, Inc., Good Start Genetics, Inc., Tesaro, Inc., ZS Pharma, Inc., Connexios Life Sciences Pvt. Ltd., Sagent Pharmaceuticals, Inc., Nuvaira, Inc., SCAI Holdings, LLC, CeQur SA, Civitas Therapeutics, Inc., Imaging Advantage LLC, Kite Pharma, Inc., Abbott Electrophysiology, Inc., CFR Pharmaceuticals S.A., Immunocore Limited, Simplificare, Inc., Truven Holding Corp., Kyruus, Inc., Kindstar Global Co., Ltd., Lumeris, Inc., HealthSpot Inc., Novast Holdings, Ltd., Geisinger Health System, OvaScience, Inc., Innopharma, Inc., Bioventus LLC, naviHealth, Inc., Team Health, Inc., Alkermes Inc., Envision Healthcare Holdings, Inc., Labrys Biologics, Inc., GenoSpace, LLC, xG Health Solutions, Inc., Oxford Immunotec Limited, MedAvail Technologies Inc., Spark Therapeutics, Inc., Juno Therapeutics, Inc., NantOmics, LLC, Capitol Street, Association for Molecular Pathology, VWR Corporation, CCHN Group Holdings, Inc., Scioderm, LLC, Oncimmune Holdings plc (AIM:ONC), Protalix BioTherapeutics, Inc. (AMEX:PLX), Vectura Group plc (LSE:VEC), AstraZeneca PLC (LSE:AZN), GlaxoSmithKline plc (LSE:GSK), Smith & Nephew plc (LSE:SN.), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Tecan Group Ltd. (SWX:TECN), Bumrungrad Hospital Public Company Limited (SET:BH), Hikma Pharmaceuticals PLC (LSE:HIK), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), NewLink Genetics Corporation (NasdaqGM:NLNK), MannKind Corporation (NasdaqGM:MNKD), NanoString Technologies, Inc. (NasdaqGM:NSTG), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Chimerix, Inc. (NasdaqGM:CMRX), Intersect ENT, Inc. (NasdaqGM:XENT), Apollo Endosurgery, Inc. (NasdaqGM:APEN), T2 Biosystems, Inc. (NasdaqGM:TTOO), Catabasis Pharmaceuticals, Inc. (NasdaqGM:CATB), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Sage Therapeutics, Inc. (NasdaqGM:SAGE), IQVIA Holdings Inc. (NYSE:IQV), Inspire Medical Systems, Inc. (NYSE:INSP), Kadmon Holdings, Inc. (NYSE:KDMN), Diplomat Pharmacy, Inc. (NYSE:DPLO), Concord Medical Services Holdings Limited (NYSE:CCM), Global Cord Blood Corporation (NYSE:CO), Teladoc Health, Inc. (NYSE:TDOC), WellCare Health Plans, Inc. (NYSE:WCG), Emergent BioSolutions Inc. (NYSE:EBS), Select Medical Holdings Corporation (NYSE:SEM), Molina Healthcare, Inc. (NYSE:MOH), Glaukos Corporation (NYSE:GKOS), JPMorgan Chase & Co. (NYSE:JPM), Vocera Communications, Inc. (NYSE:VCRA), Quest Diagnostics Incorporated (NYSE:DGX), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), Edwards Lifesciences Corporation (NYSE:EW), Ipsen S.A. (ENXTPA:IPN), NOXXON Pharma N.V. (ENXTPA:ALNOX), Sanofi (ENXTPA:SAN), EssilorLuxottica Société anonyme (ENXTPA:EL), Cegedim SA (ENXTPA:CGM), Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196), Berry Genomics Co.,Ltd (SZSE:000710), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), Novozymes A/S (CPSE:NZYM B), Samsung Biologics Co.,Ltd. (KOSE:A207940), Green Cross Corporation (KOSE:A006280), Elekta AB (publ) (OM:EKTA B), Active Biotech AB (publ) (OM:ACTI), Swedish Orphan Biovitrum AB (publ) (OM:SOBI), Daiichi Sankyo Company, Limited (TSE:4568), Otsuka Holdings Co., Ltd. (TSE:4578), Takeda Pharmaceutical Company Limited (TSE:4502), Astellas Pharma Inc. (TSE:4503), NanoCarrier Co., Ltd. (TSE:4571), IHH Healthcare Berhad (KLSE:IHH), Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B), PT Siloam International Hospitals Tbk (IDX:SILO), Lee's Pharmaceutical Holdings Limited (SEHK:950), Sino Biopharmaceutical Limited (SEHK:1177), Sinopharm Group Co. Ltd. (SEHK:1099), Sihuan Pharmaceutical Holdings Group Ltd. (SEHK:460), MicroPort Scientific Corporation (SEHK:853), Fortis Healthcare Limited (BSE:532843), Lupin Limited (BSE:500257), Dr. Reddy's Laboratories Limited (BSE:500124), CSL Limited (ASX:CSL), Qualicorp Consultoria e Corretora de Seguros S.A. (BOVESPA:QUAL3), Fleury S.A. (BOVESPA:FLRY3), UCB SA (ENXTBR:UCB), Oxurion NV (ENXTBR:OXUR), Oak Investment Partners, Atara Biotherapeutics, Inc. (NasdaqGS:ATRA)JPMorgan Chase & Co., The JPMorgan 32nd Annual Healthcare Conference, Jan 13, 2014 through Jan 16, 2014. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States.
284
12/31/20135.83x14.01x15.03x27.51x21.12x$14,181$123.74383.51%Dec-23-2013Index Constituent AddIntuitive Surgical, Inc.(NasdaqGS:ISRG) added to S&P 500 Value IndexS&P 500 Value (^SVX)Intuitive Surgical, Inc.(NasdaqGS:ISRG) added to S&P 500 Value Index
285
12/31/20135.83x14.01x15.03x27.51x21.12x$14,891$129.94360.44%Nov-08-2013Shelf Registration FilingHansen Medical, Inc. has filed a Shelf Registration in the amount of $10.37 million.Hansen Medical, Inc.Hansen Medical, Inc. has filed a Shelf Registration in the amount of $10.37 million.
286
12/31/20135.83x14.01x15.03x27.51x21.12x$14,601$127.41369.58%Nov-04-2013Lawsuits & Legal IssueIllinois Union Insurance Co. Files Lawsuit Against Intuitive Surgical Inc. Seeking to Rescind A Policy-Illinois Union Insurance Co. filed a lawsuit seeking to rescind a policy issued to a medical device company. The insurer's lawsuit claims Intuitive Surgical Inc. sought products liability coverage from Illinois Union earlier this year. Intuitive manufactures the da Vinci robotic surgical system. Illinois Union alleges that during the application process, Intuitive was also entering into agreements to toll the statute of limitations in certain underlying lawsuits involving defective surgical products. The lawsuit alleges Intuitive did not inform Illinois Union of those potential claims and the tolled statute of limitations. The suit seeks to rescind the policy on the grounds that Illinois Union is now faced with a much greater risk than anticipated when it issued the policy.
287
12/31/20135.83x14.01x15.03x27.51x21.12x$14,100$123.04386.26%Oct-25-2013Executive/Board Change - OtherIntuitive Surgical, Inc. Appoints Jamie E. Samath as Principal Accounting Officer-On October 24, 2013, the board of directors of Intuitive Surgical, Inc. voted to appoint Mr. Jamie E. Samath as the Principal Accounting Officer of the company, effective immediately. Mr. Samath will continue to serve in the capacity of Vice President and Corporate Controller. Mr. Samath joined the company in April 2013 as Vice President and Corporate Controller.
288
12/31/20135.83x14.01x15.03x27.51x21.12x$14,383$125.51376.69%Oct-18-2013Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on March 5, 2009.-From July 1, 2013 to September 30, 2013, the company has repurchased 1,739,579 shares, representing 4.38% for $693.86 million. With this, the company has completed the repurchase of 6,169,244 shares, representing 15.69% for $2,028.32 million under the buyback announced on March 5, 2009.
289
12/31/20135.83x14.01x15.03x27.51x21.12x$15,246$133.04349.71%Oct-17-2013Earnings CallIntuitive Surgical, Inc., Q3 2013 Earnings Call, Oct 17, 2013-Intuitive Surgical, Inc., Q3 2013 Earnings Call, Oct 17, 2013
290
12/31/20135.83x14.01x15.03x27.51x21.12x$15,246$133.04349.71%Oct-17-2013Corporate Guidance - New/Confirmed, Announcement of Earnings, Corporate Guidance-LoweredIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013; Revises Tax Rate Guidance for the Fourth Quarter of 2013; Revises Earnings Guidance for the Full Year 2013-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2013. For the quarter, the company reported total revenue of USD 499.0 million against USD 537.8 million a year ago. Income from operations was USD 174.2 million against USD 211.4 million a year ago. Income before taxes was USD 178.1 million against USD 215.7 million a year ago. Net income was USD 156.8 million or USD 3.99 per diluted share against USD 183.3 million or USD 4.46 per diluted share a year ago. Operating income decreased to USD 174 million from USD 211 million in the third quarter of 2012. Cash flow generated from operations was USD 204 million.

For the nine months, the company reported total revenue of USD 1,688.9 million against USD 1,569.5 million a year ago. Income from operations was USD 643.0 million against USD 630.0 million a year ago. Income before taxes was USD 656.4 against USD 642.1 million a year ago. Net income was USD 504.8 million or USD 12.46 per diluted share against USD 481.7 million or USD 11.72 per diluted share a year ago.

For the fourth quarter 2013, The company expects tax rate to be approximately 28% of pretax income, slightly lower than previously forecast, primarily due to the geographic mix of pretax income.

For the full year, during last call, the company forecast operating income to fall within a range of between 37% and 38% of net revenue. The company continues to anticipate full year 2013 operating income to fall within a range of between 37% and 38% of revenue. During last call the company projected full year 2013 revenue to range from approximately flat to 7% growth. The company now expects full year revenue growth in the lower half of that range.
291
9/30/20135.84x13.76x14.69x26.16x20.34x$14,129$123.61384.01%Sep-23-2013Product-Related AnnouncementIntuitive Surgical Announces Clearance to Expand Use of Fluorescence Imaging in Gallbladder Surgery-Intuitive Surgical, Inc. announced it received FDA 510(k) clearance for expanded use of its da Vinci(R) Fluorescence Imaging Vision System (Firefly(TM)) for the da Vinci(R) Surgical System. Firefly imaging can now be used during gallbladder surgery. The Firefly Fluorescence Imaging Vision System enables surgeons to use a special video camera and glowing dye to view blood flowing in vessels and tissue during minimally invasive surgical procedures. When a surgeon uses the Firefly camera, blood appears green and tissue without blood flow appears gray. In addition to providing the ability to view blood flow through vessels and tissue, the expanded use now includes real-time imaging of bile ducts (cystic duct, common bile duct and common hepatic duct). The Firefly imaging system is intended for use along with normal white light in imaging of the bile ducts and is not intended for standalone use. Injuries to the common bile duct represent a serious and challenging surgical complication, and most often occur during laparoscopic gallbladder removal. This occurs when the common bile duct is mistaken for the cystic duct, resulting in clipping and division of the common duct, which is then resected with the gallbladder. It is therefore beneficial in minimally invasive surgery to have the ability to properly identify the biliary duct.
292
9/30/20135.84x13.76x14.69x26.16x20.34x$14,345$125.50376.73%Sep-11-2013Company Conference PresentationIntuitive Surgical, Inc. Presents at Morgan Stanley Global Healthcare Conference, Sep-11-2013 10:35 AM-Intuitive Surgical, Inc. Presents at Morgan Stanley Global Healthcare Conference, Sep-11-2013 10:35 AM. Venue: Grand Hyatt, 109 East 42nd Street, New York, NY 10017, United States. Speakers: Aleks Cukic, Vice President of Strategy.
293
9/30/20135.84x13.76x14.69x26.16x20.34x$14,665$128.30366.32%Sep-09-2013ConferenceMorgan Stanley, Morgan Stanley Global Healthcare Conference, Sep 09, 2013 through Sep 11, 2013Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Mylan N.V. (NasdaqGS:MYL), Wright Medical Group N.V. (NasdaqGS:WMGI), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), United Therapeutics Corporation (NasdaqGS:UTHR), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Stericycle, Inc. (NasdaqGS:SRCL), Hologic, Inc. (NasdaqGS:HOLX), Henry Schein, Inc. (NasdaqGS:HSIC), Incyte Corporation (NasdaqGS:INCY), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Bruker Corporation (NasdaqGS:BRKR), Insulet Corporation (NasdaqGS:PODD), Luminex Corporation (NasdaqGS:LMNX), Align Technology, Inc. (NasdaqGS:ALGN), Alkermes plc (NasdaqGS:ALKS), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Amgen Inc. (NasdaqGS:AMGN), LivaNova PLC (NasdaqGS:LIVN), Cytokinetics, Incorporated (NasdaqGS:CYTK), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI), MorphoSys AG (XTRA:MOR), Stratec SE (XTRA:SBS), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), Hill-Rom Holdings, Inc. (NYSE:HRC), IQVIA Holdings Inc. (NYSE:IQV), AbbVie Inc. (NYSE:ABBV), Mallinckrodt plc (NYSE:MNK), Charles River Laboratories International, Inc. (NYSE:CRL), CVS Health Corporation (NYSE:CVS), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Waters Corporation (NYSE:WAT), Invacare Corporation (NYSE:IVC), Merck & Co., Inc. (NYSE:MRK), Chemed Corporation (NYSE:CHE), HCA Healthcare, Inc. (NYSE:HCA), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), PerkinElmer, Inc. (NYSE:PKI), Johnson & Johnson (NYSE:JNJ), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), AMN Healthcare Services, Inc. (NYSE:AMN), Morgan Stanley (NYSE:MS), ResMed Inc. (NYSE:RMD), Quest Diagnostics Incorporated (NYSE:DGX), Boston Scientific Corporation (NYSE:BSX), Perrigo Company plc (NYSE:PRGO), Baxter International Inc. (NYSE:BAX), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Encompass Health Corporation (NYSE:EHC), Medtronic plc (NYSE:MDT), Laboratory Corporation of America Holdings (NYSE:LH), QIAGEN N.V. (NYSE:QGEN), AmerisourceBergen Corporation (NYSE:ABC), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), Globus Medical, Inc. (NYSE:GMED), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Accuray Incorporated (NasdaqGS:ARAY), ChemoCentryx, Inc. (NasdaqGS:CCXI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), Epizyme, Inc. (NasdaqGS:EPZM), Clovis Oncology, Inc. (NasdaqGS:CLVS), China Biologic Products Holdings, Inc. (NasdaqGS:CBPO), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), Kamada Ltd. (TASE:KMDA), Sanofi (ENXTPA:SAN), ALK-Abelló A/S (CPSE:ALK B), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), XOMA Corporation (NasdaqGM:XOMA), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), Chimerix, Inc. (NasdaqGM:CMRX), MannKind Corporation (NasdaqGM:MNKD), NanoString Technologies, Inc. (NasdaqGM:NSTG), Novartis AG (SWX:NOVN), Roche Holding AG (SWX:ROG), Basilea Pharmaceutica AG (SWX:BSLN), Abaxis, Inc., ARIAD Pharmaceuticals, Inc., Array BioPharma Inc., Synageva BioPharma Corp., Cubist Pharmaceuticals LLC, Dyax Corp., The Spectranetics Corporation, The Medicines Company, Santarus, Inc., Xenoport, Inc., Catamaran Corporation, BioScrip, Inc., Celgene Corporation, Forest Laboratories, LLC, Omnicare Inc., St. Jude Medical, Inc., Thoratec LLC, Kindred Healthcare, LLC, C. R. Bard, Inc., SciClone Pharmaceuticals, Inc., Health Net, Inc., NPS Pharmaceuticals, Inc., Affymetrix Inc., Questcor Pharmaceuticals, Inc., Chindex International Inc., Covance Inc., Shire plc, MedAssets, Inc., Given Imaging Ltd., Aetna Inc., Auxilium Pharmaceuticals, LLC, The Advisory Board Company, Endocyte, Inc., Algeta ASA, Unilife Corporation, Hospira Inc., MAKO Surgical Corp., Aegerion Pharmaceuticals, Inc., Medivation, Inc., CareFusion Corporation, Tesaro, Inc.Morgan Stanley, Morgan Stanley Global Healthcare Conference, Sep 09, 2013 through Sep 11, 2013. Venue: Grand Hyatt, 109 East 42nd Street, New York, NY 10017, United States.
294
9/30/20135.84x13.76x14.69x26.16x20.34x$14,620$127.91367.74%Aug-15-2013Company Conference PresentationIntuitive Surgical, Inc. Presents at Canaccord Genuity 33rd Annual Growth Conference, Aug-15-2013 09:00 AM-Intuitive Surgical, Inc. Presents at Canaccord Genuity 33rd Annual Growth Conference, Aug-15-2013 09:00 AM. Venue: InterContinental Boston, 520 Atlantic Avenue, Boston, MA 02110, United States.
295
9/30/20135.84x13.76x14.69x26.16x20.34x$14,705$128.65365.05%Aug-14-2013ConferenceCanaccord Genuity Inc., Canaccord Genuity 33rd Annual Growth Conference, Aug 14, 2013 through Aug 15, 2013Abengoa, S.A. (BME:ABG), Cirrus Logic, Inc. (NasdaqGS:CRUS), Rent-A-Center, Inc. (NasdaqGS:RCII), Qorvo, Inc. (NasdaqGS:QRVO), QUALCOMM Incorporated (NasdaqGS:QCOM), SPS Commerce, Inc. (NasdaqGS:SPSC), Stratasys Ltd. (NasdaqGS:SSYS), TTM Technologies, Inc. (NasdaqGS:TTMI), TripAdvisor, Inc. (NasdaqGS:TRIP), RTI Surgical Holdings, Inc. (NasdaqGS:RTIX), Cree, Inc. (NasdaqGS:CREE), Cogent Communications Holdings, Inc. (NasdaqGS:CCOI), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Glu Mobile Inc. (NasdaqGS:GLUU), The Chefs' Warehouse, Inc. (NasdaqGS:CHEF), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), AngioDynamics, Inc. (NasdaqGS:ANGO), Zillow Group, Inc. (NasdaqGS:ZG), DocuSign, Inc. (NasdaqGS:DOCU), Conn's, Inc. (NasdaqGS:CONN), The ExOne Company (NasdaqGS:XONE), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Ceragon Networks Ltd. (NasdaqGS:CRNT), Insulet Corporation (NasdaqGS:PODD), Universal Display Corporation (NasdaqGS:OLED), PC Connection, Inc. (NasdaqGS:CNXN), Bottomline Technologies (de), Inc. (NasdaqGS:EPAY), MKS Instruments, Inc. (NasdaqGS:MKSI), OraSure Technologies, Inc. (NasdaqGS:OSUR), iRobot Corporation (NasdaqGS:IRBT), Veeco Instruments Inc. (NasdaqGS:VECO), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Nuance Communications, Inc. (NasdaqGS:NUAN), Steven Madden, Ltd. (NasdaqGS:SHOO), Endologix, Inc. (NasdaqGS:ELGX), Pegasystems Inc. (NasdaqGS:PEGA), Incyte Corporation (NasdaqGS:INCY), Merit Medical Systems, Inc. (NasdaqGS:MMSI), CalAmp Corp. (NasdaqGS:CAMP), Meridian Bioscience, Inc. (NasdaqGS:VIVO), Digi International Inc. (NasdaqGS:DGII), bluebird bio, Inc. (NasdaqGS:BLUE), Cytokinetics, Incorporated (NasdaqGS:CYTK), Insmed Incorporated (NasdaqGS:INSM), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Itron, Inc. (NasdaqGS:ITRI), Inseego Corp. (NasdaqGS:INSG), NuVasive, Inc. (NasdaqGS:NUVA), NVIDIA Corporation (NasdaqGS:NVDA), The Meet Group, Inc. (NasdaqCM:MEET), Exact Sciences Corporation (NasdaqCM:EXAS), Rubicon Technology, Inc. (NasdaqCM:RBCN), IMRIS Inc. (OTCPK:IMRS.Q), Towerstream Corporation (OTCPK:TWER), REVA Medical, Inc. (OTCPK:RVAL.L), ReShape Lifesciences Inc. (OTCPK:RSLS.D), TearLab Corporation (OTCPK:TEAR), Rego Payment Architectures, Inc. (OTCPK:RPMT), MiMedx Group, Inc. (OTCPK:MDXG), Fortress Biotech, Inc. (NasdaqCM:FBIO), Gevo, Inc. (NasdaqCM:GEVO), CHF Solutions, Inc. (NasdaqCM:CHFS), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), Riot Blockchain, Inc. (NasdaqCM:RIOT), AIXTRON SE (XTRA:AIXA), Zuora, Inc. (NYSE:ZUO), Wayfair Inc. (NYSE:W), Generac Holdings Inc. (NYSE:GNRC), IMAX Corporation (NYSE:IMAX), Belden Inc. (NYSE:BDC), Oxford Industries, Inc. (NYSE:OXM), Teva Pharmaceutical Industries Limited (NYSE:TEVA), 3D Systems Corporation (NYSE:DDD), Franklin Covey Co. (NYSE:FC), Ecolab Inc. (NYSE:ECL), ESCO Technologies Inc. (NYSE:ESE), Badger Meter, Inc. (NYSE:BMI), Nu Skin Enterprises, Inc. (NYSE:NUS), United Natural Foods, Inc. (NYSE:UNFI), Medifast, Inc. (NYSE:MED), Keurig Dr Pepper Inc. (NYSE:KDP), Edwards Lifesciences Corporation (NYSE:EW), InterXion Holding N.V. (NYSE:INXN), Stryker Corporation (NYSE:SYK), Globus Medical, Inc. (NYSE:GMED), Telaria, Inc. (NYSE:TLRA), Lumber Liquidators Holdings, Inc. (NYSE:LL), Acuity Brands, Inc. (NYSE:AYI), Lannett Company, Inc. (NYSE:LCI), Nanosonics Limited (ASX:NAN), GI Dynamics, Inc. (ASX:GID), Starpharma Holdings Limited (ASX:SPL), Celestica Inc. (TSX:CLS), The Descartes Systems Group Inc (TSX:DSG), Sierra Wireless, Inc. (TSX:SW), Quarterhill Inc. (TSX:QTRH), CounterPath Corporation (TSX:PATH), BlackBerry Limited (TSX:BB), Aeterna Zentaris Inc. (TSX:AEZS), SunOpta Inc. (TSX:SOY), Points International Ltd. (TSX:PTS), Stantec Inc. (TSX:STN), Westport Fuel Systems Inc. (TSX:WPRT), EcoSynthetix Inc. (TSX:ECO), Optiva Inc. (TSX:OPT), Altus Group Limited (TSX:AIF), Alaris Royalty Corp. (TSX:AD), NexJ Systems Inc. (TSX:NXJ), The Stars Group Inc. (TSX:TSGI), DeNA Co., Ltd. (TSE:2432), Nichia Steel Works, Ltd. (TSE:5658), BE Semiconductor Industries N.V. (ENXTAM:BESI), Link Motion Inc. (DB:2NQA), Amarin Corporation plc (NasdaqGM:AMRN), STAAR Surgical Company (NasdaqGM:STAA), PowerFleet, Inc. (NasdaqGM:PWFL), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), XOMA Corporation (NasdaqGM:XOMA), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), GW Pharmaceuticals plc (NasdaqGM:GWPH), NewLink Genetics Corporation (NasdaqGM:NLNK), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX), Dialight plc (LSE:DIA), Nanoco Group plc (LSE:NANO), Superdry Plc (LSE:SDRY), Playtech plc (LSE:PTEC), Telit Communications PLC (AIM:TCM), accesso Technology Group plc (AIM:ACSO), IQE plc (AIM:IQE), Bango plc (AIM:BGO), Protalix BioTherapeutics, Inc. (AMEX:PLX), Synageva BioPharma Corp., Datawatch Corporation, Derma Sciences, Inc., Echelon Corporation, Exa Corporation, Cynosure, Inc., Fairchild Semiconductor International Inc., Move, Inc., Mentor Graphics Corporation, Peregrine Semiconductor Corporation, Paladin Labs Inc., JAGGAER, Inc., The Spectranetics Corporation, Solta Medical, Inc., Qorvo US, Inc., The Ultimate Software Group, Inc., Ultratech, Inc., Vascular Solutions, Inc., Dendreon Corporation, InterMune, Inc., Spark Networks, Inc., Constant Contact, Inc., NxStage Medical, Inc., E2open, LLC, Datalink Corporation, Allergan, Inc., Anaren, Inc., Atmel Corporation, Costa Inc., Nanometrics Incorporated, Hi-Tech Pharmacal Co., Inc., Avanir Pharmaceuticals, Inc., PowerSecure International, Inc., NPS Pharmaceuticals, Inc., Numerex Corp., Exactech, Inc., Reis, Inc., Inventure Foods, Inc., Headwaters Incorporated, Omega Protein Corporation, Top Image Systems Ltd., Impax Laboratories, Inc., Applied Predictive Technologies, Inc., Integrated Device Technology, Inc., Arcam AB (publ), Planet Payment, Inc., Annie's, Inc., Angie's List, Inc., BTI Systems Inc., Synergy Pharmaceuticals Inc., FC Global Realty Incorporated, D-Wave Systems Inc., Canaccord Genuity LLC, Newalta Corporation, Pure Technologies Ltd., Kofax Limited, World Energy Solutions, Inc., Alere Inc., Shareworks by Morgan Stanley, Atrium Innovations Inc., Imprivata, Inc., Mast Therapeutics, Inc., ViXS Systems Inc., Picarro Inc., Auxilium Pharmaceuticals, LLC, Novadaq Technologies Inc., Volcano Corporation, Sandvine Corporation, Genomic Health, Inc., WaterFurnace Renewable Energy, Inc., Spreadtrum Communications Inc., Anacor Pharmaceuticals, Inc., Nanosphere, Inc., Kronos (US), Inc., Ping Identity Corporation, Coaxis, Inc., APP Winddown, LLC, BioFire Defense, LLC, Pandora Media, LLC, Enel X North America, Inc., Halogen Software Inc., Tumi Holdings, Inc., Agendia N.V., Paysafe Group Limited, KORE Telematics Inc., The SAVO Group Ltd., InvenSense, Inc., Silver Spring Networks, Inc., Demandware, LLC, Heartware International Inc., NeuLion, Inc., Accedian Networks Inc., LifeLock, Inc., Boulder Brands, Inc., HomeAway, Inc., Fallbrook Technologies Inc., RDA Microelectronics, Inc., Aegerion Pharmaceuticals, Inc., Carbonite, Inc., Horizon Pharmaceutical LLC, SillaJen Biotherapeutics, Inc., Monitise plc, Monotype Imaging Holdings Inc., Marketo, Inc., Zayo Group, LLC, Velocify, Inc., ZELTIQ Aesthetics, Inc., Acquia Inc., Avigilon Corporation, GT Advanced Technologies Inc., Seven Seas Water Corporation, Soraa, Inc., WeddingWire, Inc., magicJack VocalTec Ltd., Ten-X, LLC, Pernix Therapeutics Holdings, Inc., Receptos, Inc., 7098961 Canada Inc., Furiex Pharmaceuticals, Inc., HootSuite Media Inc., Dyn, Good Start Genetics, Inc., Civitas Therapeutics, Inc., Gazelle, Renewable Energy Group, Inc. (NasdaqGS:REGI), TrueCar, Inc. (NasdaqGS:TRUE), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA)Canaccord Genuity Inc., Canaccord Genuity 33rd Annual Growth Conference, Aug 14, 2013 through Aug 15, 2013. Venue: InterContinental Boston, 520 Atlantic Avenue, Boston, MA 02110, United States. For the 33rd year, the company will be bringing together some of the world's most innovative companies and institutional investors at Growth Conference. For two highly productive days, leaders in the growth universe will come together to share knowledge, discuss emerging trends, build relationships, identify opportunities and ignite global ideas for growth.
296
9/30/20135.84x13.76x14.69x26.16x20.34x$14,897$130.33359.06%Jul-29-2013Buyback - Change in Plan TermsIntuitive Surgical, Inc. Announced An Increase In Equity Buyback-On July 29, 2013, the Board of Directors increased the share repurchase program by $779 million, thereby increasing the total program to $3.02 billion.
297
9/30/20135.84x13.76x14.69x26.16x20.34x$16,058$140.49325.86%Jul-18-2013Earnings CallIntuitive Surgical, Inc., Q2 2013 Earnings Call, Jul 18, 2013-Intuitive Surgical, Inc., Q2 2013 Earnings Call, Jul 18, 2013
298
9/30/20135.84x13.76x14.69x26.16x20.34x$16,058$140.49325.86%Jul-18-2013Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc.'s Equity Buyback Plan-As of period ended on June 30, 2013, the company has repurchased 4,429,296 shares for $1,334.55 million.
299
9/30/20135.84x13.76x14.69x26.16x20.34x$16,058$140.49325.86%Jul-18-2013Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2013-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2013. The company reported second quarter of 2013 revenue of $579 million, up approximately 8% compared with $537 million for the second quarter of 2012. Second quarter of 2013 operating income decreased to $219 million from $225 million in the second quarter of 2012. Second quarter of 2013 net income was $159 million, or $3.90 per diluted share, compared with $155 million, or $3.75 per diluted share, for the second quarter of 2012. Income before taxes was $222.8 million against $229.3 million a year ago.

For the six months period, the company announced total revenue of $1,189.9 million against $1,031.7 million a year ago. Income from operations was $469.7 million against $418.6 million a year ago. Income before taxes was $478.3 million against $426.4 million a year ago. Net income was $348.0 million or $41.1 per diluted share against $298.4 million or $41.1 per diluted share a year ago.
300
9/30/20135.84x13.76x14.69x26.16x20.34x$16,260$142.26320.56%Jul-15-2013Client AnnouncementLuna Innovations Enters into Multi-Year Agreement with Intuitive SurgicalLuna Innovations Incorporated (NasdaqCM:LUNA)Luna Innovations Incorporated has entered into a multi-year agreement that amends its development and supply agreement with Intuitive Surgical, Inc. The new agreement builds on previous work between the companies to integrate Luna's high-speed shape-sensing technology into Intuitive's platform for robotically-assisted minimally invasive surgery. Under the existing development and supply agreement, Luna is the exclusive supplier to Intuitive of these components.
301
9/30/20135.84x13.76x14.69x26.16x20.34x$19,053$166.69258.92%Jul-08-2013Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Provides Earnings Guidance for the Second Quarter of 2013-Intuitive Surgical, Inc. provided earnings guidance for the second quarter of 2013. For the quarter, the company expects revenue of approximately $575 million, up approximately 7% from $537 million for the second quarter of 2012. The Company expects second quarter 2013 net income of approximately $160 million compared with $155 million for the second quarter of 2012.
302
9/30/20135.84x13.76x14.69x26.16x20.34x$19,202$168.00256.13%Jul-05-2013Client AnnouncementLuna Innovations Incorporated and Intuitive Surgical Operations, Inc. Enter into Amendment of Development and Supply AgreementLuna Innovations Incorporated (NasdaqCM:LUNA)On June 28, 2013, Luna Innovations Incorporated and Intuitive Surgical Operations, Inc. entered into Amendment No. 7 to their development and supply agreement dated June 11, 2007. Under the Amendment, the parties have agreed upon certain milestones to be achieved by the company under the Development and Supply Agreement through 2015, as well as the amounts to be paid by Intuitive to the Company for development work during this period and the payment mechanism for same.
303
6/30/20138.27x19.04x20.27x35.04x26.63x$19,965$167.63256.91%Jun-21-2013Lawsuits & Legal IssuePomerantz Grossman Hufford Dahlstrom & Gross LLP Files Class Action Lawsuit Against Intuitive Surgical, Inc-Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Intuitive Surgical, Inc. and certain of its officers. The class action, filed in United States District Court, Northern District of California, and docketed under 13-CV-002365, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Intuitive between October 19, 2011 and April 18, 2013 both dates inclusive. This class action seeks to recover damages against the company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated there under. The Complaint alleges that throughout the Class Period, defendants issued a series of materially false and misleading statements highlighting the purported safety and effectiveness of the Company's da Vinci Surgical System, while concomitantly announcing quarter after quarter of record financial results. Sales of Intuitive's robots, priced at $1.5 million each, have helped make Intuitive one of the hottest stocks in health care, growing 61% since the end of February 2010 to a market value of $21.7 billion by March 2013. Due in large part to what the public has recently learned were disreputable and unsafe sales practices, the number of U.S. procedures done with the robots grew to approximately 367,000 in 2012, up from 292,000 in 2011 and 228,000 in 2010. As a result of defendants' efforts to conceal significant safety and efficacy problems with the da Vinci Surgical System which were exacerbated by the Company's disreputable sales practices and false statements concerning the Company's business metrics and financial prospects, Intuitive stock traded at artificially inflated prices during the Class Period, reaching a Class Period high of nearly $595 per share in intraday trading by April 18, 2012.
304
6/30/20138.27x19.04x20.27x35.04x26.63x$19,823$166.44259.46%Jun-17-2013Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $809.75 million.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $809.75 million.
305
6/30/20138.27x19.04x20.27x35.04x26.63x$19,669$165.15262.27%Jun-12-2013Company Conference PresentationIntuitive Surgical, Inc. Presents at William Blair & Company 33(rd) Annual Growth Stock Conference, Jun-12-2013 12:00 PM-Intuitive Surgical, Inc. Presents at William Blair & Company 33(rd) Annual Growth Stock Conference, Jun-12-2013 12:00 PM. Venue: Four Seasons Hotel, Chicago, Illinois, United States.
306
6/30/20138.27x19.04x20.27x35.04x26.63x$19,833$166.52259.29%Jun-11-2013Company Conference PresentationIntuitive Surgical, Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 01:20 PM-Intuitive Surgical, Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 01:20 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
307
6/30/20138.27x19.04x20.27x35.04x26.63x$19,833$166.52259.29%Jun-11-2013ConferenceThe Goldman Sachs Group, Inc., Goldman Sachs 34th Annual Global Healthcare Conference, Jun 11, 2013 through Jun 13, 2013Innoviva, Inc. (NasdaqGS:INVA), Align Technology, Inc. (NasdaqGS:ALGN), Alkermes plc (NasdaqGS:ALKS), Amgen Inc. (NasdaqGS:AMGN), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), LivaNova PLC (NasdaqGS:LIVN), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Myriad Genetics, Inc. (NasdaqGS:MYGN), NuVasive, Inc. (NasdaqGS:NUVA), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Exelixis, Inc. (NasdaqGS:EXEL), Gilead Sciences, Inc. (NasdaqGS:GILD), Mylan N.V. (NasdaqGS:MYL), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Stericycle, Inc. (NasdaqGS:SRCL), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Hologic, Inc. (NasdaqGS:HOLX), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), Patterson Companies, Inc. (NasdaqGS:PDCO), PDL BioPharma, Inc. (NasdaqGS:PDLI), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Luminex Corporation (NasdaqGS:LMNX), Bruker Corporation (NasdaqGS:BRKR), ICON Public Limited Company (NasdaqGS:ICLR), ChemoCentryx, Inc. (NasdaqGS:CCXI), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Bausch Health Companies Inc. (NYSE:BHC), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Owens & Minor, Inc. (NYSE:OMI), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Charles River Laboratories International, Inc. (NYSE:CRL), QIAGEN N.V. (NYSE:QGEN), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Baxter International Inc. (NYSE:BAX), HCA Healthcare, Inc. (NYSE:HCA), PerkinElmer, Inc. (NYSE:PKI), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), Humana Inc. (NYSE:HUM), Community Health Systems, Inc. (NYSE:CYH), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), AmerisourceBergen Corporation (NYSE:ABC), Hill-Rom Holdings, Inc. (NYSE:HRC), AbbVie Inc. (NYSE:ABBV), Mallinckrodt plc (NYSE:MNK), Globus Medical, Inc. (NYSE:GMED), WellCare Health Plans, Inc. (NYSE:WCG), The Goldman Sachs Group, Inc. (NYSE:GS), Edwards Lifesciences Corporation (NYSE:EW), Exact Sciences Corporation (NasdaqCM:EXAS), ARIAD Pharmaceuticals, Inc., Synageva BioPharma Corp., Cepheid, Health Management Associates Inc., IPC Healthcare, Inc., Onyx Pharmaceuticals, Inc., PAREXEL International Corporation, The Medicines Company, Universal American Corp., Vanguard Health Systems Inc., ViroPharma Inc., Catamaran Corporation, Forest Laboratories, LLC, Omnicare Inc., Sigma-Aldrich Corporation, Thoratec LLC, Health Net, Inc., Questcor Pharmaceuticals, Inc., Covance Inc., FEI Company, Shire plc, Aetna Inc., Warner Chilcott plc, Alere Inc., Auxilium Pharmaceuticals, LLC, Volcano Corporation, Genomic Health, Inc., Algeta ASA, Kythera Biopharmaceuticals, Inc., Covidien plc, ZELTIQ Aesthetics, Inc., CareFusion Corporation, Actelion Pharmaceuticals Ltd, ExamWorks Group, Inc., Medivation, Inc., Heartware International Inc., Roche Holding AG (SWX:ROG), Basilea Pharmaceutica AG (SWX:BSLN), Novartis AG (SWX:NOVN), GlaxoSmithKline plc (LSE:GSK), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), ALK-Abelló A/S (CPSE:ALK B), Coloplast A/S (CPSE:COLO B), Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC), Fleury S.A. (BOVESPA:FLRY3)The Goldman Sachs Group, Inc., Goldman Sachs 34th Annual Global Healthcare Conference, Jun 11, 2013 through Jun 13, 2013. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
308
6/30/20138.27x19.04x20.27x35.04x26.63x$19,833$166.52259.29%Jun-11-2013ConferenceWilliam Blair & Company, L.L.C., William Blair & Company 33(rd) Annual Growth Stock Conference, Jun 11, 2013 through Jun 13, 2013InnerWorkings, Inc. (NasdaqGS:INWK), MoneyGram International, Inc. (NasdaqGS:MGI), Dunkin' Brands Group, Inc. (NasdaqGS:DNKN), RBC Bearings Incorporated (NasdaqGS:ROLL), Echo Global Logistics, Inc. (NasdaqGS:ECHO), LPL Financial Holdings Inc. (NasdaqGS:LPLA), Lululemon Athletica Inc. (NasdaqGS:LULU), Performant Financial Corporation (NasdaqGS:PFMT), Qiwi plc (NasdaqGS:QIWI), Bloomin' Brands, Inc. (NasdaqGS:BLMN), Cornerstone OnDemand, Inc. (NasdaqGS:CSOD), C.H. Robinson Worldwide, Inc. (NasdaqGS:CHRW), Bottomline Technologies (de), Inc. (NasdaqGS:EPAY), ICON Public Limited Company (NasdaqGS:ICLR), Encore Capital Group, Inc. (NasdaqGS:ECPG), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Henry Schein, Inc. (NasdaqGS:HSIC), FLIR Systems, Inc. (NasdaqGS:FLIR), Tractor Supply Company (NasdaqGS:TSCO), Paychex, Inc. (NasdaqGS:PAYX), The Cheesecake Factory Incorporated (NasdaqGS:CAKE), Patterson Companies, Inc. (NasdaqGS:PDCO), ExlService Holdings, Inc. (NasdaqGS:EXLS), Insulet Corporation (NasdaqGS:PODD), Bruker Corporation (NasdaqGS:BRKR), Verisk Analytics, Inc. (NasdaqGS:VRSK), Boingo Wireless, Inc. (NasdaqGS:WIFI), Cardtronics plc (NasdaqGS:CATM), PRA Group, Inc. (NasdaqGS:PRAA), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Huron Consulting Group Inc. (NasdaqGS:HURN), Fortinet, Inc. (NasdaqGS:FTNT), CEVA, Inc. (NasdaqGS:CEVA), Zumiez Inc. (NasdaqGS:ZUMZ), Titan Machinery Inc. (NasdaqGS:TITN), LKQ Corporation (NasdaqGS:LKQ), Exelixis, Inc. (NasdaqGS:EXEL), HMS Holdings Corp. (NasdaqGS:HMSY), Houston Wire & Cable Company (NasdaqGS:HWCC), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Aspen Technology, Inc. (NasdaqGS:AZPN), Align Technology, Inc. (NasdaqGS:ALGN), Citrix Systems, Inc. (NasdaqGS:CTXS), Commvault Systems, Inc. (NasdaqGS:CVLT), LivaNova PLC (NasdaqGS:LIVN), Ulta Beauty, Inc. (NasdaqGS:ULTA), NuVasive, Inc. (NasdaqGS:NUVA), Pool Corporation (NasdaqGS:POOL), Seattle Genetics, Inc. (NasdaqGS:SGEN), Silicon Laboratories Inc. (NasdaqGS:SLAB), SPS Commerce, Inc. (NasdaqGS:SPSC), Stericycle, Inc. (NasdaqGS:SRCL), PRGX Global, Inc. (NasdaqGS:PRGX), Quidel Corporation (NasdaqGS:QDEL), Trimble Inc. (NasdaqGS:TRMB), SP Plus Corporation (NasdaqGS:SP), RealPage, Inc. (NasdaqGS:RP), Abiomed, Inc. (NasdaqGS:ABMD), Xilinx, Inc. (NasdaqGS:XLNX), HealthStream, Inc. (NasdaqGS:HSTM), Cogent Communications Holdings, Inc. (NasdaqGS:CCOI), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Financial Engines, Inc., Airgas, Inc., BroadSoft, Inc., Cepheid, ARIAD Pharmaceuticals, Inc., Ellie Mae, Inc., PAREXEL International Corporation, JAGGAER, Inc., DTS, Inc., IPC Healthcare, Inc., The Ultimate Software Group, Inc., Blue Nile, Inc., Blount International Inc., Rackspace Hosting, Inc., Molex, LLC, NxStage Medical, Inc., Catamaran Corporation, Sirona Dental Systems Inc., Broadcom Corporation, Life Time, Inc., Greenway Medical Technologies, Inc., Pall Corporation, Sonic Corp., BioReference Laboratories, Inc., Komatsu Mining Corp., MICROS Systems, Inc., Express Scripts Holding Company, Covance Inc., WageWorks, Inc., Infoblox Inc., WTW Delaware Holdings LLC, William Blair & Company, L.L.C., Annie's, Inc., Cavium, Inc., Worldpay, Inc., The Advisory Board Company, Sourcefire, Inc., Polypore International, LP, Riverbed Technology, Inc., MWI Veterinary Supply, Inc., Vitamin Shoppe, Inc., Meru Networks, Inc., The Fresh Market, Inc., Sandvine Corporation, Fairway Group Holdings Corp., GSE Holdings Inc., Pandora Media, LLC, LinkedIn Corporation, Tumi Holdings, Inc., Rally Software Development Corp., Demandware, LLC, RealD Inc., Trulia, Inc., ZELTIQ Aesthetics, Inc., Fusion-io, Inc., ExamWorks Group, Inc., The ADT Security Corporation, Fleetmatics Group PLC, GenMark Diagnostics, Inc. (NasdaqGM:GNMK), NICE Ltd. (TASE:NICE), Alliance Data Systems Corporation (NYSE:ADS), Dolby Laboratories, Inc. (NYSE:DLB), CBRE Group, Inc. (NYSE:CBRE), WNS (Holdings) Limited (NYSE:WNS), Proto Labs, Inc. (NYSE:PRLB), The Western Union Company (NYSE:WU), Vocera Communications, Inc. (NYSE:VCRA), Edwards Lifesciences Corporation (NYSE:EW), Nielsen Holdings plc (NYSE:NLSN), 8x8, Inc. (NYSE:EGHT), ManpowerGroup Inc. (NYSE:MAN), The Scotts Miracle-Gro Company (NYSE:SMG), Keurig Dr Pepper Inc. (NYSE:KDP), ResMed Inc. (NYSE:RMD), Linde plc (NYSE:LIN), Designer Brands Inc. (NYSE:DBI), Rockwell Automation, Inc. (NYSE:ROK), Walmart Inc. (NYSE:WMT), Williams-Sonoma, Inc. (NYSE:WSM), AGCO Corporation (NYSE:AGCO), Jacobs Engineering Group Inc. (NYSE:J), The Cooper Companies, Inc. (NYSE:COO), Flowserve Corporation (NYSE:FLS), Ecolab Inc. (NYSE:ECL), W.W. Grainger, Inc. (NYSE:GWW), Robert Half International Inc. (NYSE:RHI), MSC Industrial Direct Co., Inc. (NYSE:MSM), ASGN Incorporated (NYSE:ASGN), American Express Company (NYSE:AXP), CVS Health Corporation (NYSE:CVS), Haemonetics Corporation (NYSE:HAE), WEX Inc. (NYSE:WEX), MEDNAX, Inc. (NYSE:MD), Abbott Laboratories (NYSE:ABT), Donaldson Company, Inc. (NYSE:DCI), Booz Allen Hamilton Holding Corporation (NYSE:BAH), Gartner, Inc. (NYSE:IT), Tiffany & Co. (NYSE:TIF), DHI Group, Inc. (NYSE:DHX), Adtalem Global Education Inc. (NYSE:ATGE), DICK'S Sporting Goods, Inc. (NYSE:DKS), Affiliated Managers Group, Inc. (NYSE:AMG), Palo Alto Networks, Inc. (NYSE:PANW), U.S. Silica Holdings, Inc. (NYSE:SLCA), EVERTEC, Inc. (NYSE:EVTC), MaxLinear, Inc. (NYSE:MXL), Shutterstock, Inc. (NYSE:SSTK), MRC Global Inc. (NYSE:MRC), Envestnet, Inc. (NYSE:ENV), IHS Markit Ltd. (NYSE:INFO), Prestige Consumer Healthcare Inc. (NYSE:PBH), MSCI Inc. (NYSE:MSCI), Globus Medical, Inc. (NYSE:GMED), Green Dot Corporation (NYSE:GDOT), Mastercard Incorporated (NYSE:MA), Exact Sciences Corporation (NasdaqCM:EXAS), Dynavax Technologies Corporation (NasdaqCM:DVAX), SAP SE (XTRA:SAP)William Blair & Company, L.L.C., William Blair & Company 33(rd) Annual Growth Stock Conference, Jun 11, 2013 through Jun 13, 2013. Venue: Four Seasons Hotel, Chicago, Illinois, United States.
309
6/30/20138.27x19.04x20.27x35.04x26.63x$19,915$167.21257.81%May-28-2013Lawsuits & Legal IssueGlancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Intuitive Surgical, Inc-Glancy Binkow & Goldberg LLP, representing investors of Intuitive Surgical, Inc. announced that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of a class (the "Class") comprising all purchasers of Intuitive common stock between October 19, 2011 and April 18, 2013, inclusive (the "Class Period"). The complaint alleges that defendants misrepresented or failed to disclose material adverse facts about the da Vinci system, including that: defects in the system had caused a substantial number of patient injuries resulting in adverse incident reports prior to and during the Class Period; not all of these adverse incident reports were being reported to the U.S. Food and Drug Administration (FDA), exposing the Company to significant regulatory risk and potential criminal sanctions; Intuitive knew there was a substantial risk that the FDA might limit or restrict sales and marketing of the system; Intuitive was engaging in sales practices that violated community standards and their own protocol agreed upon with the FDA; Intuitive was exposed to substantial potential civil liability to injured and deceased patients and their families; Intuitive failed to properly reserve for potential civil liability; and as a result, defendants lacked a reasonable basis to make positive statements about the safety and effectiveness of the da Vinci Surgical System, the Company's business metrics and its Class Period financial results and outlook.
310
6/30/20138.27x19.04x20.27x35.04x26.63x$18,671$156.77281.64%May-22-2013Lawsuits & Legal IssueKitsap County Jury Deliberates $8.45 Million Lawsuit Against Intuitive Surgical, Inc-A Kitsap County Superior Court jury in Port Orchard has begun deliberating an $8.45 million lawsuit against Intuitive Surgical, Inc.'s da Vinci robotic surgery system brought by a man who suffered injuries in a 2008 robot-assisted removal of his prostate gland. Fred Taylor's family alleges Taylor suffered because of Intuitive's inadequate training that was streamlined and compromised by the company's push to sell its robots. Taylor died four years after the operation.
311
6/30/20138.27x19.04x20.27x35.04x26.63x$19,289$161.96269.41%May-21-2013Lawsuits & Legal IssueIntuitive Surgical, Inc. Provides Updates on Lawsuit-In a lawsuit against Intuitive Surgical, Inc. an attorney for the Plaintiffs compared Intuitive Surgical to a car dealership, alleging the company wanted to tie sales andservices for its customers. Intuitive "wanted to do all the trainingto keep control of surgeons, to keep control of hospitals and keep control of surgeries,". The attorney also reiterated Plaintiff's allegations that Intuitive knew it wasn't providing adequate training to doctors when it simplified its instructional protocols in 2006. The da Vinci surgery robot lawsuit currently at trial in Washington was filed by the family of a man who died last August allegedly dueto serious injuries he sustained during prostate removal surgery. Among other things, his family claims he was not told that the surgeon performing the procedure had never before operated unassisted with the da Vinci robot. Victims of alleged bad robot surgery associated with the da Vinci Surgical System may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more.
312
6/30/20138.27x19.04x20.27x35.04x26.63x$19,231$161.47270.53%May-15-2013Company Conference PresentationIntuitive Surgical, Inc. Presents at Merrill Lynch 2013 Health Care Conference, May-15-2013 03:40 PM-Intuitive Surgical, Inc. Presents at Merrill Lynch 2013 Health Care Conference, May-15-2013 03:40 PM. Venue: Encore at Wynn, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States. Speakers: Calvin Darling, Sr Director, Finance, Marshall L. Mohr, Chief Financial Officer, Principal Accounting Officer and Senior Vice President.
313
6/30/20138.27x19.04x20.27x35.04x26.63x$19,363$162.58268.00%May-14-2013ConferenceMerrill Lynch & Co., Inc., Merrill Lynch 2013 Health Care Conference, May 14, 2013 through May 16, 2013BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Cardiovascular Systems, Inc. (NasdaqGS:CSII), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Echo Global Logistics, Inc. (NasdaqGS:ECHO), Alphatec Holdings, Inc. (NasdaqGS:ATEC), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Clovis Oncology, Inc. (NasdaqGS:CLVS), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Innoviva, Inc. (NasdaqGS:INVA), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), RadNet, Inc. (NasdaqGM:RDNT), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), MannKind Corporation (NasdaqGM:MNKD), Health Insurance Innovations, Inc. (NasdaqGM:HIIQ), Roche Holding AG (SWX:ROG), Novo Nordisk A/S (CPSE:NOVO B), Sanofi (ENXTPA:SAN), Hypera S.A. (BOVESPA:HYPE3), Oncolytics Biotech Inc. (TSX:ONC), Merrill Lynch & Co., Inc., Abaxis, Inc., ARIAD Pharmaceuticals, Inc., Array BioPharma Inc., Cascadian Therapeutics, Inc., Cepheid, Cubist Pharmaceuticals LLC, Health Management Associates Inc., IPC Healthcare, Inc., Team Health Holdings, Inc., Onyx Pharmaceuticals, Inc., Pharmacyclics LLC, Idenix Pharmaceuticals, Inc., Sequenom Inc., The Medicines Company, Universal American Corp., Vanguard Health Systems Inc., Vascular Solutions, Inc., Vical Incorporated, ViroPharma Inc., Repros Therapeutics Inc., Dendreon Corporation, InterMune, Inc., Emeritus Corp., Actelion Ltd, VCA Inc., Santarus, Inc., Catamaran Corporation, Gentiva Health Services, Inc., Sirona Dental Systems Inc., Allergan, Inc., Analogic Corporation, BioReference Laboratories, Inc., Celgene Corporation, Forest Laboratories, LLC, Omnicare Inc., St. Jude Medical, Inc., Thoratec LLC, Kindred Healthcare, LLC, Sigma-Aldrich Corporation, Express Scripts Holding Company, Hi-Tech Pharmacal Co., Inc., Stewart Enterprises Inc., Health Net, Inc., Affymetrix Inc., Questcor Pharmaceuticals, Inc., Covance Inc., FEI Company, Envision Healthcare Corporation, Legacy LifePoint Health, Inc., Impax Laboratories, Inc., MedAssets, Inc., Aetna Inc., Salix Pharmaceuticals Ltd., Auxilium Pharmaceuticals, LLC, Novadaq Technologies Inc., Genomic Health, Inc., MWI Veterinary Supply, Inc., Threshold Pharmaceuticals, Inc., Algeta ASA, Orexigen Therapeutics, Inc., Hospira Inc., Cadence Pharmaceuticals Inc., Kythera Biopharmaceuticals, Inc., Aegerion Pharmaceuticals, Inc., Covidien plc, PharMerica Corporation, Alphatec Spine, Inc., ZELTIQ Aesthetics, Inc., CareFusion Corporation, Tornier N.V., Heartware International Inc., Sagent Pharmaceuticals, Inc., Durata Therapeutics, Inc., Mettler-Toledo International Inc. (NYSE:MTD), QIAGEN N.V. (NYSE:QGEN), Laboratory Corporation of America Holdings (NYSE:LH), Hill-Rom Holdings, Inc. (NYSE:HRC), Hanger, Inc. (NYSE:HNGR), Community Health Systems, Inc. (NYSE:CYH), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), AmerisourceBergen Corporation (NYSE:ABC), AMN Healthcare Services, Inc. (NYSE:AMN), Thermo Fisher Scientific Inc. (NYSE:TMO), Tenet Healthcare Corporation (NYSE:THC), STERIS plc (NYSE:STE), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Integer Holdings Corporation (NYSE:ITGR), Stryker Corporation (NYSE:SYK), Edwards Lifesciences Corporation (NYSE:EW), Capital Senior Living Corporation (NYSE:CSU), Quest Diagnostics Incorporated (NYSE:DGX), Perrigo Company plc (NYSE:PRGO), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), West Pharmaceutical Services, Inc. (NYSE:WST), Boston Scientific Corporation (NYSE:BSX), Service Corporation International (NYSE:SCI), Owens & Minor, Inc. (NYSE:OMI), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), HCA Healthcare, Inc. (NYSE:HCA), Bio-Rad Laboratories, Inc. (NYSE:BIO), Cantel Medical Corp. (NYSE:CMD), Baxter International Inc. (NYSE:BAX), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), MEDNAX, Inc. (NYSE:MD), MAXIMUS, Inc. (NYSE:MMS), Mallinckrodt plc (NYSE:MNK), Globus Medical, Inc. (NYSE:GMED), WellCare Health Plans, Inc. (NYSE:WCG), Medical Properties Trust, Inc. (NYSE:MPW), AbbVie Inc. (NYSE:ABBV), Emergent BioSolutions Inc. (NYSE:EBS), Brookdale Senior Living Inc. (NYSE:BKD), Antares Pharma, Inc. (NasdaqCM:ATRS), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), Cassava Sciences, Inc. (NasdaqCM:SAVA), Exact Sciences Corporation (NasdaqCM:EXAS), Heska Corporation (NasdaqCM:HSKA), Fortress Biotech, Inc. (NasdaqCM:FBIO), Corcept Therapeutics Incorporated (NasdaqCM:CORT), Five Star Senior Living Inc. (NasdaqCM:FVE), MagForce AG (XTRA:MF6), Illumina, Inc. (NasdaqGS:ILMN), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), Exelixis, Inc. (NasdaqGS:EXEL), Gilead Sciences, Inc. (NasdaqGS:GILD), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), HMS Holdings Corp. (NasdaqGS:HMSY), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Quidel Corporation (NasdaqGS:QDEL), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), VIVUS, Inc. (NasdaqGS:VVUS), Wright Medical Group N.V. (NasdaqGS:WMGI), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Stericycle, Inc. (NasdaqGS:SRCL), NuVasive, Inc. (NasdaqGS:NUVA), ChemoCentryx, Inc. (NasdaqGS:CCXI), PetMed Express, Inc. (NasdaqGS:PETS), Fluidigm Corporation (NasdaqGS:FLDM), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), The Ensign Group, Inc. (NasdaqGS:ENSG), Endologix, Inc. (NasdaqGS:ELGX), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Bruker Corporation (NasdaqGS:BRKR), Diversified Healthcare Trust (NasdaqGS:DHC), Abiomed, Inc. (NasdaqGS:ABMD), Akorn, Inc. (NasdaqGS:AKRX), CONMED Corporation (NasdaqGS:CNMD), Mylan N.V. (NasdaqGS:MYL), Meridian Bioscience, Inc. (NasdaqGS:VIVO), Magellan Health, Inc. (NasdaqGS:MGLN), Incyte Corporation (NasdaqGS:INCY), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN)Merrill Lynch & Co., Inc., Merrill Lynch 2013 Health Care Conference, May 14, 2013 through May 16, 2013. Venue: Encore at Wynn, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States. The conference will feature presentations as well as small group and one-on-one meetings with the chairmen, chief executive officers, presidents, and heads of research and development of industry leading Health Care companies.
314
6/30/20138.27x19.04x20.27x35.04x26.63x$19,425$163.10266.82%May-08-2013Lawsuits & Legal IssueRyan & Maniskas, LLP Announces Class Action Lawsuit Against Intuitive Surgical, Inc-Ryan & Maniskas, LLP announced that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of purchasers of the securities of Intuitive Surgical, Inc., who purchased or otherwise acquired Intuitive Surgical securities between October 19, 2011, and April 18, 2013, inclusive. The complaint alleges that throughout the class period, defendants issued a series of materially false and misleading statements highlighting the purported safety and effectiveness of the da Vinci Surgical System, while at the same time announcing quarter after quarter of record financial results. As a result of defendants' efforts to conceal significant safety and efficacy problems with the da Vinci Surgical System and their false statements concerning the company's business metrics and financial prospects, Intuitive stock traded at artificially inflated prices during the class period, reaching a class period high of nearly $595 per share in intraday trading by April 18, 2012.
315
6/30/20138.27x19.04x20.27x35.04x26.63x$19,526$163.95264.92%May-02-2013Lawsuits & Legal IssueMorgan & Morgan Files Securities Fraud Class Action Lawsuit Against Intuitive Surgical, Inc-Morgan & Morgan announced that a class action has been filed in the United States District Court for the Northern District of California on behalf of purchasers of common stock of Intuitive Surgical, Inc. during the class period of between October 19, 2011, and April 18, 2013. The complaint charges Intuitive and certain of its officers and directors with violations of the Securities Exchange Act of 1934. The complaint alleges that throughout the Class Period, defendants issued a series of materially false and misleading statements highlighting the purported safety and effectiveness of the da Vinci Surgical System, while at the same time announcing quarter after quarter of record financial results. As a result of defendants' efforts to conceal significant safety and efficacy problems with the da Vinci Surgical System and their false statements concerning the Company's business metrics and financial prospects, Intuitive stock traded at artificially inflated prices during the Class Period, reaching a Class Period high of nearly $595 per share in intraday trading by April 18, 2012. On April 18, 2013, CNBC's Investigations, Inc. broadcast an expose on the da Vinci Surgical System consisting of interviews with patients who have filed lawsuits against Intuitive claiming they suffered injury while being operated on by surgeons using the da Vinci Surgical System. Following this news, the price of Intuitive stock fell $8.62 per share to close at $484.75 per share on April 19, 2013, down nearly 19% from its Class Period high of $595 per share.
316
6/30/20138.27x19.04x20.27x35.04x26.63x$19,544$164.10264.59%Apr-30-2013Executive/Board Change - OtherIntuitive Surgical, Inc. Appoints Alan J. Levy as Independent Lead Director-Intuitive Surgical, Inc. announced that on April 25, 2013, the Board created the position of Independent Lead Director, an independent director elected
annually by the Board's independent directors to serve in a lead capacity and to perform such duties and responsibilities as the Board may determine. The Board's independent directors appointed Alan J. Levy, Ph.D. as the Independent Lead Director, effective immediately.
317
6/30/20138.27x19.04x20.27x35.04x26.63x$19,419$163.05266.94%Apr-29-2013Lawsuits & Legal IssueFederman & Sherwood Announces a Securities Class Action Lawsuit Against Intuitive Surgical, Inc-Federman & Sherwood announced that On April 26, 2013 a securities class action lawsuit was filed in the United States District Court for the Northern District of California against Intuitive Surgical, Inc. The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is October 19, 2011 through April 18, 2013.
318
6/30/20138.27x19.04x20.27x35.04x26.63x$19,207$161.27270.99%Apr-25-2013Annual General MeetingIntuitive Surgical, Inc., Annual General Meeting, Apr 25, 2013-Intuitive Surgical, Inc., Annual General Meeting, Apr 25, 2013., at 15:00 Pacific Standard Time. Location: Santa Clara Marriott. Agenda: To consider election of directors; to approve the amendment and restatement of the company’s 2010 incentive award plan; to approve, by advisory vote, the compensation of named executive officers; and to consider ratification of the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2013.
319
6/30/20138.27x19.04x20.27x35.04x26.63x$19,244$161.58270.27%Apr-19-2013Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc.'s Equity Buyback Plan-As of period ended on March 31, 2013, the company has repurchased 3,883,296 shares for $1,064.83 million.
320
6/30/20138.27x19.04x20.27x35.04x26.63x$19,587$164.46263.79%Apr-18-2013Earnings CallIntuitive Surgical, Inc., Q1 2013 Earnings Call, Apr 18, 2013-Intuitive Surgical, Inc., Q1 2013 Earnings Call, Apr 18, 2013
321
6/30/20138.27x19.04x20.27x35.04x26.63x$19,587$164.46263.79%Apr-18-2013Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2013-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. The company reported first quarter of 2013 revenue of $611 million, up approximately 23% compared with $495 million for the first quarter of 2012. First quarter of 2013 revenue growth was driven by continued growth of da Vinci surgery procedures and higher da Vinci Surgical System sales. First quarter of 2013 net income was $189 million, or $4.56 per diluted share, compared with $144 million, or $3.50 per diluted share, for the first quarter of 2012. First quarter of 2013 operating income increased to $251 million from $193 million in the first quarter of 2012. Operating results for the first quarter of 2013 included $38 million of non-cash stock-based compensation expense compared with $34 million for the first quarter of 2012. Income before taxes was $255.5 million against $197.1 million a year ago period.
322
6/30/20138.27x19.04x20.27x35.04x26.63x$19,587$164.46263.79%Apr-18-2013Lawsuits & Legal IssueDa Vinci Robot Trial Focuses on Adequacy of Physician Training by Intuitive Surgical-Intuitive Surgical Inc. is now defending itself in the first trial brought on behalf of a surgical patient who suffered fatal complications alleged to have resulted from surgery using the da Vinci system. William Audet, an attorney with Audet and Partners, LLP, a national trial firm representing several plaintiffs allegedly injured by the da Vinci system, notesthat the issue of inadequate training of hospitals and physicians isemerging as a potentially important causal factor in serious injuries being reported by his clients.
323
6/30/20138.27x19.04x20.27x35.04x26.63x$19,485$163.60265.70%Apr-02-2013Lawsuits & Legal IssueIntuitive Surgical, Inc. Lost Petition on Da Vinci Robotic Surgery Complications-Intuitive Surgical, Inc. has lost a petition to have a Da Vinci robotic surgery complications lawsuit filed in Washington State, thrown out of court. Despite the fact that attorneys for Intuitive Surgical had argued that federal regulations do not require the manufacturer to train physicians on how to operate with the Da Vinci robot, the judge in this case rejected this claim and determined that Intuitive Surgical is required to sufficiently train doctors to use the Da Vinci surgical robots. As part of this ruling, the judge also specified that the plaintiff, namely the family of a patientwhose death was allegedly caused by Da Vinci robotic surgery complications, is entitled to try to obtain damages for the harm allegedly caused by the improper marketing of the Da Vinci surgical system. One of the most common factors cited for causing Da Vinci surgery complications is the lack of training for surgeons using these devices. Specifically, those who have pointed out problems with Intuitive Surgical's inadequate training have highlighted the fact that the industry currently does not have any standards defining what is considered to be sufficient training before surgeons are deemed ready to operate on patients with Da Vinci robots.
324
3/31/20138.50x19.78x21.08x36.13x31.09x$19,934$165.29261.96%Mar-20-2013Buyback - Change in Plan TermsIntuitive Surgical, Inc. Announced An Increase In Equity Buyback-On March 20, 2013, the Board of Directors increased the share repurchase program authorized on March 3, 2009, by $1 billion, thereby increasing the total program to $2.25 billion worth of its shares..
325
3/31/20138.50x19.78x21.08x36.13x31.09x$21,134$175.24241.41%Mar-05-2013Company Conference PresentationIntuitive Surgical, Inc. Presents at Raymond James' 34th Annual Institutional Investors Conference, Mar-05-2013 11:00 AM-Intuitive Surgical, Inc. Presents at Raymond James' 34th Annual Institutional Investors Conference, Mar-05-2013 11:00 AM. Venue: JW Marriott Grande Lakes Hotel, 4040 Central Florida Parkway, Orlando, Florida, United States.
326
3/31/20138.50x19.78x21.08x36.13x31.09x$0Mar-03-2013ConferenceRaymond James & Associates, Inc., Raymond James' 34th Annual Institutional Investors Conference, Mar 03, 2013 through Mar 06, 2013SBA Communications Corporation (NasdaqGS:SBAC), Rent-A-Center, Inc. (NasdaqGS:RCII), Qorvo, Inc. (NasdaqGS:QRVO), NIC Inc. (NasdaqGS:EGOV), ACI Worldwide, Inc. (NasdaqGS:ACIW), SS&C Technologies Holdings, Inc. (NasdaqGS:SSNC), Stericycle, Inc. (NasdaqGS:SRCL), Wintrust Financial Corporation (NasdaqGS:WTFC), Cogent Communications Holdings, Inc. (NasdaqGS:CCOI), Open Text Corporation (NasdaqGS:OTEX), MarketAxess Holdings Inc. (NasdaqGS:MKTX), j2 Global, Inc. (NasdaqGS:JCOM), Texas Capital Bancshares, Inc. (NasdaqGS:TCBI), Red Robin Gourmet Burgers, Inc. (NasdaqGS:RRGB), Avnet, Inc. (NasdaqGS:AVT), Principal Financial Group, Inc. (NasdaqGS:PFG), Dawson Geophysical Company (NasdaqGS:DWSN), Diodes Incorporated (NasdaqGS:DIOD), J.B. Hunt Transport Services, Inc. (NasdaqGS:JBHT), Micron Technology, Inc. (NasdaqGS:MU), Zillow Group, Inc. (NasdaqGS:ZG), Brightcove Inc. (NasdaqGS:BCOV), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Skyworks Solutions, Inc. (NasdaqGS:SWKS), Verisk Analytics, Inc. (NasdaqGS:VRSK), LKQ Corporation (NasdaqGS:LKQ), CME Group Inc. (NasdaqGS:CME), Texas Roadhouse, Inc. (NasdaqGS:TXRH), Iridium Communications Inc. (NasdaqGS:IRDM), Synchronoss Technologies, Inc. (NasdaqGS:SNCR), Nasdaq, Inc. (NasdaqGS:NDAQ), ORBCOMM Inc. (NasdaqGS:ORBC), Insulet Corporation (NasdaqGS:PODD), Allegiant Travel Company (NasdaqGS:ALGT), OraSure Technologies, Inc. (NasdaqGS:OSUR), Pinnacle Financial Partners, Inc. (NasdaqGS:PNFP), Bottomline Technologies (de), Inc. (NasdaqGS:EPAY), KVH Industries, Inc. (NasdaqGS:KVHI), TD Ameritrade Holding Corporation (NasdaqGS:AMTD), Newell Brands Inc. (NasdaqGS:NWL), Tech Data Corporation (NasdaqGS:TECD), Werner Enterprises, Inc. (NasdaqGS:WERN), United Bankshares, Inc. (NasdaqGS:UBSI), PotlatchDeltic Corporation (NasdaqGS:PCH), Magellan Health, Inc. (NasdaqGS:MGLN), ATN International, Inc. (NasdaqGS:ATNI), Merit Medical Systems, Inc. (NasdaqGS:MMSI), ICU Medical, Inc. (NasdaqGS:ICUI), Insight Enterprises, Inc. (NasdaqGS:NSIT), Patterson-UTI Energy, Inc. (NasdaqGS:PTEN), Virtus Investment Partners, Inc. (NasdaqGS:VRTS), ScanSource, Inc. (NasdaqGS:SCSC), E*TRADE Financial Corporation (NasdaqGS:ETFC), Commvault Systems, Inc. (NasdaqGS:CVLT), Equinix, Inc. (REIT) (NasdaqGS:EQIX), Houston Wire & Cable Company (NasdaqGS:HWCC), LivePerson, Inc. (NasdaqGS:LPSN), Marriott International, Inc. (NasdaqGS:MAR), Masimo Corporation (NasdaqGS:MASI), Natus Medical Incorporated (NasdaqGS:NTUS), NVIDIA Corporation (NasdaqGS:NVDA), Citrix Systems, Inc. (NasdaqGS:CTXS), Check Point Software Technologies Ltd. (NasdaqGS:CHKP), Intuit Inc. (NasdaqGS:INTU), Chuy's Holdings, Inc. (NasdaqGS:CHUY), CyrusOne Inc. (NasdaqGS:CONE), Cboe Global Markets, Inc. (BATS:CBOE), Key Energy Services, Inc. (OTCPK:KEG.X), Basic Energy Services, Inc. (OTCPK:BASX), Ultra Petroleum Corp. (OTCPK:UPLC), Pioneer Energy Services Corp. (OTCPK:PESX), Brunswick Bancorp (OTCPK:BRBW), Harvest Oil & Gas Corp. (OTCPK:HRST), Cal Dive International, Inc. (OTCPK:CDVI.Q), Dycom Industries, Inc. (NYSE:DY), W.W. Grainger, Inc. (NYSE:GWW), CenturyLink, Inc. (NYSE:CTL), HCA Healthcare, Inc. (NYSE:HCA), Baxter International Inc. (NYSE:BAX), Arrow Electronics, Inc. (NYSE:ARW), Booz Allen Hamilton Holding Corporation (NYSE:BAH), Cincinnati Bell Inc. (NYSE:CBB), Apache Corporation (NYSE:APA), Equifax Inc. (NYSE:EFX), GATX Corporation (NYSE:GATX), Masco Corporation (NYSE:MAS), MEDNAX, Inc. (NYSE:MD), United Parcel Service, Inc. (NYSE:UPS), Agnico Eagle Mines Limited (NYSE:AEM), Aflac Incorporated (NYSE:AFL), Kansas City Southern (NYSE:KSU), salesforce.com, inc. (NYSE:CRM), Tenet Healthcare Corporation (NYSE:THC), Motorola Solutions, Inc. (NYSE:MSI), Becton, Dickinson and Company (NYSE:BDX), Charles River Laboratories International, Inc. (NYSE:CRL), STERIS plc (NYSE:STE), Superior Energy Services, Inc. (NYSE:SPN), Helix Energy Solutions Group, Inc. (NYSE:HLX), Range Resources Corporation (NYSE:RRC), Oil States International, Inc. (NYSE:OIS), Haemonetics Corporation (NYSE:HAE), Jabil Inc. (NYSE:JBL), Ryder System, Inc. (NYSE:R), Plantronics, Inc. (NYSE:PLT), Leggett & Platt, Incorporated (NYSE:LEG), MRC Global Inc. (NYSE:MRC), Roadrunner Transportation Systems, Inc. (NYSE:RRTS), Cinemark Holdings, Inc. (NYSE:CNK), Palo Alto Networks, Inc. (NYSE:PANW), IHS Markit Ltd. (NYSE:INFO), Marathon Petroleum Corporation (NYSE:MPC), Hyatt Hotels Corporation (NYSE:H), Axos Financial, Inc. (NYSE:AX), Digital Realty Trust, Inc. (NYSE:DLR), Lumber Liquidators Holdings, Inc. (NYSE:LL), MSCI Inc. (NYSE:MSCI), WellCare Health Plans, Inc. (NYSE:WCG), Moody's Corporation (NYSE:MCO), QEP Resources, Inc. (NYSE:QEP), Tempur Sealy International, Inc. (NYSE:TPX), American Equity Investment Life Holding Company (NYSE:AEL), Whiting Petroleum Corporation (NYSE:WLL), Intercontinental Exchange, Inc. (NYSE:ICE), FBL Financial Group, Inc. (NYSE:FFG), Enterprise Products Partners L.P. (NYSE:EPD), The Williams Companies, Inc. (NYSE:WMB), Plains All American Pipeline, L.P. (NYSE:PAA), Nielsen Holdings plc (NYSE:NLSN), Capital Senior Living Corporation (NYSE:CSU), Steelcase Inc. (NYSE:SCS), Waste Connections, Inc. (NYSE:WCN), The Home Depot, Inc. (NYSE:HD), WESCO International, Inc. (NYSE:WCC), Spirit Airlines, Inc. (NYSE:SAVE), Lincoln National Corporation (NYSE:LNC), Primerica, Inc. (NYSE:PRI), Main Street Capital Corporation (NYSE:MAIN), Rayonier Inc. (NYSE:RYN), New York Community Bancorp, Inc. (NYSE:NYCB), Darden Restaurants, Inc. (NYSE:DRI), Whirlpool Corporation (NYSE:WHR), Covanta Holding Corporation (NYSE:CVA), The Scotts Miracle-Gro Company (NYSE:SMG), ProAssurance Corporation (NYSE:PRA), Chesapeake Energy Corporation (NYSE:CHK), Polaris Inc. (NYSE:PII), Teleflex Incorporated (NYSE:TFX), Toll Brothers, Inc. (NYSE:TOL), Union Pacific Corporation (NYSE:UNP), Unisys Corporation (NYSE:UIS), Walmart Inc. (NYSE:WMT), Service Corporation International (NYSE:SCI), Southwestern Energy Company (NYSE:SWN), Nabors Industries Ltd. (NYSE:NBR), PulteGroup, Inc. (NYSE:PHM), Pioneer Natural Resources Company (NYSE:PXD), Brown & Brown, Inc. (NYSE:BRO), The Allstate Corporation (NYSE:ALL), S&P Global Inc. (NYSE:SPGI), Raymond James Financial, Inc. (NYSE:RJF), Chipotle Mexican Grill, Inc. (NYSE:CMG), Alliance Data Systems Corporation (NYSE:ADS), American Tower Corporation (REIT) (NYSE:AMT), AmerisourceBergen Corporation (NYSE:ABC), AutoZone, Inc. (NYSE:AZO), Dine Brands Global, Inc. (NYSE:DIN), Ethan Allen Interiors Inc. (NYSE:ETH), FleetCor Technologies, Inc. (NYSE:FLT), Clean Harbors, Inc. (NYSE:CLH), Concho Resources Inc. (NYSE:CXO), Crown Castle International Corp. (REIT) (NYSE:CCI), Kinder Morgan, Inc. (NYSE:KMI), Abaxis, Inc., Carmike Cinemas, Inc., Cepheid, DigitalGlobe, Inc., Health Management Associates Inc., Lexmark International, Inc., Kinder Morgan Energy Partners, L.P., PAREXEL International Corporation, Regal Entertainment Group, Digital River Inc., JAGGAER, Inc., The Ultimate Software Group, Inc., Power-One Inc., Sapient Corp., Constant Contact, Inc., VCA Inc., GFI Group Inc., CafePress Inc., ARRIS International Limited, Anadarko Petroleum Corporation, Arctic Cat Inc., Protective Life Corporation, NYSE Holdings LLC, C. R. Bard, Inc., Cleco Corporate Holdings LLC, XPO CNW, Inc., Lufkin Industries Inc., MICROS Systems, Inc., Ryland Group Inc., Plum Creek Timber Co. Inc., HCC Insurance Holdings Inc., International Speedway Corporation, Legacy LifePoint Health, Inc., TW Telecom Inc., Interactive Intelligence Group, Inc., MedAssets, Inc., TeleCommunication Systems Inc., WTW Delaware Holdings LLC, NII Holdings, Inc., Raymond James & Associates, Inc., Hercules Offshore, Inc., Worldpay, Inc., Heartland Payment Systems, Inc., The Advisory Board Company, Alere Inc., Ceres, Inc., TIAA FSB Holdings, Inc., Tangoe, Inc., Hudson Valley Holding Corp., InterOil Corporation, Progressive Waste Solutions Ltd., Medidata Solutions, Inc., Mindspeed Technologies Inc., ExactTarget, LLC, Hospira Inc., BPZ Resources, Inc., Demandware, LLC, TerraVia Holdings, Inc., Heartware International Inc., Williams Partners L.P., Energy XXI Ltd, Ignite Restaurant Group, Inc., Covidien plc, Del Frisco's Restaurant Group, Inc., KiOR, Inc., Cloud Peak Energy Inc., Maximus Inc., Susser Holdings Corporation, Gildan Activewear Inc. (TSX:GIL), Logitech International S.A. (SWX:LOGN), Goodrich Petroleum Corporation (AMEX:GDP), Enphase Energy, Inc. (NasdaqGM:ENPH)Raymond James & Associates, Inc., Raymond James' 34th Annual Institutional Investors Conference, Mar 03, 2013 through Mar 06, 2013. Venue: JW Marriott Grande Lakes Hotel, 4040 Central Florida Parkway, Orlando, Florida, United States.
327
3/31/20138.50x19.78x21.08x36.13x31.09x$22,796$189.02216.52%Jan-23-2013Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc.'s Equity Buyback Plan-As of period ended on December 31, 2012, the company has repurchased 3,584,184 shares for $919.09 million.
328
3/31/20138.50x19.78x21.08x36.13x31.09x$20,843$172.83246.17%Jan-22-2013Earnings CallIntuitive Surgical, Inc., Q4 2012 Earnings Call, Jan 22, 2013-Intuitive Surgical, Inc., Q4 2012 Earnings Call, Jan 22, 2013
329
3/31/20138.50x19.78x21.08x36.13x31.09x$20,843$172.83246.17%Jan-22-2013Announcement of Earnings, Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2012; Provides Earnings Guidance for the Year 2013-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2012. For the quarter, the company reported income from operations of $248.1 million, income before taxes of $251.8 million and net income of $174.9 million or $4.25 per diluted share on total revenue of $609.3 million compared to income from operations of $199.5 million, income before taxes of $203.1 million and net income of $151.2 million or $3.75 per diluted share on total revenue of $496.8 million a year ago period. Fourth quarter of 2012 revenue growth was driven by continued adoption of da Vinci surgery procedures and higher da Vinci Surgical System sales.

For the full year, the company reported income from operations of $878.1 million, income before taxes of $893.9 million and net income of $656.6 million or $15.98 per diluted share on total revenue of $2,178.8 million compared to income from operations of $694.8 million, income before taxes of $709.7 million and net income of $495.1 million or $12.32 per diluted share on total revenue of $1,757.3 million a year ago period. Cash flow from operations was $814 million compared with $678 million last year. The revenue increase included recurring revenue growth of 27% and an increase in systems revenue of 20%.

For 2013, the company's expect to achieve annual revenue growth of between 16% and 19%. The expect typical capital sales seasonality in 2013, with the proportion of full year system units sold in each quarter to follow a pattern fairly consistent with 2012. The expect operating income to fall within a range of between 38% and 39% of revenue. Consistent with prior years, expects operating income as a percentage of revenue to be lower in the first quarter of 2013, reflecting system sales and procedure seasonality. Estimated income tax rate of between 29% and 31% of pretax income. The anticipate base full year tax rate to fall within the range of between 28% and 30% of pretax income.
330
3/31/20138.50x19.78x21.08x36.13x31.09x$20,843$172.83246.17%Jan-22-2013Earnings Release DateIntuitive Surgical, Inc. to Report Fiscal Year 2012 Results on Jan 22, 2013-Intuitive Surgical, Inc. announced that they will report fiscal year 2012 results on Jan 22, 2013
331
12/31/20128.88x20.76x22.13x37.94x29.37x$21,554$178.72234.76%Nov-13-2012Company Conference PresentationIntuitive Surgical, Inc. Presents at Lazard Capital Markets, LLC's 9th Annual Healthcare Conference, Nov-13-2012 01:00 PM-Intuitive Surgical, Inc. Presents at Lazard Capital Markets, LLC's 9th Annual Healthcare Conference, Nov-13-2012 01:00 PM. Venue: The Pierre Hotel, 2 East 61st Street, New York, New York, United States.
332
12/31/20128.88x20.76x22.13x37.94x29.37x$21,554$178.72234.76%Nov-13-2012ConferenceLazard Capital Markets, LLC, Lazard Capital Markets, LLC's 9th Annual Healthcare Conference, Nov 13, 2012 through Nov 14, 2012Novavax, Inc. (NasdaqGS:NVAX), Endologix, Inc. (NasdaqGS:ELGX), Merit Medical Systems, Inc. (NasdaqGS:MMSI), PDL BioPharma, Inc. (NasdaqGS:PDLI), CONMED Corporation (NasdaqGS:CNMD), Meridian Bioscience, Inc. (NasdaqGS:VIVO), Geron Corporation (NasdaqGS:GERN), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Computer Programs and Systems, Inc. (NasdaqGS:CPSI), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), Accuray Incorporated (NasdaqGS:ARAY), ChemoCentryx, Inc. (NasdaqGS:CCXI), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Bruker Corporation (NasdaqGS:BRKR), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Progenics Pharmaceuticals, Inc. (NasdaqGS:PGNX), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), AnaptysBio, Inc. (NasdaqGS:ANAB), uniQure N.V. (NasdaqGS:QURE), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Assembly Biosciences, Inc. (NasdaqGS:ASMB), Epizyme, Inc. (NasdaqGS:EPZM), Alphatec Holdings, Inc. (NasdaqGS:ATEC), United Therapeutics Corporation (NasdaqGS:UTHR), VIVUS, Inc. (NasdaqGS:VVUS), Cutera, Inc. (NasdaqGS:CUTR), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Mirati Therapeutics, Inc. (NasdaqGS:MRTX), ImmunoGen, Inc. (NasdaqGS:IMGN), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Masimo Corporation (NasdaqGS:MASI), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Orthofix Medical Inc. (NasdaqGS:OFIX), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), Omnicell, Inc. (NasdaqGS:OMCL), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Cytokinetics, Incorporated (NasdaqGS:CYTK), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Align Technology, Inc. (NasdaqGS:ALGN), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Abaxis, Inc., Accumetrics, Inc., ARIAD Pharmaceuticals, Inc., Array BioPharma Inc., Cascadian Therapeutics, Inc., Cepheid, Conceptus, Inc., Derma Sciences, Inc., Epocrates, Inc., Health Management Associates Inc., Argos Therapeutics, Inc., Onyx Pharmaceuticals, Inc., PAREXEL International Corporation, Sequenom Inc., Astex Pharmaceuticals, Inc., Solta Medical, Inc., Vanguard Health Systems Inc., Repros Therapeutics Inc., Dendreon Corporation, Santarus, Inc., NxStage Medical, Inc., Catamaran Corporation, Allergan, Inc., Analogic Corporation, BioReference Laboratories, Inc., Kindred Healthcare, LLC, SciClone Pharmaceuticals, Inc., Express Scripts Holding Company, NPS Pharmaceuticals, Inc., Palomar Medical Technologies, LLC, Affymetrix Inc., Vision-Sciences Inc., LCA-Vision Inc., Covance Inc., Apricus Biosciences, Inc., Transgenomic, Inc., OmniGuide, Inc., BioMimetic Therapeutics Inc., OncoGenex Pharmaceuticals, Inc., Auxilium Pharmaceuticals, LLC, Cogentix Medical, Inc., Novadaq Technologies Inc., Imprivata, Inc., GNS Healthcare, Inc., Dex Liquidating Co., Intuity Medical, Inc., Baxano Surgical, Inc., Endocyte, Inc., Threshold Pharmaceuticals, Inc., FM Partners Holdings LLC, FM Partners Holdings LLC, Synta Pharmaceuticals Corp., Nanosphere, Inc., GTx, Inc., Aptus Endosystems, Inc., Unilife Corporation, BioFire Defense, LLC, Rapid Micro Biosystems, Inc., Orexigen Therapeutics, Inc., Hansen Medical, Inc., Mazor Robotics Ltd., Opexa Therapeutics, Inc., MAP Pharmaceuticals, Inc., CardioDx, Inc., Integrated Diagnostics Inc., Kythera Biopharmaceuticals, Inc., NuPathe, Inc., Horizon Pharmaceutical LLC, SillaJen Biotherapeutics, Inc., Hutchison MediPharma Limited, Galena Biopharma, Inc., DNIB Unwind, Inc., Heartware International Inc., CircuLite, Inc., Tobira Therapeutics, Inc., PharMerica Corporation, Spine View, Inc., Hyperion Therapeutics, Inc., Aragon Pharmaceuticals, Inc., Foundation Medicine, Inc., Icon Limited, Sorrento Tech, Inc., Kindstar Global Co., Ltd., OvaScience, Inc., Gene Therapy Systems, Inc., Mauna Kea Technologies SA (ENXTPA:MKEA), Nicox S.A. (ENXTPA:COX), Sophiris Bio, Inc. (DB:BFF1), GI Dynamics, Inc. (ASX:GID), Molecular Partners AG (SWX:MOLN), Palatin Technologies, Inc. (AMEX:PTN), NovaBay Pharmaceuticals, Inc. (AMEX:NBY), Cerus Corporation (NasdaqGM:CERS), ArQule, Inc. (NasdaqGM:ARQL), Immunomedics, Inc. (NasdaqGM:IMMU), Chimerix, Inc. (NasdaqGM:CMRX), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), AtriCure, Inc. (NasdaqGM:ATRC), Amarin Corporation plc (NasdaqGM:AMRN), Flexion Therapeutics, Inc. (NasdaqGM:FLXN), Proteostasis Therapeutics, Inc. (NasdaqGM:PTI), Quotient Limited (NasdaqGM:QTNT), Verastem, Inc. (NasdaqGM:VSTM), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA), NewLink Genetics Corporation (NasdaqGM:NLNK), MediciNova, Inc. (NasdaqGM:MNOV), Revance Therapeutics, Inc. (NasdaqGM:RVNC), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), GW Pharmaceuticals plc (NasdaqGM:GWPH), Catabasis Pharmaceuticals, Inc. (NasdaqGM:CATB), IMRIS Inc. (OTCPK:IMRS.Q), ImmunoCellular Therapeutics, Ltd. (OTCPK:IMUC), Tengion, Inc. (OTCPK:TNGN.Q), Protea Biosciences Group, Inc (OTCPK:PRGB.Q), ReShape Lifesciences Inc. (OTCPK:RSLS.D), Windtree Therapeutics, Inc. (OTCPK:WINT), Diadexus, Inc. (OTCPK:DDXS.Q), BG Medicine, Inc. (OTCPK:BGMD), Affymax, Inc. (OTCPK:AFFY), Delcath Systems, Inc. (OTCPK:DCTH), Riot Blockchain, Inc. (NasdaqCM:RIOT), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), Cyclacel Pharmaceuticals, Inc. (NasdaqCM:CYCC), Celsion Corporation (NasdaqCM:CLSN), Caladrius Biosciences, Inc. (NasdaqCM:CLBS), BIOLASE, Inc. (NasdaqCM:BIOL), Exact Sciences Corporation (NasdaqCM:EXAS), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), Fortress Biotech, Inc. (NasdaqCM:FBIO), Regulus Therapeutics Inc. (NasdaqCM:RGLS), Organovo Holdings, Inc. (NasdaqCM:ONVO), InVivo Therapeutics Holdings Corp. (NasdaqCM:NVIV), TG Therapeutics, Inc. (NasdaqCM:TGTX), Cerecor Inc. (NasdaqCM:CERC), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), CHF Solutions, Inc. (NasdaqCM:CHFS), Celldex Therapeutics, Inc. (NasdaqCM:CLDX), HCA Healthcare, Inc. (NYSE:HCA), Universal Health Services, Inc. (NYSE:UHS), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), Enzo Biochem, Inc. (NYSE:ENZ), Teleflex Incorporated (NYSE:TFX), Community Health Systems, Inc. (NYSE:CYH), CryoLife, Inc. (NYSE:CRY), Encompass Health Corporation (NYSE:EHC), Tenet Healthcare Corporation (NYSE:THC), CVS Health Corporation (NYSE:CVS), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), STERIS plc (NYSE:STE)Lazard Capital Markets, LLC, Lazard Capital Markets, LLC's 9th Annual Healthcare Conference, Nov 13, 2012 through Nov 14, 2012. Venue: The Pierre Hotel, 2 East 61st Street, New York, New York, United States.
333
12/31/20128.88x20.76x22.13x37.94x29.37x$21,797$180.74231.02%Oct-31-2012Client AnnouncementHansen Medical, Inc. and Intuitive Surgical Operations, Inc. Enters into First Amendment to the Cross-License AgreementHansen Medical, Inc.On October 26, 2012, Hansen Medical, Inc. and Intuitive Surgical Operations, Inc. entered into a first amendment to the Cross-License Agreement between the Company and Intuitive dated as of September 1, 2005. Intuitive previously assigned all of its rights and obligations under the Original Agreement to ISOI. Under the terms of the Amended License Agreement, the Company agreed to expand the scope of the Company's patent portfolio license to ISOI, which license remains limited to ISI's Field of Use to include patents and patent applications conceived of or filed by the Company after the effective date of the Original Agreement until three years following the effective date of the Amended License Agreement or earlier if the Amended License Agreement is terminated pursuant to its terms. In addition, the first sentence of the definition of Hansen Field of Use was modified by the Amended License Agreement to read: Hansen Field of Use means the research, development, manufacture, use, sale, promotion, distribution and importation of medical devices and systems for intravascular approaches for the diagnosis and/or treatment of cardiovascular, neurovascular, and peripheral vascular diseases, wherein the distal end of the medical device or system, after entering a blood vessel, remains within the blood vessel or branches of the blood vessel for the delivery of the diagnostic or therapeutic modality for which the device or system is being used. In consideration of the rights and licenses granted by the Company to ISOI in the Amended License Agreement, ISOI agreed to pay the Company a $20 million upfront licensing fee.
334
12/31/20128.88x20.76x22.13x37.94x29.37x$0Oct-29-2012Private PlacementHansen Medical, Inc announced that it has received $10 million in funding from Intuitive Surgical Operations, Inc.Hansen Medical, Inc.Hansen Medical, Inc. (NasdaqGM:HNSN) announced a private placement of 5,291,005 shares at $1.89 per share for gross proceeds of $10,000,000 on October 26, 2012. New investor, Intuitive Surgical Operations, Inc will invest in the transaction. The shares will be subject to an 18-month lock-up period. The securities will be issued pursuant to Regulation D.


On October 29, 2012, Hansen Medical, Inc closed the transaction.
335
12/31/20128.88x20.76x22.13x37.94x29.37x$21,540$178.61234.97%Oct-26-2012Private PlacementHansen Medical, Inc announced that it expects to receive $10 million in funding from Intuitive Surgical Operations, Inc.Hansen Medical, Inc.Hansen Medical, Inc. (NasdaqGM:HNSN) announced a private placement of 5,291,005 shares at $1.89 per share for gross proceeds of $10,000,000 on October 26, 2012. New investor, Intuitive Surgical Operations, Inc will invest in the transaction. The shares will be subject to an 18-month lock-up period. The securities will be issued pursuant to Regulation D.
336
12/31/20128.88x20.76x22.13x37.94x29.37x$21,540$178.61234.97%Oct-18-2012Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $53.24 million.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $53.24 million.
337
12/31/20128.88x20.76x22.13x37.94x29.37x$21,403$177.47237.12%Oct-17-2012Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc.'s Equity Buyback Plan-As of period ended on September 30, 2012, the company has repurchased 3,482,575 shares for $865.83 million.
338
12/31/20128.88x20.76x22.13x37.94x29.37x$21,432$177.71236.67%Oct-16-2012Earnings CallIntuitive Surgical, Inc., Q3 2012 Earnings Call, Oct 16, 2012-Intuitive Surgical, Inc., Q3 2012 Earnings Call, Oct 16, 2012
339
12/31/20128.88x20.76x22.13x37.94x29.37x$21,432$177.71236.67%Oct-16-2012Corporate Guidance - New/Confirmed, Announcement of Earnings, Corporate Guidance - RaisedIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2012; Provides Tax Rate Guidance for the Fourth Quart of 2012 and for the Year 2013; Revises Earnings Guidance for the Year 2012-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2012. For the quarter, the company reported total revenue of USD 537.8 million against USD 446.7 million for the same period a year ago. Third quarter of 2012 revenue growth was driven by continued adoption of da Vinci surgery procedures and higher da Vinci Surgical System sales. Income from operations was USD 211.4 million against USD 178.9 million for the same period a year ago. Operating results for the third quarter of 2012 included USD 47 million of non-cash stock-based compensation expense compared with USD 35 million for the third quarter of 2011. Income before taxes was USD 215.7 million against USD 180.8 million for the same period a year ago. Net income was USD 183.3 million or USD 4.46 per diluted share against USD 122.4 million or USD 3.05 per diluted share for the same period a year ago. Included in net income are one-time tax benefits of approximately USD 38 million, including reserve reversals associated with the lapse of statutes of limitations. The company generated an operating profit of USD 259 million before noncash stock option expense, up 21% from the third quarter of last year and representing 48% of third quarter revenue. Third quarter 2012 operating income was USD 211 million or 39% of sales compared with USD 179 million or 40% of sales for the third quarter of 2011 and USD 225 million or 42% of sales for the second quarter of 2012.

For the nine months, the company reported total revenue of USD 1,569.5 million against USD 1,260.5 million for the same period a year ago. The revenue increase included recurring revenue growth of 27% and an increase in systems revenue of 21%. Income from operations was USD 630.0 million against USD 495.3 million for the same period a year ago. Operating income include USD 115 million of stock-based compensation charges compared with USD 102 million in 2011. Income before taxes was USD 642.1 against USD 506.6 million for the same period a year ago. Net income was USD 481.7 million or USD 11.72 per diluted share against USD 343.9 million or USD 8.55 per diluted share for the same period a year ago. Cash flow from operations was USD 597 million compared with USD 464 million last year.

For the fourth quarter of 2012, the company expects tax rate to be approximately 31% of pretax income, which has not assumed any reinstatement of the R&D tax credit.

The company forecasts 2012 revenues to grow between 20% and 23% above its 2011 revenue of USD 1.76 billion. The company forecasts operating income to fall within a range of between 39% and 40% of net revenue. The company expects operating income to come in at the high end of the range at about 40% for the year.

For the year 2013, the company expects to see a gradual reduction in tax rate to a range of between 29% and 31%.
340
12/31/20128.88x20.76x22.13x37.94x29.37x$21,432$177.71236.67%Oct-16-2012Earnings Release DateIntuitive Surgical, Inc. to Report Q3, 2012 Results on Oct 16, 2012-Intuitive Surgical, Inc. announced that they will report Q3, 2012 results on Oct 16, 2012
341
9/30/20129.41x21.91x23.31x39.78x33.99x$20,274$169.80252.35%Sep-19-2012Company Conference PresentationIntuitive Surgical, Inc. Presents at UBS Global Life Sciences Conference, Sep-19-2012 01:30 PM-Intuitive Surgical, Inc. Presents at UBS Global Life Sciences Conference, Sep-19-2012 01:30 PM. Venue: Grand Hyatt New York, Park Avenue at Grand Central, New York, New York, United States. Speakers: Aleks Cukic, Vice President of Strategy, Calvin Darling, Senior Director, FPandA.
342
9/30/20129.41x21.91x23.31x39.78x33.99x$20,274$169.80252.35%Sep-19-2012ConferenceUBS Investment Bank, UBS Global Life Sciences Conference, Sep 19, 2012 through Sep 21, 2012Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), MacroGenics, Inc. (NasdaqGS:MGNX), Luminex Corporation (NasdaqGS:LMNX), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Bruker Corporation (NasdaqGS:BRKR), OraSure Technologies, Inc. (NasdaqGS:OSUR), Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX), Tetraphase Pharmaceuticals, Inc. (NasdaqGS:TTPH), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Chiasma, Inc. (NasdaqGS:CHMA), Assembly Biosciences, Inc. (NasdaqGS:ASMB), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), Perrigo Company plc (NYSE:PRGO), Bausch Health Companies Inc. (NYSE:BHC), West Pharmaceutical Services, Inc. (NYSE:WST), Merck & Co., Inc. (NYSE:MRK), PerkinElmer, Inc. (NYSE:PKI), Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb Company (NYSE:BMY), Waters Corporation (NYSE:WAT), Medtronic plc (NYSE:MDT), QIAGEN N.V. (NYSE:QGEN), Lannett Company, Inc. (NYSE:LCI), Exact Sciences Corporation (NasdaqCM:EXAS), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), NeoGenomics, Inc. (NasdaqCM:NEO), MRI Interventions, Inc. (NasdaqCM:MRIC), Affymax, Inc. (OTCPK:AFFY), Response Genetics, Inc (OTCPK:RGDX.Q), Stratec SE (XTRA:SBS), Paion AG (XTRA:PA8), Epigenomics AG (XTRA:ECX), Bayer Aktiengesellschaft (XTRA:BAYN), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Natus Medical Incorporated (NasdaqGS:NTUS), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), United Therapeutics Corporation (NasdaqGS:UTHR), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), LivaNova PLC (NasdaqGS:LIVN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), Endo International plc (NasdaqGS:ENDP), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), RTI Surgical Holdings, Inc. (NasdaqGS:RTIX), Abiomed, Inc. (NasdaqGS:ABMD), CONMED Corporation (NasdaqGS:CNMD), Mylan N.V. (NasdaqGS:MYL), Meridian Bioscience, Inc. (NasdaqGS:VIVO), ICU Medical, Inc. (NasdaqGS:ICUI), Incyte Corporation (NasdaqGS:INCY), Brooks Automation, Inc. (NasdaqGS:BRKS), Merit Medical Systems, Inc. (NasdaqGS:MMSI), PDL BioPharma, Inc. (NasdaqGS:PDLI), Immunomedics, Inc. (NasdaqGM:IMMU), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Avadel Pharmaceuticals plc (NasdaqGM:AVDL), ArQule, Inc. (NasdaqGM:ARQL), Harvard Bioscience, Inc. (NasdaqGM:HBIO), BioSpecifics Technologies Corp. (NasdaqGM:BSTC), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Verastem, Inc. (NasdaqGM:VSTM), AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX), Acceleron Pharma Inc. (NasdaqGM:XLRN), Protalix BioTherapeutics, Inc. (AMEX:PLX), Tecan Group Ltd. (SWX:TECN), Cosmo Pharmaceuticals N.V. (SWX:COPN), Pharmaxis Ltd (ASX:PXS), Ion Beam Applications SA (ENXTBR:IBAB), Real Nutriceutical Group Limited (SEHK:2010), Pharming Group N.V. (ENXTAM:PHARM), Galapagos NV (ENXTAM:GLPG), Nicox S.A. (ENXTPA:COX), ALK-Abelló A/S (CPSE:ALK B), Zealand Pharma A/S (CPSE:ZEAL), H. Lundbeck A/S (CPSE:LUN), Novo Nordisk A/S (CPSE:NOVO B), Abaxis, Inc., ARIAD Pharmaceuticals, Inc., Array BioPharma Inc., Cepheid, Cubist Pharmaceuticals LLC, Cynosure, Inc., Dyax Corp., Idenix Pharmaceuticals, Inc., Life Technologies Corporation, Vical Incorporated, InterMune, Inc., Santarus, Inc., BTG Limited, Allergan, Inc., BioReference Laboratories, Inc., Celgene Corporation, Medical Action Industries Inc., Sigma-Aldrich Corporation, Thoratec LLC, Avanir Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc., Affymetrix Inc., Keryx Biopharmaceuticals, Inc., Symmetry Medical, Inc., Cytos Biotechnology AG, Given Imaging Ltd., Albany Molecular Research, Inc., Impax Laboratories, Inc., Aposense Ltd., Warner Chilcott plc, FC Global Realty Incorporated, Intercell Ag, UBS Investment Bank, Optimer Pharmaceuticals, Inc., SkinMedica Inc., Auxilium Pharmaceuticals, LLC, Labcyte Inc., Syneron Medical Ltd., Osiris Therapeutics, Inc., Ablynx NV, Threshold Pharmaceuticals, Inc., Synta Pharmaceuticals Corp., Nanosphere, Inc., Algeta ASA, Grünenthal GmbH, Regado Biosciences, Inc., ProteinSimple, Inc., Hospira Inc., Opexa Therapeutics, Inc., Saladax Biomedical, Inc., Medivation, Inc., Heartware International Inc., CardioDx, Inc., Biosensors International Group, Ltd., Ulthera, Inc., Hansen Medical, Inc., WuXi PharmaTech (Cayman) Inc., DNIB Unwind, Inc., Alphatec Spine, Inc., Inspiration Biopharmaceuticals, Inc., Trauson Holdings Company Limited, Actelion Pharmaceuticals Ltd, Top Grade Healthcare Limited, OvaScience, Inc., Bruin Biometrics, LLC, UBSUBS Investment Bank, UBS Global Life Sciences Conference, Sep 19, 2012 through Sep 21, 2012. Venue: Grand Hyatt New York, Park Avenue at Grand Central, New York, New York, United States.
343
9/30/20129.41x21.91x23.31x39.78x33.99x$19,738$165.31261.92%Sep-06-2012Company Conference PresentationIntuitive Surgical, Inc. Presents at 5th Annual Barrington Research Growth Conference, Sep-06-2012-Intuitive Surgical, Inc. Presents at 5th Annual Barrington Research Growth Conference, Sep-06-2012 . Venue: Four Seasons Hotel, 120 East Delaware Place, Chicago, IL 60611, United States.
344
9/30/20129.41x21.91x23.31x39.78x33.99x$19,411$162.57268.02%Sep-05-2012ConferenceBarrington Research Associates, Inc., 5th Annual Barrington Research Growth Conference, Sep 05, 2012 through Sep 06, 2012OPKO Health, Inc. (NasdaqGS:OPK), Grand Canyon Education, Inc. (NasdaqGS:LOPE), Blucora, Inc. (NasdaqGS:BCOR), Sirius XM Holdings Inc. (NasdaqGS:SIRI), SPS Commerce, Inc. (NasdaqGS:SPSC), Stericycle, Inc. (NasdaqGS:SRCL), Patterson Companies, Inc. (NasdaqGS:PDCO), Henry Schein, Inc. (NasdaqGS:HSIC), TiVo Corporation (NasdaqGS:TIVO), Zix Corporation (NasdaqGS:ZIXI), Surmodics, Inc. (NasdaqGS:SRDX), Hologic, Inc. (NasdaqGS:HOLX), Lincoln Educational Services Corporation (NasdaqGS:LINC), OraSure Technologies, Inc. (NasdaqGS:OSUR), Insulet Corporation (NasdaqGS:PODD), National CineMedia, Inc. (NasdaqGS:NCMI), ViacomCBS Inc. (NasdaqGS:VIAC), Align Technology, Inc. (NasdaqGS:ALGN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Tenax Therapeutics, Inc. (NasdaqCM:TENX), Sharps Compliance Corp. (NasdaqCM:SMED), Nuo Therapeutics, Inc. (OTCPK:AURX), School Specialty, Inc. (OTCPK:SCOO), ACCO Brands Corporation (NYSE:ACCO), Haemonetics Corporation (NYSE:HAE), Carriage Services, Inc. (NYSE:CSV), Cinemark Holdings, Inc. (NYSE:CNK), Envestnet, Inc. (NYSE:ENV), Dolby Laboratories, Inc. (NYSE:DLB), Rosetta Stone Inc. (NYSE:RST), K12 Inc. (NYSE:LRN), Perrigo Company plc (NYSE:PRGO), Adtalem Global Education Inc. (NYSE:ATGE), Affiliated Managers Group, Inc. (NYSE:AMG), Carmike Cinemas, Inc., Conceptus, Inc., JAGGAER, Inc., The Spectranetics Corporation, TiVo Solutions Inc., VCA Inc., Capella Education Company, Active Network, LLC, Thoratec LLC, Vocus Inc., Dealertrack Technologies, Inc., Volcano Corporation, MWI Veterinary Supply, Inc., Asset Acceptance Capital Corp., Barrington Research Associates, Inc., Pandora Media, LLC, RealD Inc., LeMaitre Vascular, Inc. (NasdaqGM:LMAT), AtriCure, Inc. (NasdaqGM:ATRC)Barrington Research Associates, Inc., 5th Annual Barrington Research Growth Conference, Sep 05, 2012 through Sep 06, 2012. Venue: Four Seasons Hotel, 120 East Delaware Place, Chicago, IL 60611, United States.
345
9/30/20129.41x21.91x23.31x39.78x33.99x$19,004$159.16275.90%Jul-23-2012Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc.'s Equity Buyback Plan-As of period ended on June 30, 2012, the company has repurchased 3,139,575 shares for $695.83 million.
346
9/30/20129.41x21.91x23.31x39.78x33.99x$21,659$181.40229.82%Jul-19-2012Earnings CallIntuitive Surgical, Inc., Q2 2012 Earnings Call, Jul 19, 2012-Intuitive Surgical, Inc., Q2 2012 Earnings Call, Jul 19, 2012
347
9/30/20129.41x21.91x23.31x39.78x33.99x$21,659$181.40229.82%Jul-19-2012Corporate Guidance - Raised, Announcement of Earnings, Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2012; Provides Revenue Guidance for the Third Quarter of 2012; Revised Revenue Guidance for the Full Year of 2012-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2012. The company reported second quarter of 2012 revenue of $537 million, up approximately 26% compared with $426 million for the second quarter of 2011. Second quarter of 2012 operating income increased to $225 million from $168 million in the second quarter of 2011. Operating results for the second quarter of 2012 included $33 million of non-cash stock-based compensation expense compared with $35 million for the second quarter of 2011. Second quarter of 2012 net income was $155 million, or $3.75 per diluted share, compared with $117 million, or $2.91 per diluted share, for the second quarter of 2011. Income before income taxes was $229.3 million against $172.2 million a year ago. Second quarter of 2012 revenue growth was driven by continued adoption of da Vinci surgery procedures and higher da Vinci Surgical System sales.

For the six months, total revenue was $1,031.7 million, income from operations was $418.6 million, income before income taxes was $426.4 million and net income was $298.4 million or $7.26 per diluted share against total revenue of $813.8 million, income from operations of $316.4 million, income before income taxes of $325.8 million and net income of $221.5 million or $5.51 per diluted share for the same period a year ago. Cash flows from operations were $383 million compared with $306 million last year.

The company expects its total third quarter of 2012 revenue to be near or possibly below its second quarter of 2012 level.

The company is increasing its 2012 revenue guidance. The company expects 2012 revenue to grow between 20% and 23% above total 2011 revenue of $1.76 billion. This is up from the 19% to 21% revenue growth forecast.
348
6/30/201211.27x26.66x28.41x47.53x40.27x$21,213$177.22237.60%Jun-15-2012Lawsuits & Legal IssueThe U.S. District Court for the Northern District of California Dismisses Securities Fraud Class Action Claims Against Intuitive Surgical-The U.S. District Court for the Northern District of California dismissed securities fraud class action claims brought by shareholders against Intuitive Surgical, Inc. arising from alleged misrepresentations concerning the effect of the 2008 financial crisis on the firm's revenues and prospects. Shareholders in the company sued the firm and certain of its officers alleging violations of securities laws arising from misrepresentations concerning the effect of the 2008 financial crisis on the firm's revenues. The complaint alleged that Intuitive knew by late 2007 but failed to disclose that it had "hit a penetration ceiling" as to the growth rate for some of its most popular products and that, although the disruption of hospital incomes became apparent to the market by March 2008, Intuitive failed to disclose the effect of that disruption on its sales to the hospital sector. The defendants moved to dismiss. The court concluded that a number of the defendants' challenged statements relating to the potential for further sales growth, and denying that its core products had hit a "penetration ceiling," were general expressions of confidence constituting "mere puffery" and as a result were not actionable under the Private Securities Litigation Reform Act of 1995 (PSLRA).
349
6/30/201211.27x26.66x28.41x47.53x40.27x$20,843$174.13243.59%Jun-05-2012Company Conference PresentationIntuitive Surgical, Inc. Presents at Goldman Sachs 33rd Annual Global Healthcare Conference, Jun-05-2012 01:20 PM-Intuitive Surgical, Inc. Presents at Goldman Sachs 33rd Annual Global Healthcare Conference, Jun-05-2012 01:20 PM. Venue: Terranea Resort, 100 Terranea Way, Rancho Palos Verdes, CA 90275, United States. Speakers: Aleks Cukic, Vice President of Strategy, Marshall L. Mohr, Chief Financial Officer, Principal Accounting Officer and Senior Vice President.
350
6/30/201211.27x26.66x28.41x47.53x40.27x$20,843$174.13243.59%Jun-05-2012ConferenceThe Goldman Sachs Group, Inc., Goldman Sachs 33rd Annual Global Healthcare Conference, Jun 05, 2012 through Jun 07, 2012Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), NuVasive, Inc. (NasdaqGS:NUVA), Illumina, Inc. (NasdaqGS:ILMN), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Amgen Inc. (NasdaqGS:AMGN), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Endo International plc (NasdaqGS:ENDP), Exelixis, Inc. (NasdaqGS:EXEL), Gilead Sciences, Inc. (NasdaqGS:GILD), Innoviva, Inc. (NasdaqGS:INVA), Alkermes plc (NasdaqGS:ALKS), Computer Programs and Systems, Inc. (NasdaqGS:CPSI), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Sinovac Biotech Ltd. (NasdaqGS:SVA), Bruker Corporation (NasdaqGS:BRKR), ICON Public Limited Company (NasdaqGS:ICLR), Cerner Corporation (NasdaqGS:CERN), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Hologic, Inc. (NasdaqGS:HOLX), Quidel Corporation (NasdaqGS:QDEL), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Mylan N.V. (NasdaqGS:MYL), Patterson Companies, Inc. (NasdaqGS:PDCO), PDL BioPharma, Inc. (NasdaqGS:PDLI), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Henry Schein, Inc. (NasdaqGS:HSIC), Magellan Health, Inc. (NasdaqGS:MGLN), Incyte Corporation (NasdaqGS:INCY), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), Fresenius SE & Co. KGaA (XTRA:FRE), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Bayer Aktiengesellschaft (XTRA:BAYN), Hill-Rom Holdings, Inc. (NYSE:HRC), Community Health Systems, Inc. (NYSE:CYH), AmerisourceBergen Corporation (NYSE:ABC), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Becton, Dickinson and Company (NYSE:BDX), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Charles River Laboratories International, Inc. (NYSE:CRL), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), QIAGEN N.V. (NYSE:QGEN), Humana Inc. (NYSE:HUM), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), ResMed Inc. (NYSE:RMD), Perrigo Company plc (NYSE:PRGO), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Owens & Minor, Inc. (NYSE:OMI), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Abbott Laboratories (NYSE:ABT), HCA Healthcare, Inc. (NYSE:HCA), PerkinElmer, Inc. (NYSE:PKI), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Edwards Lifesciences Corporation (NYSE:EW), Six Flags Entertainment Corporation (NYSE:SIX), The Goldman Sachs Group, Inc. (NYSE:GS), WellCare Health Plans, Inc. (NYSE:WCG), GlaxoSmithKline plc (LSE:GSK), AstraZeneca PLC (LSE:AZN), ScinoPharm Taiwan, Ltd. (TSEC:1789), UCB SA (ENXTBR:UCB), Odontoprev S.A. (BOVESPA:ODPV3), Lonza Group Ltd (SWX:LONN), Basilea Pharmaceutica AG (SWX:BSLN), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Koninklijke Philips N.V. (ENXTAM:PHIA), Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH), Otsuka Holdings Co., Ltd. (TSE:4578), Daiichi Sankyo Company, Limited (TSE:4568), Zealand Pharma A/S (CPSE:ZEAL), ALK-Abelló A/S (CPSE:ALK B), Novo Nordisk A/S (CPSE:NOVO B), Sanofi (ENXTPA:SAN), Ipsen S.A. (ENXTPA:IPN), Sino Biopharmaceutical Limited (SEHK:1177), Amylin Pharmaceuticals, LLC, ARIAD Pharmaceuticals, Inc., Cepheid, Human Genome Sciences Inc., Onyx Pharmaceuticals, Inc., PAREXEL International Corporation, Universal American Corp., ViroPharma Inc., Dendreon Corporation, InterMune, Inc., Actelion Ltd, Mckesson Medical-Surgical Top Holdings Inc., Sirona Dental Systems Inc., athenahealth, Inc., Allergan, Inc., Forest Laboratories, LLC, Omnicare Inc., Par Pharmaceutical Companies Inc., Sigma-Aldrich Corporation, Thoratec LLC, Medicis Pharmaceutical Corporation, Health Net, Inc., Affymetrix Inc., Covance Inc., FEI Company, Impax Laboratories, Inc., Shire plc, Aetna Inc., Salix Pharmaceuticals Ltd., Auxilium Pharmaceuticals, LLC, Genomic Health, Inc., ev3 Inc., Algeta ASA, Alere Inc., Hospira Inc., MAKO Surgical Corp., Covidien plc, ZELTIQ Aesthetics, Inc., Arcoda Capital Management, L.P., CareFusion Corporation, Foundation Medicine, Inc., ExamWorks Group, Inc.The Goldman Sachs Group, Inc., Goldman Sachs 33rd Annual Global Healthcare Conference, Jun 05, 2012 through Jun 07, 2012. Venue: Terranea Resort, 100 Terranea Way, Rancho Palos Verdes, CA 90275, United States.
351
6/30/201211.27x26.66x28.41x47.53x40.27x$21,819$182.28228.23%May-15-2012Company Conference PresentationIntuitive Surgical, Inc. Presents at BofA Merrill Lynch 2012 Health Care Conference, May-15-2012 03:40 PM-Intuitive Surgical, Inc. Presents at BofA Merrill Lynch 2012 Health Care Conference, May-15-2012 03:40 PM. Venue: Encore at Wynn Las Vegas, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States. Speakers: Aleks Cukic, Vice President of Strategy, Marshall L. Mohr, Chief Financial Officer, Principal Accounting Officer and Senior Vice President.
352
6/30/201211.27x26.66x28.41x47.53x40.27x$21,819$182.28228.23%May-15-2012ConferenceMerrill Lynch & Co., Inc., BofA Merrill Lynch 2012 Health Care Conference, May 15, 2012 through May 17, 2012Merrill Lynch & Co., Inc., Abaxis, Inc., AMERIGROUP Corporation, Air Methods Corporation, ARIAD Pharmaceuticals, Inc., Synageva BioPharma Corp., Cascadian Therapeutics, Inc., Cepheid, Conceptus, Inc., Cubist Pharmaceuticals LLC, Derma Sciences, Inc., Health Management Associates Inc., IPC Healthcare, Inc., Team Health Holdings, Inc., Life Technologies Corporation, Lincare Holdings Inc., Idenix Pharmaceuticals, Inc., Pharmacyclics LLC, Onyx Pharmaceuticals, Inc., Sequenom Inc., The Medicines Company, Universal American Corp., Vanguard Health Systems Inc., Vascular Solutions, Inc., Vical Incorporated, ViroPharma Inc., Dendreon Corporation, Emeritus Corp., Actelion Ltd, Santarus, Inc., Sirona Dental Systems Inc., VCA Inc., Gentiva Health Services, Inc., BioScrip, Inc., Allergan, Inc., Analogic Corporation, Celgene Corporation, BioReference Laboratories, Inc., Savient Pharmaceuticals, Inc., Forest Laboratories, LLC, Omnicare Inc., St. Jude Medical, Inc., Almost Family, Inc., Sigma-Aldrich Corporation, Landauer, Inc., Thoratec LLC, Express Scripts Holding Company, Hi-Tech Pharmacal Co., Inc., Stewart Enterprises Inc., Medicis Pharmaceutical Corporation, Avanir Pharmaceuticals, Inc., Health Net, Inc., Affymetrix Inc., Questcor Pharmaceuticals, Inc., Schiff Nutrition International Inc., FEI Company, Metropolitan Health Networks Inc., Legacy LifePoint Health, Inc., Impax Laboratories, Inc., Symmetry Medical, Inc., MedAssets, Inc., Salix Pharmaceuticals Ltd., Warner Chilcott plc, YM BioSciences Inc., Optimer Pharmaceuticals, Inc., Auxilium Pharmaceuticals, LLC, Baxano Surgical, Inc., MWI Veterinary Supply, Inc., Orthofix Inc., WuXi PharmaTech (Cayman) Inc., Orexigen Therapeutics, Inc., Transcept Pharmaceuticals, Inc., Hospira Inc., MAP Pharmaceuticals, Inc., Medivation, Inc., Heartware International Inc., Trius Therapeutics LLC, MAKO Surgical Corp., Horizon Pharmaceutical LLC, CHS/Community Health Systems, Inc., Covidien plc, PharMerica Corporation, Alphatec Spine, Inc., CareFusion Corporation, Tornier N.V., Aegerion Pharmaceuticals, Inc., Pernix Therapeutics Holdings, Inc., Sagent Pharmaceuticals, Inc., GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND), RadNet, Inc. (NasdaqGM:RDNT), Immunomedics, Inc. (NasdaqGM:IMMU), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), MannKind Corporation (NasdaqGM:MNKD), Roche Holding AG (SWX:ROG), Oncolytics Biotech Inc. (TSX:ONC), Hypera S.A. (BOVESPA:HYPE3), Sanofi (ENXTPA:SAN), Hill-Rom Holdings, Inc. (NYSE:HRC), Hanger, Inc. (NYSE:HNGR), Bristol-Myers Squibb Company (NYSE:BMY), AmerisourceBergen Corporation (NYSE:ABC), AMN Healthcare Services, Inc. (NYSE:AMN), Laboratory Corporation of America Holdings (NYSE:LH), QIAGEN N.V. (NYSE:QGEN), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), STERIS plc (NYSE:STE), Charles River Laboratories International, Inc. (NYSE:CRL), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Integer Holdings Corporation (NYSE:ITGR), Humana Inc. (NYSE:HUM), Encompass Health Corporation (NYSE:EHC), Brookdale Senior Living Inc. (NYSE:BKD), Select Medical Holdings Corporation (NYSE:SEM), Medical Properties Trust, Inc. (NYSE:MPW), Invacare Corporation (NYSE:IVC), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Service Corporation International (NYSE:SCI), Owens & Minor, Inc. (NYSE:OMI), Bio-Rad Laboratories, Inc. (NYSE:BIO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), PerkinElmer, Inc. (NYSE:PKI), Chemed Corporation (NYSE:CHE), HCA Healthcare, Inc. (NYSE:HCA), Baxter International Inc. (NYSE:BAX), MEDNAX, Inc. (NYSE:MD), MAXIMUS, Inc. (NYSE:MMS), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Capital Senior Living Corporation (NYSE:CSU), Perrigo Company plc (NYSE:PRGO), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), Teleflex Incorporated (NYSE:TFX), Exact Sciences Corporation (NasdaqCM:EXAS), Heska Corporation (NasdaqCM:HSKA), Affymax, Inc. (OTCPK:AFFY), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Innoviva, Inc. (NasdaqGS:INVA), HMS Holdings Corp. (NasdaqGS:HMSY), Exelixis, Inc. (NasdaqGS:EXEL), Gilead Sciences, Inc. (NasdaqGS:GILD), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), Align Technology, Inc. (NasdaqGS:ALGN), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), Endo International plc (NasdaqGS:ENDP), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Wright Medical Group N.V. (NasdaqGS:WMGI), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), VIVUS, Inc. (NasdaqGS:VVUS), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Stericycle, Inc. (NasdaqGS:SRCL), Orthofix Medical Inc. (NasdaqGS:OFIX), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), NuVasive, Inc. (NasdaqGS:NUVA), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Abiomed, Inc. (NasdaqGS:ABMD), Akorn, Inc. (NasdaqGS:AKRX), CONMED Corporation (NasdaqGS:CNMD), Mylan N.V. (NasdaqGS:MYL), Bruker Corporation (NasdaqGS:BRKR), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Diversified Healthcare Trust (NasdaqGS:DHC), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Endologix, Inc. (NasdaqGS:ELGX), Incyte Corporation (NasdaqGS:INCY), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Cardiovascular Systems, Inc. (NasdaqGS:CSII), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Clovis Oncology, Inc. (NasdaqGS:CLVS), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Assembly Biosciences, Inc. (NasdaqGS:ASMB), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Corcept Therapeutics Incorporated (NasdaqCM:CORT), Antares Pharma, Inc. (NasdaqCM:ATRS), Cassava Sciences, Inc. (NasdaqCM:SAVA)Merrill Lynch & Co., Inc., BofA Merrill Lynch 2012 Health Care Conference, May 15, 2012 through May 17, 2012. Venue: Encore at Wynn Las Vegas, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States.
353
6/30/201211.27x26.66x28.41x47.53x40.27x$22,348$186.70220.46%Apr-24-2012Change in Company Bylaws/RulesIntuitive Surgical, Inc. Approves Amendments to its Certificate of Incorporation and to its Byelaw-Intuitive Surgical, Inc. at its annual general meeting held on April 19, 2012. the company approved an amendment to the Certificate of Incorporation to eliminate the classified structure of the Board and to provide for the annual election of directors and the filing and effectiveness of the Certificate of Amendment with the Secretary of State of the State of Delaware and the amendments to the Bylaws.
354
6/30/201211.27x26.66x28.41x47.53x40.27x$23,005$192.19211.30%Apr-20-2012Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $752.99 million.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $752.99 million.
355
6/30/201211.27x26.66x28.41x47.53x40.27x$23,110$193.07209.88%Apr-19-2012Annual General MeetingIntuitive Surgical, Inc., Annual General Meeting, Apr 19, 2012-Intuitive Surgical, Inc., Annual General Meeting, Apr 19, 2012., at 15:04 Pacific Standard Time. Location: Marriott Santa Clara, 2700 Mission College Boulevard. Agenda: To elect three Class III members to the board of directors to serve until the 2015 annual meeting of stockholders; to approve an amendment and restatement of the company’s 2010 incentive award plan; to consider an advisory vote on the approval of the compensation of named executive officers; to approve an amendment to the Certificate of Incorporation to eliminate the classified structure of the board and to provide for the annual election of directors; to ratify the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2012; and to transact any other business which is properly brought before the annual meeting or adjournments or postponements thereof.
356
6/30/201211.27x26.66x28.41x47.53x40.27x$23,110$193.07209.88%Apr-19-2012Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc.'s Equity Buyback Plan-As of period ended on March 31, 2012, the company has repurchased 3,110,469 shares for $680.61 million.
357
6/30/201211.27x26.66x28.41x47.53x40.27x$21,766$181.84229.02%Apr-17-2012Earnings CallIntuitive Surgical, Inc., Q1 2012 Earnings Call, Apr 17, 2012-Intuitive Surgical, Inc., Q1 2012 Earnings Call, Apr 17, 2012
358
6/30/201211.27x26.66x28.41x47.53x40.27x$21,766$181.84229.02%Apr-17-2012Corporate Guidance - Raised, Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2012 ; Revised Earnings Guidance for the Year 2012-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2012. For the period, the company reported revenue of $495.2 million, up 28% compared with $388.1 million for the first quarter of 2011. First quarter of 2012 revenue growth was driven by continued robotic procedure adoption and higher da Vinci Surgical System sales. Operating income increased to $193.3 million from $148.3 million in the first quarter of 2011. Net income was $143.5 million, or $3.50 per diluted share, compared with $104.1 million, or $2.59 per diluted share for the first quarter of 2011. Income before income taxes was $197.1 million against $153.6 million a year ago. The company generated an operating profit of $228 million before noncash stock option expense, up 26% from the first quarter of last year and representing 46% of the revenue. Significant cash outlays included $50 million invested in the acquisition of Korean distributor, fixed assets and intellectual property. Excluding the impact of these outlays as well as $83 million from stock proceeds and $30 million used for working capital, company generated $211 million in gross cash flow from operations, which is 147% of reported GAAP net income in the first quarter.

For the year 2012, company was increasing revenue guidance. Based upon higher procedure expectations and revenue contributions from new products, it now expected revenue to grow between 19% at 21% above total 2011 revenue of $1.76 billion. This is up from 17% and 19% revenue growth forecast on previous call. Consistent with previous forecast, company continued to expect operating income to fall within a range of between 39% and 40% of net revenue. It will likely trend towards the lower end of this range as a result of lower gross profit percentages realized on recently launched instrument products. Amortization of purchased intellectual property, which is mostly recorded as R&D expense, is still expected to fall within a range of between $20 million and $24 million in 2012. Company expected tax rate in quarters 2 through 4 to come in at the higher end of range at around 31% of pretax income.
359
6/30/201211.27x26.66x28.41x47.53x40.27x$21,755$181.75229.18%Apr-05-2012Lawsuits & Legal IssueIntuitive Surgical Sued in New York for Death Arising Out of Use of its da Vinci Robot-The father of his deceased 24 year old daughter has commenced a lawsuit in New York against Intuitive Surgical, Inc. In his complaint, filed by the firm of Rheingold, Valet, Rheingold, McCartney & Giuffra LLP of New York City, Gilmore McCalla asserts that when his daughter was having a hysterectomy in a Bronx hospital in August 2010, the robot caused burns to an artery and her intestines, which led to her death two weeks later. The complaint alleges design flaws in the da Vinci robot, including un-insulated surgical arms and use of electrical current which can jump to healthy internal organs and tissue. It also alleges that physicians are not properly trained on the device, and that Intuitive Surgery has failed to run randomized tests as to complications with its robot. The McCalla complaint, filed in the federal court in New York City on April 4, 2012, 12civ2597, also asserts that the manufacturer has suppressed reports of complications, and has oversold the merits of its da Vinci robot to hospitals considering buying it. The machine costs of upwards of $2 million to purchase and then has a sizeable annual maintenance cost. McCalla is also asserting, in separate litigation, that the surgeon operating the robot and the hospital where the procedure was being done were careless, in part in not discovering the damage done by the robot. The da Vinci robot is operated remotely from a console by a surgeon. Several arms are placed into the patient, for burning away tissue in order to remove the diseased organ, and also for a camera.
360
3/31/201211.63x27.57x29.42x49.10x40.12x$21,621$181.54229.56%Mar-28-2012Client AnnouncementLuna Innovations Incorporated and Intuitive Surgical Extend RelationshipLuna Innovations Incorporated (NasdaqCM:LUNA)Luna Innovations Incorporated announced that it will be extending its development work through 2012 under its development and supply agreement with Intuitive Surgical, Inc., as they work towards the integration of Luna's shape and position sensing technology into Intuitive's medical robotic products. This extension is to the multi-year development and supply agreement the companies entered into in June 2007, under which Luna would supply and license to Intuitive its fiber-optic based shape sensing and position tracking system for use in Intuitive's products. Intuitive Surgical is the global technology leader in robotic-assisted minimally invasive surgery. Luna has made great leaps in advancing its shape sensing technology and will continue these efforts through 2012 as Luna and Intuitive aim towards commercialization. Through this partnership, Luna and Intuitive strive to help surgeons more precisely guide and control surgical tools during robotically-assisted procedures.
361
3/31/201211.63x27.57x29.42x49.10x40.12x$20,970$176.07239.80%Mar-14-2012Company Conference PresentationIntuitive Surgical, Inc. Presents at Barclays Capital 2012 Global Healthcare Conference, Mar-14-2012 10:15 AM-Intuitive Surgical, Inc. Presents at Barclays Capital 2012 Global Healthcare Conference, Mar-14-2012 10:15 AM. Venue: Loews Miami Hotel, Miami, Florida, United States.
362
3/31/201211.63x27.57x29.42x49.10x40.12x$20,901$175.49240.93%Mar-12-2012ConferenceBarclays Capital PLC, Barclays Capital 2012 Global Healthcare Conference, Mar 12, 2012 through Mar 15, 2012Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), NuVasive, Inc. (NasdaqGS:NUVA), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), Mylan N.V. (NasdaqGS:MYL), NextGen Healthcare, Inc. (NasdaqGS:NXGN), ICU Medical, Inc. (NasdaqGS:ICUI), Magellan Health, Inc. (NasdaqGS:MGLN), Incyte Corporation (NasdaqGS:INCY), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Henry Schein, Inc. (NasdaqGS:HSIC), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), Gilead Sciences, Inc. (NasdaqGS:GILD), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), eHealth, Inc. (NasdaqGS:EHTH), Tivity Health, Inc. (NasdaqGS:TVTY), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Bruker Corporation (NasdaqGS:BRKR), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), AmerisourceBergen Corporation (NYSE:ABC), Brookdale Senior Living Inc. (NYSE:BKD), Hanger, Inc. (NYSE:HNGR), Quest Diagnostics Incorporated (NYSE:DGX), WellCare Health Plans, Inc. (NYSE:WCG), ResMed Inc. (NYSE:RMD), Perrigo Company plc (NYSE:PRGO), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Owens & Minor, Inc. (NYSE:OMI), Welltower Inc. (NYSE:WELL), Eli Lilly and Company (NYSE:LLY), Merck & Co., Inc. (NYSE:MRK), Chemed Corporation (NYSE:CHE), HCA Healthcare, Inc. (NYSE:HCA), The Cooper Companies, Inc. (NYSE:COO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), PerkinElmer, Inc. (NYSE:PKI), MEDNAX, Inc. (NYSE:MD), MAXIMUS, Inc. (NYSE:MMS), Abbott Laboratories (NYSE:ABT), Baxter International Inc. (NYSE:BAX), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Tenet Healthcare Corporation (NYSE:THC), CVS Health Corporation (NYSE:CVS), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Charles River Laboratories International, Inc. (NYSE:CRL), Universal Health Services, Inc. (NYSE:UHS), QIAGEN N.V. (NYSE:QGEN), Laboratory Corporation of America Holdings (NYSE:LH), Medtronic plc (NYSE:MDT), Sanofi (ENXTPA:SAN), Barclays Capital PLC, AMERIGROUP Corporation, Cascadian Therapeutics, Inc., Coventry Health Care, Inc., Amylin Pharmaceuticals, LLC, ARIAD Pharmaceuticals, Inc., Skilled Healthcare Group, Inc., Human Genome Sciences Inc., Health Management Associates Inc., Team Health Holdings, Inc., Life Technologies Corporation, Onyx Pharmaceuticals, Inc., OpenTable, Inc., PAREXEL International Corporation, Idenix Pharmaceuticals, Inc., Catalent Pharma Solutions, Inc., Sequenom Inc., The Medicines Company, Universal American Corp., Vanguard Health Systems Inc., Dendreon Corporation, Actelion Ltd, Mckesson Medical-Surgical Top Holdings Inc., Catamaran Corporation, Sirona Dental Systems Inc., Gentiva Health Services, Inc., Celgene Corporation, Forest Laboratories, LLC, Pall Corporation, Omnicare Inc., St. Jude Medical, Inc., Thoratec LLC, Kindred Healthcare, LLC, Express Scripts Holding Company, NPS Pharmaceuticals, Inc., Covance Inc., Envision Healthcare Corporation, Legacy LifePoint Health, Inc., Aetna Inc., Gen-Probe Incorporated, MWI Veterinary Supply, Inc., Auxilium Pharmaceuticals, LLC, Hospira Inc., Medivation, Inc., Heartware International Inc., MAKO Surgical Corp., Complete Genomics, Inc., PharMerica Corporation, West Pharmaceutical Services Italia S.r.l., CareFusion Corporation, Sun Healthcare Group, Inc.Barclays Capital PLC, Barclays Capital 2012 Global Healthcare Conference, Mar 12, 2012 through Mar 15, 2012. Venue: Loews Miami Hotel, Miami, Florida, United States.
363
3/31/201211.63x27.57x29.42x49.10x40.12x$20,697$173.78244.28%Mar-01-2012Change in Company Bylaws/RulesIntuitive Surgical, Inc. Proposes an Amendment to the Certificate of Incorporation-Intuitive Surgical, Inc. announced at its AGM to be held on April 19, 2012, the shareholders proposed an amendment to the Certificate of Incorporation to eliminate the classified structure of the board and to provide for the annual election of directors.
364
3/31/201211.63x27.57x29.42x49.10x40.12x$20,473$171.90248.05%Feb-28-2012Company Conference PresentationIntuitive Surgical, Inc. Presents at Citi Global Healthcare Conference 2012, Feb-28-2012 03:30 PM-Intuitive Surgical, Inc. Presents at Citi Global Healthcare Conference 2012, Feb-28-2012 03:30 PM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, NY 10022, United States. Speakers: Marshall L. Mohr, Chief Financial Officer, Principal Accounting Officer and Senior Vice President.
365
3/31/201211.63x27.57x29.42x49.10x40.12x$20,415$171.41249.04%Feb-27-2012ConferenceCitigroup, Inc., Citi Global Healthcare Conference 2012, Feb 27, 2012 through Feb 29, 2012Amgen Inc. (NasdaqGS:AMGN), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Innoviva, Inc. (NasdaqGS:INVA), Exelixis, Inc. (NasdaqGS:EXEL), Gilead Sciences, Inc. (NasdaqGS:GILD), Biogen Inc. (NasdaqGS:BIIB), Nektar Therapeutics (NasdaqGS:NKTR), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), LivaNova PLC (NasdaqGS:LIVN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Omnicell, Inc. (NasdaqGS:OMCL), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Clovis Oncology, Inc. (NasdaqGS:CLVS), Epizyme, Inc. (NasdaqGS:EPZM), OPKO Health, Inc. (NasdaqGS:OPK), Natera, Inc. (NasdaqGS:NTRA), Orthofix Medical Inc. (NasdaqGS:OFIX), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), United Therapeutics Corporation (NasdaqGS:UTHR), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Geron Corporation (NasdaqGS:GERN), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Akorn, Inc. (NasdaqGS:AKRX), Hologic, Inc. (NasdaqGS:HOLX), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), Magellan Health, Inc. (NasdaqGS:MGLN), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Cerner Corporation (NasdaqGS:CERN), Mylan N.V. (NasdaqGS:MYL), Computer Programs and Systems, Inc. (NasdaqGS:CPSI), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), AngioDynamics, Inc. (NasdaqGS:ANGO), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Accuray Incorporated (NasdaqGS:ARAY), Bruker Corporation (NasdaqGS:BRKR), OraSure Technologies, Inc. (NasdaqGS:OSUR), MacroGenics, Inc. (NasdaqGS:MGNX), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Exact Sciences Corporation (NasdaqCM:EXAS), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), Celldex Therapeutics, Inc. (NasdaqCM:CLDX), Corcept Therapeutics Incorporated (NasdaqCM:CORT), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), Dynavax Technologies Corporation (NasdaqCM:DVAX), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), Fortress Biotech, Inc. (NasdaqCM:FBIO), Humana Inc. (NYSE:HUM), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), Hill-Rom Holdings, Inc. (NYSE:HRC), Mettler-Toledo International Inc. (NYSE:MTD), Medtronic plc (NYSE:MDT), AmerisourceBergen Corporation (NYSE:ABC), Eli Lilly and Company (NYSE:LLY), Merck & Co., Inc. (NYSE:MRK), Bio-Rad Laboratories, Inc. (NYSE:BIO), Baxter International Inc. (NYSE:BAX), Varian Medical Systems, Inc. (NYSE:VAR), Teva Pharmaceutical Industries Limited (NYSE:TEVA), HCA Healthcare, Inc. (NYSE:HCA), Owens & Minor, Inc. (NYSE:OMI), Citigroup Inc. (NYSE:C), Becton, Dickinson and Company (NYSE:BDX), MEDNAX, Inc. (NYSE:MD), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Haemonetics Corporation (NYSE:HAE), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Charles River Laboratories International, Inc. (NYSE:CRL), Brookdale Senior Living Inc. (NYSE:BKD), Triple-S Management Corporation (NYSE:GTS), Fresenius SE & Co. KGaA (XTRA:FRE), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Affymax, Inc. (OTCPK:AFFY), REVA Medical, Inc. (OTCPK:RVAL.L), Anthera Pharmaceuticals, Inc. (OTCPK:ANTH), AMERIGROUP Corporation, Abaxis, Inc., ARIAD Pharmaceuticals, Inc., Cascadian Therapeutics, Inc., Cynosure, Inc., Dyax Corp., Health Management Associates Inc., Team Health Holdings, Inc., Life Technologies Corporation, Merge Healthcare Incorporated, Lincare Holdings Inc., Idenix Pharmaceuticals, Inc., PAREXEL International Corporation, Pharmacyclics LLC, Onyx Pharmaceuticals, Inc., The Spectranetics Corporation, Astex Pharmaceuticals, Inc., The Medicines Company, Universal American Corp., Vanguard Health Systems Inc., Vical Incorporated, Dendreon Corporation, InterMune, Inc., Optumrx Health Solutions, LLC, Catamaran Corporation, BTG Limited, Sirona Dental Systems Inc., Protein Sciences Corporation, PatientKeeper, Inc., athenahealth, Inc., Allergan, Inc., Savient Pharmaceuticals, Inc., Forest Laboratories, LLC, Celgene Corporation, Sigma-Aldrich Corporation, Kindred Healthcare, LLC, ZOLL Medical Corporation, Avanir Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc., Affymetrix Inc., Questcor Pharmaceuticals, Inc., eResearchTechnology, Inc., Covance Inc., Metropolitan Health Networks Inc., Envision Healthcare Corporation, Legacy LifePoint Health, Inc., Keryx Biopharmaceuticals, Inc., MedAssets, Inc., Given Imaging Ltd., Aetna Inc., Warner Chilcott plc, BioSante Pharmaceuticals, Inc., Nobel Biocare Holding AG, OncoGenex Pharmaceuticals, Inc., YM BioSciences Inc., Optimer Pharmaceuticals, Inc., SkinMedica Inc., Auxilium Pharmaceuticals, LLC, Ambit Biosciences Corporation, CVRx, Inc., Endo Pharmaceuticals Inc., Endocyte, Inc., Cameron Health, Inc., Anacor Pharmaceuticals, Inc., Synta Pharmaceuticals Corp., GTx, Inc., Algeta ASA, Regado Biosciences, Inc., PharmAthene, Inc., Sorin SpA, immatics biotechnologies GmbH, ProteinSimple, Inc., Tranzyme Pharma, Inc., OPKO Biologics, MAP Pharmaceuticals, Inc., MedSolutions, Inc., OncoMed Pharmaceuticals, Inc., invendo medical GmbH, Capella Healthcare, Inc., Check Capital Management Inc., Trius Therapeutics LLC, RainDance Technologies, Inc., Medivation, Inc., IASIS Healthcare Corporation, Aegerion Pharmaceuticals, Inc., Horizon Pharmaceutical LLC, WaveMark, Inc., EUSA Pharma, Inc., Skilled Healthcare, LLC, Universal Health Care Group, Inc., Covidien plc, Ardea Biosciences, Inc., Spine View, Inc., Xlumena, Inc., Neuraltus Pharmaceuticals, Inc., Acceleron, Inc., RCCH HealthCare Partners, Abbott Electrophysiology, Inc., Omthera Pharmaceuticals, Inc., Actelion Pharmaceuticals Ltd, SuperSonic Imagine SA (ENXTPA:SSI), Novo Nordisk A/S (CPSE:NOVO B), Basilea Pharmaceutica AG (SWX:BSLN), Roche Holding AG (SWX:ROG), Straumann Holding AG (SWX:STMN), Novartis AG (SWX:NOVN), ImpediMed Limited (ASX:IPD), Mesoblast Limited (ASX:MSB), Oxurion NV (ENXTBR:OXUR), Biocartis Group NV (ENXTBR:BCART), TransEnterix, Inc. (AMEX:TRXC), Navidea Biopharmaceuticals, Inc. (AMEX:NAVB), Protalix BioTherapeutics, Inc. (AMEX:PLX), ArQule, Inc. (NasdaqGM:ARQL), Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND), Curis, Inc. (NasdaqGM:CRIS), Alimera Sciences, Inc. (NasdaqGM:ALIM), Lantheus Holdings, Inc. (NasdaqGM:LNTH), Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Amarin Corporation plc (NasdaqGM:AMRN), Immunomedics, Inc. (NasdaqGM:IMMU), AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX), Verastem, Inc. (NasdaqGM:VSTM)Citigroup, Inc., Citi Global Healthcare Conference 2012, Feb 27, 2012 through Feb 29, 2012. Venue: The Waldorf Astoria, 301 Park Avenue, New York, NY 10022, United States.
366
3/31/201211.63x27.57x29.42x49.10x40.12x$18,844$158.22278.14%Jan-19-2012Earnings Release DateIntuitive Surgical, Inc. to Report Q4, 2011 Results on Jan 19, 2012-Intuitive Surgical, Inc. announced that they will report Q4, 2011 results at 1:30 PM, Pacific Standard Time on Jan 19, 2012
367
3/31/201211.63x27.57x29.42x49.10x40.12x$18,844$158.22278.14%Jan-19-2012Earnings CallIntuitive Surgical, Inc., Q4 2011 Earnings Call, Jan 19, 2012-Intuitive Surgical, Inc., Q4 2011 Earnings Call, Jan 19, 2012
368
3/31/201211.63x27.57x29.42x49.10x40.12x$18,844$158.22278.14%Jan-19-2012Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc.'s Equity Buyback Plan-As of period ended on December 31, 2011, the company has repurchased 3,110,469 shares, for a total cost of $680.61 million.
369
3/31/201211.63x27.57x29.42x49.10x40.12x$18,844$158.22278.14%Jan-19-2012Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2011-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2011. For the quarter, the company reported total revenue of $496.8 million against $389.3 million a year ago. Income from operations was $199.5 million against $153.8 million a year ago. Income before income taxes was $203.1 million against $157.2 million a year ago. Net income was $151.2 million, or $3.75 per diluted share against net income of $121.2 million, or $3.02 per diluted share a year ago. Fourth quarter of 2011 revenue growth was driven by continued robotic procedure adoption and higher da Vinci Surgical System sales.

For the year, the company reported total revenue of $1,757.3 million against $1,413.0 million a year ago. Income from operations was $694.8 million against $555.2 million a year ago. Income before income taxes was $709.7 million against $572.3 million a year ago. Net income was $495.1 million, or $12.32 per diluted share against net income of $381.8 million, or $9.47 per diluted share a year ago.
370
3/31/201211.63x27.57x29.42x49.10x40.12x$18,538$155.65284.38%Jan-04-2012Product-Related AnnouncementIntuitive Surgical, Inc Receives FDA Clearance to Market its EndoWrist One Vessel Sealer Instrument-Intuitive Surgical, Inc. announced that it received FDA clearance to market its EndoWrist(R) One(TM) Vessel Sealer instrument for use with the da Vinci(R) Si(TM) Surgical System. The EndoWrist One Vessel Sealer is a wristed, single-use instrument intended for bipolar coagulation and mechanical transection of vessels up to 7 mm in diameter and tissue bundles that fit in the jaws of the instrument. The EndoWrist One Vessel Sealer enables da Vinci Si surgeons to fully control vessel sealing, while providing the benefits of da Vinci Surgery -- enhanced surgical precision, control and stability and 3D HD visualization. With the purchase of a dedicated radio frequency energy generator, the EndoWrist One Vessel Sealer is compatible with all da Vinci Si Surgical Systems. Customers seeking additional information should contact their local da Vinci Sales Representative.
371
12/31/201110.39x24.71x26.42x44.81x38.85x$16,834$142.78319.03%Dec-15-2011ConferenceBofA Merrill Lynch, 2011 Denver Health Care One-on-One Conference, Dec 15, 2011Patterson Companies, Inc. (NasdaqGS:PDCO), Quest Diagnostics Incorporated (NYSE:DGX), DaVita Inc. (NYSE:DVA), HCA Healthcare, Inc. (NYSE:HCA), Merrill Lynch & Co., Inc., Cubist Pharmaceuticals LLC, Omnicare Inc., Thoratec LLC, Express Scripts Holding Company, Legacy LifePoint Health, Inc., Optimer Pharmaceuticals, Inc., MAP Pharmaceuticals, Inc., Sagent Pharmaceuticals, Inc., Dendreon Corporation, VCA Inc.BofA Merrill Lynch, 2011 Denver Health Care One-on-One Conference, Dec 15, 2011. Venue: The J.W. Marriott, Denver at Cherry Creek, 150 Clayton Lane, Denver, Colorado, United States.
372
12/31/201110.39x24.71x26.42x44.81x38.85x$16,834$142.78319.03%Dec-15-2011Company Conference PresentationIntuitive Surgical, Inc. Presents at 2011 Denver Health Care One-on-One Conference, Dec-15-2011-Intuitive Surgical, Inc. Presents at 2011 Denver Health Care One-on-One Conference, Dec-15-2011 . Venue: The J.W. Marriott, Denver at Cherry Creek, 150 Clayton Lane, Denver, Colorado, United States.
373
12/31/201110.39x24.71x26.42x44.81x38.85x$17,072$144.80313.18%Dec-13-2011Product-Related AnnouncementIntuitive Surgical, Inc. Announces New Single-Site(TM) Instrumentation for the da Vinci(R) Si(TM) Surgical System-Intuitive Surgical, Inc. announced that it received FDA clearance to market its Single-Site Instrumentation for laparoscopic cholecystectomy procedures, the surgical removal of the gall bladder. Single-Site Instrumentation provides da Vinci Si customers with a technology that enables cholecystectomy via a single incision, while providing the benefits of traditional multi-port da Vinci Surgery-- enhanced surgical precision, control and stability and 3D HD visualization. The Single-Site suite of instruments and accessories consists of the Single-Site Port, specialized curved cannulae and 5mm semi-rigid instruments, which are compatible with any da Vinci Si Surgical System. The design of the instruments and the da Vinci System's Remote Center Technology are intended to reduce instrument crowding and external collisions typically associated with hand-held, laparoscopic single-incision devices. All da Vinci Si Surgical Systems are compatible with Single-Site(TM) Technology. The standard da Vinci and the da Vinci S Systems are not compatible with Single-Site Technology.
374
12/31/201110.39x24.71x26.42x44.81x38.85x$17,231$146.15309.37%Nov-16-2011Company Conference PresentationIntuitive Surgical, Inc. Presents at Lazard Capital Markets 8th Annual Healthcare Conference, Nov-16-2011 10:30 AM-Intuitive Surgical, Inc. Presents at Lazard Capital Markets 8th Annual Healthcare Conference, Nov-16-2011 10:30 AM. Venue: The Pierre Hotel, 2 East 61st Street, New York, NY 110065, United States.
375
12/31/201110.39x24.71x26.42x44.81x38.85x$17,637$149.59299.95%Nov-15-2011ConferenceLazard Capital Markets, LLC, Lazard Capital Markets 8th Annual Healthcare Conference, Nov 15, 2011 through Nov 16, 2011Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Align Technology, Inc. (NasdaqGS:ALGN), Alkermes plc (NasdaqGS:ALKS), Exelixis, Inc. (NasdaqGS:EXEL), Gilead Sciences, Inc. (NasdaqGS:GILD), ImmunoGen, Inc. (NasdaqGS:IMGN), Cytokinetics, Incorporated (NasdaqGS:CYTK), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), Assembly Biosciences, Inc. (NasdaqGS:ASMB), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), Accuray Incorporated (NasdaqGS:ARAY), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Progenics Pharmaceuticals, Inc. (NasdaqGS:PGNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), ICON Public Limited Company (NasdaqGS:ICLR), Bruker Corporation (NasdaqGS:BRKR), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Geron Corporation (NasdaqGS:GERN), Abiomed, Inc. (NasdaqGS:ABMD), DexCom, Inc. (NasdaqGS:DXCM), RTI Surgical Holdings, Inc. (NasdaqGS:RTIX), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Seattle Genetics, Inc. (NasdaqGS:SGEN), Orthofix Medical Inc. (NasdaqGS:OFIX), Masimo Corporation (NasdaqGS:MASI), CymaBay Therapeutics, Inc. (NasdaqGS:CBAY), NuVasive, Inc. (NasdaqGS:NUVA), Novavax, Inc. (NasdaqGS:NVAX), Endologix, Inc. (NasdaqGS:ELGX), Merit Medical Systems, Inc. (NasdaqGS:MMSI), PDL BioPharma, Inc. (NasdaqGS:PDLI), CONMED Corporation (NasdaqGS:CNMD), Meridian Bioscience, Inc. (NasdaqGS:VIVO), Exact Sciences Corporation (NasdaqCM:EXAS), Vermillion, Inc. (NasdaqCM:VRML), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), BG Medicine, Inc. (OTCPK:BGMD), Delcath Systems, Inc. (OTCPK:DCTH), IMRIS Inc. (OTCPK:IMRS.Q), Tengion, Inc. (OTCPK:TNGN.Q), Urologix, Inc. (OTCPK:ULGX), Aeolus Pharmaceuticals, Inc. (OTCPK:AOLS), CytRx Corporation (OTCPK:CYTR), ReShape Lifesciences Inc. (OTCPK:RSLS.D), Windtree Therapeutics, Inc. (OTCPK:WINT), Fortress Biotech, Inc. (NasdaqCM:FBIO), Regulus Therapeutics Inc. (NasdaqCM:RGLS), AxoGen, Inc. (NasdaqCM:AXGN), CHF Solutions, Inc. (NasdaqCM:CHFS), STRATA Skin Sciences, Inc. (NasdaqCM:SSKN), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), InVivo Therapeutics Holdings Corp. (NasdaqCM:NVIV), Organovo Holdings, Inc. (NasdaqCM:ONVO), Plus Therapeutics, Inc. (NasdaqCM:PSTV), Celsion Corporation (NasdaqCM:CLSN), Caladrius Biosciences, Inc. (NasdaqCM:CLBS), BIOLASE, Inc. (NasdaqCM:BIOL), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), Cyclacel Pharmaceuticals, Inc. (NasdaqCM:CYCC), Avid Bioservices, Inc. (NasdaqCM:CDMO), MEI Pharma, Inc. (NasdaqCM:MEIP), NeoGenomics, Inc. (NasdaqCM:NEO), Enzo Biochem, Inc. (NYSE:ENZ), McKesson Corporation (NYSE:MCK), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), CVS Health Corporation (NYSE:CVS), HCA Healthcare, Inc. (NYSE:HCA), Teleflex Incorporated (NYSE:TFX), Tenet Healthcare Corporation (NYSE:THC), STERIS plc (NYSE:STE), Waters Corporation (NYSE:WAT), Integer Holdings Corporation (NYSE:ITGR), Universal Health Services, Inc. (NYSE:UHS), Lannett Company, Inc. (NYSE:LCI), Quest Diagnostics Incorporated (NYSE:DGX), Emergent BioSolutions Inc. (NYSE:EBS), Bristol-Myers Squibb Company (NYSE:BMY), CryoLife, Inc. (NYSE:CRY), AmerisourceBergen Corporation (NYSE:ABC), Community Health Systems, Inc. (NYSE:CYH), Encompass Health Corporation (NYSE:EHC), Sinopharm Group Co. Ltd. (SEHK:1099), GI Dynamics, Inc. (ASX:GID), Neovasc Inc. (TSX:NVCN), Oncolytics Biotech Inc. (TSX:ONC), Theratechnologies Inc. (TSX:TH), GlaxoSmithKline plc (LSE:GSK), Roche Holding AG (SWX:ROG), Curis, Inc. (NasdaqGM:CRIS), Cerus Corporation (NasdaqGM:CERS), ArQule, Inc. (NasdaqGM:ARQL), AtriCure, Inc. (NasdaqGM:ATRC), Amarin Corporation plc (NasdaqGM:AMRN), BioSpecifics Technologies Corp. (NasdaqGM:BSTC), Chimerix, Inc. (NasdaqGM:CMRX), CareDx, Inc (NasdaqGM:CDNA), Radius Health, Inc. (NasdaqGM:RDUS), MediciNova, Inc. (NasdaqGM:MNOV), MannKind Corporation (NasdaqGM:MNKD), Revance Therapeutics, Inc. (NasdaqGM:RVNC), Aquestive Therapeutics, Inc. (NasdaqGM:AQST), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Immunomedics, Inc. (NasdaqGM:IMMU), Navidea Biopharmaceuticals, Inc. (AMEX:NAVB), Protalix BioTherapeutics, Inc. (AMEX:PLX), Xtant Medical Holdings, Inc. (AMEX:XTNT), TRACON Pharmaceuticals, Inc. (NasdaqGM:TCON), Apollo Endosurgery, Inc. (NasdaqGM:APEN), ARIAD Pharmaceuticals, Inc., Synageva BioPharma Corp., Cascadian Therapeutics, Inc., Cepheid, Conceptus, Inc., Derma Sciences, Inc., Cubist Pharmaceuticals LLC, Health Management Associates Inc., Inhibitex, Inc., Lincare Holdings Inc., Onyx Pharmaceuticals, Inc., PAREXEL International Corporation, Anadys Pharmaceuticals Inc., Astex Pharmaceuticals, Inc., Solta Medical, Inc., U.S. Healthworks, Inc., Vanguard Health Systems Inc., ViroPharma Inc., Sequenom Inc., Dendreon Corporation, Santarus, Inc., NxStage Medical, Inc., Gilead Pharmasset LLC, Catamaran Corporation, Medicago Inc., Old API Wind-down Ltd., Agennix AG, Allergan, Inc., BioReference Laboratories, Inc., Juniper Pharmaceuticals, Inc., Thoratec LLC, Unigene Laboratories, Inc., SciClone Pharmaceuticals, Inc., Express Scripts Holding Company, Omnicare Inc., Vision-Sciences Inc., Transcend Services, Inc., NPS Pharmaceuticals, Inc., Kensey Nash Corporation, Affymetrix Inc., Covance Inc., LCA-Vision Inc., World Heart Corp., Legacy LifePoint Health, Inc., Keryx Biopharmaceuticals, Inc., Targacept, Inc., Symmetry Medical, Inc., Given Imaging Ltd., NeurogesX, Inc., TriVascular, Inc., TEI Biosciences Inc., SeraCare Life Sciences, Inc., YM BioSciences Inc., Cogentix Medical, Inc., Novadaq Technologies Inc., Syneron Medical Ltd., Dex Liquidating Co., Intuity Medical, Inc., Baxano Surgical, Inc., Gen-Probe Incorporated, Threshold Pharmaceuticals, Inc., FM Partners Holdings LLC, Synta Pharmaceuticals Corp., GTx, Inc., Algeta ASA, Metabolon, Inc., Regado Biosciences, Inc., Pathwork Diagnostics, Inc., Hansen Medical, Inc., VaxInnate Corporation, Romark, L.C., Pulmonx Corporation, Orexigen Therapeutics, Inc., Mazor Robotics Ltd., Opexa Therapeutics, Inc., Clarus Therapeutics, Inc., OPKO Biologics, PolyMedix, Inc., MAP Pharmaceuticals, Inc., Cardiva Medical, Inc., Direct Flow Medical, Inc., CardioDx, Inc., Ikaria, Inc., PrimeraDx, Inc., MAKO Surgical Corp., NuPathe, Inc., Alexza Pharmaceuticals Inc., Xoma (US) LLC, CircuLite, Inc., Horizon Pharmaceutical LLC, Sonitus Medical, Inc., SillaJen Biotherapeutics, Inc., HeartWare, Inc., Galena Biopharma, Inc., Covidien plc, Ardea Biosciences, Inc., Spine View, Inc., Entellus Medical, Inc., Celgene Avilomics Research, Inc., Furiex Pharmaceuticals, Inc., Foundation Medicine, Inc., Good Start Genetics, Inc., China Kanghui Holdings, OvaScience, Inc., Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX), Alphatec Holdings, Inc. (NasdaqGS:ATEC), AnaptysBio, Inc. (NasdaqGS:ANAB), Tetraphase Pharmaceuticals, Inc. (NasdaqGS:TTPH), OPKO Health, Inc. (NasdaqGS:OPK), Epizyme, Inc. (NasdaqGS:EPZM)Lazard Capital Markets, LLC, Lazard Capital Markets 8th Annual Healthcare Conference, Nov 15, 2011 through Nov 16, 2011. Venue: The Pierre Hotel, 2 East 61st Street, New York, NY 110065, United States.
376
12/31/201110.39x24.71x26.42x44.81x38.85x$17,107$145.10312.33%Oct-27-2011Buyback - Change in Plan TermsIntuitive Surgical, Inc. Announced an Increase in Equity Buyback-On October 27, 2011, the Board of Directors of Intuitive Surgical, Inc. increased the program in the amount of $500 million, thereby increasing the total program to approximately $1.25 billion. The timing and total amount of repurchases will depend upon the market conditions. The repurchases will be made in compliance with, and at such times as permitted by, federal securities law and may be suspended or discontinued at any time.
377
12/31/201110.39x24.71x26.42x44.81x38.85x$16,413$139.21329.78%Oct-19-2011Corporate Guidance - RaisedIntuitive Surgical, Inc. Revises Earnings Guidance for the Year 2011-Intuitive Surgical, Inc. revised earnings guidance for the year 2011. For the year, the company boosted revenue guidance, calling for 22% to 23% growth, up from 19% to 21%.
378
12/31/201110.39x24.71x26.42x44.81x38.85x$15,043$127.59368.92%Oct-18-2011Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc.'s Equity Buyback Plan-As of period ended on September 30, 2011, the company has repurchased 3,110,469 shares for $680.61 million.
379
12/31/201110.39x24.71x26.42x44.81x38.85x$15,043$127.59368.92%Oct-18-2011Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2011-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2011. For the quarter, the company reported income from operations of $178.9 million, income before income taxes of $180.8 million, net income of $122.4 million or $3.05 diluted per share on total revenue of $446.7 million against income from operations of $132.1 million, income before income taxes of $137.1 million, net income of $86.6 million or $2.14 diluted per share on total revenue of $344.4 million for the same period a year ago. Third quarter of 2011 revenue growth was driven by continued robotic procedure adoption and higher da Vinci Surgical System sales.

For the nine months, the company reported income from operations of $495.3 million, income before income taxes of $506.6 million, net income of $343.9 million or $8.55 diluted per share on total revenue of $1,260.5 million against income from operations of $401.5 million, income before income taxes of $415.1 million, net income of $260.6 million or $6.45 diluted per share on total revenue of $1,023.7 million for the same period a year ago.
380
12/31/201110.39x24.71x26.42x44.81x38.85x$15,043$127.59368.92%Oct-18-2011Earnings CallIntuitive Surgical, Inc., Q3 2011 Earnings Call, Oct 18, 2011-Intuitive Surgical, Inc., Q3 2011 Earnings Call, Oct 18, 2011
381
12/31/201110.39x24.71x26.42x44.81x38.85x$15,043$127.59368.92%Oct-18-2011Earnings Release DateIntuitive Surgical, Inc. to Report Q3, 2011 Results on Oct 18, 2011-Intuitive Surgical, Inc. announced that they will report Q3, 2011 results on Oct 18, 2011
382
9/30/20118.56x20.51x21.99x37.89x33.94x$14,831$126.76371.99%Sep-21-2011Company Conference PresentationIntuitive Surgical, Inc. Presents at UBS Investment Bank's Global Life Sciences Conference, Sep-21-2011 11:00 AM-Intuitive Surgical, Inc. Presents at UBS Investment Bank's Global Life Sciences Conference, Sep-21-2011 11:00 AM. Venue: Grand Hyatt New York, Park Avenue at Grand Central, New York, New York, United States.
383
9/30/20118.56x20.51x21.99x37.89x33.94x$15,348$131.18356.08%Sep-19-2011ConferenceUBS Investment Bank, UBS Investment Bank's Global Life Sciences Conference, Sep 19, 2011 through Sep 21, 2011Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Align Technology, Inc. (NasdaqGS:ALGN), Alkermes plc (NasdaqGS:ALKS), Amgen Inc. (NasdaqGS:AMGN), Exelixis, Inc. (NasdaqGS:EXEL), Gilead Sciences, Inc. (NasdaqGS:GILD), Cytokinetics, Incorporated (NasdaqGS:CYTK), Pacira BioSciences, Inc. (NasdaqGS:PCRX), LivaNova PLC (NasdaqGS:LIVN), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Pluristem Therapeutics Inc. (NasdaqCM:PSTI), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), Dynavax Technologies Corporation (NasdaqCM:DVAX), Interpace Biosciences, Inc. (NasdaqCM:IDXG), DURECT Corporation (NasdaqCM:DRRX), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), Seattle Genetics, Inc. (NasdaqGS:SGEN), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), Nektar Therapeutics (NasdaqGS:NKTR), VIVUS, Inc. (NasdaqGS:VVUS), Cutera, Inc. (NasdaqGS:CUTR), United Therapeutics Corporation (NasdaqGS:UTHR), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Mylan N.V. (NasdaqGS:MYL), CONMED Corporation (NasdaqGS:CNMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Geron Corporation (NasdaqGS:GERN), ICU Medical, Inc. (NasdaqGS:ICUI), Incyte Corporation (NasdaqGS:INCY), Merit Medical Systems, Inc. (NasdaqGS:MMSI), PDL BioPharma, Inc. (NasdaqGS:PDLI), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Endologix, Inc. (NasdaqGS:ELGX), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Progenics Pharmaceuticals, Inc. (NasdaqGS:PGNX), Bruker Corporation (NasdaqGS:BRKR), OraSure Technologies, Inc. (NasdaqGS:OSUR), Accuray Incorporated (NasdaqGS:ARAY), Fluidigm Corporation (NasdaqGS:FLDM), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Sinovac Biotech Ltd. (NasdaqGS:SVA), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), China Biologic Products Holdings, Inc. (NasdaqGS:CBPO), Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX), Chiasma, Inc. (NasdaqGS:CHMA), MorphoSys AG (XTRA:MOR), Bayer Aktiengesellschaft (XTRA:BAYN), Novelion Therapeutics Inc. (OTCPK:NVLN.F), Tengion, Inc. (OTCPK:TNGN.Q), Myrexis, Inc. (OTCPK:MYRX), Concord Medical Services Holdings Limited (NYSE:CCM), Global Cord Blood Corporation (NYSE:CO), ResMed Inc. (NYSE:RMD), Lannett Company, Inc. (NYSE:LCI), Integer Holdings Corporation (NYSE:ITGR), Haemonetics Corporation (NYSE:HAE), Thermo Fisher Scientific Inc. (NYSE:TMO), QIAGEN N.V. (NYSE:QGEN), Mettler-Toledo International Inc. (NYSE:MTD), Bausch Health Companies Inc. (NYSE:BHC), Teva Pharmaceutical Industries Limited (NYSE:TEVA), West Pharmaceutical Services, Inc. (NYSE:WST), Baxter International Inc. (NYSE:BAX), PerkinElmer, Inc. (NYSE:PKI), Agilent Technologies, Inc. (NYSE:A), Abaxis, Inc., Cellectis S.A. (ENXTPA:ALCLS), Genmab A/S (CPSE:GMAB), BioLineRx Ltd. (TASE:BLRX), Neovasc Inc. (TSX:NVCN), GI Dynamics, Inc. (ASX:GID), ArQule, Inc. (NasdaqGM:ARQL), Protalix BioTherapeutics, Inc. (AMEX:PLX), Vascular Biogenics Ltd. (NasdaqGM:VBLT), Harvard Bioscience, Inc. (NasdaqGM:HBIO), BioSpecifics Technologies Corp. (NasdaqGM:BSTC), Amarin Corporation plc (NasdaqGM:AMRN), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Zogenix, Inc. (NasdaqGM:ZGNX), Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA), AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX), Vectura Group plc (LSE:VEC), Tecan Group Ltd. (SWX:TECN), Array BioPharma Inc., ArthroCare Corporation, Cepheid, Cubist Pharmaceuticals LLC, Cynosure, Inc., Dyax Corp., Human Genome Sciences Inc., Life Technologies Corporation, Idenix Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., Anadys Pharmaceuticals Inc., Sequenom Inc., Astex Pharmaceuticals, Inc., The Medicines Company, Vical Incorporated, Santarus, Inc., NxStage Medical, Inc., Gilead Pharmasset LLC, Xenoport, Inc., Old API Wind-down Ltd., Sirona Dental Systems Inc., Micromet, Inc., Pall Corporation, BioScrip, Inc., Analogic Corporation, BioReference Laboratories, Inc., Celgene Corporation, Sigma-Aldrich Corporation, SciClone Pharmaceuticals, Inc., ZOLL Medical Corporation, Medicis Pharmaceutical Corporation, Avanir Pharmaceuticals, Inc., Kensey Nash Corporation, Questcor Pharmaceuticals, Inc., Albany Molecular Research, Inc., Impax Laboratories, Inc., Keryx Biopharmaceuticals, Inc., Symmetry Medical, Inc., Given Imaging Ltd., UBS Investment Bank, Warner Chilcott plc, Zalicus Inc., OncoGenex Pharmaceuticals, Inc., Optimer Pharmaceuticals, Inc., Fibrocell Science, Inc., Auxilium Pharmaceuticals, LLC, Tranzyme, Inc., Syneron Medical Ltd., Endo Pharmaceuticals Inc., Osiris Therapeutics, Inc., Ablynx NV, Regado Biosciences, Inc., Unilife Corporation, Healthpoint, Ltd., OPKO Biologics, Cadence Pharmaceuticals Inc., PolyMedix, Inc., Hansen Medical, Inc., MAP Pharmaceuticals, Inc., Aperion Biologics, Inc., Saladax Biomedical, Inc., Medivation, Inc., Heartware International Inc., RainDance Technologies, Inc., Complete Genomics, Inc., ShangPharma Corporation, Pronova BioPharma ASA, Arizona Mineral Resources, Inc., Macrocure Ltd., Ardea Biosciences, Inc.UBS Investment Bank, UBS Investment Bank's Global Life Sciences Conference, Sep 19, 2011 through Sep 21, 2011. Venue: Grand Hyatt New York, Park Avenue at Grand Central, New York, New York, United States.
384
9/30/20118.56x20.51x21.99x37.89x33.94x$15,622$133.52348.09%Jul-29-2011Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $70.17 million.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $70.17 million.
385
9/30/20118.56x20.51x21.99x37.89x33.94x$14,621$124.97378.75%Jul-19-2011Earnings CallIntuitive Surgical, Inc., Q2 2011 Earnings Call, Jul 19, 2011-Intuitive Surgical, Inc., Q2 2011 Earnings Call, Jul 19, 2011
386
9/30/20118.56x20.51x21.99x37.89x33.94x$14,621$124.97378.75%Jul-19-2011Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc.'s Equity Buyback Plan-As of period ended on June 30, 2011, the company has repurchased 2,584,542 shares for $499.50 million.
387
9/30/20118.56x20.51x21.99x37.89x33.94x$14,621$124.97378.75%Jul-19-2011Corporate Guidance - Raised, Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2011; Revises Earnings Guidance for the Full Year of 2011-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2011. For the quarter, the company reported total revenue of $426 million, up 21% compared with $351 million for the second quarter of 2010. Second quarter of 2011 revenue growth was driven by continued robotic procedure adoption and higher da Vinci Surgical System sales. Operating income increased 20% to $168 million from $140 million during the second quarter of 2010. Operating results for the second quarter of 2011 included $35 million of non-cash stock-based compensation expense compared with $30 million for the second quarter of 2010. Net income increased 32% to $117 million, or $2.91 per diluted share, from $89 million, or $2.19 per diluted share for the second quarter of 2010. Income before income taxes was $172.2 million compared to $144.2 million last year.

For the six months, the company reported total revenue of $813.8 million compared to total revenue $679.3 million last year. Income from operations was $316.4 million compared to $269.4 million last year. Net income was $221.5 million or $5.51 per diluted share compared to 174.0 million or $4.31 per diluted share last year. Income before income taxes was $325.8 million compared to $278.0 million last year. Cash flows from operations was $296 million against $291 million for the same period a year ago.

The company revised earnings guidance for the full year of 2011. The company estimated 2011 revenue to grow 16% to 20% above 2010. The company is now forecasting total 2011 revenue to increase 19% to 21% for the year. In terms of noncash expenses, the company now expects noncash stock compensation to total between $135 million and $140 million, $5 million less than forecast on previous calls, up from $118 million reported in 2010. The company expects amortization of purchases of intellectual property to total between $17 million and $20 million. Other income, which is mainly comprised of interest income, is expected to come in at between $17 million and $18 million, consistent with previous estimate. With regard to income tax, the company now expects income tax rate to fall within the range between 32% and 33% of pretax income, compared to previous forecast of approximately 33%.
388
9/30/20118.56x20.51x21.99x37.89x33.94x$14,621$124.97378.75%Jul-19-2011Earnings Release DateIntuitive Surgical, Inc. to Report Q2, 2011 Results on Jul 19, 2011-Intuitive Surgical, Inc. announced that they will report Q2, 2011 results on Jul 19, 2011
389
6/30/20119.19x21.96x23.58x40.64x34.69x$13,441$114.59422.11%Jun-08-2011Company Conference PresentationIntuitive Surgical, Inc. Presents at Goldman Sachs 32nd Annual Global Healthcare Conference, Jun-08-2011 11:20 AM-Intuitive Surgical, Inc. Presents at Goldman Sachs 32nd Annual Global Healthcare Conference, Jun-08-2011 11:20 AM. Venue: Terranea Resort, 100 Terranea Way, Rancho Palos Verdes, Los Angeles, California, United States.
390
6/30/20119.19x21.96x23.58x40.64x34.69x$13,280$113.21428.48%Jun-06-2011ConferenceThe Goldman Sachs Group, Inc., Goldman Sachs 32nd Annual Global Healthcare Conference, Jun 06, 2011 through Jun 09, 2011Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), Bruker Corporation (NasdaqGS:BRKR), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), R1 RCM Inc. (NasdaqGS:RCM), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Magellan Health, Inc. (NasdaqGS:MGLN), Hologic, Inc. (NasdaqGS:HOLX), Mylan N.V. (NasdaqGS:MYL), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), NuVasive, Inc. (NasdaqGS:NUVA), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Endo International plc (NasdaqGS:ENDP), Exelixis, Inc. (NasdaqGS:EXEL), Gilead Sciences, Inc. (NasdaqGS:GILD), Seattle Genetics, Inc. (NasdaqGS:SGEN), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Masimo Corporation (NasdaqGS:MASI), Innoviva, Inc. (NasdaqGS:INVA), Alkermes plc (NasdaqGS:ALKS), Edwards Lifesciences Corporation (NYSE:EW), The Goldman Sachs Group, Inc. (NYSE:GS), ResMed Inc. (NYSE:RMD), WellCare Health Plans, Inc. (NYSE:WCG), Hill-Rom Holdings, Inc. (NYSE:HRC), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), AmerisourceBergen Corporation (NYSE:ABC), Humana Inc. (NYSE:HUM), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Integer Holdings Corporation (NYSE:ITGR), Charles River Laboratories International, Inc. (NYSE:CRL), Community Health Systems, Inc. (NYSE:CYH), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Abbott Laboratories (NYSE:ABT), Baxter International Inc. (NYSE:BAX), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Varian Medical Systems, Inc. (NYSE:VAR), Perrigo Company plc (NYSE:PRGO), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Owens & Minor, Inc. (NYSE:OMI), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Tenet Healthcare Corporation (NYSE:THC), Thermo Fisher Scientific Inc. (NYSE:TMO), Universal Health Services, Inc. (NYSE:UHS), Bayer Aktiengesellschaft (XTRA:BAYN), Stratec SE (XTRA:SBS), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), AMERIGROUP Corporation, Amylin Pharmaceuticals, LLC, Health Management Associates Inc., Human Genome Sciences Inc., Cubist Pharmaceuticals LLC, Cepheid, Onyx Pharmaceuticals, Inc., PAREXEL International Corporation, VNUS Medical Technologies, Inc., Dendreon Corporation, Actelion Ltd, Mckesson Medical-Surgical Top Holdings Inc., Gilead Pharmasset LLC, Micromet, Inc., athenahealth, Inc., Forest Laboratories, LLC, Omnicare Inc., St. Jude Medical, Inc., Sigma-Aldrich Corporation, Thoratec LLC, Health Net, Inc., Covance Inc., Shire plc, Aetna Inc., Salix Pharmaceuticals Ltd., Impax Laboratories, Inc., Hoffmann-La Roche Inc., Volcano Corporation, Genomic Health, Inc., ev3 Inc., Gen-Probe Incorporated, Novartis Corporation, Medco Health Solutions, Inc., Zimmer, Inc., Hospira Inc., HealthSpring Inc., MAKO Surgical Corp., Covidien plc, CareFusion Corporation, Merck Sharp & Dohme Corp., China Kanghui Holdings, Roche Holding AG (SWX:ROG), Basilea Pharmaceutica AG (SWX:BSLN), GlaxoSmithKline plc (LSE:GSK), Mesoblast Limited (ASX:MSB), Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC), ALK-Abelló A/S (CPSE:ALK B), Novo Nordisk A/S (CPSE:NOVO B), Sanofi (ENXTPA:SAN)The Goldman Sachs Group, Inc., Goldman Sachs 32nd Annual Global Healthcare Conference, Jun 06, 2011 through Jun 09, 2011. Venue: Terranea Resort, 100 Terranea Way, Rancho Palos Verdes, Los Angeles, California, United States.
391
6/30/20119.19x21.96x23.58x40.64x34.69x$13,868$118.23406.04%May-11-2011Company Conference PresentationIntuitive Surgical, Inc. Presents at BofA Merrill Lynch Health Care Conference, May-10-2011 05:00 PM-Intuitive Surgical, Inc. Presents at BofA Merrill Lynch Health Care Conference, May-10-2011 05:00 PM. Venue: Encore at Wynn Las Vegas, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States. Speakers: Aleks Cukic, Vice President of Strategy.
392
6/30/20119.19x21.96x23.58x40.64x34.69x$14,103$120.23397.62%May-10-2011ConferenceBofA Merrill Lynch, BofA Merrill Lynch Health Care Conference, May 10, 2011 through May 12, 2011Merrill Lynch & Co., Inc., Abaxis, Inc., ISTA Pharmaceuticals, Inc., Allos Therapeutics, Inc., American Dental Partners, Inc., WuXi PharmaTech (Cayman) Inc., Orexigen Therapeutics, Inc., ARIAD Pharmaceuticals, Inc., Conceptus, Inc., Cubist Pharmaceuticals LLC, IPC Healthcare, Inc., Team Health Holdings, Inc., Health Management Associates Inc., Acelity L.P. Inc., Lincare Holdings Inc., Idenix Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., Orthovita Inc., Pharmacyclics LLC, The Medicines Company, Universal American Corp., Vascular Solutions, Inc., Vical Incorporated, ViroPharma Inc., Dendreon Corporation, InterMune, Inc., Emeritus Corp., VCA Inc., Gilead Pharmasset LLC, Sirona Dental Systems Inc., BioScrip, Inc., Allergan, Inc., Analogic Corporation, C. R. Bard, Inc., BioReference Laboratories, Inc., Savient Pharmaceuticals, Inc., Celgene Corporation, Forest Laboratories, LLC, Lumara Health, Inc., Nationwide Health Properties, LLC, Omnicare Inc., Par Pharmaceutical Companies Inc., St. Jude Medical, Inc., Almost Family, Inc., Thoratec LLC, Kindred Healthcare, LLC, Express Scripts Holding Company, Hi-Tech Pharmacal Co., Inc., Stewart Enterprises Inc., Avanir Pharmaceuticals, Inc., Health Net, Inc., Kensey Nash Corporation, Affymetrix Inc., Impax Laboratories, Inc., Targacept, Inc., Symmetry Medical, Inc., MedAssets, Inc., Aetna Inc., Salix Pharmaceuticals Ltd., Intercell Ag, Warner Chilcott plc, Synergy Pharmaceuticals Inc., YM BioSciences Inc., Optimer Pharmaceuticals, Inc., Medco Health Solutions, Inc., Auxilium Pharmaceuticals, LLC, Volcano Corporation, LifePoint Hospitals Holdings, LLC, Hospira Inc., Cadence Pharmaceuticals Inc., MAP Pharmaceuticals, Inc., Medivation, Inc., Heartware International Inc., HealthSpring Inc., MAKO Surgical Corp., Covidien plc, Ardea Biosciences, Inc., PharMerica Corporation, CareFusion Corporation, Tornier N.V., MWI Veterinary Supply Co., China Kanghui Holdings, Immunomedics, Inc. (NasdaqGM:IMMU), MannKind Corporation (NasdaqGM:MNKD), Correvio Pharma Corp. (TSX:CORV), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Sanofi (ENXTPA:SAN), Invacare Corporation (NYSE:IVC), McKesson Corporation (NYSE:MCK), Welltower Inc. (NYSE:WELL), Healthpeak Properties, Inc. (NYSE:PEAK), HCA Healthcare, Inc. (NYSE:HCA), Stryker Corporation (NYSE:SYK), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Perrigo Company plc (NYSE:PRGO), Boston Scientific Corporation (NYSE:BSX), Teleflex Incorporated (NYSE:TFX), Service Corporation International (NYSE:SCI), Owens & Minor, Inc. (NYSE:OMI), Abbott Laboratories (NYSE:ABT), MEDNAX, Inc. (NYSE:MD), MAXIMUS, Inc. (NYSE:MMS), Johnson & Johnson (NYSE:JNJ), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Hanger, Inc. (NYSE:HNGR), Charles River Laboratories International, Inc. (NYSE:CRL), Integer Holdings Corporation (NYSE:ITGR), Universal Health Services, Inc. (NYSE:UHS), QIAGEN N.V. (NYSE:QGEN), WellCare Health Plans, Inc. (NYSE:WCG), Brookdale Senior Living Inc. (NYSE:BKD), Select Medical Holdings Corporation (NYSE:SEM), Carriage Services, Inc. (NYSE:CSV), Quest Diagnostics Incorporated (NYSE:DGX), Laboratory Corporation of America Holdings (NYSE:LH), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), AmerisourceBergen Corporation (NYSE:ABC), AMN Healthcare Services, Inc. (NYSE:AMN), Hill-Rom Holdings, Inc. (NYSE:HRC), Exact Sciences Corporation (NasdaqCM:EXAS), Cassava Sciences, Inc. (NasdaqCM:SAVA), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Affymax, Inc. (OTCPK:AFFY), Anthera Pharmaceuticals, Inc. (OTCPK:ANTH), RTI Surgical Holdings, Inc. (NasdaqGS:RTIX), Quidel Corporation (NasdaqGS:QDEL), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Abiomed, Inc. (NasdaqGS:ABMD), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), Stericycle, Inc. (NasdaqGS:SRCL), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Wright Medical Group N.V. (NasdaqGS:WMGI), VIVUS, Inc. (NasdaqGS:VVUS), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), PDL BioPharma, Inc. (NasdaqGS:PDLI), Incyte Corporation (NasdaqGS:INCY), Magellan Health, Inc. (NasdaqGS:MGLN), CONMED Corporation (NasdaqGS:CNMD), Cerner Corporation (NasdaqGS:CERN), CorVel Corporation (NasdaqGS:CRVL), Mylan N.V. (NasdaqGS:MYL), Exelixis, Inc. (NasdaqGS:EXEL), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Endo International plc (NasdaqGS:ENDP), Biogen Inc. (NasdaqGS:BIIB), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), HMS Holdings Corp. (NasdaqGS:HMSY), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Orthofix Medical Inc. (NasdaqGS:OFIX), NuVasive, Inc. (NasdaqGS:NUVA), Masimo Corporation (NasdaqGS:MASI), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Natus Medical Incorporated (NasdaqGS:NTUS), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Innoviva, Inc. (NasdaqGS:INVA), Align Technology, Inc. (NasdaqGS:ALGN), Alkermes plc (NasdaqGS:ALKS), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), AngioDynamics, Inc. (NasdaqGS:ANGO), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), ICON Public Limited Company (NasdaqGS:ICLR), Diversified Healthcare Trust (NasdaqGS:DHC), Endologix, Inc. (NasdaqGS:ELGX), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN)BofA Merrill Lynch, BofA Merrill Lynch Health Care Conference, May 10, 2011 through May 12, 2011. Venue: Encore at Wynn Las Vegas, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States.
393
6/30/20119.19x21.96x23.58x40.64x34.69x$13,674$116.57413.25%Apr-29-2011Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $437.13 million.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $437.13 million.
394
6/30/20119.19x21.96x23.58x40.64x34.69x$13,796$117.61408.71%Apr-26-2011Executive/Board Change - OtherIntuitive Surgical, Inc. Elects Craig H. Barratt, Ph.D. to its Board of Directors-Intuitive Surgical, Inc. announced that its Annual Meeting of Stockholders held on April 21, 2011. At the Annual Meeting, the stockholders elected Craig H. Barratt, Ph.D. to the board of directors to serve a three-year term expiring at the 2014 Annual Meeting of Stockholders.
395
6/30/20119.19x21.96x23.58x40.64x34.69x$13,966$119.06402.51%Apr-21-2011Annual General MeetingIntuitive Surgical, Inc., Annual General Meeting, Apr 21, 2011-Intuitive Surgical, Inc., Annual General Meeting, Apr 21, 2011., at 15:04 Pacific Daylight. Location: Marriott Santa Clara. Agenda: To elect three class II members to the board of directors to serve until the 2014 annual meeting of stockholders; to approve an amendment and restatement to company's 2010 incentive award plan; to consider a non-binding advisory vote on the compensation of its named executive officers; to consider a non-binding advisory vote on the frequency of the advisory vote on the compensation of named executive officers; to ratify the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2011; and to transact any other business which is properly brought before the annual meeting or adjournments or postponements thereof.
396
6/30/20119.19x21.96x23.58x40.64x34.69x$14,259$121.56392.18%Apr-19-2011Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc.'s Equity Buyback Plan-As of period ended on March 31, 2011, the company has repurchased 2,183,786 shares for $360.27 million.
397
6/30/20119.19x21.96x23.58x40.64x34.69x$14,259$121.56392.18%Apr-19-2011Earnings CallIntuitive Surgical, Inc., Q1 2011 Earnings Call, Apr 19, 2011-Intuitive Surgical, Inc., Q1 2011 Earnings Call, Apr 19, 2011
398
6/30/20119.19x21.96x23.58x40.64x34.69x$14,259$121.56392.18%Apr-19-2011Corporate Guidance - New/Confirmed, Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2011; Provides Earnings Guidance for the Year 2011-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2011. For the quarter, the company reported net income of $104.1 million or $2.59 per diluted share on total revenue of $388.1 million against net income of $85.3 million or $2.12 per diluted share on total revenue of $328.6 million for the same period of the last year. Income from operations was $148.3 million, income before income taxes was $153.6 million against income from operations of $129.7 million, income before income taxes of $133.8 million for the same period of the last year. The company generated $168 million in gross cash flow from operations, which is 162% of reported GAAP net income for the first quarter.

The company provided earnings guidance for the year 2011. For the period, the company expects full year 2011 revenue to grow approximately 16% to 20%. The company estimated 2011 gross margin percentage to fall between 72% and 73% of revenue.
399
6/30/20119.19x21.96x23.58x40.64x34.69x$13,484$114.95420.48%Apr-01-2011Client AnnouncementLuna Innovations Incorporated Extends Development and Supply Agreement with Intuitive Surgical, IncLuna Innovations Incorporated (NasdaqCM:LUNA)Luna Innovations Incorporated has announced that it has agreed with Intuitive Surgical, Inc. to extend its development efforts under its development and supply agreement with Intuitive, a manufacturer of da Vinci Surgical Systems, towards further integrating Luna's shape sensing technology into Intuitive's products. In June 2007, Luna and Intuitive entered into a multi-year development and supply agreement under which Luna would supply and license to Intuitive its fiber optic based shape sensing system for integration into Intuitive's medical robotics products. Intuitive is the global technology leader in robotic-assisted minimally invasive surgery. Luna has satisfied its development obligations under the existing agreement, which had previously been extended in January 2010 to cover 2010 development work. The new agreement will cover development work in 2011.
400
3/31/20118.61x20.43x21.92x37.57x29.95x$12,546$106.41462.25%Mar-16-2011Company Conference PresentationIntuitive Surgical, Inc. Presents at Barclays Capital 2011 Global Healthcare Conference, Mar-16-2011 09:30 AM-Intuitive Surgical, Inc. Presents at Barclays Capital 2011 Global Healthcare Conference, Mar-16-2011 09:30 AM. Venue: Loews Miami Hotel, Miami, Florida, United States.
401
3/31/20118.61x20.43x21.92x37.57x29.95x$12,819$108.73450.25%Mar-15-2011ConferenceBarclays Capital, Barclays Capital 2011 Global Healthcare Conference, Mar 15, 2011 through Mar 17, 2011Tivity Health, Inc. (NasdaqGS:TVTY), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Mylan N.V. (NasdaqGS:MYL), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Hologic, Inc. (NasdaqGS:HOLX), Patterson Companies, Inc. (NasdaqGS:PDCO), Magellan Health, Inc. (NasdaqGS:MGLN), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Henry Schein, Inc. (NasdaqGS:HSIC), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), ICON Public Limited Company (NasdaqGS:ICLR), Gilead Sciences, Inc. (NasdaqGS:GILD), Illumina, Inc. (NasdaqGS:ILMN), Nektar Therapeutics (NasdaqGS:NKTR), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Endo International plc (NasdaqGS:ENDP), Exelixis, Inc. (NasdaqGS:EXEL), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), NuVasive, Inc. (NasdaqGS:NUVA), Affymax, Inc. (OTCPK:AFFY), MorphoSys AG (XTRA:MOR), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), AmerisourceBergen Corporation (NYSE:ABC), Universal Health Services, Inc. (NYSE:UHS), QIAGEN N.V. (NYSE:QGEN), Medtronic plc (NYSE:MDT), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Hanger, Inc. (NYSE:HNGR), Community Health Systems, Inc. (NYSE:CYH), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), WellCare Health Plans, Inc. (NYSE:WCG), Laboratory Corporation of America Holdings (NYSE:LH), Quest Diagnostics Incorporated (NYSE:DGX), Perrigo Company plc (NYSE:PRGO), West Pharmaceutical Services, Inc. (NYSE:WST), Boston Scientific Corporation (NYSE:BSX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Owens & Minor, Inc. (NYSE:OMI), Merck & Co., Inc. (NYSE:MRK), Chemed Corporation (NYSE:CHE), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), PerkinElmer, Inc. (NYSE:PKI), MEDNAX, Inc. (NYSE:MD), MAXIMUS, Inc. (NYSE:MMS), Abbott Laboratories (NYSE:ABT), Baxter International Inc. (NYSE:BAX), Becton, Dickinson and Company (NYSE:BDX), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Thermo Fisher Scientific Inc. (NYSE:TMO), Charles River Laboratories International, Inc. (NYSE:CRL), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Brookdale Senior Living Inc. (NYSE:BKD), Select Medical Holdings Corporation (NYSE:SEM), Genesis Healthcare, Inc. (NYSE:GEN), Triple-S Management Corporation (NYSE:GTS), Genmab A/S (CPSE:GMAB), Sanofi (ENXTPA:SAN), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Sumitomo Dainippon Pharma Co., Ltd. (TSE:4506), Correvio Pharma Corp. (TSX:CORV), Amarin Corporation plc (NasdaqGM:AMRN), Pernix Sleep, Inc., Barclays Capital PLC, AMERIGROUP Corporation, Amylin Pharmaceuticals, LLC, ARIAD Pharmaceuticals, Inc., Array BioPharma Inc., Cephalon, Inc., Coventry Health Care, Inc., Skilled Healthcare Group, Inc., Human Genome Sciences Inc., Team Health Holdings, Inc., Health Management Associates Inc., Lincare Holdings Inc., Onyx Pharmaceuticals, Inc., PAREXEL International Corporation, Pharmacyclics LLC, Idenix Pharmaceuticals, Inc., Sequenom Inc., Universal American Corp., Vanguard Health Systems Inc., Pharmaceutical Product Development, LLC, Optumrx Health Solutions, LLC, Actelion Ltd, Mckesson Medical-Surgical Top Holdings Inc., Catamaran Corporation, Sirona Dental Systems Inc., Pall Corporation, Gentiva Health Services, Inc., BioReference Laboratories, Inc., Celgene Corporation, Elan Corporation Limited, Forest Laboratories, LLC, Omnicare Inc., Par Pharmaceutical Companies Inc., Sigma-Aldrich Corporation, Thoratec LLC, Kindred Healthcare, LLC, Express Scripts Holding Company, Medicis Pharmaceutical Corporation, Health Net, Inc., NPS Pharmaceuticals, Inc., Genzyme Corporation, Affymetrix Inc., Questcor Pharmaceuticals, Inc., Covance Inc., Shire plc, MedAssets, Inc., Aetna Inc., Salix Pharmaceuticals Ltd., Legacy LifePoint Health, Inc., Novo Nordisk Inc., LipoScience, Inc., Medco Health Solutions, Inc., Auxilium Pharmaceuticals, LLC, Gen-Probe Incorporated, Synta Pharmaceuticals Corp., Hoffmann-La Roche Inc., Hospira Inc., AstraZeneca Pharmaceuticals LP, MAP Pharmaceuticals, Inc., Medivation, Inc., Heartware International Inc., IASIS Healthcare Corporation, HealthSpring Inc., MAKO Surgical Corp., Complete Genomics, Inc., PharMerica Corporation, Change Healthcare Holdings, Inc., CareFusion Corporation, ExamWorks Group, Inc.Barclays Capital, Barclays Capital 2011 Global Healthcare Conference, Mar 15, 2011 through Mar 17, 2011. Venue: Loews Miami Hotel, Miami, Florida, United States.
402
3/31/20118.61x20.43x21.92x37.57x29.95x$12,819$108.73450.25%Mar-15-2011Lawsuits & Legal IssueJack Perlmutter Sues Intuitive Surgical, Inc-The U.S. District Court for the Northern District of California appointed a lead plaintiff in a securities fraud class action brought against Intuitive Surgical, Inc. arising from alleged misstatements concerning the existing and potential market for the firm's key product and technology. Jack Perlmutter sued Intuitive Surgical Inc. and certain of its officers alleging the defendants utilized a series of false and misleading statements and omissions regarding the existing and potential market for the company's da Vinci surgical control system in order to artificially inflate the firm's true prospects and financial results. Perlmutter alleged violations of 10(b) and 20(a) of the Securities Exchange Act of 1934. The case came before the court on competing motions for appointment of lead plaintiff. The district court noted that the Private Securities Litigation Reform Act of 1995 established a presumption that the most adequate plaintiff, entitled to appointment as lead plaintiff, was the candidate who possessed the financial interest in the relief sought by the class. The court concluded that candidate Police Retirement System of St. Louis (St. Louis PRS) was the plaintiff with the largest financial interest in the action because St. Louis PRS had the largest approximate losses using the 'last in first out' method of calculating losses, which was the most widely adopted method of calculation. Moreover, candidate Michael Marcus, although able to show nominal losses in excess of those sustained by St. Louis PRS, was a net seller who gained more money during the class period than he expended. Accordingly, the district court granted the motion of St. Louis PRS for appointment as lead plaintiff, and denied the competing motions of Perlmutter and Marcus.
403
3/31/20118.61x20.43x21.92x37.57x29.95x$12,988$110.16443.11%Feb-03-2011Buyback - Change in Plan TermsIntuitive Surgical, Inc. Announced An Increase In Share Buyback-On February 3, 2011, the Board of Directors increased the share repurchase program by $298.8 million, thereby increasing the total program to $748.8 million.
404
3/31/20118.61x20.43x21.92x37.57x29.95x$13,070$110.86439.68%Feb-01-2011Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan-As of period ended on December 31, 2010, the company has repurchased 2,147,845 shares for $348.66 million.
405
3/31/20118.61x20.43x21.92x37.57x29.95x$11,390$96.61519.28%Jan-20-2011Earnings Release DateIntuitive Surgical, Inc. to Report Q4, 2010 Results on Jan 20, 2011-Intuitive Surgical, Inc. announced that they will report Q4, 2010 results at 1:30 PM, Pacific Standard Time on Jan 20, 2011
406
3/31/20118.61x20.43x21.92x37.57x29.95x$11,390$96.61519.28%Jan-20-2011Earnings CallIntuitive Surgical, Inc., Q4 2010 Earnings Call, Jan 20, 2011-Intuitive Surgical, Inc., Q4 2010 Earnings Call, Jan 20, 2011
407
3/31/20118.61x20.43x21.92x37.57x29.95x$11,390$96.61519.28%Jan-20-2011Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Provides Revenue Guidance for the Year 2011-Intuitive Surgical, Inc. provided revenue guidance for the year 2011. The company expects to achieve annual revenue growth of between 16% and 20%.
408
3/31/20118.61x20.43x21.92x37.57x29.95x$11,390$96.61519.28%Jan-20-2011Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2010-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2010. For the quarter, the company reported revenue of $389 million, up 21% compared with $323 million for the fourth quarter of 2009. Fourth quarter of 2010 revenue growth was driven by continued robotic procedure adoption and higher da Vinci Surgical System sales. Fourth quarter of 2010 operating income increased to $154 million from $128 million during the fourth quarter of 2009. Operating results for the fourth quarter of 2010 included $30 million of non-cash stock-based compensation expense compared with $25 million for the fourth quarter of 2009. Net income was $121 million, or $3.02 per diluted share, compared with $78 million, or $1.95 per diluted share for the fourth quarter of 2009. Income before income taxes was $157.2 million compared to $132.5 million for the same period last year.

For the full year, the company reported revenue of $1,413 million, increasing 34% from $1,052 million for the year ended December 31, 2009. Net income was $382 million, or $9.47 per diluted share, compared to net income of $233 million, or $5.93 per diluted share for the year ended December 31, 2009. Income before income taxes was $572.3 million compared to $396.1 million for the same period last year. Income from operations was $555.2 million compared to $377.4 million for the same period last year.
409
12/31/20106.79x16.10x17.26x30.08x21.92x$9,969$85.42600.41%Dec-15-2010Shelf Registration FilingDex Liquidating Co. has filed a Shelf Registration in the amount of $4.085999 million.Dex Liquidating Co.Dex Liquidating Co. has filed a Shelf Registration in the amount of $4.085999 million.

Security Name: Common Stock
Securities Offered: 1,249,541
410
12/31/20106.79x16.10x17.26x30.08x21.92x$10,208$87.47583.99%Nov-17-2010Company Conference PresentationIntuitive Surgical, Inc. Presents at LCM 7th Annual Healthcare Conference, Nov-17-2010 11:00 AM-Intuitive Surgical, Inc. Presents at LCM 7th Annual Healthcare Conference, Nov-17-2010 11:00 AM. Venue: The St. Regis, 2 East 55th Street, New York, NY 10022, United States.
411
12/31/20106.79x16.10x17.26x30.08x21.92x$10,214$87.52583.60%Nov-16-2010ConferenceLazard Capital Markets, LLC, LCM 7th Annual Healthcare Conference, Nov 16, 2010 through Nov 17, 2010Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Align Technology, Inc. (NasdaqGS:ALGN), Alkermes plc (NasdaqGS:ALKS), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX), OPKO Health, Inc. (NasdaqGS:OPK), Tetraphase Pharmaceuticals, Inc. (NasdaqGS:TTPH), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Accuray Incorporated (NasdaqGS:ARAY), Endologix, Inc. (NasdaqGS:ELGX), Novavax, Inc. (NasdaqGS:NVAX), Progenics Pharmaceuticals, Inc. (NasdaqGS:PGNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), ICON Public Limited Company (NasdaqGS:ICLR), Bruker Corporation (NasdaqGS:BRKR), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), DexCom, Inc. (NasdaqGS:DXCM), Geron Corporation (NasdaqGS:GERN), Abiomed, Inc. (NasdaqGS:ABMD), VIVUS, Inc. (NasdaqGS:VVUS), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Merit Medical Systems, Inc. (NasdaqGS:MMSI), PDL BioPharma, Inc. (NasdaqGS:PDLI), Meridian Bioscience, Inc. (NasdaqGS:VIVO), United Therapeutics Corporation (NasdaqGS:UTHR), Myriad Genetics, Inc. (NasdaqGS:MYGN), Repligen Corporation (NasdaqGS:RGEN), Masimo Corporation (NasdaqGS:MASI), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Exelixis, Inc. (NasdaqGS:EXEL), Biogen Inc. (NasdaqGS:BIIB), ImmunoGen, Inc. (NasdaqGS:IMGN), Cytokinetics, Incorporated (NasdaqGS:CYTK), AmerisourceBergen Corporation (NYSE:ABC), CryoLife, Inc. (NYSE:CRY), STERIS plc (NYSE:STE), Universal Health Services, Inc. (NYSE:UHS), Waters Corporation (NYSE:WAT), Integer Holdings Corporation (NYSE:ITGR), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), CVS Health Corporation (NYSE:CVS), Eli Lilly and Company (NYSE:LLY), Enzo Biochem, Inc. (NYSE:ENZ), McKesson Corporation (NYSE:MCK), Owens & Minor, Inc. (NYSE:OMI), Teleflex Incorporated (NYSE:TFX), Varian Medical Systems, Inc. (NYSE:VAR), Select Medical Holdings Corporation (NYSE:SEM), Emergent BioSolutions Inc. (NYSE:EBS), Quest Diagnostics Incorporated (NYSE:DGX), Exact Sciences Corporation (NasdaqCM:EXAS), Athersys, Inc. (NasdaqCM:ATHX), Vermillion, Inc. (NasdaqCM:VRML), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), Cyclacel Pharmaceuticals, Inc. (NasdaqCM:CYCC), NeoGenomics, Inc. (NasdaqCM:NEO), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), MEI Pharma, Inc. (NasdaqCM:MEIP), Corcept Therapeutics Incorporated (NasdaqCM:CORT), Regulus Therapeutics Inc. (NasdaqCM:RGLS), InVivo Therapeutics Holdings Corp. (NasdaqCM:NVIV), Epigenomics AG (XTRA:ECX), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Affymax, Inc. (OTCPK:AFFY), Aeolus Pharmaceuticals, Inc. (OTCPK:AOLS), Winston Pharmaceuticals, Inc. (OTCPK:WPHM), Humanigen, Inc. (OTCPK:HGEN), Windtree Therapeutics, Inc. (OTCPK:WINT), Abaxis, Inc., ARIAD Pharmaceuticals, Inc., Array BioPharma Inc., Biolex Therapeutics, Inc., Intarcia Therapeutics, Inc., Cephalon, Inc., Cepheid, Cubist Pharmaceuticals LLC, Inhibitex, Inc., Kendle International Inc., Integramed America Inc., Onyx Pharmaceuticals, Inc., Orthovita Inc., PAREXEL International Corporation, Anadys Pharmaceuticals Inc., Sequenom Inc., Argos Therapeutics, Inc., Astex Pharmaceuticals, Inc., TomoTherapy Incorporated, ViroPharma Inc., Pharmaceutical Product Development, LLC, NxStage Medical, Inc., Gilead Pharmasset LLC, Allergan, Inc., BioReference Laboratories, Inc., Celgene Corporation, Elan Corporation Limited, Forest Laboratories, LLC, SciClone Pharmaceuticals, Inc., Express Scripts Holding Company, ZOLL Medical Corporation, Vision-Sciences Inc., Transcend Services, Inc., BioClinica, Inc., eResearchTechnology, Inc., World Heart Corp., Keryx Biopharmaceuticals, Inc., Targacept, Inc., Given Imaging Ltd., NeurogesX, Inc., SeraCare Life Sciences, Inc., Vyteris, Inc., Alere Inc., Medco Health Solutions, Inc., Novadaq Technologies Inc., Institute for the Study of Aging, The, Icahn Associates Corp., Threshold Pharmaceuticals, Inc., FM Partners Holdings LLC, FM Partners Holdings LLC, Synta Pharmaceuticals Corp., Nanosphere, Inc., GTx, Inc., AxioMed LLC, Algeta ASA, Regado Biosciences, Inc., Gen-Probe Incorporated, Arcadia Resources, Inc., Romark, L.C., OPKO Biologics, NeurAxon Inc., MAP Pharmaceuticals, Inc., U.S. Preventive Medicine, Inc., Heartware International Inc., CircuLite, Inc., OncoMed Pharmaceuticals, Inc., MAKO Surgical Corp., Pernix Sleep, Inc., NuPathe, Inc., Winner Medical Group Inc., Tianyin Pharmaceutical Co., Inc., Aegerion Pharmaceuticals, Inc., Horizon Pharmaceutical LLC, Cempra, Inc., Conmed Healthcare Management, Inc, Galena Biopharma, Inc., Covidien plc, Ardea Biosciences, Inc., Calistoga Pharmaceuticals, Inc., Arstasis, Inc., Health Management Associates, Inc., EndoStim, Inc., Omthera Pharmaceuticals, Inc., TridentUSA Health Services, LLC, China Kanghui Holdings, Elorac, Inc., MannKind Corporation (NasdaqGM:MNKD), Amarin Corporation plc (NasdaqGM:AMRN), BioSpecifics Technologies Corp. (NasdaqGM:BSTC), Aquestive Therapeutics, Inc. (NasdaqGM:AQST), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), Chimerix, Inc. (NasdaqGM:CMRX), Reata Pharmaceuticals, Inc. (NasdaqGM:RETA), Immunomedics, Inc. (NasdaqGM:IMMU), XOMA Corporation (NasdaqGM:XOMA), Cerus Corporation (NasdaqGM:CERS), ArQule, Inc. (NasdaqGM:ARQL), GlaxoSmithKline plc (LSE:GSK), InfuSystem Holdings Inc. (AMEX:INFU), China Pharma Holdings, Inc. (AMEX:CPHI), Resverlogix Corp. (TSX:RVX), Theratechnologies Inc. (TSX:TH), Elekta AB (publ) (OM:EKTA B), Roche Holding AG (SWX:ROG), Vivoryon Therapeutics AG (ENXTAM:VVY), bioMérieux S.A. (ENXTPA:BIM), Bavarian Nordic A/S (CPSE:BAVA)Lazard Capital Markets, LLC, LCM 7th Annual Healthcare Conference, Nov 16, 2010 through Nov 17, 2010. Venue: The St. Regis, 2 East 55th Street, New York, NY 10022, United States.
412
12/31/20106.79x16.10x17.26x30.08x21.92x$10,092$86.48591.82%Oct-20-2010Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan-As of period ended on September 30, 2010, the company has repurchased 1,617,845 shares for $208.86 million.
413
12/31/20106.79x16.10x17.26x30.08x21.92x$10,854$93.01543.25%Oct-19-2010Earnings CallIntuitive Surgical, Inc., Q3 2010 Earnings Call, Oct 19, 2010-Intuitive Surgical, Inc., Q3 2010 Earnings Call, Oct 19, 2010
414
12/31/20106.79x16.10x17.26x30.08x21.92x$10,854$93.01543.25%Oct-19-2010Earnings Release DateIntuitive Surgical, Inc. to Report Q3, 2010 Results on Oct 19, 2010-Intuitive Surgical, Inc. announced that they will report Q3, 2010 results on Oct 19, 2010
415
12/31/20106.79x16.10x17.26x30.08x21.92x$10,854$93.01543.25%Oct-19-2010Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2010-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2010. For the quarter, the company’s revenue was $344 million, up from $280 million for the third quarter of 2009. Third quarter of 2010 revenue growth was driven by continued robotic procedure adoption and higher da Vinci Surgical System sales. For comparison purposes, as previously reported, third quarter 2009 revenue was impacted by the recognition of $6 million in revenue deferred in the first quarter of 2009 related to da Vinci Si system upgrade offers made. For the quarter operating income increased to $132 million from $105 million during the third quarter of 2009. Net income was $87 million, or $2.14 per diluted share, compared with $65 million, or $1.64 per diluted share for the third quarter of 2009. Income before income taxes was $137.1 million against $108.8 million over the same period last year.



For the nine months, the company reported total revenue of $1,023.7 million, income from operations of $401.5 million, income before income taxes of $415.1 million and net income of $260.6 million or $6.45 per diluted share compared to total revenue of $729.1 million, income from operations of $249 million, income before income taxes of $263.5 million and net income of $155 million or $3.97 per diluted share over the same period last year.
416
9/30/20107.95x18.91x20.30x34.65x23.53x$12,158$103.12480.19%Aug-16-2010Private PlacementCardica Inc. announced that it has received $3 million in funding from Intuitive Surgical Operations, Inc.Dex Liquidating Co.Cardica Inc. (NasdaqGM: CRDC) announced a private placement of 1,249,541 common shares at a price of $2.40088 per share for gross proceeds of $2,999,997.99 on August 16, 2010. The transaction saw participation from new investor Intuitive Surgical Operations, Inc. Cooley LLP served as the legal advisor to the company and Latham & Watkins LLP served as the legal advisor to Intuitive Surgical Operations, Inc. The company will issue the securities pursuant to Regulation D.


On August 16, 2010, Cardica Inc. closed the transaction.
417
9/30/20107.95x18.91x20.30x34.65x23.53x$13,024$110.47441.59%Aug-09-2010Lawsuits & Legal IssueFederman & Sherwood Files a Securities Class Action Lawsuit against Intuitive Surgical, Inc-On August 6, 2010, a class action lawsuit was filed in the United States District Court for the Northern District of California against Intuitive Surgical, Inc. The complaint alleges violations of federal securities laws, Sections 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material misrepresentations to the market which had the effect of artificially inflating the market price. is from February 1, 2008 through January 7, 2009. Plaintiff seeks to recover damages on behalf of the Class.
418
9/30/20107.95x18.91x20.30x34.65x23.53x$13,382$113.50427.13%Jul-26-2010Change in Company Bylaws/RulesIntuitive Surgical, Inc. Approves Amendments to Articles of Incorporation-On July 22, 2010, following the recommendation of the Nominating and Governance Committee of the Board of Intuitive Surgical, Inc., the Board adopted and approved, effective immediately, the Amended and Restated Bylaws of the company, to adopt a majority vote standard for directors in an uncontested election of directors.
419
9/30/20107.95x18.91x20.30x34.65x23.53x$13,141$111.46436.78%Jul-23-2010Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan-As of period ended on June 30, 2010, the company has repurchased 1,406,049 shares for $150.00mm.
420
9/30/20107.95x18.91x20.30x34.65x23.53x$13,141$111.46436.78%Jul-23-2010Buyback - Change in Plan TermsIntuitive Surgical, Inc. Announced an Increase in Share Buyback-On July 22, 2010, the company authorized an additional $150 million to the program, thereby increasing the authorization to $450 million.
421
9/30/20107.95x18.91x20.30x34.65x23.53x$12,423$105.37467.80%Jul-21-2010Earnings CallIntuitive Surgical, Inc., Q2 2010 Earnings Call, Jul-21-2010-Intuitive Surgical, Inc., Q2 2010 Earnings Call, Jul-21-2010
422
9/30/20107.95x18.91x20.30x34.65x23.53x$12,423$105.37467.80%Jul-21-2010Corporate Guidance - Raised, Announcement of EarningsIntuitive Surgical, Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2010; Revised Earnings Guidance for the Full Year of 2010-Intuitive Surgical, Inc. reported consolidated unaudited earnings results for the second quarter and six months ended June 30, 2010. For the quarter, the company reported revenue of $351 million, up from $261 million for the second quarter of 2009. Second quarter of 2010 revenue growth was driven by continued robotic procedure adoption and higher da Vinci Surgical System sales. For comparison purposes, as previously reported, second quarter 2009 revenue was impacted by the recognition of $14 million in revenue deferred in the first quarter of 2009 related to da Vinci Si system upgrade revenue offers made. Operating income increased to $140 million from $100 million during the second quarter of 2009. Second quarter 2009 operating income included the impact of recognizing $14 million of revenue that was originally deferred in the first quarter of 2009. Net income was $89 million, or $2.19 per diluted share, compared with $62 million, or $1.62 per diluted share for the second quarter of 2009. Income before income taxes was $144.2 million as compared to $133.8 million for the same period last year. The increase during the current quarter reflects $137 million of cash flows from operations and $23 million from the exercise of stock options, partially offset by $20 million of capital expenditures. $10 million of capital expenditures relate to the construction of a new manufacturing facility next to corporate head quarters in Sunnyvale.

For the six months, the company reported total revenue was $679.3 million, income from operations was $269.4 million, income before income taxes was $278.0 million, net income was $174.0 million or $4.31 diluted per share as compared to total revenue was $449.0 million, income from operations was $144.5 million, income before income taxes was $154.7 million, net income was $90.5 million or $2.32 diluted per share for the same period last year.

Other income, which is mainly comprised of interest income is expected to come in around $18 million for the year, at the high end of the $16 million to $18 million range forecasted last quarter.
423
6/30/20109.74x23.32x25.14x41.14x33.86x$13,334$112.81430.35%Jun-23-2010Company Conference PresentationIntuitive Surgical, Inc. Presents at 2010 Wells Fargo Healthcare Conference, Jun-23-2010 10:15 AM-Intuitive Surgical, Inc. Presents at 2010 Wells Fargo Healthcare Conference, Jun-23-2010 10:15 AM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, Massachusetts, United States.
424
6/30/20109.74x23.32x25.14x41.14x33.86x$13,597$115.03420.12%Jun-22-2010ConferenceWells Fargo Securities, LLC, 2010 Wells Fargo Healthcare Conference, Jun 22, 2010 through Jun 24, 2010Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX), Alphatec Holdings, Inc. (NasdaqGS:ATEC), Hologic, Inc. (NasdaqGS:HOLX), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Cerner Corporation (NasdaqGS:CERN), ICON Public Limited Company (NasdaqGS:ICLR), Accuray Incorporated (NasdaqGS:ARAY), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), Endo International plc (NasdaqGS:ENDP), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), NuVasive, Inc. (NasdaqGS:NUVA), Orthofix Medical Inc. (NasdaqGS:OFIX), Wright Medical Group N.V. (NasdaqGS:WMGI), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), VIVUS, Inc. (NasdaqGS:VVUS), Select Medical Holdings Corporation (NYSE:SEM), Triple-S Management Corporation (NYSE:GTS), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), The Cooper Companies, Inc. (NYSE:COO), Edwards Lifesciences Corporation (NYSE:EW), ResMed Inc. (NYSE:RMD), Varian Medical Systems, Inc. (NYSE:VAR), Boston Scientific Corporation (NYSE:BSX), Anthem, Inc. (NYSE:ANTM), Stryker Corporation (NYSE:SYK), UnitedHealth Group Incorporated (NYSE:UNH), Bristol-Myers Squibb Company (NYSE:BMY), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), Charles River Laboratories International, Inc. (NYSE:CRL), Allergan plc (NYSE:AGN), Universal Health Services, Inc. (NYSE:UHS), Medtronic plc (NYSE:MDT), AMERIGROUP Corporation, CardioFocus, Inc., Health Management Associates Inc., Kendle International Inc., Lincare Holdings Inc., Idenix Pharmaceuticals, Inc., Orthovita Inc., PAREXEL International Corporation, Psychiatric Solutions, Inc., Agiliti Health, Inc., Vanguard Health Systems Inc., Pharmaceutical Product Development, LLC, Dendreon Corporation, IASIS Healthcare LLC, Old API Wind-down Ltd., Allergan, Inc., Celgene Corporation, Thoratec LLC, Kindred Healthcare, LLC, Medicis Pharmaceutical Corporation, Sun Healthcare Group Inc., Prior to spin-off into SHG Services and Sabra Health Care REIT, Inc., Health Net, Inc., World Heart Corp., Albany Molecular Research, Inc., Impax Laboratories, Inc., Wells Fargo Securities, LLC, BioMimetic Therapeutics Inc., Atritech, Inc., Symmetry Medical, Inc., Warner Chilcott plc, Baxano Surgical, Inc., 21st Century Oncology Holdings, Inc., Regado Biosciences, Inc., Talecris Biotherapeutics Holdings Corp., Heartware International Inc., Light Sciences Oncology, Inc., MAKO Surgical Corp., Ocera Therapeutics, Inc., Covidien plc, Biorez, Inc., AGA Medical Holdings, Inc., Molecular Detection Inc., DynaVox Inc., NuPathe, Inc., Correvio Pharma Corp. (TSX:CORV), Immunomedics, Inc. (NasdaqGM:IMMU), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), NewLink Genetics Corporation (NasdaqGM:NLNK), MannKind Corporation (NasdaqGM:MNKD)Wells Fargo Securities, LLC, 2010 Wells Fargo Healthcare Conference, Jun 22, 2010 through Jun 24, 2010. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, Massachusetts, United States.
425
6/30/20109.74x23.32x25.14x41.14x33.86x$13,164$111.37437.21%Jun-02-2010Executive/Board Change - OtherTitan Medical Inc. Appoints Joseph Talarico as the Senior Vice President of Business Development-Titan Medical Inc. announce the appointment of Joseph Talarico as the Senior Vice President, Business Development, a newly created position, for the company. Talarico has been involved in the surgical medical device industry for over seven years, most notably with Intuitive Surgical, Inc. for five years. From 2004 to 2009, Mr. Talarico held various positions with Intuitive Surgical, Inc., including Area Training Director (East Coast), Clinical Sales Manager, Area Sales Manager and Clinical Sales Representative.
426
6/30/20109.74x23.32x25.14x41.14x33.86x$13,400$113.37427.73%May-14-2010Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $438.51 million.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $438.51 million.
427
6/30/20109.74x23.32x25.14x41.14x33.86x$13,670$115.65417.33%May-05-2010Company Conference PresentationIntuitive Surgical, Inc. Presents at Deutsche Bank 35th Annual Health Care Conference, May-05-2010 11:20 AM-Intuitive Surgical, Inc. Presents at Deutsche Bank 35th Annual Health Care Conference, May-05-2010 11:20 AM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Aleks Cukic, Vice President of Strategy, Marshall L. Mohr, Chief Financial Officer, Principal Accounting Office and Senior Vice President.
428
6/30/20109.74x23.32x25.14x41.14x33.86x$14,251$120.57396.22%May-04-2010Strategic AllianceStryker Corp.'S Communications Business Unit and Intuitive Surgical Signs an Agreement to Integrate Both Companies' Technologies into Advanced Minimally Invasive Robotic SurgeryStryker Corporation (NYSE:SYK)Stryker Corp.'s Communications business unit and Intuitive Surgical, Inc. announced that they have signed an agreement to integrate both companies' technologies into advanced minimally invasive (MIS) robotic surgery suites. Through this collaboration, operating rooms containing the da Vinci Si robot and SwitchPoint Infinity Control System will provide surgeons and OR staff more flexibility and additional information during each surgical procedure. By integrating Intuitive Surgical's da Vinci Si robot into a Stryker iSuite, images and video can be transmitted throughout the operating room and into the surgeon's console. The TilePro feature of the da Vinci Si robot allows multiple high definition (HD) images from the Stryker Integration System to be accessed simultaneously during a surgical procedure. These HD images are also routed to other ceiling- and wall-mounted monitors within the OR to keep staff informed and engaged. By placing the da Vinci Si surgical equipment on a ceiling-mounted boom, cables are removed from the floor and valuable space is freed up within the sterile field. In addition, through Stryker's connectivity, hospitals have the ability to share robotic surgical footage within and outside the hospital campus for remote teaching applications. The construction of a da Vinci Si integrated iSuite is currently underway at Intuitive Surgical's training lab in Sunnyvale, California. At this demonstration facility, surgeons will be able to experience Intuitive's da Vinci Si System within a Stryker Integrated Operating Room.
429
6/30/20109.74x23.32x25.14x41.14x33.86x$14,665$124.07382.22%May-03-2010ConferenceDeutsche Bank Securities Inc., Deutsche Bank 35th Annual Health Care Conference, May 03, 2010 through May 05, 2010Amgen Inc. (NasdaqGS:AMGN), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), eHealth, Inc. (NasdaqGS:EHTH), Exelixis, Inc. (NasdaqGS:EXEL), Cytokinetics, Incorporated (NasdaqGS:CYTK), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Illumina, Inc. (NasdaqGS:ILMN), Nektar Therapeutics (NasdaqGS:NKTR), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), Seattle Genetics, Inc. (NasdaqGS:SGEN), Innoviva, Inc. (NasdaqGS:INVA), Align Technology, Inc. (NasdaqGS:ALGN), Tivity Health, Inc. (NasdaqGS:TVTY), Bruker Corporation (NasdaqGS:BRKR), ICON Public Limited Company (NasdaqGS:ICLR), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Meridian Bioscience, Inc. (NasdaqGS:VIVO), Cerner Corporation (NasdaqGS:CERN), United Therapeutics Corporation (NasdaqGS:UTHR), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), VIVUS, Inc. (NasdaqGS:VVUS), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), AngioDynamics, Inc. (NasdaqGS:ANGO), LHC Group, Inc. (NasdaqGS:LHCG), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Amedisys, Inc. (NasdaqGS:AMED), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Magellan Health, Inc. (NasdaqGS:MGLN), Henry Schein, Inc. (NasdaqGS:HSIC), Anthera Pharmaceuticals, Inc. (OTCPK:ANTH), Biotest Aktiengesellschaft (XTRA:BIO3), Gerresheimer AG (XTRA:GXI), MorphoSys AG (XTRA:MOR), MagForce AG (XTRA:MF6), STADA Arzneimittel Aktiengesellschaft (MUN:SAZ), Brookdale Senior Living Inc. (NYSE:BKD), KKR & Co. Inc. (NYSE:KKR), QIAGEN N.V. (NYSE:QGEN), Mettler-Toledo International Inc. (NYSE:MTD), Humana Inc. (NYSE:HUM), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), AmerisourceBergen Corporation (NYSE:ABC), Waters Corporation (NYSE:WAT), UnitedHealth Group Incorporated (NYSE:UNH), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Universal Health Services, Inc. (NYSE:UHS), Community Health Systems, Inc. (NYSE:CYH), Chemed Corporation (NYSE:CHE), McKesson Corporation (NYSE:MCK), Owens & Minor, Inc. (NYSE:OMI), MEDNAX, Inc. (NYSE:MD), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Boston Scientific Corporation (NYSE:BSX), Perrigo Company plc (NYSE:PRGO), ResMed Inc. (NYSE:RMD), Stereotaxis, Inc. (AMEX:STXS), Omeros Corporation (NasdaqGM:OMER), RadNet, Inc. (NasdaqGM:RDNT), Amarin Corporation plc (NasdaqGM:AMRN), MannKind Corporation (NasdaqGM:MNKD), Novo Nordisk A/S (CPSE:NOVO B), Sanofi (ENXTPA:SAN), Opto Circuits (India) Limited (BSE:532391), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Fleury S.A. (BOVESPA:FLRY3), Healius Limited (ASX:HLS), Bain Capital, LP, Amylin Pharmaceuticals, LLC, Caliper Life Sciences, Inc., Conceptus, Inc., Coventry Health Care, Inc., Dionex Corp., Dyax Corp., Skilled Healthcare Group, Inc., Health Management Associates Inc., Human Genome Sciences Inc., IPC Healthcare, Inc., Inspire Pharmaceuticals, Inc., Acelity L.P. Inc., Lincare Holdings Inc., NovaMed Inc., Odyssey HealthCare, Inc., Clarient, Inc., The Medicines Company, TriZetto Corporation, Universal American Corp., ViroPharma Inc., Pharmaceutical Product Development, LLC, Dendreon Corporation, Actelion Ltd, Deloitte Consulting LLP, Xenoport, Inc., Gentiva Health Services, Inc., C. R. Bard, Inc., BioReference Laboratories, Inc., Celgene Corporation, Par Pharmaceutical Companies Inc., Sigma-Aldrich Corporation, Medicis Pharmaceutical Corporation, Express Scripts Holding Company, Affymetrix Inc., eResearchTechnology, Inc., Covance Inc., BioMimetic Therapeutics Inc., Alliance Healthcare Services, Inc., Alere Inc., Medco Health Solutions, Inc., McDermott Will & Emery LLP, Auxilium Pharmaceuticals, LLC, Gen-Probe Incorporated, Deutsche Bank Securities Inc., Deutsche Bank Securities Inc., BCBSM, Inc., Partners HealthCare System, Inc., Beth Israel Deaconess Medical Center, Inc., Shire plc, Envision Healthcare Corporation, Legacy LifePoint Health, Inc., Impax Laboratories, Inc., Targacept, Inc., Senomyx, Inc., Aetna Inc., Intercell Ag, Kyowa Kirin International plc, U.S. Food and Drug Administration, Eurand N.V., Hospira Inc., Cadence Pharmaceuticals Inc., MAP Pharmaceuticals, Inc., Chiesi USA, Inc., Vivacta Limited, Envision Healthcare Corporation, Oxford Nanopore Technologies Limited, Arstasis, Inc., AGA Medical Holdings, Inc., Icahn Capital LP, BioSante Pharmaceuticals, Inc., Covidien plc, PharMerica CorporationDeutsche Bank Securities Inc., Deutsche Bank 35th Annual Health Care Conference, May 03, 2010 through May 05, 2010. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States.
430
6/30/20109.74x23.32x25.14x41.14x33.86x$14,380$121.66391.77%Apr-23-2010Executive/Board Change - OtherIntuitive Surgical, Inc. Announces Election of Board of Directors-Intuitive Surgical, Inc. announced that its annual meeting of stockholders held on April 21, 2010, stockholders elected Alan J. Levy, Eric H. Halvorson and Amal M. Johnson as directors to the board of directors to serve a three-year term expiring at the 2013 Annual Meeting of Stockholders.
431
6/30/20109.74x23.32x25.14x41.14x33.86x$14,419$121.99390.44%Apr-21-2010Annual General MeetingIntuitive Surgical Inc., Annual General Meeting, Apr 21, 2010-Intuitive Surgical Inc., Annual General Meeting, Apr 21, 2010, at 15:00 US Pacific Time. Location: Marriott Santa Clara, 2700 Mission College Boulevard, Santa Clara, CA 95054, United States. Agenda: To elect three Class I members to the Board of Directors to serve until the 2013 Annual Meeting of Stockholders; to approve Intuitive Surgical's 2010 Incentive Award Plan; and to transact any other business which is properly brought before the Annual Meeting or adjournments or postponements thereof.
432
6/30/20109.74x23.32x25.14x41.14x33.86x$14,448$122.23389.48%Apr-20-2010Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan-As of period ended on March 31, 2010, the company has repurchased 1,406,049 shares for $150.00mm.
433
6/30/20109.74x23.32x25.14x41.14x33.86x$15,288$129.34362.57%Apr-15-2010Earnings CallIntuitive Surgical, Inc., Q1 2010 Earnings Call, Apr 15, 2010-Intuitive Surgical, Inc., Q1 2010 Earnings Call, Apr 15, 2010
434
6/30/20109.74x23.32x25.14x41.14x33.86x$15,288$129.34362.57%Apr-15-2010Announcement of EarningsIntuitive Surgical, Inc. Reports Cash Flow Results for the First Quarter Ended March 31, 2010-Intuitive Surgical, Inc. reported earnings results for the first quarter ended March 31, 2010. For the quarter, the company reported cash flows from operations of $153 million and capital expenditure of $16 million, $3 million of capital expenditures relate to the construction of new manufacturing facility next to corporate headquarters in Sunnyvale.
435
6/30/20109.74x23.32x25.14x41.14x33.86x$15,288$129.34362.57%Apr-15-2010Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2010-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2010. For the quarter, the company reported revenue of $329 million, up from $188.4 million for the first quarter of 2009. First quarter of 2010 revenue growth was driven by continued robotic procedure adoption and higher da Vinci Surgical System sales. For comparison purposes, as previously reported, first quarter 2009 revenue was reduced by a total of $20 million related to revenue deferred in association with the introduction of the da Vinci Si system, $18 million from systems revenue and $2 million from accessory revenue. Operating income increased to $130 million from $45 million during the first quarter of 2009. First quarter 2009 operating income was reduced by $20 million related to the revenue deferrals. Net income was $85.3 million or $2.12 per diluted share compared with $28.1 million or $0.72 per diluted share for the first quarter of 2009. The first quarter 2009 revenue deferral reduced net income for the period by approximately $12 million or $0.30 per diluted share. Income before income taxes was $133.8 million compared to $50.0 million reported a year ago.
436
3/31/201012.35x31.55x34.44x54.56x41.45x$12,813$108.95449.14%Feb-09-2010Company Conference PresentationIntuitive Surgical, Inc. Presents at Deutsche Bank Securities 2010 Small and Mid Cap Conference, Feb-09-2010 12:00 PM-Intuitive Surgical, Inc. Presents at Deutsche Bank Securities 2010 Small and Mid Cap Conference, Feb-09-2010 12:00 PM. Venue: The Ritz-Carlton Resort, Naples, 280 Vanderbilt Beach Road, Naples, FL 34108, United States. Speakers: Aleks Cukic, Vice President of Strategy, Benjamin B. Gong, Vice President of Finance.
437
3/31/201012.35x31.55x34.44x54.56x41.45x$12,698$107.98454.07%Feb-08-2010ConferenceDeutsche Bank Securities Inc., Deutsche Bank Securities 2010 Small and Mid Cap Conference, Feb 08, 2010 through Feb 10, 2010ArcBest Corporation (NasdaqGS:ARCB), Power Integrations, Inc. (NasdaqGS:POWI), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Landstar System, Inc. (NasdaqGS:LSTR), Universal Electronics Inc. (NasdaqGS:UEIC), American Superconductor Corporation (NasdaqGS:AMSC), Silgan Holdings Inc. (NasdaqGS:SLGN), Grand Canyon Education, Inc. (NasdaqGS:LOPE), American Public Education, Inc. (NasdaqGS:APEI), Synchronoss Technologies, Inc. (NasdaqGS:SNCR), Zovio Inc (NasdaqGS:ZVO), Lincoln Educational Services Corporation (NasdaqGS:LINC), Cardtronics plc (NasdaqGS:CATM), Beacon Roofing Supply, Inc. (NasdaqGS:BECN), Fortinet, Inc. (NasdaqGS:FTNT), Old Dominion Freight Line, Inc. (NasdaqGS:ODFL), Penn National Gaming, Inc. (NasdaqGS:PENN), F5 Networks, Inc. (NasdaqGS:FFIV), Henry Schein, Inc. (NasdaqGS:HSIC), Kforce Inc. (NasdaqGS:KFRC), Mobile Mini, Inc. (NasdaqGS:MINI), Cognizant Technology Solutions Corporation (NasdaqGS:CTSH), ON Semiconductor Corporation (NasdaqGS:ON), American Outdoor Brands Corporation (NasdaqGS:AOBC), Sigma Designs, Inc. (OTCPK:SIGM), Navios Maritime Partners L.P. (NYSE:NMM), Adtalem Global Education Inc. (NYSE:ATGE), FMC Corporation (NYSE:FMC), Ball Corporation (NYSE:BLL), MEDNAX, Inc. (NYSE:MD), Trex Company, Inc. (NYSE:TREX), ESCO Technologies Inc. (NYSE:ESE), Lennar Corporation (NYSE:LEN), Universal Technical Institute, Inc. (NYSE:UTI), K12 Inc. (NYSE:LRN), Flowers Foods, Inc. (NYSE:FLO), Restaurant Brands International Inc. (NYSE:QSR), Bausch Health Companies Inc. (NYSE:BHC), Nu Skin Enterprises, Inc. (NYSE:NUS), Waste Connections, Inc. (NYSE:WCN), Greif, Inc. (NYSE:GEF), Eagle Materials Inc. (NYSE:EXP), Beazer Homes USA, Inc. (NYSE:BZH), Regal Beloit Corporation (NYSE:RBC), Griffon Corporation (NYSE:GFF), D.R. Horton, Inc. (NYSE:DHI), Information Services Group, Inc. (NasdaqGM:III), Ariba, Inc., Art Technology Group, Inc., Blackboard Inc., Big Heart Pet Brands, G&K Services, Inc., Informatica LLC, IPC Healthcare, Inc., Diamond Management & Technology Consultants, Inc., Polycom, Inc., ShoreTel, Inc., Sonic Solutions LLC, SuccessFactors, Inc., Qualcomm Atheros, Inc., Rentrak Corporation, NxStage Medical, Inc., Fusion CB Holdings, Inc., Neustar, Inc., SS&C Advent, Ener1, Inc., Digital River Inc., DemandTec, Inc., Rackspace Hosting, Inc., Premiere Global Services, Inc., Websense, Inc., Family Dollar Stores Inc., Microsemi Corporation, Bally Technologies, Inc., WMS Industries Inc., Cytec Industries Inc., Brightpoint Inc., The Hertz Corporation, Solutia Inc., Genesee & Wyoming Inc., Headwaters Incorporated, Terremark Worldwide, Inc., Vocus Inc., WTW Delaware Holdings LLC, NetLogic I LLC, Infor (US), Inc., Aon Hewitt LLC, The Advisory Board Company, Deutsche Bank Securities Inc., Rockwood Holdings, Inc., Eurand N.V., Great Wolf Resorts, Inc., Boulder Brands, Inc., AGA Medical Holdings, Inc.Deutsche Bank Securities Inc., Deutsche Bank Securities 2010 Small and Mid Cap Conference, Feb 08, 2010 through Feb 10, 2010. Venue: The Ritz-Carlton Resort, Naples, 280 Vanderbilt Beach Road, Naples, FL 34108, United States.
438
3/31/201012.35x31.55x34.44x54.56x41.45x$12,860$109.35447.13%Jan-29-2010Buyback Tranche UpdateUpdate to Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan-As of period ended on December 31, 2009, the company has repurchased 1,406,049 shares for $150.00mm.
439
3/31/201012.35x31.55x34.44x54.56x41.45x$12,860$109.35447.13%Jan-29-2010Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $100.50 million.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $100.50 million.
440
3/31/201012.35x31.55x34.44x54.56x41.45x$11,936$101.50489.45%Jan-21-2010Earnings CallIntuitive Surgical, Inc., Q4 2009 Earnings Call, Jan 21, 2010-Intuitive Surgical, Inc., Q4 2009 Earnings Call, Jan 21, 2010
441
3/31/201012.35x31.55x34.44x54.56x41.45x$11,936$101.50489.45%Jan-21-2010Announcement of Earnings, Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Reports Cash Flow Results for the Year Ended December 31, 2009 ; Provides Earnings Guidance for 2010-Intuitive Surgical, Inc. reported cash flow results for the year ended December 31, 2009. For the year, the company reported cash flow from operations of $385 million and capital expenditures of $53 million. The company generated $377 million in gross cash flow from operations in 2009.

The company expects to achieve annual revenue growth of approximately 25%. The company’s revenues can fluctuate quarter-to-quarter as system placements may vary. Since it is forecasting to report over $140 million in non-cash expense in 2010, cash flows will continue to be significantly higher than reported net income.
442
3/31/201012.35x31.55x34.44x54.56x41.45x$11,936$101.50489.45%Jan-21-2010Earnings Release DateIntuitive Surgical Inc. to Report Q4, 2009 Results on January 21, 2010-Intuitive Surgical Inc. announced that they will report Q4, 2009 results on January 21, 2010.
443
3/31/201012.35x31.55x34.44x54.56x41.45x$11,936$101.50489.45%Jan-21-2010Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2009-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2009. For the quarter, the company reported revenue of $323.0 million, up 40% compared with $231.5 million for the fourth quarter of 2008. Fourth quarter of 2009 revenue growth was driven by continued robotic procedure adoption and higher da Vinci Surgical System sales. The company's operating income increased to $128.4 million from $82.7 million during the fourth quarter of 2008. Operating results for the fourth quarter of 2009 included $25.0 million of non-cash stock-based compensation expense compared with $21.4 million for the fourth quarter of 2008. Net income was $77.6 million, or $1.95 per diluted share, compared with $50.8 million, or $1.27 per diluted share for the fourth quarter of 2008. Income before income taxes was $132.5 million compared to $108.9 million for the same quarter a year ago.

For the year ended December 31, 2009, the company's revenue totaled $1,052.2 million, increasing 20% from $874.9 million for the year ended December 31, 2008. Net income was $232.6 million, or $5.93 per diluted share compared to net income of $204.3 million or $5.12 per diluted share for the previous year. Income from operations was $377.4 million and income before income taxes of $396.1 million compared to income from operations of $310.8 million and income before income taxes of $335.2 million for the previous year.
444
12/31/200911.53x30.33x33.38x55.99x39.67x$11,454$99.17503.30%Dec-22-2009Client AnnouncementIntuitive Surgical Sarl Wins GBP 1.6 Million Contract-Intuitive Surgical Sarl won a GBP 1.6 million (excluding VAT) contract award from Nottingham University Hospitals NHS Trust for the supply of a da vinci si robotic surgical system. (Ref. No.: 296899-2009).
445
12/31/200911.53x30.33x33.38x55.99x39.67x$10,811$93.60539.20%Nov-23-2009Product-Related AnnouncementIntuitive Surgical, Inc. Receives Regulatory Approval from the Ministry of Health, Labor and Welfare-Intuitive Surgical, Inc. announced that it has received regulatory approval from the Ministry of Health, Labor and Welfare to allow marketing of its da Vinci S System in Japan. The da Vinci® System is a breakthrough surgical platform designed to enable complex surgery using a minimally invasive approach. The da Vinci® System consists of an ergonomic surgeon console, a patient-side cart with four interactive robotic arms, a high-performance vision system and proprietary EndoWrist® instruments. Powered by state-of-the-art robotic and computer technology, the da Vinci® System is designed to scale, filter and seamlessly translate the surgeon’s hand movements into more precise movements of the EndoWrist® instruments.
446
12/31/200911.53x30.33x33.38x55.99x39.67x$10,643$92.15549.26%Nov-20-2009Business ExpansionIntuitive Surgical Inc. Receives Regulatory Approval from MHLW to Allow Marketing of its da Vinci S System in Japan-Intuitive Surgical Inc. announced that it has received regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) to allow marketing of its da Vinci S System in Japan.
447
12/31/200911.53x30.33x33.38x55.99x39.67x$10,841$93.86537.43%Nov-17-2009Company Conference PresentationIntuitive Surgical, Inc. Presents at LCM 6th Annual Healthcare Conference, Nov-17-2009 03:10 PM-Intuitive Surgical, Inc. Presents at LCM 6th Annual Healthcare Conference, Nov-17-2009 03:10 PM. Venue: The St. Regis, 2 East 55th Street, New York, NY 10022, United States.
448
12/31/200911.53x30.33x33.38x55.99x39.67x$10,841$93.86537.43%Nov-17-2009Conference(Cancelled)Lazard Capital Markets, LLC, LCM 6th Annual Healthcare Conference, Nov 17, 2009 through Nov 18, 2009ARIAD Pharmaceuticals, Inc., Biolex Therapeutics, Inc., Cephalon, Inc., Clarient, Inc., Conceptus, Inc., Cubist Pharmaceuticals LLC, Genta Incorporated, Health Management Associates Inc., Human Genome Sciences Inc., Inhibitex, Inc., EMD Millipore Corporation, Onyx Pharmaceuticals, Inc., Orthovita Inc., Psychiatric Solutions, Inc., Astex Pharmaceuticals, Inc., U.S. Healthworks, Inc., ViroPharma Inc., Dendreon Corporation, InterMune, Inc., Santarus, Inc., Genoptix, Inc., Micromet, Inc., Agennix AG, Allergan, Inc., C. R. Bard, Inc., Celgene Corporation, Elan Corporation Limited, Forest Laboratories, LLC, Gilead Pharmasset LLC, Omnicare Inc., OSI Pharmaceuticals Inc., Kindred Healthcare, LLC, SciClone Pharmaceuticals, Inc., Avanir Pharmaceuticals, Inc., Genzyme Corporation, Mateon Therapeutics, Inc., King Pharmaceuticals LLC, World Heart Corp., Targacept, Inc., Sygnis Pharma AG, Given Imaging Ltd., BioSante Pharmaceuticals, Inc., TEI Biosciences Inc., NeurogesX, Inc., Optimer Pharmaceuticals, Inc., Transition Therapeutics Inc., Ambit Biosciences Corporation, Alere Inc., CVRx, Inc., Medco Health Solutions, Inc., Auxilium Pharmaceuticals, LLC, Transave LLC, Molecular Insight Pharmaceuticals, Inc., Gen-Probe Incorporated, Threshold Pharmaceuticals, Inc., FM Partners Holdings LLC, Synta Pharmaceuticals Corp., GTx, Inc., Algeta ASA, Arcadia Resources, Inc., Regado Biosciences, Inc., Transcept Pharmaceuticals, Inc., KAI Pharmaceuticals, Inc., Vangent, Inc., Xcellerex, Inc., Orexigen Therapeutics, Inc., BMP Sunstone Corporation, NeurAxon Inc., Aerovance, Inc., MAP Pharmaceuticals, Inc., Accera, Inc., Chiesi USA, Inc., U.S. Preventive Medicine, Inc., Medivation, Inc., Heartware International Inc., Avid Radiopharmaceuticals, Inc., CircuLite, Inc., MAKO Surgical Corp., Alder BioPharmaceuticals, Inc., Lux Biosciences, Inc., EKR Therapeutics, Inc., Cempra, Inc., Alvine Pharmaceuticals, Inc., Aurora Diagnostics Holdings, LLC, Covidien plc, Ardea Biosciences, Inc., Calistoga Pharmaceuticals, Inc., CeNeRx BioPharma, Inc., Graceway Pharmaceuticals, LLC, PharMerica Corporation, Abraxis BioScience, Inc., Alphatec Spine, Inc., Amnestix Inc., Arstasis, Inc., Tiger X Medical, Inc., CareFusion Corporation, Sagent Pharmaceuticals, Inc., Allos Therapeutics, Inc., US Oncology, Inc., AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX), MannKind Corporation (NasdaqGM:MNKD), Reata Pharmaceuticals, Inc. (NasdaqGM:RETA), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Chimerix, Inc. (NasdaqGM:CMRX), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK), Aquestive Therapeutics, Inc. (NasdaqGM:AQST), Immunomedics, Inc. (NasdaqGM:IMMU), XOMA Corporation (NasdaqGM:XOMA), Curis, Inc. (NasdaqGM:CRIS), ArQule, Inc. (NasdaqGM:ARQL), InfuSystem Holdings Inc. (AMEX:INFU), Resverlogix Corp. (TSX:RVX), Theratechnologies Inc. (TSX:TH), Novo Nordisk A/S (CPSE:NOVO B), CryoLife, Inc. (NYSE:CRY), Encompass Health Corporation (NYSE:EHC), CVS Health Corporation (NYSE:CVS), Universal Health Services, Inc. (NYSE:UHS), Community Health Systems, Inc. (NYSE:CYH), QIAGEN N.V. (NYSE:QGEN), Integer Holdings Corporation (NYSE:ITGR), Cardinal Health, Inc. (NYSE:CAH), Eli Lilly and Company (NYSE:LLY), Enzo Biochem, Inc. (NYSE:ENZ), Bausch Health Companies Inc. (NYSE:BHC), Quest Diagnostics Incorporated (NYSE:DGX), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), Teleflex Incorporated (NYSE:TFX), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), AmerisourceBergen Corporation (NYSE:ABC), Emergent BioSolutions Inc. (NYSE:EBS), Agile Therapeutics, Inc. (NasdaqCM:AGRX), Riot Blockchain, Inc. (NasdaqCM:RIOT), NeoGenomics, Inc. (NasdaqCM:NEO), STRATA Skin Sciences, Inc. (NasdaqCM:SSKN), Vermillion, Inc. (NasdaqCM:VRML), Exact Sciences Corporation (NasdaqCM:EXAS), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), Cyclacel Pharmaceuticals, Inc. (NasdaqCM:CYCC), Windtree Therapeutics, Inc. (OTCPK:WINT), Winston Pharmaceuticals, Inc. (OTCPK:WPHM), Delcath Systems, Inc. (OTCPK:DCTH), Affymax, Inc. (OTCPK:AFFY), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), ChemoCentryx, Inc. (NasdaqGS:CCXI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Accuray Incorporated (NasdaqGS:ARAY), MacroGenics, Inc. (NasdaqGS:MGNX), Bruker Corporation (NasdaqGS:BRKR), Progenics Pharmaceuticals, Inc. (NasdaqGS:PGNX), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Endologix, Inc. (NasdaqGS:ELGX), Meridian Bioscience, Inc. (NasdaqGS:VIVO), Geron Corporation (NasdaqGS:GERN), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), United Therapeutics Corporation (NasdaqGS:UTHR), Seattle Genetics, Inc. (NasdaqGS:SGEN), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), VIVUS, Inc. (NasdaqGS:VVUS), DexCom, Inc. (NasdaqGS:DXCM), Exelixis, Inc. (NasdaqGS:EXEL), Gilead Sciences, Inc. (NasdaqGS:GILD), Cytokinetics, Incorporated (NasdaqGS:CYTK), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Biogen Inc. (NasdaqGS:BIIB), Myriad Genetics, Inc. (NasdaqGS:MYGN), Masimo Corporation (NasdaqGS:MASI), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Alkermes plc (NasdaqGS:ALKS), Amgen Inc. (NasdaqGS:AMGN), Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX), OPKO Health, Inc. (NasdaqGS:OPK), Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX)Lazard Capital Markets, LLC, LCM 6th Annual Healthcare Conference, Nov 17, 2009 through Nov 18, 2009. Venue: The St. Regis, 2 East 55th Street, New York, NY 10022, United States.
449
12/31/200911.53x30.33x33.38x55.99x39.67x$10,124$87.65582.59%Oct-23-2009Executive/Board Change - Other, Executive Change - CEOIntuitive Surgical, Inc. Announces Management Changes-Intuitive Surgical, Inc. announced the next step in its CEO succession plan. Lonnie Smith, currently Chairman and CEO, will transition to the role of Chairman of the Board and Gary Guthart, currently President and Chief Operating Officer, has been appointed by the Board of Directors to the roles of President and CEO, both actions effective January 1, 2010. Mr. Guthart joined Intuitive Surgical, Inc. in April 1996 and became Vice President, Engineering in November 1999. He was promoted to Sr. Vice President, Product Operations in 2002 and President and Chief Operating Officer in 2006.
450
12/31/200911.53x30.33x33.38x55.99x39.67x$10,297$89.15571.10%Oct-20-2009Earnings CallIntuitive Surgical, Inc., Q3 2009 Earnings Call, Oct-20-2009-Intuitive Surgical, Inc., Q3 2009 Earnings Call, Oct 20 2009
451
12/31/200911.53x30.33x33.38x55.99x39.67x$10,297$89.15571.10%Oct-20-2009Announcement of EarningsIntuitive Surgical Inc. Reports Cash Flow Results for Third Quarter and Nine Months Ended September 30, 2009-Intuitive Surgical Inc. reported financial results for third quarter and nine months ended September 30, 2009. For the quarter, the company generated $96 million cash from operations.

Year-to-date, the company generated $269 million in cash flow from operations.
452
12/31/200911.53x30.33x33.38x55.99x39.67x$10,297$89.15571.10%Oct-20-2009Announcement of EarningsIntuitive Surgical Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009-Intuitive Surgical Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. The company reported third quarter revenue of $280.1 million, compared with $236.0 million for the third quarter of 2008. Third quarter of 2009 revenue included $6.3 million of revenue that was originally deferred in the first quarter of 2009 in association with discounted offers made to certain customers to upgrade da Vinci S Surgical Systems to recently introduced da Vinci Si Surgical Systems. Third quarter of 2009 operating income increased to $104.5 million from $85.0 million during the third quarter of 2008, reflecting growth in revenue but also included the impact of recognizing $6.3 million of revenue that was originally deferred in the first quarter of 2009. Third quarter of 2009 net income was $64.5 million or $1.64 per diluted share compared with $57.6 million or $1.44 per diluted share for the third quarter of 2008. The $6.3 million of revenue recognized in the third quarter of 2009, related to revenue deferred in the first quarter, increased third quarter 2009 net income by approximately $3.8 million, or $0.09 per diluted share. Income before income taxes $108.8 million against $89.6 million in 2008.

For the nine months, the company reported income from operations of $249.0 million, income before income taxes of $263.6 million, net income of $155.0 million or $3.97 per diluted share on the revenue of $729 million against the income from operations of $228.0 million, income before income taxes of $246.9 million, net income of $153.5 million or $3.84 per diluted share on the revenue of $643.3 million for the same period a year ago.
453
12/31/200911.53x30.33x33.38x55.99x39.67x$10,297$89.15571.10%Oct-20-2009Earnings Release DateIntuitive Surgical, Inc. to Report Q3, 2009 Results on October 20, 2009-Intuitive Surgical, Inc. announced that they will report Q3, 2009 results on October 20, 2009.
454
9/30/200910.44x27.85x30.63x51.57x40.89x$6,486$56.60957.05%Jul-22-2009Earnings CallIntuitive Surgical, Inc., Q2 2009 Earnings Call, Jul-22-2009-Intuitive Surgical, Inc., Q2 2009 Earnings Call, Jul 22 2009
455
9/30/200910.44x27.85x30.63x51.57x40.89x$6,486$56.60957.05%Jul-22-2009Corporate Guidance - New/Confirmed, Corporate Guidance - RaisedIntuitive Surgical, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2009; Revised Earnings Guidance for 2009-Intuitive Surgical, Inc. provides earnings guidance for the third quarter and full year of 2009. The company anticipate for the third quarter, total revenues to range between $666 million and $681 million. Same store sales are expected to decline between 4% and 6%, a portion of this decline will again be the result of the 2007 consolidation plan. As for diluted earnings per share, the company is guiding the third quarter to a range of between $0.46 and $0.52, as compared to the $0.44 posted in third quarter of 2008.

For all of 2009, total revenues are expected to be within a range of $2.75 billion and $2.78 billion, and it expect same store sales for the full year to decline between 2% and 4%. In terms of EBITDA and free cash flow, the Company continues to expect EBITDA to range between $345 million and $365 million, with free cash flow now expected to be in the range between $280 million and $300 million.

The Company is increasing overall diluted earnings per share guidance for 2009, and now expect it to be in the range of $2.32 and $2.42, which the midpoint of this range would equate to just over a 16% improvement, as compared to the $2.04 reported for all of 2008.
456
9/30/200910.44x27.85x30.63x51.57x40.89x$6,486$56.60957.05%Jul-22-2009Earnings Release DateIntuitive Surgical Inc. to Report Q2, 2009 Results on July 22, 2009-Intuitive Surgical Inc. announced that they will report Q2, 2009 results on July 22, 2009.
457
9/30/200910.44x27.85x30.63x51.57x40.89x$6,486$56.60957.05%Jul-22-2009Announcement of EarningsIntuitive Surgical Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2009-Intuitive Surgical Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2009. For the second quarter, the company reported revenue of $260.6 million, compared with $219.2 million for the second quarter of 2008. Second quarter of 2009 revenue included $13.8 million of revenue that was originally deferred in the first quarter of 2009 in association with discounted offers made to certain customers to upgrade da Vinci S Surgical Systems to recently introduced da Vinci Si Surgical Systems. Instruments and accessories revenue increased to $95.8 million from $73.6 million in the second quarter of 2008. The growth in instruments and accessories revenue was primarily driven by growth in da Vinci surgical procedures of approximately 52%, partially offset by lower instruments and accessories revenue per procedure. Operating income increased to $99.5 million from $78.2 million during the second quarter of 2008, reflecting growth in revenue but also included the impact of recognizing $13.8 million of revenue that was originally deferred in the first quarter of 2009. Since there was no cost deferred in association with the deferred revenue, the $13.8 million of revenue recognized had an equal impact on total revenue, operating income and pretax income. Operating results for the second quarter of 2009 also included $24.6 million of non-cash stock-based compensation expense in accordance with the Financial Accounting Standards Board SFAS 123R, compared with $19.7 million for the second quarter of 2008. Income before income taxes was $104.7 million against the $83.9 million for the same period a year ago. Net income was $62.4 million, or $1.62 per diluted share, compared with $51.2 million, or $1.28 per diluted share for the second quarter of 2008. The $13.8 million of revenue recognized in the second quarter of 2009, related to revenue deferred in the first quarter, increased second quarter 2009 net income by approximately $8.3 million, or $0.22 per diluted share.

For the six months, the company reported an income from operations of $144.6 million, income before income taxes of $154.8 million, net income of $90.5 million or $2.32 per share on the revenue of $449 million against the income from operations of $143.1 million, income before income taxes of $157.3 million, net income of $96 million or $2.40 per share on the revenue of $407.4 million for the same period a year ago.
458
9/30/200910.44x27.85x30.63x51.57x40.89x$6,486$56.60957.05%Jul-22-2009Announcement of EarningsIntuitive Surgical Inc. Reports Cash Flow Results for the First Six Months Ended June 30, 2009-Intuitive Surgical Inc. reported cash flow results for the first six months ended June 30, 2009. For the first six months of 2009, the company generated $173 million in cash flow from operations.
459
6/30/20096.69x18.33x20.12x34.30x32.01x$6,317$55.51977.81%Jun-11-2009Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
460
6/30/20096.69x18.33x20.12x34.30x32.01x$5,946$52.251045.05%Jun-09-2009Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
461
6/30/20096.69x18.33x20.12x34.30x32.01x$5,663$49.761102.35%Jun-01-2009M&A Transaction AnnouncementIntuitive Surgical, Inc. (NasdaqGS: ISRG) acquired NeoGuide Systems Inc. from a group of investors.The Angels' Forum LLC, Versant Venture Management, LLC, Kaiser Permanente Ventures, SBV Venture Partners, The Halo Funds, NeoGuide Systems Inc., Rockport Venture Partners, Arboretum Ventures LLC, DC Capital Partners, LLC, Advent Venture Partners, Pelion Venture Partners, Westech Investment Advisors, LLC, 3i Group plc (LSE:III)Intuitive Surgical, Inc. (NasdaqGS: ISRG) acquired NeoGuide Systems Inc. from a group of investors on May 15, 2009. The financial terms of the deal were not disclosed. The group of investors includes Advent Venture Partners, Angels Forum/Halo Fund, Arboretum Ventures, 3i, DC Capital, Kaiser Permanente Ventures, SBV Venture Partners, UV Partners and Versant Ventures.
462
6/30/20096.69x18.33x20.12x34.30x32.01x$5,877$51.641058.58%May-19-2009Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
463
6/30/20096.69x18.33x20.12x34.30x32.01x$5,877$51.641058.58%May-19-2009Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
464
6/30/20096.69x18.33x20.12x34.30x32.01x$5,824$51.181068.99%May-14-2009Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $340.01 million.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $340.01 million.
465
6/30/20096.69x18.33x20.12x34.30x32.01x$5,136$45.131225.70%Apr-22-2009Annual General MeetingIntuitive Surgical, Inc., Annual General Meeting, Apr 22, 2009-Intuitive Surgical, Inc., Annual General Meeting, Apr 22, 2009, at 15:00 US Pacific Time. Location: The Grand Hotel, 865 W. El Camino Real, Sunnyvale, CA 94086,United States. Agenda: To elect three Class III members to the Board of Directors to serve until the 2012 Annual Meeting of stockholders; and to transact any other business, which is properly brought before the Annual Meeting or adjournment or postponement thereof.
466
6/30/20096.69x18.33x20.12x34.30x32.01x$4,476$39.331421.21%Apr-16-2009Earnings CallIntuitive Surgical, Inc., Q1 2009 Earnings Call, Apr-16-2009-Intuitive Surgical, Inc., Q1 2009 Earnings Call, Apr 16 2009
467
6/30/20096.69x18.33x20.12x34.30x32.01x$4,476$39.331421.21%Apr-16-2009Announcement of EarningsIntuitive Surgical Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2009-Intuitive Surgical Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2009. The company reported first quarter 2009 revenue of $188.4 million, compared to $188.2 for the first quarter of 2008. First quarter 2009 revenue of $188.4 million was net of $20.1 million of revenue deferrals associated with offers made to certain customers to upgrade their recently purchased da Vinci(r) S(tm) Surgical Systems to recently announced da Vinci(r) Si(tm) Surgical System. First quarter 2009 operating income of $45.0 million was $19.8 million lower than the first quarter 2008 due primarily to the $20.1 million operating income impact of the da Vinci Si launch revenue deferral, offset in part by growth in recurring revenue. Operating results for the first quarter of 2009 included $22.7 million of non-cash stock-based compensation expense in accordance with the Financial Accounting Standards Board SFAS 123R, compared with $14.6 million for the first quarter of 2008. First quarter 2009 net income was $28.1 million, or $0.72 per basic and diluted share, compared with $44.8 million, or $1.16 per basic and $1.12 per diluted share for the first quarter of 2008. The first quarter 2009 revenue deferral reduced net income by approximately $12.1 million, or $0.30 per diluted share.
468
6/30/20096.69x18.33x20.12x34.30x32.01x$4,476$39.331421.21%Apr-16-2009Earnings Release DateIntuitive Surgical Inc. to Report Q1, 2009 Results on April 16, 2009-Intuitive Surgical Inc. announced that they will report Q1, 2009 results on April 16, 2009.
469
6/30/20096.69x18.33x20.12x34.30x32.01x$3,849$33.821669.04%Apr-08-2009Client AnnouncementEncision Signs a Non-Exclusive Manufacturing, Supply and Licensing Agreement With Intuitive SurgicalEncision Inc. (OTCPK:ECIA)Encision Inc. announced that it has entered into a non-exclusive manufacturing, supply and licensing agreement with Intuitive Surgical Inc. for the purchase and use of Encision's patented AEM(R) technology with Intuitive Surgical's da Vinci(R) Surgical Systems. Encision's agreement with Intuitive Surgical will allow Encision access beyond conventional laparoscopy to the next generation of minimally invasive surgery.
470
6/30/20096.69x18.33x20.12x34.30x32.01x$3,729$32.771725.72%Apr-02-2009Product-Related AnnouncementIntuitive Surgical Announces New da Vinci Si Surgical System-Intuitive Surgical Inc. announced a new addition to its da Vinci(r) product line--the da Vinci(r) Si(tm) Surgical System. The da Vinci Si System introduces several new features designed to provide additional clinical benefits and operational efficiencies: Enhanced 3D HD resolution offers superior visual clarity of target tissue and anatomy, potentially allowing for greater surgical precision; an updated and simplified user interface enhances operating room efficiency; newly upgradeable architecture and compatibility with existing OR suite technology facilitates the seamless integration of the da Vinci Si System into the OR of the 21st century; an optional dual console allows a second surgeon to provide a da Vinci-enabled assist and may also facilitate teaching da Vinci Surgery; and finally, the addition of new ergonomic settings to the surgeon console allows greater surgeon comfort during procedures.
471
3/31/20093.76x9.80x10.59x18.83x21.60x$3,631$31.961772.00%Mar-06-2009Change in Company Bylaws/RulesIntuitive Surgical Inc. Amends and Restates Bylaws of the Company-On March 3, 2009, the Board of Directors of Intuitive Surgical Inc. adopted and approved, effective immediately, the Amended and Restated Bylaws of Intuitive. The Board’s Nominating and Governance Committee previously reviewed these amendments and recommended their adoption to the full Board. The Amended and Restated Bylaws revise, among other things, the advance notice provisions for stockholder proposals and nominations and were made to ensure such provisions are clear and unambiguous in light of recent Delaware case law developments. Specifically, the Amended and Restated Bylaws include the revisions: clarify the requirements set forth in Section 5 of the Amended and Restated Bylaws that apply to all stockholder proposals and director nominations by stockholders and are the exclusive means for stockholders to submit such matters, other than proposals and nominations governed by Rule 14a-8 under the Securities Exchange Act of 1934, as amended (which provides certain procedural requirements); require stockholders to disclose all ownership interests in the company, including, among other things, all ownership interests, hedges, economic incentives and rights to vote any shares of any security of the company, in light of increased use by investors of derivative instruments that are not reflected in an investor’s beneficial ownership of the company’s securities; require stockholders nominating directors to disclose the same information about a proposed director nominee that would be required if the director nominee were submitting a proposal and any material relationships between the stockholder proponents and their affiliates, on the one hand, and the director nominees and their affiliates, on the other hand; and require that the additional disclosures discussed above be updated and supplemented, if necessary, so as to be accurate as of the record date for a meeting and as of shortly prior to the meeting. In addition, the Amended and Restated Bylaws: eliminate the ability of the stockholders to act by written consent or to call a special meeting of the stockholders; allow annual or special meetings of Intuitive’s stockholders to be held by means of remote communication; and allow notice to be given by electronic transmission.
472
3/31/20093.76x9.80x10.59x18.83x21.60x$3,416$30.071889.66%Mar-05-2009Buyback Transaction AnnouncementsIntuitive Surgical, Inc. (NasdaqGS:ISRG) announces an Equity Buyback for $3,027.8 million worth of its shares.-The Board of Directors of Intuitive Surgical, Inc. (Nasdaq: ISRG) authorized a share repurchase program on March 3, 2009. Under the program, Intuitive will repurchase up to $300 million of its outstanding common stock. The shares will be repurchased from time to time in the open market, privately negotiated transactions, accelerated stock repurchase programs, issuer self-tender offers or otherwise, as determined by Intuitive's management. Intuitive expects to fund the $300 million program through cash and investments. In connection with the program, Intuitive entered into a collared accelerated share repurchase program with Goldman, Sachs & Co. Pursuant to the ASR, Intuitive will repurchase $150 million of its common stock from Goldman. A majority of the shares purchased under the ASR Program will be received and retired within 2 weeks. The remaining shares, if any, under the program will be received and retired by June, although they could be received earlier if the ASR Program is ended earlier. On March 9, 2009, Intuitive will make a payment of $150 million to Goldman against the delivery of shares by Goldman to it. Purchases under the ASR Agreement are subject to collar provisions that will establish minimum and maximum numbers of shares based on the average daily volume-weighted average share price over an initial hedge period. The actual number of shares repurchased will be determined at the completion of the ASR Program. As of December 31, 2008, Intuitive had approximately $902 million of cash, cash equivalents and investments.
473
3/31/20093.76x9.80x10.59x18.83x21.60x$4,044$35.601580.59%Feb-18-2009Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
474
3/31/20093.76x9.80x10.59x18.83x21.60x$4,261$37.511495.01%Feb-03-2009M&A Rumors and DiscussionJohnson & Johnson Reportedly Eyeing Intuitive SurgicalJohnson & Johnson (NYSE:JNJ)Intuitive Surgical, Inc. saw a 9% jump in its share price after CNBC reported that Johnson & Johnson may be interested in buying Intuitive Surgical. A report in optionmonster.com, added that; Intuitive Surgical has rallied more than $20 in the last five sessions since we cited unusual buying of stock and options in the company. There have been persistent rumors that, Johnson & Johnson may acquire Intuitive Surgical. The report added that, Intuitive Surgical could not be immediately reached for comment and Johnson & Johnson declined to comment.
475
3/31/20093.76x9.80x10.59x18.83x21.60x$3,635$32.001769.66%Jan-22-2009Earnings CallIntuitive Surgical, Inc., Q4 2008 Earnings Call, Jan-22-2009-Intuitive Surgical, Inc., Q4 2008 Earnings Call, Jan 22 2009
476
3/31/20093.76x9.80x10.59x18.83x21.60x$3,635$32.001769.66%Jan-22-2009Announcement of EarningsIntuitive Surgical Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2008-Intuitive Surgical Inc. reported earnings results for the fourth quarter and full year ended December 31, 2008. For the quarter, the company reported revenue of $231.5 million, increasing 22% from $189.4 million for the fourth quarter of 2007. Diluted earnings per share increased to $1.27 from $1.24 for the fourth quarter of 2007. Fourth quarter 2008 net income increased 3% to $50.8 million, compared with $49.2 million for the fourth quarter of 2007. Fourth quarter 2008 revenue growth was driven by continued robotic procedure adoption.

For the year, the company reported that its revenue totaled $874.9 million, increasing 46% from $600.8 million for the year ended December 31, 2007. Net income for the year ended December 31, 2008 was $204.3 million, or $5.12 per diluted share, compared to net income of $144.5 million, or $3.70 per diluted share for the year ended December 31, 2007.
477
3/31/20093.76x9.80x10.59x18.83x21.60x$3,635$32.001769.66%Jan-22-2009Earnings Release DateIntuitive Surgical Inc. to Report Q4, 2008 Results on January 22, 2009-Intuitive Surgical Inc. announced that they will report Q4, 2008 results on January 22, 2009.
478
3/31/20093.76x9.80x10.59x18.83x21.60x$3,673$32.331750.57%Jan-21-2009Index Constituent AddIntuitive Surgical, Inc.(NasdaqGS:ISRG) added to S&P Global 1200S&P Global 1200 (^SPG1200)Intuitive Surgical, Inc.(NasdaqGS:ISRG) added to S&P Global 1200
479
3/31/20093.76x9.80x10.59x18.83x21.60x$3,761$33.111706.98%Jan-14-2009Client AnnouncementNovadaq Signs License, Development and Supply Agreements with IntuitiveNovadaq Technologies Inc.Novadaq Technologies Inc. announced that it has entered into a multi-year technology alliance with Intuitive Surgical Inc. Under the License and Development Agreement, Novadaq and Intuitive will work together to integrate Novadaq's SPY imaging technology into the 3D high definition imaging capabilities of Intuitive's da Vinci(R) Surgical Robotic Systems. Novadaq will receive an upfront license payment, additional payments based upon the achievement of pre-defined development milestones and a royalty payment for each da Vinci(R) Surgical System sold with, or upgraded to include, the SPY integrated imaging system.
480
3/31/20093.76x9.80x10.59x18.83x21.60x$4,463$39.291422.75%Jan-07-2009Corporate Guidance - New/Confirmed, Announcements of Sales/Trading StatementIntuitive Surgical Inc. Announces Preliminary Revenue Results for the Fourth Quarter of 2008; Provides Preliminary Revenue Guidance for the Full Year 2008; Provides Revenue Guidance for the Full Year 2009-Intuitive Surgical Inc. announced preliminary revenue results for the fourth quarter of 2008. For the quarter, the company reported revenue of approximately $232 million, increasing 22% from $189 million for the fourth quarter of 2007.

The company provided preliminary revenue guidance for the full year 2008. For the year, the company expects preliminary revenue to be approximately $875 million, increasing 46% from $601 million for the year ended 2007.

The company provided revenue guidance for the full year 2009. For the year, the company expects revenue to increase approximately 15% reflecting increased instrument, accessory and service revenue, while systems revenue is expected to remain relatively flat.
481
3/31/20093.76x9.80x10.59x18.83x21.60x$4,627$40.731368.92%Jan-06-2009Client AnnouncementIntuitive Surgical, Inc. Wins $3.43 Million Federal Contract-Intuitive Surgical, Inc., Sunnyvale, Calif., won $3,425,400 federal contract from the U.S. Department of Veterans Affairs' Fayetteville VA Medical Center, Fayetteville, N.C., for da Vinci robotics.
482
12/31/20085.47x14.09x15.08x24.61x28.44x$8,413$71.60735.60%Oct-16-2008Earnings CallIntuitive Surgical, Inc., Q3 2008 Earnings Call, Oct-16-2008-Intuitive Surgical, Inc., Q3 2008 Earnings Call, Oct 16 2008
483
12/31/20085.47x14.09x15.08x24.61x28.44x$8,413$71.60735.60%Oct-16-2008Announcement of EarningsIntuitive Surgical Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2008-Intuitive Surgical Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2008. For the quarter, the company reported net income of $57,594,000 or diluted earnings per share of $1.44 on total revenue of $235,992,000 compared to net income of $40,919,000 or diluted earnings per share of $1.04 on total revenue of $156,904,000 for the same period a year ago. Third quarter 2008 revenue growth was driven by continued robotic procedure adoption and higher da Vinci (r) Surgical System sales. Third quarter 2008 operating income increased 58% to $85.0 million, compared with $54.0 million for the third quarter of 2007. Operating results for the third quarter of 2008 included $21.0 million of non-cash stock-based compensation expense in accordance with the Financial Accounting Standards Board SFAS 123R, compared with $8.7 million for the third quarter of 2007.

For the nine months, the company reported net income of $153,557,000 or diluted earnings per share of $3.84 on total revenue of $643,374,000 compared to net income of $95,384,000 or diluted earnings per share of $2.46 on total revenue of $411,382,000 for the same period a year ago. For the period income from operations were $228,098,000 compared to $133,361,000 reported in the same period a year ago.
484
12/31/20085.47x14.09x15.08x24.61x28.44x$8,413$71.60735.60%Oct-16-2008Earnings Release DateIntuitive Surgical Inc. to Report Q3, 2008 Results on October 16, 2008-Intuitive Surgical Inc. announced that they will report Q3, 2008 results on October 16, 2008.
485
9/30/200811.97x31.19x33.25x50.69x64.74x$10,877$92.73545.20%Sep-12-2008Strategic AlliancePower Medical Interventions Inc. Enters License and Supply Agreement with Intuitive Surgical, IncPower Medical Interventions, Inc.Power Medical Interventions Inc. entered into two definitive agreements with Intuitive Surgical Inc. The first is a License and Development agreement for the two companies to jointly develop a surgical stapling device which will attach to Intuitive's da Vinci(R) Surgical Systems and will utilize Power Medical's patented technology. Once developed, this attachment will enable Intuitive Surgical's da Vinci(R) Surgical Systems to cut and staple tissue in a broad array of surgical applications. Power Medical will receive an upfront license payment and additional payments based upon the achievement of agreed upon milestones. The second agreement is an exclusive Reload Supply agreement whereby Power Medical will be the manufacturer and exclusive supplier of staple reload cartridges for the newly developed device. Details of the supply agreement were not disclosed.
486
9/30/200811.97x31.19x33.25x50.69x64.74x$11,642$99.25502.81%Aug-26-2008Client AnnouncementAllina Hospitals & Clinic Announces Agreement with Intuitive Surgical, Inc-Allina Hospitals & Clinic patients have another option to consider when faced with the need for surgery. Surgeons at United Hospital are using Intuitive Surgical Inc.'s new robotic system called the da Vinci S(R) Surgical System to perform a variety of procedures including prostate surgery, hysterectomies and myomectomies (removal of uterine fibroids). With the da Vinci S(R) device, the surgeon is actually seated a few feet away from the patient at a console. The console controls robotic arms holding a tiny camera and special surgical tools. These instruments operate through several small incisions. The camera sends images back to the surgeon who sees them on a 3D monitor. The surgeon makes decisions based on what is shown and sends surgical directions back through the device to be carried out. Benefits of robotic surgery include:-Increased surgical precision;-Reduced trauma;-Reduced blood loss;-Less post-operative pain;-Shorter hospital stay;-Faster recovery and return to activities;-Less scarring.
487
9/30/200811.97x31.19x33.25x50.69x64.74x$12,593$107.36457.27%Jul-25-2008Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $742.60 million.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $742.60 million.
488
9/30/200811.97x31.19x33.25x50.69x64.74x$10,957$93.41540.50%Jul-22-2008Earnings CallIntuitive Surgical, Inc., Q2 2008 Earnings Call, Jul-22-2008-Intuitive Surgical, Inc., Q2 2008 Earnings Call, Jul 22 2008
489
9/30/200811.97x31.19x33.25x50.69x64.74x$10,957$93.41540.50%Jul-22-2008Announcement of EarningsIntuitive Surgical Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2008-Intuitive Surgical Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2008. For the quarter, the company reported revenue of $219.2 million, an increase of 56% from $140.2 million for the second quarter of 2007. Second quarter 2008 revenue growth was driven by continued robotic procedure adoption and higher da Vinci(r) Surgical System sales. Net income increased 67% to $51.2 million, compared with $30.7 million for the second quarter of 2007. Diluted earnings per share increased to $1.28 for the second quarter of 2008 from $0.79 for the second quarter of 2007. These results reflect the continued adoption of the da Vinci Surgical System platform across a broadening group of surgical procedures. Second quarter 2008 operating income increased 74% to $78.2 million, compared with $45.0 million for the second quarter of 2007. Operating results for the second quarter of 2008 included $19.7 million of non-cash stock-based compensation expense in accordance with the Financial Accounting Standards Board SFAS 123R, compared with $9.4 million for the second quarter of 2007.

For the six months, the company reported net income of $95,963,000 or $2.40 per diluted share on total revenue of $407,383,000 against net income of $54,465,000 or $1.41 per diluted share on total revenue of $254,478,000 for the same period a year ago. For the period income from operations were $143,067,000 compared to $79,372,000 a year ago.
490
9/30/200811.97x31.19x33.25x50.69x64.74x$10,957$93.41540.50%Jul-22-2008Earnings Release DateIntuitive Surgical, Inc. to Report Q2, 2008 Results on July 22, 2008-Intuitive Surgical, Inc. announced that they will report Q2, 2008 results on July 22, 2008.
491
6/30/200814.88x39.70x42.17x63.24x63.56x$10,952$94.01536.41%Jun-17-2008Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
492
6/30/200814.88x39.70x42.17x63.24x63.56x$10,327$88.64574.97%Jun-11-2008Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
493
6/30/200814.88x39.70x42.17x63.24x63.56x$11,206$96.19521.99%Jun-02-2008Index Constituent DropIntuitive Surgical, Inc. dropped from S&P MidCap 400 IndexS&P 400 (^MID)Intuitive Surgical, Inc. will be removed from the S&P MidCap 400 Index after the close of trading on May 30, 2008. The company will be added to the S&P 500 Index.
494
6/30/200814.88x39.70x42.17x63.24x63.56x$11,206$96.19521.99%Jun-02-2008Index Constituent AddIntuitive Surgical, Inc. added to S&P 500 Sector Indices - Healthcare Sector IndexS&P 500 Health Care (Sector) (^HCX)Intuitive Surgical, Inc. will be added to the S&P 500 Sector Indices - Healthcare Sector Index.
495
6/30/200814.88x39.70x42.17x63.24x63.56x$11,206$96.19521.99%Jun-02-2008Index Constituent AddIntuitive Surgical, Inc. added to S&P 500 IndexS&P 500 (^SPX)Intuitive Surgical, Inc. will be added to the S&P 500 Index.
496
6/30/200814.88x39.70x42.17x63.24x63.56x$11,206$96.19521.99%Jun-02-2008Index Constituent AddIntuitive Surgical, Inc.(NasdaqGS:ISRG) added to S&P 500 Equal Weighted IndexS&P 500 EQUAL WEIGHTED (^SPXE)Intuitive Surgical, Inc.(NasdaqGS:ISRG) added to S&P 500 Equal Weighted Index
497
6/30/200814.88x39.70x42.17x63.24x63.56x$11,586$99.45501.60%May-20-2008Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
498
6/30/200814.88x39.70x42.17x63.24x63.56x$11,391$97.78511.87%May-06-2008Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
499
6/30/200814.88x39.70x42.17x63.24x63.56x$11,204$96.17522.12%Apr-18-2008Annual General MeetingIntuitive Surgical Inc., Annual General Meeting, Apr 18, 2008-Intuitive Surgical Inc., Annual General Meeting, Apr 18, 2008, at 15:00 Pacific Daylight. Location: The Grand Hotel, 865 W. El Camino Real, Sunnyvale, CA 94086, United States. Agenda: To elect three Class II members of the Board of Directors to serve until the 2011 Annual Meeting of stockholders; and to transact any other business which is properly brought before the Annual Meeting or any adjournment or postponement thereof.
500
6/30/200814.88x39.70x42.17x63.24x63.56x$11,204$96.17522.12%Apr-18-2008Corporate Guidance - RaisedIntuitive Surgical, Inc. Revised Earnings Guidance for the Year 2008-Intuitive Surgical, Inc. revised earnings guidance for the year 2008. The company expects revenue to increase 42% for the year, which implies sales of $853.2 million. Earlier, the company projected 40% growth.
501
6/30/200814.88x39.70x42.17x63.24x63.56x$13,534$116.17415.01%Apr-17-2008Earnings CallIntuitive Surgical, Inc., Q1 2008 Earnings Call, Apr-17-2008-Intuitive Surgical, Inc., Q1 2008 Earnings Call, Apr 17 2008
502
6/30/200814.88x39.70x42.17x63.24x63.56x$13,534$116.17415.01%Apr-17-2008Announcement of EarningsIntuitive Surgical Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2008-Intuitive Surgical announced unaudited consolidated earnings results for the first quarter ended March 31, 2008. The company reported first quarter 2008 revenue of $188.2 million, increasing 65% from $114.2 million for the first quarter of 2007. First quarter 2008 net income increased 88% to $44.8 million, compared with $23.8 million for the first quarter of 2007. Diluted earnings per share increased to $1.12 for the first quarter of 2008 from $0.62 for the first quarter of 2007. First quarter 2008 operating income increased 89% to $64.9 million, compared with $34.3 million for the first quarter of 2007. Operating results for the first quarter of 2008 included $14.6 million of non-cash stock-based compensation expense in accordance with the Financial Accounting Standards Board SFAS 123R, compared with $8.1 million for the first quarter of 2007.
503
6/30/200814.88x39.70x42.17x63.24x63.56x$13,534$116.17415.01%Apr-17-2008Earnings Release DateIntuitive Surgical Inc. to Report Q1, 2008 Results on April 17, 2008-Intuitive Surgical Inc. announced that they will report Q1, 2008 results on April 17, 2008.
504
3/31/200820.14x54.86x58.31x86.55x76.25x$9,830$84.67606.61%Jan-31-2008Earnings CallIntuitive Surgical, Inc., Q4 2007 Earnings Call, Jan-31-2008-Intuitive Surgical, Inc., Q4 2007 Earnings Call, Jan 31 2008
505
3/31/200820.14x54.86x58.31x86.55x76.25x$9,830$84.67606.61%Jan-31-2008Announcement of EarningsIntuitive Surgical Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2007-Intuitive Surgical Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2007. For the quarter, the Company reported revenue of $189.4 million, increasing 68% from $112.6 million for the fourth quarter of 2006. Fourth quarter 2007 revenue growth was driven by continued robotic procedure adoption and higher da Vinci(r) Surgical System sales. Fourth quarter 2007 net income increased 108% to $49.2 million, compared with $23.6 million for the fourth quarter of 2006. Diluted earnings per share increased to $1.24 for the fourth quarter of 2007 from $0.62 for the fourth quarter of 2006. Fourth quarter 2007 operating income increased 107% to $73.4 million, compared with $35.4 million for the fourth quarter of 2006. Operating results for the fourth quarter of 2007 included $10.1 million of stock-based compensation expense in accordance with the Financial Accounting Standards Board SFAS 123R, compared with $6.8 million for the fourth quarter of 2006.

Revenue for the year ended December 31, 2007 totaled $600.8 million, increasing 61% from $372.7 million for the year ended December 31, 2006. Net income for the year ended December 31, 2007 was $144.5 million, or $3.70 per diluted share, compared to net income of $72.0 million, or $1.89 per diluted share for the year ended December 31, 2006. For the year income from operations were $206.7 million compared to $107.4 million a year ago.
506
3/31/200820.14x54.86x58.31x86.55x76.25x$9,830$84.67606.61%Jan-31-2008Earnings Release DateIntuitive Surgical Inc. to Report Q4, 2007 Results on January 31, 2008-Intuitive Surgical Inc. announced that they will report Q4, 2007 results on January 31, 2008.
507
12/31/200722.85x66.09x70.92x102.39x102.13x$11,753$101.85487.42%Dec-17-2007Executive/Board Change - OtherIntuitive Surgical Inc. Appoints Mark Meltzer as Senior Vice President, General Counsel Replacing Runkel-Intuitive Surgical Inc. announced the appointment of Mark Meltzer as Senior Vice
President, General Counsel effective December 17, 2007, replacing Mr. Runkel. Prior to joining Intuitive, Mr. Meltzer served as General Counsel of FoxHollow Technologies Inc. Mr. Meltzer has also served as General Counsel for Epicor Medical Inc. and Ventritex Inc.
508
12/31/200722.85x66.09x70.92x102.39x102.13x$13,370$115.86416.39%Dec-10-2007Client Announcement, Lawsuits & Legal IssueCalifornia Institute of Technology to Dismiss its Lawsuit Against Intuitive Surgical; Intuitive and California Institute of Technology Enter into Non-Exclusive Licensing Deal-Intuitive Surgical Inc. announced that the California Institute of Technology will dismiss its lawsuit against the company as part of a licensing deal. In January, the company said the university filed a lawsuit, claiming patent infringement.

According to a filing with the Securities and Exchange Commission, Intuitive and the university entered a non-exclusive licensing deal under the university's patent portfolio. Terms of the deal have not been disclosed.
509
12/31/200722.85x66.09x70.92x102.39x102.13x$12,483$108.17453.10%Nov-28-2007Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
510
12/31/200722.85x66.09x70.92x102.39x102.13x$10,599$91.85551.38%Nov-13-2007Client Announcementda Vinci Enhances the Art of Surgery at Northwest Hospital & Medical Center-Northwest Hospital & Medical Center announced that it is now home to the da Vinci(R) S Robotic Surgical System. Northwest Hospital is the first facility in the Seattle area to install the da Vinci S Surgical System, the most advanced da Vinci system to-date, incorporating 3-D, high-definition, visualization and many capabilities earlier versions did not have. Named after the legendary artist, who invented the first robot and who used three-dimensional detail to bring his art to life, the da Vinci Surgical System creates a virtual extension of the surgeon's eyes and hands, using 3- D, high-definition vision and four robotic hands as extensions of the surgeon's own to go where human hands typically cannot. Used for a wide variety of minimally invasive surgical procedures, da Vinci offers a state-of-the-art alternative to conventional laparoscopic and traditional open surgery methods. Guided by the surgeon, who sits at a separate viewing console, the da Vinci robot translates the natural movements of the surgeon's hands, wrists and fingers into micro-movements of the robot in order to create and maneuver within smaller incisions and to perform delicate and complex procedures with greater precision and dexterity.
511
12/31/200722.85x66.09x70.92x102.39x102.13x$11,902$103.14480.08%Nov-05-2007Client AnnouncementInTouch Health and Intuitive Surgical Form Partnership to Develop New Technology Platform for Surgical Proctoring, Training, and CollaborationInTouch Technologies, Inc.InTouch Technologies Inc. announced a Development and Licensing agreement with Intuitive Surgical Inc. Under the agreement, InTouch Health will integrate its remote presence technology with Intuitive's da Vinci surgical system to enable surgeons located in different geographies to perform remote surgical proctoring, training and collaboration. The incorporation of the two systems should allow for more efficient means of training surgeons. The da Vinci® Surgical System is a surgical robot that seamlessly translates the surgeon's natural hand movements on instrument controls outside the patient's body into corresponding micro-movements of the instrument tips positioned inside the patient through small puncture incisions. The Remote Presence System enables a remotely based surgeon to project his presence into an operating room where a surgeon is performing a da Vinci surgical procedure. The connection is made over a high speed Internet connection, and the system provides high quality, real-time audio and video allowing the remote surgeon to effectively view the surgery from multiple cameras while interacting with the surgeon and staff operating via da Vinci.
512
12/31/200722.85x66.09x70.92x102.39x102.13x$12,574$108.96449.09%Oct-31-2007M&A Transaction ClosingIntuitive Surgical Inc. (NasdaqNM: ISRG) completed the acquisition of EndoNav, Inc. from Sears Capital Management, Inc.Sears Capital Management, Inc., EndoNav, Inc.Intuitive Surgical Inc. (NasdaqNM: ISRG) agreed to acquire EndoNav, Inc. from Sears Capital Management, Inc. for $4 million in cash on October 29, 2007. Dorsey & Whitney LLP acted as legal advisor to EndoNav. Latham & Watkins LLP acted as legal advisor to Intuitive Surgical.


Intuitive Surgical Inc. (NasdaqNM: ISRG) completed the acquisition of EndoNav, Inc. from Sears Capital Management, Inc. on October 31, 2007.
513
12/31/200722.85x66.09x70.92x102.39x102.13x$12,359$107.10458.63%Oct-29-2007M&A Transaction AnnouncementIntuitive Surgical Inc. (NasdaqNM: ISRG) agreed to acquire EndoNav, Inc. from Sears Capital Management, Inc. for $4 million.Sears Capital Management, Inc., EndoNav, Inc.Intuitive Surgical Inc. (NasdaqNM: ISRG) agreed to acquire EndoNav, Inc. from Sears Capital Management, Inc. for $4 million in cash on October 29, 2007. Dorsey & Whitney LLP acted as legal advisor to EndoNav. Latham & Watkins LLP acted as legal advisor to Intuitive Surgical.
514
12/31/200722.85x66.09x70.92x102.39x102.13x$12,673$109.82444.79%Oct-25-2007Executive/Board Change - OtherIntuitive Surgical Inc. Announces Directors Appointments-On October 19, 2007, the Board of Directors of Intuitive Surgical Inc. elected George Stalk, Jr. and Mark J. Rubash to the Board of Directors, effective as of October 19, 2007, to fill a vacant seat and to fill a newly created directorship resulting from the increase in the authorized number of directors under the Bylaws of Intuitive Surgical Inc. Mr. Stalk is a Senior Partner and Managing Director at The Boston Consulting Group (BCG) in the Toronto office. Mr. Rubash is the Chief Financial Officer at Rearden Commerce. Prior to joining Rearden, Mr. Rubash was a Senior Vice President at Yahoo! Inc. from February to July 2007. Mr. George Stalk, Jr. was elected as Class II director, and Mr. Mark J. Rubash was elected as a Class III director. Mr. Stalk was appointed as a member of the Governance and Nominating Committee of the Board of Directors, and Mr. Rubash has been appointed as a member of the Audit Committee of the Board of Directors.
515
12/31/200722.85x66.09x70.92x102.39x102.13x$9,864$85.48599.92%Oct-18-2007Announcement of EarningsIntuitive Surgical Inc. Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2007-Intuitive Surgical Inc. announced earnings results for the third quarter and nine months ended September 30, 2007. For the quarter, the company reported total revenue of $156,904,000 an increase of 64% from $95,832,000 for the third quarter of 2006. Third quarter 2007 revenue growth was driven by continued robotic procedure adoption and higher da Vinci(r) Surgical System sales. Net income increased 137% to $40,919,000 compared with $17,263,000 for the third quarter of 2006. Diluted earnings per share increased to $1.04 from $0.45 for the third quarter of 2006. Third quarter 2007 results included unusual, non-operating income resulting from gains on sales of equity investments of $4.1 million and foreign exchange gains of $1.8 million, impacting net income by approximately $3.7 million, or $0.09 per share, net of tax.

For the nine months, the company reported a net income of $95,384,000 or $2.46 per diluted share on total revenues of $411,382,000 against net income of $48,403,000 or $1.27 per diluted share on total revenues of $260,115,000 for the same period a year ago.
516
12/31/200722.85x66.09x70.92x102.39x102.13x$9,864$85.48599.92%Oct-18-2007Earnings CallIntuitive Surgical, Inc., Q3 2007 Earnings Call, Oct-18-2007-Intuitive Surgical, Inc., Q3 2007 Earnings Call, Oct 18 2007
517
12/31/200722.85x66.09x70.92x102.39x102.13x$9,864$85.48599.92%Oct-18-2007Earnings Release DateIntuitive Surgical Inc. to Report Q3, 2007 Results on October 18, 2007-Intuitive Surgical Inc. announced that they will report Q3, 2007 results on October 18, 2007.
518
9/30/200718.10x54.46x58.88x88.55x73.14x$8,696$75.88688.47%Sep-25-2007Executive/Board Change - OtherNeoGuide Systems Appoints John Cifarelli as Vice President of Sales-NeoGuide Systems Inc. has named John Cifarelli as vice president of sales. Cifarelli will be responsible for establishing and leading the company's worldwide sales organization. Cifarelli most recently served as vice president and general manager of the company's Surgical Products Group. Prior to NeoGuide, Cifarelli was executive vice president of sales and marketing for CDx Laboratories.
519
9/30/200718.10x54.46x58.88x88.55x73.14x$8,378$73.11718.34%Sep-11-2007Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
520
9/30/200718.10x54.46x58.88x88.55x73.14x$0Aug-18-2007Executive/Board Change - OtherNeoGuide Systems Appoints Jim Talbot Vice President of Quality and Regulatory Affairs-NeoGuide Systems Inc. appointed Jim Talbot vice president of quality and regulatory affairs. He served as director of quality at Boston Scientific and vice president of quality and regulatory affairs at Cutera.
521
9/30/200718.10x54.46x58.88x88.55x73.14x$8,031$70.08753.72%Aug-07-2007Executive/Board Change - OtherNeoGuide Systems Inc. Names Jim Talbot to Vice President, Quality and Regulatory Affairs-NeoGuide Systems Inc. announced the appointment of Jim Talbot to vice president, quality and regulatory affairs. In this role, he will oversee all aspects of the company's quality assurance and control system and will manage the regulatory approval process for new products in the U.S. and abroad. He most recently served as director of quality at Boston Scientific's Fremont, Calif. facility, where he oversaw the design and development of the company's neurological catheters, GDC coils and interventional ultrasound products.
522
9/30/200718.10x54.46x58.88x88.55x73.14x$5,733$50.031095.86%Jul-19-2007Announcement of EarningsIntuitive Surgical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2007-Intuitive Surgical Inc. reported earnings results for the second quarter and six months ended June 30, 2007. For the quarter, the company reported operating income of $45,033,000 and net income of $30,663,000 or $0.79 diluted earnings per share on total revenues of $140,249,000 compared to the operating income of $24,507,000 and net income of $16,682,000 or $0.44 diluted earnings per share on total revenues of $87,025,000 for the same quarter year ago.

For the six months period, the company reported operating income of $79,372,000 and net income of $54,465,000 or $1.41 diluted earnings per share on total revenues of $254,478,000 compared to the operating income of $46,231,000 and net income of $31,140,000 or $0.82 diluted earnings per share on total revenues of $164,283,000 for the same period year ago.
523
9/30/200718.10x54.46x58.88x88.55x73.14x$5,733$50.031095.86%Jul-19-2007Earnings CallIntuitive Surgical, Inc., Q2 2007 Earnings Call, Jul-19-2007-Intuitive Surgical, Inc., Q2 2007 Earnings Call, Jul 19 2007
524
9/30/200718.10x54.46x58.88x88.55x73.14x$5,733$50.031095.86%Jul-19-2007Earnings Release DateIntuitive Surgical Inc. to Report Q2, 2007 Results on July 19, 2007-Intuitive Surgical Inc. announced that they will report Q2, 2007 results on July 19, 2007.
525
9/30/200718.10x54.46x58.88x88.55x73.14x$5,688$49.631105.50%Jul-12-2007Executive/Board Change - OtherIntuitive Surgical Announces Executive Changes-Intuitive Surgical Inc. announced the promotion of Gary S. Guthart, Ph.D. to President and Chief Operating Officer and Jerome J. McNamara to Executive Vice President, Worldwide Sales and Marketing. Prior to joining Intuitive, Dr. Guthart was part of the core team developing foundation technology for computer-enhanced surgery at SRI International.
526
6/30/200712.02x37.62x40.96x62.69x55.50x$5,059$44.691238.76%May-02-2007Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
527
6/30/200712.02x37.62x40.96x62.69x55.50x$5,031$44.441246.29%Apr-27-2007Annual General MeetingIntuitive Surgical Inc., Annual General Meeting, Apr 27, 2007-Intuitive Surgical Inc., Annual General Meeting, Apr 27, 2007, at 15:00 Pacific Daylight. Location: The Grand Hotel, 865 W. El Camino Real, Sunnyvale, CA 94086,United States. Agenda: to elect three Class I members of the Board of Directors to serve until the 2010 annual meeting of stockholders; and to transact any other business which is properly brought before the meeting or any adjournment or postponement thereof.
528
6/30/200712.02x37.62x40.96x62.69x55.50x$4,573$40.401380.92%Apr-19-2007Announcement of EarningsIntuitive Surgical Inc. Reports Earnings Results for the First Quarter of 2007-Intuitive Surgical Inc. reported earnings results for the first quarter of 2007. For the quarter, profit surged 65% on double-digit growth across business lines. The company earned $23.8 million, or 62 cents per share, compared with $14.5 million, or 38 cents per share, for the same quarter in 2006. Revenue rose 48% to $114.2 million from $77.3 million in the year-ago period. The company credited the sales increase to strong recurring revenue growth and increased sales of its da Vinci Surgical System.
529
6/30/200712.02x37.62x40.96x62.69x55.50x$4,573$40.401380.92%Apr-19-2007Earnings CallIntuitive Surgical, Inc., Q1 2007 Earnings Call, Apr-19-2007-Intuitive Surgical, Inc., Q1 2007 Earnings Call, Apr 19 2007
530
6/30/200712.02x37.62x40.96x62.69x55.50x$4,573$40.401380.92%Apr-19-2007Earnings Release DateIntuitive Surgical Inc. to Report Q1, 2007 Results on April 19, 2007-Intuitive Surgical Inc. announced that they will report Q1, 2007 results on April 19, 2007.
531
3/31/200711.55x36.69x40.11x61.68x83.20x$4,241$37.731485.71%Feb-13-2007Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
532
3/31/200711.55x36.69x40.11x61.68x83.20x$3,722$33.111706.98%Feb-01-2007Announcement of EarningsIntuitive Surgical Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2006-Intuitive Surgical Inc. announced earnings results for the fourth quarter and full year ended December 31, 2006. For the quarter, the company reported revenue of $112.6 million, increasing 56% from $72.1 million for the fourth quarter of 2005. Higher revenue was driven by increased da Vinci(r) Surgical System sales and continued growth in recurring revenue. Net income including non-cash stock compensation expense, was $23.6 million or $0.62 per diluted share against $49.5 million or $1.31 per share for the same period a year ago. Excluding the impact of stock compensation expenses, net income was $28.1 million, or $0.73 per diluted share. Earnings before interest, taxes, depreciation, amortization, and non-cash stock compensation expenses (EBITDA) was $45.1 million, up 78% compared to $25.3 million for the fourth quarter 2005.

For the year, revenue totaled $372.7 million, increasing 64% from $227.3 million for the year ended December 31, 2005. Net income including non-cash stock compensation expense, was $72.0 million or $1.89 per diluted share against $94.1 million or $2.51 per share for the same period a year ago. Excluding the impact of stock compensation expenses, net income was $88.3 million, or $2.32 per diluted share. EBITDA was $142.4 million, up 89% compared to $75.5 million for the twelve months ended December 31, 2005.
533
3/31/200711.55x36.69x40.11x61.68x83.20x$3,722$33.111706.98%Feb-01-2007Earnings CallIntuitive Surgical, Inc., Q4 2006 Earnings Call, Feb-01-2007-Intuitive Surgical, Inc., Q4 2006 Earnings Call, Feb-01 2007
534
3/31/200711.55x36.69x40.11x61.68x83.20x$3,679$32.731727.96%Jan-30-2007Executive/Board Change - OtherIntuitive Surgical Names Rick Epstein as Senior Vice President of Marketing-Intuitive Surgical Inc. announced the addition of Rick Epstein to its management team as Senior Vice President of Marketing. Mr. Epstein joins Intuitive Surgical from Cardinal Health Inc. Rick spent 7 years at Cardinal Health, most recently as Vice President and General Manager for V. Mueller.
535
3/31/200711.55x36.69x40.11x61.68x83.20x$3,348$29.791908.36%Jan-09-2007Lawsuits & Legal IssueIntuitive Surgical Inc. Faces Patent Lawsuit from California Institute of Technology-Intuitive Surgical Inc. announced that the California Institute of Technology filed a patent infringement lawsuit against the company in the U.S. District Court for the Eastern District of Texas. The company announced that the lawsuit is without merit and has filed an action in the U.S. District Court for the Northern District of California seeking declaration that the company isn't infringing Cal Tech patents.
536
12/31/200610.06x32.08x35.02x54.96x241.20x$3,579$32.161760.35%Nov-09-2006Executive/Board Change - Other, Executive Change - CEONeoGuide Systems Inc. Appoints Austin Noll as President and Chief Executive Officer-NeoGuide Systems Inc. has named Austin Noll its new president and chief executive officer. A seasoned health-care executive with nearly two decades of experience in the medical device industry, Noll takes the helm of NeoGuide as it prepares for commercialization of its flagship product, the NeoGuide Endoscopy System. Company founder and the inventor of the technology Amir Belson, M.D., will remain full-time with NeoGuide as a board member and the chief technology officer. In this role, he will lead the development of new technology applications to support future company growth.
537
12/31/200610.06x32.08x35.02x54.96x241.20x$4,162$37.391500.13%Oct-26-2006Earnings CallIntuitive Surgical, Inc., Q3 2006 Earnings Call, Oct-26-2006-Intuitive Surgical, Inc., Q3 2006 Earnings Call, Oct 26 2006
538
12/31/200610.06x32.08x35.02x54.96x241.20x$4,162$37.391500.13%Oct-26-2006Announcement of EarningsIntuitive Surgical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2006-Intuitive Surgical Inc. reported earnings results for the nine months ended September 30, 2006. For the nine months ended September 30, 2006, revenues totaled $260.1 million increasing 68% from $155.2 million for the nine months ended September 30, 2005. Net income of $48.4 million or $1.27 per diluted share compared to net income of $45.0 million or $1.19 per diluted share a year ago.
539
12/31/200610.06x32.08x35.02x54.96x241.20x$4,162$37.391500.13%Oct-26-2006Announcement of EarningsIntuitive Reports Earnings Results for the Third Quarter of 2006-Intuitive Surgical Inc. reported earnings results for the third quarter of 2006. The company announced that it had third-quarter net income of $17.3 million, or 45 cents a share, a 16% decrease from the year-ago period. The company reported $95.8 million in revenue, a 57% increase over last year's $60.9 revenue. Excluding items, including $6.9 million in stock-based compensation, the company would have reported income of $21.7 million, or 57 cents a share.
540
12/31/200610.06x32.08x35.02x54.96x241.20x$3,954$35.531583.90%Oct-05-2006Executive/Board Change - OtherNeoGuide Systems Inc. Appoints Ian Felix as Vice President of Operations-NeoGuide Systems Inc. announced that it has appointed Ian Felix as vice president of operations. Felix will be responsible for helping the company ramp up operations for the commercial launch of its NeoGuide Endoscopy System. Most recently, he served as vice president of operations at Velocity 11, which designs and manufactures high performance lab automation equipment processes.
541
9/30/200612.51x37.74x40.98x64.24xNM$3,861$34.851616.76%Sep-26-2006Private PlacementNeoGuide Systems, Inc. announced that it has received $25.14 million in funding from a group of investors.Advent Venture Partners, Pelion Venture Partners, The Angels' Forum LLC, Versant Venture Management, LLC, Kaiser Permanente Ventures, SBV Venture Partners, The Halo Funds, Rockport Venture Partners, Arboretum Ventures LLC, 3i Group plc (LSE:III)NeoGuide Systems, Inc. announced that it has raised $25.141 million in its series C round of funding from 25 investors led by new investor Advent Venture Partners on September 26, 2006. The company issued Series C preferred stock pursuant to Regulation D of the Securities Act. The round included the participation from other new investor Rockport Venture Partners and existing investors SBV Venture Partners, The Halo Fund, Versant Ventures which invested $2 million, Utah Ventures which invested $3.2 million, 3i Group Plc, Kaiser Permanente Ventures, Arboretum Ventures, and The Angels' Forum LLC. NeoGuide Systems has raised $43 million in venture funding since 2001. As part of the round, Shahzad Malik, General Partner at Advent Venture Partners, will join NeoGuide Systems' board of directors.

Wilson Sonsini Goodrich and Rosati served as legal advisor to NeoGuide Systems while Morrison & Foerster LLP served as legal advisor to Advent Venture Partners. The company incurred $0.19 million in legal fees for the transaction.


On September 26, 2006, NeoGuide Systems, Inc. closed the transaction.
542
9/30/200612.51x37.74x40.98x64.24xNM$3,667$33.101707.52%Jul-27-2006Earnings Release DateIntuitive Surgical Inc. to Report Q2, 2006 Results on July 27, 2006-Intuitive Surgical Inc. announced that they will report Q2, 2006 results on July 27, 2006.
543
9/30/200612.51x37.74x40.98x64.24xNM$4,116$37.151510.47%Jul-26-2006Earnings CallIntuitive Surgical, Inc., Q2 2006 Earnings Call, Jul-26-2006-Intuitive Surgical, Inc., Q2 2006 Earnings Call, Jul 26 2006
544
9/30/200612.51x37.74x40.98x64.24xNM$4,116$37.151510.47%Jul-26-2006Announcement of EarningsIntuitive Surgical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2006-Intuitive Surgical Inc. reported earnings results for the second quarter and six months ended June 30, 2006. For the quarter, the company reported total revenue of $87.02 million increasing 65% from $52.80 million for the second quarter of 2005. Net income was $16.68 million or $0.44 per diluted share compared to $14.78 million or $0.40 per diluted share for the second quarter of 2005. The proforma net income was $21.06 million or $0.55 per diluted share.

For the six months, the company reported net income of $31.14 million or diluted earnings per share of $0.82 on total revenue of $164.28 million against net income of $23.88 million or diluted earnings per share of $0.64 on total revenue of $94.37 million for the same period earlier. The proforma net income was $38.57 million or $1.02 per diluted share.

Higher sales were driven by increased da Vinci(R) Surgical System sales and continued growth in recurring revenue.
545
9/30/200612.51x37.74x40.98x64.24xNM$4,334$39.121429.37%Jul-03-2006Index Constituent DropIntuitive Surgical, Inc. dropped from Russell 2000 IndexRussell 2000 Index (^RUT)Intuitive Surgical Inc. will be removed from Russell 2000 Index.
546
6/30/200615.36x45.48x49.51x78.72xNM$4,266$38.641448.37%May-19-2006Annual General MeetingIntuitive Surgical Inc., Annual General Meeting , May 19, 2006-Intuitive Surgical Inc., Annual General Meeting , May 19, 2006, at 14:30 Pacific Daylight. Location: The Grand Hotel, 865 W. El Camino Real, Sunnyvale, California,United States. Agenda: to elect two Class III members of the Board of Directors to serve until the 2009 annual meeting of stockholders; and to transact any other business which is properly brought before the meeting or any adjournment or postponement thereof..
547
6/30/200615.36x45.48x49.51x78.72xNM$4,539$41.111355.34%May-03-2006Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
548
6/30/200615.36x45.48x49.51x78.72xNM$3,797$34.391639.72%Apr-27-2006Earnings CallIntuitive Surgical, Inc., Q1 2006 Earnings Call, Apr-27-2006-Intuitive Surgical, Inc., Q1 2006 Earnings Call, Apr 27 2006
549
6/30/200615.36x45.48x49.51x78.72xNM$3,797$34.391639.72%Apr-27-2006Announcement of EarningsIntuitive Surgical Inc. Announces Earnings Results for the First Quarter Ended March 31, 2006-Intuitive Surgical Inc. announced earnings results for the first quarter ended March 31, 2006. The company reported a revenue of $77.3 million, up 86% from $41.6 million for the first quarter of 2005. Net income was $14,458,000 or $0.38 per share against net income of $9,104,000 or $0.25 per share for the same period a year ago.

According to Non-GAAP Pro Forma results, the company reported a net income of $17,518,000 or $0.46 per share on revenues of $77,258,000.

Higher revenue was driven by increased da Vinci(R) Surgical System sales and continued growth in recurring revenue.
550
3/31/200618.36x55.29x60.70x95.90xNM$3,597$32.791724.61%Mar-16-2006Executive/Board Change - Other, Executive Change - CFOIntuitive Surgical Names Marshall L. Mohr as Senior Vice President and Chief Financial Officer-Intuitive Surgical Inc. announced the addition of Marshall L. Mohr to its management team as Senior Vice President and Chief Financial Officer. Mr. Mohr joins Intuitive Surgical from Adaptec Inc. where he had served as Vice President and Chief Financial Officer since July 2003. Ben Gong, who has served as the Interim Chief Financial Officer since November 2005, will continue his duties as Vice President, Finance and Treasurer.
551
3/31/200618.36x55.29x60.70x95.90xNM$3,689$33.631679.04%Feb-16-2006Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
552
3/31/200618.36x55.29x60.70x95.90xNM$3,736$34.061656.58%Feb-15-2006Executive/Board Change - OtherIntuitive Surgical Inc. Appoints Heather Hand as Vice President of Human Resources-Intuitive Surgical Inc. announced the addition of Heather Hand to its management team as Vice President of Human Resources. Over the past 20 years, Ms. Hand has held several executive-level Human Resource positions in the medical device and healthcare industry. Most recently, and for the previous five years, she worked as Senior Vice President, Global Human Resources for Sunrise Medical Inc., a medical equipment manufacturer based in Carlsbad, California. Prior to Sunrise, Ms. Hand served for three years as Vice President, Human Resources for Biosense Webster, a division of Johnson and Johnson. She previously worked as Vice President of Human Resources for City of Hope, a leading cancer treatment and research center located in Duarte, California. Ms. Hand received her MBA from Pepperdine University and her B.A. from Claremont McKenna College.
553
3/31/200618.36x55.29x60.70x95.90xNM$3,711$33.831668.52%Feb-09-2006Product-Related AnnouncementNeoGuide Announces FDA Clearance of Its Breakthrough Computer-Assisted Colonoscopy System-NeoGuide Systems Inc. announced that it received FDA 510(k) clearance to market its NeoGuide Endoscopy System. The system is designed to enhance physician control of the colonoscope and to eliminate looping, the principle reason why conventional colonoscopy procedures are painful, time consuming, and difficult. In conventional colonoscopy, a flexible endoscope is inserted into the colon, which is essentially a flexible and highly tortuous tube. Advancing the colonoscope displaces the colon and stretches the surrounding tissue, a phenomenon known as looping. Unlike conventional scopes, the NeoGuide colonoscope is built out of multiple segments that can be actively controlled. As the physician inserts the NeoGuide scope, the system automatically creates a three-dimensional map of the colon and then directs these segments to follow the path taken by the tip.
554
3/31/200618.36x55.29x60.70x95.90xNM$3,711$33.831668.52%Feb-09-2006Executive/Board Change - OtherIntuitive Surgical Announces the Promotion of Gary Guthart to Chief Operating Officer-Intuitive Surgical Inc. announced the promotion of Dr. Gary Guthart to the role of Chief Operating Officer. Dr. Guthart, 40, will lead Intuitive's research, product design, manufacturing, regulatory and IT operations. Most recently, Dr. Guthart served as Intuitive's Senior Vice President of Product Operations. Dr. Guthart joined Intuitive Surgical Inc. in April 1996 and became Vice President, Engineering in November 1999.
555
3/31/200618.36x55.29x60.70x95.90xNM$4,653$42.421310.40%Feb-02-2006Earnings CallIntuitive Surgical, Inc., Q4 2005 Earnings Call, Feb-02-2006-Intuitive Surgical, Inc., Q4 2005 Earnings Call, Feb-02 2006
556
3/31/200618.36x55.29x60.70x95.90xNM$4,653$42.421310.40%Feb-02-2006Announcement of EarningsIntuitive Surgical Inc. Announces Earnings Results for the Fourth Quarter and Full Year of 2005-Intuitive Surgical Inc. announced earnings results for the fourth quarter and full year of 2005. For the period net income was $49.5 million, or $1.31 per share, up from $11.7 million, or 32 cents per share, in the year-ago period. Sales increased 60% to $72.1 million from $45.2 million, as sales of products, particularly its da Vinci surgical system and services surged.

For the full year, earnings increased to $94.1 million, or $2.51 per share, from $23.4 million, or 67 cents per share, in 2004. Total sales for the year grew to $227.3 million from $138.8 million.
557
3/31/200618.36x55.29x60.70x95.90xNM$5,020$45.761207.45%Jan-31-2006Index Constituent AddIntuitive Surgical Inc. added to NASDAQ-100 IndexNASDAQ-100 Index (^NDX)Intuitive Surgical Inc. will be added to the NASDAQ-100 Index.
558
3/31/200618.36x55.29x60.70x95.90xNM$4,656$42.441309.73%Jan-11-2006Product-Related AnnouncementIntuitive Surgical Inc. Announces Addition to its Da Vinci(R) Product Line-Intuitive Surgical Inc. announced the introduction of an addition to its da Vinci System product line. The latest addition, called the da Vinci(R) S(TM) Surgical System, features fast setup, rapid instrument exchange, multi-quadrant access and multi-image display capabilities. In addition, the da Vinci S shares the same core technology as the standard da Vinci System, providing surgeons with unparalleled precision, dexterity and control. The da Vinci S System will list for $1.53 million, which is approximately $200,000 more than the standard da Vinci System. Intuitive Surgical will showcase the da Vinci S System at the Society of Thoracic Surgeons meeting in Chicago later this month.
559
3/31/200618.36x55.29x60.70x95.90xNM$4,398$40.091392.37%Jan-05-2006Executive/Board Change - OtherIntuitive Surgical Names John F. Runkel as Senior Vice President and General Counsel-Intuitive Surgical Inc. announced the addition of John F. (Rick) Runkel to its management team as Senior Vice President and General Counsel. Mr. Runkel joins Intuitive Surgical from VISX, Incorporated, a leader in laser vision correction technology, where he served as Senior Vice President, Business Development, General Counsel and Secretary. Prior to joining VISX, Mr. Runkel was a partner in the law firm of Sheppard, Mullin, Richter & Hampton, where he practiced law for 17 years and served as Managing Partner of the firm's San Francisco office.
560
12/31/200519.81x63.99x71.66x117.11x185.31x$3,910$36.001561.92%Nov-18-2005Client AnnouncementChindex International Announces First Intuitive Surgical Sale in ChinaChindex International Inc.Chindex International Inc. announced that it has concluded its first sale in China of the da Vinci(R) Surgical System, manufactured by Intuitive Surgical Inc. The system was purchased by The Chinese University of Hong Kong (CUHK) and was installed at the Prince of Wales Hospital under the management of the CUHK Jockey Club Minimally Invasive Surgical Skills (MISS) Centre, one of the comprehensive multi-disciplinary surgical skills centers in the Asia Pacific region.
561
12/31/200519.81x63.99x71.66x117.11x185.31x$2,606$24.002392.88%Oct-25-2005Earnings CallIntuitive Surgical, Inc., Q3 2005 Earnings Call, Oct-25-2005-Intuitive Surgical, Inc., Q3 2005 Earnings Call, Oct 25 2005
562
12/31/200519.81x63.99x71.66x117.11x185.31x$2,606$24.002392.88%Oct-25-2005Announcement of EarningsIntuitive Surgical Inc. Announces Earnings Results for the Third Quarter and Nine Months Ended Sep. 30, 2005-Intuitive Surgical Inc. announced earnings results for the third quarter and nine months ended Sep. 30, 2005. For the quarter, the company reported a net profit of $20,720,000 or $0.55 per share on total sales of $60,874,000 against net profit of $6,113,000 or $0.17 per share on total sales of $35,493,000 for the same period a year ago.

For the nine months, the company reported a net profit of $44,608,000 or $1.19 per share on total sales of $155,244,000 against net profit of $11,796,000 or $0.34 per share on total sales of $93,609,000 for the same period a year ago.
563
9/30/200513.72x51.52x60.21x98.85x136.21x$2,547$23.962397.04%Sep-07-2005Client AnnouncementIntuitive Surgical Inc. Enters into a Cross-Licensing Agreement with Hansen Medical IncHansen Medical, Inc.Intuitive Surgical Inc. announced that it has entered into a cross-licensing agreement with Hansen Medical Inc. Under the cross-licensing agreement, Hansen Medical has the right to apply Intuitive Surgical's patent portfolio in the field of intravascular approaches for the diagnosis or treatment of cardiovascular, neurovascular and peripheral vascular diseases. In exchange, Intuitive Surgical received the right to apply Hansen Medical's patent portfolio in the fields of endoscopic, laparoscopic, thoracoscopic or open surgery, and in endoluminal applications in gastrointenstinal, respiratory, ENT, urologic and gynecologic surgery. Royalties on future Hansen Medical product sales and equity in Hansen Medical. Each party retains full rights to practice its own technology for all purposes. Specific financial terms of the agreement were not disclosed.
564
9/30/200513.72x51.52x60.21x98.85x136.21x$2,636$24.802312.46%Aug-31-2005Executive Change - CFOIntuitive Surgical Inc. Announces Planned Departure of Chief Financial Officer Susan Barnes-Intuitive Surgical Inc. announced that Susan Barnes, Chief Financial Officer will be leaving the company in November. Ms. Barnes will remain active in the role of Chief Financial Officer through Intuitive Surgical's third quarter earnings release in October. During her eight years at Intuitive Surgical, Ms. Barnes has overseen a number of significant milestones, including the company's initial public offering in 2000 and follow-on offering in 2003.
565
9/30/200513.72x51.52x60.21x98.85x136.21x$2,439$22.942508.06%Aug-02-2005Executive/Board Change - OtherIntuitive Surgical Inc. Appoints Floyd D. Loop to its Board of Directors-Intuitive Surgical Inc. has appointed Floyd D. Loop, M.D. to its Board of Directors. With the addition of Dr. Loop, the Intuitive Board is now comprised of eight members, including six independent outside Directors. Dr. Loop is an internationally recognized cardiovascular surgeon and a recipient of the American Heart Association Citation for International Service.
566
9/30/200513.72x51.52x60.21x98.85x136.21x$2,459$23.132486.64%Jul-29-2005Index Constituent AddIntuitive Surgical, Inc. added to S&P Midcap 400 Sector Indices - Health Care Sector IndexS&P 400 Health Care (Sector) (^SP400-35)Intuitive Surgical, Inc. added to S&P Midcap 400 Sector Indices - Health Care Sector Index
567
9/30/200513.72x51.52x60.21x98.85x136.21x$1,818$17.103398.77%Jul-26-2005Earnings CallIntuitive Surgical, Inc., Q2 2005 Earnings Call, Jul-26-2005-Intuitive Surgical, Inc., Q2 2005 Earnings Call, Jul 26 2005
568
9/30/200513.72x51.52x60.21x98.85x136.21x$1,818$17.103398.77%Jul-26-2005Announcement of EarningsIntuitive Surgical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2005-Intuitive Surgical Inc. reported earnings results for the second quarter and six months ended June 30, 2005. For the quarter, the company reported sales of $52.8 million increasing 70% from $31.1 million for the second quarter of 2004. Net income was $14.8 million or $0.40 per diluted share compared to $4.8 million or $0.14 per diluted share for the second quarter of 2004.

For the six months, the company reported net income of $23.88 million or diluted earnings per share of $0.64 on sales of $94.4 million against net income of $23.88 million or diluted earnings per share of $0.64 on sales of $58.1 million for the same period earlier.
569
6/30/20059.59x40.98x50.54x82.85x226.21x$1,488$14.234104.43%May-03-2005Company Conference PresentationIntuitive Surgical, Inc. - Conference Presentation Call-Intuitive Surgical, Inc. - Conference Presentation Calls
570
6/30/20059.59x40.98x50.54x82.85x226.21x$1,810$17.303358.32%Apr-21-2005Earnings CallIntuitive Surgical, Inc., Q1 2005 Earnings Call, Apr-21-2005-Intuitive Surgical, Inc., Q1 2005 Earnings Call, Apr 21 2005
571
6/30/20059.59x40.98x50.54x82.85x226.21x$1,810$17.303358.32%Apr-21-2005Client AnnouncementIntuitive Surgical Inc. Wins $25,800 Contract-The U.S. Army awarded a $25,800 contract to Intuitive Surgical Inc., Sunnyvale, Calif. for medical equipment for the Walter Reed Army Medical Center. The contract was awarded by the U.S. Army Medical Command.
572
6/30/20059.59x40.98x50.54x82.85x226.21x$1,810$17.303358.32%Apr-21-2005Announcement of EarningsIntuitive Surgical Inc. Reports Financial Results for the First Quarter Ended March 31, 2005-Intuitive Surgical Inc. reported first quarter 2005 sales of $41.6 million, increasing 54% from $27.1 million for the first quarter of 2004. First quarter 2005 recurring revenue, consisting of instrument, accessory, service and training revenue, increased to $20.3 million from $12.5 million during the first quarter 2004. First quarter 2005 operating income increased to $8.9 million, up from $0.3 million reported for the first quarter 2004. The company reported first quarter 2005 net income of $9.1 million, or $0.25 per diluted share, compared to $0.9 million, or $0.02 per diluted share for the first quarter 2004.
573
6/30/20059.59x40.98x50.54x82.85x226.21x$1,632$15.603735.19%Apr-01-2005Announcement of EarningsIntuitive Surgical Announces Earnings for the Fourth quarter of 2004-Intuitive Surgical Inc. announced that its fourth-quarter 2004 earnings vaulted 700% to 32 cents per share while Sales jumped 52%.
574
3/31/200510.42x51.37x68.26x105.57xNM$1,428$13.704267.08%Feb-08-2005Earnings CallIntuitive Surgical, Inc., Q4 2004 Earnings Call, Feb-08-2005-Intuitive Surgical, Inc., Q4 2004 Earnings Call, Feb-08 2005
575
3/31/200510.42x51.37x68.26x105.57xNM$1,428$13.704267.08%Feb-08-2005Earnings Release DateIntuitive Surgical Inc. to Report Q4, 2004 Results on February 08, 2005-Intuitive Surgical Inc. announced that they will report Q4, 2004 results on February 08, 2005.
576
3/31/200510.42x51.37x68.26x105.57xNM$1,428$13.704267.08%Feb-08-2005Announcement of EarningsIntuitive Surgical Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2004-Intuitive Surgical Inc. reported earnings results for the fourth quarter and full year ended December 31, 2004. For the quarter, the company reported sales of $45.2 million, increasing 64% from $27.6 million for the fourth quarter of 2003. The company reported fourth quarter 2004 net income of $11.7 million, or $0.32 per diluted share, against net loss of $4.9 million, or $0.16 loss per diluted share for the fourth quarter 2003.

Total sales for the fiscal year ended December 31, 2004 were $138.8 million, up 51% from $91.7 million in 2003. Intuitive reported fiscal year 2004 net income of $23.5 million, or $0.67 per diluted share, against a net loss of $9.6 million, or $0.41 loss per diluted share in fiscal 2003.
577
3/31/200510.42x51.37x68.26x105.57xNM$0Jan-29-2005Index Constituent AddIntuitive Surgical Inc. added to Russell 2000 IndexRussell 2000 Index (^RUT)Intuitive Surgical Inc. added to Russell 2000 Index
578
3/31/200510.42x51.37x68.26x105.57xNM$1,292$12.404724.92%Jan-07-2005Client AnnouncementChindex International Announces Exclusive Distribution Agreement with Intuitive Surgical for ChinaChindex International Inc.Chindex International Inc. announced an exclusive, multi-year distribution agreement for the People's Republic of China with Intuitive Surgical. Under the terms of the agreement, Chindex will market and distribute the da Vinci(R) Surgical System throughout the healthcare industry in China. Intuitive Surgical's da Vinci(R) Surgical System is the first totally intuitive laparoscopic surgical robot. It was the first operative surgical robotic system cleared by the United States Food and Drug Administration (FDA) and is now used in more than 160 sites in the USA as well as many countries in Europe but has yet to be introduced in China. The da Vinci(R) Surgical System is a cutting edge technology that is redefining the world of minimally invasive surgery around the world, shortening the operating time and dramatically reducing post-operative complications in such important procedures as Cardiac By-Pass, Radical Prostatectomy and other life saving surgeries.
579
12/31/200410.23x69.50x120.11x166.48xNM$0Dec-24-2004Executive/Board Change - OtherNeoGuide Systems Appoints Robert P. Eno as Vice President of Marketing-NeoGuide Systems Inc. named Robert P. Eno vice president of marketing. Before joining the company, Eno was vice president of marketing and sales at Avantec Vascular, a medical device company in Sunnyvale. He also held marketing and planning positions at Guidant.
580
12/31/200410.23x69.50x120.11x166.48xNM$0Nov-28-2004Announcement of EarningsIntuitive Surgical Inc. Reports Results for the Third Quarter of 2004-Intuitive Surgical Inc. reported record third quarter 2004 sales of $35.5 million, increasing 52% from $23.4 million for the third quarter of 2003. The company reported third quarter 2004 net income of $6.1 million, or $0.17 per diluted share, compared to a net loss of $3.4 million, or ($0.12) per diluted share for the third quarter 2003.
581
12/31/200410.23x69.50x120.11x166.48xNM$849$8.277134.46%Oct-26-2004Earnings CallIntuitive Surgical, Inc., Q3 2004 Earnings Call, Oct-26-2004-Intuitive Surgical, Inc., Q3 2004 Earnings Call, Oct 26 2004
582
12/31/200410.23x69.50x120.11x166.48xNM$849$8.277134.46%Oct-26-2004Earnings Release DateIntuitive Surgical Inc. to Report Q3, 2004 Results on October 26, 2004-Intuitive Surgical Inc. announced that they will report Q3, 2004 results on October 26, 2004.
583
12/31/200410.23x69.50x120.11x166.48xNM$849$8.277134.46%Oct-26-2004Announcement of EarningsIntuitive Surgical Inc. Reports Results for the Third Quarter and Nine Months Ended September 30, 2004-Intuitive Surgical Inc. the industry leader in surgical robotics, reported record third quarter 2004 sales of $35.5 million, increasing 52% from $23.4 million for the third quarter of 2003. The company reported third quarter 2004 net income of $6.1 million, or $0.17 per diluted share against a net loss of $3.4 million or $0.12 per diluted share for the third quarter 2003.

Net income for the nine months ended September 30, 2004 was $11.7 million or $0.34 per share on sales of $93.6 million against net loss of $4.7 million or $0.22 loss per share on sales of $64 million for the same period a year earlier.
584
9/30/20046.67x71.56xNM275.06xNM$782$7.677700.39%Jul-27-2004Earnings CallIntuitive Surgical, Inc., Q2 2004 Earnings Call, Jul-27-2004-Intuitive Surgical, Inc., Q2 2004 Earnings Call, Jul 27 2004
585
9/30/20046.67x71.56xNM275.06xNM$782$7.677700.39%Jul-27-2004Earnings Release DateIntuitive Surgical Inc. to Report Q2, 2004 Results on July 27, 2004-Intuitive Surgical Inc. announced that they will report Q2, 2004 results on July 27, 2004.
586
9/30/20046.67x71.56xNM275.06xNM$782$7.677700.39%Jul-27-2004Announcement of EarningsIntuitive Surgical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2004-Intuitive Surgical Inc. reported earnings results for the second quarter ended June 30, 2004. For the three months period ended, the company net income of $4,830,000 or $0.14 diluted per share and net sales of $31,057,000 as against net income of $878,000 or $0.05 diluted per share and net sales of $21,453,000 reported for the same period a year ago.

For the six months period ended, the company reported net income of $5,683,000 or $0.17 diluted per share and net sales of $58,116,000 as against net loss of $1,415,000 or $0.08 diluted loss per share and net sales of $40,688,000 reported for the same period a year ago.
587
6/30/20045.25x92.78xNMNMNM$556$5.5110758.26%May-28-2004Executive/Board Change - OtherIntuitive Surgical Names Frank D. Nguyen as Vice President, General Counsel-Intuitive Surgical Inc. announced the addition of Frank D. Nguyen to its Management. Mr. Nguyen joined Intuitive at the end of April as Vice President and General Counsel. He has nearly two decades of engineering and legal experience. Prior to joining Intuitive Surgical, Mr. Nguyen was Director of Intellectual Property (IP) and Patent Counsel at Macrovision Corporation, an IP-centric developer of copy protection and rights management solutions for software, audio, and video content, during Macrovision's explosive growth period over the past 5 years. At Macrovision Mr. Nguyen was responsible for managing and developing Macrovision's worldwide patent portfolio, leading and managing Macrovision's IP related litigations, as well as forming and implementing Macrovision's IP strategies.
588
6/30/20045.25x92.78xNMNMNM$543$5.3811020.63%May-24-2004Executive/Board Change - OtherIntuitive Surgical Announces Board of Directors Addition-Intuitive Surgical Inc. announced the addition of D. Keith Grossman to its Board of Directors. With the addition of Mr. Grossman, the Intuitive Board is now comprised of eight members, including seven independent outside Directors. Mr. Grossman has held positions as Division President of Major Pharmaceuticals Inc., Vice President of Sales and Marketing for the Calcitek division of Sulzermedica, and various sales and marketing management positions within American Hospital Supply Corporation. Mr. Grossman also serves as a member of the board of directors of Acorn Cardiovascular, Incorporated.
589
6/30/20045.25x92.78xNMNMNM$509$5.0411770.83%Apr-29-2004Announcement of EarningsIntuitive Surgical Inc. Announces Results for the First Quarter of 2004-Intuitive Surgical Inc. reported first quarter 2004 sales of $27.1 million, increasing 41% from $19.2 million for the first quarter of 2003. Intuitive reported first quarter 2004 net income of $0.9 million, or $0.02 per diluted share, compared to a net loss of $2.3 million, or $0.12 per share for the first quarter 2003.
590
3/31/20044.95xNMNMNMNM$557$5.5410699.46%Mar-25-2004Executive/Board Change - OtherIntuitive Surgical Announces Additions to Its Board of Directors-Intuitive Surgical Inc. announced the addition of William J. Mercer and William Clark Meyers, M.D. to its Board of Directors. Mr. Mercer is the Founder and Managing Member of Avocet Ventures, LLC, a private equity investment firm. Dr. Meyers is currently the Dean of Clinical Affairs and Chairman of the Department of Surgery at Drexel University College of Medicine, where he has been associated since January 2001.
591
3/31/20044.95xNMNMNMNM$620$6.179596.76%Feb-12-2004Announcement of EarningsIntuitive Surgical Inc. Announces Results for the Fourth Quarter and Full Year of 2003-Intuitive Surgical Inc. announced fourth quarter 2003 sales of $27.6 million, increasing 30% from $21.1 million for the fourth quarter of 2002. Intuitive reported a fourth quarter 2003 net loss of $4.9 million, or $0.16 per share. During the fourth quarter 2002, Intuitive reported a net loss of $2.6 million, or $0.14 per share.

Intuitive reported a fiscal year 2003 net loss of $9.6 million, or $0.41 per share, compared to a net loss of $18.4 million, or $1.01 per share in fiscal 2002. Sales for 2003 totaled $91.7 million for the year, up 27% from $72.0 million in 2002.
592
3/31/20044.95xNMNMNMNM$613$6.109708.03%Feb-09-2004Lawsuits & Legal IssueIntuitive Surgical Settles Pending LitigationBrookhill-Wilk 1 LLCIntuitive Surgical Inc. has settled its pending litigation with Brookhill-Wilk 1 LLC. Under the terms of the settlement, Brookhill-Wilk will grant a perpetual, exclusive license and certain covenants to Intuitive in consideration of a one-time license fee in the amount of $2.6 million. The settlement will result in the dismissal with prejudice of all pending litigation between the companies, including Brookhill-Wilk's related claims against Computer Motion Inc., and several customers of Intuitive Surgical.Intuitive Surgical also announced that it has settled its pending litigation with two former patients of The Valley Hospital in New Jersey.
593
3/31/20044.95xNMNMNMNM$0Jan-19-2004Executive/Board Change - OtherIntuitive Surgical Inc. Announces Resignation & Appointment Of Directors-Intuitive Surgical Inc. has announced that Bennett Nussbaum has tendered his resignation from the board of directors.

Intuitive also announced that Mr. Richard J. Kramer, who already holds a position on Intuitive's board, has been appointed to the role of chairman of the audit committee.
594
3/31/20044.95xNMNMNMNM$573$5.7010396.32%Jan-14-2004Lawsuits & Legal IssueIntuitive Surgical Settles Pending Litigation Brookhill-Wilk 1 LLC-Intuitive Surgical Inc. announced that it has settled its pending litigation with Brookhill-Wilk 1, LLC. Under the terms of the settlement, Brookhill-Wilk will grant a perpetual, exclusive license and certain covenants to Intuitive in consideration of a one-time license fee in the amount of $2.6 million. The settlement will result in the dismissal with prejudice of all pending litigation between the companies, including Brookhill-Wilk's related claims against Computer Motion Inc. and several customers of Intuitive Surgical. Intuitive Surgical also announced that it has settled its pending litigation with two former patients of The Valley Hospital in New Jersey.
595
12/31/20036.22xNMNMNMNM$558$5.6310526.82%Dec-22-2003Executive/Board Change - OtherIntuitive Surgical Announces Change To Its Board Of Directors-Intuitive Surgical Inc. the leader in operative surgical robotics, announced that Bennett Nussbaum has tendered his resignation from the Board of Directors of Intuitive. The Company also announced that Mr. Richard J. Kramer, who already holds a position on Intuitive's Board, has been appointed to the role of Chairman of the Audit Committee. Following Mr. Nussbaum's resignation, the Intuitive Board will be comprised of six members. The Board presently includes five independent outside Directors.
596
12/31/20036.22xNMNMNMNM$528$5.3211146.05%Dec-12-2003Private PlacementNeoGuide Systems Inc. announced that it has received $14 million in funding from a group of investors.3i Group plc (LSE:III), Pelion Venture Partners, The Angels' Forum LLC, Versant Venture Management, LLC, Arboretum Ventures LLC, DC Capital Partners, LLCNeoGuide Systems Inc. announced it will raise gross proceeds of $13,876,250.21 in a round of funding on November 28, 2003. The company will issue preferred stock pursuant to Regulation D of the Securities Act.

As of the same day, NeoGuide Systems Inc. has raised $ 499,999.82 from 6 investors. The company incurred $87,500 in legal fees for the tranche.


On December 12, 2003, NeoGuide Systems Inc. closed the transaction. The company raised $14,000,000 in the Series B round of funding. New investor Utah Ventures led the transaction. Existing investors Versant Ventures and The Angels' Forum along with new investors 3i Group, DC Capital Partners, LLC, and Arboretum Ventures also participated in the transaction. As part of the transaction, Allan Wolfe of Utah Ventures and Nelson Stacks of 3i Group will join NeoGuide Systems Inc.’s board of directors.
597
12/31/20036.22xNMNMNMNM$528$5.3211146.05%Dec-12-2003Executive/Board Change - OtherIntuitive Surgical Announces Changes To Its Board Of Directors-Intuitive Surgical Inc. announced that Directors Frederic H. Moll, M.D., and Russell C. Hirsch, M.D., Ph.D., have tendered their resignations from the Board of Directors of Intuitive in order to pursue other interests and meet other obligations. Following these resignations the Intuitive Board will be comprised of seven members including Robert Duggan and Eric Halvorson, who joined the board in July when the company merged with Computer Motion. The Board presently includes six independent outside Directors.
598
12/31/20036.22xNMNMNMNM$505$5.0911654.22%Nov-28-2003Private PlacementNeoGuide Systems Inc. announced that it expects to receive $13.88 million in funding.Pelion Venture Partners, The Angels' Forum LLC, Versant Venture Management, LLC, Arboretum Ventures LLC, DC Capital Partners, LLC, 3i Group plc (LSE:III)NeoGuide Systems Inc. announced it will raise gross proceeds of $13,876,250.21 in a round of funding on November 28, 2003. The company will issue preferred stock pursuant to Regulation D of the Securities Act.

As of the same day, NeoGuide Systems Inc. has raised $ 499,999.82 from 6 investors. The company incurred $87,500 in legal fees for the tranche.
599
12/31/20036.22xNMNMNMNM$502$5.0611723.91%Nov-04-2003Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $11.48 million.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $11.48 million.
600
12/31/20036.22xNMNMNMNM$479$4.8312286.96%Oct-31-2003Follow-on Equity OfferingIntuitive Surgical, Inc. has completed a Follow-on Equity Offering in the amount of $72.5 million.-Intuitive Surgical, Inc. has completed a Follow-on Equity Offering in the amount of $72.5 million.

Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 5,000,000
Price\Range: $14.5
Discount Per Security: $0.87
601
12/31/20036.22xNMNMNMNM$539$5.4310918.23%Oct-27-2003Announcement of EarningsIntuitive Surgical Announces Record $23.4 Million Third Quarter 2003 Revenue up 37%-Intuitive Surgical Inc. reported third quarter 2003 sales of $23.4 million, increasing 37% from $17.1 million for the third quarter of 2002. Third quarter 2003 recurring revenue totaled $7.7 million, up 98% over the prior year and up $1.4 million, or 21%, sequentially from the second quarter of 2003. Recurring revenue increased to 33% of total sales from 23% during the third quarter last year. Net loss for the third quarter 2003 was $3.4 million, or $0.12 per share, compared to $6.5 million, or $0.35 per share, last year.

For the nine months ended September 30, 2003 Total Sales $64,081,000 and Net Loss $4,768,000 and Net Loss per share Basic and Diluted $0.22 compared to Total Sales $50,877,000 and Net Loss $15,821,000 and Net Income per share Basic and Diluted $0.87 for the same period previous year.
602
9/30/20035.13xNMNMNMNM$434$5.3311124.95%Sep-17-2003Shelf Registration FilingThe SEC has declared the Shelf Registration registration filed by Intuitive Surgical Inc. in the amount of $100 mm effective as of Sep-17-2003-The SEC has declared the Shelf Registration registration filed by Intuitive Surgical Inc. in the amount of $100 mm effective as of Sep-17-2003
603
9/30/20035.13xNMNMNMNM$412$5.0511747.33%Sep-11-2003Shelf Registration FilingIntuitive Surgical Inc. has filed a Shelf Registration in the amount of $100 mm-Intuitive Surgical Inc. has filed a Shelf Registration in the amount of $100 mm
604
9/30/20035.13xNMNMNMNM$394$4.8312286.96%Aug-07-2003Announcement of EarningsIntuitive Surgical Announces Profitable Second Quarter 2003 sales record-Intuitive Surgical Inc. reported its first profitable quarter with second quarter 2003 net income of $0.9 million, or $0.05 per share, compared to a net loss of $3.7 million, or $0.21 per share, during the second quarter of 2002. Second quarter 2003 profitability was driven by record sales, a significant improvement in gross margin, and reduced operating expenses. Second quarter 2003 total sales of $21.5 million Increased 11% from $19.4 million in total sales in the second quarter of 2002, driven primarily by continued recurring revenue growth. Second quarter 2003 recurring revenue totaled $6.4 million, up $2.6 million over the prior year period and up $1.0 million sequentially from the first quarter of 2003.
605
9/30/20035.13xNMNMNMNM$397$4.8712185.22%Jul-01-2003Stock Splits & Significant Stock DividendIntuitive Surgical Inc., 1 : 2, Stock Split or Significant Stock Dividend, Jul-01-2003-Intuitive Surgical Inc., 1 : 2, Stock Split or Significant Stock Dividend, Jul-01-2003
606
6/30/20033.12xNMNMNMNM$404$5.0611723.91%Jun-30-2003M&A Transaction ClosingIntuitive Surgical, Inc. (NASDAQ: ISRG) completed the acquisition of Computer Motion, Inc. for $44.33 million.SDS Capital Partners, LLC, Midsummer Capital, LLC, Downsview Capital, Inc., Carpe Diem Capital Management LLC, John Lang, Inc., St. Cloud Capital, LLC, Catalpa Enterprises, Ltd., Gryphon Management Partners, L.P., Iroquois Capital Management L.L.C., Crestview Capital Funds, Pequot Capital Management Inc., SF Capital Partners LLC, Investment Arm, Clarion Capital Corporation, Cowen Capital Partners, LLC, Redpoint Ventures, Computer Motion, Inc., BayStar Capital, Castle Creek Partners, LP, Redwood Partners, LLC, Sargon Capital, LLC, Cleveland Overseas Ltd.Intuitive Surgical, Inc. (NASDAQ: ISRG) signed a definitive agreement to acquire Computer Motion, Inc. from a group of sellers on March 7, 2003. Under the terms of the definitive merger agreement, Computer Motion's equity holders would receive 32 percent of the combined company on a fully diluted basis (including out-of-the-money options and warrants), and Intuitive's equity holders would receive 68 percent. The merger agreement exchange ratio formula anticipates that each outstanding share of Computer Motion common stock would be converted into approximately $0.52 shares of Intuitive common stock. In the event that Computer Motion's common stock trades at an average of less than $1.86 per share before the merger, the exchange ratio will be reduced, but shall in no event be less than approximately $0.48. The agreement also provides for a termination fee of $2.5 million and will be paid by the defaulting party.

The sellers included CD Investment Partners, Ltd., Carpe Diem Capital Management LLC, Carpe Diem Capital Management LLC, Castle Creek Partners, LP, Cleveland Overseas Ltd., Cranshire Capital L.P., Gryphon Master Fund LP, Redwood Partners, LLC, Pequot Capital Management Inc., SF Capital Partners, Redpoint Ventures, BayStar Capital and Clarion Capital Corporation.

Intuitive had agreed to provide a bridge loan to Computer Motion to provide working capital for its operations through the closure period if necessary. The merged company will be traded on NASDAQ under same ticker symbol. Mr. Lonnie Smith, President and CEO of Intuitive Surgical will serve as President and CEO of the merged entity and Mr. Duggan, CEO and Chairman of Computer Motion, will serve as member of the Board of Directors. Mr. Darrin Uecker, Chief Operating Officer of Computer Motion, will join the new executive team as Vice President and Chief Technical Officer and will report to Dr. Gary Guthart, Senior Vice President of Operations. The company will be headquartered in Sunnyvale, California, with operations in both Sunnyvale and Goleta, California.

The transaction is subject to regulatory approval, approval by shareholders of Computer Motion, registration statement effectiveness, listing of new shares on stock exchange and execution of non solicitation agreement. The transaction has been approved by Board of Directors of Computer Motion and Intuitive. The transaction is expected to close on June 30, 2003.

Ernst & Young LLP acted as accountant to Computer Motion and Intuitive Surgical. Bear, Stearns & Co. Inc. acted as financial advisor to Intuitive Surgical. David E. Lafitte of Stradling Yocca Carlson & Rauth acted as legal advisor to Computer Motion. Cadwalader, Wickersham & Taft LLP acted as legal advisor to Bear Stearns. Holly M. Bauer, William C Davisson, III, Robert Goldman, Robert Koenig, Alan C. Mendelson, Daniel Miller, Jeffrey Miller, John Newell, Robert Phillips, R. Brandon Tidwell, Daniel Wall, Allen Wang, Andrew Williamson and Joseph Yaffe of Latham & Watkins LLP acted as legal advisors to Intuitive Surgical. Jason Adelman was the lead advisor for the transaction.


Intuitive Surgical, Inc. (NASDAQ: ISRG) completed the acquisition of Computer Motion, Inc. from a group of sellers for $44.33 million on June 30, 2003. Each outstanding share of common stock of Computer Motion was converted into the right to receive 0.514269 of one share of common stock of Intuitive. The purchase consideration also includes assumption of options of Computer Motion by Intuitive, valued at $3.77 million.
607
6/30/20033.12xNMNMNMNM$467$5.8410144.69%May-30-2003Shelf Registration FilingThe SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $0.71 mm effective as of May-30-2003-The SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $0.71 mm effective as of May-30-2003
608
6/30/20033.12xNMNMNMNM$320$4.0114819.95%Apr-24-2003Announcement of EarningsIntuitive Surgical Announces $19.2 Million 2003 First Quarter Revenue, up 33%-Intuitive Surgical Inc. reported sales of $19.2 million in the first quarter of 2003, up 33% from $14.4 million in sales reported in the first quarter of 2002. First quarter 2003 recurring revenue totaled $5.4 million, up 103% over the prior year and up $0.7 million.
609
6/30/20033.12xNMNMNMNM$320$4.0114819.95%Apr-24-2003Announcement of EarningsComputer Motion Announces Record 2003 First Quarter Revenue-Computer Motion Inc. announced record revenue results for the first quarter ended March 31, 2003. Revenues for the quarter totaled $7,011,000 as compared to $5,691,000 recorded in the first quarter ended March 31, 2002, up 23%. Net loss per share for the first quarter of 2003 totaled $0.52 as compared to $0.65 for the first quarter of 2002.
610
3/31/20032.62xNMNMNMNM$194$3.4817092.24%Mar-19-2003Client AnnouncementIntuitive Surgical Announces Agreement with Medtronic Inc-Intuitive Surgical Inc. announces an agreement with Medtronic Cardiac Surgery. The agreement involves initiatives on several fronts Including training, marketing and product development for cardiac stabilization devices used during beating heart surgery. As part of this agreement, Intuitive Surgical will transfer ownership of it's EndoStabilizer System to Medtronic.
611
3/31/20032.62xNMNMNMNM$179$3.2118538.32%Mar-12-2003Shelf Registration FilingComputer Motion, Inc. has filed a Shelf Registration in the amount of $0.71 mm-Computer Motion, Inc. has filed a Shelf Registration in the amount of $0.71 mm
612
3/31/20032.62xNMNMNMNM$179$3.2118538.32%Mar-12-2003Announcement of EarningsComputer Motion Posts Big Revenues for the Fourth Quarter 2002-Computer Motion announced record revenues for the fourth quarter of last year. The Company announced revenue for the three months ending Dec. 31 was $8,822,000, just ahead of the $8,654,000 recorded in the same period a year earlier. The full year revenues for 2002 came in at just over $24 million compared with $25.5 million in 2001.
613
3/31/20032.62xNMNMNMNM$178$3.2018596.56%Mar-10-2003Announcement of EarningsComputer Motion Announces Record Fourth Quarter and 2002 Year End Results-Computer Motion Inc. announced record revenue results for the fourth quarter ending December 31, 2002. Revenues for the fourth quarter 2002 totaled $8,822,000 as compared to $8,654,000 recorded in the fourth quarter ended December 31, 2001. Net loss per share for the fourth quarter of 2002 totaled $0.70 as compared to $0.43 for the fourth quarter of 2001.

Revenues for the year totaled $24,111,000 as compared to $25,531,000 recorded in 2001.Net loss per share for the year totaled $1.93 as compared to $1.98 for the year 2001.
614
3/31/20032.62xNMNMNMNM$155$2.7921344.09%Mar-07-2003M&A Transaction AnnouncementIntuitive Surgical, Inc. (NASDAQ: ISRG) signed a definitive agreement to acquire Computer Motion, Inc.Clarion Capital Corporation, Cowen Capital Partners, LLC, Redpoint Ventures, Carpe Diem Capital Management LLC, John Lang, Inc., St. Cloud Capital, LLC, Redwood Partners, LLC, Sargon Capital, LLC, Cleveland Overseas Ltd., Crestview Capital Funds, Pequot Capital Management Inc., SF Capital Partners LLC, Investment Arm, SDS Capital Partners, LLC, Midsummer Capital, LLC, Downsview Capital, Inc., Computer Motion, Inc., BayStar Capital, Castle Creek Partners, LP, Catalpa Enterprises, Ltd., Gryphon Management Partners, L.P., Iroquois Capital Management L.L.C.Intuitive Surgical, Inc. (NASDAQ: ISRG) signed a definitive agreement to acquire Computer Motion, Inc. from a group of sellers on March 7, 2003. Under the terms of the definitive merger agreement, Computer Motion's equity holders would receive 32 percent of the combined company on a fully diluted basis (including out-of-the-money options and warrants), and Intuitive's equity holders would receive 68 percent. The merger agreement exchange ratio formula anticipates that each outstanding share of Computer Motion common stock would be converted into approximately $0.52 shares of Intuitive common stock. In the event that Computer Motion's common stock trades at an average of less than $1.86 per share before the merger, the exchange ratio will be reduced, but shall in no event be less than approximately $0.48. The agreement also provides for a termination fee of $2.5 million and will be paid by the defaulting party.

The sellers included CD Investment Partners, Ltd., Carpe Diem Capital Management LLC, Carpe Diem Capital Management LLC, Castle Creek Partners, LP, Cleveland Overseas Ltd., Cranshire Capital L.P., Gryphon Master Fund LP, Redwood Partners, LLC, Pequot Capital Management Inc., SF Capital Partners, Redpoint Ventures, BayStar Capital and Clarion Capital Corporation.

Intuitive had agreed to provide a bridge loan to Computer Motion to provide working capital for its operations through the closure period if necessary. The merged company will be traded on NASDAQ under same ticker symbol. Mr. Lonnie Smith, President and CEO of Intuitive Surgical will serve as President and CEO of the merged entity and Mr. Duggan, CEO and Chairman of Computer Motion, will serve as member of the Board of Directors. Mr. Darrin Uecker, Chief Operating Officer of Computer Motion, will join the new executive team as Vice President and Chief Technical Officer and will report to Dr. Gary Guthart, Senior Vice President of Operations. The company will be headquartered in Sunnyvale, California, with operations in both Sunnyvale and Goleta, California.

The transaction is subject to regulatory approval, approval by shareholders of Computer Motion, registration statement effectiveness, listing of new shares on stock exchange and execution of non solicitation agreement. The transaction has been approved by Board of Directors of Computer Motion and Intuitive. The transaction is expected to close on June 30, 2003.

Ernst & Young LLP acted as accountant to Computer Motion and Intuitive Surgical. Bear, Stearns & Co. Inc. acted as financial advisor to Intuitive Surgical. David E. Lafitte of Stradling Yocca Carlson & Rauth acted as legal advisor to Computer Motion. Cadwalader, Wickersham & Taft LLP acted as legal advisor to Bear Stearns. Holly M. Bauer, William C Davisson, III, Robert Goldman, Robert Koenig, Alan C. Mendelson, Daniel Miller, Jeffrey Miller, John Newell, Robert Phillips, R. Brandon Tidwell, Daniel Wall, Allen Wang, Andrew Williamson and Joseph Yaffe of Latham & Watkins LLP acted as legal advisors to Intuitive Surgical. Jason Adelman was the lead advisor for the transaction.
615
3/31/20032.62xNMNMNMNM$198$3.5616705.90%Feb-11-2003Lawsuits & Legal IssueCourt Holds That Intuitive Surgical's da Vinci System Infringes Computer Motion Patent, Computer Motion Discusses Impact of Ruling-Computer Motion Inc., the world's leading developer of surgical robotic systems serving over 900 customers and 3,000 surgeons in 32 countries, announced that the District Court for the Central District of California has ruled that Intuitive Surgical's da Vinci Surgical System literally infringes Computer Motion's 6,244,809 patent. Both Computer Motion and Intuitive filed motions for summary judgment and after hearing oral arguments, the Court has denied Intuitive's motion while finding in favor of Computer Motion. Since the Court has concluded that Intuitive Surgical literally infringes Computer Motion's 809 patent, the burden now falls on Intuitive to show by clear and convincing evidence that the U.S. Patent Office was wrong in granting the patent and that the patent is somehow invalid or unenforceable.
616
3/31/20032.62xNMNMNMNM$198$3.5616705.90%Feb-11-2003Lawsuits & Legal IssueIntuitive Surgical Announces Two Summary Judgment Rulings in California Patent Litigation-Intuitive Surgical Inc. announced that the Central California Court recently issued two rulings in the patent litigation between Intuitive and Computer Motion pending in Los Angeles. First, the Court recently issued an opinion granting partial summary judgment of literal infringement of one claim of Computer Motion's 6,244,809 patent against Intuitive. Intuitive has two further motions for summary judgment of noninfringement pending, addressing two others of Computer Motion's patents.
617
3/31/20032.62xNMNMNMNM$218$3.9215162.50%Feb-07-2003Announcement of EarningsIntuitive Surgical Announces $21.1 Million Final Fourth Quarter Revenue for the year 2002-Intuitive Surgical Inc. reported sales of $21.1 million in the fourth quarter of 2002, up 32% from $16.0 million in sales reported in the fourth quarter of 2001. Full year 2002 sales totaled $72.0 million, up 39% from $51.7 million in 2001. Net loss for the fourth quarter 2002 was $2.6 million, or ( $0.07) per share compared to $4.3 million, or ( $0.12) per share during the fourth quarter 2001. Full year 2002 net loss was $18.4 million, or ( $0.51) per share compared to $16.7 million, or ( $0.47) per share in fiscal 2001.
618
3/31/20032.62xNMNMNMNM$227$4.0714600.00%Jan-29-2003Corporate Guidance - New/ConfirmedComputer Motion Announces Fourth Quarter For The 2003 Fiscal Year Revenue Guidance-Computer Motion Inc. announced that the projected annual revenue target of $40 million to $50 million, and a profitable fourth quarter for the 2003 fiscal year. Reported that gross margins for the fourth quarter are estimated to be a record 65% and that net loss from operations is estimated to be approximately $2.5 million Including $600,000 in estimated intellectual property litigation expenses.
619
3/31/20032.62xNMNMNMNM$243$4.3713590.85%Jan-22-2003Announcements of Sales/Trading StatementComputer Motion's Fourth Quarter 2002 Revenue Up 95% Sequentially-Computer Motion Inc. announced record revenue results for the fourth quarter ended December 31, 2002. The company recorded approximately $8,800,000 in revenue, exceeding previous written guidance and up 95%, when compared to the third quarter of 2002, and 2% year over year.
620
3/31/20032.62xNMNMNMNM$240$4.3113781.44%Jan-16-2003Lawsuits & Legal IssueComputer Motion Retains Top Litigator in Ongoing Intellectual Property Litigation-Computer Motion Inc. the world's leading developer of surgical systems serving over 900 customers and 3000 surgeons in 32 countries, announced that it has retained Mr. John Desmarais, Esq. of Kirkland & Ellis' New York office as its lead counsel in both the Delaware and California intellectual property court cases.

Mr. Desmarais was recently selected by The American Lawyer for the 45 Under Forty-Five: The Rising Stars of the Private Bar. He was selected as one of the 7 best IP trial lawyers in the IP Worldwide article, The Magnificent Seven, IP's Best Young Trial Lawyers. He was also recognized as one of the most successful young litigators in America in The National Law Journal's, 40 Under 40, A look at some of the most successful young litigators in America. Kenneth Stein, Director of Intellectual Property for Computer Motion stated, John is an exceptional attorney and his track record speaks for itself.
621
3/31/20032.62xNMNMNMNM$215$3.8615399.74%Jan-15-2003Corporate Guidance - New/ConfirmedIntuitive Surgical Announces $20 Million Preliminary Fourth Quarter Revenue For Fiscal Year 2002-Intuitive Surgical Inc. announced that it anticipates fourth quarter 2002 revenue to total approximately $20 million, up 25% from fourth quarter 2001 revenue of $16 million. Recurring revenue is expected to total $4.7 million, up 104% over the prior year and up $0.8 million sequentially from the third quarter of 2002. The company expects fiscal year 2002 revenue to total approximately $71 million, up 37% over 2001 results.
622
12/31/20022.69xNMNMNMNM$241$4.3713590.85%Dec-23-2002Shelf Registration FilingThe SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $16.93 mm effective as of Dec-23-2002-The SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $16.93 mm effective as of Dec-23-2002
623
12/31/20022.69xNMNMNMNM$239$4.3413685.48%Dec-13-2002Shelf Registration FilingComputer Motion, Inc. has filed a Shelf Registration in the amount of $16.93 mm-Computer Motion, Inc. has filed a Shelf Registration in the amount of $16.93 mm
624
12/31/20022.69xNMNMNMNM$253$4.5912934.64%Dec-11-2002Lawsuits & Legal IssueIntuitive Surgical Wins 'Prosecution Laches' Phase of Delaware Patent Litigation Against Computer MotionComputer Motion, Inc.Intuitive Surgical Inc. the industry leader in operative surgical robotics, announced that the Delaware District Court overseeing Intuitive's and IBM's joint patent litigation against Computer Motion issued an order wherein the Court concluded the defense of prosecution laches does not apply to the circumstances of IBM's voice-controlled surgical robot patent and does not render that patent unenforceable.
With the Court's ruling that prosecution laches does not apply, the earlier jury verdict finding Computer Motion liable for patent infringement and awarding Intuitive $4.4 million for the damage caused by Computer Motion's infringing AESOP and ZEUS products remains intact.
625
12/31/20022.69xNMNMNMNM$253$4.5912934.64%Dec-11-2002Lawsuits & Legal IssueComputer Motion Updates Status of Patent Litigation-Computer Motion Inc. announced that the U.S. District Court in Delaware has entered an opinion finding against Computer Motion's prosecution laches defense. The judge has entered a final judgment in this case and the $4.4 million jury verdict is subject to judicial review. Computer Motion is exploring all options, including requesting a new trial and reduction of the jury's damage award.
626
12/31/20022.69xNMNMNMNM$242$4.4013497.50%Nov-13-2002Executive/Board Change - OtherComputer Motion Names Mauro Mastropasqua as Vice President of Sales, Europe-Computer Motion Inc. announced that Mauro Mastropasqua has joined Computer Motion as Vice President of Sales, Europe. Mr. Mastropasqua is now responsible for European sales activities and reports to Mr. John Soto, General manager and Vice President, Operations Europe, Middle East, and Africa. Mr. Mastropasqua has considerable experience in the healthcare industry.
627
12/31/20022.69xNMNMNMNM$246$4.4713284.56%Oct-31-2002Private PlacementComputer Motion, Inc. announced that it has received $12.32 million in funding from a group of investors.Clarion Capital Corporation, Crestview Capital Funds, Bedford Oak Advisors, LLC, North Sound Capital LLC, SDS Capital Partners, LLC, Midsummer Capital, LLC, Carpe Diem Capital Management LLC, John Lang, Inc., The Larry Haimovitch 2000 Separate Property Revocable Trust, St. Cloud Capital, LLC, Sargon Capital, LLCComputer Motion, Inc. (Nasdaq: RBOT) announced a private placement of 8,797 shares of series C convertible preferred stock for gross proceeds of $12.32 million on October 31, 2002. The series C convertible preferred stock consists of 7,726 shares of series C-1 convertible preferred stock and 1,071 shares of series C-2 convertible preferred stock at $1,400 per share. The company also issued 3,518,690 five year warrants to purchase shares of common stock, 1,759,345 series C-1 warrants of which have a purchase price of $1.80 per share and 1,759,345 series C-2 warrants of which have a purchase price of $2.20 per share. The dividend rate payable on each share of series C convertible preferred stock shall be at the rate of 12% per annum until January 31, 2003, decreasing to 8% per annum thereafter and increasing to the rate of 12% per annum on the second anniversary of the initial issuance date. The disclosed fees and expenses incurred by the company are $0.82 million. The net proceeds received by the company are $11.50 million.

Bedford Oak Advisors, LLC, which invested through its fund Bedford Oak Partners received 715 shares and 286,000 warrants for $1 million; Carpe Diem Capital Management LLC, which invested through its fund Carpe Diem Long Short Fund received 36 shares and 14,400 warrants for $0.05 million; Clarion Capital Corporation, which invested through its funds Clarion Partners, L.P. and Clarion Offshore Fund Ltd. received 179 shares and 71,600 warrants for $0.26 million; Crestview Capital, which invested through its fund Crestview Capital Fund II, LP received 465 shares and 186,000 warrants for $0.65 million; David Wilstein and Susan Wilstein received 36 shares and 14,400 warrants for $0.05 million; North Sound Capital LLC, which invested through its fund DMG Legacy Fund LLC, DMG Legacy Institutional Fund LLC, and DMG Legacy International, Ltd. received 1,322 shares and 528,746 warrants for $1.85 million; John Lang, Inc., which invested through its fund Islandia, L.P. received 250 shares and 100,000 warrants for $0.35 million; Larry Haimovitch 2000 Separate Property Revocable Trust received 35 shares and 14,000 warrants for $0.05 million; Liss Brothers Partnership Trust received 20 shares and 8,000 warrants for $0.03 million; Midsummer Capital received 714 shares and 285,600 warrants for $1.00 million; Omicron Mater Trust received 714 shares and 285,600 warrants for $1.00 million; Sargon Capital, which invested through its fund Sargon Capital International Fund Ltd. received 358 shares and 143,200 warrants for $0.50 million; SDS Capital Partners, LLC which invested through its fund SDS Merchant Fund, L.P. received 1,322 shares and 528,744 warrants for $1.85 million; St. Cloud Capital received 1,071 shares and 428,400 warrants for $1.50 million; and Tamkin Living Trust received 10 shares and 4,000 warrants for $0.01 million.

Individual investors Barrett, Stephen received 10 shares and 4,000 warrants for $0.01 million; Duggan, Robert received 1,428 shares and 571,200 warrants for $2.00 million; and Jurkowitz, Morris M. received 112 shares and 44,800 warrants for $0.16 million. H.C. Wainwright & Co., Inc. acted as a placement agent for Computer Motion, Inc. and received a warrant to purchase 290,306 shares of common stock at an exercise price of $0.001 per share. David E. Lafitte, Esq. of Stradling, Yocca, Carlson & Rauth served as a legal advisor for Computer Motion, Inc. Christopher S. Auguste of Jenkens & Gilchrist Parker Chapin LLP; and Kramer Levin Naftalis & Frankel LLP served as legal advisors for the investors.


On October 31, 2002, Computer Motion, Inc. closed the transaction.
628
12/31/20022.69xNMNMNMNM$246$4.4713284.56%Oct-31-2002Announcement of EarningsComputer Motion Announces 2002 Third Quarter Revenue-Computer Motion Inc. announced revenue results for the third quarter ended September 30, 2002. The company recorded $4,534,000 in revenue. Revenues recorded in the third quarter of 2001 were $7,158,000. Net loss per share for the third quarter of 2002 totaled $0.32 compared to net loss per share of $0.31 for the third quarter of 2001. Net loss for the third quarter was $5,526,000 compared to a net loss of $3,244,000 for the third quarter of 2001.
629
12/31/20022.69xNMNMNMNM$240$4.3613622.25%Oct-30-2002Client AnnouncementPatent Allows Use of Robotic Surgical Products in Canada-Computer Motion Inc. it has received a Class IV license to market its ZEUS robotic surgical products in Canada for full cardiac surgery and telesurgery applications. The company previously had a license in Canada to other surgical specialities. The system is designed to enable minimally invasive and open surgical procedures.
630
12/31/20022.69xNMNMNMNM$289$5.2511296.00%Oct-24-2002Announcement of EarningsIntuitive Surgical Announces 2002 Third Quarter Results-Intuitive Surgical Inc. reported sales of $17.1 million in the third quarter of 2002, up 57% from $10.9 million reported in the third quarter of 2001. Net loss for the third quarter of 2002 was $6.5 million, compared to a net loss of $4.8 million for the third quarter of 2001. Basic and diluted net loss per share was $0.18, compared to a net loss per share of $0.13 for the third quarter of 2001.

Sales for nine months ended 2002 is $50,877,000 when compared to $35,660,000 to the same period last year. Net loss for nine months ended 2002 is $(15,821,000) when compared to $(12,448,000) to the same period last year. Loss per share - basic and diluted for nine months ended 2002 is $(0.43) when compared to $(0.35) to the same period last year.
631
9/30/20023.92xNMNMNMNM$293$5.3311124.95%Sep-19-2002Executive/Board Change - OtherComputer Motion Names Charles J. Vivian as Executive Vice President of Sales for the Americas-Computer Motion Inc. the world's leading developer of surgical robotic systems serving over 900 customers and 3,000 surgeons in 32 countries, announced that Mr. Charles J. Vivian has joined Computer Motion as Executive Vice President of Sales for the Americas. Mr. Vivian will immediately assume responsibility for Computer Motion's sales operations in the Americas, and will report directly to Mr. Joseph DeVivo, Computer Motion's President and Chief Operating Officer.
632
9/30/20023.92xNMNMNMNM$285$5.1911427.75%Sep-12-2002Executive/Board Change - OtherComputer Motion Names John Soto as Vice President and General Manager, Operations for Europe, Middle East, and Africa-Computer Motion Inc. announced that Mr. John Soto has joined Computer Motion as Vice President and General Manager, Operations for Europe, Middle East, and Africa. Mr. Soto will manage the international sales and marketing efforts for the company, and will report directly to Mr. Joseph DeVivo, Computer Motion's President and Chief Operating Officer. Mr. Soto most recently served as the Managing Director of Europe for Surgical Dynamics, a division of TYCO International's Healthcare Business.
633
9/30/20023.92xNMNMNMNM$270$4.9212060.37%Aug-30-2002Business ExpansionUCLA and Business Partners Announce Opening of Revolutionary New Robotic and Technology Center for Clinical, Educational and Research AdvancesBERCHTOLD Corporation, KARL STORZ Endoscopy-America, Inc.In a unique academic and business partnership, UCLA, Computer Motion Inc., Karl Storz Endoscopy-America Inc. and BERCHTOLD Corp., announce the opening of a new robotic and technology center at UCLA. One of the first of its kind in the country, the new center will help promote clinical, educational and research use of surgical robots and digital imaging in surgery and medicine. The new center a minimally invasive surgery think tank is called CASIT, the Center for Advanced Surgical and Interventional Technology. The partners have created an environment for industry innovators in minimally invasive surgery and advanced operating room technology and scientists to work together to fuel robotic and imaging research and development to further define the operating room of the future.
634
9/30/20023.92xNMNMNMNM$281$5.1111608.22%Aug-29-2002Lawsuits & Legal IssueComputer Motion Hopes $ 4.4 Million Verdict Is Dismissed-Computer Motion Inc. is waiting for a judge to determine whether it must pay $4.4 million in damages to its rival. Computer Motion is in a patent infringement battle with competitor Intuitive Surgical Inc. Intuitive has a patent on the robotic surgical technology, licensed from IBM. The case is playing out in U.S. District Court in Delaware. Last week, jurors reached a verdict finding IBM's patent valid and awarded $4.4 million in damages to Intuitive. Prior to the jury's decision, the court ruled that Computer Motion had not willfully infringed. Immediately following the trial, the parties tried Computer Motion's defense in front of the judge. The court is now considering the arguments made by both sides, a process that is expected to take several weeks.
635
9/30/20023.92xNMNMNMNM$275$5.0111841.92%Aug-15-2002Executive/Board Change - OtherComputer Motion Names Joseph M. DeVivo as President and Chief Operating Officer-Computer Motion Inc. announced that the Board of Directors has approved Joseph M. DeVivo as President and Chief Operating Officer. Most recently he served as Vice President and General Manager of a $350 million annual revenue division of TYCO International's Healthcare Business, U.S. Surgical/Davis and Geck Sutures.
636
9/30/20023.92xNMNMNMNM$275$5.0111841.92%Aug-15-2002Delayed SEC FilingComputer Motion, Inc. announced delayed 10-Q filing-On 08/15/2002, Computer Motion, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
637
9/30/20023.92xNMNMNMNM$256$4.6612738.84%Jul-30-2002Announcement of EarningsIntuitive Surgical Announces Second Quarter 2002 Results-Intuitive Surgical Inc. announced financial results for the second quarter of 2002. Net loss for the second quarter of 2002 was $3.7 million, compared to a net loss of $4.2 million for the second quarter of 2001. Basic and diluted net loss per share was $0.10, compared to a net loss per share of $0.12 for the second quarter of 2001. sales for the second quarter of 2002 amounted to $19,387,000 compared to $12,720,000 for the same period last year.

For Six months ended June 30, 2002, Net loss amounted to $9,357,000 or $0.26 per share on sales of $33,796,000.
638
9/30/20023.92xNMNMNMNM$270$4.9212060.37%Jul-15-2002Announcement of EarningsComputer Motion Announces Second Quarter 2002 Revenue Up And Gross Profit Up-Computer Motion Inc. announced revenue results for the second quarter ended June 30, 2002. The company recorded $5,064,000 in revenue, up 27% year over year. Revenues recorded in the second quarter of 2001 were $4,003,000. For the second quarter of 2002, gross profit was $2,847,000 or 56%. The gross profit in the second quarter of 2001 was $2,121,000 or 53%. Gross profit was up 34% year over year. Net loss per share for the second quarter of 2002 totaled $0.29 compared to net loss per share of $0.53 for the second quarter of 2001, which includes the non-cash dividend to preferred shareholders of $0.01. Net loss for the second quarter was $4,934,000 compared to a loss of $5,361,000 for the second quarter of 2001, which includes the non-cash dividend to preferred shareholders of $61,000.

Revenues for the six months ended June 30, 2002 were $10.8 million. Net loss for the six months ended June 30, 2002 was $9.4 million or $0.97 basic and diluted loss per share.
639
9/30/20023.92xNMNMNMNM$281$5.1111608.22%Jul-08-2002Executive/Board Change - OtherComputer Motion Names New Member To Board Of Directors-Computer Motion Inc. announced that Eric H. Halvorson has joined Computer Motion's Board of Directors. Mr. Halvorson is currently a Visiting Professor of Business Law and Accounting at Pepperdine University, Malibu, California where he instructs classes in the Legal and Regulatory Environment of Business and Financial Accounting.
640
6/30/20024.71xNMNMNMNM$324$5.939989.21%Jun-07-2002Auditor ChangeComputer Motion Inc. determined not torenew the engagement of its independent accountants-Computer Motion Inc. determined not torenew the engagement of its independent accountants, Arthur Andersen LLP(Andersen) and appointed Ernst Young LLP (Ernst Young) as its new independent accountants, effective as of June 7, 2002. This determination followedthe Company's decision to seek proposals from independent accountants to auditthe Company financial statements for the fiscal year ending December 31,2002. The decision not to renew the engagement of Andersen and to retain Ernst Young was approved by the Company's Board of Directors upon therecommendation of its Audit Committee.
641
6/30/20024.71xNMNMNMNM$350$6.409248.28%May-06-2002Client AnnouncementMontefiore Institute For Minimally Invasive Surgery Launches Surgical Robotic Program With Computer Motion-Computer Motion Inc. announced the company is working with Montefiore Medical Center in Bronx, NY to provide significant technical and educational support for the establishment of a robotic center of excellence for surgical procedure development and physician training programs. The relationship includes provisions for extensive collaboration, contributing to Computer Motion's leadership position in robotic and computer-assisted medicine through cooperative product and procedure development. The company and the Institute intend to collaborate closely on educational grant submissions, joint participation in product and procedure development, and creating the robotic residency program for Montefiore Medical Center.
642
6/30/20024.71xNMNMNMNM$382$6.998459.23%Apr-25-2002Announcement of EarningsIntuitive Surgical Announces $14.4 Million First Quarter 2002 Revenue-Intuitive Surgical Inc. reported sales of $14.4 million in the first quarter of 2002, up 19% from $12.1 million reported in the first quarter of 2001. Sales growth was driven by increased recurring revenue and higher da Vinci(TM) Surgical System placements. First quarter 2002 recurring revenue, consisting of instruments, accessories, and service was $2.7 million, up 120% from $1.2 million for the same period last year. Total first quarter 2002 systems sales were $11.7 million, instruments and accessories $1.7 million, and service revenue $1.0 million.
643
6/30/20024.71xNMNMNMNM$359$6.579006.39%Apr-15-2002Announcement of EarningsComputer Motion Announces financial results for First quarter ended March 31, 2002-Computer Motion Inc. announced revenue results for the first quarter ended March 31, 2002. The company recor ded $6.9million in bookings and $5.7 million in revenue. Bookings were up 47% year over year and reported revenue was essentially flat. The first quarter of 2002 saw a 20% year over year rise in business in North America. Results in the U.S. were in-line with expectations. Net loss for the quarter totaled $9,436,000 ( $0.65 baisc and diluted per share) compared to $6,833,000 ($0.65 baisc and diluted per share) for the same period in 2001.
644
6/30/20024.71xNMNMNMNM$343$6.279442.11%Apr-04-2002Shelf Registration FilingThe SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $19.77 mm effective as of Apr-04-2002-The SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $19.77 mm effective as of Apr-04-2002
645
3/31/20025.95xNMNMNMNM$334$6.119691.98%Mar-04-2002Product-Related AnnouncementChildren's Hospital of Michigan Launches Nation's First Pediatric Computer-Assisted Robot-Enhanced Surgery ProgramVHS Children's Hospital of Michigan, Inc.Working in partnership with Computer Motion Inc. of Santa Barbara, California and the College of Engineering at Wayne State University, Childrens Hospital of Michigan doctors and researchers have helped to develop the first application for surgical robots uniquely designed for minimally invasive operations on pediatric patients. Children's is the first children's hospital in the country to operate on a child using the Zeus(R) Robotic Surgical System.
646
3/31/20025.95xNMNMNMNM$335$6.139660.03%Feb-28-2002Shelf Registration FilingComputer Motion, Inc. has filed a Shelf Registration in the amount of $19.77 mm-Computer Motion, Inc. has filed a Shelf Registration in the amount of $19.77 mm
647
3/31/20025.95xNMNMNMNM$335$6.139660.03%Feb-28-2002Client AnnouncementComputer Motion and Karl Storz Form Strategic Alliance-Computer Motion Inc. announced the signing of a strategic alliance agreement with Karl Storz Endoscopy, The companies intend to collaborate in the development of products that enhance the compatibility between Karl Storz Communication Bus (SCB) and HERMES-Ready(TM) devices in an OR1(TM) integrated operating room. The agreement specifies terms for Karl Storz to license speech and voice recognition technology from Computer Motion, and for the products developed as a result of the agreement to be co-marketed.
648
3/31/20025.95xNMNMNMNM$334$6.119691.98%Feb-25-2002Announcement of EarningsComputer Motion Announces 11th Consecutive Year of Revenue Growth For 2001-Computer Motion Inc., the world's leading developer of surgical robotic systems, announced record revenue results for the fourth quarter and fiscal year 2001 ending December 31. Revenues for the quarter totaled $8,654,000 as compared to $8,191,000 recorded in the fourth quarter ended December 31, 2000. Revenues for the year totaled $25,531,000 as compared to $21,732,000 recorded in 2000. Net loss per share for the fourth quarter of 2001 totaled $0.43 as compared to $0.41 for the fourth quarter of 2000. Net loss per share for the year totaled $1.98 as compared to $1.90 for the year 2000. Net loss for the year 2001 was $16,413,000 versus a loss of $16,349,000 recorded in the prior year 2000.
649
3/31/20025.95xNMNMNMNM$359$6.579006.39%Feb-13-2002Private PlacementComputer Motion, Inc. announced that it has received $11.60 million in funding from a group of investors.Clarion Capital Corporation, Redpoint Ventures, Castle Creek Partners, LP, Gryphon Management Partners, L.P., Vertical Ventures, LLC, Cleveland Overseas Ltd., Bedford Oak Partners L.P., Pequot Capital Management Inc., SF Capital Partners LLC, Investment Arm, SDS Capital Partners, LLC, Downsview Capital, Inc., Carpe Diem Capital Management LLC, Redwood Partners, LLCComputer Motion, Inc. announced a private placement of common stock with certain institutional and accredited investors, including members of management, raising gross proceeds of $11,598,347 on February 13, 2002. The company issued 2,828,865 common shares at a price of $4.10. The company also issued five-year warrants to purchase 1,414,435 share of common stock at $5.00 per share. H.C. Wainwright & Co., Inc. acted as the placement agent and received warrants to purchase an aggregate 282,886 shares of common stock at an exercise price of $4.60 per share.

Bedford Oak Partners, L.P., Castle Creek Healthcare Partners LLc, CC Life Sciences, Ltd., CD Capital Management, LLC, Clarion Capital Corporation, Clarion Offshore Fund Ltd., Clarion Partners, L.P., Cleveland Overseas, Ltd., Cranshire Capital, L.P, Gryphon Master Fund, L.P., Larry Haimovitch 2000 Separate Property Revocable Trust, MRT, L.P., Pequot Navigator Offshore Fund Inc., Pequot Scout Fund, L.P., Quantico Partners L.P., Radyr Investments Limited, Redpoint Partners L.P., Redwood Partners LLC, SDS Merchant Fund L.P., SF Capital Partners, Ltd., Tamkin Living Trust, Triton West Group, Inc., and Vertical Ventures, LLC participated in the transaction.

Individual investors Barrett Stephen, Robert W. Duggan, the company’s Chief Executive Officer and Chairman, Qian Xue Li, and Ruan Pei Jin also participated in the funding.

The company received $10,527,000 as net proceeds after paying fees and expenses. Kramer Levin Naftalis & Frankel LLP acted as legal advisor to the investors.


On February 13, 2002, Computer Motion, Inc. closed the transaction.
650
3/31/20025.95xNMNMNMNM$313$5.7310341.36%Feb-11-2002Executive/Board Change - OtherComputer Motion Announces the Hiring of Eugene W. Teal as Executive Vice President, Finance & Administration-Computer Motion Inc. announced the hiring of Eugene W. Teal as Executive Vice President, Finance & Administration. He joins Computer Motion from a position as Business Consulting Director at Oracle Corporation.
651
3/31/20025.95xNMNMNMNM$313$5.7310341.36%Feb-11-2002Announcements of Sales/Trading StatementComputer Motion Announces Record Annual Revenue in Excess of $25.5 Million for 2001-Computer Motion Inc., the world's leading developer of surgical robotic systems, announced record annual revenue in excess of $25,500,000.
652
3/31/20025.95xNMNMNMNM$349$6.399262.91%Feb-07-2002Announcement of EarningsIntuitive Surgical Announces Fourth Quarter Results For The Year 2001-Intuitive Surgical Inc., the leader in operative surgical robotics, reported sales of $16.0 million in the fourth quarter of 2001, up 50% from $10.7 million in sales reported in the fourth quarter of 2000. Fourth quarter 2001 sales increased $5.1 million, or 47%, compared to third quarter 2001. Intuitive reported full fiscal year 2001 sales of $51.7 million, up 94% over $26.6 million for fiscal year 2000. Including the impact of the non-routine royalty charges, fourth quarter 2001 net loss was $4.3 million and fourth quarter 2000 was $5.0 million. Fourth quarter 2001 basic and diluted net loss per share was $0.09, or $0.12 compared to a net loss per share of $0.11, or $0.14, including non-routine royalty for the fourth quarter of 2000 and $0.13 for the third quarter of 2001. Net Loss for the fiscal year ending December 31, 2001 was $16.7 million compared to a net loss of $18.5 million for fiscal year 2000.
653
3/31/20025.95xNMNMNMNM$321$5.8710092.33%Jan-28-2002Client AnnouncementLeading Worldwide Medical Device Company Forms Strategic Alliance With Computer Motion-Computer Motion Inc. announced the signing of a strategic alliance agreement with Smith & Nephew Inc., Endoscopy Division, a subsidiary of Smith & Nephew plc Under terms of the agreement, Smith & Nephew Endoscopy will sell and service customers with a full line of HERMES products. Also as part of the agreement, Smith & Nephew Endoscopy products will be offered for sale as HERMES Ready on a worldwide basis in the coming year. Smith & Nephew Endoscopy intends to offer a fully integrated digitally controlled intelligent operating suite to their customers across multiple surgical disciplines.
654
3/31/20025.95xNMNMNMNM$321$5.8710092.33%Jan-28-2002Announcements of Sales/Trading StatementComputer Motion Announces Record Preliminary Fourth Quarter Revenue in Fiscal Year 2001-Computer Motion Inc. announced preliminary revenue results for the fourth quarter of fiscal year 2001 ending December 31. Preliminary revenue for the fourth quarter was in excess of $8,600,000, which is above the company's stated projection of $8,200,000. Computer Motion's previous revenue record was $8,200,000 recorded in the fourth quarter of 2000. The previous record for bookings was $9,250,000, also achieved in the fourth quarter of 2000.
655
9/30/20013.51xNMNMNMNM$195$3.6016519.17%Sep-24-2001Shelf Registration FilingThe SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $14.6 mm effective as of Sep-24-2001-The SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $14.6 mm effective as of Sep-24-2001
656
9/30/20013.51xNMNMNMNM$195$3.6016519.17%Sep-24-2001Shelf Registration FilingThe SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $12.63 mm effective as of Sep-24-2001-The SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $12.63 mm effective as of Sep-24-2001
657
9/30/20013.51xNMNMNMNM$330$6.079756.51%Aug-31-2001Private PlacementNeoGuide Systems Inc. announced that it has received $3.5 million in funding from Versant Ventures and other investors.Versant Venture Management, LLCNeoGuide Systems Inc. announced that it has received $3.5 million in Series A round of funding in August 2001. New investor Versant Ventures led the transaction along with participation from other investors.


In August 2001, NeoGuide Systems Inc. closed the transaction.
658
9/30/20013.51xNMNMNMNM$400$7.368028.94%Jul-26-2001Shelf Registration FilingComputer Motion, Inc. has filed a Shelf Registration in the amount of $14.6 mm-Computer Motion, Inc. has filed a Shelf Registration in the amount of $14.6 mm
659
9/30/20013.51xNMNMNMNM$400$7.368028.94%Jul-26-2001Shelf Registration FilingThe SEC has declared the Shelf Registration registration filed by Intuitive Surgical Inc. in the amount of $2.61 mm effective as of Jul-26-2001-The SEC has declared the Shelf Registration registration filed by Intuitive Surgical Inc. in the amount of $2.61 mm effective as of Jul-26-2001
660
9/30/20013.51xNMNMNMNM$487$8.976569.90%Jul-16-2001Shelf Registration FilingIntuitive Surgical Inc. has filed a Shelf Registration in the amount of $2.61 mm-Intuitive Surgical Inc. has filed a Shelf Registration in the amount of $2.61 mm
661
6/30/200111.47xNMNMNMNM$0Apr-13-2001Shelf Registration FilingComputer Motion, Inc. has filed a Shelf Registration in the amount of $12.63 mm-Computer Motion, Inc. has filed a Shelf Registration in the amount of $12.63 mm
662
6/30/200111.47xNMNMNMNM$131$2.4324520.99%Apr-10-2001Private PlacementAnnounced Private Placement Transaction - Target: Computer Motion, Inc.; Transaction Size: $12 mm-This PIPE provided equity-line structure enabling Computer Motion, Inc. to obtain up to $12 million over a two-year period through the issue of additional common stock.
663
6/30/200111.47xNMNMNMNM$153$2.8321040.99%Apr-03-2001Delayed SEC FilingComputer Motion, Inc. announced delayed annual 10-K filing-On 04/03/2001, Computer Motion, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
664
3/31/20013.32xNMNMNMNM$286$5.3311124.95%Feb-16-2001Private PlacementComputer Motion Inc. announced that it has received $10.02 million in funding from Catalpa Enterprises, BayStar Capital, SG Capital Partners LLC, and other investors.Cowen Capital Partners, LLC, BayStar Capital, Catalpa Enterprises, Ltd.Computer Motion Inc. (Nasdaq:RBOT) announced that it has received $10,024,000 in funding by issuing 10,024 Series B convertible preferred stock at the price of $1,000 per share to investors led by Cowen Capital Partners LLC, formerly known as SG Capital Partners LLC on February 16, 2001. The company also issued warrants for the purchase of up to 577,931 shares of the company's common stock at an exercise price of $8.12 per share. The preferred stock bears a cumulative dividend of 4.9% per annum and can be converted into common stock, for a purchase price of $5.77 per share.

Catalpa Enterprises purchased 3,000 preferred shares and 166,051 warrants for $3,000,000, Baystar Capital I, L.P, managed by Baystar Capital, purchased 700 preferred shares and 38,745 warrants for $700,000, BayStar International, Ltd. purchased 300 preferred shares and 16,605 warrants for $300,000, and SG Merchant Banking Fund, L.P, managed by SG Capital Partners LLC purchased 4,000 preferred shares and 221,402 warrants for $4,000,000. Robert W. Duggan, Chairman and Chief Executive Officer of Computer Motion purchased 1,500 preferred shares and 83,025 warrants for $1,500,000; and Jeffrey O. Henley, a board of director at Computer Motion purchased 500 preferred shares for $500,000 and 27,675 warrants. Mahkam Zanganeh purchased 24 preferred shares and 1,328 warrants for $24,000.

The transaction expenses were $35,658. J. Eric Maki at Jones Day, formerly known as Jones, Day, Reavis & Pogue was the legal advisor of SG Capital Partners LLC. Stradling Yocca Carlson & Rauth and Irell & Manella LLP were the legal advisors of Computer Motion, Inc.


On February 16, 2001, Computer Motion Inc. closed the transaction.
665
12/31/200011.40xNMNMNM-$303$5.6710451.85%Dec-29-2000Shelf Registration FilingThe SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $1.51 mm effective as of Dec-29-2000-The SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $1.51 mm effective as of Dec-29-2000
666
12/31/200011.40xNMNMNM-$270$5.0411770.83%Dec-13-2000End of Lock-Up Period25,638,929 Common Stock of Intuitive Surgical, Inc. are subject to a Lock-Up Agreement Ending on 10-DEC-2000.-25,638,929 Common Stock of Intuitive Surgical, Inc. are subject to a Lock-Up Agreement Ending on 10-DEC-2000. These Common Stock will be under lockup for 180 days starting from 13-JUN-2000 to 10-DEC-2000.

Details:
The executive officers, directors and substantially all of the stockholders have agreed that they will not offer, sell or otherwise dispose of 25,638,929 shares of common stock or any securities for a period of 180 days from the date of the prospectus, without the prior consent of Lehman Brothers Inc.
667
12/31/200011.40xNMNMNM-$299$5.5810622.04%Dec-11-2000Shelf Registration FilingComputer Motion, Inc. has filed a Shelf Registration in the amount of $1.51 mm-Computer Motion, Inc. has filed a Shelf Registration in the amount of $1.51 mm
668
12/31/200011.40xNMNMNM-$0Dec-10-2000End of Lock-Up PeriodCertain Options of Intuitive Surgical, Inc. are subject to a Lock-Up Agreement Ending on 10-DEC-2000.-Certain Options of Intuitive Surgical, Inc. are subject to a Lock-Up Agreement Ending on 10-DEC-2000. These Options will be under lockup for 180 days starting from 13-JUN-2000 to 10-DEC-2000.

Details:
The executive officers, directors and substantially all of the stockholders have agreed that they will not offer, sell or otherwise dispose of 25,638,929 shares of common stock or any securities for a period of 180 days from the date of the prospectus, without the prior consent of Lehman Brothers Inc.
669
9/30/2000$497$9.296340.15%Sep-05-2000Shelf Registration FilingThe SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $4.81 mm effective as of Sep-05-2000-The SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $4.81 mm effective as of Sep-05-2000
670
9/30/2000$472$8.836675.65%Aug-22-2000Shelf Registration FilingComputer Motion, Inc. has filed a Shelf Registration in the amount of $4.81 mm-Computer Motion, Inc. has filed a Shelf Registration in the amount of $4.81 mm
671
6/30/2000$319$6.089740.30%Jun-16-2000Public Offering Lead Underwriter ChangeFidelity Capital Markets has been added as a Co-Lead Underwriter for Intuitive Surgical, Inc.'s $104.00 million IPO.-Fidelity Capital Markets has been added as a Co-Lead Underwriter for Intuitive Surgical, Inc.'s $104.00 million IPO.
672
6/30/2000$315$6.029838.37%Jun-13-2000IPOIntuitive Surgical, Inc. has completed an IPO in the amount of $45 million.-Intuitive Surgical, Inc. has completed an IPO in the amount of $45 million.

Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 5,000,000
Price\Range: $9
Discount Per Security: $0.63

Transaction Features: Reserved Share Offering; Sponsor Backed Offering
673
6/30/2000$0May-31-2000Shelf Registration FilingThe SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $10 mm effective as of May-31-2000-The SEC has declared the Shelf Registration registration filed by Computer Motion, Inc. in the amount of $10 mm effective as of May-31-2000
674
6/30/2000$0May-19-2000Shelf Registration FilingComputer Motion, Inc. has filed a Shelf Registration in the amount of $10 mm-Computer Motion, Inc. has filed a Shelf Registration in the amount of $10 mm
675
3/31/2000$0Mar-31-2000Delayed SEC FilingComputer Motion, Inc. announced delayed annual 10-K filing-On 03/31/2000, Computer Motion, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
676
3/31/2000$0Mar-22-2000IPOIntuitive Surgical, Inc. has filed an IPO in the amount of $115 million.-Intuitive Surgical, Inc. has filed an IPO in the amount of $115 million.

Security Name: Common Stock
Security Type: Common Stock

Transaction Features: Reserved Share Offering; Sponsor Backed Offering